[{"data":1,"prerenderedAt":771},["ShallowReactive",2],{"media-slots-en":3,"home-en":59},{"about.hero":4,"about.video":6,"about.video-cover":8,"charity.hero":10,"contact.hero":12,"footer.qr-blood":14,"footer.qr-mini":16,"footer.qr-official":18,"footer.qr-solid":20,"guide.hero":22,"home.hero":24,"home.news-featured":26,"home.story-featured":28,"news.hero":30,"news.lead":32,"news.thumb":34,"stories.cover":39,"stories.hero":46,"stories.lead":48,"wiki.cat":50,"wiki.detail-hero":55,"wiki.hero":57},[5],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%B3%E4%BA%8E%E5%8D%9A%E5%8C%BB%E5%90%8C%E8%A1%8C_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[7],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_compressed.mp4",[9],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_frame1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[11],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%AC%E7%9B%8A%E8%B5%84%E6%BA%90%E9%93%BE%E6%8E%A5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[13],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F08\u002Fbde8f2354d29ffca7dcfe395ef4711b2.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[15],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-blood.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[17],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-mini.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[19],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-official.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[21],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-solid.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[23],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E7%96%BE%E7%97%85%E7%9F%A5%E8%AF%86%E5%BA%93_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[25],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E9%A6%96%E9%A1%B5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[27],"\u002Fimages\u002Fhome\u002Fnews-featured.jpg",[29],"\u002Fimages\u002Fhome\u002Fstory-featured.jpg",[31],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E5%8F%8B%E5%85%B3%E6%B3%A8_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[33],"\u002Fimages\u002Fnews\u002Flead.jpg",[35,36,37,38],"\u002Fimages\u002Fnews\u002Fn1.jpg","\u002Fimages\u002Fnews\u002Fn2.jpg","\u002Fimages\u002Fnews\u002Fn3.jpg","\u002Fimages\u002Fnews\u002Fn4.jpg",[40,41,42,43,44,45],"\u002Fimages\u002Fstories\u002Fs1.jpg","\u002Fimages\u002Fstories\u002Fs2.jpg","\u002Fimages\u002Fstories\u002Fs3.jpg","\u002Fimages\u002Fstories\u002Fs4.jpg","\u002Fimages\u002Fstories\u002Fs5.jpg","\u002Fimages\u002Fstories\u002Fs6.jpg",[47],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E8%80%85%E6%95%85%E4%BA%8B_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[49],"\u002Fimages\u002Fstories\u002Flead.jpg",[51,52,53,54],"\u002Fimages\u002Fwiki\u002Fcat-1.jpg","\u002Fimages\u002Fwiki\u002Fcat-2.jpg","\u002Fimages\u002Fwiki\u002Fcat-3.jpg","\u002Fimages\u002Fwiki\u002Fcat-4.jpg",[56],"\u002Fimages\u002Fwiki\u002Fdetail-hero.jpg",[58],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%8A%97%E7%99%8C%E7%99%BE%E7%A7%91_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",{"stories":60,"hotGuides":405,"manuals":406,"news":424},[61,75,84,93,101,109,118,127,135,143,151,159,167,176,184,192,201,207,215,223,233,241,250,259,267,275,283,292,300,310,320,329,339,347,355,362,370,379,387,396],{"slug":62,"title":63,"summary":64,"cover":65,"disease":66,"treatment":67,"patientType":68,"publishedAt":69,"contentHtml":70,"expertView":71,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"relapsed-refractory-follicular-lymphoma-car-t-treatment","After Multiple Lines of Treatment and Four CAR-T Therapies, Her Disease Still Progressed - She and Her Doctors Are Still Looking for What Comes Next","From multiple lines of treatment to repeated CAR-T therapies, Ms. Wang has seen her disease change again and again. With every new set of test results, she and her medical team continue to look for the next treatment possibility.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1761d4b78468d162a0230fe17eb52175.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Follicular Lymphoma","CAR-T","Adult","2026-08-21","\u003Cp>\u003Cspan style=\"font-size: 15px;\">Summary: In 2020, 41-year-old Ms. Wang (pseudonym) was diagnosed with Grade 3A, Stage IV follicular lymphoma with bone marrow involvement. Over the years that followed, she received chemotherapy, targeted and immunotherapy combinations, clinical-trial treatment, antibody-based therapy, radiotherapy, and multiple CAR-T cell therapies, yet the disease continued to relapse and progress. After she came to Beijing GoBroad Boren Hospital in 2025, Dr. Yajing Zhang and her team reviewed her entire treatment history and repeatedly adjusted the strategy according to tumor burden, target expression, blood counts, and her overall condition. Along the way, autologous CAR-T cells failed to expand effectively, universal CAR-T responses were not durable, and massive splenomegaly and thrombocytopenia became new barriers to treatment. Through splenectomy, CD22 CAR-T, and subsequent sequential treatment, the team kept creating conditions for the next step. Ms. Wang is still receiving treatment and being monitored closely today. Her story is a real account of long-term treatment, repeated reassessment, and the continuing search for another possibility.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Rapid Progression After First-Line Treatment Made Her Realize This Would Be a Long Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In the summer of 2020, 41-year-old Ms. Wang sought medical care for persistent abdominal pain and fever.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After ultrasound, CT, PET-CT, and a pathology biopsy, she was diagnosed with Grade 3A, Stage IV follicular lymphoma with bone marrow involvement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After diagnosis, she received six cycles of R-CHOP followed by two courses of rituximab maintenance. Early follow-up showed a marked reduction in disease, and for a while Ms. Wang thought that once treatment was over, life might finally return to normal.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">But not long after completing treatment, new lymph nodes appeared and abnormal findings returned in the bone marrow. The disease was progressing again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Over the next several years, she enrolled in clinical trials and received therapies with different mechanisms, including targeted and immunotherapy combinations, chemotherapy, antibody-drug conjugate therapy, and splenic radiotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Some treatments brought a short period of remission. Others showed progression again after only one or two cycles.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For Ms. Wang, the hardest part was not any single piece of bad news. It was the repeated cycle of "just starting to see hope, then having to change course again."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"text-align: center;\">After Three Universal CAR-T Treatments, the Disease Still Could Not Be Controlled for Long\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In 2023, Ms. Wang's disease progressed significantly again. On the advice of other patients, she began learning about CAR-T cell therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">During evaluation, her own T cells were found to be in poor condition, so autologous CAR-T could not be manufactured as originally planned. She therefore received universal CD19 CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After the first infusion, she developed persistent high fever and shortness of breath. One month later, however, follow-up showed a complete metabolic response. Unfortunately, the remission did not last long. Abnormal findings soon returned in both bone marrow and imaging studies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In 2024, Ms. Wang received a second and then a third universal CD19 CAR-T treatment. Each brought a period of response, but the disease never achieved stable, long-term control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">By early 2025, fever, fatigue, and enlarged lymph nodes had returned. Tests showed involvement of multiple lymph nodes, the spleen, and bone marrow, with abnormal cells also appearing in peripheral blood.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">At the same time, years of treatment had reduced both the number and function of her lymphocytes, while her platelet count remained low. Treatment options were narrowing, and her body had less reserve to tolerate further therapy. At that point, her previous attending doctor recommended that she travel to Beijing GoBroad Boren Hospital for further evaluation by Dr. Yajing Zhang and her team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">At Beijing GoBroad Boren Hospital, the Team First Reconstructed Her Entire Treatment History\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ms. Wang first met Dr. Yajing Zhang at the end of February 2025. Rather than focusing only on the latest test report, the team began by reviewing her pathology, every previous treatment, and the pattern of each response and progression since diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">At this stage, the question was no longer simply, "What drug is left to try?" The team needed to address several issues at the same time:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp>\u003Cspan style=\"font-size: 15px;\">How high is the current tumor burden?\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Which treatment targets are the tumor cells still expressing?\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Are the patient's own lymphocytes still suitable for another attempt at cellular therapy?\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp>\u003Cspan style=\"font-size: 15px;\">What level of treatment can her blood counts and overall condition still tolerate?\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Could the treatment chosen now limit options later?\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After a comprehensive assessment, the team initially aimed to reduce the tumor burden and create the conditions for another attempt at autologous CD19 CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After lymphocyte collection, tumor-reduction treatment, and lymphodepleting conditioning, Ms. Wang received an autologous CD19 CAR-T cell infusion on April 7, 2025.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Autologous CAR-T Cells Failed to Expand, So the Team Quickly Looked for a New Treatment Window\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After the CAR-T infusion, repeated monitoring showed no effective cellular expansion. Even after pomalidomide was used in an attempt to stimulate expansion, the expected response did not occur.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For Ms. Wang, this was another heavy blow. But the team did not stop at the conclusion that the treatment had "failed." Based on her disease status and the narrow treatment window at the time, they moved promptly to universal CD19 CAR-T on day 12 after the autologous infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The new CAR-T cells did expand in her body. Ms. Wang developed high fever, capillary leak syndrome, diarrhea, and low blood pressure, but with close monitoring and supportive care, these problems gradually stabilized. Her spleen shrank substantially, and her blood counts also improved.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Even so, the effect of this CAR-T treatment did not last. Subsequent monitoring again showed no sustained cellular expansion, further attempts at stimulation did not produce the hoped-for response, and her platelet count continued to fall.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Treatment had reached another crossroads.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Massive Splenomegaly and Low Platelets Became the Next Bottleneck - Splenectomy Reopened the Path to Treatment\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">As treatment continued, Ms. Wang's massive splenomegaly and thrombocytopenia increasingly became major barriers to the next stage of care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The spleen continued to enlarge. This reflected the tumor burden, while also interfering with recovery of her blood cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">With platelets too low, many treatments could not be given safely.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After repeated assessment, Dr. Yajing Zhang's team concluded that treating the spleen was not simply about solving a local problem. More importantly, it could create new room for subsequent treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The team actively coordinated with a partner hospital in the medical network to move the surgical plan forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">On May 26, 2025, Ms. Wang successfully underwent total splenectomy. After surgery, her blood counts and overall condition gradually improved. Fever and night sweats eased, her weight began to recover, and most importantly, she became physically able to continue treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For Ms. Wang, the surgery also helped her understand something important: long-term treatment is not about continuously adding more drugs. At each stage, the team first has to identify the problem that most limits the next step - and address that problem first.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">As Tumor Targets Changed, the Treatment Strategy Changed with Them\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After splenectomy, follow-up still found a small number of abnormal B cells in the bone marrow and peripheral blood. Because the tumor cells were still expressing CD22, the team decided to try CD22 CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After the July 2025 infusion, the CAR-T cells initially expanded but soon became undetectable again. Drug-based stimulation and reinfusion of the remaining cells also failed to produce a durable effect.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Over the following months, the disease continued to fluctuate. The team repeatedly adjusted targeted therapy, antibody therapy, and cellular immunotherapy based on peripheral blood tests, bone marrow examinations, PET-CT, and reassessment of tumor targets.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Sometimes the abnormal cells fell and then rose again. Sometimes a new combination worked briefly but could not maintain the response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ongoing treatment was also changing the tumor itself. CD19 expression had shifted, which meant that approaches that had worked before - or had once seemed theoretically possible - could not simply be repeated.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ms. Wang gradually came to understand why the doctors kept repeating bone marrow tests, blood tests, and target-expression testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">They were not treating an unchanging disease called "follicular lymphoma." They were treating a disease that could evolve under treatment pressure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Every Time the Disease Progresses, Four Questions Need to Be Asked Again\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For a patient with relapsed or refractory disease like Ms. Wang, every progression requires the team to reassess four questions:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Where is the disease mainly active now?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Is it in the bone marrow, spleen, lymph nodes, or several sites at the same time?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Which targets are the tumor cells expressing now?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Are targets such as CD19 and CD22 that were previously usable still present?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">What treatment can the patient tolerate at this point?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Platelet count, immune function, organ status, and damage from previous therapies can all change what is feasible next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Could this step affect the options that come after it?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Treatment needs to control the disease as much as possible while also preserving the patient's ability to move on to the next stage of care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In May 2026, testing again showed disease progression, with a higher proportion of abnormal cells in the bone marrow and new lesions on PET-CT. Instead of repeating approaches that had already stopped working, the team used the latest target-testing results to switch to inotuzumab ozogamicin combined with targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After the first cycle, abnormal cells in peripheral blood fell markedly. At the June follow-up, peripheral blood immunophenotyping temporarily showed no abnormal population.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The treatment also caused a further drop in platelets, so the team adjusted the treatment schedule again and replanned the next steps. This was still not the endpoint, but it showed that even as the disease changed, there were still directions worth exploring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>In Long-Term Treatment, It Is Not Only About the Tumor - It Is Also About Whether the Patient Can Keep Going\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Over the years, Ms. Wang has already gone through many different treatments. In addition to the disease itself, she has had to deal with repeated testing, treatment side effects, financial pressure, and the psychological impact of one progression after another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">One thing she values about working with the team is that the doctors do not look only at tumor markers on a report. They also ask whether she can still eat, sleep, and move normally; whether her blood counts can support the next treatment; and whether the financial and physical burden of the current plan is manageable. Dr. Yajing Zhang once even gave her a small duck mascot nicknamed "Turn Negative" - a lighthearted good-luck charm for better test results.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Whenever a test result is disappointing, the team explains why the plan needs to change and what options may still remain, rather than simply saying, "We will try another regimen." That kind of understanding and communication has helped Ms. Wang keep moving forward after repeated setbacks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">She Is Still in Treatment, but She No Longer Treats Every Test Report as a Final Verdict\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ms. Wang's weight has now recovered from a low of about 45 kg to more than 55 kg. Her energy, stamina, and appetite have also improved compared with when she first arrived at the hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">She is still receiving treatment and undergoing dynamic follow-up. The disease has not ended, and there is still considerable uncertainty. But unlike before, she no longer sees the next test report as a "verdict" that decides everything.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Looking back over the past six years, there are three things she most wants to share with other patients:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: If one treatment does not work as expected, does that mean there are no other options?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Not necessarily.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In relapsed or refractory lymphoma, disease status, target expression, and the patient's physical condition can all change after each treatment. The next step needs to be based on a new assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ms. Wang has experienced multiple treatment challenges: failure of autologous CAR-T cells to expand, a universal CAR-T response that was not durable, and only brief expansion after CD22 CAR-T. Each time, the team returned to the latest test results to look for another potentially usable treatment direction.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: Why does relapsed or refractory lymphoma require repeated target testing?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Because the tumor does not stay the same.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ongoing treatment can create selective pressure on the tumor, changing target expression and clonal composition. A target that was present before may later decrease or change, so after progression the treatment direction needs to be reconsidered using updated test results.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: During long-term treatment, what matters besides controlling the tumor?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Blood counts, infection, organ function, nutrition, physical strength, and whether the patient can tolerate the next stage of treatment all matter.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For patients with complex relapsed disease, keeping the patient well enough to remain eligible for treatment - and creating an opportunity for the next effective intervention - is itself an important long-term goal.\u003C\u002Fspan>\u003C\u002Fp>","Case Commentary by Dr. Fangfang Cheng, Attending Physician: \nMs. Wang has a typical case of relapsed or refractory follicular lymphoma, but the difficulty of her treatment is substantially greater than in many other patients who have relapsed after multiple lines of therapy.\nShe has had a long disease course and many prior lines of treatment, with recurrent involvement of the bone marrow and spleen. By the time she transferred to our hospital, she had a high tumor burden together with significant thrombocytopenia, impaired immune function, and poor lymphocyte quantity and function.\nThese factors not only affect drug efficacy; they also directly limit cell collection, manufacturing, expansion in the body, and the range of subsequent treatment options.\nThe team first reduced the tumor burden to create better conditions for cellular therapy. When the autologous CD19 CAR-T cells failed to expand effectively, we used the treatment window available at the time to transition promptly to universal CD19 CAR-T, which temporarily improved both splenomegaly and blood counts.\nLater, massive splenomegaly and thrombocytopenia became the main barriers to continuing treatment, so the team facilitated total splenectomy. After surgery, her fever, night sweats, blood counts, weight, and quality of life all improved, and she became physically able to proceed with CD22 CAR-T and subsequent sequential therapy.\nSince then, we have continued adjusting treatment according to peripheral blood, bone marrow, imaging, and target-expression results rather than mechanically repeating previous regimens. A recent new treatment led to a marked drop in abnormal cells in peripheral blood, but close dynamic follow-up is still needed.\nThis case shows that the goal in complex relapsed disease cannot be reduced to any one drug or any one cell infusion. The more important task is to identify the key problem at each stage, control the tumor while managing infection, blood counts, and organ function, and preserve the patient's treatment fitness as much as possible so there is still an opportunity for the next effective intervention.\nThe long-standing trust, understanding, and cooperation of the patient and her family have also been essential in allowing this journey to keep moving forward.\n\nCommentary by Dr. Yajing Zhang: Do Not Predetermine the Endpoint - Keep Looking for Better Options as the Disease Changes\nFollicular lymphoma is generally considered an indolent lymphoma with a relatively slow course and multiple treatment options. But having \"many options\" does not mean that every patient will achieve a long and stable remission.\nMs. Wang had Stage IV disease with bone marrow involvement at diagnosis and progressed soon after first-line immunochemotherapy. Her responses to several subsequent treatments with different mechanisms were short-lived, showing that her lymphoma had strongly refractory features.\nAs the number of prior treatments increased, she gradually developed a high tumor burden, massive splenomegaly, bone marrow involvement, thrombocytopenia, immunoglobulin deficiency, reduced lymphocyte number and function, and changes in tumor targets and phenotype.\nThe team was therefore not facing a single question of \"which drug should we choose?\" We were dealing with a system in which disease biology, damage from previous treatment, and the patient's overall ability to tolerate therapy were all intertwined.\nFor a patient like this, treatment cannot be understood as a series of isolated regimens, and hope cannot be placed entirely on any single cell infusion.\nThe core approach is full-course sequential management: first identify the most important problem at the current stage, then consider how tumor reduction, targeted therapy, antibody therapy, cellular therapy, surgery, and supportive care can work together to create the conditions for the next step.\nWhen Ms. Wang's autologous CD19 CAR-T cells failed to expand effectively, we used the treatment window at that time to transition promptly to universal CAR-T, which still produced meaningful splenic shrinkage and improved blood counts.\nThe subsequent splenectomy was not simply a replacement for drug therapy. It was intended to relieve the bottleneck created by massive splenomegaly and blood-cell consumption, improve her overall condition, and reopen treatment options.\nAnother defining feature of relapsed or refractory lymphoma is that the tumor is not static.\nTreatment creates selective pressure. Target expression, clonal composition, and the tumor microenvironment can all change as a result. That is why every progression requires a new assessment rather than a plan based only on the original pathology label or previous target results.\nThe team must keep asking four questions:\n·Where is the disease mainly active now?\n·What are the tumor cells expressing now?\n·What can the patient tolerate now?\n·Could this treatment step affect what can be done next?\nCellular therapy also cannot be judged only by whether a target is present.\nCell source and quality, the effect of prior treatment on T cells, whether the cells can expand and persist in the body, tumor burden, the immune microenvironment, and infection risk can all influence the outcome.\nFailure of one cell product to expand does not mean that every cellular therapy will fail. Likewise, one remission does not mean that monitoring can stop.\nTrue individualized care means putting all of these variables on the same treatment map and reprioritizing them as the patient's condition changes, rather than simply stacking one therapy on top of another.\nThe team also pays close attention to the patient's overall condition.\nBeyond disease control, the ability to eat, sleep, and remain active; whether blood counts can support the next treatment; whether infections can be prevented; whether the patient understands the plan; and whether the financial and psychological burden is manageable all influence how far long-term treatment can go.\n\"Not giving up\" does not mean promising that every treatment will work, and it does not mean adding more therapy when there is no evidence to support it.\nAs long as the patient still wishes to continue and there remains a medically reasonable opportunity to intervene, the team will keep looking for a more appropriate next step through scientific assessment, risk control, and full communication. Even when treatment needs to slow down, we try to preserve the patient's ability to keep living - and to keep having choices.\nFor relapsed or refractory lymphoma, the most meaningful kind of persistence is to keep identifying problems as they change, create the conditions for the next step, and continue walking this long road together with the patient.","This content is published with the authorization of the patient and their family, intended solely to share real experiences and health knowledge. It does not constitute a recommendation of any treatment plan or medical diagnostic advice. For specific treatment, please follow the guidance of a professional physician.",false,"2026-09-13",{"slug":76,"title":77,"summary":78,"cover":79,"disease":80,"treatment":81,"patientType":82,"publishedAt":69,"contentHtml":83,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"childhood-b-all-car-t-five-year-recovery","Five Years After CAR-T for Relapsed Leukemia, He's Now the Fastest Runner in His Class","Keke (pseudonym) was diagnosed with leukemia before the age of two. After relapse in the bone marrow and both testes, he received CAR-T ","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F5bdd781f2c320daaa52809289ccd4685.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","B-Cell Acute Lymphoblastic Leukemia"," CAR-T","Child","\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Summary: Keke was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) before he turned two. After nearly three and a half years of treatment, he stopped therapy, only to develop a bone marrow relapse with leukemic involvement of both testes a little over six months later. After the relapse, his family began actively exploring new treatment options. Following medical evaluation, Keke received sequential CD19 and CD22 CAR-T cell therapy, followed by consolidation treatment. He also faced infectious complications after CAR-T, including Pneumocystis jirovecii pneumonia (PJP), but gradually recovered with appropriate treatment and long-term follow-up. Now, five years after CAR-T therapy, Keke is back at school. He loves PE, running, and badminton, and has begun imagining what he wants to be when he grows up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 13px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Leukemia Relapsed Just Over Six Months After Treatment Ended\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Keke was diagnosed with B-cell acute lymphoblastic leukemia before he was two years old.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">For nearly three and a half years, he received chemotherapy according to his treatment plan. Overall, the course went relatively smoothly. After treatment ended, Keke was eating well, running around, and full of energy. To anyone looking at him, he seemed just like any other child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">The family thought the long treatment journey was finally behind them. But a little over six months later, before Keke's mother returned to work, she decided to take him for a comprehensive follow-up. The results brought news no one had expected: the leukemia had relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">The relapse involved not only the bone marrow, but also leukemic infiltration of both testes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">"When he was first diagnosed, we knew childhood leukemia could often be treated successfully. We were scared, of course, but we still felt that if we followed the treatment plan, things would work out. We never imagined the leukemia would come back only a little over six months after he stopped treatment." This time, the situation was more complex than at initial diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(15, 71, 97); text-align: center;\">\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Why Did the Family Start Looking Into CAR-T After Relapse?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">During Keke's initial treatment, his mother mostly followed the medical team's plan step by step and did not actively research many other treatment options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Once the leukemia relapsed, she gradually realized that the decisions ahead would be very different from those they had faced during first-line treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">She began looking for information on her own, speaking with other parents, and learning more about treatment options that might be considered for children with relapsed leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">"At the time, we had very limited access to information. We didn't know which children had been through relapse, or even who we should ask. Eventually, we found two families with similar experiences. Both had gone to Beijing, and that was when we started looking there too."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Through conversations with other families, consultations with different doctors, and formal medical evaluation, the family gradually learned about CAR-T cell therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Keke's mother asked very practical questions: "How many children have you treated? Have you seen cases similar to ours? What were the outcomes?"\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Other families' experiences helped broaden what they knew, but she also came to understand an important point: every child's disease biology, site of relapse, previous treatment, and overall condition are different. Another patient's treatment journey can be useful for learning, but it cannot simply be copied.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">After gathering more information and completing further evaluation, the family decided to seek treatment from Dr. Jing PAN's team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 13px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">With Relapse in Both the Bone Marrow and Testes, Where Did CAR-T Fit Into the Treatment Plan?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After arriving in Beijing, the medical team carried out a comprehensive assessment, taking into account Keke's bone marrow relapse, bilateral testicular leukemic involvement, and previous treatment history.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">The team first used treatment to bring the disease under control. Once remission was achieved, Keke moved on to CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">He subsequently received CD19 CAR-T followed by CD22 CAR-T, and then completed additional consolidation treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">After CAR-T cell infusion, Keke developed lower blood counts and a mild fever. Before treatment began, however, the doctors had already explained the reactions that might occur, which symptoms the family should watch for, and what would happen if a problem arose. So when these issues did appear, the family was still anxious, but no longer felt completely unprepared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Every day, Keke's mother recorded his temperature, energy level, and any physical changes. She followed the team's guidance on diet, medications, and daily care, and reported anything unusual promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">She later reflected: "Parents don't have to force themselves to understand every piece of medical knowledge. What really matters is knowing what stage of treatment your child is in, what the doctors want you to watch for, and which changes need to be reported right away. Doing those things well is already very important."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 13px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Why Does Infection Prevention Still Matter After CAR-T?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">About five months after his first CAR-T infusion, Keke suddenly developed a high fever.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">He had seemed completely well that morning, but by the afternoon he was running a high fever, without obvious respiratory symptoms such as cough or a runny nose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">For the first two days, the cause was unclear. Considering Keke's stage of treatment and medical history, Dr. Jing PAN's team carried out further evaluation for infection. He was ultimately diagnosed with Pneumocystis jirovecii pneumonia (PJP).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">The infection kept Keke in the hospital for 23 days. Looking back, his mother feels the family may have relaxed their precautions a little too soon.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">"He looked no different from a healthy child, so we thought he had probably recovered quite well. We even took him to the park to play in the sand."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">The experience made the family understand more clearly that looking well and feeling energetic after CAR-T does not necessarily mean the immune system has fully recovered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">During the recovery period recommended by the medical team, infection precautions, food hygiene, and a clean environment may still be important. If a child develops an unexpected fever or other concerning symptoms, the family should contact the treating team or seek medical care promptly. When normal activities can gradually resume should be decided according to follow-up results and the treating physician's assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Five Years After CAR-T, He's Back on the Playground\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">After treatment ended, Keke's mother did not rush to send him straight back to school. Instead, she let him rest at home for another year. "I wanted him to recover as fully as possible first. One more year didn't matter."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">When Keke first returned to school, he still wore a mask. At first, his mother was also hesitant to let him join PE classes, although Keke himself loved being active.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">As his health became more stable, he gradually returned to normal physical activity. His mother also spoke with his teacher and said, "Just treat him like any other child. He doesn't need to be singled out."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Now, five years after CAR-T therapy, PE is Keke's favorite class, and he also loves badminton. What makes his mother especially happy is that the little boy who once spent so much of his childhood in treatment is now one of the fastest runners in his class.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">When asked what he wants to be when he grows up, he answers seriously, "A soldier." He says he was impressed by how strong and proud the soldiers looked when he watched a military parade on television.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy, follow-up visits, infections, and treatment once dominated the family's conversations. Today, they talk much more about school, PE, badminton, and what Keke might want to do in the future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">It is the ordinary family life they once hoped so deeply to have again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 13px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Five Lessons Keke's Mother Would Like to Share with Other Families\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"color: rgb(0, 0, 0);\">Q: After a child's leukemia relapses, how can parents look for reliable information about new treatment options?\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Relapsed disease may be very different from newly diagnosed leukemia, and treatment decisions can become more complex. Keke's mother suggests staying in close communication with the treating physician while also learning about the disease, experienced medical teams, and newer treatment developments, so that families are not left feeling powerless simply because they lack information.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Q: Can another family's treatment experience be used as a direct guide for your own child?\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Other families' experiences can help parents discover treatment options they may not have known about, but they should not be treated as a ready-made plan for another child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Children can differ in disease subtype, site of relapse, target antigen expression, previous treatment, and overall health. The treatment plan still needs to be individualized by an experienced medical team.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Q: If leukemia relapses outside the bone marrow, such as in the testes, does that automatically mean CAR-T is needed?\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">No. Not every child with relapsed leukemia needs CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">For children with relapse involving both the bone marrow and an extramedullary site such as the testes, the medical team needs to consider the location of relapse, disease burden, previous treatment, target antigen expression, and other clinical factors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">CAR-T became an important part of Keke's treatment, but whether CAR-T is appropriate for a particular child should be decided individually by a team with relevant experience.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Q: If a child looks back to normal after CAR-T, do infection precautions still need to continue?\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Yes, precautions may still be needed depending on the child's immune recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Keke developed Pneumocystis jirovecii pneumonia about five months after CAR-T. A child may look and feel much better before the immune system has fully recovered. During the period advised by the medical team, families may still need to pay attention to masking, environmental hygiene, food safety, and unexpected fever or other signs of infection.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">Q: Do parents need to understand every medical detail about CAR-T?\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">No. Parents do not need to put that kind of pressure on themselves.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">More important than mastering every technical detail is understanding what stage of treatment the child is in, what symptoms need to be watched, when the medical team should be contacted immediately, and how to maintain clear communication with the child's doctors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 13px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>\u003Cspan style=\"color: rgb(0, 0, 0);\">From the Hospital Ward to the Playground: A Child's Life Is About More Than Treatment\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(0, 0, 0);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">From being diagnosed with B-cell acute lymphoblastic leukemia before the age of two, to relapsing after treatment, receiving CAR-T therapy, facing a serious infection, and going through a long recovery, Keke and his family have traveled a very long road.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">Today, treatment is no longer the center of this child's life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">He is back in the classroom and out on the playground, joining PE with his classmates, playing badminton, and seriously imagining what he might want to become when he grows up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">For children and parents who are still in treatment, there may still be procedures, tests, and long periods of waiting ahead. But illness is only one part of a child's story. It does not mean they have lost the chance to have a future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px;\">They can still return to school, make new friends, discover new interests, and gradually build a life that belongs to them.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":85,"title":86,"summary":87,"cover":88,"disease":89,"treatment":90,"patientType":68,"publishedAt":69,"contentHtml":91,"expertView":92,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"mds-haploidentical-transplant-one-year-recovery","Diagnosed with High-Risk MDS at 53, She Marks One Year of Recovery After a Haploidentical Transplant","After being diagnosed with high-risk MDS, Ms. Jiang underwent a haploidentical allogeneic stem cell transplant using her son as the donor. One year later, she remains in remission and is gradually returning to everyday life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F261bb11b36a5f535ae679f4c43154296.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Myelodysplastic Syndrome","Hematopoietic Stem Cell Transplantation","\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Summary: In 2025, 53-year-old Ms. Jiang (pseudonym) sought medical care after developing difficulty walking and a persistent roaring sensation in her head. She was ultimately diagnosed with myelodysplastic syndrome (MDS), subtype MDS-IB2, and was assessed as high risk. After a comprehensive evaluation, she underwent a related haploidentical allogeneic hematopoietic stem cell transplant in July, with her son as the donor. Her blood production recovered successfully after transplant. At the one-month follow-up, she was in complete remission with 99.49% donor chimerism. Recovery was not completely smooth, and she experienced an infection after leaving the transplant unit. Now one year post-transplant, her immune system has reconstituted well, she is off immunosuppressive therapy, and she has shown no signs of graft-versus-host disease (GVHD). Looking back, her message to other patients is simple: trust an experienced medical team, follow the treatment plan, and do not relax infection precautions too early just because you start feeling better.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">In June 2025, 53-year-old Ms. Jiang went to the hospital after developing difficulty walking and a persistent roaring sensation in her head.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">After a routine blood test showed abnormalities, she underwent a bone marrow examination and was ultimately diagnosed with myelodysplastic syndrome (MDS).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The diagnosis came without warning. At first, she even asked her doctor, "How long would I have if I did not get treated?" But when the doctor told her that the disease could be treated, her fear gradually gave way to a clearer thought: if there was a treatment option, she would give it her best. Based on her age, disease subtype, and risk assessment, the medical team recommended proceeding with allogeneic hematopoietic stem cell transplantation as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">In July 2025, Ms. Jiang underwent a related haploidentical allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Liquan Hospital, with her son as the donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Neutrophil engraftment was achieved on day +20. At the one-month follow-up, her disease was in complete remission, with donor chimerism of 99.49%. She is now one year post-transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Ms. Jiang has achieved good immune reconstitution, has discontinued immunosuppressive therapy, and has shown no signs of graft-versus-host disease (GVHD). She has returned to a familiar rhythm of life and is willing to share what she has learned over the past year with other patients preparing for transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>Why Did She Choose Hematopoietic Stem Cell Transplantation After an MDS Diagnosis?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Q: How did you first realize something was wrong?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: In June 2025, it started with difficulty walking. Then I developed this constant roaring sensation in my head, so I went to the hospital. My blood test was abnormal, and the doctor asked me to have a bone marrow examination. That was when I was diagnosed with myelodysplastic syndrome.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">I had always been healthy, so it came completely out of the blue. I felt lost when I was first diagnosed. I even asked the doctor how long I might live if I chose not to be treated.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The doctor told me the disease could progress quickly without treatment. My younger sister was so frightened that her legs went weak. In the end, I was the one helping her walk out of the consultation room.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Later, my son started looking up information online and learned that hematopoietic stem cell transplantation could offer better treatment outcomes for some people with MDS. He told me, "Mom, this can be treated. Let us go for the transplant."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">After we came to the hospital, the doctors looked at my age and the details of my disease and recommended that I have the transplant as soon as possible. Hearing the words "it can be treated" actually made me feel calmer. My thinking was very simple: if the doctors said there was a way forward, then I would take it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>Before Transplant, the Most Important Thing Was Understanding the Risks\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Q: The doctors explained many risks and precautions before transplant. Were you frightened?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: We came to GoBroad Shanghai Liquan Hospital in July 2025. Before the transplant, Dr. Su Li sat down with me and explained the entire allogeneic hematopoietic stem cell transplant process in detail, including what might happen at different stages.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The informed consent documents were a thick stack.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">To be honest, I may not have understood every medical detail. But what mattered most to me was that the doctors explained in advance what could happen. That way, when something did happen, I was less likely to panic.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For example, Dr. Li told me that I might develop a fever while my blood counts were recovering. And sure enough, I had a low-grade fever for several days when my cells started to come back.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Because the doctors had already explained it, I paid attention to the fever, but I was not especially scared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For me, having a general understanding of the transplant process and knowing how the doctors would respond was much more reassuring than staring at every test report and worrying about what each number might mean.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>In the Transplant Unit, What Reassured Me Most Was Knowing the Doctors Knew What to Expect Next\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Q: What stands out most from your time in the transplant unit?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: I spent about a month in the transplant unit. After the stem cell infusion, I got anxious when my white blood cell count still had not risen by day 12. I asked Dr. Jun Zhu, "Why is it still not going up?"\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Dr. Zhu told me to wait another two days. If it still had not risen, they would consider medication to stimulate white blood cell recovery. Then on day 14, my white blood cell count really did start to rise.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">I was amazed and asked him, "How did you predict that so accurately?" He joked, "I wrote this script - I am the director." I still remember that line today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For patients, so much of this is happening for the first time, and every change in a blood count can be stressful. But experienced doctors recognize the patterns. They know when it is appropriate to watch and wait and when it is time to intervene.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">That kind of clinical judgment gives patients a real sense of security. Over time, I came to feel that I did not need to understand every line of every report myself. It was more reassuring to follow the treatment plan, cooperate with the team, and ask my doctors whenever I had questions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>Feeling Better After Leaving the Transplant Unit Does Not Mean Infection Precautions Can Stop\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Q: During recovery after transplant, what do you think patients need to pay the most attention to?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: At first, things went quite smoothly when I moved from the transplant unit to the general ward. I felt so well that day that I thought I could walk there myself, but the care staff still insisted on taking me in a wheelchair.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Looking back, I was a little too relaxed. I felt well, I had plenty of energy to talk, and wearing a mask was uncomfortable, so I took it off. I also walked around the hallway and used the elevator by myself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">I developed an infection soon afterward. It took more than ten days to get through it, and for at least a week I could barely even drink water. So if I could give one piece of advice to patients who have just left the transplant unit, it would be this: feeling physically well does not mean your immune system has recovered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Especially early after leaving the transplant unit, do not relax precautions such as masking, environmental hygiene, and food safety simply because you feel better. Around day 100 after transplant, I wanted to return to my hometown in Jiangxi.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Dr. Li agreed that I could go home, but asked me to come back for follow-up every two weeks. He also recommended having a family member drive me to reduce infection exposure during the journey. I really appreciated that approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The doctors did not simply tell me, "You cannot do this" or "You cannot do that." Instead, they tried to help me live as normally as possible while still keeping safety first.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>After Returning Home, Food Safety, Hygiene, and Regular Follow-Up All Matter\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Q: What do you pay the most attention to in everyday life at home?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: For me, the two most important things are keeping food clean and keeping the living environment hygienic. We have a little child at home who is just over one year old.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">At first I was so weak that I could not even pick the child up. Around nine or ten months after transplant, I gradually became strong enough to hold him again. He likes to run into my room at night, so I ask him to bathe and get clean before coming in.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">I am just as careful with food. After all, it goes directly into my body, so I do not take chances.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Of course, exactly how strict you need to be and when precautions can gradually be relaxed should always be discussed with your treating doctor. Everyone recovers at a different pace, so you cannot simply copy another patient's experience.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Ch2 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);text-align: center\">\u003Cspan style=\"color: rgb(0, 0, 0); font-size: 16px;\">\u003Cstrong>One Year After Transplant, She Feels Life Is Gradually Coming Back\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fh2>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fh3>\u003Ch3 style=\"margin-top: 11px;margin-bottom: 5px;break-after: avoid;color: rgb(15, 71, 97);\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Q: After going through a serious illness, do you feel different from the person you were before?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>A: People often say that a serious illness changes you completely. But I still feel like myself. Sometimes I even feel as though I was never sick.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">I also chat with other patients in support groups now. If someone asks about my experience, I share what I know. The main thing I want to tell them is very simple: there will be frightening moments and setbacks during treatment, but do not let one difficult stage convince you that there are no possibilities ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">From diagnosis through transplant, I never cried because I was afraid. Now, when I do tear up sometimes, it is more often because I am moved by the people I met and the help I received along the way.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Illness is a difficult chapter in life, but it is not the whole story. Once you get through that chapter, life still moves forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Q: Does every patient with MDS need a hematopoietic stem cell transplant?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">No. Not every patient with MDS needs hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">The decision depends on multiple factors, including the MDS subtype, risk category, age, overall health, and whether a suitable donor is available.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Ms. Jiang had MDS-IB2 and was assessed as high risk, so her medical team recommended allogeneic hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Q: Can a haploidentical family donor be used for an allogeneic hematopoietic stem cell transplant?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For some patients, a related haploidentical donor can be used for allogeneic hematopoietic stem cell transplantation after a comprehensive evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Ms. Jiang's son served as her donor, and she successfully achieved hematopoietic reconstitution after transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Q: Why is infection prevention still so important after leaving the transplant unit?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Leaving the transplant unit means that blood cell production has begun to recover, but immune recovery usually takes much longer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">So even if a patient already feels much stronger and more energetic, masking, food safety, environmental hygiene, and scheduled follow-up remain important during the recovery period recommended by the medical team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">\u003Cstrong>Q: If a patient reaches complete remission after transplant, does that mean no further treatment is needed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Not necessarily.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">For some high-risk patients, doctors may recommend maintenance therapy and long-term follow-up based on the risk of the underlying disease and the patient's recovery after transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-top: 12px;margin-bottom: 12px;\">\u003Cspan style=\"font-size: 15px; color: rgb(0, 0, 0);\">Ms. Jiang started decitabine maintenance therapy three months after transplant and continues to receive long-term follow-up as planned.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Su Li (Associate Chief Physician, MD; Director, Department of Hematology, GoBroad Shanghai Liquan Hospital; Director, Myeloma Center): \nWhy Should Allogeneic Hematopoietic Stem Cell Transplantation Be Considered for High-Risk MDS?\nMs. Jiang came to GoBroad Shanghai Liquan Hospital in June 2025 with fatigue and dizziness. Laboratory testing showed severe anemia and leukopenia. To identify the cause, she underwent a bone marrow examination. Bone marrow smear morphology showed that blasts and immature monocyte-like cells accounted for 18.5%.\n\nBased on her clinical presentation and laboratory findings, she was diagnosed with myelodysplastic syndrome (MDS), subtype MDS-IB2.\n\nRisk assessment placed her in the very-high-risk category under IPSS-R and the high-risk category under IPSS, providing a clear indication for allogeneic hematopoietic stem cell transplantation.\n\nHer son was selected as the donor and successfully completed the pre-transplant evaluation.\n\nOn July 18, 2025, Ms. Jiang began conditioning in the transplant unit. On July 24, her son's allogeneic hematopoietic stem cells were infused.\n\nDuring transplant, she experienced gastrointestinal reactions and manifestations related to bone marrow suppression. Neutrophil engraftment was achieved on day +20, marking successful hematopoietic reconstitution.\n\nA bone marrow examination one month after transplant confirmed complete remission, with donor chimerism of 99.49%.\n\nAfter completing the initial transplant phase, Ms. Jiang was discharged and continued regular outpatient follow-up. As instructed, she took immunosuppressive therapy together with antiviral and antifungal prophylaxis.\n\nBecause her MDS was high risk, decitabine maintenance therapy was started three months after transplant to reduce the risk of relapse.\n\nMs. Jiang is now one year post-transplant. Her immune system has reconstituted well, she has discontinued immunosuppressive therapy, and she has shown no signs of graft-versus-host disease (GVHD).\n\nShe will continue to be monitored and managed according to her post-transplant follow-up plan.",{"slug":94,"title":95,"summary":96,"cover":97,"disease":80,"treatment":98,"patientType":82,"publishedAt":99,"contentHtml":100,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"childhood-all-blood-leukemia-survivor-story","Five Years On: From Childhood Leukemia to Moyamoya Disease - A Mother's Practical Lessons from the Journey","Diagnosed with B-cell acute lymphoblastic leukemia at age three and a half, Xiaojin completed nearly three years of treatment and achieved long-term remission. During recovery, he was also diagnosed with moyamoya disease, underwent surgery, and has now returned to school.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fd30fb548a8783028b45a2127a78cc178.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Chemotherapy","2026-08-07","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">A routine preschool health check first revealed an abnormal blood count in three-and-a-half-year-old Xiaojin (pseudonym), leading to a diagnosis of B-cell acute lymphoblastic leukemia. He went through chemotherapy, serious infection, and other treatment-related challenges, ultimately completing standard therapy and entering long-term remission. During recovery, a new set of symptoms led to another unexpected diagnosis: moyamoya disease, a rare cerebrovascular condition, for which he underwent surgery. Five years later, Xiaojin is growing well and back at school. Along the way, his mother has gone from an ordinary parent suddenly facing a frightening diagnosis to someone who has learned how to understand disease, manage treatment, ask questions, and support other families on the same road.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>One Blood Test Changed Everything\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaojin is my only child. Before he was three and a half, he had hardly ever been sick. I never imagined that a routine preschool health check would change the course of our entire family's life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On August 7, 2021, I took him for his preschool health check. When I saw the complete blood count, my heart sank: his hemoglobin was only 86 g\u002FL, showing moderate anemia. The doctor simply told us that his blood results did not meet the requirement and that they could not issue the health certificate he needed to start preschool.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The next day was my birthday. All seven members of our family went away to a hot-spring resort. It was the last trip we would ever take together as a complete family. Even sitting in the warm water, I couldn't stop thinking about that test report with all the abnormal arrows.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On Monday, I immediately took my husband and Xiaojin to a tertiary hospital for repeat testing. The results were worse. After examining his abdomen, the doctor told us, "He needs to be admitted. There is a very high chance this is leukemia."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The moment I heard the word leukemia, everything started ringing in my ears. Earlier that year, my mother-in-law had been diagnosed with advanced stomach cancer. Within a single year, two serious illnesses had hit our ordinary family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We didn't dare tell my mother-in-law. She had waited so many years for this grandson. At that point, I didn't even have time to cry. I had only one thought: we needed to transfer him somewhere with the right expertise.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Our First Decision After Diagnosis: Find the Right Pediatric Leukemia Team\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In fact, blood disorders had crossed my path once before. In 2019, when Xiaojin was just over a year old, I saw a post on Weibo about a child three months younger than him who had juvenile myelomonocytic leukemia (JMML), a particularly aggressive childhood blood cancer. I started making a small donation every month and continued for two years.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That child was treated at what is now GoBroad Chunfu Institute of Hematology & Oncology in Dongguan and recovered well. At the time, I simply thought I was helping another family and quietly remembered the hospital's reputation. I never imagined that two years later, that small connection would help point the way for my own son.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before all of the bone marrow, genetic, and MRD results were even back, we had already decided to transfer. After five days at the local hospital, we discharged him and went straight to Dongguan. My mother thought I would be crying so hard I couldn't stand, but I didn't. Crying wasn't going to help. My first job was to get my child to a team that knew how to treat him.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaojin was ultimately diagnosed with B-cell acute lymphoblastic leukemia. Dr. Huaying LIU developed a detailed treatment plan for him, beginning what would become a nearly three-year journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fb5a1bdc30718d301a55c37ced16486e6_20260913164821.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"b5a1bdc30718d301a55c37ced16486e6_20260913164821.png\" alt=\"131925eb-63a0-4e79-9491-20d14bb273e0.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo courtesy of Lin Wan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>A Serious Viral Infection: Why Infection Prevention Became Non-Negotiable\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first days after we arrived were the hardest. Xiaojin was only three and a half. After having a PICC line placed under general anesthesia, he woke up groggy and clung tightly to me, refusing to let go. My husband had to return home to care for his mother, who was receiving chemotherapy, so I was alone with Xiaojin. Even buying food or going to the bathroom became difficult because I couldn't leave him.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once chemotherapy began, the steroids made him cry for three days and nights. Fortunately, his leukemia responded well to treatment. At the day-19 bone marrow assessment, MRD was negative and the genetic markers being monitored had also become negative. For the first time since the diagnosis, I felt I could breathe a little easier.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then, near the end of his first treatment phase, he suddenly developed adenovirus pneumonia. In a healthy person, adenovirus may cause little more than a respiratory infection, but Xiaojin's white blood cell count was nearly zero and his immune defenses were profoundly suppressed. The infection went straight to his lungs, and his oxygen saturation dropped into the low 80% range. A ventilator was brought to the ward, and transfer to the ICU seemed imminent.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">None of us slept that night. His oxygen saturation was checked and reported every 30 minutes. At around three or four in the morning, the number finally began to rise little by little. He made it through.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The infection delayed chemotherapy for more than a month. His weight dropped from about 15 kg to 12 kg, the muscles in his legs became weak, and when he left the hospital he needed someone to support him while he walked.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After that experience, I became extremely cautious about infection prevention. During high-dose chemotherapy, his white blood cell count stayed near zero for about 20 days. I arranged for him to stay alone in a private room, disinfected anything that visitors touched, and made my husband change clothes after coming back from grocery shopping before he went near Xiaojin. He got through those 20-plus days without another infection, and to me, every precaution was worth it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We also ran into an unusual reaction to one of his chemotherapy drugs: whenever he lay down, his oxygen saturation would drop. Even the doctor said it was uncommon. With an increased steroid dose, the reaction was brought under control, and he ultimately completed the full course of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F2d30dbc3c756964ee1742d29c72cca28_20260913164852.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"2d30dbc3c756964ee1742d29c72cca28_20260913164852.png\" alt=\"de6c191b-755e-4b52-98df-ca23238bdfc1.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo courtesy of Lin Wan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>One Challenge After Another, but We Kept Moving Forward\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the first ten months of Xiaojin's treatment, our family went through loss after loss. My mother-in-law died of stomach cancer, and my father died of multiple myeloma. I was caring for a child who needed me every day while being unable to stay close to other family members who were also seriously ill. Unless you have lived through something like that, it is hard to explain. But life leaves you no choice sometimes. You grit your teeth and keep moving.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2022, Xiaojin completed intensive treatment and came home to begin maintenance therapy. I also went back to work. Life slowly settled into a rhythm again: weekly blood tests and monthly hospital visits for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July 2024, Xiaojin officially stopped treatment after a total course lasting nearly three years. That September, he put on his backpack and started primary school. Watching him run and bounce along, I thought, "Maybe those three difficult years are finally behind us."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F955246acce673d1e047741346523e5bd_20260913164920.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"955246acce673d1e047741346523e5bd_20260913164920.png\" alt=\"5df60ecc-38bb-4a96-b81c-5c4b55988b10.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo courtesy of Lin Wan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>After Leukemia Treatment, Another Rare Diagnosis: Moyamoya Disease\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I thought finishing leukemia treatment meant we had finally reached the end of the road. Then life gave us another problem to solve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In early 2025, my son's mouth suddenly drooped to one side and he began drooling, almost like a stroke. My first fear was that the leukemia had relapsed and involved the central nervous system. Lumbar puncture and MRI evaluation ruled out CNS leukemia. We then went from hospital to hospital looking for an explanation. One doctor thought it might be epilepsy and recommended long-term medication. But after everything I had learned during his leukemia treatment, something did not feel right to me: his symptoms did not fit the typical pattern of epilepsy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I started researching, reading patient-group discussions, and comparing cases, until I finally took my questions to a hospital specializing in neurological disease. That was when we learned that Xiaojin had moyamoya disease, a rare cerebrovascular disorder. The doctors explained that the "white spots" seen on an MRI three years earlier were not signs of CNS leukemia; they were traces left by repeated small cerebral infarctions. In other words, this condition had been quietly present even while we were focused on leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the diagnosis, Xiaojin underwent two cranial surgeries to improve blood flow to the brain. During the first operation, severe bleeding occurred unexpectedly and his condition became critical for a time. The second surgery went smoothly, and he was discharged active and energetic again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, I have learned that facing illness takes more than courage. It also takes calm judgment, a willingness to keep learning, and the confidence to think independently and ask questions. Every time we actively searched for an answer, we may have gained precious time for our child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>I Could Never Repay What His Doctors Have Done for Us\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I look back on these five years, one of the things I feel most fortunate about is the doctors we met. They genuinely cared about helping my child get better.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying LIU from the hematology team was rigorous and professional, but also warm and approachable. Whether I had questions about chemotherapy adjustments or everyday care, she would respond - even when I messaged late at night. During ward rounds, she always remembered how Xiaojin was doing and regularly checked in on him. Later, when he had severe bleeding during brain surgery and I was completely overwhelmed, Dr. Liu was the first person I thought of. Every reply from her helped me steady myself again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The neurosurgeon who operated on him was the same way. He was down-to-earth and gave me a direct way to stay in touch. If something unusual happened after surgery, he would respond with guidance even late at night. We lived more than a thousand kilometers away, but those messages made me feel as though the doctor was still nearby.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Meeting doctors like these has been an enormous blessing for our family. I don't think a lifetime would be enough to express how grateful I am.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Staying in the Light - and Becoming a Light for Someone Else\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaojin is now in second grade. He is a little more prone to colds than some other children, but overall he is doing well. In July 2026, he reached five years from his leukemia diagnosis, and his follow-up results were all reassuring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">People often ask me: if your child is doing well now, why do you still stay involved in patient groups? My answer is that you cannot erase what happened simply by leaving the community or pretending to forget it. If I stay, keep learning, and help newly diagnosed families understand where to start, maybe they can avoid some of the detours we had to take.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Years ago, I happened to help a child I had never met. I never imagined that the kindness I put into the world would eventually circle back and help guide my own son. There is something remarkable about the way people support one another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Practical Lessons I Would Share with Other Families\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Don't make major decisions in a rush immediately after diagnosis - first find a team with the right expertise. Learn about experienced pediatric hematology centers, their treatment approaches, and their clinical experience. The right team can help your child avoid unnecessary detours and risks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Take infection prevention seriously. The period when blood counts are at their lowest during chemotherapy is a high-risk time for infection. Careful disinfection, changing clothes before entering the child's room, and limiting visitors may feel excessive, but prevention can spare a child the additional suffering and treatment burden that a serious infection can bring. Follow the infection-control advice of your child's medical team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. If unexplained symptoms appear, keep asking questions and seek appropriate evaluation. After treatment or after stopping therapy, symptoms such as unexplained weakness in an arm or leg, facial weakness, or dizziness should prompt medical assessment. In addition to checking for hematologic relapse, neurological or vascular causes may also need to be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. A basic understanding of the disease can help families participate more confidently in decisions. You do not need to become a medical expert, but it helps to understand the basic disease subtype, commonly used treatments, and major assessment milestones. That background can make conversations with the medical team clearer and help you ask the questions that matter for your child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">5. When you have the capacity, share what you have learned. Patient communities have a remarkable way of coming full circle. A piece of information or encouragement you offer another family today may one day return in a form you never expected. Helping one another can make a difficult road a little easier.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There is still a long road ahead. As long as my child can run and laugh, and we can still eat meals and take walks together, I don't consider us defeated. For the days ahead, we will simply live well. One step forward is one step won.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":102,"title":103,"summary":104,"cover":105,"disease":106,"treatment":67,"patientType":68,"publishedAt":107,"contentHtml":108,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"burkitt-lymphoma-car-t-survivor-story","After His Lymphoma Mass Grew Beyond 10 cm, He Chose CAR-T. Now He Is Back to Fishing, Hiking, and Watching His Children Grow","After being diagnosed with Burkitt lymphoma and facing major treatment challenges, Mr. Wei received CAR-T therapy and achieved remission. Today, he is back to everyday family life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F4e78708923e7a3ab4eab2881ad11c7b8.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Burkitt Lymphoma","2026-07-24","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: At the end of 2023, Mr. Wei was diagnosed with Burkitt lymphoma after developing a lump beneath his jaw. His treatment journey included a revised pathology diagnosis, chemotherapy resistance, and a severe infection, while the disease at one point progressed rapidly. After evaluation by Dr. Yajing Zhang and her team at Beijing GoBroad Boren Hospital, he received CAR-T cell therapy followed by a second CAR-T treatment targeting a different antigen, and ultimately achieved complete remission (CR). Now, two years after treatment, Mr. Wei has returned to daily life and is once again able to spend time with his family and watch his children grow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the 3rd CAR-T Cell Immunotherapy Survivorship Conference, we met many people who had made their way back to everyday life after difficult illnesses. Mr. Wei was one of them. At the event, he shared his experience of facing lymphoma in the hope that his story might help other patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the end of 2023, Mr. Wei, the main breadwinner in his family, was diagnosed with Burkitt lymphoma. His wife was two months pregnant at the time, and the diagnosis placed enormous pressure on the whole family. Today, two years after CAR-T therapy, he has returned to a normal routine - fishing and hiking with friends, spending time with his family, and watching his two children grow. Looking back, he says, "It really feels like I've been given a second chance at life."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fcd5628fe3dc92ee0ddb8b07f4aa11b69_20260913170327.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"cd5628fe3dc92ee0ddb8b07f4aa11b69_20260913170327.png\" alt=\"f4bbced0-d1c7-4f7a-8d49-34e53f0efcbe.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>A Small Lump Led to a Lymphoma Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It started with a small lump beneath his jaw. At first, everyone assumed it was an enlarged lymph node. He took medication and watched it for a while, but instead of going away, the lump kept getting bigger. In December 2023, his doctor recommended surgical removal and a pathology examination. The result confirmed lymphoma. "I was terrified," Mr. Wei recalls. His wife was two months pregnant when he received the diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"I can barely remember how I drove home that day, or what I said to my wife on the way." For many families, a diagnosis of lymphoma brings an overwhelming mix of fear and uncertainty. For Mr. Wei, this was only the beginning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>From Diffuse Large B-Cell Lymphoma to Burkitt Lymphoma: Getting the Diagnosis Right\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After diagnosis, Mr. Wei began treatment. Initially, he was treated for diffuse large B-cell lymphoma (DLBCL), and the tumor shrank for a time. But only one week after discharge, the mass began growing rapidly again. On the advice of another patient, he went to a larger hospital for an expert pathology review. This time, the diagnosis was confirmed as Burkitt lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With the diagnosis clarified, he restarted chemotherapy. Then another major problem emerged: he developed severe pneumonia and treatment had to be interrupted. For a long period, he needed supplemental oxygen and was too weak to get out of bed. "The treatment had started to work, but the infection delayed everything that was supposed to come next."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The disease did not wait. The tumor continued to grow rapidly, while his overall condition became weaker and weaker.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Tumor Over 10 cm and Chemotherapy Resistance: He Decides to Go to Beijing for CAR-T\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Wei had heard about CAR-T soon after he was first diagnosed, but at the time it seemed far removed from his own situation. As he learned more about Burkitt lymphoma, he came to understand how aggressive the disease can be, and that once treatment stops working or resistance develops, the number of remaining options can narrow quickly. By then, he no longer felt he had time to keep waiting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"I didn't want to keep switching from one chemotherapy regimen to another just to see what might work. At that point, I was very clear in my mind - I wanted to pursue CAR-T." Through another patient, he learned about Dr. Yajing Zhang and her team at Beijing GoBroad Boren Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as his pneumonia improved, he traveled to Beijing. He was admitted on the day he arrived, and preparations for the next stage of treatment began the following day.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Twenty-Eight Days Later, He Achieved Complete Remission\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After admission, the medical team carried out a comprehensive assessment. Mr. Wei had a high tumor burden, and his recent history of severe infection and interrupted treatment made the situation particularly challenging. Taking into account the biology of Burkitt lymphoma and his previous treatment course, the team developed a comprehensive treatment strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After cell collection, Mr. Wei successfully received his first CAR-T infusion. During treatment, the tumor in his neck temporarily became much more swollen as part of the treatment response. Seeing the mass enlarge again made him understandably anxious. "During chemotherapy, whenever it got bigger, it was always bad news, so I was really nervous." The medical team closely monitored the changes and explained the types of treatment-related reactions that could occur. Over the next several days, the mass began to shrink. A tumor that had grown to more than 10 cm decreased markedly within just over ten days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A subsequent PET-CT showed complete remission (CR). On the team's recommendation, Mr. Wei returned two months later for a sequential second CAR-T treatment targeting a different antigen to further consolidate the response. Looking back on his treatment in Beijing, he says the doctors spent a great deal of time discussing his condition, the next steps, and the overall treatment plan with him. "That made me feel much more reassured. As a patient, I understood what might happen and what we could do to prevent or manage it."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Getting Back to Ordinary Life Is the Greatest Happiness\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It has now been two years since Mr. Wei received CAR-T therapy. Although his stamina has not yet fully returned to what it was before he became ill, he has resumed a normal daily life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In his spare time, he goes fishing and hiking with friends, spends time with his family, and watches his children grow little by little. Asked what matters most to him now, he smiles and says, "I'm already very content. It feels like I've been given another life."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F1187d02a7c28fb8487dd6f43cff55bb0_20260913170411.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1187d02a7c28fb8487dd6f43cff55bb0_20260913170411.png\" alt=\"b5aab977-68ad-453c-88ea-a69339e3437a.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Mr. Wei with his two children (photo provided by Mr. Wei)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Mr. Wei Would Like to Share with Other Patients and Families\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. When lymphoma is diagnosed, consider expert pathology review. Accurate classification is essential to choosing the right treatment.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Pathology subtype directly affects treatment decisions and outcomes. Talk openly with your doctors, and when appropriate, seek an additional pathology opinion. Experiences shared by well-informed patients can also help families know what questions to ask.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. If treatment is not working, do not simply wait.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the disease changes or the response is not what you and your doctors hoped for, discuss the next step proactively. Acting in time may open up more treatment opportunities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Learn about new research and emerging treatment options for your disease.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I learned a great deal from talking with other patients. In hematologic cancers, and lymphoma in particular, new drugs and treatment approaches are developing quickly. Understanding the available options can help you and your medical team think ahead if the situation changes later.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Keep going, even when treatment becomes difficult.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If you encounter drug resistance, tumor growth, or a serious infection during treatment, do not give up on yourself. Follow your medical team's guidance, keep treating the problems in front of you, and hold on to the belief that you can make it through. For many patients, mindset can also be an important source of strength during a difficult treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Behind every recovery story is a difficult road. More people with lymphoma, like Mr. Wei, are gaining opportunities for long-term survival and a return to everyday life through appropriate, standardized treatment. We hope every patient still in treatment can make it through the challenges ahead, one step at a time, and eventually receive the good news they have been waiting for.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":110,"title":111,"summary":112,"cover":113,"disease":114,"treatment":67,"patientType":82,"publishedAt":115,"contentHtml":116,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"b-all-car-t-recovery","After Two CAR-T Infusions, She Is Finally Ready to Put on Her Backpack and Start School","After relapse, central nervous system involvement, and sequential CD19\u002FCD22 CAR-T therapy, she completed all planned treatment and is ready for a new chapter in life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fd727fe2e6147a170f603ade38602b969.webp?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","B-cell Acute Lymphoblastic Leukemia","2026-07-19","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Jiajia was 6 years old when she was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in 2022. Despite prolonged chemotherapy, she later developed bone marrow relapse with central nervous system involvement. In 2024, her family brought her to the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital, where Dr. Jing Pan and her team developed a sequential CD19\u002FCD22 CAR-T treatment strategy, followed by consolidation and maintenance therapy. Her leukemia has remained in remission. In July 2026, Jiajia completed all planned treatment and officially stopped therapy. Her story follows a child with relapsed, difficult-to-treat B-ALL from CAR-T treatment back to school, and highlights the importance of standardized treatment, continued follow-up, and multidisciplinary care in complex hematologic cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On July 7, 2026, in the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital, 6-year-old Jiajia underwent her final bone marrow aspiration and lumbar puncture assessment. The results showed that her leukemia remained in remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That day, she officially completed treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than four years had passed since Jiajia first became ill in May 2022. At last, this long course of treatment had reached an important milestone. It had also been exactly two years since her first CAR-T infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But for Jiajia and her family, the journey was never as simple as receiving a single CAR-T infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>From Diagnosis to Relapse: Falling Back, Then Finding the Strength to Keep Going\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On May 7, 2022, Jiajia became unusually listless and developed fever and retching. Her family took her to a local hospital, where a bone marrow MICM assessment led to a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For this young child, it was the beginning of a long and difficult course of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After induction chemotherapy, measurable residual disease (MRD) remained positive. She went through multiple additional rounds of chemotherapy, but the MRD did not turn negative. Her family faced one cycle of hope and disappointment after another. It was only after nearly a year of chemotherapy that MRD finally became negative, giving the family a brief sense of relief after such a long wait.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The relief did not last. In March 2024, follow-up testing showed bone marrow MRD relapse, while cerebrospinal fluid testing was also positive, indicating central nervous system involvement by leukemia. Urgent chemotherapy was given at the local hospital, but this time the disease did not go into remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The news was devastating for Jiajia's family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Watching such a young child endure repeated punctures, infusions, and treatment side effects was heartbreaking. Still, her family held on to hope, waiting for the next treatment to bring a turning point.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Turning Point: From the Darkest Moment to a Clinic Visit That Changed the Course\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When treatment had reached an impasse, Jiajia's parents refused to give up. They read extensively, sought advice wherever they could, and eventually turned to Dr. Jing Pan in the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2024, Jiajia's parents brought her to see Dr. Pan for the first time. Dr. Pan carefully reviewed her previous medical records - including the fact that it had taken nearly a year of chemotherapy for MRD to turn negative, and that chemotherapy after relapse had failed to achieve remission - and assessed her current condition. After detailed discussions with the family, the team developed a sequential CD19\u002FCD22 CAR-T strategy tailored to Jiajia's disease characteristics and treatment history.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Cell Therapy Is Not a Single Procedure - It Is an Entire Treatment Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T therapy is sometimes understood as simply receiving a one-time cell infusion. In clinical practice, however, the infusion is only one part of a much longer process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It begins with a comprehensive assessment. The medical team evaluates the patient's current condition, disease status, progression, and previous treatments to determine whether CAR-T is an appropriate option. From there, the treatment plan is developed and adjusted over time, followed by key steps such as cell preparation and infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After infusion, patients may experience fever, inflammatory reactions such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and challenges related to immune recovery. Ongoing follow-up is then needed to monitor treatment response and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These stages are closely connected and rarely stand alone. From a patient's perspective, CAR-T is better understood as a treatment journey that unfolds over time, rather than a single procedure. The outcome depends not only on what happens on infusion day, but on the care delivered before and after it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So what is a patient really choosing in this process? Once the full treatment pathway is laid out, the answer becomes clearer: it is not only a particular technology, but the broader clinical capabilities needed to carry that treatment safely and consistently from one stage to the next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Those capabilities include systematic risk assessment and stratification, reliable execution of the treatment pathway at each stage, experience in managing complex complications, and the ability to adjust the pace and direction of care through multidisciplinary collaboration.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These strengths may not be obvious at any single point, but they run through the entire treatment process. For complex diseases such as hematologic cancers, the choice is therefore not simply about selecting a technology. It is also about choosing a clinical team that can deliver that technology consistently and take responsibility for the full course of care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Is a Patient Really Choosing in This Process?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once the full treatment pathway is laid out, the answer becomes clearer: the patient is choosing not only a particular technology, but the broader clinical capabilities needed to support treatment from beginning to end. These include systematic risk assessment and stratification, reliable execution at each stage, experience in managing complex complications, and the ability to continually adjust treatment through multidisciplinary collaboration. These strengths may not be obvious at a single point, but they run through the entire process. For complex diseases such as hematologic cancers, the choice is therefore not simply about a technology. It is also about choosing a clinical team that can deliver it consistently and take responsibility for the full course of care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Sequential Dual-Target Therapy: Two CAR-T Infusions, One Integrated Strategy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After Jiajia transferred to Beijing GoBroad Hospital, her treatment pathway was re-evaluated and redesigned.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On June 20, 2024, she received a CD19 CAR-T cell infusion. Fourteen days later, bone marrow and cerebrospinal fluid assessments showed complete remission. As planned, the team then proceeded with CD22 CAR-T therapy to consolidate the response and reduce the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This sequential CD19\u002FCD22 CAR-T strategy is an area of expertise for Dr. Pan's team. It uses two separate infusions targeting two different antigens, with the aim of reducing relapse associated with antigen loss or downregulation after single-target therapy. The approach requires careful timing of the CD22 CAR-T infusion while keeping patient safety at the forefront, so that there is as little opportunity as possible for immune escape of the target antigen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After sequential CAR-T therapy, Jiajia's leukemia remained in sustained remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment did not end there. Jiajia subsequently received monthly decitabine as consolidation therapy. Based on her previous treatment and individual condition, the team also developed a maintenance chemotherapy plan for her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>July 7, 2026: Two Years After CAR-T, Treatment Officially Ends\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On July 7, 2026, Jiajia completed all planned treatment. Bone marrow aspiration and lumbar puncture assessments showed that her leukemia remained in remission. It had been exactly two years since her first CAR-T infusion, and four years and two months since she first became ill.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Over those four-plus years, Jiajia went through repeated punctures, rounds of chemotherapy, and cycles of hope and disappointment. Her family also changed along the way - from feeling lost and overwhelmed, to searching everywhere for answers, and finally finding a team they felt they could trust. What they chose was not simply CAR-T technology, but a clinical team and care system capable of delivering it consistently and supporting the entire treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F6b26df8c134972cea2111b3580c191f1_20260912211204.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6b26df8c134972cea2111b3580c191f1_20260912211204.png\" alt=\"269ef5a3-fb3e-4d1b-ac98-2af2e35bece9.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Later this year, Jiajia will start school. Like any other 6-year-old, she will put on her backpack, walk into a classroom, and begin a new chapter of childhood.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The days of punctures, infusions, chemotherapy, and CAR-T can now begin to recede into the past, marked by July 7, 2026 - the day she officially completed treatment, two years after CAR-T. On the Department of Hemato-Oncology & Immunotherapy's CAR-T "Cure Summit" display at Beijing GoBroad Hospital, Jiajia placed her photo at the two-year milestone. The climb begins from the day of infusion: two years marks an important stage of victory, while five years is the milestone they call being truly "free of leukemia." Her family and doctors believe that one day, her photo will make it all the way to the summit.\u003C\u002Fspan>\u003C\u002Fp>","2026-09-12",{"slug":119,"title":120,"summary":121,"cover":122,"disease":123,"treatment":90,"patientType":68,"publishedAt":124,"contentHtml":125,"expertView":126,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"nkt-cell-lymphoma-allogeneic-transplant-survivor-story","Diagnosed with NK\u002FT-Cell Lymphoma in His Sophomore Year; Three and a Half Years After Transplant, He Has Graduated, Found Love, and Embraced Life Again","Diagnosed with extranodal NK\u002FT-cell lymphoma during his sophomore year, Xiao Hao endured multiple treatment challenges before undergoing an allogeneic hematopoietic stem cell transplant. Three and a half years later, he has returned to campus and begun a new chapter of life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fd60da009eb56aa6f0d6bdac0f958c794.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Extranodal NK\u002FT-Cell Lymphoma","2026-07-17","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Xiao Hao (pseudonym) was diagnosed with high-risk stage IVB extranodal NK\u002FT-cell lymphoma during his sophomore year after experiencing recurrent fevers and persistent nasal symptoms. His treatment journey was complicated by pneumonia and hemophagocytic lymphohistiocytosis (HLH), and he traveled across China in search of further treatment. In late 2022, he underwent an allogeneic hematopoietic stem cell transplant from an unrelated donor at Beijing GoBroad Boren Hospital, and his condition gradually stabilized. Now, three and a half years after transplant, Xiao Hao has not only completed his university degree but also found love and returned to the everyday life of a young adult. Looking back, he hopes his experience can remind other patients that as long as they keep going, life can still open up new possibilities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It is graduation season again. Across campuses, young graduates pose for photos, hug their friends goodbye, and look ahead to whatever comes next. For 24-year-old university student Xiao Hao (pseudonym), however, this summer arrived two years later than expected.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In December 2021, while still a sophomore, Xiao Hao was diagnosed with high-risk stage IVB extranodal NK\u002FT-cell lymphoma. During treatment, he also developed pneumonia and an episode of hemophagocytic lymphohistiocytosis (HLH). From Yunnan to Beijing, he moved between several hospitals and underwent chemotherapy, radiotherapy, immunotherapy, and targeted treatment. In late 2022, he received an allogeneic hematopoietic stem cell transplant from a 10\u002F10 HLA-matched unrelated donor at Beijing GoBroad Boren Hospital. Now, three and a half years after transplant, his follow-up results remain normal. In the summer of 2026, he stood on campus in his graduation gown, with warm sunshine overhead, his partner of more than three years beside him, and a future full of possibilities ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F839e5f6a34f9957f02fd0dd74b870519_20260913080711.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"839e5f6a34f9957f02fd0dd74b870519_20260913080711.png\" alt=\"85ab0572-7b0b-4cba-9ad7-57cae6a96485.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>An Overlooked Warning Sign: From “Rhinitis” to Advanced Lymphoma\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In December 2021, I was a sophomore studying in Tianjin. My nose had been blocked for a while, and I assumed it was the same old rhinitis I had dealt with before. I thought I could just wait it out. But then I started losing weight, and a large ulcer developed on the roof of my mouth and throat. Medication did nothing. My throat hurt so badly that I could barely swallow, I woke up at night with my clothes soaked in sweat, and eventually I developed a persistent high fever.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It was during a period of strict campus restrictions, so I stayed in my dorm for four or five days, alternating cold medicine and fever reducers. Nothing worked. When I finally couldn't take it anymore and decided I needed to go to the hospital, I called my family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because I had a fever, I was isolated in a quiet hospital room. Almost the entire floor was empty, and someone brought me two simple meals each day. At first I still thought it was just a bad cold. I even bought some fruit, thinking a few extra vitamins might help me recover faster. Then I had a laryngoscopy and nasal endoscopy. The doctors contacted my university, and the university contacted my parents. They traveled overnight from Yunnan to Tianjin. I was still confused at the time and thought everyone was making too much of it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fa34411f99323c7dc74d5d9fe4542ad4c_20260913080734.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"a34411f99323c7dc74d5d9fe4542ad4c_20260913080734.png\" alt=\"60a77fa4-83df-4305-a442-2d6bfd01da2e.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The hospital then arranged a biopsy. A week later, the results came back. My parents didn't tell me anything; they simply completed the discharge paperwork and took me back to Kunming. I still didn't know exactly what I had. It wasn't until I was being treated at a hospital in Kunming and happened to see the word “tumor” that I suddenly understood.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“Lymphoma.” When I finally learned the truth, I didn't fall apart. I felt down for a little while, but I've always handled pressure fairly well. And after my first round of chemotherapy, my throat stopped hurting and I could swallow again. Part of me even thought, “Maybe I'm getting better.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first time I truly felt how close death could be, it came quietly. Medical resources in Kunming were limited and beds were tight. After one round of chemotherapy, I developed pneumonia. Because I was already very weak, it quickly triggered hemophagocytic lymphohistiocytosis. The illness progressed fast. The doctors told us I needed to get to Beijing immediately and warned that if we delayed, I might have only a month left.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Heading North as the Disease Worsened: Hitting Rock Bottom\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as the plane landed, my fever came back. I was taken to an observation room in the fever clinic. I still remember that night clearly—the sound of patients moaning around me went on hour after hour without stopping.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was admitted the next day, but not long afterward I had a seizure and fell into a coma for a week. By the time I woke up, Chinese New Year was approaching. My mom later told me that while I was unconscious, the doctors had told my family to prepare for the worst. I'm their only child, and hearing that nearly broke her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I woke up, I was overwhelmed by a kind of weakness I had never experienced before. Once the HLH was under control, we decided to transfer again because the hospital I was in did not specialize in lymphoma. By then I was so weak that I could only get around in a wheelchair, and emotionally I had hit rock bottom.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the next hospital, the doctor was very straightforward: if the disease could not be controlled, I might have only about three months to live.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I walked out of the consultation room, I broke down completely for the first time. I told my parents I didn't want any more treatment. I didn't want to put them through more, and I didn't want them spending so much money on me. My dad said just one thing: “Whatever happens, we keep trying. We do everything we can.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That night, I called my closest friend back home and talked as if I were saying goodbye. I told him that if one day I really wasn't there anymore, I wanted him to help look after my parents. That was the darkest point of my entire treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fortunately, I met two attending physicians who took my case extremely seriously. They went back through all of my medical records and developed a new plan. I first received two cycles of the GPED regimen. When a follow-up PET\u002FCT showed that the lymphoma was still progressing, they switched me to a DEP-L regimen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My parents and I rented an apartment near the hospital. Those days felt like a blur, but one thing was always clear to me: wherever my parents were, that was home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Three months passed, and I was still here. My numbers didn't improve overnight, but little by little, the disease began to stabilize.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The next step was preparing for transplant, which meant going to another hospital for radiotherapy. We moved again. Slowly, I began to come out of the mindset of “I don't want treatment anymore.” I followed the treatment plan each day and went for radiotherapy every evening without fail.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, I barely noticed anything. Then one day, everything I ate felt like chewing paper—I had lost my sense of taste. Soon after, the lining of my mouth and nasal passages became badly damaged, and the tissue on the roof of my mouth ulcerated. Even taking a sip of water felt like swallowing a knife. I couldn't eat at all and had to rely on intravenous nutrition. The treatment came at a very real cost.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Thankfully, a follow-up PET\u002FCT showed that the disease had gone into remission. My doctors adjusted the plan again and treated me with the targeted and immunotherapy combination of brentuximab vedotin plus tislelizumab.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After everything I had already been through, transplant was finally the next step. But then I hit another wall: because my case was so complex and the risks were so high, finding a transplant center willing to take me on was difficult. Some centers had never successfully transplanted a patient with a case like mine. It felt as though the hardship would never end, and the hope I had worked so hard to rebuild was crushed all over again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So when Boren finally confirmed that they could take my case, my first reaction wasn't excitement. It was relief: finally, someone was willing to take me through the next step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>The Transplant Unit, a New Beginning, and a Bowl of Salty Pumpkin Porridge\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I arrived at Beijing GoBroad Boren Hospital, the transplant team led by Dr. Tong Wu carried out another comprehensive evaluation. The night before my PET\u002FCT results were due, two pieces of necrotic tissue from the ulcerated area on the roof of my mouth came away on their own. I told my dad that maybe it was a good sign—the damaged tissue had fallen away so something new could grow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The next day, the results came back: the disease was in remission. Looking at that report, for the first time in a long while, I felt as if I could finally see the end of this road.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After entering the transplant unit, I received BU\u002FFLU conditioning. On October 11, 2022, I received stem cells from an unrelated donor who was a 10\u002F10 HLA match. My blood type was B positive and the donor's was O positive. Neutrophil engraftment occurred on day +17 and platelet engraftment on day +15.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px; text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F09d50a5ccee2a89b640abdfbbb10db24_20260913080834.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"09d50a5ccee2a89b640abdfbbb10db24_20260913080834.png\" alt=\"c52d99f5-303f-45fb-8518-1ab5f044ad5e.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At one point in the transplant unit, I had abdominal pain so severe that it felt as if something inside me was twisting hard. The doctors and nurses responded immediately, gave me medication, and brought it under control quickly. My mom later told me, “If you hadn't had this transplant at Boren, you might not even have made it out of the transplant unit. And even if you had, you probably wouldn't be doing as well as you are now.” I knew what she meant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After I left the transplant unit, we rented an apartment near the hospital and stayed for another six months so I could return regularly for follow-up. One day, my mom made pumpkin porridge for me. She knew my sodium was low, so she added a little salt, hoping it might help. I took one spoonful—and it tasted salty. Suddenly every emotion I had been holding in came rushing out: hurt, exhaustion, anxiety. I had a huge argument with my mom and, like a child, finally let out everything I had kept bottled up for so long.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2023, my follow-up results were stable. With my doctors' approval, my parents took me back home to Yunnan to continue recovering.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F41d4b09dd5a7d7430537a99c663149b3_20260913080933.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"41d4b09dd5a7d7430537a99c663149b3_20260913080933.png\" alt=\"1ad8cad0-1354-4c24-93aa-bdf5003cd83d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px; text-align: justify;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Telling Her How I Felt Beneath the Tianjin Eye—and a Graduation Photo Two Years Late\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">While I was recovering, I also found love. My girlfriend and I had known each other since freshman year, and we stayed in touch after I became ill. Once, when she was feeling down and wanted to go to the seaside, I happened to be in Beijing for a follow-up appointment, so I went to Tianjin to see her. We talked for a long time, and beneath the Tianjin Eye, I finally told her how I felt.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Day by day, my health improved. But after transplant, I still had to be extremely careful about food hygiene, and I couldn't eat food prepared outside. So on our early dates, she would eat while I sat beside her and talked with her. Then I would go home and eat whatever my mom had cooked. It was simple, but it made me feel safe and happy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We've now been together for three years, and this year I finally graduated from university. My classmates are looking for jobs and making plans for the future, and I'm thinking about those things too—but differently than I did before I got sick. Back then, I wanted to achieve something huge. Now what I want is much simpler: to live well, build a steady life, stay close to my parents, and take care of the people I love. That sense of stability means more to me than anything.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">People tell me I'm lucky, but I think my greatest blessing is having my mom and dad. In a novel I love, the main character tells his parents, “In my next life, I still want to be your son.” Every time I think of that line, it hits me deeply. It's not about feeling that I owe them something. I just know that being alive, healthy, and living my life well is the greatest reassurance I can give them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Never Give Up on Life—Believe in the Power of Believing\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am still deeply grateful to the specialists and medical team at Boren. They are the reason I can live the life I have today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In patient support groups, when someone asks a question, I often share what I went through, especially when it comes to transplantation. I recommend Boren because, from my own experience, I believe its transplant program is highly experienced—and I am living proof of what that care made possible for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The last thing I want to say to patients going through something similar is this: never give up on life. We are not fighting only for ourselves. There are people supporting us, and even if it is only a handful of people, they are reason enough to keep going. Believe in the power of believing. You have to believe something is possible before you can have a chance to reach it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It has now been three and a half years since my transplant, and all of my follow-up results are normal. Looking back, being healthy, being alive, and moving forward one day at a time—that is probably the best answer I can give.\u003C\u002Fspan>\u003C\u002Fp>","Case Commentary (Dr. Zhanxiang Liu, from the team led by Dr. Tong Wu and Dr. Yanzhi Song): \n\nMalignant tumors are often described as ruthless because when serious illness strikes, it does not take a person's age, plans, or circumstances into account. This case involves extranodal NK\u002FT-cell lymphoma, an aggressive disease for which ideal chemotherapy options remain limited. Patients diagnosed at an earlier stage may have a better chance of achieving favorable outcomes with radiotherapy. Unfortunately, Xiao Hao was already at stage IV, the most advanced stage, when he was first diagnosed. His treatment course was equally difficult. At the most critical point, the lymphoma progressed together with an episode of HLH, placing his life at immediate risk. Fortunately, radiotherapy and salvage chemotherapy brought the lymphoma into remission. He was also able to find a suitably matched unrelated donor and, just as importantly, undergo allogeneic hematopoietic stem cell transplantation within the narrow therapeutic window. The transplant was successful: he developed neither severe graft-versus-host disease (GVHD) nor lymphoma relapse afterward.\n\nThe fundamental purpose of medicine is to treat disease and save lives. Hematopoietic stem cell transplantation is a highly complex procedure, but it plays an irreplaceable role in the treatment of hematologic malignancies. Xiao Hao's outcome was not simply a matter of luck; it reflects the efforts of the transplant team at Beijing GoBroad Boren Hospital. It also embodies the team's goal: to treat difficult disease, restore health, and help patients return to their families and society.",{"slug":128,"title":129,"summary":130,"cover":131,"disease":132,"treatment":90,"patientType":68,"publishedAt":124,"contentHtml":133,"expertView":134,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"severe-aplastic-anemia-hsct-five-year","The Light I Received from Strangers - Now I Want to Pass It On","After being diagnosed with severe aplastic anemia, he nearly gave up on treatment. The determination of his family, encouragement from fellow patients, and support from his medical team helped him choose hematopoietic stem cell transplantation - and five years later, he is back in the classroom he loves.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F3c7048040c007b159173eb122a5e9ee9.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Severe Aplastic Anemia","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Mr. Liu (pseudonym) was diagnosed with severe aplastic anemia (SAA) after abnormalities were found on a routine blood test. As supportive treatment became less effective and he needed transfusions more and more frequently, he lost confidence and at one point considered giving up treatment altogether. His family refused to give up, and the transplant experiences shared by several patients he had never met helped restore his hope. In 2021, he underwent allogeneic hematopoietic stem cell transplantation at GoBroad Shanghai Zhaxin Hospital. Although his recovery was complicated by viral infections, intestinal infection, and chronic graft-versus-host disease (cGVHD), his condition gradually stabilized with treatment and long-term follow-up from Dr. Su Li, Dr. Huixia Liu, and their teams. About a year after transplant, he returned to teaching. Now, five years later, he remains relapse-free and has no ongoing GVHD. He hopes to pass on the kindness that once helped him, encouraging other patients with blood disorders to keep moving forward through treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fac0cae86eee59f881ff011e85f4f79b5_20260912224824.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ac0cae86eee59f881ff011e85f4f79b5_20260912224824.png\" alt=\"10761a13-dd9c-48ff-a4e5-1cf25465401f.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Liu (pseudonym) had spent decades as a teacher and had always considered himself healthy. He rarely got sick, so he never imagined that a routine blood test before a physical therapy session would lead to an urgent referral to hematology - and a diagnosis of severe aplastic anemia (SAA). At first, he chose supportive treatment. But the disease progressed far more quickly than expected: the interval between transfusions shortened from about ten days, to one week, and eventually to just three days. Frequent trips between home and the hospital became part of his life. The teacher who had once stood confidently in front of a classroom soon found even basic daily activities exhausting.\u003Cbr\u002F>\u003Cbr\u002F>Just as he was losing hope, Mr. Liu met several fellow patients he had never known before. One was the father of a child who had had leukemia. Hearing that the child had returned to normal life five years after transplant gave Mr. Liu his first real sense of hope. Another younger patient told him that he had spent more than 20 relatively stable days in the transplant unit, easing Mr. Liu's fear of the procedure. An older man in the same ward also supported him with his optimism and encouragement. Mr. Liu often says, “I've been lucky. Somehow, I always meet kind people when things are at their hardest.” The light and hope these people offered at different points in his treatment helped him find direction again - and the courage to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2021, with the full support of his family, Mr. Liu underwent an allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital. His underlying disease went into complete remission. About a year later, he returned to school and stepped back into the classroom he had missed so much.\u003Cbr\u002F>\u003Cbr\u002F>To mark five years since his transplant, Mr. Liu returned for a comprehensive follow-up evaluation, bringing his son with him so they could thank the medical teams at GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital in person. He also has a message for other people living with blood disorders: seek treatment while your body is still strong enough, make decisions promptly with an experienced medical team, and do not let delay close off treatment options. He once drew strength from the kindness of strangers. Now he hopes to pass that kindness on - and become a source of light for someone else.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F39484e6ef5233329af978c13b470d0c8_20260912224841.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"39484e6ef5233329af978c13b470d0c8_20260912224841.png\" alt=\"6cf8126c-d82d-4819-a380-d4518cfbb343.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">June 2026: Mr. Liu with Dr. Su Li\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: What symptoms did you have at first, and how were you eventually diagnosed with SAA?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: In September 2020, I went to a county hospital for physical therapy. As part of the routine process, they did a complete blood count first. I felt perfectly fine after the blood draw and even went out for lunch as usual. But when I returned to the hospital that afternoon, the doctor looked very serious. He told me to sit down, avoid moving around, and arranged for me to be transferred urgently to the hematology department at the local central hospital. After a series of detailed tests, I was diagnosed with severe aplastic anemia (SAA).\u003Cbr\u002F>\u003Cbr\u002F>I had a hard time accepting it at first. I had always been healthy and rarely got sick, and I knew almost nothing about blood disorders, so part of me kept hoping it could not be that serious. But the disease progressed quickly. While I was receiving supportive treatment locally, a transfusion initially lasted me about ten days. Then the interval shortened to a week, and eventually to only three days. My platelet count kept falling, my gums bled frequently, and I felt extremely weak. Everyday life became difficult, and I had to travel to the hospital several times a week for treatment.\u003Cbr\u002F>\u003Cbr\u002F>There were also a lot of discouraging conversations in the ward. Some patients felt that treatment would only prolong things while draining the family's finances. Hearing that repeatedly affected me. I became lost and hopeless. I had two children still in school, and at one point I thought it might be better to sell our property and leave the money for their education rather than spend all of our savings on treatment when I did not know what the outcome would be. I was ready to give up.\u003Cbr\u002F>\u003Cbr\u002F>But my family never wavered. They stayed by my side, encouraged me, and refused to give up on even the smallest chance. Their support helped me rebuild my confidence step by step and gave me the strength to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: What was the turning point that helped you and your family decide to proceed with hematopoietic stem cell transplantation?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: My family's refusal to give up helped me pull myself together and start actively looking into treatment options. Around that time, I met a fellow patient who had a huge influence on me. His son had been diagnosed with leukemia while still in primary school, and he told me how devastated he had felt at the time. But his son was already five years out from a hematopoietic stem cell transplant and had returned to a normal life. He told me that medicine had advanced tremendously, and that because supportive treatment was no longer doing much for me, transplant might offer a better chance of getting back to work and everyday life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hearing that from someone who had lived through it with his own family gave me enormous encouragement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There was another younger patient who had already undergone an allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital while I was still hesitating. He called me specifically to reassure me: “Uncle, I spent more than 20 days in the transplant unit and I was doing pretty well. It really wasn't as frightening as I had imagined.” Hearing that eased a lot of my fear.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After many conversations, my family and I agreed that transplant was the path we wanted to take, and we came to GoBroad Shanghai Zhaxin Hospital with a mixture of hope and anxiety. I was still weighed down when I first arrived and did not talk much. An older gentleman in my room noticed how worried I looked and started talking with me. He had lymphoma and had also come here because of Prof. Chun Wang's expertise in hematopoietic stem cell transplantation. He was full of confidence and always spoke positively about treatment. During that difficult period, we encouraged each other and helped one another through some of the most uncertain days.\u003Cbr\u002F>\u003Cbr\u002F>Before the transplant, my attending physician, Dr. Su Li, also gave me clear and reassuring answers. He explained that allogeneic hematopoietic stem cell transplantation is an established treatment option for severe aplastic anemia and may offer the possibility of long-term disease-free survival and a return to normal work and life. I had also worried that donating stem cells might harm my son. Dr. Li explained the process and donor safety clearly, which finally put that concern to rest.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: What stands out most when you look back on the transplant itself?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: In June 2021, I underwent a hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital, with my younger son as the donor. His HLA match was more suitable for me, and we also happened to have the same blood type. Both of my sons cared for me in their own ways throughout treatment. In those difficult days, they were not only the people I worried about most, but also a major source of strength.\u003Cbr\u002F>\u003Cbr\u002F>The transplant itself was not as frightening as I had imagined. My vital signs were generally stable in the transplant unit, and the side effects were relatively manageable. Dr. Huixia Liu, who oversaw my transplant care, often encouraged and reassured me. With careful support from the doctors and nurses, I made it through more than 20 days in the transplant unit fairly smoothly.\u003Cbr\u002F>\u003Cbr\u002F>The setback came after I left the unit. I had planned to rent a place near the hospital to recover, but severe diarrhea forced me to return. Tests showed Clostridioides difficile-associated colitis. Dr. Liu treated me using an integrative approach combining conventional medicine and traditional Chinese medicine. The symptoms gradually came under control, and my strength slowly returned.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Apart from that intestinal complication, my overall recovery after transplant went relatively well. The doctors' expertise was essential, but so was the care my wife gave me every day. For the first six months after transplant, I barely left home, and almost all of the responsibility for my daily care fell on her. We had to be extremely careful about food, hygiene, and infection prevention. During the worst period of diarrhea, even basic cleaning required meticulous care, and my wife stayed beside me through it all without complaint.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I became ill, I was a teacher and loved my work. The diagnosis forced me to step away from the classroom for a while. About a year after transplant, I returned to school and gradually resumed teaching. Looking back, treatment for a serious blood disorder is never a short journey. From the first diagnosis, to seeking care in different places, to eventually traveling to Shanghai, my wife was beside me every step of the way. I remember clearly that before I got sick, she did not have a single gray hair. Over these years, many have appeared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: How has this illness changed you? Has it changed the way you think about life, family, and happiness?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Before I got sick, I had many expectations for my children and many plans for our family's future. I wanted everything to move in a particular direction. After going through this illness, I have learned to let go of a lot of those expectations. What matters most is simply having the whole family together, safe and healthy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My hopes for my sons are much simpler now. I just want them to find work that allows them to support themselves, build stable families of their own, and meet partners who are kind, responsible, and share their values. That is enough for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Since leaving the transplant unit, I have continued regular follow-up at GoBroad Shanghai Liquan Hospital. I came back specifically for my five-year evaluation, but also because I wanted to thank Dr. Su Li and his team in person. After all the tests are finished, my son and I plan to spend a little time exploring Shanghai and relaxing. For years, every trip here was for treatment. We were always rushing and never had the heart to look around. This time, I can finally walk around the city with a lighter heart before heading home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q5: What would you most like to say to other people going through treatment for blood disorders, and to their families?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I want to share something from my own experience. When you are looking for treatment, choosing a specialized hospital and an experienced medical team can make a real difference. Seek appropriate treatment while your physical condition still allows it, rather than waiting until your health has deteriorated so much that options become more limited. For me, the lesson was simple: get treated early, proceed to transplant when it is the right option, and give yourself the best chance to recover sooner.\u003Cbr\u002F>\u003Cbr\u002F>Delays can mean more complications and a weaker body by the time treatment begins. Rather than waiting until you feel you have no options left, act early and seek help from a qualified, experienced team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F99da1b107e79b75f852dce5d8dd2c8e6_20260912224909.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"99da1b107e79b75f852dce5d8dd2c8e6_20260912224909.png\" alt=\"2cf301af-7635-4217-bad7-c408919737c2.png\"\u002F>\u003C\u002Fp>","Dr. Su Li (Associate Chief Physician, MD; Director, Department of Hematology, GoBroad Shanghai Liquan Hospital; Director, Myeloma Center):\n\nHematopoietic stem cell transplantation is an important treatment option for achieving durable remission in severe aplastic anemia (SAA). Mr. Liu achieved good disease control after transplantation, although his post-transplant course included several complications.\n\nDuring the early post-transplant period (months 1-2), he developed cytomegalovirus (CMV) infection and Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Both were brought under control with antiviral and related treatment. During months 3-6, he experienced recurrent Clostridioides difficile-associated colitis together with chronic cutaneous graft-versus-host disease (cGVHD). These complications improved with timely intervention. As his immune function gradually recovered, his overall condition continued to improve, and all immunosuppressive medications were discontinued approximately 2.5 years after transplant.\n\nMr. Liu has now been followed for five years. He remains relapse-free and free of ongoing GVHD, and has returned to normal work and everyday life.",{"slug":136,"title":137,"summary":138,"cover":139,"disease":140,"treatment":67,"patientType":82,"publishedAt":141,"contentHtml":142,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"childhood-all-car-t-survivor-story"," Once Fighting for Her Life with Leukemia, She Is Now Five Years Post-CAR-T—and Beloved by Her Classmates","After being diagnosed with acute lymphoblastic leukemia and later experiencing relapse, Qiqi received CAR-T therapy and has remained in remission. Today, she is back at school and beginning a new chapter of growing up.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1f4e9cbeb19b90b6f2a2ca1aa9aad857.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Acute Lymphoblastic Leukemia","2026-07-16","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In 2021, Qiqi, still only a young child, was diagnosed with acute lymphoblastic leukemia after developing persistent high fever. Her treatment journey included severe infections, hemophagocytic syndrome, and disease relapse. After the family traveled to Beijing, Dr. Jing Pan and her team reviewed Qiqi's previous treatment history and the features of her relapse, and developed a sequential CD19\u002FCD22 CAR-T treatment strategy. With comprehensive care throughout the process, Qiqi gradually recovered. Now, five years after CAR-T therapy, she is back at school and even dreams of becoming a doctor so she can help others one day.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2021, young Qiqi was diagnosed with acute lymphoblastic leukemia after developing a persistent high fever.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Five years later, she is now a third-grade elementary school student, learning and playing with her classmates and making plans for her future. It is hard to imagine that this lively, cheerful girl once went through leukemia relapse and major turning points in treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the 3rd CAR-T Cell Therapy Survivorship Conference, Qiqi's mother shared what it was like to accompany her daughter through leukemia treatment. From the shock of diagnosis, to repeated challenges during treatment, and finally the return to school, Qiqi's family never stopped looking for the next treatment opportunity. Step by step, they helped her find her way back to the childhood she deserved.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fb0dc3caf356181cc4b2de17e9b727c5e_20260913165840.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"b0dc3caf356181cc4b2de17e9b727c5e_20260913165840.png\" alt=\"779d8671-1a84-4e8b-b645-e8504664b6d3.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Qiqi and her mother\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>One High Fever Changed an Entire Family\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In October 2021, Qiqi suddenly developed a persistent high fever. At first, her mother thought it was just a common cold. The test results, however, caught the entire family off guard: acute lymphoblastic leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"We'd had a relative with leukemia before, but I never imagined it would one day happen to my own child."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On the day of diagnosis, the doctor reassured the family while explaining the current outlook for childhood leukemia: "Children often have meaningful treatment opportunities. Don't let the diagnosis frighten you before treatment has even begun."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From that day on, Qiqi and her family began a long treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Early Treatment Brings a Life-Threatening Infection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Qiqi started chemotherapy soon after diagnosis, but the early phase of treatment was anything but smooth. During her second course, she developed a severe infection and had to be transferred urgently to the ICU. She later faced a pulmonary infection, hemophagocytic syndrome, and other critical complications, making the entire treatment course extraordinarily difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"At the time, we truly didn't know whether we would ever see her wake up again." People around the family began gently preparing them for the worst. But the doctors and other patient families kept encouraging them: "Hold on a little longer."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Qiqi's mother remembers the medical team talking with them again and again, asking them not to give up too soon. After more than 30 days of treatment, Qiqi's condition finally began to stabilize. But when she left the ICU, her mother was heartbroken by how much the illness had taken from her. Qiqi's weight had fallen from more than 15 kilograms to under 10 kilograms. She could not stand and no longer recognized her parents. "It was as if she had become a baby all over again." Her mother stayed beside her every day, talking to her and playing recordings of her own voice from when she was younger.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than 20 days later, Qiqi slowly regained awareness. "She couldn't say 'Mom,' but she kept looking at me. I knew she recognized me."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>When Leukemia Relapsed, the Family Headed to Beijing\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Around six months after completing treatment, Qiqi faced another major setback: the leukemia relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For a child who had already survived a critical infection and had not yet fully regained her strength, relapse made the next stage of treatment even more difficult. To make matters worse, this was during the pandemic, but Qiqi's disease could not wait. "She had already relapsed. We simply didn't have time to sit around and think." With help from other patient families and healthcare professionals, Qiqi's family began looking for another treatment option. They learned about Dr. Jing Pan's team and decided to take Qiqi to Beijing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Travel between provinces was tightly restricted at the time, making the trip far from easy. Qiqi's family completed her discharge paperwork overnight and set off for Beijing. They stayed in close contact with the receiving hospital along the way. "As long as someone in Beijing was willing to take her, we could get there." With active coordination from the hospital, Qiqi was ultimately able to reach Dr. Pan's team and begin treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>CAR-T Offers New Hope After Relapse\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as Qiqi arrived, the medical team assessed her condition and began planning the next stage of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"I remember it so clearly. The doctors and nurses kept reassuring us, saying, 'Now that she's here, let us take care of her.'" Qiqi's mother recalls that her daughter was in a fragile condition at the time: the leukemia had relapsed, infection remained a concern, and her body was still very weak.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Taking into account the pattern of relapse, Qiqi's previous treatment, and her current condition, Dr. Jing Pan's team developed a strategy centered on sequential CD19 and CD22 CAR-T therapy. The goal was to target and clear leukemia cells while creating the best possible opportunity for durable disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Throughout treatment, the medical team managed Qiqi's complex condition as a whole. They worked to control her pulmonary infection and improve her physical condition so she could proceed with therapy, while also closely monitoring treatment response and the risk of complications and addressing problems promptly when they arose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This time, Qiqi did not need to return to the ICU because of infection and was able to complete treatment successfully.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Five Years Later, She Is Back at School\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Throughout Qiqi's treatment, her parents put nearly all of their work aside so they could stay with her. Her mother even fractured her tailbone while caring for Qiqi, but still remained at the hospital. "Moms aren't superheroes. We just feel like we can't afford to fall down."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, five years after CAR-T therapy, Qiqi has returned to school. She studies and lives much like other children her age, and she already has a dream of her own. "I want to become a doctor and invent a needle that doesn't have to pierce the skin, so other children won't have to hurt the way I did." Her experience has also helped her understand how much her mother went through: "Mom worked so hard taking care of me. I hope she gets better and better too." From once needing help herself to now hoping she can help others in the future, Qiqi is finding her own meaning in what she has lived through.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Qiqi's Mother Wants to Share with Other Families\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Understand Your Child's Condition and Keep Communicating with the Medical Team\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A child's condition can change throughout treatment, so parents need to actively understand their child's current health status, treatment goals, and what comes next. "Don't only wait for the doctor to tell you the result. Learn to ask questions and understand what your child is going through and what may come next." Having enough information at key decision points can help families make choices that better fit their child's situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Find a Medical Team You Can Truly Trust\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treating a hematologic disease is about much more than choosing a single regimen. Infection prevention, complication management, and long-term follow-up can all affect recovery. For a child facing a complex illness, finding an experienced, responsible medical team that can manage the full treatment journey is critically important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Connect with Other Patient Families and Learn from Their Experiences\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient and family support groups can be valuable sources of new information and different perspectives. Sometimes, simply talking with people who understand what you are going through can also make the days of treatment feel a little less difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Stay Committed to Treatment and Keep Believing in Your Child's Recovery\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When disease relapses or treatment becomes difficult, a parent's emotional state can affect the child as well. Stay committed to treatment, stay present for your child, and focus on what can be done today. That is how families can accompany children, one step at a time, toward a better future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From the hospital ward back to the classroom, Qiqi's five-year journey shows that going through something difficult does not mean losing the future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Every child still in treatment deserves to have a future to look forward to. We hope every family can find a treatment direction that fits their child and move forward with confidence and hope, waiting together for brighter days ahead.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":144,"title":145,"summary":146,"cover":147,"disease":132,"treatment":148,"patientType":82,"publishedAt":149,"contentHtml":150,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"severe-aplastic-anemia-ist-treatment-student-recovery","A 100-Day Comeback: An 18-Year-Old with Severe Aplastic Anemia Returns to School and Takes the Gaokao","After being diagnosed with severe aplastic anemia during her final year of high school, she received IST, became transfusion-independent within 16 days, achieved a complete hematologic response at three months, and returned to school in time to take the Gaokao.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F0dcaef58b64a4bb3af6ec01a49f56e4c.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Immunosuppressive Therapy (IST)","2026-07-10","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Xiaoyu (pseudonym) was in her final year of high school, preparing for China's national college entrance examination, when persistent dizziness, fatigue, recurrent infections, and unexplained bleeding spots led to a diagnosis of severe aplastic anemia. Faced with a choice between transplant and non-transplant treatment, the medical team considered her age, disease characteristics, and family circumstances and developed an immunosuppressive therapy (IST) plan using antithymocyte globulin (ATG), cyclosporine, and a thrombopoietin receptor agonist (TPO-RA). Just 16 days after treatment began, she no longer needed blood-product transfusions. Three months later, she achieved a complete hematologic response, returned to school, and went on to complete the Gaokao.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In the autumn of 2025, a worried mother hurried into the outpatient corridor of the Anemia Diagnosis and Treatment Center at Beijing GoBroad Boren Hospital. Walking behind her was a thin teenage girl. As a high school senior, she should have been focused on classes and university entrance exams, yet even standing was difficult; after only a few steps, she had to stop and rest.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By then, mother and daughter had already been to one hospital after another looking for answers...\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The story began just as her final year of high school was getting underway.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Instead of throwing herself into exam preparation, Xiaoyu began experiencing frequent dizziness and lightheadedness. Climbing stairs caused uncomfortable palpitations. She developed recurrent mouth ulcers, repeated respiratory infections, progressive weight loss, and clusters of unexplained pinpoint bleeding spots on her skin. Alarmed, her mother took her from their local hospital to a major tertiary hospital in Beijing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The blood test showed marked reductions across all three blood cell lines: white blood cells 2.98 x 10^9\u002FL, neutrophils 0.63 x 10^9\u002FL, hemoglobin 67 g\u002FL, and platelets only 20 x 10^9\u002FL. A bone marrow examination ruled out malignancy. The outside hospital initially considered infection-related pancytopenia and treated her with anti-infective therapy and androgen therapy to support blood-cell production.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fc5ae8f27758a952da0ab080c5f7cbfb4_20260913162348.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c5ae8f27758a952da0ab080c5f7cbfb4_20260913162348.png\" alt=\"15ecee3e-abdb-429a-885a-93c35dbf7b50.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">The patient's first complete blood count at a tertiary hospital in Beijing\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A month passed, but her symptoms did not improve. Instead, her condition continued to worsen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The downward arrows on each new blood count were frightening for her mother: white blood cells 2.39 x 10^9\u002FL, neutrophils 0.41 x 10^9\u002FL, hemoglobin 63 g\u002FL, and platelets 24 x 10^9\u002FL. A local hospital gave her a red blood cell transfusion, which helped stabilize her temporarily, but everyone knew transfusions alone were not a long-term solution.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In October 2025, mother and daughter came to the Anemia Diagnosis and Treatment Center at Beijing GoBroad Boren Hospital. Xiaoyu was so weak that she could barely sit down without her mother's support. Her face showed exhaustion, helplessness, and uncertainty about the future. Her mother had only a few questions in mind: What exactly was wrong with her daughter? Could it be treated? Would she be able to go back to school?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We arranged admission immediately and quickly completed a comprehensive bone marrow and hematologic evaluation. The diagnosis was clear: severe aplastic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Severe aplastic anemia is a serious bone marrow failure disorder. It can progress quickly, and without timely and effective treatment, patients may face life-threatening infection or bleeding. For a student like Xiaoyu, it could also put any return to school far out of reach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because she was so young, we evaluated her particularly carefully and first ruled out inherited bone marrow failure. Genetic testing found no evidence of a congenital cause. Under standard treatment principles, for patients under 40 with severe aplastic anemia who have an HLA-matched sibling donor, allogeneic hematopoietic stem cell transplantation is generally the preferred first-line option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But the family was facing several very real concerns:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">HLA typing had not yet been completed for her younger siblings. Her parents were deeply worried about transplant-related risks. The possibility of impaired fertility weighed heavily on the family, and treatment costs were another major concern. On top of all this, Xiaoyu was in the most critical year of high school, preparing for the Gaokao.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Every concern carried weight, and every decision felt difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After repeated discussions and careful consideration, Xiaoyu's mother made a difficult but firm decision to proceed with intensive immunosuppressive therapy (IST). The regimen combined ATG, cyclosporine, and a TPO receptor agonist - a contemporary three-drug non-transplant strategy for severe aplastic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment began.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaoyu handled the treatment remarkably well and experienced few significant side effects. Even more encouraging, just 16 days after starting therapy, she became independent of blood-product transfusions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In the hospital, the once-exhausted teenager picked up her textbooks again. She memorized vocabulary between infusions and worked through practice questions whenever she had a quiet moment. The nurses cheered her on: "Keep going - the exam room and your future are waiting for you."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After discharge, she continued oral medications to support hematopoietic recovery and returned for weekly monitoring of her blood counts, liver function, and kidney function. Her mother stayed in close contact with the medical team through WeChat, and each change in her blood counts or medication plan was managed through close communication between the family and clinicians.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Three months later, spring brought the news everyone had been hoping for.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the three-month IST evaluation, Xiaoyu had achieved a complete hematologic response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Her white blood cell count was 4.29 x 10^9\u002FL, neutrophils 3.29 x 10^9\u002FL, hemoglobin 116 g\u002FL, and platelets 206 x 10^9\u002FL. Her bone marrow function had recovered rapidly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5b8fd71ed1d86bb03289151354df7e75_20260913164158.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5b8fd71ed1d86bb03289151354df7e75_20260913164158.png\" alt=\"be7e94c3-0615-4d66-a8bc-7e3f58ac4aad.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Complete blood count at the three-month follow-up after intensive IST\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The girl who had once struggled even to stand was back on her feet. She returned to school and to the goal she had been working toward. Her final-year coursework was demanding, and she had months of material to catch up on, but she kept taking her medication while working steadily through the missed lessons. Few of the students around her knew that only months earlier, she had been hospitalized with a life-threatening bone marrow failure disorder.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then came the day of the Gaokao.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">She walked calmly into the examination room, just like millions of other students who had spent years working toward this moment, and began writing the next chapter of her future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The wait for the results felt long. Then the good news finally arrived.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Her score was well above the undergraduate admission cutoff in her province.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Feeb59f0ff63486419c06a384840c95d8_20260913164245.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"eeb59f0ff63486419c06a384840c95d8_20260913164245.png\" alt=\"53de9f40-6808-4765-8c1d-1c9726356439.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Ff2cfe4db309e9f9c8d4e52f925a90ad2_20260913164310.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"f2cfe4db309e9f9c8d4e52f925a90ad2_20260913164310.png\" alt=\"4ff475ca-1683-400b-9f79-f357275434b4.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">The patient's exam results (only the total score is shown to protect privacy)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The whole family cried with joy. Her mother immediately sent us a screenshot of the result, her messages filled with excitement and gratitude.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We still remember something Xiaoyu once told us in the ward: "I want to study education and become a teacher someday."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now that dream is within reach. She is preparing to enter the university she hoped for and move closer to the classroom she has imagined herself standing in so many times.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What makes us proudest is not the number on the score report. It is that while recovering from a serious illness and racing against time, she still made it through one of the most demanding years in a Chinese student's education.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, what is a doctor's role?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Often, it is simply to do everything possible to keep a patient's unfinished dreams within reach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From diagnosis and treatment decisions, to becoming transfusion-independent in 16 days and reaching a complete hematologic response in three months, from memorizing vocabulary in the hospital to answering questions in the Gaokao examination room - this was more than a medical success. It was a story of determination and courage shared by one young woman, her family, and the people caring for her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaoyu is now preparing for a new chapter. We still have one more goal together: to help her gradually reduce and eventually come off medication when medically appropriate, so she can move into adulthood healthy and free to pursue the life she wants.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This summer, we wish her a safe and joyful journey ahead, with many more possibilities waiting to unfold.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fcdfa0d6afd6a86703c0ad0b19c2876a1_20260913164334.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"cdfa0d6afd6a86703c0ad0b19c2876a1_20260913164334.png\" alt=\"461a617f-f461-4712-8cb2-ff6fff62c979.png\"\u002F>\u003Cspan style=\"font-size: 15px; text-align: center; color: rgb(136, 136, 136);\">The patient presented a banner of thanks to the medical team upon discharge\u003C\u002Fspan>\u003C\u002Fp>",{"slug":152,"title":153,"summary":154,"cover":155,"disease":132,"treatment":90,"patientType":68,"publishedAt":156,"contentHtml":157,"expertView":158,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"severe-aplastic-anemia-gvhd-recovery","Six Years After Transplant, She Never Let Chronic GVHD Hold Her Back","Diagnosed with severe aplastic anemia at 19, she underwent a stem cell transplant and then faced years of chronic GVHD. With long-term medical follow-up and her own persistence, she returned to university, graduated, and began a new chapter in life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fa0a33bedc4d03a0c7a1bc4b1a692e21d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-07-09","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: At 19, Xiaoling (pseudonym) underwent a related-donor haploidentical hematopoietic stem cell transplant for severe aplastic anemia and achieved remission. But chronic graft-versus-host disease (GVHD) after transplant affected multiple systems, including her lungs, skin, and joints, leading to a long and difficult recovery. With ongoing follow-up and care from Dr. Chuxian ZHAO's team at GoBroad Shanghai Zhaxin Hospital, she stayed on treatment, attended regular checkups, committed to rehabilitation, and also received supportive care combining conventional medicine and traditional Chinese medicine. Her chronic GVHD symptoms gradually improved. In 2021, she returned to university and successfully completed her studies. Now, nearly six years after transplant, she has started a job she wanted and is gradually returning to everyday life. Her experience traces the full journey from transplantation and chronic GVHD management to long-term recovery, offering encouragement to others navigating life after transplant: consistent treatment, rehabilitation, and a positive approach to life can open the door to a new beginning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003C\u002Fp>\u003Cp style=\";\">\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fcc0d0f98333d9c50f16e9646adf40063_20260912224323.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"cc0d0f98333d9c50f16e9646adf40063_20260912224323.png\" alt=\"0ce2f4fe-3cca-4b39-99fb-ff5de08e69a0.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 19, life should have been just beginning, full of possibilities. But in the year Xiaoling (pseudonym) entered university, everything changed: she was diagnosed with severe aplastic anemia, and her college life was abruptly put on hold. Yet there was still a path forward. In July 2020, she underwent a related-donor haploidentical hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital, giving her the chance to begin again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The road after transplant, however, was far from easy. Chronic graft-versus-host disease (GVHD) followed, bringing both physical and emotional challenges. Lung involvement left her short of breath with even light activity. Stiffness in the muscles and joints of her hands made simple everyday movements difficult. Changes caused by skin GVHD made it hard for her, for a time, even to recognize herself in the mirror. With professional care and steady support from the team at GoBroad Shanghai Zhaxin Hospital, Xiaoling kept going. She returned for regular follow-ups, adjusted her medications as instructed, and worked through rehabilitation under medical guidance, gradually regaining function step by step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In September 2021, she returned to university and went on to graduate with excellent results. Chronic GVHD remained a long-term challenge, but she refused to let it stop her. With determination beyond her years, she kept working through each setback and slowly found her rhythm in life again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There were still emotional ups and downs during treatment and recovery, and her body continued to adjust. But today, her chronic GVHD symptoms have improved substantially. She has also continued supportive care with Dr. Huixia LIU through a hematology clinic integrating traditional Chinese medicine, with the goal of supporting her longer-term recovery. Late last year, she also landed a job she had hoped for.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In her sixth year after transplant, the hospital prepared a special "graduation ceremony" for her. That day, Xiaoling received the first bouquet of flowers she had ever been given. Smiling, she said, "I can't believe this is the first bouquet I've ever received." Looking back, she does not avoid the what-ifs. "If I had never gotten sick, maybe my life would have been easier." Then she paused and added firmly, "But I don't think the version of me who never got sick would necessarily be stronger than the person standing here today."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In that moment, she had moved beyond more than illness - she had also grown beyond the person she once was. She chose to share her story not to dwell on hardship, but to offer a little light and courage to others still making their way through recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Patient Conversation\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: When did you first realize that something might be wrong with your health?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: When I started university, I moved alone to a city I didn't know. I wasn't used to the new environment or the pace of life. At first, I noticed purpura and a few small bleeding spots on my skin, but I didn't think much of them and assumed it was just a skin issue. Gradually, though, I became more and more tired. Climbing the stairs to my dorm would leave me completely out of breath.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One weekend, I stayed with my aunt in Shanghai. On Sunday morning, I got out of bed and suddenly everything went dark in front of me. My heart was racing, and I felt so weak that I could barely stand. My family rushed me to a nearby hospital. After a series of tests, I was diagnosed with severe aplastic anemia in October 2019.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I first heard the diagnosis, I couldn't accept it at all. But I was already so physically weak that I hardly had time to process the sadness or fear. I just had to focus on the treatment in front of me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: Hematopoietic stem cell transplantation is a major decision. How did you and your family decide to go ahead with it?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: My parents were extremely worried and took me from place to place looking for treatment. At first, I chose non-transplant treatment, but I remained very weak. We had heard that allogeneic hematopoietic stem cell transplantation could be an effective treatment for aplastic anemia, but the risks of transplant and the uncertainty around GVHD made us hesitant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During that time, I met another patient around my age who had exactly the same type of disease. I chose non-transplant treatment, while he decided to go ahead with a transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Two or three years later, I was still dealing with blood counts that kept fluctuating, while he had recovered and returned to normal life. That had a huge impact on me. I realized that transplant wasn't necessarily as frightening as I had imagined. What scared me more was the possibility of hesitating for too long and missing the best treatment window.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My non-transplant treatment also wasn't working very well. My blood counts stayed low and my quality of life was poor. In the end, my family and I made up our minds to proceed with transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July 2020, I successfully underwent a related-donor haploidentical hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: You dealt with chronic GVHD for a long time after transplant. What was that period like for you, and how did you get through it?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: A successful transplant was only the first step. The GVHD afterward was the real test.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first problem was pulmonary GVHD. For a while, even walking a few steps left me badly short of breath. Climbing stairs felt almost impossible. For someone who had once been energetic and active, that change was very hard to accept.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then came stiffness in the muscles and joints of my hands. At its worst, I could barely make a fist, and even simple everyday tasks took a lot of effort.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I also developed skin GVHD. My skin became rough and uneven in color, and sometimes when I looked in the mirror, I barely recognized myself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There were times when I felt completely overwhelmed. I kept asking myself, "Why me? Why do I still have to go through all of this after the disease itself has been treated?"\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But every time I returned to the hospital for follow-up, the doctors and nurses encouraged me. They told me that recovery could take time, and that if I stayed with the treatment and rehabilitation, things could gradually improve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With my family beside me, I began rehabilitation with the simplest movements and built up little by little. Progress was slow, but every small improvement gave me a little more courage to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: You mentioned receiving ongoing care from Dr. Huixia LIU through a hematology clinic integrating traditional Chinese medicine. How did that support your recovery?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Recovery after transplant is a long process. Conventional medicine was very important for controlling GVHD, while I felt that traditional Chinese medicine also helped support my overall recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huixia LIU developed an individualized supportive care plan based on how I was doing. It included approaches such as Chinese herbal medicine and acupuncture, aimed at supporting my energy and overall physical condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After staying with the plan for a while, I could feel my condition gradually improving. I had more energy, I was sleeping better, and even the symptoms affecting my skin became much less noticeable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For me, conventional medicine and traditional Chinese medicine were not an either-or choice; they could complement each other. During rehabilitation after transplant, this integrated approach helped make my recovery feel steadier.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fb23be6c1870d11cce775690a5a646dd3_20260912224407.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"b23be6c1870d11cce775690a5a646dd3_20260912224407.png\" alt=\"6883a848-c883-4bbc-a84b-254f9672f4b8.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo of Xiaoling taken in spring 2023\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: Returning to university, graduating, and finding a job have all been major milestones. Looking back, how do you think illness changed you?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Before I got sick, I was very driven. I wanted to do everything as well as possible and set very high standards for myself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After getting sick, I learned to accept that I don't have to be perfect. I used to think life had to follow a fixed path - university, graduation, a job, marriage - and that I couldn't fall behind at any step. Illness taught me that life isn't a race. Everyone has their own journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the years I was away from school, I watched my classmates graduate and start working. I definitely felt anxious and left behind at times. Eventually, I came to understand that everyone moves at their own pace, and I didn't need to measure my life against someone else's timeline.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I finally returned to university, I appreciated the experience far more than I had before. Things I once took for granted became precious once I had lost them and then gotten them back.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now that I'm working, I still take each day seriously, but I don't push myself as harshly as I used to. I allow myself to go a little slower, and I allow myself to have days when I don't feel my best. That's one of the most important things illness taught me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: You said, "The version of me who never got sick wouldn't necessarily be stronger than the person I am today." What does that mean to you?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: That's genuinely how I feel.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If I had never gotten sick, I probably would have finished university on schedule, found a job, and lived a fairly ordinary, steady life. Things might have gone more smoothly, but I might never have developed the resilience or perspective I have now.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Illness made me face life and death, the limits of my body, and a long recovery while I was still very young. Those experiences were painful, but they also helped me understand earlier than many people my age what really matters and what I can let go of.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now I value my health, my family, and every ordinary day much more. I also have a deeper sense of empathy. Because I know what it's like to be caught in the rain, I want to hold an umbrella for someone else.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That's why I say the version of me who never got sick wouldn't necessarily be stronger than the person I am today. It's not that I'm grateful for being ill. It's that the strength I had to build through illness is something an easy life could never have taught me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: left;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Xiaoling also asked us to include this personal message:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I especially want to thank Dr. Chuxian ZHAO. Over the six years since my transplant, whenever anything has gone wrong with my health, she has been the first person I turn to. She always responds promptly, helps me understand what's happening, and points me toward the next step in treatment. Whether I'm dealing with another flare of chronic GVHD, an ordinary viral infection, or even moments when I'm anxious and emotionally overwhelmed, she always knows how to steady me. She is professional, calm, and incredibly patient. She gives me an enormous sense of security.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another thing I really admire is Dr. Zhao's amazing memory. She knows my entire medical history and remembers the medications I've taken and so many details from every stage of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Zhao, you're my absolute hero. I love you!\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian ZHAO (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nAplastic anemia is a bone marrow failure disorder in which the marrow cannot produce adequate blood cells. Allogeneic hematopoietic stem cell transplantation is an effective treatment for aplastic anemia. Xiaoling underwent a haploidentical hematopoietic stem cell transplant and achieved complete remission.\n\nXiaoling is cheerful, resilient, and optimistic. She encountered many setbacks at different stages of treatment, but she consistently faced each challenge with a positive attitude and actively worked with the medical team. Her inner strength inspired everyone around her. At one point, we were very concerned that tendon contractures in her fingers caused by chronic GVHD might affect her studies and daily life. Rehabilitation required difficult stretching exercises, but Xiaoling kept at them and gradually regained function, little by little.\n\nXiaoling's recovery has deeply moved us as well. The resilience of life is often greater than we imagine. Medicine is essential in the face of disease, but a patient's hope and persistence are also powerful sources of strength throughout recovery. Illness may put life on pause, but it does not define an entire life. We hope Xiaoling receives many more flowers and rounds of applause in the years ahead, and embraces all the possibilities that belong to her.",{"slug":160,"title":161,"summary":162,"cover":163,"disease":164,"treatment":67,"patientType":82,"publishedAt":165,"contentHtml":166,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"primary-mediastinal-b-cell-lymphoma-car-t-survivor-story","Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at 15, He Finally Achieves CMR After Multiple Treatment Setbacks","After multiple lines of treatment and two rounds of CAR-T therapy, 15-year-old Xiao Chen finally achieved a complete metabolic response (CMR) after his treatment strategy was precisely reassessed and adjusted.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F41a2d3609eff452a9f58159483a7ae35.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Primary Mediastinal Large B-Cell Lymphoma","2026-07-06","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">Xiao Chen (pseudonym) was diagnosed with stage IV primary mediastinal large B-cell lymphoma (PMBCL) at age 15. He went through chemotherapy resistance, multiple courses of immunotherapy, and two rounds of CAR-T therapy, with the disease progressing more than once. Through repeated multidisciplinary review and ongoing refinement of his treatment plan, he ultimately received immunotherapy followed by dual-target CD19\u002FCD22 CAR-T cell therapy. On June 2, 2026, his PET\u002FCT showed a complete metabolic response (CMR) for the first time. His story captures not only a teenager’s difficult journey through cancer treatment, but also the importance of precise reassessment, timely treatment adjustments, and long-term management in relapsed or refractory lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cstrong style=\"font-size: 15px;\"> \u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>01\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hello, I’m Xiao Chen’s mother. My son is 16 now, 175 cm tall, and has always been a bright, outgoing boy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before he became ill, he had just started high school and was placed in an advanced class. He loved programming. He won first prize in a provincial robotics competition and a gold medal in the middle-school division of the VEX EDR Asia Championship.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before last October, I worked at a public-sector institution in Chengdu. We had a son and a daughter, and our life followed a steady routine. Then my son suddenly became ill, and I had to become the person holding the family together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiao Chen was diagnosed with stage IV primary mediastinal large B-cell lymphoma from the start. Over the next year and a half, we went to 16 hospitals. He underwent 9 biopsies, 16 courses of chemotherapy, 7 courses of immunotherapy, 2 rounds of CAR-T therapy, 10 bone marrow aspirations, and 15 lumbar punctures.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I learned to search medical literature using Haodf.com, DeepSeek, and Yuanbao. I got used to traveling with my son between hospitals in different cities, and we went through several moments when his life was in immediate danger.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It was not until he was treated by Dr. Kai Hu at Beijing GoBroad Hospital that we finally saw a major turning point. On June 2, 2026, his PET\u002FCT showed a complete metabolic response (CMR) for the first time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I cried many times along the way. This was the first time I cried because I was happy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F6c67a74e617c715eccf3d0557d012a06_20260913165525.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6c67a74e617c715eccf3d0557d012a06_20260913165525.png\" alt=\"dce49903-88c8-4a4d-bb0d-5f160cbd1146.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Xiao Chen recovering at home after achieving CMR\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>02\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In October 2024, Xiao Chen began having recurrent fevers of around 38°C, along with fatigue, night sweats, and weight loss.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When we went to the hospital, the doctor called me into the office alone. Imaging showed a large 13.6 × 9.1 cm mass in the anterior mediastinum, enlarged lymph nodes in both hilar regions, the supraclavicular fossae, the retroperitoneum, and the abdomen, as well as multiple lesions in the liver, spleen, and both kidneys. A needle biopsy of a left cervical lymph node then confirmed primary mediastinal large B-cell lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There was no time to process it. He was so young, and we knew treatment had to start as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He received his first treatment at a local hospital with DA-EPOCH-R, an intensive dose-adjusted regimen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After chemotherapy, Xiao Chen had black stools for about two weeks, but the regimen was not adjusted. Then one day, he suddenly vomited a large amount of blood and his blood pressure dropped. He was rushed to the ICU. Standing outside the ICU, my legs were shaking.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After he left the ICU, we transferred to the hematology department of another hospital. Because he had recently experienced major bleeding, the doctors did not want to use another intensive regimen and changed treatment to R-CHOP.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But at that hospital, every cycle of chemotherapy required a new admission appointment, and a bed was not guaranteed. For a critically ill patient, that made continuity of treatment difficult. His primary doctor also changed frequently, and I was extremely anxious.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To keep his treatment on schedule, we found a way to transfer him to another department within the same hospital. For cycles 3 and 4, he received an adult CR-CHOP regimen. After four cycles, PET\u002FCT showed disease progression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The specialists told us chemotherapy was no longer working and suggested that we explore commercial CAR-T therapy. At the same time, they acknowledged that their department had limited experience using CAR-T in adolescents. Hearing even the specialist say that, I stood in the corridor feeling as though we had reached a dead end.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>03\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I did not have time to fall apart. I urgently asked for advice in patient support groups, took Xiao Chen’s PET\u002FCT report, and flew to Beijing the next day. With help from a friend, I visited five hospitals in Beijing in a single day.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Every specialist recommended an adult treatment approach. But Xiao Chen was only 15.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">People in the patient groups strongly urged us to try a children’s hospital and pursue a pediatric approach. I went to a pediatric specialty hospital and met with the head of its lymphoma program. The answer was clear: they could not take him. His condition was too severe and too complex, and it had moved beyond the usual scope of pediatric lymphoma treatment. We were told that by the fourth cycle of chemotherapy, the best treatment window had already been missed. Adult programs had limited experience with younger patients, while the pediatric hospital felt his disease was already too advanced. Both paths seemed closed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On the third day, I decided to go to Guangzhou because I knew there were hospitals there with pediatric oncology departments.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>04\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The doctors at the hospital in Guangzhou took good care of Xiao Chen. But after every cycle of chemotherapy, he developed a severe infection. His immune system was extremely weak, and the crowded inpatient environment of a large public hospital, with so many patients around, was simply too much for him.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the seventh cycle, treatment had to be interrupted for two weeks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the eighth cycle, the assessment showed a partial response but also new lesions. The hospital organized a multidisciplinary consultation. The conclusion was clear: the lymphoma had become resistant to chemotherapy. The team suggested considering a bispecific antibody or CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the MDT meeting, a pathologist asked me, “Do you have any other children?” I froze.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It felt as though everyone else had given up. But I would not.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>05\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The tumor was still progressing. We could not stop.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A friend of a distant relative had received compassionate-use CAR-T therapy at a hematology hospital in Beijing. I went there looking for another chance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The Beijing specialists developed a plan to first reduce the tumor burden with blinatumomab.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During treatment, Xiao Chen suddenly developed generalized body stiffening at around 3 a.m. It lasted about a minute. I was the only person with him, and I was terrified.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The doctors said the medication could potentially be continued, but they had not encountered this kind of reaction before and could only proceed cautiously. We had already paid RMB 50,000–60,000 out of pocket for the blinatumomab. It could not be returned or transferred to another patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My family said we could try again. I said no. I could not gamble with my son’s life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>06\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After leaving that hospital, I went to two more hospitals in Guangzhou to look for a CAR-T option. At one cancer hospital, patients aged 15 and older who wanted commercial CAR-T therapy had to go through the hospital’s ethics review process. We did not have time to wait.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At another hospital, the treatment was not controlling the tumor well, and Xiao Chen developed side effects including a rash and hypoglycemia. His attending doctor told us directly that they had not seen a similar situation and could only try to manage it step by step. I could not let Xiao Chen keep feeling like a test case.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>07\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We returned to Beijing, where I found a leading pediatric lymphoma specialist. By then, Xiao Chen could no longer lie flat because he was short of breath. Even for an MRI, he had to be positioned on his side.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After a detailed assessment, the specialist developed a new plan. After several courses of treatment, the tumor was finally brought under control and began to shrink. For the first time, I saw hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He then received three sessions of radiotherapy, with a plan to infuse CD19 CAR-T cells afterward. But he developed a fever after radiotherapy. The CAR-T infusion was given a week later, but the cells did not expand well, and the disease progressed again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiao Chen did not know. He happily told me, “Mom, once I’m discharged, I’ll take online classes at home, and on weekends I want to go out with my classmates and just hang out and talk.” I could not hold it together. I hid in the bathroom and cried, then went outside and let the winter wind in Beijing dry my tears.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He was at an age when life should have been opening up, yet he had already been through so much.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He did not know that after so many rounds of chemotherapy, radiotherapy, and CAR-T therapy, the disease had progressed again. I could not imagine how hopeless he would have felt if he had known.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Three children with lymphoma in the room next door passed away one after another. I did not even have time to break down.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>08\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So I started searching for a way forward again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I went to other major general hospitals in Beijing to seek expert opinions, doing everything I could to get appointments with top national specialists, including academicians. Online, I read other patients’ experiences on Haodf.com and used DeepSeek and Yuanbao to search and analyze medical literature.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I gradually began to suspect that Xiao Chen’s disease might need to be treated specifically as primary mediastinal large B-cell lymphoma, and that adult and pediatric treatment strategies could be very different. I raised this with his specialist twice. She also consulted a pathologist, who felt the diagnosis was not primary mediastinal lymphoma and continued to favor a diffuse large B-cell lymphoma treatment approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To her credit, the specialist was very open to discussion and quickly organized a multidisciplinary consultation. During the meeting, I heard Dr. Kai Hu from Beijing GoBroad Hospital propose a new pola-based regimen. It was exactly in line with the direction I had found in the cases I had been reading.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Hu’s comments at the meeting stayed with me. He was not the kind of doctor who simply gave a conclusion. He explained the reasoning—why the previous direction might not have been right, and why a pola-based approach might be more suitable for Xiao Chen. His logic was very clear.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The hospital adopted Dr. Hu’s recommendation and gave two cycles of the new pola-based regimen. The tumor came under control and shrank.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It felt like sunlight finally breaking through a crack. But by then, Xiao Chen’s body was exhausted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After so much chemotherapy, he was in very poor physical condition. Drug side effects had accumulated, infections kept recurring, and for more than ten days he was unable to pass gas on his own.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I learned that Dr. Hu had managed more than 2,000 complex lymphoma cases and had extensive experience. I decided to transfer Xiao Chen to Beijing GoBroad Hospital to be treated by Dr. Hu.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>09\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Hu’s team developed a clear strategy: four cycles of immunotherapy followed by dual-target CD19\u002FCD22 CAR-T cell therapy. Each step was carefully paced. Xiao Chen did not develop severe cytokine release syndrome (CRS), there were no uncontrollable complications, and his infections were brought under control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Little by little, Xiao Chen began to recover. On June 2, 2026, a follow-up PET\u002FCT showed a complete metabolic response (CMR), and circulating tumor DNA (ctDNA) was negative.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, achieving CMR depended on making the right decisions at key points and continuing to refine the treatment strategy. Dr. Hu played a critical role in the timing and sequencing of therapy—knowing when immunotherapy was needed to reduce tumor burden, when it was time to move into CAR-T therapy, and when to select the treatment targets. Every step was based on ongoing reassessment of Xiao Chen’s condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The entire team also worked with strong coordination and execution. From physicians and nurses to the inpatient environment and infection control, every part of the care mattered. With a complex, difficult-to-treat lymphoma, you need more than one experienced specialist—you need an entire team that can work together under pressure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My son has changed a lot over the past year and a half.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before he became ill, he was cheerful and outgoing. He smiled a lot, loved basketball, and had many friends. Now he talks less and is often quiet. I understand. Anyone who has spent so long in a hospital bed and gone through so many rounds of chemotherapy, bone marrow aspirations, and lumbar punctures would have difficult days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But he finds his own way to make peace with what he has been through.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I told him, “What you’ve experienced is something most of your classmates may never face in their entire lives. It is a different kind of life experience. In the future, you might even consider studying integrative medicine or biomedical science. What you’ve lived through has already given you a very personal understanding of healthcare.” I wanted him to know that this year and a half had not simply been lost time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">His younger sister often sends me messages on her smartwatch: “Mom, how is my brother? When is he coming home?” Every time, all I could say was, “Soon.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now, finally, he can go home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If Xiao Chen continues to recover, I want to do something for other patients with blood diseases when we get home. So many people helped us along the way—strangers in patient support groups, doctors who replied to my messages late at night, relatives and friends who helped us contact hospitals. I want to pay that kindness forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Finally, I want to share a few words with patients and families who are still in the middle of treatment:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">First, hold on to hope. Refractory disease, relapse, infection, or blood counts hitting their lowest point—none of it is easy. As long as you do not give up, there may still be choices and possibilities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Second, find a medical team you trust and work closely with them. Trust can make a real difference in how treatment moves forward. At the same time, stay informed: look for relevant treatment experiences and published cases, and share useful information with your care team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Third, take infection prevention and supportive care seriously. When the immune system is weak, infection can be one of the greatest dangers. Every mask, every careful hand wash, and every clean, nutritious meal is part of the defense.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">And remember: you are not fighting alone. Family support gives strength, encouragement from other patients can be a light in the dark, and the medical team is there to protect and support you. Most importantly, be kind to yourself and take care of yourself too.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One more lesson I learned the hard way: make sure your family has adequate critical illness insurance. A relatively small premium can make a major difference when serious illness strikes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I wish every patient a smooth recovery.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":168,"title":169,"summary":170,"cover":171,"disease":80,"treatment":172,"patientType":82,"publishedAt":173,"contentHtml":174,"expertView":175,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"childhood-b-all-second-transplant-cart-survival-story","Diagnosed with Leukemia at Age 3, He Finds a New Beginning After a Second Transplant Following a 10-Year Journey","Diagnosed with B-cell acute lymphoblastic leukemia at age 3, Lele went through relapse, CAR-T therapy, and two stem cell transplants. Ten years after his leukemia journey began, he is gradually returning to everyday life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F7d827d40a5c7be3bd410d88b5f6c130b.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","CAR-T, Hematopoietic Stem Cell Transplantation","2026-06-30","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">In 2016, 3-year-old Lele (pseudonym) was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). After achieving remission with chemotherapy, he later relapsed and received CAR-T therapy followed by a first related haploidentical hematopoietic stem cell transplant. The leukemia nevertheless returned again in 2022. After Lele came to Beijing GoBroad Boren Hospital, the specialist team developed an individualized treatment pathway based on his disease characteristics: chemotherapy to reduce tumor burden, CD22 CAR-T therapy, total body irradiation (TBI), and an unrelated-donor allogeneic hematopoietic stem cell transplant. The strategy brought him back into complete remission. Now, more than three years after his second transplant, Lele continues to regain his strength. The little boy who endured years of treatment is growing into an upbeat, cheerful teenager.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lele was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) in 2016, when he was only 3 years old. After three years of chemotherapy, he was able to return to school, but the disease relapsed at the end of 2020. He subsequently received CAR-T therapy and a related haploidentical stem cell transplant, yet the leukemia returned again in September 2022. At one of the family's most difficult moments, they came to Beijing GoBroad Boren Hospital. The specialist team developed a combined strategy of chemotherapy, CAR-T therapy, total body irradiation, and a second transplant. In February 2023, Lele successfully received an unrelated-donor allogeneic hematopoietic stem cell transplant and again achieved complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than three years after the second transplant, the little boy who once faced one challenge after another has grown into a bright, cheerful teenager. Watching his son smile on stage, Lele's father quietly felt his eyes fill with tears.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fc00a344cd7b5ff98e7976190d6835587_20260913160501.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c00a344cd7b5ff98e7976190d6835587_20260913160501.png\" alt=\"b4184dfb-ff7e-4451-b7e9-b58a1e628212.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Lele Meets His Donor for the First Time\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>One Diagnosis Ended All the Joy of That Lunar New Year\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My family is originally from Anhui, and my wife and I later settled in Wuhan. Lele was born in 2013. He was a child who loved to smile and run around, and he brought us so much joy. During the 2016 Lunar New Year holiday, we went back to my wife's parents' home. Over those few days, I noticed that Lele looked pale and yellowish, had little appetite, and kept saying his legs hurt. At first, we thought he was simply tired from all the holiday activity. But his energy kept getting worse, so we quickly took him to a local children's hospital. When the blood test results came back, the pediatrician looked very concerned, strongly suspected a hematologic disorder, and told us to transfer him immediately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That same night, we traveled overnight to a major hospital in Wuhan. After a bone marrow aspiration, immunophenotyping, fusion-gene testing, and a series of other evaluations, Lele was diagnosed in March 2016 with B-cell acute lymphoblastic leukemia, with a positive TEL-AML1 fusion. His initial risk assessment placed him in the intermediate-risk group. He had not yet turned 3.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Chemotherapy, CAR-T, Transplant - Hope and Setbacks, Again and Again\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After diagnosis, Lele began treatment on the low-risk arm of the CCCG-ALL-2015 protocol. On day 33 of induction, bone marrow flow cytometry showed MRD negativity. We thought we had finally crossed the hardest hurdle. But less than two weeks later, the day-46 assessment showed residual MRD of 0.01%. His treatment was therefore adjusted to the intermediate-risk arm, and chemotherapy continued.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In May 2019, Lele finally completed treatment and stopped medication. He returned to school, made friends, and life slowly began to feel normal again. We almost believed the darkest part was behind us. Then, without warning, the disease returned. In December 2020, a routine bone marrow assessment showed relapse together with central nervous system leukemia. Lymphoblasts accounted for 2% of the bone marrow, with flow MRD at 1.5%. Even worse, MRI showed extramedullary leukemic infiltration. The news of relapse felt like being knocked all the way back to the beginning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the local hospital, Lele received re-induction chemotherapy and multiple lumbar punctures with intrathecal therapy until the cerebrospinal fluid became negative. In January 2021, he received CD19 CAR-T cell therapy, and his bone marrow again reached complete remission. But the doctors told us that this remission might not last and that he needed hematopoietic stem cell transplantation as soon as possible. In May 2021, Lele underwent a related haploidentical transplant, with me as his donor. After transplant, severe pulmonary infection and skin graft-versus-host disease (GVHD) followed one after another. His weight dropped from more than 50 kilograms to just over 30 kilograms, and he became painfully thin. Somehow, despite how young he was, he fought his way through. I thought that must surely be the last major test. But a little over a year later, at the end of September 2022, another bone marrow assessment showed relapse, and the extramedullary disease had returned as well. I sat on a bench in the hospital corridor with the report in my hands and could not speak for a long time. I had never felt so powerless.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5bd7eaf73cf3ffaeff2d634ad4b512ff_20260913160547.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5bd7eaf73cf3ffaeff2d634ad4b512ff_20260913160547.png\" alt=\"4f592df8-98b5-4b88-8a2f-81521ff0aebe.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>With Few Options Left, We Came to Beijing: CAR-T as a Bridge to a Second Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The local hospital recommended a second transplant, but by then we no longer knew what to think. Then several parents in a patient group pointed us toward another possibility: a number of children had undergone successful second transplants at Beijing GoBroad Boren Hospital. They told us that the Boren team had extensive experience with relapsed and refractory leukemia, highly individualized treatment planning, and post-transplant complication management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We decided to try. Through a video consultation, we gave Dr. Tong Wu from the Boren transplant team a detailed account of Lele's history: poor CD19 target expression, previous CAR-T treatment and transplant, and another relapse. Dr. Wu gave us a clear recommendation, and for the first time in a long while, we could see a small path forward. Once we decided to transfer, getting to Beijing became the next challenge because travel restrictions were still very strict at the time. We were fortunate to receive help from a parent volunteer known as 'Hao's dad' from the Xiaobai Chuntian patient community. In October 2022, Lele was discharged from the Wuhan hospital. We took a train north that same afternoon and, with Hao's dad helping us through the arrangements, completed admission procedures late that night. In the early hours of the morning, Lele was admitted to Ward 12 at Beijing GoBroad Boren Hospital under Dr. Shuangyou Liu's team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After admission, the Boren specialists carried out a comprehensive reassessment. The transplant team led by Dr. Tong Wu and Dr. Yongqiang Zhao repeatedly discussed the case with the immunotherapy team led by Dr. Shuangyou Liu and Dr. Ruifeng Hou. Taking into account Lele's poor CD19 target expression, his prior therapies, and the complexity of planning a second transplant, they developed an individualized strategy: chemotherapy to reduce disease burden, followed by CD22 CAR-T, then total body irradiation (TBI), and finally a second hematopoietic stem cell transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2022, Lele successfully received a CD22 CAR-T cell infusion. Follow-up assessment showed molecular remission in the bone marrow, with the residual TEL-AML1 fusion level falling to 0.020%. That created a more favorable window for the second transplant. What followed was a long, difficult wait for donor matching and the call to enter the transplant unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F49c308d944705b4586f2208bca61d07b_20260913160654.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"49c308d944705b4586f2208bca61d07b_20260913160654.png\" alt=\"5e733a72-5657-4d7c-b5e3-ff69a6e51114.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On January 29, 2023, the news finally came: Dr. Yongqiang Zhao told me that Lele could enter the transplant unit and begin preparing for transplant. The next day, Lele entered the unit and started TBI-based conditioning. Then an infection was detected. The myeloablative conditioning had already been completed, so the transplant could not simply be postponed. We were so worried that we barely slept that night. Fortunately, after antiviral treatment, the infection test turned negative the day before stem cell infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On February 9, Lele successfully received allogeneic hematopoietic stem cells from an unrelated donor - a life-giving gift from someone he had never met.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">His time in the transplant unit went more smoothly than we had expected. Lele had mild diarrhea but no severe infection or high fever. Platelet engraftment occurred on day 10 after infusion, and white blood cell engraftment on day 13.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F1bd06ab0b64f822a8ee156e14bd42f30_20260913160722.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1bd06ab0b64f822a8ee156e14bd42f30_20260913160722.png\" alt=\"5c50945f-a2a1-48f2-848d-c1be3466b1fd.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>GVHD, Viral Infection, and One Hurdle After Another\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We knew that leaving the transplant unit was only the first step. Controlling infection and preventing and treating graft-versus-host disease (GVHD) after transplant would bring their own challenges. Fortunately, the Boren transplant team had extensive experience, and each time a problem arose, they responded quickly and precisely.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first major complication was severe skin GVHD, with widespread peeling and redness across Lele's face and trunk. In late 2024, the GVHD worsened again, with extensive skin lesions. Dr. Tong Wu, Dr. Yongqiang Zhao, and their team promptly adjusted treatment, and the GVHD was brought under control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the same time, the cause of Lele's longstanding proteinuria was finally clarified. In April 2024, he was admitted again because of elevated urinary protein. The Boren team arranged a kidney biopsy and genetic testing, which confirmed X-linked Alport syndrome, an inherited kidney disorder passed through the maternal line. Once the diagnosis was clear, the transplant and nephrology teams developed a lifelong kidney-protection plan, with regular monitoring and carefully selected medication to preserve his kidney function as much as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The challenges did not end there. Beginning in May 2025, Lele developed recurrent high fevers. At our local hospital, three days of anti-infective treatment would bring the fever down, but after three days at home it would return. This cycle continued for nearly a month. In June, we returned to Boren. Rather than simply treating the fever symptomatically, Dr. Yongqiang Zhao's team carried out an extensive pathogen work-up and eventually identified the cause: reactivation of human herpesvirus 6 (HHV-6). After reviewing the available evidence, Dr. Zhao recommended trying a newer antiviral medication. It was not until November 2025 that the HHV-6 testing finally became negative, bringing the six-month infection episode to an end.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lele himself was much stronger than we had ever imagined. As he grew older, he sometimes spoke with the dry calm of a teenager who had already been through far too much. Half joking, he once said, 'Every day I get is a bonus.' Hearing a teenager say that after everything he had endured left us, as his parents, both heartbroken and incredibly proud.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F252763b0af009ba01573dffafd64ccbe_20260913160747.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"252763b0af009ba01573dffafd64ccbe_20260913160747.png\" alt=\"f1ae61cb-9b7d-4cd5-8b59-2c12f2a710e8.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px; text-align: justify;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>After a Ten-Year Leukemia Journey, the Rainbow Finally Appears\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One challenge followed another, and each time, the Boren team was there to catch us. People often ask me what left the deepest impression on us. For me, it was two things: expertise and compassion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From a medical perspective, the transplant team led by Dr. Tong Wu and Dr. Yongqiang Zhao designed Lele's entire pathway from CAR-T to a second transplant, making each decision carefully and decisively. With such a complex case, they never dismissed a concern. They repeatedly brought the case to full-department discussions and personally reviewed the critical details. The nursing team was equally dedicated - technically skilled, but also consistently warm and caring toward Lele.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Over the years of treatment, we had nearly exhausted our family's savings and at one point faced serious financial strain. After we came to Boren, the Patient Services team learned about our situation and helped us apply for financial assistance through an Angel Fund and a transplant support program. Ms. Qiao Li also came to the ward specifically to check on us, asking what we still needed and what difficulties we were facing. When it came time to search for an unrelated donor for Lele, the team went out of their way to help. I can say without hesitation that Boren played an essential role in helping Lele reach where he is today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By October 2024, Lele's condition had become more stable. After detailed discussions with the specialists, we were finally able to return to our home in Wuhan after a long time away.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lele has now lived with leukemia for more than ten years. After his second transplant, the GVHD has eased to a mild level and his overall condition has improved well. We are planning for him to return to school this September.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This time, Lele was invited to take part in the 'Rainbow Project,' where he finally met the donor he had been hoping to see for so long. On stage, Lele hugged him tightly and said through tears, 'Thank you for giving me a second life. I've been waiting for so long to meet you.' His donor gently patted him on the back and answered softly. I stood beside them with a thousand things I wanted to say, but in that moment, I could not find the words.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ten years of leukemia treatment took us from Wuhan to Beijing, from relapse after the first transplant to a second transplant at Boren that brought a new beginning. Our family lived through more dark moments than I can count. We are deeply grateful to the transplant and multidisciplinary teams at Beijing GoBroad Boren Hospital for their precise care, and for the compassion that stayed with us throughout. You helped make it possible for Lele to stand in the sunlight today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, there is something I also want to say to my son: Lele, you didn't just make it through - you did better than any of us could have imagined. For the years ahead, I hope you can finally put down some of the strength and weight you have had to carry for so long, and simply grow up happy, like any other child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fa0f585dfaad295626a0e6a0729b41450_20260913160857.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"a0f585dfaad295626a0e6a0729b41450_20260913160857.png\" alt=\"b625c5c6-dfa4-4719-a317-b9dc5265b07f.png\"\u002F>\u003C\u002Fp>","Clinical Commentary (Dr. Feifei Li, on behalf of the team led by Dr. Tong Wu and Dr. Yongqiang Zhao): \n\n1. Treatment Standardization: \n\nLele was initially diagnosed with B-ALL (TEL-AML1 positive) and treated according to the CCCG-ALL-2015 protocol. MRD became negative early during induction but later reappeared. After his first relapse, the strategy of re-induction chemotherapy followed by CAR-T and haploidentical transplantation was clinically reasonable. However, relapse again 15 months after the first transplant underscored the complexity of his disease.\n\n2. Strategy for the Second Transplant: \n\nThe second treatment course had to address three major challenges: loss of the CD19 target, extramedullary involvement, and the need for a second transplant. Our team used a sequential strategy of chemotherapy -> CD22 CAR-T -> total body irradiation (TBI) -> a second allogeneic transplant from an unrelated donor. CD22 CAR-T provided precise antigen targeting, TBI offered particular value for extramedullary disease, and changing the donor reflected a highly individualized treatment decision.\n\n3. Management of Complications: \n\nPost-transplant skin GVHD was brought under control promptly. Recurrent fever was investigated systematically and ultimately traced to HHV-6 reactivation, which was successfully cleared with a newer antiviral medication. Kidney biopsy together with genetic testing confirmed X-linked Alport syndrome, allowing the team to establish a lifelong kidney-protection plan. Multidisciplinary collaboration across transplantation, immunotherapy, and nephrology remained central throughout and has been an important part of supporting long-term survival.\n\n4. Overall Assessment: \n\nThis case illustrates an individualized approach built around precise risk assessment, immune targeting, transplant consolidation, and full-course management. Across a ten-year journey with repeated setbacks, treatment decisions were made systematically and complications were managed in detail. It is an important example of how children with relapsed or refractory leukemia can still achieve a meaningful long-term outcome through carefully coordinated care. What Lele has achieved is hard-won. We hope he continues to grow strong, run freely in the sunshine, and move forward into the life ahead.",{"slug":177,"title":178,"summary":179,"cover":180,"disease":181,"treatment":90,"patientType":68,"publishedAt":173,"contentHtml":182,"expertView":183,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"aml-hsct-five-year-recovery","After Two Rounds of Chemotherapy Failed to Achieve Remission, She Marks Five Years of Recovery After Transplant","After two rounds of chemotherapy failed to achieve remission, an adjusted treatment strategy finally brought her into complete remission. She then underwent allogeneic hematopoietic stem cell transplantation and has now reached her five-year recovery milestone.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F98b9f0929d1d6ab4a754c9f4cffc54ac.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Acute Myeloid Leukemia","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Ms. Zhang was diagnosed with acute myeloid leukemia (AML) after what initially seemed like a routine case of tonsillitis. When the first two rounds of chemotherapy failed to achieve remission, she was diagnosed with primary refractory AML. After transferring to GoBroad Shanghai Zhaxin Hospital, Dr. Shan Shao and her team tailored the treatment strategy to the features of her disease, using a non-cross-resistant regimen combined with targeted therapy. For the first time, Ms. Zhang achieved hematologic complete remission and went on to successfully receive a related haploidentical allogeneic hematopoietic stem cell transplant. Nearly five years after transplant, her leukemia remains in complete remission and she has largely returned to everyday life. Today, she is back with her family, enjoying a normal routine, and often shares her experience in patient support groups to encourage others still going through treatment. Her journey traces the full course of refractory AML - from treatment setbacks to remission and long-term recovery - and highlights the value of individualized treatment, well-managed transplantation, and long-term follow-up in improving outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F6c7a151954bd912c5740e0aedcebd351_20260912223719.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6c7a151954bd912c5740e0aedcebd351_20260912223719.png\" alt=\"b6c775e9-bf0d-4ecb-ace5-8f53bda29c3d.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Zhang (pseudonym) has an upbeat, cheerful personality. Wherever she goes, she is like a ray of sunshine, bringing warmth and energy to the people around her. It is hard for anyone meeting her today to imagine that behind her bright smile is a story that once took her through some of life's darkest moments, when despair set in and her life hung in the balance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In March 2021, Ms. Zhang went to the hospital thinking she simply had tonsillitis, only to be unexpectedly diagnosed with leukemia. After two rounds of chemotherapy, the disease still had not gone into remission. Even someone as strong and optimistic as she was broke down in tears, fearing that her life might be coming to an end. But a turning point came that May, when she arrived at GoBroad Shanghai Zhaxin Hospital. The medical team switched her to a new, non-cross-resistant chemotherapy regimen, and follow-up testing showed that she had achieved hematologic complete remission. Because she had primary refractory AML and had failed to respond to her first two rounds of chemotherapy, the team recommended transplant to give her the best chance of long-term survival. In September 2021, she underwent a related haploidentical allogeneic hematopoietic stem cell transplant. Her leukemia remained in complete remission, and she recovered well.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Nearly five years after transplant, Ms. Zhang returned to GoBroad Shanghai Zhaxin Hospital for follow-up and successfully reached what patients affectionately call their "graduation" milestone. She says the shadow of illness has long since faded, and in daily life she can almost forget that she was ever a leukemia patient. Coming back at this special five-year point was both a way to close an important chapter of treatment and to mark a life experience she will never forget. As an old friend of the Zhaxin team and something of a veteran among fellow patients, Ms. Zhang often encourages people in patient groups who are still confused, frightened, or struggling. She remains a warm ray of sunshine, quietly passing that light on to others.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F169cb04ef5d30be7be6563c859cbea81_20260912223737.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"169cb04ef5d30be7be6563c859cbea81_20260912223737.png\" alt=\"a21aba5d-4934-4bd4-87f6-3e26b1efdded.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">August 2023\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F7971239245d746eae13671e6f98f0e9e_20260912223747.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7971239245d746eae13671e6f98f0e9e_20260912223747.png\" alt=\"78cd0219-359b-4fca-aaf2-89ffc44024dd.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">June 2026\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- Patient Q&A -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: How were you first diagnosed?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: In the spring of 2021, I went to the hospital because of a sore throat. I thought it was just a common cold and that a little medication would take care of it. But a routine blood test unexpectedly showed that my white blood cell count was abnormally high. The doctor immediately suspected a hematologic condition and recommended that I be admitted for further evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It felt like a bolt from the blue. I had always been healthy, and apart from the sore throat I had no other symptoms, so I found it very hard to accept. I went to another hospital for a second opinion, but the repeat test still showed a persistently high white blood cell count. It was only after I was admitted and underwent a full work-up that I was finally diagnosed with acute myeloid leukemia. When I heard the diagnosis, my mind went completely blank.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: What was the major turning point in your treatment, and how did you make the key decisions along the way?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Once the diagnosis was in front of me, I knew I had no choice but to face it. What truly pulled me into despair, though, was not the word "leukemia" itself - it was going through treatment after treatment without seeing a response. The first-line regimen failed, and then the second-line regimen failed too. I was told that if the disease still could not be brought into remission, the only remaining option might be to proceed directly to transplant despite active disease, just to fight for a chance. I had never felt so lost. The thought that I might not be able to stay with my family made me cry uncontrollably.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After finishing chemotherapy at another hospital, I came to GoBroad Shanghai Zhaxin Hospital. I had already heard from other patients about the care here, but once I arrived, I experienced the team's professionalism and warmth for myself. Their attentive care helped ease not only the physical pain of treatment, but also much of the fear and anxiety I was carrying. A younger woman in the same room, Ms. Yu, also had refractory leukemia. She had three gene mutations, and one of mine was the same as one of hers. Seeing how well she responded to treatment at Zhaxin gave me enormous encouragement (Read Ms. Yu's story). That sense of warmth and hope helped me make up my mind: I would have my stem cell transplant here. Even if things did not turn out exactly as I hoped, I felt I could accept that choice because I felt safe and cared for here.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before transplant, the team developed a new chemotherapy plan for me - and this time, the response was better than I ever expected. I will always remember Dr. Shan Shao telling me, "Your results are back. Most of the leukemia cells are gone." In that moment, it felt as though a light had appeared in the middle of complete darkness. Reaching complete remission before transplant meant my chances with transplant were much better. I was so overwhelmed that I burst into tears.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: What helped you keep going through the transplant?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: My family's support was the biggest reason I kept moving forward, especially my daughter. At the time, she was preparing for the gaokao, China's national college entrance examination. As a mother, my first instinct was to put her first. I worried that donating stem cells might affect her health or interfere with her exams. While I was hesitating, she looked at me and said firmly, "Mom, you're going to get better." I immediately started crying. I wanted to live. I wanted to be there to watch her grow up. With the understanding and support of her teachers, she took a few days away from school to come to the hospital and donate stem cells for me. Whenever I think about it, I am still deeply moved. I gave her life, and in turn, she helped save mine.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once I entered the transplant unit, my body went through an extremely difficult period. I had forceful vomiting and severe mouth ulcers that made it impossible to eat. But I did not give up on myself. I kept working with the medical team and following treatment. I kept telling myself: if I can still feel this pain, at least I am alive, and I still have a chance to see tomorrow's sun. Whenever I thought about the love and encouragement from my family and friends, I knew I had to keep going, no matter how hard it was. Day by day, my daughter's cells began to engraft and grow inside me, and I gradually started feeling better. Finally, the day came when I could leave the transplant unit. When that door opened, I felt as if I had been given my life back.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: How did you gradually return to everyday life after transplant? What would you say to other patients who are recovering?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: During the first year after transplant, I barely went out because I was worried about infection. Most of my activity was limited to walking around my residential community or a nearby park, and occasionally using some simple outdoor fitness equipment. After the first year, as my strength gradually returned, I started meeting friends for small get-togethers and traveling with my family. I have always been someone who enjoys good food, going out, and being around people. Staying home with nothing to do actually made me feel worse emotionally. So whenever my health allowed, I tried a little exercise or a short trip and slowly found my way back into the rhythm of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What I want to say is that, within your own limits, it is important to find things that make you happy. Illness does not mean you have to shut yourself away from life. As your body recovers, you might try foods you enjoy or take a short walk somewhere nearby, just as I did. But everyone recovers differently, so always listen to your body, pace yourself, and put your health first.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fe5b92c6c9d73d97c8a1f5594c25a0db4_20260912223834.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e5b92c6c9d73d97c8a1f5594c25a0db4_20260912223834.png\" alt=\"f5d863ea-7414-42d3-9e3c-cf656c58beeb.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Ms. Zhang traveling more than one year after her transplant\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: What is life like for you now, and what do you hope for in the future?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I am now approaching retirement, and life has returned to a simple, steady rhythm that I really value. I spend time with my elderly parents and try to be there for them in the small moments of everyday life. When I have time, I meet a few close friends for a meal and a chat. It is an ordinary life, but it feels peaceful and grounding.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, I want to say this to patients who are still going through the hardest part: do not be afraid. Be brave enough to face the disease, and place your trust in the medical team caring for you. The process can be very hard, but when you finally come through it, you may discover that you are much stronger than you ever imagined. There is tremendous strength inside us, and much of that strength comes from one simple belief: keep living. As long as you are here, you still have the chance to give back to the people who love you and the time to fulfill the hopes you once had for your life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F72ee717e16ead6216282cddcbb7703c7_20260912224004.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"72ee717e16ead6216282cddcbb7703c7_20260912224004.png\" alt=\"72a9388f-da46-43a3-9bff-79ba4b7035d8.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Ms. Zhang during a trip to Jiuhua Mountain in May 2026\u003C\u002Fspan>\u003C\u002Fp>","Dr. Shan Shao (Associate Chief Physician, MD; Medical Team Leader, GoBroad Shanghai Zhaxin Hospital):\n\nRefractory acute myeloid leukemia (AML) remains one of the major challenges in hematology. We are very pleased that, through the joint efforts of the entire team, Ms. Zhang was able to come through an extremely difficult period and move into a new chapter of life.\n\nMs. Zhang had high-risk AML that was FLT3-positive and NUP98-positive. Her disease had remained refractory to earlier treatment. After she came to our hospital, we used sorafenib as part of an induction strategy to achieve remission, followed by a related haploidentical allogeneic hematopoietic stem cell transplant. When she first arrived, she was understandably discouraged after so many setbacks in treatment, and our doctors and nurses spent time encouraging her every day.\n\nOnce she achieved her first remission after sorafenib-based treatment, her energy gradually returned. Throughout everything that followed, including transplant, she remained optimistic and actively engaged in her care. She became our team's \"little sun\" and would even try to comfort other patients when they were having a difficult time. In the end, three young women who became close friends while going through treatment around the same time all achieved complete remission (CR) after transplant and received their own milestone pins. (Read Ms. Yu's story) (Read Ms. Gu's story)\n\nSuccessful treatment for hematologic diseases depends on the work of doctors and nurses, but it is also closely tied to a patient's willingness to keep going and actively participate in care. To our \"little sun,\" I want to say: a new chapter has already begun. Keep embracing life with the same brightness and optimism - shining for yourself and bringing warmth to those around you.",{"slug":185,"title":186,"summary":187,"cover":188,"disease":189,"treatment":67,"patientType":68,"publishedAt":190,"contentHtml":191,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"dlbcl-car-t-complete-remission","Relapsed Diffuse Large B-Cell Lymphoma: A 41-Year-Old Achieves Complete Remission After CAR-T Therapy","Just over six months after completing treatment, his lymphoma relapsed. After bridging therapy, CAR-T infusion, and subsequent maintenance treatment, his response deepened from partial remission to complete remission.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F3a9bc6103920e3df0aa11a1bf366befa.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Diffuse Large B-Cell Lymphoma","2026-06-20","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Li Xiang (pseudonym), 41, was diagnosed with diffuse large B-cell lymphoma (DLBCL) after developing a persistent dry cough and night sweats. He initially achieved complete remission after systemic chemotherapy and local radiotherapy, but new hypermetabolic lesions were found just over six months after treatment ended, indicating an early relapse. After transferring to Beijing GoBroad Hospital, Dr. Kai Hu and his team assessed his overall condition, tumor burden, target expression, and the absence of central nervous system involvement, and developed an individualized treatment plan consisting of bridging therapy followed by CD19 CAR-T cell therapy. After infusion, he developed Grade 1 cytokine release syndrome (CRS), which resolved with timely management, and he experienced no immune effector cell-associated neurotoxicity syndrome (ICANS). One month after CAR-T therapy, he achieved a partial response. He then received maintenance therapy, and approximately three months after infusion, the lesions had completely disappeared, indicating complete remission. He has since returned to his normal daily life and continues regular follow-up. His experience illustrates the full treatment journey for early-relapsed DLBCL, from reassessment and bridging therapy to CAR-T infusion and deepening response, and highlights the importance of comprehensive care throughout cell therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the first lymphoma diagnosis felt like a storm that came without warning, for 41-year-old Li Xiang, having the disease return only six months after complete remission was an even greater test.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It all began in August 2024 with what seemed like an ordinary irritating dry cough. What followed was a prolonged battle between his immune system and lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Long Road to a Clear Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, Li Xiang simply felt tired, with night sweats and a dry cough that worsened at night. At a hospital outside his home region, a mediastinal needle biopsy performed during bronchoscopy produced an inconclusive result: “reactive hyperplasia of fragmented lymphoid tissue.” Oral steroid treatment did not improve his condition, and the enlarged lymph nodes persisted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After seeking care at several hospitals, an outside pathology review finally provided a clearer diagnosis: a lymphoproliferative lesion consistent with B-cell lymphoma, possibly nodal marginal zone lymphoma with transformation toward large B-cell lymphoma, or Grade 3A follicular lymphoma. Genetic testing identified a CD79B mutation, and PET-CT showed a Deauville score of 5. Li Xiang was ultimately diagnosed with diffuse large B-cell lymphoma (DLBCL), non-GCB subtype, Stage IVB, with an IPI score of 2 and an ECOG performance status of 1.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He then received six cycles of R2-CHOP together with local mediastinal radiotherapy. At the end of treatment, PET-CT showed complete disappearance of the lesions and a Deauville score of 1, confirming complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But the remission lasted only six months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Relapse: What Comes Next?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2026, just over six months after completing treatment, ultrasound detected abnormal lymph nodes in the left supraclavicular and axillary regions. A subsequent PET-CT confirmed a new hypermetabolic retroperitoneal lesion, and the Deauville score had returned to 5. The lymphoma had relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Li Xiang and his family did not give in to panic. They began researching the latest lymphoma treatments in China and abroad, and through both their own research and recommendations from other patients, one name came up repeatedly: Dr. Kai Hu, Director of the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Hu and his team were among the earlier groups in China to systematically incorporate CAR-T cell therapy into clinical practice and have accumulated extensive experience in individualized treatment for relapsed or refractory lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Li Xiang's family brought his complete medical records to Dr. Hu. After carefully reviewing his diagnosis and treatment history, Dr. Hu identified several key points: although the disease had relapsed, Li Xiang remained in relatively good overall condition and his tumor burden was still manageable; biopsy after relapse showed high expression of CD19, CD20, CD22, and CD79b; and there was no central nervous system involvement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Taken together, these features made CAR-T therapy a particularly suitable treatment option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During detailed discussions with the family, Dr. Hu explained who may benefit from CAR-T therapy, its potential risks and benefits, and the careful management required at each stage of treatment. After fully understanding the treatment plan, the family chose ranicabtagene autoleucel (HICARA®), a CD19-directed CAR-T therapy approved in China.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Bridging, Lymphodepletion, and Infusion: Each Step Matters\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once the decision to proceed with CAR-T therapy was made, Dr. Hu's team first used cytoreductive treatment to bring the disease burden down. In February 2026, Li Xiang received a second-line regimen centered on POLA plus platinum-based chemotherapy, together with targeted therapy. This “bridging therapy” was intended to reduce tumor burden as much as possible before CAR-T infusion and create a more favorable setting for the infused immune cells to work.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On March 6, 2026, Li Xiang began FC lymphodepleting conditioning. On March 11, ranicabtagene autoleucel was infused.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On Day 4 after infusion, Li Xiang developed recurrent high fever and headache. The team promptly assessed this as Grade 1 cytokine release syndrome (CRS). He had no hypotension or hypoxemia, his ICE score was 10, and there were no signs of ICANS.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Following the team's pre-established, risk-stratified management plan, an IL-6 antagonist was administered promptly to control the immune reaction. His temperature gradually normalized, and the CAR-T cells expanded well in his body. He did not develop higher-grade CRS or ICANS at any point.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>After the Initial Response: Moving into Maintenance Therapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">About one month after CAR-T infusion, Li Xiang underwent his first response assessment. PET-CT showed a marked decrease in metabolic activity in both the original and newly developed lesions, with the Deauville score falling to 3. He had achieved a partial response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The result gave both the care team and the family renewed confidence. After evaluation, Dr. Hu's team believed the response could deepen further as the CAR-T cells continued to exert their effect.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Li Xiang then moved into maintenance treatment. Under the plan developed by Dr. Hu's team, he received lenalidomide plus a BTK inhibitor to consolidate the response to CAR-T therapy and reduce the longer-term risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2026, approximately three months after infusion, Li Xiang underwent another PET-CT. This time, the lesions had completely disappeared and the Deauville score had fallen to 1 — confirming complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From a Deauville score of 5 at relapse to a score of 1 three months after CAR-T therapy, Li Xiang had made remarkable progress in just three months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Li Xiang is back to his normal life. He exercises moderately, follows a regular diet, and returns to the hospital for scheduled follow-up. “After going through this twice, I understand the value of good health more than ever,” he said. “I am grateful to Dr. Hu and his team, and to my family for always being there for me.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai Hu said: “Li Xiang's treatment course again demonstrates the value of CAR-T cell therapy in relapsed or refractory diffuse large B-cell lymphoma. For patients with early relapse, high target expression, and no central nervous system involvement, CAR-T therapy can be an important potentially curative option. CAR-T therapy is not the end of treatment, however. Maintenance therapy and long-term follow-up remain equally important.”\u003C\u002Fspan>\u003C\u002Fp>",{"slug":193,"title":194,"summary":195,"cover":196,"disease":197,"treatment":90,"patientType":68,"publishedAt":198,"contentHtml":199,"expertView":200,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"hlh-unrelated-donor-hsct-recovery","Diagnosed with HLH at 28, an Unrelated Donor Gave Him a Second Chance at Life","After a sudden HLH diagnosis and no suitable donor match within his family, a fully HLA-matched unrelated donor found through the China Marrow Donor Program helped make an allogeneic stem cell transplant possible - and gave him a new beginning.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fec62e8f5f1c7a543ac74ba082bea3412.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Hemophagocytic Lymphohistiocytosis","2026-06-12","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: At 28, Xiao Wei (pseudonym) sought medical care for persistent fever, severe fatigue, and yellowing of his skin and eyes, and was ultimately diagnosed with hemophagocytic lymphohistiocytosis (HLH). Because the disease was progressing rapidly and his condition was critical, Dr. Jun Zhu's team at GoBroad Shanghai Liquan Hospital developed a treatment plan to first bring the disease under control and then proceed to allogeneic hematopoietic stem cell transplantation. When no family member was a suitable donor match, the team promptly initiated an unrelated donor search through the China Marrow Donor Program (CMDP) and found a fully HLA-matched donor. In March 2026, Xiao Wei underwent an allogeneic stem cell transplant and left the transplant unit after more than 20 days of treatment. Now more than two months post-transplant, his strength and ability to manage everyday activities are gradually returning. He has also begun sharing his treatment experience online, hoping to encourage others living with blood disorders. His story traces the journey from an acute, life-threatening diagnosis and the search for a donor to transplantation and early recovery - and shows how an unrelated stem cell donor can offer a patient a vital second chance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F990d9b621342a7d9dcf539ef678b7002_20260912220500.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"990d9b621342a7d9dcf539ef678b7002_20260912220500.png\" alt=\"10216bcd-641f-49cd-a3c6-4c8785885814.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiao Wei never imagined that life would force him to stop so suddenly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 18, he packed his bags and left home for an unfamiliar city. Over the next decade, he built a career in mobile phone sales and became a consistent top performer. He was always on the move, filling every day with work and measuring his progress by results. Illness barely crossed his mind - he had hardly even caught a cold in the previous nine years. He assumed life would keep moving at the same relentless pace.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then, in December 2025, everything stopped. It began with a fever and an overwhelming heaviness in his arms and legs. He thought it was an ordinary cold and expected it to pass. But the fever persisted, and then his eyes and skin began to turn yellow. His older brother drove him overnight from Ningbo to Shanghai, where doctors gave him a diagnosis he had never heard of before: hemophagocytic lymphohistiocytosis (HLH).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It felt as if someone had suddenly pressed pause on his life. The days that followed were spent beneath the white ceiling of a hospital room. The young man who had once thrived in the fast-moving world of sales was now lying in a hospital bed, watching every number on every lab report.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F16da8b238a50f391e5833fc8b8dd0339_20260912220522.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"16da8b238a50f391e5833fc8b8dd0339_20260912220522.png\" alt=\"040fee58-b1d5-41e9-a351-44eca56a37d0.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">January 2026\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Yet even in the middle of that uncertainty, a turning point came. When no one in his family proved to be a suitable donor match, GoBroad Shanghai Liquan Hospital quickly initiated an unrelated donor search through the China Marrow Donor Program (CMDP). Fortunately, a stranger he had never met was found to be a fully HLA-matched donor - and was willing to donate hematopoietic stem cells. In March 2026, Xiao Wei successfully underwent an allogeneic hematopoietic stem cell transplant. After more than 20 days in the transplant unit, he was able to leave and begin the next stage of recovery. More than two months later, his hair is growing back, his strength and sense of control over his body are returning, and the facial swelling caused by steroids has subsided.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He can now drive himself to the hospital for follow-up appointments.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Only half a year has passed, yet to Xiao Wei it feels like half a lifetime. Illness disrupted the pace of his old life, but it also opened a new chapter. Throughout treatment, he continued sharing his experience online and livestreaming to encourage people to pay more attention to their health. He also connected with many other patients and exchanged words of support. “I received so much kindness from people I had never met,” he said. “Now I want to be a light for someone else.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F58a4c47ab984dea7912c01304b3c561c_20260912220549.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"58a4c47ab984dea7912c01304b3c561c_20260912220549.png\" alt=\"21042319-8a09-422e-8c03-151b18df0b1c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127); text-align: center;\">June 2026: Xiao Wei with Dr. Bo Lü, a member of Dr. Jun Zhu's team\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Patient Q&A\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: At first you thought it was just a cold. What went through your mind as you learned you actually had HLH?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: At first, I really thought it was just a minor cold. I had a fever and felt weak all over, and I assumed I could just push through it. But the fever went on for days. Then my eyes started turning yellow, and so did my skin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was still forcing myself to go to work. Eventually I just couldn't keep going, so I went to a nearby hospital for a blood test. When the results came back, I was stunned. Hemophagocytic lymphohistiocytosis - I had never even heard of it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The local doctor told me this was not something that could wait and advised me to get to a hospital in Shanghai as soon as possible so I wouldn't miss the best window for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That same night, my brother drove me from Ningbo to Shanghai. My mind was completely blank on the way. I kept thinking about how healthy I had always been - I hardly ever even caught a cold. How could I suddenly have something this serious? Part of me kept wondering whether the doctors had made a mistake, whether it could be a misdiagnosis. I just didn't want to believe it was real.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It wasn't until all the test results were back and the hematologist sat down with me to explain the diagnosis and the treatment plan that it really sank in. I had no choice but to face what was happening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: How did you feel when your family members were not suitable matches, and then a fully matched unrelated donor was found?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: HLH can progress very quickly and become life-threatening. In January 2026, I was transferred to GoBroad Shanghai Liquan Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Jun Zhu was leading my care. He explained the plan clearly: first use chemotherapy to get the disease into the best possible remission, and then move ahead with an allogeneic hematopoietic stem cell transplant at the right time, with the goal of achieving durable complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The medical team was highly experienced. I was still afraid of the unknown, of course, but once I started treatment there, I felt much more settled.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as chemotherapy began, my family members were tested as potential donors. When the results came back, none of them was a suitable match.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Zhu told me that because my disease had come on so quickly and was so severe, an allogeneic transplant offered the best path forward. He recommended that, while I continued treatment, we immediately contact the China Marrow Donor Program to search for an unrelated donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The waiting was the hardest part. Every day brought a little more anxiety. What if there was no match? And even if there was, what if the person didn't want to donate? Those thoughts kept circling in my head, though I tried not to let myself dwell on them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then, a few days later, Dr. Zhu brought me the news I had been hoping for: there was a fully HLA-matched donor in the registry - and the donor was willing to help.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At that moment, a huge part of the weight on my mind lifted. I knew there were still many challenges ahead - the transplant unit, the risk of graft-versus-host disease, and everything else that comes with transplant - but the most important piece was finally in place.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: Once you learned that a fully matched donor had been found, how did you prepare for transplant? Were you nervous before entering the transplant unit?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Finding a donor made me feel much more secure, but I also knew the hardest part was still ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I went into the transplant unit, Dr. Zhu and the medical team walked me through the entire process again and again. They explained what side effects I might experience and how they would manage them. By turning the unknown into something I could understand, they made me feel much more prepared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Of course I was nervous. But by then I had accepted that fear wasn't going to change what needed to be done. Instead of spending every day imagining what might go wrong, I decided to get myself into the best condition I could and face the transplant head-on.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In March 2026, I entered the transplant unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F8f4a94c17ec1c96eab3c59b4b1c0d896_20260912220640.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"8f4a94c17ec1c96eab3c59b4b1c0d896_20260912220640.png\" alt=\"0ab3062d-9e9a-4fdf-bfd3-7e1f6503b377.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">March 2026, inside the transplant unit at Shanghai Liquan Hospital\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: How did you get through those more than 20 days in the transplant unit?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Once I entered the unit, I first received high-dose conditioning chemotherapy to prepare my body for the transplant. Those days were difficult. I had almost no appetite and felt groggy and exhausted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But the hardest part was actually waiting for my blood counts to recover. Every day, I looked at my blood test results and hoped the numbers would rise even a little. The waiting felt like counting the hours in the dark without knowing when morning would come.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The nurses and care staff in the unit were incredibly attentive. They would talk with me and help ease my anxiety. My family couldn't come inside, but they encouraged me every day by video call.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Around the second week after the stem cell infusion, my counts finally began to come up. When I saw that upward arrow on the report, something in me lit up. I knew I had made it through the hardest part.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: How has recovery been since you left the transplant unit? What is everyday life like now?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Leaving the transplant unit was only the first step. Recovery afterward is a much longer process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first I was still very weak and would get out of breath after walking only a few steps. But I could genuinely feel myself getting a little better every day. My hair started growing back, and my strength slowly returned.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now, more than two months after transplant, I can drive myself to the hospital for follow-up visits. I'm still recovering, but compared with how I felt when I first became ill, I'm doing so much better.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This illness taught me something very simple: health is the “1,” and everything else is just the zeros that come after it. I used to think I was young and healthy and had nothing to worry about. Now I understand that without your health, everything else becomes harder.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: After everything you've been through, what do you hope for in the future?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Before I got sick, all I thought about was work, targets, and pushing forward. I always felt that slowing down meant wasting time. Looking back now, I was like a machine that never stopped running.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Getting sick taught me what it really means to slow down. It doesn't mean giving up. It means understanding what matters - every breath, time with my family, and all those ordinary moments I used to overlook.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now I share my experience online and livestream to encourage people to take their health seriously. I've received so many messages of support from strangers, and many patients have written to tell me that my story gave them courage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That has made me feel that, although this illness knocked me down hard, it also gave me a new purpose: to use what I've been through to help people who are still trying to find their way through the dark.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In the future, I want to live well, work well, and keep being someone who can offer a little light to others.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Jun Zhu (Chief Physician; Medical Director, GoBroad Shanghai Zhaxin Hospital \u002F Shanghai Liquan Hospital):\n\nAs Xiao Wei's primary physician, I witnessed every step of his journey, from his HLH diagnosis through transplantation and into recovery.\n\nHLH can be extremely aggressive. In a patient like Xiao Wei, allogeneic hematopoietic stem cell transplantation offered the best chance of achieving durable remission.\n\nTreating a serious blood disorder requires a true partnership between the patient, family, and medical team. Xiao Wei and his family's trust allowed us to make the transplant decision decisively and move forward at the right time. Their constant support throughout treatment was equally important.\n\nDischarge after transplant is only the beginning of a long recovery. Rehabilitation, prevention and management of graft-versus-host disease, infection prevention, and relapse monitoring all require time and patience. We will continue to walk alongside Xiao Wei throughout this next stage.\n\nWe are also grateful that Xiao Wei chose to share his experience. His story can offer hope and strength to other patients who may be facing some of the darkest moments of their own treatment journey.",{"slug":202,"title":203,"summary":204,"cover":205,"disease":80,"treatment":67,"patientType":82,"publishedAt":198,"contentHtml":206,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"b-all-car-t-relapse","Leukemia Returned After Five Years: A 9-Year-Old Girl's CAR-T Journey Despite Severely Low Blood Counts","After initial treatment, completing therapy, relapse, and chemotherapy resistance, she achieved remission again with CAR-T therapy, creating a new opportunity for the next stage of treatment.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F9dd29357512d4eb20a4011e2baabaa0d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Xinxin (pseudonym), now 9, was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) at age 5. She completed standard treatment and was able to stop therapy, but the leukemia relapsed nearly three years later. Conventional re-induction chemotherapy did not achieve remission, and lymphoblasts remained at very high levels in her bone marrow, placing her disease in the relapsed\u002Frefractory setting. After she was transferred to Beijing GoBroad Hospital, Dr. Jing Pan's team comprehensively assessed her disease burden, treatment history, and overall condition and developed a CAR-T treatment plan. Despite profoundly low blood counts, the team successfully completed autologous lymphocyte collection, bridging therapy, CAR-T cell infusion, and comprehensive management of treatment-related complications. Xinxin developed only mild cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS). Bone marrow assessment after infusion showed remission, and she has now moved into recovery and follow-up. Her experience offers a look at the full CAR-T treatment journey for a child with relapsed\u002Frefractory B-ALL and highlights the value of careful assessment, end-to-end management, and multidisciplinary collaboration in cellular therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For children with relapsed\u002Frefractory B-cell acute lymphoblastic leukemia, approved CAR-T therapies have opened up an additional treatment option for some patients. This story follows one child who received CAR-T therapy despite profoundly low blood counts and achieved remission, while also showing the full clinical pathway delivered by Dr. Jing Pan's team - from disease assessment, cell collection and manufacturing to infusion management and follow-up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Looked Like an Ordinary Cold Turned Out to Be a Sign of Relapse\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In December 2025, 9-year-old Xinxin went to a local hospital with a respiratory infection. Fever, throat discomfort, and nasal congestion made it look like an ordinary cold.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But her complete blood count immediately raised concern: she had neutropenia along with anemia. Further testing confirmed what no family wanted to hear - Xinxin's leukemia had relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the family, the news came as a devastating shock.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xinxin's first encounter with leukemia dated back to October 2020. She was 5 years old when a bone marrow abnormality was discovered after an accidental fall, leading to a diagnosis of B-cell acute lymphoblastic leukemia in the low-risk group. Over the next two and a half years, she completed standard induction, consolidation, re-induction, and maintenance therapy, enduring the many challenges of chemotherapy along the way. In March 2023, she finally completed treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For nearly three years after treatment ended, Xinxin's bone marrow examinations remained normal and life seemed to be back on track. Then the relapse came without warning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Critical Turn: Chemotherapy Fails as Lymphoblasts Fill the Bone Marrow\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2026, Xinxin's parents took her to a local hematology hospital. The bone marrow results were alarming: lymphoblasts accounted for 98.5%, and measurable residual disease (MRD) was as high as 90.5%. Immunophenotyping showed a common B-ALL phenotype, consistent with relapsed\u002Frefractory B-cell acute lymphoblastic leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Doctors urgently started induction chemotherapy with venetoclax plus a VDP regimen. However, bone marrow assessments in mid-February and again at the end of February 2026 showed persistently high lymphoblast levels of 93.5% and 88%, respectively, while MRD remained above 87%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The leukemia had become refractory to chemotherapy, conventional treatment was no longer controlling it, and the disease continued to progress.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Choosing the Next Treatment: Helping Their Daughter Get Better With Less Suffering\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Faced with their daughter's rapidly worsening condition, Xinxin's parents were desperate to find another way forward. Their wish was simple: for her to get better as quickly as possible and endure as little additional treatment-related suffering as possible. After researching extensively, they eventually found Dr. Jing Pan's team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Pan's team carried out a comprehensive assessment of Xinxin's treatment history, current disease burden, and overall condition and determined that CAR-T cell therapy offered the most promising option at that point. After detailed discussions with Xinxin and her family, the team decided to proceed with Puzolcabtagene Autoleucel Injection, an autologous humanized CD19 CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The family had also previously purchased commercial health insurance for Xinxin that included coverage for approved CAR-T treatment, providing important financial support during the course of therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>The Most Demanding Part of CAR-T Treatment Is Not the Infusion Day Alone\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T therapy is sometimes thought of as a single cell infusion. In reality, the infusion itself is only one step in a much longer treatment process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From the initial assessment, physicians need to evaluate the patient's current condition, disease course, and prior treatment to determine whether CAR-T is appropriate. The team then develops and continuously adjusts the treatment plan while moving through key steps such as cell collection, manufacturing, and infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After infusion, patients may experience fever, cytokine release syndrome (CRS), neurological toxicities such as ICANS, infection, and challenges related to immune recovery. Follow-up then continues to monitor treatment response and recovery over time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These stages are closely connected and influence one another; they rarely exist in isolation. For patients, CAR-T is better understood as an ongoing treatment journey rather than a one-time procedure. What often matters most is not the infusion day alone, but the care delivered before and after it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xinxin's experience illustrates exactly why the entire process matters.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Collecting Enough Autologous Cells Despite Profoundly Low Blood Counts\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In early March 2026, Xinxin was admitted to the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital. Her blood counts were severely suppressed on admission, with very low white blood cells, neutrophils, and platelets - an expected consequence of her previous chemotherapy, but one that made the next stage of treatment more challenging.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even so, Dr. Pan's team quickly put a detailed treatment plan in place. Bone marrow testing showed that lymphoblasts still accounted for nearly 90%, making time critical. The team decided to move ahead with lymphocyte collection as quickly as possible so CAR-T manufacturing could begin without delay.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before her blood counts had recovered, the team successfully collected peripheral blood lymphocytes from Xinxin. To ensure that enough backup cells were available, a second collection was performed several days later.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This was one of the most technically demanding steps in the treatment: despite Xinxin's profound cytopenias, the team was able to collect an adequate number of autologous lymphocytes for CAR-T manufacturing. It required not only clinical and procedural expertise, but also careful control of timing across the entire treatment pathway.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">While the CAR-T cells were being manufactured, Xinxin received bridging chemotherapy to keep the leukemia burden under control and create the best possible conditions for infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>After Infusion: Rapid CAR-T Expansion With Mild Toxicity\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In mid-April 2026, Xinxin received her infusion of Puzolcabtagene Autoleucel. Within just a few days, monitoring showed that the CAR-T cells had begun to expand, indicating that the manufactured cells were active and proliferating in her body as they targeted the leukemia cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Encouragingly, Xinxin's cytokine release syndrome remained mild. Her main symptom was intermittent fever, which improved quickly with prompt supportive treatment and one bedside plasma exchange procedure, with both the frequency and peak of the fevers decreasing soon afterward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CRS is a common complication of CAR-T therapy that requires close monitoring, and severe cases can be life-threatening. Xinxin's CRS remained Grade 1 throughout treatment, presenting mainly as intermittent fever and improving quickly with timely supportive care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the same time, the team remained highly alert for another potentially serious complication: immune effector cell-associated neurotoxicity syndrome (ICANS). According to the product label, in the PB07 clinical trial (N=56), ICANS occurred in 50.00% of patients and Grade 3 or higher ICANS occurred in 37.50%. The median time to onset was 7.0 days after infusion (range, 5-13 days), with a median duration of 3.5 days (range, 1-14 days); Grade 3 or higher ICANS had a median duration of 3 days (range, 1-17 days). Reported manifestations and neurological toxicities included tremor (19.64%), convulsive seizures (17.86%), epilepsy (14.29%), decreased level of consciousness (12.50%), increased intracranial pressure (10.71%), cerebral edema (5.36%), and delirium (5.36%).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Given these risks, Dr. Pan's team took no chances. Neurological monitoring began from the first day after infusion, together with a graded plan for early intervention if symptoms emerged. Fortunately, Xinxin developed no ICANS-related symptoms throughout treatment and remained at ICANS Grade 0.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">About two weeks after infusion, Xinxin underwent her first response assessment. The bone marrow results brought welcome news: her leukemia was in remission. Her inflammatory markers continued to fall, medications were gradually reduced and discontinued as appropriate, and her blood counts began to recover steadily. In early May 2026, on Day 23 after infusion, Xinxin was discharged home to continue her recovery. Her total hospital stay was 60 days, and the overall CAR-T treatment course went smoothly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Choosing Cellular Therapy Also Means Choosing a Complete Care System\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking at the full treatment pathway makes one point especially clear: patients are not simply choosing a single technology. They are choosing a healthcare system capable of supporting that treatment safely and consistently from beginning to end.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That capability includes systematic risk assessment and stratification, reliable execution of each stage of the treatment pathway, experience managing complex complications, and the ability to continuously adjust treatment through multidisciplinary collaboration.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These strengths are rarely visible at just one moment; they run through the entire course of care. For complex diseases such as hematologic malignancies, the decision is therefore not only about selecting a technology, but also about selecting a clinical team that can deliver it reliably and take responsibility for the whole treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xinxin's course is a clear example. From disease assessment and treatment planning to cell collection during profound cytopenias, bridging chemotherapy, CRS management after infusion, response assessment, discharge, and follow-up, every step depends on experience, anticipation, and execution.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Afterword\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From her diagnosis in 2020 to completing treatment in 2023 and then relapsing at the end of 2025, Xinxin's journey with leukemia had already lasted more than five years. This time, with support from Dr. Jing Pan's team, she was able to complete CAR-T therapy despite profoundly low blood counts and achieve remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For Xinxin and her family, treatment is not over. Follow-up and long-term recovery are still ahead. But this time, they have been given a new reason to hope.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":208,"title":209,"summary":210,"cover":211,"disease":106,"treatment":212,"patientType":82,"publishedAt":198,"contentHtml":213,"expertView":214,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"burkitt-lymphoma-targeted-immunotherapy"," 5-Year-Old with High-Risk Burkitt Lymphoma Achieves Complete Remission with Chemotherapy and Targeted Immunotherapy","After multiple rounds of chemotherapy failed to achieve complete remission, a fresh assessment and personalized combination treatment opened up a new path forward.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F6f48ad1a611db8477d0a5e30992c5dd2.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Chemotherapy, Targeted therapy","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Five-year-old Dingding (pseudonym) was diagnosed with high-risk stage III Burkitt lymphoma after developing a persistent fever. Genetic testing identified several tumor-related abnormalities, including TP53, MYC, ID3, and GNA13. He received multiple courses of first- and second-line chemotherapy at another hospital. Although the lesions became smaller, he did not achieve complete remission. In January 2026, Dingding was transferred to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital. Prof. Yonghong Zhang's team repeated the pathology and imaging review and completed additional target-expression testing. Based on his previous response to treatment and strong CD79b expression, the team developed a personalized regimen combining chemotherapy with targeted immunotherapy. After several courses of treatment and consolidation therapy, Dingding achieved complete remission and has continued to maintain it. He is now steadily recovering and looking forward to returning to school. His experience shows how comprehensive reassessment and individualized combination therapy can create new possibilities for children with high-risk Burkitt lymphoma when multiple rounds of chemotherapy have not achieved remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In October 2025, five-year-old Dingding (pseudonym) was diagnosed with high-risk stage III Burkitt lymphoma after seeking care for a persistent low-grade fever. Genetic testing showed a TP53 mutation as well as abnormalities involving MYC, ID3, GNA13, and other tumor-related genes. After four courses of chemotherapy at a hospital in Tianjin, he still had not achieved complete remission. His family refused to give up. In January 2026, his parents brought him to Beijing GoBroad Boren Hospital to see pediatric hematology-oncology specialist Prof. Yonghong Zhang. Soon after admission, Prof. Zhang and her team carried out a new pathology review and developed a risk-adapted, individualized plan combining chemotherapy with targeted immunotherapy. After just over three months of structured treatment, Dingding achieved complete remission (CR) and was discharged to continue his recovery at home. Today, he is getting stronger day by day and looking forward to the moment he can return to school.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fd3ba1fbaf3c4eb890844e2c5c9a4ee30_20260912212404.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d3ba1fbaf3c4eb890844e2c5c9a4ee30_20260912212404.png\" alt=\"9be106c9-fce5-4b05-b105-a24d039058e7.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Group photo at discharge\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Persistent Fever Leads to a Diagnosis of High-Risk Lymphoma at Age Five\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before Dingding became ill, our family life was calm and ordinary. Then, on the evening of September 25, 2025, he suddenly developed a fever of 39.4°C. The fever came down after medicine, but for more than a week afterward he kept running a low-grade fever during the day that would settle at night.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On October 4, we took him to our county hospital. Based on his blood test and chest X-ray, the doctor initially thought it was pneumonia. But after three days of IV treatment, he was no better at all. I kept thinking, if this really is pneumonia, why is the treatment not helping? I did not want to wait any longer, so that same day I decided to take him to a major hospital in Tianjin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That afternoon, Dingding had an ultrasound, blood tests, and other examinations. The results came back quickly. His attending doctor did not give us a diagnosis right away, but his expression was serious. He told us lymphoma was suspected and arranged a biopsy and further pathology testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A few days later, after review by a higher-level pathology center, Dingding was diagnosed with high-risk stage III Burkitt lymphoma. Genetic testing also showed a TP53 mutation and abnormalities involving MYC, ID3, GNA13, and several other tumor-related genes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the time, I knew almost nothing about the disease. I only understood that it could take my son away from us very quickly. I had one thought in my mind: save my child.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>After Multiple Rounds of Chemotherapy, Complete Remission Remained Out of Reach\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Burkitt lymphoma can progress extremely quickly, so Dingding started chemotherapy soon after diagnosis. He received R-AA, R-BB, and R-CC regimens. At the interim assessment, PET-CT showed that the lesions had improved but remained metabolically active, while ultrasound showed that the thickest part of the bowel wall was still 6 mm. Because Dingding had a TP53 mutation and other genetic features associated with an unfavorable prognosis, his doctors switched the fourth course to second-line R-ICE chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Each round of chemotherapy brought side effects to some degree - nausea, vomiting, and loss of appetite became common. Yet Dingding handled everything with a maturity that was hard to watch in such a young child. He endured bone marrow aspirations and injections without crying.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once, after we had taken him home for a few days, I asked, "Do you still want to go back to the hospital?" He said, "Yes." When I asked why, he replied, "I want to get better soon so I can go home and go back to school."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hearing that from a child who was not yet six was heartbreaking and comforting at the same time. As his father, all I wanted was for him to get better as soon as possible and not have to suffer anymore.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the R-ICE course, Dingding had another ultrasound. The thickened area of bowel wall was almost unchanged. When I saw the result, I made a firm decision. In fact, from the day he was diagnosed, I had been reading everything I could find and, on the recommendation of other parents, started following Prof. Yonghong Zhang's WeChat account. I remember clearly that there were already more than 920 posts at the time. I read every new update - case discussions, educational articles, and answers to parents' questions. The more I read, the more confidence I had in Prof. Zhang's expertise in pediatric lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as the interim assessment results came out, I booked a consultation with Prof. Zhang. After learning about Dingding's situation, she advised us that if he showed a response after the fourth course, he could continue treatment where he was; if not, we should come to Boren as soon as possible. So when the assessment showed no meaningful improvement, I immediately decided to bring Dingding to see her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Fresh Assessment and Personalized Combination Therapy Lead to Complete Remission\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2026, Dingding was transferred to Beijing GoBroad Boren Hospital. Prof. Yonghong Zhang's team immediately arranged a repeat pathology review and additional target-expression testing. Because Dingding had a TP53 mutation, multiple germinal-center-related gene abnormalities, and resistance-associated mutations, the team also collected his autologous peripheral blood lymphocytes in advance to keep future treatment options open.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After a comprehensive review of Dingding's disease course, Prof. Zhang's team decided to continue treatment based on the CNCL-NHL-2017 protocol for mature B-cell lymphoma, while tailoring the regimen more precisely to his individual situation:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. First course: Dingding received R + COPADM1. At the end of the course, follow-up imaging showed that the bowel wall thickness had decreased from 6 mm to 4 mm. After treatment had appeared to stall at the previous hospital, this was the first time we had seen the lesion continue to shrink. It gave me hope again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Second course: Because immunohistochemistry showed strong CD79b expression, the team adjusted treatment to an anti-CD79b antibody + CYVE2 regimen. The residual lesion became smaller again, and the response continued to improve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Third course: Based on the changes in the lesion, the team switched to an anti-CD79b antibody + M1 regimen. In March 2026, a comprehensive imaging assessment brought the news we had been waiting for: the lesion had completely disappeared, indicating an initial complete remission (CR). I was so overwhelmed that I could not speak. Nearly six months of worry, travel, fear, and uncertainty suddenly felt worth it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Consolidation therapy: To strengthen the response and reduce the risk of relapse, Dingding then completed one course each of anti-CD79b antibody + M2 and anti-CD79b antibody + M3 as consolidation. Imaging at the end of treatment continued to show CR.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During treatment, Dingding experienced common chemotherapy-related complications, including neutropenia, thrombocytopenia, and diarrhea. With close nursing care and supportive treatment, each was managed successfully. At the end of all planned therapy, his results looked good and he was discharged to continue recovering at home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Recovering Well and Looking Forward to Going Back to School\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dingding is now recovering steadily and feeling better day by day. We are hoping he can return to school next September, and he cannot wait to be back with his teachers and classmates.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back on the past several months, the people I most want to thank are Prof. Yonghong Zhang and her entire team. To me, Prof. Zhang was the person who helped turn things around for my son. She brought him back from an extremely difficult situation and gave him another chance at life. When we felt most helpless, her expertise and sense of responsibility showed us a way forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am also deeply grateful to Beijing GoBroad Boren Hospital. The hospital made it possible for us to meet such a strong team and for so many children to move toward recovery. I was especially touched by the efficiency of the care, the service philosophy, and the compassion shown here - above all, the professional and attentive support provided to children with blood disorders and cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Finally, I want to say to every parent going through something similar: please do not give up easily. I know how hard this road can be. I have felt the helplessness of watching your child suffer when there is nothing you can do, and the fear of not knowing what tomorrow will bring. But children are often stronger than we imagine, and as parents, we sometimes have to find more strength in ourselves than we thought we had. I hope every child can grow up healthy, safe, and surrounded by kindness.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Ying Liu, Ward Director, Department of Pediatric Hematology & Oncology, on Prof. Yonghong Zhang's team): \nThe patient was diagnosed with Burkitt lymphoma in October 2025. At presentation, the disease involved the small-bowel wall in the mid and lower abdomen and multiple lymph nodes anterior to the right kidney. No tumor cells were detected in the bone marrow or cerebrospinal fluid. At the referring hospital, he was classified as high-risk stage III according to the 2025 guideline for the diagnosis and treatment of lymphoma in children and adolescents. He received cytoreductive therapy followed by R-AA, R-BB, and R-CC chemotherapy. Interim PET-CT showed reduced small-bowel wall thickening but persistent hypermetabolism (Deauville score 5), while ultrasound continued to show thickening of the right abdominal bowel wall, suggesting residual active disease without remission. He was then switched to second-line R-ICE chemotherapy. The residual bowel wall thickening remained unchanged, indicating no disease progression but failure to achieve complete remission (CR), and he was therefore referred to our hospital.\n\nAfter admission, the diagnosis was reviewed using pathology consultation, expert review of all prior PET\u002FCT scans, MRI performed at our hospital, and gastrointestinal ultrasound by Dr. Liqun Jia of Beijing Children's Hospital. The final diagnosis was high-risk stage III, CNS1 Burkitt lymphoma with bulky disease. After four courses of first- and second-line chemotherapy at the referring hospital, CR had not been achieved, and a small amount of residual tumor could not be excluded at the thickened terminal ileum. The patient had several adverse prognostic factors: 1) extensive small-bowel wall involvement at diagnosis with bulky disease measuring more than 10 cm; 2) a TP53 variant associated with treatment resistance; and 3) failure to achieve remission at interim assessment, an independent adverse prognostic factor.\n\nBecause there was no disease progression, we recommended switching to the CNCL-2017 frontline chemotherapy protocol for mature B-cell lymphoma. Taking into account his cumulative prior chemotherapy exposure, the planned sequence was COPADM, CYVE2, M1, M2, and M3 chemotherapy combined with monoclonal antibody therapy. Before chemotherapy began, autologous peripheral blood lymphocytes were collected and cryopreserved in case CAR-T cell therapy was needed later. The pathology workup at the referring hospital had not included target markers such as CD19, CD22, and CD79b, so these were added after admission. Rituximab was combined with COPADM during the first course, with subsequent treatment to be adjusted according to target-expression results and tumor response.\n\nAfter the first course of rituximab + COPADM, assessment still showed irregular thickening of the terminal ileum, with residual tumor mixed with scar tissue, but the overall appearance had improved and areas of complete scarring were present. Because tumor response was clearly delayed and the tumor tissue showed strong CD79b expression, an anti-CD79b antibody was added to subsequent chemotherapy to reduce relapse risk. After the second course of anti-CD79b antibody + CYVE2 and the third course of anti-CD79b antibody + M1, gastrointestinal ultrasound showed no obvious residual bowel wall thickening at the original terminal ileal lesion, suggesting an initial CR. He then completed a fourth course of anti-CD79b antibody + M2 and a fifth course of anti-CD79b antibody + M3. End-of-treatment imaging continued to show CR.\n\nA key factor in the success of this case was the individualized combination strategy. The TP53 mutation and markedly delayed response suggested possible primary resistance to chemotherapy, so frontline chemotherapy was combined with second-line targeted immunotherapy.",{"slug":216,"title":217,"summary":218,"cover":219,"disease":181,"treatment":90,"patientType":68,"publishedAt":220,"contentHtml":221,"expertView":222,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"76-year-old-patient-allogeneic-hematopoietic-stem-cell-transplantation","At 76, She Underwent Allogeneic Stem Cell Transplantation and Remains Stable at Six-Month Follow-Up","At 76, Mrs. Xiao (pseudonym) faced progression of leukemia and increasingly limited treatment options. After a comprehensive evaluation, she underwent allogeneic hematopoietic stem cell transplantation and is now steadily regaining her strength.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fa1ad00a947818903f18b9aa742543768.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-06-05","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">Mrs. Xiao (pseudonym), 76, had been enjoying a quiet retirement when chronic myelomonocytic leukemia (CMML) progressed to acute myeloid leukemia (AML), leaving her with increasingly limited treatment options. Her age added another layer of complexity to the possibility of hematopoietic stem cell transplantation. After a comprehensive assessment by Dr. Tong Wu, Dr. Yanzhi Song, and the transplant team at Beijing GoBroad Boren Hospital, she underwent allogeneic hematopoietic stem cell transplantation. After 36 challenging days in the transplant unit, she was able to leave protective isolation. At her six-month follow-up, her laboratory results were stable and her overall condition was continuing to improve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On December 5, 2025, after 36 days in the transplant unit, 76-year-old Mrs. Xiao (pseudonym) from Xi'an, Shaanxi, was wheeled out of protective isolation by the medical team. Her son, Mr. Li (pseudonym), had been waiting outside for her. Mrs. Xiao had seen her chronic myelomonocytic leukemia (CMML) transform into acute myeloid leukemia (AML). With the care of Dr. Tong Wu, Dr. Yanzhi Song, and the transplant team at Beijing GoBroad Boren Hospital, she successfully completed an allogeneic hematopoietic stem cell transplant, setting a new age record for transplantation within GoBroad Healthcare Group. On May 10, 2026, six months after transplant, follow-up testing showed stable results and continued recovery. Her son shared the family's experience of navigating this difficult treatment journey with an elderly parent.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F98d85b2c1f7c65ee07098275c226349d_20260913001023.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"98d85b2c1f7c65ee07098275c226349d_20260913001023.png\" alt=\"e432d62d-ddf5-4811-b2c6-1024b0786d12.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo taken when she left the transplant unit\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Leukemia Diagnosis in Her Seventies - and an Age Barrier to Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother had always kept up with regular health checks. Because she also had underlying conditions such as diabetes, we were especially attentive to her health. In July 2024, routine testing showed several abnormalities in her blood counts, including a white blood cell count above 40,000\u002FμL. A subsequent bone marrow aspiration confirmed chronic myelomonocytic leukemia (CMML), with DNMT3A, FLT3, IDH2, and NPM1 mutations. For someone in her seventies who should have been enjoying retirement, the diagnosis came as a profound shock.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother soon began treatment at a hospital in Xi'an. She initially received cytoreductive chemotherapy and intermittent azacitidine plus venetoclax, which kept the disease relatively stable for nearly six months. In January 2025, however, her condition worsened sharply, and bone marrow testing showed transformation to acute myeloid leukemia (AML). Her doctors adjusted the regimen and added the targeted agent gilteritinib. Her blood counts stabilized for a time, but only for a few months. By June 2025, the disease was progressing again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As the disease worsened, my mother had to begin chemotherapy, but she reacted very strongly. Her blood counts fell rapidly and she needed daily supportive care, including platelet transfusions, while the chemotherapy itself was not producing the response we had hoped for. When the doctors began considering another chemotherapy adjustment, we hesitated. At her age, we worried that her body could no longer withstand repeated rounds of intensive treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We contacted several hospitals in Xi'an to ask whether hematopoietic stem cell transplantation might still be possible. The answers were almost always the same: "She is too old, the disease is too complicated, and the transplant risk is too high. We would recommend continuing conservative treatment."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>When Options Were Running Out, Beijing Offered a New Possibility\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Just when we felt we had almost run out of options, one specialist suggested that we take my mother to Beijing for another opinion and recommended three hospitals, including Beijing GoBroad Boren Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In early August 2025, I took time off work and traveled to Beijing. Over two days, I visited the hospitals and spoke with specialists in detail. At Boren, I met Dr. Yanzhi Song. He carefully reviewed all of my mother's medical records and patiently discussed her condition with me. Most importantly, he addressed the question that had been weighing on me: age alone is not an absolute contraindication to hematopoietic stem cell transplantation. What matters is a systematic assessment of the patient's overall condition, including organ function, as well as the wishes of the patient and family. His candid and professional explanation was the first thing that gave me real hope after days of anxious searching. Another important factor was an article I had read about Boren successfully performing transplantation for a 74-year-old patient with AML. That experience strengthened our decision to bring my mother here.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Going Beyond the Usual Age Limits: Working Together for a Second Chance\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On August 18, 2025, my mother was admitted to Ward 5 of the transplant department at Beijing GoBroad Boren Hospital. Dr. Tong Wu, Dr. Yanzhi Song, and their team carried out a comprehensive evaluation. Bone marrow testing showed 18.69% abnormal myeloid blasts by flow cytometry, an NPM1 quantitative level of 52.84%, and FLT3-ITD and IDH2 mutations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother had leukemia as well as several chronic conditions, including diabetes, hypertension, hypertrophic cardiomyopathy, and Hashimoto's thyroiditis. The hospital quickly organized a multidisciplinary consultation. After a detailed assessment, the team determined that her overall condition met the requirements for transplantation. After weeks of uncertainty, that conclusion finally gave us some relief.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because my mother's leukemia burden was still high, the transplant team first designed an individualized chemotherapy regimen to reduce the disease burden and create the best possible conditions for transplant. The treatment was difficult, and she also developed allergic purpura during chemotherapy, but the complication was brought under control. By late September, abnormal cells in her bone marrow had fallen from 12% to 0.1%, and the window for transplantation had opened.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then we encountered an unexpected problem. I had originally planned to be my mother's stem cell donor, but a key test showed that she had strongly positive HLA antibodies directed against me. Using me as the donor would therefore have increased the risk of graft failure, so we had to turn to the donor registry and search for an unrelated donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother's disease was moving faster than we had expected, and the leukemia cells were beginning to rise again. The longer we waited, the less favorable the situation became. Those were some of the most anxious days for me. Fortunately, we soon received good news from the China Marrow Donor Program: a matching volunteer donor had been found. What moved us even more was how quickly and generously the donor cooperated. From confirmation of the match, through the medical examination and collection preparations, to the successful infusion of the stem cells into my mother, the entire process took only 25 days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F8b58d1c86a71754d383ff0337b175e1d_20260913001056.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"8b58d1c86a71754d383ff0337b175e1d_20260913001056.png\" alt=\"febbb840-6895-4cea-a4d1-2b4f3d97c139.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I remain deeply grateful to this donor, someone we have never met. Without hesitation, they gave my mother something priceless: the treatment time she urgently needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because of my mother's age, engraftment was somewhat slower. Even so, the transplant course was more stable than we had expected. She did not develop any severe infections, and although each step of recovery took time, she kept working with the medical team with remarkable determination. Day by day, she continued moving forward at her own pace.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On December 5, 2025, after 36 days in the transplant unit, my mother safely left protective isolation. While I was waiting outside, I also saw a 15-year-old girl walk briskly out of the unit. My mother, by contrast, was wheeled out slowly and still looked frail. But I knew that for a 76-year-old woman, making it through this stage and reaching the other side was an extraordinary and deeply meaningful victory.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Age Is Not the End of the Road: Recovery Brings New Hope\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother is now six months post-transplant. Her follow-up results remain stable, and she is gradually regaining her strength. Looking back on everything our family went through, there are a few things I would like to share with other patients and families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Information and choices matter. When we consulted hospitals in Xi'an, one of the responses we heard most often was, "Seventy-five is too old. We only transplant patients under 65." I am very grateful to the doctor who encouraged us to seek another opinion, and I am glad I did not hesitate to come to Beijing and speak with specialists in person. That decision helped us find another possibility at a time when we thought there were none left.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Trust expertise and communicate openly. At Boren, we experienced the transplant team's professionalism and depth of experience, particularly in caring for older adults undergoing hematopoietic stem cell transplantation. From designing the conditioning regimen, to round-the-clock monitoring in the transplant unit, to preventing and managing post-transplant complications and providing day-to-day care guidance, every step was handled carefully. I am deeply grateful to the Boren team for giving an elderly patient like my mother a chance to move forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Details matter, and caregiving is an important part of treatment. My mother had always been very frugal and would even hesitate to throw away leftovers. But after transplant, anything she ate could affect her infection risk. I explained it to her in practical terms: "Food is less than 1% of what we spend on treatment. But if unsafe food causes an infection, the cost could be tens of thousands of yuan - and more importantly, you would suffer and face additional risk." That helped her understand why following the medical team's instructions so carefully mattered. For older transplant patients in particular, attentive day-to-day care can make a meaningful difference.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As medicine continues to advance, I hope more patients and families are able to find their own door to hope. May every effort to keep going find an answer, and may every life placed in the hands of a medical team be treated with the care it deserves.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Zhanxiang Liu, on behalf of the team led by Dr. Tong Wu and Dr. Yanzhi Song): \n\nScientific understanding is never built in a single step, and medicine is no different. At 76, Mrs. Xiao successfully underwent an allogeneic hematopoietic stem cell transplant from an unrelated donor at our hospital. For our transplant center, this represented both a new age milestone and another example of how mature transplant techniques can be applied to carefully selected older patients. Hematopoietic stem cell transplantation is a complex and time-intensive process. Before proceeding with Mrs. Xiao's transplant, we carried out extensive preparation, repeatedly reviewing her pre-existing conditions and the complications she might face. With careful treatment and nursing from the medical team, close coordination from patient services and the unrelated donor registry, and strong support from her family, the donor stem cells were finally infused and successfully began to engraft. Mrs. Xiao's optimism and determination helped her work through the discomfort of treatment, leave the transplant unit, and eventually leave the hospital. Completing the early post-transplant period was the first critical step; she is now continuing with the second, third, and many steps that follow.\n\nMrs. Xiao remained in Beijing for follow-up for six months after transplant. During that period, she experienced nausea, diarrhea, poor appetite, and substantial weight loss compared with before transplant. Even so, her resilience and optimism gradually carried her out of the darkest part of the illness. When the six-month bone marrow assessment came back with very encouraging results, she immediately got into the family car to begin the journey home. It was clear how much she had missed being there.\n\nNow that she is back home, the long distance means that routine tests are usually done at a local hospital. If a test is not available locally, samples can be sent to Beijing. We share results by phone and provide remote guidance on diet, medication, and other aspects of follow-up care. Mrs. Xiao is still recovering little by little - something we can see both in her laboratory results and in the photos she sends us.\n\nWe wish Mrs. Xiao continued progress throughout her follow-up and recovery, and we hope her treatment journey offers encouragement to other patients and families. Science has no fixed borders, and neither should the possibilities of medicine. Our team will continue to approach transplantation with commitment, rigor, and evidence-based care, working to help more patients gain another chance at life.",{"slug":224,"title":225,"summary":226,"cover":227,"disease":228,"treatment":229,"patientType":68,"publishedAt":230,"contentHtml":231,"expertView":232,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"multiple-myeloma-car-t-retirement-life","A New Lease on Life After CAR-T: Reflections from a Patient with Relapsed\u002FRefractory Multiple Myeloma","After multiple rounds of treatment, an autologous stem cell transplant, and another relapse, CAR-T therapy brought him sustained complete remission - and helped him return to a peaceful life with his family.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F0c8054daedfdcc89f43b26d4252539b1.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Multiple Myeloma","CAR-T, Autologous Hematopoietic Stem Cell Transplantation","2026-05-21","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Soon after retirement, Mr. He developed recurrent fever, fatigue, and bone pain and was diagnosed with IgG lambda multiple myeloma. He underwent chemotherapy followed by autologous hematopoietic stem cell transplantation, but the disease did not achieve the hoped-for response. He later came to GoBroad Shanghai Zhaxin Hospital, where targeted and immunotherapy-based treatment combined with chemotherapy kept his disease under control for several years. In 2025, follow-up testing again raised concern for relapse, at a time when several previous drugs and treatment approaches were no longer providing sufficient control. After comprehensive evaluation and detailed discussions with the medical team, Mr. He received CAR-T cell therapy with zevorcabtagene autoleucel (zevor-cel) in September 2025. His myeloma remains in complete remission, his strength is gradually returning, and he has resumed traveling with his wife and enjoying retirement. His story reflects the long treatment journey that many patients with relapsed or refractory multiple myeloma may face - from chemotherapy and autologous transplant to CAR-T - and the difference that advances in medicine, family support, and access to healthcare can make in everyday life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fbf38a6f83ffc36792adc6e378fe3ba71_20260912214822.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"bf38a6f83ffc36792adc6e378fe3ba71_20260912214822.png\" alt=\"575ba3d1-4bd9-4443-b039-cc86e523a273.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Six years ago, soon after retiring, Mr. He (pseudonym) signed up for a piano class at a university for older adults. He was ready to enjoy a colorful new chapter of retirement. Then recurrent fevers, fatigue, and persistent bone pain began to worry his family. A comprehensive health check showed several abnormalities, and further hematology testing ultimately confirmed the diagnosis: IgG lambda multiple myeloma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With his family by his side, Mr. He began treatment. In November 2020, he underwent an autologous hematopoietic stem cell transplant, but the disease did not go into remission. He then received a combination of targeted therapy, immunotherapy, and chemotherapy, which kept the disease stable for several years. By May 2025, however, myeloma-related markers that had long been controlled began to rise again, suggesting another relapse. By then, several drugs and treatment approaches had already provided limited benefit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Just when options seemed to be running out, CAR-T cell therapy offered a new possibility. In September 2025, the medical team at GoBroad Shanghai Zhaxin Hospital treated Mr. He with CAR-T cell therapy using zevorcabtagene autoleucel (zevor-cel).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now, more than eight months after treatment, his multiple myeloma remains in complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At last, he can enjoy the retirement he had once imagined - traveling with his wife, Mrs. Yang, visiting new places, and living a calm and fulfilling everyday life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F329d3b941c4b5accb1fa93151db0ca7d_20260912214837.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"329d3b941c4b5accb1fa93151db0ca7d_20260912214837.png\" alt=\"b60bb128-54e9-4767-acb5-546cbe87d033.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Mr. He and Mrs. Yang traveling together in late 2025\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As both his longtime caregiver and a healthcare professional herself, Mrs. Yang has many reflections on the journey:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"My father was diagnosed with multiple myeloma in 1993, before he had even turned 70. Medical options were much more limited then, and he was unable to receive sufficiently effective treatment. His quality of life was very poor, and he suffered greatly from the disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So much has changed since then. With rapid advances in medicine in China, new drugs and treatment approaches continue to become available. Today, patients like my husband can not only receive standardized, effective treatment, but can also maintain a good quality of life during treatment - something that would have been difficult to imagine in the past.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That is why I want other people living with myeloma to keep believing that there is hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It is also worth mentioning that GoBroad Shanghai Zhaxin Hospital is one of the designated hospitals for CAR-T treatment under Shanghai's 'Huhuibao' supplementary health insurance program. This coverage greatly reduced the financial pressure on our family and made an otherwise very costly advanced therapy much more accessible and affordable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We are deeply grateful for the progress in medical care, the support provided through healthcare policy, and the dedication of every member of the medical team at Zhaxin Hospital."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F2ec7c64c5e7ac69df3b4f789ec5c37a4_20260912214851.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"2ec7c64c5e7ac69df3b4f789ec5c37a4_20260912214851.png\" alt=\"9f3a6237-3454-47c5-86e1-5b8bb56a9dce.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">October 2025: Mr. and Mrs. He with Dr. Ying Jiang and Nurse Manager Xia Yan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- Patient Q&A -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: Mrs. Yang, how was Mr. He's multiple myeloma first diagnosed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Yang: In April 2020, he suddenly began having recurrent fevers, usually a little above 38°C. At first, we thought it was a cold. The symptoms improved after a few days, but then the fever came back. He also began to feel some discomfort in his lower back. We did not know what was causing it or even which specialty to see, so we decided to start with a full health check.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That same day, the hospital called to tell me that several test results were abnormal and recommended that we see a hematologist for further evaluation. We were very worried and arranged for him to be admitted right away. The next morning, after PET-CT and other tests, he was diagnosed with multiple myeloma. Fortunately, it was identified relatively early. If we had waited another week or two, his disease markers might have worsened further.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: Mr. He, what ultimately led you to choose GoBroad Shanghai Zhaxin Hospital?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. He: After the diagnosis, I started chemotherapy. That year was extremely difficult. I spent more than half of each month either in the hospital or traveling back and forth for treatment. I was particularly sensitive to some chemotherapy drugs, and one side effect followed another - fever, diarrhea, rashes, and more. I felt miserable, yet the treatment response was still not what we had hoped for.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2020, because the standard chemotherapy regimen had not worked well enough, I followed my doctor's recommendation and underwent an autologous hematopoietic stem cell transplant. My disease was not in complete remission before the transplant, and afterward the result was still not as expected. More discouragingly, within one or two months, the disease-related markers began to rise again. That period was very hard, both physically and emotionally.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When treatment seemed to have reached a dead end, we learned that Professor Chun Wang had extensive experience in relapsed and refractory hematologic diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So in January 2022, we came to GoBroad Shanghai Zhaxin Hospital for further treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After I arrived, Professor Wang adjusted my treatment based on my condition. He introduced targeted therapy combined with chemotherapy and also modified some of the medications I had not tolerated well before. Gradually, the disease stabilized, and symptoms such as fever and diarrhea became much less troublesome. Although some markers fluctuated again about a year later, the doctors adjusted my medications promptly based on each follow-up result, so overall the disease remained under control. I kept up with regular follow-up, monitored my results closely, and adjusted treatment when needed. That allowed me to maintain a reasonably good quality of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then, at a follow-up visit in May 2025, the markers began to rise again, suggesting that the myeloma might be returning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: Mr. He, when the disease began to relapse again, how did you decide to proceed with CAR-T therapy using zevorcabtagene autoleucel (zevor-cel)?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. He: Based on my condition, the medical team at Zhaxin Hospital recommended CAR-T as the most appropriate treatment option for me at that point. We had always trusted the team's decisions, but I still hesitated before making this one.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We had learned a little about CAR-T before. In my mind, it felt like the 'ultimate weapon.' Part of me wanted to wait and see whether medication could keep things under control a little longer. I hoped the markers might not rise too quickly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But during the two months I hesitated, the abnormal markers climbed rapidly. My attending physician, Dr. Ying Jiang, understood my concerns and explained patiently: "You have already tried several previous treatment approaches, and repeating them may not work well. If we wait until the myeloma burden rises further before proceeding with CAR-T, the outcome may not be any better than treating earlier, and the side effects could also be greater."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The cost of CAR-T was another major reason we hesitated. Later, we learned that GoBroad Shanghai Zhaxin Hospital is a designated CAR-T treatment hospital under 'Huhuibao,' and that I met the reimbursement criteria for adults with relapsed or refractory multiple myeloma whose disease had progressed after at least three prior lines of therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That coverage greatly reduced the financial burden of treatment and removed one of our biggest concerns.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: Mr. He, you have experienced both an autologous stem cell transplant and CAR-T therapy. How did the two treatments feel different to you?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. He: As another patient once shared, the overall experience of CAR-T felt much easier for me than the autologous transplant. I did not need to stay in a transplant isolation room. Instead, a protective laminar-flow canopy was placed over my hospital bed, and my family could remain nearby to care for me. That made a big difference psychologically.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the CAR-T infusion, I had a high fever for two or three days, with the temperature rising above 39°C. But Dr. Jiang had prepared us for that in advance. She explained that the engineered T cells would enter the body and 'fight' the myeloma cells, so some discomfort could be expected along the way. Because I knew what might happen, the whole process felt relatively manageable and I was not frightened.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was discharged successfully after about two weeks and only needed to return for regular follow-up. About three months after CAR-T, my strength had improved a great deal, and my wife and I even traveled to Guangzhou together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q5: Mrs. Yang, you have been by Mr. He's side throughout these years. What do you think matters most when caring for someone with multiple myeloma?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Yang: Caring for someone with myeloma is a long-term commitment. Family caregivers first need to take care of their own mindset so they can better support the patient. Test results will inevitably go up and down from one follow-up to the next. I used to become very anxious whenever his results were not ideal. Once, a nurse manager saw how worried I was and came over to reassure me: "Let the doctors worry about the numbers. What you need to focus on is his meals, daily routine, and day-to-day care. Leave the medical decisions to the professionals." Those words lifted a huge weight from me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As family caregivers, we should try not to exhaust ourselves by worrying constantly about every medical number. It is often better to put our energy into the parts of care that we can actually do well.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q6: Mr. He, after everything you have been through, how has this illness changed the way you think about life?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. He: Before I became ill, I had planned to sign up for a piano class at a university for older adults and finally pursue a dream I had carried since I was young. But before I ever got the chance to touch the keys, the illness arrived first. Life does not always follow our plans. Instead of always thinking about 'someday,' I would rather live each day in front of me as fully as I can.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am especially grateful to my wife. Through all these years, she has stayed beside me, caring for me with patience and gentleness. What I want now is very simple: she loves traveling, so I go with her whenever I can. Even if we are in the same city and she goes out sightseeing while I rest at the hotel and wait for her to come back, I still feel at peace.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I do not spend much time thinking about the distant future anymore. If I can eat well today, walk around today, and the two of us can still sit together and talk, that is enough.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This illness taught me something important: life does not have to be perfect to feel complete. Sometimes, having 'just enough' is its own kind of happiness.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Ying Jiang (Associate Chief Physician, MD; Medical Team Leader, GoBroad Shanghai Zhaxin Hospital):\n\nMultiple myeloma requires long-term monitoring, with treatment adjusted over time according to changes in laboratory and disease-related markers. In recent years, the continued introduction of new drugs and immunotherapies such as CAR-T has significantly extended survival for many patients. At the same time, quality of life has also improved meaningfully during what can be a long course of treatment and follow-up.\n\nWe wish Mr. He and Mrs. Yang many more years of traveling side by side, seeing beautiful places together, and sharing the simple joys of everyday life.",{"slug":234,"title":235,"summary":236,"cover":237,"disease":80,"treatment":172,"patientType":82,"publishedAt":238,"contentHtml":239,"expertView":240,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"b-all-cart-hsct-five-year-survival","Relapse After Chemotherapy, Then Again After CAR-T: A Young Man Reaches Five Years in Remission After CD22 CAR-T and Transplant","After multiple rounds of treatment and relapse, Yangyang (pseudonym) is now back at university and hopes his experience can encourage others to keep going.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fe5fb2a5f1b295916a1e43dd71e229626.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-05-18","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\">At 17, Yangyang (pseudonym) should have been focused on school and the future. Instead, he was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). He achieved remission with chemotherapy but later relapsed, and then relapsed again after CD19 CAR-T therapy. In 2021, he and his mother traveled to Beijing GoBroad Boren Hospital. Given his high-risk disease, including an E2A-PBX1 fusion and multiple relapses, the teams led by Dr. Tong WU and Dr. Yanzhi SONG developed an integrated treatment plan using CD22 CAR-T therapy as a bridge to a related-donor haploidentical hematopoietic stem cell transplant. Yangyang ultimately achieved long-term remission. Now, five years after transplant, his bone marrow remains in complete remission, donor chimerism remains fully donor-derived, and he has returned to university to continue the life that illness once interrupted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 17, Yangyang, from Sichuan, should have been studying in the classroom and running across the school field. Instead, he was diagnosed with B-cell acute lymphoblastic leukemia. He relapsed after achieving remission with chemotherapy and then relapsed again after CAR-T immunotherapy, leaving his family with few options. In early 2021, after searching widely for help, Yangyang and his mother traveled to Beijing GoBroad Boren Hospital. Taking into account his E2A-PBX1 fusion-positive disease and history of multiple relapses, the teams led by Dr. Tong WU and Dr. Yanzhi SONG developed a personalized plan using CAR-T therapy as a bridge to a related-donor haploidentical hematopoietic stem cell transplant, with his father as the donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, at 22, Yangyang has reached the important five-year post-transplant milestone. His bone marrow remains in complete remission, donor chimerism remains fully donor-derived, and his overall results are stable. The teenager who stayed optimistic even at the hardest moments is now a second-year university student. He still has the same warm smile, but with a calmness that comes from everything he has been through. His story carries a simple message: when you choose not to give up, a way forward can still appear.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F35aea199126eb192da3585837185d266_20260913000808.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"35aea199126eb192da3585837185d266_20260913000808.png\" alt=\"ed02475a-883f-47ec-989d-56926fa29243.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo from Yangyang's five-year post-transplant follow-up\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>From Over 75 kg to 54 kg: An Unexpected Health Crisis at 17\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the beginning of 2020, I was in my first year of high school. At some point, I started feeling exhausted all the time and lost my appetite. My weight dropped from more than 75 kg to about 54 kg. I became so thin that even my pajamas hung loosely on me. I went to the hospital twice because of weakness and joint swelling after eating seafood. But I had always been healthy, had never been hospitalized, and did not even know what an IV infusion felt like, so I did not think much of it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Then one morning in February 2020, I was getting ready for breakfast when my nose started itching. I scratched it casually and suddenly began bleeding. The blood looked unusually thin and watery rather than the normal thick, bright red. My mother's expression changed immediately, and she rushed me to the emergency department.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I underwent a full evaluation at a local hospital in Sichuan. My blood count showed a hemoglobin level of just 53 g\u002FL and a platelet count of only 15 x 10^9\u002FL. A bone marrow examination found that blasts accounted for 65% of the cells. I was diagnosed with acute lymphoblastic leukemia, common B-ALL, with an E2A-PBX1 fusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My family worried that I would not be able to handle the truth, so they did not tell me exactly what the diagnosis was. I did not ask many questions either. All I wanted was to get better and go back to school. Looking back now, I had no idea how difficult the road ahead would become.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Relapse After Relapse: Running Out of Options\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After diagnosis, I began a long course of treatment. I first received VDCLP induction chemotherapy. At the end of treatment, my bone marrow showed morphologic remission, flow cytometry was negative, and the E2A-PBX1 fusion became undetectable. I then completed Hyper-CVAD A consolidation chemotherapy and went home to recover as instructed. I was so happy at the time and thought the illness was finally behind me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Only about two weeks later, a repeat bone marrow examination showed that blasts had risen to 94%. My mother wanted to take me to a major tertiary hospital in Sichuan, but there were no beds available and we could not afford to wait. We transferred to a hospital in Xi'an for further treatment. After FC chemotherapy, my bone marrow morphology improved, but flow-cytometric MRD remained positive, the E2A-PBX1 fusion remained detectable, and a new PAX5 mutation was also identified.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July 2020, another bone marrow examination showed that blasts had risen again to 81.5%. My treating physician promptly arranged an infusion of CD19 CAR-T cells. Assessments on days 17 and 30 after CAR-T showed sustained bone marrow remission, and both E2A-PBX1 and PAX5 became undetectable. Once my condition stabilized, I even returned to school briefly and completed part of a semester.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Around that time, on the way to a follow-up visit, my mother carefully asked me, "Have you ever wondered what illness you actually have?" When she saw that I was calm, she told me the truth. Strangely, knowing the diagnosis made me feel less burdened. I have always been someone who does not swing too far between highs and lows. I also feel that the better your mindset, the easier it is to focus on recovery. The more you avoid talking about the illness, the more it can feel like a weight pressing down on you.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Unfortunately, the remission did not last. In January 2021, PET-CT showed extramedullary disease. After repeated relapses and increasingly difficult-to-control leukemia, the local hospital had no effective options left to offer. Once again, we had to look elsewhere for a way forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Traveling to Beijing: CD22 CAR-T as a Bridge to Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even then, my mother refused to give up. She kept asking around and learned that Beijing GoBroad Boren Hospital had extensive experience treating refractory and relapsed leukemia. Chinese New Year was approaching, but she did not want treatment to be delayed, so she took me to Beijing as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We arrived at Beijing GoBroad Boren Hospital on January 28, 2021. A comprehensive evaluation showed morphologic bone marrow remission and negative flow cytometry, but the E2A-PBX1 fusion was still detectable at 0.022%. The teams led by Dr. Tong WU and Dr. Yanzhi SONG quickly developed a treatment plan. Given my young age and history of multiple relapses, they recommended CAR-T therapy followed by transplantation as the best next step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On February 10, I received CD22 CAR-T cells. Follow-up evaluations at two weeks and one month showed remission by both bone marrow assessment and flow cytometry, and the fusion gene finally became undetectable. PET-CT also showed that the lesions had shrunk substantially and their metabolic activity had fallen markedly. After reviewing everything together, however, the team felt that a small risk of residual disease remained. Dr. Yanzhi SONG spoke with my mother in detail about the next phase of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The transplant teams led by Dr. Tong WU and Dr. Yanzhi SONG then designed an individualized transplant plan for me. On March 24, 2021, I began an intensified conditioning regimen with TBI\u002FAra-C\u002FVP-16\u002FFLU\u002FATG. On April 6, I received my father's bone marrow, followed by peripheral blood stem cell infusions over the next two days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I entered the transplant unit, I really had no idea what transplantation would be like. I have always thought of myself as an optimistic person, but being alone in a closed protective-isolation room could still make me feel low and irritable. Eventually I developed a routine: every afternoon at around two or three, I would take a nap. When I woke up, I usually felt calmer again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I had free time, I would play online games with friends. But they still had school and their own lives, so they could not always be there. The loneliness could be intense. I knew, though, that this was one part of the journey I had to get through myself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During transplant, I developed severe mouth ulcers, my platelet count was slow to recover, and steroids caused noticeable facial swelling. It was a difficult period. Fortunately, engraftment went relatively smoothly: my platelets engrafted on day +11 and my white blood cells on day +16. Compared with what some other patients went through, I felt I had been fortunate. The day I left protective isolation and breathed the air outside again, I felt as though I had finally come back to life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At my one-month post-transplant evaluation, the results were reassuring: both bone marrow and cerebrospinal fluid were in complete remission, and chimerism had become fully donor-derived. I soon met the criteria for discharge and went home to continue recovering.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As my health steadily improved, I finally returned to school a little over a year after transplant. I went on to finish high school and was admitted to university, where I wanted to learn a practical skill and build my future step by step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The five years after transplant were not completely smooth. My white blood cell and platelet counts sometimes dropped again, and my blood pressure fluctuated frequently. Fortunately, Dr. Tong WU and Dr. Yanzhi SONG continued to follow me closely. With their clinical experience, they evaluated each new problem carefully and adjusted my care as needed, helping me through one recovery challenge after another. The hardest setback for me came about two years after transplant, when I developed avascular necrosis of the right femoral head. Before I became ill, I loved playing table tennis and could move quickly around the table. Afterward, walking too much made my leg feel so heavy that it was hard to lift. By following the medical team's advice, resting when needed, and taking care of the joint over the long term, the discomfort gradually improved. I now have very little pain and can manage normal daily activities without difficulty.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Since becoming ill, I have never felt an overwhelming emotional burden about the diagnosis. When friends ask, I do not try to hide it. They know I am generally optimistic and they treat it matter-of-factly, which actually makes me feel more comfortable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Going through all of this also helped me change some careless habits from when I was younger. My parents used to run a restaurant, and I would help out. As a reward, they let me have one bottle of soda a day. I remember lying in bed at night happily wondering whether I would choose Coke or Sprite the next day. I still buy a bottle once in a while as a treat, and I still enjoy it, but now I automatically remind myself not to overdo things the way I used to.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Gratitude and a New Beginning: The Things I Never Said Out Loud\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back over these five years, there is so much I could say. But the first thing I want to tell my mother is simply: Mom, I'm sorry.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There was a period during treatment when I became very irritable and would lose my temper for no reason. I did not really notice how much I had changed, but my mother did. I have always felt that I owed her that apology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I also want to thank my father. While my mother stayed with me in Beijing for treatment, he remained back home, working from early morning until late at night to earn money for my care, while carrying the worry about my condition largely on his own. It is hard to imagine how much pressure he was under.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">And of course, I want to thank the medical team at Beijing GoBroad Boren Hospital. Dr. Tong WU, Dr. Yanzhi SONG, and all the nurses who looked after me every day gave me hope through their expertise, patience, and constant care. I still remember the day I finished my five-year follow-up. My attending physician, Dr. Erhui YUAN, smiled and said, "You won't need to keep coming back like this anymore." In that moment, all the difficult days and all the persistence suddenly felt worth it. I felt relieved, fortunate, and deeply grateful all at once.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If someone asks me how I got through all of this, I would say that mindset really matters. I knew another patient who became completely discouraged after learning about the diagnosis, stopped following medical advice, secretly ordered takeout, and ignored dietary precautions. The disease later relapsed, which was heartbreaking. I have always felt that we cannot choose whether illness happens to us, but we can choose how we respond to it. If we give up on ourselves, even the best doctors and the best treatment plans can only do so much.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Five years have passed since my transplant almost before I realized it. At this latest follow-up, my results remained stable and the leukemia was still in complete remission. I am now back at university, studying steadily and trying to make the most of each day. For me, an ordinary, peaceful life like this is the best kind of life. I hope my story can offer even a small amount of light and strength to someone who is still trying to find a way through the dark. Do not give up. The night can feel darkest just before dawn, but if you keep going, morning will come.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Erhui YUAN, from the teams of Prof. Tong WU and Dr. Yanzhi SONG): \n\nYangyang had B-cell acute lymphoblastic leukemia (B-ALL) with an E2A-PBX1 fusion, a high-risk subtype associated with a tendency toward extramedullary involvement and refractory or relapsed disease. He relapsed only six months after his first CD19 CAR-T treatment, raising concern for CD19 antigen escape or insufficient persistence of CAR-T cells in vivo. Promptly switching targets and giving sequential CD22 CAR-T therapy was therefore a critical salvage strategy. CD22 CAR-T could target residual leukemic clones that may have lost CD19 expression while also achieving another deep response at extramedullary sites, creating a valuable window for subsequent therapy. This was followed by allogeneic hematopoietic stem cell transplantation, ultimately resulting in a five-year clinical cure after transplant. The case demonstrates the integrated value of sequential dual-target CAR-T therapy bridging to allogeneic transplantation in refractory\u002Frelapsed B-ALL, combining precision immunotherapy with established transplant strategies to overcome high-risk disease.\n\nLong-term complications also require close attention. During extended survival, the patient developed avascular necrosis of the femoral head as well as hypertension requiring combination antihypertensive therapy. Although the avascular necrosis is currently not causing significant symptoms, regular imaging follow-up remains important, excessive weight-bearing should be avoided, and progression should be monitored. For hypertension, combination treatment should aim to maintain blood pressure within target range, with close monitoring of renal function and electrolytes.\n\nOverall, this case achieved long-term control of high-risk, refractory B-ALL. However, managing late complications is just as important as controlling the leukemia itself. Long-term multidisciplinary follow-up involving hematology, orthopedics, cardiology, endocrinology, and other specialties is needed to help patients move from simply surviving to living well.\n\nThroughout years of treatment and recovery, Yangyang remained remarkably cheerful and optimistic. For this patient, reaching the five-year milestone represents what we call a \"clinical cure\" in oncology. It is not only a victory of treatment, but also a reflection of his resilience and inner strength. Yangyang has shown how a positive outlook can help turn medical possibilities into real life. We are delighted to see him reach this new beginning. There is still a long road ahead, so keep that smile. \"You are your own hero, and you are also one of the reasons we, as doctors, keep moving forward.\"",{"slug":242,"title":243,"summary":244,"cover":245,"disease":228,"treatment":246,"patientType":68,"publishedAt":247,"contentHtml":248,"expertView":249,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"multiple-myeloma-car-t-remission","After CAR-T Therapy, I Got My Quality of Life Back","After multiple rounds of chemotherapy, an autologous transplant, and a relapse, she achieved complete remission with CAR-T therapy—and gradually found her way back to a life with rhythm, purpose, and quality.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F2f474be97daf8bba2f93472a5351176d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp"," CAR-T, Autologous Hematopoietic Stem Cell Transplantation","2026-05-09","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Ms. Zhang, 55, was diagnosed with IgD-λ multiple myeloma after developing lower-back discomfort and widespread bone pain. After several courses of treatment, she achieved only a partial response. In 2023, she came to GoBroad Shanghai Liquan Hospital for further treatment and underwent an autologous hematopoietic stem cell transplant, achieving complete remission for a period of time. Two years after the transplant, follow-up tests showed signs that the disease might be returning. By then, she had reached fourth-line treatment and was struggling to tolerate long-term drug therapy. After a comprehensive assessment, Dr. Su Li’s team recommended CAR-T cell therapy with FUCASO® (equecabtagene autoleucel). More than six months after CAR-T therapy, she achieved MRD-negative complete remission. As her physical and emotional well-being improved, she returned to painting, embroidery, travel, and other things she loves. Her story traces the journey of a patient with relapsed\u002Frefractory multiple myeloma from chemotherapy and autologous transplantation to CAR-T therapy—and shows why quality of life matters just as much as the goal of living longer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F94ec5e05e659d289c2f356636e10b6a2_20260912213651.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"94ec5e05e659d289c2f356636e10b6a2_20260912213651.png\" alt=\"9d5f19d4-baeb-4c7c-9fca-b4be66863b8f.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July 2025, nearly two years after her autologous transplant, Ms. Zhang (pseudonym) had been keeping up with regular follow-up visits when tests began to show signs that her multiple myeloma might be returning. The shadow of repeated chemotherapy—something she had hoped was finally behind her—seemed to be closing in again. “I don’t want to go through chemotherapy anymore,” she said. “I want to live well, not just stay alive.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With the goals of long-term disease control and a better quality of life, the medical team at GoBroad Shanghai Liquan Hospital carried out a comprehensive assessment. After detailed discussions with Ms. Zhang and her family, the team proceeded with CAR-T cell therapy using FUCASO® (equecabtagene autoleucel) in September 2025. More than six months later, her multiple myeloma is in complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F508c68874e5d72d7da37c919ff38668b_20260912213707.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"508c68874e5d72d7da37c919ff38668b_20260912213707.png\" alt=\"5d8d39e0-a1fc-4f7a-a898-fde14a17ac06.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Ms. Zhang teaching her students in the classroom in 2021\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now 55, Ms. Zhang spent more than 30 years as a devoted schoolteacher. In the second half of 2022, as a new school year approached, she was preparing for her classes just as she always had. Then a nagging ache appeared in her lower back and gradually developed into bone pain throughout her body. At first, she did not think much of it. But one evening after work, she suddenly became very unwell and vomited through the night. Further tests at the hospital eventually led to a diagnosis of IgD-λ multiple myeloma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“At the time, I was worried about my students. I was afraid my absence would disrupt their learning,” Ms. Zhang recalled, still emotional when speaking about her diagnosis. She never imagined that once she stepped away from the classroom she loved, she would not be able to return.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After that, whenever she passed by the school and saw the familiar playground, she would often tear up, missing the life she had left behind.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment turned out to be far more difficult than she had expected. After several courses of standard chemotherapy, she achieved only a partial response (PR). In February 2023, Ms. Zhang came to GoBroad Shanghai Liquan Hospital for further treatment and underwent an autologous hematopoietic stem cell transplant that June. She then moved into maintenance treatment, and for a while everything seemed to be improving. But two years later, her IgD level began to rise again during follow-up, suggesting that the myeloma might be returning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Zhang had relapsed\u002Frefractory multiple myeloma, with several episodes of disease progression in less than three years. By this point, she had reached fourth-line treatment, and CAR-T cell therapy offered a new option. GoBroad Shanghai Liquan Hospital is also a designated CAR-T treatment center under Shanghai Hu Hui Bao, a supplemental health insurance program, which substantially reduced the financial burden of treatment for her family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">She had been through chemotherapy, an autologous transplant, and then CAR-T therapy. Along the way, she endured the physical toll of repeated disease progression and fell into a deep depression during especially difficult periods of chemotherapy. Step by step, she worked through both the physical and emotional challenges. Today, she has returned to a quieter, fuller life shaped by painting, embroidery, travel, and the things that bring her joy—and her smile has returned with it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Zhang says she is sharing her experience in the hope that her treatment journey can be a source of light for other people with blood disorders who may still be going through their darkest days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For anyone living through illness right now, we hope her story offers a little more hope and courage—and reminds you that it is possible to find your way back to the life, places, and moments that matter to you.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fe02babdc6a8373fdf5ceb7112578de0d_20260912213728.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e02babdc6a8373fdf5ceb7112578de0d_20260912213728.png\" alt=\"3b8ab996-731b-40d4-bc75-f3fd5bbd9cc6.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Ms. Zhang with Dr. Su Li in April 2026\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: What symptoms did you first notice in 2022, and how were you eventually diagnosed with multiple myeloma?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: It started when I hurt my lower back while doing yoga. I thought it was just a muscle strain, so I tried massage therapy, but it never got better. Not long after that, I started having bone pain all over my body. Then one day after work, I couldn’t eat and spent the entire night vomiting. The next day, I went to an internal medicine clinic. My blood tests were abnormal—both my calcium and creatinine were significantly elevated.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A doctor I knew looked at the results and called me that evening because he was concerned. He explained that the combination of these findings fit the “CRAB” features commonly associated with myeloma and urged me to see a hematologist as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I then had a bone marrow aspiration in the hematology department, which confirmed multiple myeloma. I burst into tears. I thought having a blood cancer meant I was going to die. I even asked my husband to take me to hospice. I had completely lost hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Later, a hematologist sat down with me and explained very patiently that although multiple myeloma is not currently considered curable, standardized treatment can help people live longer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So I began chemotherapy. But that was only the beginning. The road ahead was much harder than I had imagined.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: What brought you to GoBroad Shanghai Liquan Hospital, and why did you choose to have an autologous hematopoietic stem cell transplant there?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: After several courses of standard treatment for myeloma, I had achieved only a partial response. At the same time, chemotherapy was extremely hard on me. I needed an injection every week, and by the next day I would feel terrible. Going through the same cycle week after week wore me down physically and emotionally.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That was when I came to GoBroad Shanghai Liquan Hospital to look for another option. As part of the treatment plan, I went on to have an autologous hematopoietic stem cell transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I became ill, I was a teacher and I loved my job. If this disease had not appeared so suddenly, I would have stayed in the classroom until retirement. Even after I started chemotherapy, I still imagined that one day I might go back to teaching. But weekly treatment and constant hospital visits slowly made that hope feel less realistic. Spending all day at home, I often felt useless, as though I no longer had a place or purpose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What made things even harder was that my M-protein level was still high before the autologous transplant, so I had to continue taking chemotherapy drugs to bring it down. Emotionally, I was at my limit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I don’t know how much of it was related to the medication, but I couldn’t sleep, I was extremely anxious, and there were times when I wanted to stop treatment altogether because death felt like an escape.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F84c958a35e0e401c430f2ef26a541232_20260912214348.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"84c958a35e0e401c430f2ef26a541232_20260912214348.png\" alt=\"cd68da01-af00-413b-b156-f18a0a6be5fd.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Ms. Zhang receiving further treatment at GoBroad Shanghai Liquan Hospital in February 2023\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On my doctor’s advice, I went to the neurology department at another hospital and started medication to help with my anxiety and sleep. During that time, my family stayed close and encouraged me every day. My doctors also checked in often and helped me keep going. Before every dose of chemotherapy, I had to talk myself through it. No matter how difficult it felt, I forced myself to take the medication. Eventually, my M-protein level came under control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Next, I received targeted therapy to reduce the remaining myeloma cells further and prepare for the autologous transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was very afraid of entering the transplant isolation unit, but once I was actually there, it was not as frightening as I had imagined. The nurses and care staff were very professional and often chatted with me. Dr. Su Li also came in every day to see how I was doing. I spent more than 20 days in the unit, and eventually I was able to leave it successfully.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The transplant worked well, and I achieved complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During follow-up, Dr. Su Li recommended consolidation treatment every two months. As I became stronger, the interval between visits gradually became longer and my emotional state also improved. I slowly tapered off the medication I had been taking for my mental health symptoms, and little by little, life began to feel normal again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: After the transplant, things seemed to be settling down—until your IgD level started rising again during maintenance treatment. How did you learn about CAR-T therapy, and what ultimately led you to choose it?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Things had been improving, and I was approaching the two-year mark after my transplant when one follow-up test showed that my IgD level had started to rise. That suggested the disease might be coming back.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I had learned that IgD multiple myeloma tends to relapse more easily. I also did a lot of reading on my own and understood that myeloma cannot yet be completely cured. One reason I had chosen an autologous transplant was to reduce how often I needed chemotherapy and improve my quality of life. I simply did not want to spend the rest of my life going through chemotherapy. It was too hard for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Given my situation, Dr. Su Li recommended CAR-T therapy for myeloma. He told me that approved CAR-T therapies were already well established in clinical practice in China and that Liquan Hospital had treated many patients with commercial CAR-T products and seen good outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, I was very hesitant. I searched online and found so many different opinions that I didn’t know what to believe. Then one day, another patient with myeloma told me he had undergone CAR-T therapy and had responded very well. I asked him, “Did you still need chemotherapy afterward?” He said no. Seeing him living just like anyone else—and knowing he no longer needed chemotherapy—finally helped me make up my mind.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another important factor was that Shanghai Liquan Hospital is a designated CAR-T treatment center under Shanghai Hu Hui Bao. Commercial CAR-T therapy is expensive, but I met the coverage criteria for adults with relapsed or refractory multiple myeloma whose disease had progressed after three prior lines of therapy. The insurance coverage reduced a substantial portion of our out-of-pocket cost and greatly eased the financial pressure on my family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: Many patients worry about side effects from CAR-T therapy, including cytokine release syndrome (CRS). Did you experience fever, fatigue, or other reactions after the CAR-T cell infusion?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: For me personally, CAR-T therapy was much easier to tolerate than the autologous transplant. To begin with, I didn’t have to stay in a transplant isolation unit. I only needed a bedside laminar-airflow canopy, which already made the experience feel much less stressful.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the first few days, I received lymphodepleting chemotherapy, and that part was uncomfortable. But after the CAR-T cells were infused, I felt much better. I wasn’t vomiting much, and I didn’t lose my hair—the way I had during the autologous transplant, when I had to shave my head. I stayed under the laminar-airflow canopy for about 20 days. My highest fever was around 38°C and it resolved within two or three days. The main issue was a poor appetite. Compared with the autologous transplant, when I was vomiting constantly and my fever reached 39°C, this experience was much easier for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Of course, everyone responds differently, but in my own case, the overall discomfort was much less.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q5: It has been more than six months since your CAR-T therapy. How has your recovery been in terms of energy, appetite, and sleep? What feels most different compared with the time when you were ill?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: CAR-T is not a magic injection that cures everything overnight. Recovery still takes time, and you have to rebuild your strength gradually.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After discharge, I went home to recover and returned to the hospital regularly for follow-up. About three months later, my appetite started to come back and I was gradually able to go outside for short walks. I could genuinely feel myself getting a little better every day.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For me, the happiest thing is not having to go through chemotherapy anymore. I can eat, I can sleep, and I feel so much lighter emotionally.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This April, when I went to Zhejiang during the Qingming holiday to visit family graves, I spent a day sightseeing as well. Seeing spring everywhere—the green grass, birds, peach blossoms, and fresh willow leaves—I felt the joy of simply being alive in a way I hadn’t for a long time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F853d2c7fe0982045cbeba39a118ecce3_20260912214414.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"853d2c7fe0982045cbeba39a118ecce3_20260912214414.png\" alt=\"27fa832b-68a8-4634-8fe0-facc5851bbd0.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Spring scenery photographed by Ms. Zhang in April 2026\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q6: After such a difficult treatment journey and gradually finding your way back to everyday life, has your perspective on life changed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A serious illness completely disrupted the life I had planned and forced me to leave the classroom I loved. The repeated setbacks and the pain of treatment pushed me into a deep depression for a time. Looking back on those darkest days, it was my family’s unwavering support and encouragement, together with the professional treatment and thoughtful care I received from every healthcare professional I met, that helped me reach this important milestone in my recovery and gradually find my way out of that emotional darkness.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, I am more open-minded and at peace than I used to be. Before I became ill, work left me little time for many of the things I enjoyed. Now I can return to them slowly—practicing calligraphy, painting, and embroidery. Each one helps me settle my mind and notice the small, beautiful details of everyday life. I also have opportunities to visit cities I had always wanted to see and experience places I once knew only from books.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If I ever have the chance to stand in a classroom again, I would like to tell my students what this experience taught me about life after facing mortality: strength does not mean never breaking down. It means that even after your defenses have given way, you can still find a way to climb back up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Life is unpredictable, but that uncertainty has also taught me how to value what I have and live with greater calm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F7cd6791b9dae2f6af504ec02cf8659cb_20260912214456.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7cd6791b9dae2f6af504ec02cf8659cb_20260912214456.png\" alt=\"67d253cf-15c7-4cc1-8fd1-b90b432bd0f8.png\"\u002F>\u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Ms. Zhang’s life through painting and calligraphy\u003C\u002Fspan>\u003C\u002Fp>","Dr. Su Li (Associate Chief Physician, MD; Director of Hematology and Myeloma Center, GoBroad Shanghai Liquan Hospital):\n\nMs. Zhang has IgD multiple myeloma and has poor tolerance to myeloma medications. She was unable to tolerate immunomodulatory drugs such as lenalidomide and pomalidomide because of significant adverse effects, which limited the intensity of treatment. As a result, her myeloma progressed several times in less than three years, bringing her to fourth-line therapy.\n\nAt that point, CAR-T therapy was an appropriate option. We had already identified CAR-T as the treatment strategy early in the relapse. There was one additional challenge: a bone marrow sample from the posterior superior iliac spine did not detect myeloma cells, so we could not confirm the BCMA target. Guided by MRI, we then sampled an abnormal area in the sternum, successfully obtained myeloma cells, and were able to confirm the target.\n\nDuring CAR-T treatment, Ms. Zhang experienced only mild cytokine release syndrome (CRS), while the response was very encouraging. She achieved MRD-negative complete remission (CR). She continues regular follow-up and receives periodic immunoglobulin infusions to help prevent infection, and her quality of life has improved significantly. We will continue to monitor her response and manage any treatment-related effects over the long term.",{"slug":251,"title":252,"summary":253,"cover":254,"disease":255,"treatment":256,"patientType":68,"publishedAt":257,"contentHtml":258,"disclaimer":72,"hasAlternate":73,"updatedAt":74},"vsaa-pnh-complement-inhibitor-treatment","At 65, Very Severe Aplastic Anemia and PNH Led to Persistent Hemolysis—Complement Inhibition Helped Him Regain Quality of Life","After being diagnosed with very severe aplastic anemia (VSAA) and later developing PNH, 65-year-old Mr. Liu faced persistent hemolysis, transfusion dependence, and limited treatment options; individualized complement inhibition and enrollment in a PNH clinical trial at Beijing GoBroad Boren Hospital gradually improved his blood counts and quality of life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F99b0dba67a2747faf8fda7ab656ed380.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Aplastic Anemia","Clinical Trials Related to PNH","2026-05-08","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Mr. Liu, 65, was found to have pancytopenia after seeking care for a fever and was diagnosed with very severe aplastic anemia (VSAA). His condition initially stabilized after immunosuppressive therapy, but about a year later his PNH clone began to expand, and he developed VSAA-PNH overlap syndrome with hemolysis, anemia, and a large gallstone that complicated treatment. Persistently low platelet counts made surgery high risk, leaving him with limited options. In 2025, he came to the Anemia Diagnosis & Treatment Center at Beijing GoBroad Boren Hospital, where the team developed an individualized plan that included complement inhibition to control hemolysis and enrollment in a PNH-related clinical trial. With treatment, he gradually became transfusion independent, his hemoglobin and platelet counts continued to improve, and his quality of life improved markedly. After years of difficult treatment, he could finally see hope again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Very severe aplastic anemia with paroxysmal nocturnal hemoglobinuria (VSAA-PNH overlap syndrome) is a high-risk hematologic overlap condition characterized by severe bone marrow failure together with persistent intravascular hemolysis. When gallstones and obstructive jaundice are also present, very low platelet counts can make surgery especially risky, creating a major treatment challenge and an unfavorable prognosis. In this case, the Anemia Diagnosis & Treatment Center at Beijing GoBroad Boren Hospital shares the management of a critically ill patient with VSAA-PNH overlap syndrome complicated by obstructive jaundice. The team's experience with individualized comprehensive treatment and a clinical trial offers a practical reference for similarly complex patients with severe hematologic disease and surgical complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Liu (pseudonym), a 65-year-old from Tianjin, had been living a quiet, ordinary life. Then in 2023, he went to a local hospital because of a fever, and the blood test results immediately alarmed his family: all three blood cell lines were low. His white blood cell count was only 1.53 × 10^9\u002FL, hemoglobin was 74 g\u002FL, platelets were as low as 9 × 10^9\u002FL, and neutrophils were just 0.18 × 10^9\u002FL. The local hospital promptly treated him for infection, but his blood counts failed to recover. His family then took him to the hematology department of a tertiary hospital, where bone marrow aspiration and other detailed tests finally revealed the cause: very severe aplastic anemia (VSAA). He was started on intensive immunosuppressive therapy (IST), and fortunately his blood counts gradually returned to normal.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But the disease was not finished with him. About a year after IST, follow-up testing detected a PNH clone—a population of abnormal blood cells associated with paroxysmal nocturnal hemoglobinuria—and the clone continued to expand. By July 2025, it had reached 91.1%. Taken together, the findings led to a diagnosis of VSAA-PNH overlap syndrome. At that point, Mr. Liu also had markedly elevated direct bilirubin, and imaging showed a gallstone about 3 cm in size that was already causing partial obstructive jaundice. Doctors advised stopping his medication that was supporting blood cell production, but once it was stopped, the aplastic anemia relapsed, his blood counts fell sharply, and he again required frequent transfusions. With platelets persistently below 20 × 10^9\u002FL and no acute abdominal emergency, outside hospitals considered surgery too risky. His family felt desperate and unsure where to turn.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F7be4f72eda750d81a349771532711544_20260913000234.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7be4f72eda750d81a349771532711544_20260913000234.png\" alt=\"9109f9e9-0d78-4ec6-9740-0f70a77502eb.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Progression of Mr. Liu's PNH clone\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With few options left, Mr. Liu came to Beijing GoBroad Boren Hospital. On admission, repeat blood counts showed a white blood cell count of 5.18 × 10^9\u002FL, hemoglobin 65 g\u002FL, mean corpuscular volume 118.6 fL, platelets 14 × 10^9\u002FL, neutrophils 3.38 × 10^9\u002FL, and a reticulocyte count of 48.30 × 10^9\u002FL. Lactate dehydrogenase (LDH) was markedly elevated at 871.6 U\u002FL. Because he also had underlying bone marrow failure, the Anemia Diagnosis & Treatment Center developed an individualized plan that combined treatment to support hematopoiesis with complement inhibition to control hemolysis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On July 29, 2025, Mr. Liu began treatment with eculizumab, a C5 complement inhibitor. His platelet count improved, reaching 48 × 10^9\u002FL by November 11, 2025, but when his hemoglobin dropped to its lowest levels, he still needed transfusions. Years of medical care had consumed nearly all of this ordinary family's savings. Mr. Liu's son worked away from home and used his modest income to help support the family. With limited finances and little room left in the treatment budget, Mr. Liu felt anxious and helpless. More than anything, he hoped there might be an option that was both more effective and financially manageable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F74ff45035885ae1910e2162a05a566ef_20260913000252.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"74ff45035885ae1910e2162a05a566ef_20260913000252.png\" alt=\"c63e2e52-9a4b-46d5-8be2-95c2d4a2f29f.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Specialists from the Anemia Diagnosis & Treatment Center during rounds with Mr. Liu\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At this difficult point, a new possibility emerged. The Anemia Diagnosis & Treatment Center at Beijing GoBroad Boren Hospital had a PNH-related clinical trial underway. When Mr. Liu heard about it, he immediately expressed strong interest in participating.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After rigorous eligibility screening, he qualified and enrolled in the clinical trial on November 11, 2025, starting treatment with a new complement inhibitor. From that point, his course began to change again: he gradually became transfusion independent, his LDH level fell substantially, and hemolysis came under effective control. His hemoglobin has now risen to 94 g\u002FL and his platelet count to 84 × 10^9\u002FL. The fatigue and dizziness caused by anemia have resolved, his quality of life has improved significantly, and his risk of thrombosis has also been markedly reduced.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F86000cff296409da303cdf9d06372d30_20260913000308.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"86000cff296409da303cdf9d06372d30_20260913000308.png\" alt=\"1d3436e6-ab4d-42cb-a9d1-e2850e9466bb.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Changes in Mr. Liu's blood counts at first admission and before and after the clinical trial\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"I will never forget it. The doctors and the clinical trial pulled me back when I felt I had run out of options." Whenever Mr. Liu talks about his experience, his gratitude is clear. At a recent follow-up visit, he brought two commemorative banners to thank the people who had supported him. One was for the blood bank staff, who repeatedly helped him through the difficult period when transfusions were essential. The other was for the entire Anemia Diagnosis & Treatment Center team, whose attention to every detail made him feel genuinely cared for throughout treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Liu speaks with deep appreciation for the Anemia Diagnosis & Treatment Center. In his words, the doctors and nurses did more than treat his illness—they gave him back the confidence and dignity to keep living. That bond between patient and care team means more to him than any words that could be written on a banner.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fa82a4f698f0021835bc2db52d40c3fc3_20260913000327.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"a82a4f698f0021835bc2db52d40c3fc3_20260913000327.png\" alt=\"c38bb24d-0ce9-4974-9108-7597bcd207e8.png\"\u002F>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Ffacca5b2e72ea9464f40577f8c52a972_20260913000336.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"facca5b2e72ea9464f40577f8c52a972_20260913000336.png\" alt=\"711fadd8-02d8-4c4b-9026-007f66afaff0.png\"\u002F>\u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Mr. Liu personally presents commemorative banners to express his thanks\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This kind of warmth and hope is not unique to one patient. Prof. Liping Jing's team keeps each patient's individual circumstances at the center of care, carefully assessing the disease and tailoring treatment to find the best possible balance between safety and effectiveness. That commitment to individualized, precision care is helping more patients like Mr. Liu find a way forward even when treatment options seem limited—and feel supported along the way.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":260,"title":261,"summary":262,"cover":263,"disease":189,"treatment":67,"patientType":68,"publishedAt":264,"contentHtml":265,"expertView":266,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"dlbcl-patient-car-t-autologous-transplant-five-year-remission"," After Relapsed\u002FRefractory Lymphoma and a Long Search for Care, Autologous Transplant Combined with CAR-T Brings Five Years of Sustained Remission","Diagnosed with diffuse large B-cell lymphoma at 19, she later faced relapse and limited treatment options. At Beijing GoBroad Boren Hospital, she received autologous hematopoietic stem cell transplantation combined with CAR-T cell therapy. Five years later, she remains in complete remission and has returned to everyday life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F52f2548fe0c0e171eb4b471280262953.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-30","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Article Summary: Yanyan (pseudonym) was 19 and had just started university when a persistent cough led to a diagnosis of diffuse large B-cell lymphoma. Her disease initially responded to treatment, but relapsed only three months later, and subsequent therapy provided limited benefit. At one point, she felt close to giving up. In 2020, after her family searched widely for another treatment option, Yanyan came to Beijing GoBroad Boren Hospital. The specialist team developed an individualized strategy to reduce her tumor burden, followed by autologous hematopoietic stem cell transplantation combined with CAR-T cell therapy to give her the best chance of durable remission. Now, five years after treatment, Yanyan remains in complete remission. She has returned to an ordinary, fulfilling life and hopes her experience can encourage others who are still going through treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Youth is supposed to be full of possibilities: enjoying life, chasing dreams, and imagining the future. But sometimes it also means facing a life-threatening illness head-on and fighting with everything you have.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2019, 19-year-old Yanyan (pseudonym), a university student from Inner Mongolia, was diagnosed with diffuse large B-cell lymphoma. Chemotherapy at another hospital initially brought the disease under control, but only three months later it relapsed. Further chemotherapy had little effect. Again and again, Yanyan and her family allowed themselves to hope, only to be met with disappointment. Just as she was close to giving up, they heard about Beijing GoBroad Boren Hospital through other patients and began looking there for another chance. With an individualized combination of chemotherapy, autologous hematopoietic stem cell transplantation, and CAR-T cell immunotherapy, Yanyan eventually achieved complete remission (CR). Today, she has passed the five-year milestone with reassuring follow-up results. The young woman who once cried from her hospital bed that she wanted to stop treatment has moved beyond that chapter and stepped into a new life of her own.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fda20f210dd943e86341d45b674f710b4_20260912235847.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"da20f210dd943e86341d45b674f710b4_20260912235847.png\" alt=\"7ec565c7-7420-452b-abbf-675a8753acd6.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo from her five-year complete remission follow-up\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Cancer Diagnosis Put My Life on Pause\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2019, I had just started my second year of university. If life had gone as expected, I would have been doing what other people my age were doing: going to class, shopping, traveling with friends, taking photos, and trying different foods. Instead, life suddenly took a very different turn.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, I only had a cough and assumed it was a common cold. I did not think much of it until the shortness of breath became worse and even climbing stairs left me breathless. A CT scan led to devastating news. Pathology ultimately confirmed diffuse large B-cell lymphoma. This type is more common in adults. My disease was in the mediastinum and accompanied by fibrous connective tissue proliferation, almost like a layer of 'armor' around the tumor cells, which made conventional chemotherapy more difficult to penetrate and the disease more challenging to treat.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, I did not know the full truth about my condition. My parents were afraid the diagnosis would be too much for me, so they tried to protect me with a well-intentioned explanation. I had always been healthy growing up, and even while lying in an ICU bed, I was still relatively calm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That changed when I watched a patient in the bed next to mine being covered with a yellow sheet and wheeled away. Then I heard heart-wrenching crying outside the room. In that moment, it suddenly hit me: death was much closer than I had realized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Eventually, my attending doctor told me the truth. She looked at me seriously and asked, 'Do you understand how serious this disease is?' I said I did not, but I was not afraid. Looking back, I suppose I simply did not yet understand enough to be afraid.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Caught Between Hope and Despair: Remission Lasted Only Three Months Before Relapse\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once treatment really began, I understood just how hard it could be.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My first chemotherapy regimen was standard R-CHOP. The nausea, vomiting, and hair loss were overwhelming. Vomiting was the hardest part. Other patients might feel sick for two or three days, but I would vomit for half a month, sometimes until there was only bile left, and I became so weak I could barely manage a spoonful of porridge. Standing or walking for long periods was exhausting. I looked in the mirror at my bald head, hunched posture, and steroid-related 'moon face' and could hardly recognize the person looking back at me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Meanwhile, people my age were still living the life that had once felt completely normal to me - going to class, traveling, meeting friends, taking pictures. I felt as if everyone else was moving forward while I had been forced to stay still.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But was I going to let that defeat me? No. If chemotherapy made me vomit, I would still try to eat. If I felt low, I would find something to distract myself. My life could not stay on pause forever.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So I pushed through eight cycles of chemotherapy. By the end of 2019, PET\u002FCT showed complete metabolic response (CMR). I was overjoyed. I thought the chemotherapy was finally over and I could go back to normal life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That happiness lasted only three months. In April 2020, follow-up testing showed a new FDG-avid lesion in the mediastinum, raising concern for relapse. I completely broke down when I saw the result. How could it come back so quickly? Hadn't I already been told I was in remission?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My doctors recommended another needle biopsy to confirm the diagnosis, but because of the tumor's location and the procedural risk, I declined. I then received R-DHAP chemotherapy. I forced myself through another full course, only to find at follow-up that the tumor had not shrunk - it had grown.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Each new hope seemed to end in another disappointment. I felt completely powerless, as if no matter how hard I tried, I could not escape the disease. I kept crying to my family, 'Why me? I'm exhausted. I want to give up.'\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fortunately, my parents refused to give up on me. My mother said, 'You're only in your early twenties. There are still so many beautiful things in life you haven't experienced. Your dad and I don't want you to give up so young. We helped you through this once - let us help you again. Don't give up. You are what keeps us going.'\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My father kept searching for lymphoma specialists. Through another patient, he learned about Dr. Shaomei Feng and the lymphoma team at Beijing GoBroad Boren Hospital. That patient had a similar situation and had achieved complete remission after treatment at Boren.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Precision Treatment: Autologous Transplant Combined with CAR-T Brings a New Beginning\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2020, with what felt like our last remaining hope, my family and I came to Beijing GoBroad Boren Hospital. I was emotionally overwhelmed that day and cried, 'I don't want any more treatment.' Instead of becoming frustrated, the doctor patiently encouraged me to try one more time. When she learned how severe my chemotherapy-related nausea and vomiting had been, she reassured me, 'We'll find a way to make it easier on you.'\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After admission, the specialist team reassessed my condition from the beginning. To clarify the diagnosis, they arranged a needle biopsy of the mediastinal mass and sent the specimen for expert pathology review by Professor Zifen Gao. I later learned that Professor Gao is a leading lymphoma pathologist in China. The review confirmed diffuse large B-cell lymphoma, with features favoring primary mediastinal large B-cell lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Based on that detailed reassessment, the team developed a comprehensive, individualized treatment plan. To reduce my tumor burden, I received antitumor immunotherapy combined with multi-agent chemotherapy. After the first course, contrast-enhanced chest CT showed that the tumor had shrunk by more than two-thirds, giving our whole family renewed hope. After the second course, PET\u002FCT showed complete remission. I was so happy I could hardly hold back tears.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The team then moved to the most important stage of treatment: autologous stem cell transplantation combined with CAR-T cell therapy. There was one small episode before I entered the transplant unit. I tried to bargain with the doctors, saying, 'I'll do CAR-T, but I don't want the transplant!' In the end, with a lot of reassurance and persuasion, I went into the transplant unit. On February 5, 2021, I underwent autologous hematopoietic stem cell transplantation. On February 8, I received an infusion of murine CD19-directed CAR-T cells. Both procedures went smoothly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back now, the transplant itself was not as frightening as I had imagined, and the stem cell infusion was actually quite straightforward. The hardest part was the high-dose conditioning chemotherapy beforehand. I felt constantly nauseated without being able to vomit, and the mouth ulcers were even worse - my entire mouth was covered with them and I could not eat. I weighed about 60 kilograms before treatment and just over 40 kilograms when I left the transplant unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But I made it through. PET\u002FCT after leaving the transplant unit showed complete remission. I had won that round.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Throughout treatment, the specialist team closely monitored my condition and treated side effects promptly. At my previous hospital, every chemotherapy cycle left me vomiting for half a month. At Boren, with careful symptom management, I usually had only a couple of days of nausea and could still manage to eat a little. The overall treatment experience was much more manageable. Dr. Shaomei Feng was like an older sister. She would smile and ask how I was doing on every ward round, and she was always patient. My mother later said, 'At Boren, we never felt that same fear or tension. The doctors and nurses felt like friends and family. They always answered our questions and were incredibly patient.'\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Turning Toward the Sun: Five Years in Complete Remission, and Back to Everyday Life\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, I have been in complete remission for five years. I still remember one follow-up visit when Dr. Feng was delighted for me and said, 'You finally don't need to keep coming back. You're free.'\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, I understand more deeply how fragile and precious life can be. In the darkest period, the thing that carried me through was simply refusing to give up. My parents were a huge part of that, but so was the medical team at Boren. I want to say thank you to Dr. Feng and to every doctor and nurse who helped me. If I had not met you when I did, I might truly have stopped treatment. You encouraged me with extraordinary patience, almost as if you were coaxing a frightened child, and helped me press the restart button on my life. I will never forget that.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now I have finally returned to an ordinary life: working, shopping and eating out with friends, and using my camera to capture the small, beautiful moments that make everyday life worth remembering.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I once wrote in an essay, 'A few hundred words can never capture everything we go through during treatment, but I want to tell people facing something similar: nothing has the right to put our lives on permanent pause. The restart button is still in our hands.' I still want to say the same thing today. I understand the discomfort, despair, and helplessness that treatment can bring. But even if life has been forced onto pause, it can start again. Keep going. There is still a road ahead.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Shaomei Feng, on behalf of Dr. Chunrong Tong's team): \n\nThe patient had received guideline-based treatment at another hospital, yet the disease did not achieve adequate remission and instead continued to progress, while the burden of treatment remained substantial. Clinical guidelines provide standardized recommendations for most patients, but every patient also has individual disease features. Applying a standard regimen without adapting it to those differences may limit benefit for some people. By taking into account each patient's immunophenotype, genetic alterations, lesion location, and surrounding tissue environment, and by flexibly combining targeted agents with cytotoxic drugs, treatment can be better individualized and more patients may benefit.\n\nCAR-T cell therapy has distinct advantages because it can selectively target tumor cells. For young patients with relapsed or refractory disease, however, autologous transplantation can also be an important consolidation strategy. When tumor burden has been reduced, integrating autologous transplantation with CAR-T therapy can make use of the period after transplant conditioning and before full immune reconstitution, allowing CAR-T cells to target residual tumor cells that conditioning may not have eliminated completely. This may improve the chance of durable remission.\n\nTraditional cytotoxic chemotherapy, monoclonal or bispecific antibodies, CAR-T cell immunotherapy, autologous transplantation, local radiotherapy, and targeted therapies are not mutually exclusive treatment approaches. For an individual patient, carefully integrating several of these modalities can attack the disease from different directions and may make sustained, long-term remission more achievable. This patient has now remained in remission for five years, and her current risk of relapse is considered very low.\n\nAs the saying goes, the sun comes out after the storm. The young woman whose life was once forced onto pause has now started again. The road behind her was difficult; we hope the road ahead will be much smoother.",{"slug":268,"title":269,"summary":270,"cover":271,"disease":189,"treatment":272,"patientType":68,"publishedAt":264,"contentHtml":273,"expertView":274,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"diffuse-large-b-cell-lymphoma-stem-cell-transplantation","After Two Transplants, He Finally Found His Way Back to Everyday Life","After a liver transplant and treatment for lymphoma, he spent five years rebuilding his health and returning to work and family life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F605bdbc303f368fec724ccd899e23150.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Hematopoietic Stem Cell Transplantation, Chemotherapy","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: Mr. Wang, 45, had already been through a liver transplant and made his way back to everyday life when sudden abdominal pain led to a diagnosis of diffuse large B-cell lymphoma (DLBCL). When chemotherapy failed to control the disease and it continued to progress, he went through an extremely difficult period. After seeking other treatment options, he came to GoBroad Shanghai Zhaxin Hospital \u002F Shanghai Liquan Hospital. Following an adjustment to his treatment plan, he achieved complete remission and underwent an autologous hematopoietic stem cell transplant in 2021. Five years later, he is doing well and has returned to work and family life. From a liver transplant to a stem cell transplant, Mr. Wang has faced two major health crises. He hopes his story can give strength and confidence to others going through treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F28fc0371b699c9273f4cd3ad3ac94fd8_20260912205102.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"28fc0371b699c9273f4cd3ad3ac94fd8_20260912205102.png\" alt=\"61e98944-c3a7-4410-a31d-d295ff82b60c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, GoBroad Shanghai Liquan Hospital welcomed back a very special “graduate.” Now 45, Mr. Wang (pseudonym) walked in with a steady stride and an easy smile, speaking openly about everything he had been through. “Looking at me now, no one would guess I’ve had two major procedures,” he said. “One was a liver transplant, and the other was a hematopoietic stem cell transplant.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He still remembers the sudden abdominal pain that changed his life five years ago. At first, he thought it was acute gastroenteritis. But the pain kept getting worse. While he was in hospital waiting for the pathology results, even morphine could not bring the pain under control—an experience he has never forgotten. It was only after he was diagnosed with diffuse large B-cell lymphoma and started chemotherapy that the pain finally eased.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">His treatment journey, however, was far from straightforward. He went through the shock of diagnosis, the disappointment of chemotherapy not working as hoped, the stress of poor stem cell collection, and the anxiety of entering the transplant ward. Now, five years later, Mr. Wang chose this milestone to return to Liquan Hospital for a follow-up. For him, it was a way to close one difficult chapter and begin the next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When asked about the future, he smiled and said, “Three meals a day, simple food on the table, and my family by my side—that’s happiness.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From a liver transplant to a hematopoietic stem cell transplant, from life-threatening illness back to the rhythms of ordinary life, Mr. Wang has spent five years rebuilding his life. His message to others going through treatment is simple: even the hardest road can be finished one step at a time, and even the longest night eventually gives way to morning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F889cdad12f0d3481801bb8170d849d59_20260912205130.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"889cdad12f0d3481801bb8170d849d59_20260912205130.png\" alt=\"5a4b1509-2752-4392-959d-ffc329c7359d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Today, Mr. Wang is back on the badminton court, enjoying an active life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: Looking back, what symptoms did you first notice, and how did you feel when you received the diagnosis?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: In September 2019, I went to hospital because of sudden abdominal pain. At first, I thought it was acute gastroenteritis, and the symptoms improved somewhat after IV treatment. But soon after the National Day holiday, the severe abdominal pain came back. A contrast-enhanced CT scan showed enlarged lymph nodes in my neck and multiple enlarged retroperitoneal lymph nodes, so I was transferred to hepatobiliary surgery. A biopsy and pathology report ultimately confirmed diffuse large B-cell lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I had already undergone a liver transplant in 2011. It had taken so much to come through that experience and return to a normal life. Being diagnosed with lymphoma after all that was another huge blow, both emotionally and financially.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I kept asking myself, “Why me again?” The nightmares I thought I had put behind me seemed to come rushing back overnight. The emotional pressure and financial worries fed into each other, and there were many nights when I lay awake until morning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But my family never gave up on me. Their support, encouragement, and constant presence became the light that slowly pulled me out of that dark place. I began telling myself: I made it through once before, so I had to give it everything I had one more time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even then, treatment was difficult. After four cycles of first-line chemotherapy, the disease was still progressing. I then had four cycles of second-line chemotherapy, but the lymphoma still did not go into remission. Every follow-up felt like a roller coaster—hope, disappointment, then finding the strength to keep going again. My body and emotions were both being pushed to the limit, but I wasn’t ready to give up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: What brought you to GoBroad Shanghai Zhaxin Hospital \u002F Shanghai Liquan Hospital?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I had my liver transplant at Shanghai General Hospital, so I had known for years about Prof. Chun Wang, then Director of Hematology there, and his reputation for treating complex hematologic diseases. When lymphoma treatment kept failing and I felt I was running out of options, his name stayed in my mind.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At that point, I saw two main options: join a clinical trial, or go to GoBroad Shanghai Zhaxin Hospital to see Prof. Chun Wang and look for another chance. I thought it over again and again, asked around, and discussed it with my family many times. In the end, I decided to put my trust in a specialist whose expertise and reputation I had known for years. In October 2020, I went to Zhaxin Hospital for further treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Chun Wang’s team developed a new chemotherapy plan for me. I had mixed feelings at the time—I was hopeful, but also afraid of being disappointed again. Then, finally, things began to turn around. The new regimen worked very well, and my assessment showed that I had achieved complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Chun Wang and my attending physician, Dr. Su Li, recommended consolidating that remission with an autologous hematopoietic stem cell transplant, with the goal of achieving a deeper and more durable response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I later learned that the Department of Hematology at GoBroad Shanghai Liquan Hospital had just opened. As someone coming from outside Shanghai, whether I was treated at Zhaxin or Liquan made little difference medically. What stood out at Liquan was the practical support for families: rooms were available for accompanying family members, and the hospital provided complimentary transportation for patients on the day of admission and discharge. Those thoughtful details made the travel and logistics much easier for all of us. In March 2021, I successfully underwent an autologous hematopoietic stem cell transplant at Liquan Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: What was the hardest part of treatment for you?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: For me, the hardest part was often the anxiety—the mental strain more than anything else.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During stem cell mobilization and collection, things did not go as smoothly as we hoped because I had been taking immunosuppressive medication long-term after my liver transplant. The first collection produced only a very small number of stem cells—nowhere near enough. We tried mobilization a second time, and only after combining the two collections did we barely reach the amount needed. I’ll admit I was very nervous before entering the transplant ward. I kept worrying that something might go wrong and was afraid of what I didn’t know.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But once I was actually in the transplant ward, the experience was much smoother than I had imagined. I did feel weak and lost my appetite, but compared with my liver transplant in 2011, both the physical discomfort and the fear were much more manageable. The care and attention from the medical team also gave me a great deal of confidence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I had very little appetite in the transplant ward, but I made myself eat every day. I kept thinking: I’ve already come this far—I can’t stop at the final hurdle. One bite at a time, one day at a time. Before I knew it, more than 20 days in the transplant ward had passed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back now, I feel very fortunate. I made it through two major hurdles: a liver transplant and an autologous hematopoietic stem cell transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Life has thrown plenty of challenges my way, but each time things were at their hardest, there was still a path forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: Has going through these serious illnesses changed the way you look at life?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I would never have made it this far without my family standing behind me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Going through two major illnesses placed a huge financial burden on our family. The liver transplant alone cost more than we could cover even after selling a property. I’m especially grateful to my younger brother, my wife, my aunt, and my uncle. None of them had money to spare, but they each found a way to help—some contributed 50,000 yuan, some 40,000, and some more than 10,000. I still haven’t been able to repay all of it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My mother passed away around 2000. When I became ill, my aunt and uncle looked after me as if I were their own child, and I will always be grateful for that. I also have two children. My wife had to carry the weight of the household while caring for them, so she could not always be with me in hospital. My younger brother was the family member who stayed with me most during my hospitalizations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, I’m back to a normal working and family life. I work as a driving instructor. I keep a regular routine, eat three meals a day, and most importantly, I have my family around me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I’m still paying back some of the debt from my treatment, little by little, but I’m content with where I am.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What I want now is simple: to live each day well. Waking up to sunlight, being free from pain, being able to eat and sleep normally—that is a good day to me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q5: What would you like to say to other patients who are still going through treatment?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I know how hard this road can be. I’ve had to work my way through setback after setback too.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That’s why, looking back on everything I’ve been through, I want to say this: keep believing in yourself, keep trusting your doctors, and believe that after the difficult stretches and the storms, there can still be a new beginning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today may be hard. Tomorrow may be hard too. But the day after that, the light may finally start to come through.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Su Li (Associate Chief Physician, MD; Director, Department of Hematology, and Director, Myeloma Center, GoBroad Shanghai Liquan Hospital):\n\nThis patient had an exceptionally difficult treatment course. He developed diffuse large B-cell lymphoma after a liver transplant, and the disease continued to progress despite both first- and second-line treatment. At the time, he was also under significant financial pressure.\n\nAfter he came to our hospital, we adjusted his treatment plan. We used a regimen combining rituximab, a BTK inhibitor, and lenalidomide, together with ESHAP chemotherapy. He successfully achieved complete remission (CR), and we were then able to complete stem cell collection.\n\nThroughout chemotherapy and transplantation, we also took his history of hepatitis B into account and continued hepatitis B immunoglobulin prophylaxis to reduce the risk of HBV reactivation and support the safe completion of treatment. Five years have now passed, and it is deeply rewarding to see him continuing to do well and back to his normal work and family life.",{"slug":276,"title":277,"summary":278,"cover":279,"disease":181,"treatment":90,"patientType":68,"publishedAt":280,"contentHtml":281,"expertView":282,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"elderly-aml-patient-five-year-survival-after-transplant","At 62, His Leukemia Did Not Respond to Chemotherapy. Five Years After Transplant, He Reached a Major Recovery Milestone","Diagnosed with acute myeloid leukemia at 62, he went through chemotherapy without remission and even an ICU stay before receiving a haploidentical hematopoietic stem cell transplant at Beijing GoBroad Boren Hospital. Five years later, he remains disease-free and is once again enjoying retirement.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F05adfba22db456472916956b7fdb55f8.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-17","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In 2020, 62-year-old Mr. Liu (pseudonym) was preparing for surgery for varicose veins when abnormal blood test results led to an unexpected diagnosis of acute myeloid leukemia. Older age, failure to achieve remission with chemotherapy, and serious complications during treatment left him feeling hopeless at times. With his family’s support, he came to Beijing GoBroad Boren Hospital, where Dr. Tong Wu’s team evaluated him and proceeded with a haploidentical hematopoietic stem cell transplant. After making it through the transplant unit, management of graft-versus-host disease, and years of follow-up, he has now passed the important five-year post-transplant milestone with stable blood counts and has returned to everyday life. His experience shows that age alone does not determine what treatment is possible, and that appropriate treatment, close medical care, and a strong partnership between patients, families, and clinicians can open new possibilities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In hematologic care, five years of disease-free survival is often regarded as an important milestone toward clinical cure. For a 62-year-old patient with acute myeloid leukemia (AML) whose disease had not gone into remission with chemotherapy and who had once required ICU care, reaching that milestone was especially hard-won. After undergoing a haploidentical hematopoietic stem cell transplant at Beijing GoBroad Boren Hospital, he made it through those five years and recorded his own story of recovery - one shaped by perseverance and trust.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Faddb6912e09734b3c48cde6d223cbfa8_20260912233937.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"addb6912e09734b3c48cde6d223cbfa8_20260912233937.png\" alt=\"3684402c-f9cf-40a4-beb5-d34daf00780c.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo from his five-year post-transplant follow-up\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>My Recovery Story - Facing Leukemia in My 60s and Reaching the Five-Year Milestone\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In September 2020, I was 62. I had imagined retirement would mean spending time with my grandchildren and traveling with my family. Then one diagnosis suddenly put everything on hold: acute myeloid leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the time, I was at a hospital in Beijing preparing for surgery for varicose veins that had bothered me for years. My preoperative blood tests showed a high white blood cell count and low platelets, and the doctor suggested a bone marrow test. I felt as though the ground had fallen away beneath me. At my age, chemotherapy was not only risky - it was exhausting. I did not achieve remission after either the first or second cycle. I even had a brief loss of consciousness and was admitted to the ICU. Once I stabilized, I was transferred back to the hematology chemotherapy unit, but I could no longer tolerate standard-dose chemotherapy, and the leukemia cells were still there. Lying in the laminar-flow ward and watching birds outside the window, I kept thinking: this cannot be how my life ends.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My wife and daughter actively searched for other treatment options. They asked around and eventually found Dr. Tong Wu’s team at Beijing GoBroad Boren Hospital. They came back and told me the hospital could take my case and that a haploidentical hematopoietic stem cell transplant was possible. My daughter held my hand and said, “Dad, let’s give it a chance.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After one cycle of treatment at Boren Hospital, my bone marrow was MRD-negative. Then came donor matching, conditioning, and the stem cell infusion - a long process. I still remember the smell of disinfectant, all the tubes attached to my body, and the rash and diarrhea caused by graft-versus-host disease. I got through each of them. The hardest part was the month in the transplant unit. I was so weak that even taking a sip of water felt like a struggle. But I kept telling myself: now that I’ve chosen treatment, I cannot let my family’s tears or the medical team’s efforts be in vain.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The day I left the transplant unit, the sunlight felt especially bright. Dr. Yongqiang Zhao told me that the donor stem cells had successfully engrafted and my blood counts were beginning to recover. To me, it felt as though a new blood-forming system had been planted inside my body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Over the five years since transplant, I have never taken recovery for granted. Regular follow-ups, a consistent routine, a balanced diet, and rehabilitation exercise became non-negotiable parts of my life. For the first three years, I would lose sleep before almost every checkup, terrified that the word “relapse” might return to my life. But with one reassuring test after another, my confidence gradually came back.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, I am 67. I can walk with my wife - often around 15,000 steps a day - take my granddaughter to and from school, and even play chess with neighbors in our community. Looking back on these five years, there is one thing I want to tell other patients: age is never, by itself, a reason to give up. Leukemia once brought me to the lowest point of my life, but modern medicine and my family’s love helped pull me back. I am grateful to the part of me that kept going, to the medical team for their expertise, and to my family for never leaving my side.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I have crossed the five-year milestone that, clinically, marks an important threshold toward cure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To everyone who is still on this road, I hope you too will one day look up and see your own clear sky after five years.\u003C\u002Fspan>\u003C\u002Fp>","A Message from the Medical Team: Age Is Not a Barrier - Patients and Clinicians Can Create New Possibilities Together.\n\nWhen we first met this patient, he was 62 and had been diagnosed with acute myeloid leukemia (AML). Older age, high-risk disease, and underlying health conditions all made his treatment particularly challenging.\n\nOlder patients with AML often tolerate conventional chemotherapy less well and face a higher risk of relapse, with less favorable long-term outcomes. After repeated discussions with the patient and his family, we decided to pursue a more demanding but potentially more promising path: allogeneic hematopoietic stem cell transplantation.\n\nThe transplant was not easy. Mucosal injury from conditioning, infection risk, and repeated fevers during bone marrow suppression tested both his resilience and our clinical judgment every day. Yet his engagement with treatment exceeded our expectations. He never complained. Even at the hardest moments, he would simply say quietly, “Doctor, I trust you. Thank you.”\n\nBy day 14 after the stem cell infusion, his peripheral blood counts began to recover. By day 28, donor chimerism had reached full-donor status - evidence that the new hematopoietic system had successfully engrafted.\n\nBut successful engraftment was only the first step. Managing graft-versus-host disease, preventing infection, and monitoring for relapse are all part of the long-term work after transplant. Over the past five years, he has followed medical advice closely and returned for every scheduled follow-up. His blood counts, bone marrow findings, donor chimerism, and viral load measurements have remained stable and within the expected range.\n\nToday marks a full five years since his transplant. In hematology, five years of disease-free survival is regarded as an important marker of clinical cure. For this patient, it means the leukemia has remained controlled over the long term and the donor-derived hematopoietic system has continued to function successfully.\n\nMedically, this is an excellent transplant outcome. But as a doctor, I see something more: a recovery made possible by patients, families, and clinicians working together with the same goal.\n\nTo all patients living with a blood disorder, we would like to say:\n\nAge is not an absolute barrier, and courage can create possibilities. Advances in modern medicine - particularly in transplantation - are making treatment possible for more patients who might once have had very limited options.\n\nCongratulations to Mr. Liu, and thank you for the trust he placed in us.\n\nFive years is a milestone, not an endpoint. We hope the next five and ten years bring him continued health and peace of mind.",{"slug":284,"title":285,"summary":286,"cover":287,"disease":80,"treatment":288,"patientType":68,"publishedAt":289,"contentHtml":290,"expertView":291,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"ph-positive-all-transplant-recovery","Diagnosed with B-ALL at 62, She Returns to Everyday Life After a Stem Cell Transplant","An unexpected health check changed the course of her life, but optimism and perseverance carried her through leukemia treatment and back to everyday living.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fce402178ecfac1d3a5ab14560ccc594f.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp"," Hematopoietic Stem Cell Transplantation","2026-04-10","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: At 62, Ms. Chen (pseudonym) joined a friend for a hospital visit and decided to have a health check of her own. Unexpectedly, her blood tests were abnormal, and she was later diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The sudden diagnosis left her and her family frightened and unsure where to turn, but they soon began searching for treatment options. After coming to GoBroad Shanghai Zhaxin Hospital, the medical team developed an individualized treatment plan, and she underwent autologous hematopoietic stem cell transplantation, achieving complete remission. In the years since transplant, Ms. Chen has gradually returned to normal life. She now manages household chores, gets around independently, travels with friends, and once again enjoys ordinary moments with family and loved ones. By sharing her story, she hopes to encourage other patients to hold on to hope, trust their medical team, and stay actively engaged in treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F5eab334e3ca31f5b3667a6a569e5f267_20260912204744.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5eab334e3ca31f5b3667a6a569e5f267_20260912204744.png\" alt=\"22cfb1b4-728c-4d3b-9e30-a1ee9172fe44.png\"\u002F> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen (pseudonym), now 62, was accompanying a friend to the hospital in the spring of 2021 when she decided to have a health check herself. That casual decision changed everything. Her blood test results were abnormal, and before she had even completed the rest of the routine checkup, she received an urgent call from the doctor asking her to be admitted to the hospital immediately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In May 2021, after further testing, Ms. Chen was diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The news felt devastating, as though life had suddenly been put on a countdown. She and her family were shocked, frightened, and unsure what to do next. Still, they did not give up. They quickly began asking around and looking for treatment options. Their search eventually brought them to GoBroad Shanghai Zhaxin Hospital. After a comprehensive assessment, the medical team developed a treatment plan tailored to her condition. In February 2022, Ms. Chen underwent an autologous hematopoietic stem cell transplant and recovered smoothly through the transplant phase. Her leukemia went into complete remission. More than four years later, she is back to doing household chores, riding her e-bike independently, and going out with friends. Most days, she hardly feels like someone who once had a serious blood cancer. At this follow-up visit, accompanied by her younger sister, Ms. Chen completed all her scheduled tests and shared her treatment experience with other patients. Her message to them is simple: believe in yourself, stay hopeful, and keep moving forward through treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen's sister also shared advice for families: stay close, offer reassurance, pay attention to the patient's emotional needs, and do what you can to make everyday life more comfortable — including helping with food and meals when appetite is difficult. Small acts of care can help patients feel supported and less alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: When you think back to the moment Ms. Chen was first diagnosed, what was going through your mind as her sister?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen's sister: I still remember getting a phone call from my niece. She was crying and said, 'Auntie, Mom has leukemia.' Just hearing the word 'leukemia' was terrifying. Before that, it was something I had only heard about on television. I never imagined it could happen to someone in our own family. While my sister was in the local hospital, the doctors gave us devastating news — they said she might have as little as one month to live. We simply could not accept it. She had seemed perfectly well and had only gone for a checkup. How could she suddenly be so seriously ill? When we first heard the diagnosis, it felt as if the sky had fallen in. The whole family was crying, and none of us knew what to do. We kept asking people where we should go and what treatment might help. It was an incredibly frightening and painful time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: Ms. Chen, what helped you regain confidence and decide to go ahead with an autologous stem cell transplant? What was the transplant-unit experience like for you, both physically and emotionally?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen: I really feel that coming to GoBroad Shanghai Zhaxin Hospital was meant to be. Before we arrived, my family and I had no sense of direction. We were ordinary people facing something completely unfamiliar, and we were deeply afraid. But after speaking with the medical team here and understanding the treatment plan, we realized that leukemia was not necessarily a hopeless diagnosis. With appropriate treatment, there was a real possibility of recovery and returning to normal life. The doctors and nurses were patient and attentive. My Mandarin is not very good, but they never made me feel rushed. They explained things again and again, and sometimes spoke through my daughter to make sure I understood what was happening at every step. The atmosphere here felt warm and reassuring, and everyone around us was kind. Slowly, our whole family began to relax after the fear and panic we had felt at the beginning. Before I entered the transplant unit, my family was very worried because I was already close to 60. But once I was there, the 20-plus days passed faster than I expected. My two daughters rented a place near the hospital and brought me food every day. Things went smoothly throughout. I was definitely scared before the transplant, but looking back now, it was not nearly as frightening as I had imagined.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After I was discharged, I went home to recover. Whenever I felt unwell or had questions after follow-up tests at my local hospital, I would contact Dr. Chuxian Zhao. She always responded promptly, answered my questions, and reassured me. That helped me feel much more at ease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: More than four years after your transplant, how is life different from before you became ill? How have you recovered, and is there anything you pay particular attention to now?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen: I have never been very good at sitting still, and I tend to worry about everything. But during the first year after transplant, I wanted to focus completely on recovery, so I bought a small place out in the countryside — what I jokingly called the 'middle of nowhere.' The air was fresh, and my daughters would not let me do any housework at all. After about a year, I could feel my strength gradually coming back, and I started taking care of things around the house again, just as I used to. When I first came home after the transplant, I had lost all my hair, and that affected my confidence. Now it has all grown back. Today I can ride my e-bike to buy groceries and go out on my own. If I do not tell people, they would never know I once had leukemia. For me, mindset matters a lot. During treatment, trust your doctors and believe that you can get through the difficult days. During recovery, do not rush — take it one step at a time and listen to your body. Once you are well again, try not to think of yourself only as a patient. Go back to living your life and enjoy it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fad77b51fa307a54d733239c009c04250_20260912204807.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ad77b51fa307a54d733239c009c04250_20260912204807.png\" alt=\"ac7a9179-3994-4c4e-9680-a56eae0cfbd5.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo taken in April 2026 during a self-drive trip with a friend.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: Recovery from a blood disorder often depends on the quiet, day-to-day support of family. From a caregiver’s perspective, what advice would you give families going through a similar experience?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chen's sister: Her two daughters were her main caregivers. To me, they were still 'kids' themselves, but when their mother became seriously ill, they stepped up and carried an enormous responsibility. They gave her strength and confidence, both in practical ways and emotionally. They learned how to care for her and often asked other caregivers on the ward for advice. Their attentive care played an important part in my sister's recovery. For this follow-up, I insisted on coming with her. I wanted to witness this important milestone and hoped that, after passing this latest 'exam,' she might finally be able to 'graduate' from the hospital. When someone in the family becomes seriously ill, caregivers also go through tremendous emotional strain. The most important thing is to look after your own emotional wellbeing so you can keep supporting the patient. If the patient becomes upset or discouraged, try to be patient and understanding. When the whole family pulls together, it becomes much easier to get through the hardest parts of treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fdd998aff1e71c82c49117eb968e7c2f6_20260912204826.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"dd998aff1e71c82c49117eb968e7c2f6_20260912204826.png\" alt=\"07bda77f-3a3f-4410-b347-f7bbceffeee2.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Photo taken in March 2026 during Ms. Chen’s follow-up visit at GoBroad Shanghai Zhaxin Hospital.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian ZHAO (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nMs. Chen's bright, infectious laughter has stayed with us. As the gentle spring breeze returns and blossoms appear on the branches, we hope this new season brings her continued health and recovery.\n\nTreatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has advanced significantly in recent years. As non-transplant approaches have become more effective, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become more individualized. For some patients who achieve a deep molecular response with a tyrosine kinase inhibitor (TKI) plus immunotherapy, allo-HSCT may not be necessary.\n\nLooking ahead, treatment for Ph+ ALL is moving toward more individualized and less toxic strategies. For selected patients, combinations of immunotherapy and molecularly targeted therapy may even make it possible to avoid both chemotherapy and transplantation, creating more treatment possibilities for patients.",{"slug":293,"title":294,"summary":295,"cover":296,"disease":80,"treatment":172,"patientType":82,"publishedAt":297,"contentHtml":298,"expertView":299,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"b-all-child-car-t-transplant-five-year-remission","A New Start After Leukemia Relapse: CAR-T Followed by Transplant, and Five Years Later, Back to a Bright Teenage Life","Diagnosed with leukemia at age 6, Xixi relapsed and went on to receive CAR-T therapy followed by hematopoietic stem cell transplantation. Now 15, she has reached her five-year post-transplant milestone in sustained remission and is embracing teenage life again.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F27a0589bbcade659e0bd71c7a274d284.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-03","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Article summary: Xixi (pseudonym) was diagnosed with B-cell acute lymphoblastic leukemia at age 6 in 2017 and was able to return to everyday life after treatment. Three years later, however, the leukemia relapsed with central nervous system (CNS) involvement. In 2020, after a recommendation from another patient family, Xixi and her parents traveled to Beijing GoBroad Boren Hospital. Under the close care of the teams led by Dr. Tong WU and Dr. Yanzhi SONG, she achieved remission with CD19 CAR-T cell therapy and then underwent a related-donor haploidentical hematopoietic stem cell transplant. Over the five years that followed, she faced infections, graft-versus-host disease (GVHD), and other challenges, gradually recovering with the support of her medical team and family. Today, at 15, she has successfully completed her five-year post-transplant evaluation. Her bone marrow remains in remission and donor chimerism remains at 100%. The little girl who once battled leukemia has grown into a quiet, confident teenager looking ahead with hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2017, when Xixi was only 6, she was diagnosed with B-cell acute lymphoblastic leukemia. After treatment at another hospital, she briefly returned to normal life, only for the disease to relapse three years later. In November 2020, on the recommendation of another family from their hometown, Xixi and her parents came to Beijing GoBroad Boren Hospital. With treatment from the teams led by Dr. Tong WU and Dr. Yanzhi SONG, she successfully underwent a related-donor haploidentical hematopoietic stem cell transplant. Now, five years after transplant, her comprehensive follow-up results are reassuring: her bone marrow remains in remission and donor chimerism is still 100%. Over a nine-year leukemia journey, the little girl who once had bleeding spots all over her legs has grown into a calm, cheerful, and hopeful teenager.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F46cd706eeb35368cbedac377d1199a0b_20260912230551.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"46cd706eeb35368cbedac377d1199a0b_20260912230551.png\" alt=\"2bec3ecc-f08f-4ea0-94c4-a205758643a4.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo from Xixi's five-year post-transplant follow-up\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Few Tiny Red Spots Marked the Start of a Life-Changing Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2017, my daughter Xixi was 6 years old and still in kindergarten. One day, I noticed a few small red spots on her legs. They didn't hurt or itch, so I assumed it was a simple skin allergy and took her to a dermatologist for some ointment. The spots faded after a few days, and I felt relieved. I had no idea that this was the beginning of something much more serious.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That March, a few days after we took her to a hot spring, the red spots appeared again - this time with nosebleeds. My heart sank, and I took her to see a doctor right away. As soon as the blood test results came back, the doctor became very serious and told us to take her to a major hospital as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At a hospital in Kunming, MICM testing soon confirmed that Xixi had B-cell acute lymphoblastic leukemia, classified as intermediate risk. Hearing the diagnosis felt like being struck by lightning. Leukemia was something I had only ever heard about on television. I couldn't understand how it had suddenly happened to my little girl.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy was incredibly hard on her. Xixi had severe nausea and vomiting and could barely eat. But she was far more resilient than I had imagined. She quietly endured each treatment without crying or complaining and cooperated with everything the doctors asked of her. Watching such a young child be so brave broke my heart, but I kept telling myself that the hardest days would eventually pass.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">She made it through 12 courses of chemotherapy, one after another. During the next three years of maintenance therapy, she was eating and sleeping well and remained stable. For a while, I truly believed the storm had passed and our lives were finally getting back on track.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Relapse Changes Everything: Traveling to Beijing for Another Chance\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But the disease returned. In May 2020, a routine bone marrow examination brought devastating news: MRD was 25.63%. My daughter's leukemia had relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I didn't want to believe it. We held on until another evaluation that October, but the result was even harder to hear: hematologic relapse. Her treating doctor told us that conventional chemotherapy was unlikely to offer much benefit at that point and recommended CAR-T therapy. But CAR-T was not yet well established at the hospital where she was being treated, and we had no idea what to do next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When our family felt completely lost, a phone call from another patient family from our hometown gave us a new direction. Their child also had B-ALL and had successfully undergone transplantation at Beijing GoBroad Boren Hospital. They told us the specialists there had extensive experience and encouraged us to go and seek another opinion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2020, carrying all of our hope and anxiety with us, we boarded a flight to Beijing to look for another chance for our daughter.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>CAR-T Followed by Transplant: A New Path Forward\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After arriving at Beijing GoBroad Boren Hospital, the immunotherapy team carried out a comprehensive assessment. The results were difficult to take in: Xixi had an overt leukemia relapse, a high disease burden, and CNS involvement. With concurrent leukoencephalopathy, she needed repeated lumbar punctures every other day for a period of time. She gritted her teeth and cooperated each time. Standing beside her, I could only wish I could take some of that pain for her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On November 17, 2020, Xixi received an infusion of CD19 CAR-T cells and achieved sustained bone marrow remission. Before we could fully relax, the medical team explained that because her leukemia burden had been so high, proceeding to transplantation promptly would offer the best chance of consolidating the response and reducing the risk of the disease returning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We had originally come to Boren for CAR-T and had never expected transplantation to be the next step. But at that point, we didn't hesitate. We had chosen to trust the team. I told the doctor, "We're not going anywhere else. We want to continue her treatment here."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Tong WU's transplant team soon developed an individualized plan for Xixi, using a TBI-based myeloablative conditioning regimen and selecting her father as the related haploidentical donor. In mid-to-late December 2020, she began pre-transplant conditioning. I still remember watching her small figure enter the transplant unit. She wasn't even 10 years old and had to face so much on her own. In early January 2021, she received her father's hematopoietic stem cells in two infusions. With close care from the transplant team, platelet engraftment was achieved on day +13 and white blood cell engraftment on day +15. She had made it through another major milestone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After leaving protective isolation, skin GVHD, diarrhea, and a pulmonary infection followed one after another. Dr. WU's team adjusted treatment carefully and managed each complication as it arose. Eventually, Xixi's clinical indicators stabilized and she was discharged, continuing regular medications and scheduled follow-up visits.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the most part, Xixi remained stable afterward. The most frightening episode came at the end of 2022, when a viral infection left her with profound weakness in her arms and legs and her condition became critical. Once again, the medical team treated her intensively and helped her through the crisis. Each time she recovered from a setback, our trust in the team grew stronger.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When we were treated in Yunnan, we rarely had much opportunity to communicate directly with the doctors, let alone stay in touch after leaving the hospital. At Boren, the experience felt very different. Dr. Tong WU was thorough during every ward round and patient whenever we asked questions. Dr. Yanzhi SONG was equally attentive; even after we went home, she would message us to ask how Xixi was doing and remind us about follow-up visits and medications. Once, after returning from a business trip, Dr. Qi Wang brought Xixi a Frozen doll. She was so happy and still treasures it today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xixi often says, "Dr. Wu, Dr. Song, and everyone here are so gentle." Whenever she felt frightened during treatment, the doctors and nurses would speak softly to her, encourage her, and tell her what a brave little fighter she was.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Xinxin, a teacher at the ward school, organized crafts and activities for the children every week. Xixi loved going while she was in the hospital and still remembers those classes fondly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treating our daughter had used up nearly all of our family's savings. The hospital proactively helped us apply for financial assistance for major illness, which came at a time when we desperately needed it. Xiaobai Chuntian, a patient-family support charity, also provided practical help and a warm community for families going through treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Those small acts of kindness and steady support meant that our nine-year leukemia journey was not defined only by pain and uncertainty. They also gave us the strength and hope to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Five Years After Transplant: A Milestone Worth Celebrating\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xixi is 15 now, almost as tall as I am. The fragile little girl I remember has grown into a calm, bright teenager. She loves quietly working on crafts and sometimes shares small moments from her everyday life on social media, one post at a time. Things that once felt impossibly far away have now become ordinary parts of her life - and that makes them all the more precious.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Her five-year post-transplant evaluation brought the news we had been hoping for: all of her results met the expected targets. She had passed this major five-year milestone. I asked what she wanted to say to her doctors. She didn't use many words. She simply looked at me and said sincerely, "Thank you for taking care of me all these years - and most of all, thank you for giving me a second chance at life."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From 2017 to 2026, nine full years and more than 3,000 days have passed. Only our family truly knows how much fear, exhaustion, disappointment, and hope were packed into that time. But if I could pass one thing on to families who are still going through leukemia treatment, it would be this: please keep going. The nights that feel endless and the challenges that seem impossible will eventually pass, and there can still be light ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My greatest wish for the years ahead is that Xixi can finally set aside the identity of a "leukemia fighter" and simply live like other girls her age - return to school, make friends who share her interests, pursue the things she loves, and experience all the ordinary joys of being a teenager. I hope life is gentler with her from here on, and that she can keep growing toward the light.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Qi Wang, from the teams of Dr. Tong WU and Dr. Yanzhi SONG): \n\nThis patient had refractory\u002Frelapsed B-ALL with CNS involvement, for which conventional chemotherapy was unlikely to eradicate the disease. CD19 CAR-T therapy was used as a bridge to transplantation, rapidly achieving a deep bone marrow remission and creating an optimal window for HSCT. Transplantation was initiated approximately 1.5 months after CAR-T, providing close treatment continuity and helping reduce the risk of immune escape and disease rebound. A TBI-based myeloablative conditioning regimen was selected for its tissue penetration and ability to address residual CNS disease, with the aim of reducing post-transplant CNS relapse. After transplantation, the patient developed gastrointestinal, pulmonary, and neurologic GVHD. Neurologic GVHD manifested as severe myasthenia gravis, with an inability to lift her limbs or head - a rare and serious form of GVHD. Her eventual return to normal function reflects precise adjustment of immunosuppressive therapy and effective multidisciplinary care. She also developed a secondary renal tumor after transplant and underwent surgical resection, underscoring the importance of monitoring for second malignancies during long-term follow-up. Structured surveillance enabled early detection and intervention.\n\nFrom a clinical perspective, five years of disease-free survival after transplant is considered a clinical cure. Xixi has reached that milestone. Behind it are her own resilience, her parents' unwavering support, and the trust built between the family and the medical team. Xixi's mother said she hopes her daughter can finally take off the armor of a \"leukemia fighter\" and live like any other girl. That is also what we, as doctors, hope for most. After nine years, this leukemia journey has finally reached its end. We wish Xixi a healthy, peaceful life ahead, always moving toward the light.",{"slug":301,"title":302,"summary":303,"cover":304,"disease":305,"treatment":306,"patientType":82,"publishedAt":307,"contentHtml":308,"expertView":309,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"t-lymphoblastic-lymphoma-teenager-treatment","At 15, He Was Diagnosed with T-Lymphoblastic Lymphoma. His Father Kept Learning, Searching, and Standing Beside Him on the Road to Sustained Deep Remission","After 15-year-old Xiaohao was diagnosed with T-lymphoblastic lymphoma (T-LBL), his family sought care in different cities to find a treatment plan better suited to him. With careful, risk-adapted management by Professor Yonghong Zhang's team, nearly a year of standardized treatment brought Xiaohao into sustained deep remission, and he is now steadily moving toward recovery.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F394543c0abb9753b4ad3da1a7c7b399d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","T-Lymphoblastic Lymphoma","Chemotherapy‌","2026-03-27","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Fifteen-year-old Xiaohao had been enjoying high school life when a lump in his neck led to an unexpected diagnosis of T-lymphoblastic lymphoma. As treatment became more complex, his father began reading extensively, searching for a more standardized approach that could offer his son the best chance of long-term benefit. In 2025, Xiaohao came to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital. Professor Yonghong Zhang's team conducted a comprehensive reassessment and carefully planned his subsequent treatment based on the disease characteristics, treatment response, and risk factors. After nearly a year of guideline-aligned, systematic treatment, Xiaohao achieved sustained deep remission and has now entered maintenance therapy. His father, whom other families came to call a 'research-minded parent,' shares what he learned along the way in the hope that their experience can offer practical reference and encouragement to other families facing adolescent hematologic cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2025, 15-year-old Xiaohao (pseudonym), from Jiangsu, was diagnosed with T-lymphoblastic lymphoma. After completing four initial cycles of chemotherapy at another hospital, his family traveled to Beijing in search of more standardized and precise follow-up treatment that could give him the best chance of long-term disease control. They came to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital. Based on Xiaohao's disease features, Professor Yonghong Zhang's team developed an individualized treatment plan and managed every stage closely. After nearly a year of systematic treatment, Xiaohao achieved sustained deep remission and successfully transitioned to maintenance therapy. He is now moving steadily toward recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F4d0359593b08ebbb943efe66d4f6cafa_20260912230138.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"4d0359593b08ebbb943efe66d4f6cafa_20260912230138.png\" alt=\"39827cec-4ed4-4310-8b80-c04d5e0a8d07.png\"\u002F>\u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Photo at Discharge\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Lump Appears in a 15-Year-Old's Neck - and Leads to an Unexpected Cancer Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Just after the 2025 New Year holiday, we received a call from our son's high school. His teacher said she had felt a fairly large lump on Xiaohao's neck and suggested that we take him to a hospital as soon as possible. We did not dare delay. We took him to a local hospital immediately, where ultrasound and CT scans showed enlarged lymph nodes in his neck and in several other areas of his body. The doctor advised us to transfer him to a higher-level hospital for further evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We took Xiaohao to a provincial hospital right away. The days waiting for the pathology result felt endless; I barely slept, and every minute seemed to drag. Then the pathology report finally came back: T-lymphoblastic lymphoma, Stage II, Group A.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 15, Xiaohao's life was only just beginning to unfold, yet suddenly he had been handed a challenge none of us had ever imagined. From the moment we received that report, the calm, ordinary life our family had known was completely changed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Chemotherapy Starts to Work, but the Family Travels to Beijing for More Standardized Care\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the provincial hospital, Xiaohao quickly started chemotherapy. The first two cycles worked well, shrinking the mediastinal tumor by 65%. But we could not relax. T-LBL is an aggressive disease, long-term outcomes can vary, and relapse is always a concern. What worried us most was that Xiaohao had not been treated with a pediatric protocol; instead, he was receiving a modified adult regimen. That left us uncertain about whether the treatment was truly standardized for someone his age and what it might mean for his long-term outcome.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During that period, I began reading everything I could find about T-LBL: Chinese medical papers, English-language guidelines, clinical studies, patient forums - anything related to the disease. I went through the information carefully, trying to work out which direction might be most appropriate for my son. That was how I first learned about Professor Yonghong Zhang. She is a leading specialist in pediatric lymphoma in China and founded the China National Childhood Lymphoma Cooperative Group (CNCL). Her team has extensive clinical experience in standardized treatment and the management of difficult pediatric T-LBL cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My wife and I also learned a great deal from other families and from published clinical cases. We kept hearing that for T-LBL, families often sought specialist care in either Shanghai or Beijing. In the end, we decided to go to Beijing to see Professor Zhang's team. We felt that her expertise and clinical experience in T-LBL gave us the greatest confidence and made her team the one we most trusted with our son's care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In April 2025, as soon as Xiaohao completed his fourth cycle of chemotherapy at the provincial hospital, we took him to Beijing and began the next stage of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Switching to a Pediatric Protocol: Precision Treatment for a Stronger Path to Long-Term Recovery\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In May 2025, we brought Xiaohao to Beijing GoBroad Boren Hospital. The team promptly completed additional evaluations and invited Professor Chunju Zhou to review his recent outside PET\u002FCT imaging. The review showed residual disease in the mediastinum but no evidence of progression. Because Xiaohao was an adolescent, Professor Zhang's team reassessed his stage using the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHSS). Given the bulky mediastinal disease, he was reclassified as Stage III, CNS2.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Continuing the modified adult regimen would have meant a lower likelihood of durable remission and a higher risk of relapse. After a comprehensive review, Professor Zhang's team quickly optimized the treatment strategy. They switched Xiaohao from the modified adult regimen to the CNCL-NHL-2017-LBL high-risk protocol, which is better suited to children and adolescents. Treatment restarted from the induction phase with VDLP chemotherapy, with bortezomib added to improve steroid sensitivity and strengthen the foundation for the stages that followed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As I stayed beside my son and continued learning, I gradually came to understand how different pediatric lymphoma care can be from adult lymphoma treatment. Accurate staging, a standardized protocol, and a plan that reflects the physiology of children and adolescents can all have a direct impact on long-term outcomes and relapse risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Two weeks after starting induction chemotherapy, MRI showed that the residual mediastinal lesion had shrunk further, and there was no progression through discharge. That result made us even more confident that coming to Beijing had been the right decision. Taking into account the initially bulky disease, the possibility that residual tumor was still active when he arrived in Beijing, and several potentially adverse mutations identified on genetic testing, Professor Zhang's team ultimately chose a high-risk treatment protocol to maximize his chance of durable disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy brought one challenge after another: bone marrow suppression, infections and fever, mouth ulcers, drug-induced liver injury, and coagulation abnormalities. Each episode was frightening for us as parents. Fortunately, Professor Zhang's team responded calmly and promptly every time, helping Xiaohao safely through one complication after another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By early February 2026, after precise risk stratification and standardized treatment by the specialist team, Xiaohao had achieved sustained deep remission and smoothly entered the maintenance phase. On the day he was discharged, seeing how happy and excited he was made all the travel, worry, and difficult days feel worthwhile. Now, I simply look forward to staying beside him as he takes one steady step after another toward recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F439fe7bd88e368acbf930e1fd645d48e_20260912230212.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"439fe7bd88e368acbf930e1fd645d48e_20260912230212.png\" alt=\"b0df148e-d157-4ac9-ae37-4ea9b7977ff8.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Becoming a 'Research-Minded Parent': What One Father Learned Along the Way\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Over the year I spent accompanying Xiaohao through treatment, I gradually changed from an anxious, overwhelmed parent into what other families jokingly called a 'research-minded parent.' That probably has something to do with my own work in data analysis. In my spare time, I also run an online account with more than 50,000 followers where I share analysis and observations. I am used to organizing information in a rational, structured way, so I approached the details of my son's treatment the same way. It helped make this complicated medical journey feel clearer and more manageable. I want to share some of the lessons I learned in the hope that our real experience can help other families facing similar uncertainty.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. The Right Specialist Team Can Matter Even More Than the Name of the Hospital\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaohao's initial treatment at the provincial hospital produced a reasonable response, but I still insisted on bringing him to Beijing because I wanted a team with deep expertise in pediatric T-LBL. At Boren, Professor Zhang's team used precise risk stratification, individualized treatment, and tightly coordinated scheduling. Whenever Xiaohao's clinical condition and blood counts allowed, the next stage of treatment moved forward promptly, without unnecessary delay.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Through nationwide patient and parent groups, I met many families and heard about children whose treatment was interrupted or delayed before the disease had been adequately controlled. In some cases, treatment gaps can give tumor cells an opportunity to become resistant, which is heartbreaking. For an aggressive hematologic cancer such as T-LBL, timely and standardized treatment is critically important. An experienced team can make the right judgment at key moments. The team also uses molecular testing to refine disease classification, guide treatment choices, and assess risk, making treatment more evidence-based and more individualized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Infection Is Never a Small Issue - Prevention Matters More Than Rescue\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before coming to Beijing, Xiaohao had two significant infections at the provincial hospital: influenza A and influenza B. The crowded ward environment made infection prevention particularly difficult. During chemotherapy-induced bone marrow suppression, a child's immune defenses can be extremely low. A serious infection can interrupt chemotherapy, worsen the overall condition, add financial burden, and in severe cases become life-threatening. From my perspective, reducing the risk of cross-infection is an important part of safely delivering intensive chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Nutrition Is the Foundation: Eating Well Helps the Body Get Through Treatment\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During chemotherapy, Xiaohao often had poor appetite, nausea, bloating, and periods when he needed a low-fat diet. I spent a lot of time working out foods he might actually want to eat - for example, making braised chicken with minimally processed seasonings or a mild, non-spicy version of dishes he normally liked. I also found that plain sparkling water sometimes helped his bloating after medication. Ultimately, recovery requires adequate nutrition. White blood cell recovery and hematopoietic recovery both depend on sufficient protein and overall nutritional support. With the medical team's approval, and only when it would not interfere with treatment or add unnecessary liver or kidney burden, I also used appropriate nutritional supplements. These cannot replace medical treatment, but they may help address nutritional gaps when dietary intake is limited.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. A Positive Mindset Is Not Just a Slogan - It Is Part of Getting Through Treatment\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the provincial hospital, most of the patients around Xiaohao were middle-aged or older adults, and the ward often felt quiet and heavy. After transferring to Boren, he was surrounded mostly by children and teenagers, and the atmosphere immediately felt more lively. The hospital also regularly organized activities such as birthday celebrations, craft sessions, and charity events. Xiaohao received several small gifts as well. He may no longer think of himself as a little child, but the happiness on his face whenever he received one was impossible to hide. A positive, hopeful state of mind may be invisible, but for us it clearly helped him get through one cycle of treatment after another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back on this past year, it was undeniably difficult, but it also changed the way our whole family sees life. We adjusted our diet and daily routines alongside Xiaohao, and we learned how to find a sense of certainty even when so much felt uncertain. As I gradually began sharing the things I had learned, I discovered that helping other people can also be a way of healing yourself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There is still a long road ahead, but at least for now, sunlight has returned to our lives. Xiaohao is feeling better day by day, and our family is filled with renewed hope. We are deeply grateful to Professor Yonghong Zhang's team for their expertise and attentive care, and to every person who reached out to help us along the way. We also hope that our experience can offer even a small measure of reassurance and confidence to families who are still going through their own difficult season.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Ying Liu, on behalf of Professor Yonghong Zhang's team): \n\nXiaohao initially presented with a bulky mediastinal mass. At a local adult hematology department, he was diagnosed with T-lymphoblastic lymphoma and classified as Stage II, Group A. He received two cycles of an adult regimen consisting of Hyper-CVAD plus pegaspargase. No lumbar puncture with intrathecal therapy was performed at the start of chemotherapy, and only one intrathecal treatment was given later. After the final treatment cycle, therapy was interrupted for 37 days because of a pulmonary infection. Repeat PET\u002FCT continued to show residual disease in the mediastinum.\n\nAfter admission to our hospital, pathology review by Professor Chunju Zhou confirmed T-lymphoblastic lymphoma and excluded an early T-cell precursor immunophenotype. Because the patient was an adolescent, we reassessed him using the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHSS). Given the bulky mediastinal disease, he was classified as Stage III, CNS2. Outside MRI, CT, and PET\u002FCT images were reviewed together with MRI performed at our hospital. The lesions were continuing to shrink without progression, with only a small amount of low-activity residual disease in the mediastinum. Archived diagnostic tumor tissue from the outside hospital was submitted for RNA sequencing and tumor-related mutation testing to identify adverse prognostic molecular features.\n\nTaken together, Xiaohao had several high-risk features. First, as a child\u002Fadolescent with T-LBL, he should have been treated using a pediatric\u002Fadolescent protocol, but he had initially received an adult regimen. Intrathecal therapy was not given at the start of chemotherapy and was clearly insufficient afterward, increasing the risk of central nervous system relapse. Second, there was a substantial treatment delay after the last chemotherapy cycle, increasing the risk of progression or relapse. Third, the tumor carried adverse genetic alterations, including JAK3 and TP53 variants.\n\nIn view of these adverse prognostic factors, treatment was changed to the BFM-modified CNCL-NHL-2017-LBL high-risk protocol. Bortezomib, a proteasome inhibitor, was added during VDLP induction to reduce the risk of treatment resistance. At interim assessment, the patient achieved complete remission. There was no indication for allogeneic hematopoietic stem cell transplantation in first remission, so sequential chemotherapy was continued. He has now entered maintenance therapy.\n\nPrecise risk stratification based on multidimensional prognostic assessment is critical to improving cure rates in T-LBL and can raise cure rates to above 80%. This approach is appropriate not only for children and adolescents, but also for young adults under 25. Through this case, we hope to remind families that adolescents older than 14 who develop lymphoblastic lymphoma should seek early, standardized care in a pediatric hematology-oncology setting to maximize the chance of cure.",{"slug":311,"title":312,"summary":313,"cover":314,"disease":315,"treatment":90,"patientType":68,"publishedAt":316,"contentHtml":317,"expertView":318,"disclaimer":72,"hasAlternate":73,"updatedAt":319},"myelodysplastic-syndrome-transplant-recovery","Diagnosed with Myelodysplastic Syndrome at Nearly 60, Five Years After Transplant He Celebrates a \"Second Birthday\"","In the five years spanning from his MDS diagnosis to his recovery following the transplant, Uncle Ji has come to regard the day of the procedure as his \"second birthday,\" while also channeling his own experiences into a source of encouragement for fellow patients.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F865b932e95d7fda0d8d11e96982f9ee8.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Myelodysplastic Syndrome,","2026-03-25","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In 2019, Mr. Ji learned he was anemic during a routine workplace health check. As fatigue and a persistent cough worsened, he sought further medical care and was diagnosed with myelodysplastic syndrome (MDS) in April 2020. As his blood counts continued to fall and his condition deteriorated, he underwent a thorough evaluation and, in December of that year, received a related haploidentical allogeneic hematopoietic stem cell transplant from his younger brother. The transplant journey was difficult, with bleeding and painful ulcers in his mouth and esophagus, but he kept eating, stayed engaged in his care, and gradually recovered with the support of his family and medical team. More than five years later, Mr. Ji is back to everyday life and now considers the day of his transplant his "second birthday." His story follows an MDS patient approaching 60 from diagnosis through transplant and long-term stability, and shows how hope, perseverance, and supporting others can become a source of strength.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"letter-spacing: 0px; font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now 64, Mr. Ji (pseudonym) first learned that he was anemic during a routine workplace health check in November 2019. Because he felt well at the time, he did not think much of it. As his fatigue gradually worsened and a persistent cough failed to improve, he sought further medical care. In April 2020, he was diagnosed with myelodysplastic syndrome (MDS).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That December, Mr. Ji successfully underwent a related haploidentical allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital. The road was far from easy, but with his own determination, the steady support of his family, and dedicated care from the medical team, he made it through transplantation and began a new chapter of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than five years later, Mr. Ji remains clinically stable and has returned to his normal routine. He sees transplantation as a new beginning and marks the transplant date as his second birthday. Over time, he has also become more open and at peace. One idea he often shares is that strength comes from looking beyond oneself, treating others with kindness, and thinking of their needs as well. During his recovery, he has repeatedly offered encouragement and practical advice to other patients, hoping his own experience can help them through difficult moments.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As he reaches the five-year milestone after transplant, Mr. Ji hopes that sharing his experience - especially his decision to undergo transplantation when he was close to 60 - can offer hope and encouragement to others still going through treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: When you were first diagnosed with myelodysplastic syndrome (MDS) in April 2020, what symptoms were you experiencing?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: My blood test results had already shown some mild abnormalities during my workplace health check in 2019. But because I did not feel unwell at the time, I did not pay much attention to it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the 2020 Spring Festival period, I spent more than a month helping with community COVID-19 response shifts as a Communist Party member. After that, I began to feel unusually tired and weak, and I had a cough that just would not go away. I went to the hospital, and a complete blood count showed that several of my blood counts had dropped significantly. That was when I realized something was wrong. I was referred to hematology and was eventually diagnosed with MDS.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When I was first diagnosed, my thinking was actually very simple: if my body was not making enough blood cells, couldn't I just go to the hospital for regular transfusions? I later realized it was nowhere near that simple. A colleague working in Shanghai helped me make connections, and I eventually came to GoBroad Shanghai Zhaxin Hospital to see Professor Chun Wang. Over the next few months, I was losing almost half a kilogram a day. I kept getting thinner and weaker. At one point, my platelet count fell to around 7 or 8, and even a small cut could keep bleeding. The situation became very difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: When your doctors recommended an allogeneic hematopoietic stem cell transplant, you were already close to 60. Many people worry that transplantation at an older age carries substantial risk. What helped you decide to move forward?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: At first, I was afraid of transplantation because I did not understand much about it. Professor Chun Wang reviewed my condition and felt that going directly to an allogeneic hematopoietic stem cell transplant would offer me greater potential benefit. Through conversations with other patients and by learning more about my disease, I gradually came to understand that MDS is different from leukemia. In my own way of thinking about it, it was not simply a matter of "bad cells attacking"; the blood-forming stem cells themselves were abnormal and could no longer produce healthy blood cells properly. I also came to understand that prolonged chemotherapy was unlikely to be the best approach for my situation, so transplantation seemed like the better option. To me, a stem cell transplant was like replacing the body's "blood-making factory" with a new, healthy one - one of the best ways to aim for long-term control of MDS and reduce the risk of progression to leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I had read online that people over 55 were often advised against transplant and treated more conservatively because of the risks. Then I followed the hospital's WeChat account and learned that, in 2017, Professor Chun Wang's team had been the first in China to successfully perform a haploidentical allogeneic stem cell transplant in a 67-year-old patient. While I was receiving treatment, I also heard about a 71-year-old man from Guangdong who had successfully undergone an allogeneic transplant. Those cases showed me how experienced Professor Wang's team was and gave me more confidence in my decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My family fully supported my decision, especially my younger brother. He is an incredibly generous person. Not only did he donate hematopoietic stem cells for me, he had already registered with the China Marrow Donor Program (CMDP). He kept encouraging me to stay confident in the decision to proceed with transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, I feel I did not lose time going down the wrong path. For me, choosing transplantation directly was the right decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: Which part of the treatment journey was the hardest for you?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: For me, the hardest time was actually before I decided to have the transplant. Twice, I had bleeding from both my nose and mouth. Blood was dripping from my nose, and when I pinched it, blood started coming out of my mouth as well. I was terrified because it just would not stop. That was the most frightening part of the whole experience.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once the transplant actually started, I was not as afraid anymore. I was in Transplant Room 5. The patient in the next room could barely get out of bed, but I kept getting up to use the bathroom on my own and sat up to eat. My mouth and esophagus were covered in painful ulcers, but I still made myself eat. Sometimes it took me two hours to finish one bowl of food. No matter how much it hurt, I swallowed one bite at a time. I even asked the nurses for ice and numbed my mouth before trying to eat again. At my weakest, I could barely get up from bed, but I still pushed myself to sit up and eat because I knew my body needed calories and nutrition to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I believe that once you have a goal and something to hope for, you have a reason to keep going. When the fear and uncertainty about what lies ahead begin to fade, what remains is the determination to hold on and get through it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: After going through such a serious illness, has the experience changed the way you see life?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Even now, when I think back on that period, I still feel a little tense. Some things are impossible to fully understand unless you have lived through them yourself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After transplant, many of us felt the same way: it was like being given another life, like coming back from the edge. When I talked with other patients, some said they had changed their birthday to the day of their transplant; one person even renamed his company because he wanted to mark the start of a new life. Back then, when we talked, we did not ask, "How old are you?" We asked, "How many days or months has it been since your transplant?" - almost like asking the age of a newborn. I will never forget that time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am a Communist Party member, and in Party lectures and in my own regular study I often came across the idea of "selflessness" - not thinking only about yourself, but considering others as well. I believe that if you treat people with kindness, even when life is difficult, you can still find something good and a way forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: What would you like to say to other patients who are still in treatment and fighting their illness?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I remember a woman in her 50s who could not decide whether to go ahead with a transplant. Patients in the hospital often talk with one another and ask who is recovering well or responding well to treatment. She heard that I was doing well and came to ask about my experience, so I shared what I had been through and tried to encourage her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I told her three things. First, trust the clinical expertise of the team at GoBroad Shanghai Zhaxin Hospital. Second, trust that the team genuinely cares about its patients. Third, trust in how far medicine has come - conditions that once felt untreatable now have more treatment options. Most importantly, have confidence in yourself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If fear or indecision takes over and keeps you from moving forward, you may end up missing an important window for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That is what I most want to say to others still going through treatment: stay confident and keep believing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F619832dbd36660aa547ba9a61bd1161c_20260910155032.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"619832dbd36660aa547ba9a61bd1161c_20260910155032.png\" alt=\"045de88a-609c-4769-8c01-9b5010f574a0.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Mr. Ji during a spring outing in a park, March 2026\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>A Message of Thanks from Mr. Ji\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am deeply grateful to the medical team led by Professor Chun Wang. Their expertise, dedication, and compassion gave me a second chance at life. I am especially grateful to Dr. Chuxian Zhao for the thoughtful care and support she has provided throughout my long-term follow-up after transplant. At GoBroad Shanghai Zhaxin Hospital, everyone - from doctors and nurses to patient services and support staff - made me feel genuinely cared for. You are all people with great compassion. For the rest of my life, I will always speak warmly of Zhaxin Hospital. Words can hardly express how thankful I am.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian Zhao (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nMr. Ji is optimistic, determined, and always willing to help others. By sharing his recovery journey and what he has learned along the way, I hope he can give encouragement, confidence, and strength to many patients who are still in treatment.\n\nAs transplantation medicine continues to advance, age alone is no longer an absolute barrier to hematopoietic stem cell transplantation, giving more patients with blood disorders the opportunity to pursue long-term remission and, in selected cases, cure.\n\nEven in the darkest moments, there can be a way forward. We hope our team's work can help patients facing difficult treatment decisions find a breakthrough and move toward brighter days ahead.","2026-09-10",{"slug":321,"title":322,"summary":323,"cover":324,"disease":181,"treatment":90,"patientType":68,"publishedAt":325,"contentHtml":326,"expertView":327,"disclaimer":72,"hasAlternate":73,"updatedAt":328},"acute-myeloid-leukemia-haploidentical-transplant-recovery","Diagnosed with Acute Myeloid Leukemia at 60, She Found a Second Chance at Life with Stem Cells Donated by Her Son","After her diagnosis, she underwent a hematopoietic stem cell transplant with her son as the donor. Today, she is back to enjoying life with her family.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1b7cd578491ad72461e7370fe2fde5f6.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-03-11","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: At 60, Ms. Chao sought medical care for persistent fatigue and pain in both legs. She was ultimately diagnosed with acute myeloid leukemia (AML) that had transformed from myelofibrosis. Her disease was high-risk and difficult to treat, and multiple rounds of chemotherapy failed to bring it into remission. Worried about the risks of treatment - and about asking her son to become her stem cell donor - she once considered giving up on transplant. With encouragement from her family, however, she came to GoBroad Shanghai Zhaxin Hospital, where she underwent a haploidentical allogeneic hematopoietic stem cell transplant using stem cells donated by her son. Her leukemia went into complete remission after transplant, and her health gradually returned. Today, she is once again enjoying everyday family life. Her story follows a 60-year-old patient from a difficult diagnosis to renewed hope, and reflects the strength that can come from family support, compassionate medical care, and the determination to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002Fd52d4e7722edcab31ed396c6fef5c172_20260911221420.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d52d4e7722edcab31ed396c6fef5c172_20260911221420.png\" alt=\"677d9d0b-1939-4494-9123-71962843bbea.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 60, Ms. Chao (a pseudonym) had a happy family and was looking forward to a peaceful retirement. Instead, persistent fatigue and pain in her legs led her to seek medical care, where she was diagnosed with acute myeloid leukemia. Further testing showed a markedly enlarged spleen, and a bone marrow biopsy revealed myelofibrosis, suggesting transformation from a myeloproliferative neoplasm and an overall poor prognosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Chao has always been cheerful and optimistic. But when she first learned that her disease was difficult to treat and that therapy could carry significant risks - and then learned that her son might need to donate stem cells - she considered giving up. Her family, however, never gave up on her. They kept searching for another path forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With her family beside her, Ms. Chao came to GoBroad Shanghai Zhaxin Hospital. The medical team’s careful assessment and extensive experience in hematopoietic stem cell transplantation gave her renewed confidence. In January 2024, she successfully underwent an allogeneic hematopoietic stem cell transplant with her son as the donor. The new stem cells successfully engrafted and began to grow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After transplant, her leukemia achieved complete remission and her recovery went well. Recently, she returned to GoBroad Shanghai Zhaxin Hospital for her two-year post-transplant follow-up. She hopes that sharing both the setbacks she encountered and the practical lessons she learned during recovery can encourage other patients on the same journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002F1f7f101883a107fe0c6d677c63980a0c_20260911221455.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1f7f101883a107fe0c6d677c63980a0c_20260911221455.png\" alt=\"ccf09208-18cd-4f55-843d-d83f30f6fd26.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">January 2026: Ms. Chao with Nurse Manager Bo Wang\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- Patient Q&A -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: Looking back, what were the first warning signs that something was wrong?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: At the end of 2022, I had a viral cold. The cold itself cleared up within a few days, but from then until February 2023 I constantly felt weak and exhausted. Even walking felt difficult. At first I assumed I was just taking a long time to recover from the cold, so I rested at home and did not think too much of it. Then the pain in both legs became so severe that I could not sleep at night, and that was when I finally went to the hematology department at a local hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My blood test came back abnormal. The doctor told me to be admitted right away because my blood cell counts were very low. After I was hospitalized, I had a bone marrow aspiration and a series of further tests. The final diagnosis was acute myeloid leukemia transformed from myelofibrosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That was the beginning of a long and difficult course of treatment. I went through several rounds of chemotherapy, but the disease never went into remission. The doctors told me that mine was a high-risk, refractory case and that an allogeneic hematopoietic stem cell transplant was the only treatment that could potentially offer long-term survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back now, my body had actually been sending warning signs about six months earlier. I had developed many small bleeding spots on both legs, but I did not pay much attention. I thought they were like ordinary bruises from bumps and would disappear after a few days, but they never did. It was only when the weakness and leg pain became obvious that I realized something more serious was going on.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: What led you to choose GoBroad Shanghai Zhaxin Hospital for your transplant?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: The doctors had recommended an allogeneic hematopoietic stem cell transplant. We could not find a fully matched donor in the registry, so both my son and my younger brother were tested. My brother was 57 and was a half match, and my son was also a half match. After an overall assessment, my son was considered the better stem cell donor for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I asked the doctor what my chances would be if I had the transplant at the local hospital. Based on my age and condition, I was told it was around 30%. Hearing that number, my heart sank and I immediately thought about giving up. I was already 60, and I did not feel that a 30% chance was worth such a gamble. As a mother, I also could not bear the thought of my son donating stem cells for me. I did not understand the donation process at the time and assumed it would harm his health. So I thought I should just continue with conservative treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The doctor told me that giving up on transplant would essentially mean giving up on treatment, but I still chose to go home. I had several more rounds of chemotherapy, yet the disease still did not respond. My platelet count fell into the single digits. Every week I had to go to the hospital for a transfusion. It might rise into the teens or twenties afterward, only to fall back into the single digits a few days later. It was no longer helping.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I may have been ready to give up, but my family never stopped looking for hope. They asked around to find out which hospitals had the most experience treating a disease like mine. After speaking with many people, we learned about Professor Chun Wang and his team at GoBroad Shanghai Zhaxin Hospital. With nothing to lose, we made an appointment with him.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Professor Wang was impressive. He reviewed my previous medical records and described my condition very precisely. The question that mattered most to me was still the chance of success, so I gathered my courage and asked again. Professor Wang answered calmly, “Based on your condition, there is a good chance that transplant could lead to a cure.” His confidence made me feel that he truly knew what he was doing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the consultation, we also raised our biggest concern: would donating stem cells harm my son? Professor Wang patiently explained that the current approach uses medication to mobilize stem cells from the bone marrow into the peripheral blood. The cells can then be collected in a process similar to giving blood; a machine separates out the stem cells and returns the remaining blood components to the donor. His explanation put our whole family at ease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Professor Wang also used a simple analogy. He said my disease was like a field overgrown with weeds: first you clear away the weeds, then plant healthy seeds from my son so that good crops can grow. That made everything much easier to understand, and much of our fear about transplant disappeared. I remember taking his hand and saying again and again, “That’s wonderful.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the appointment, my son and I sat in the hospital lobby and talked it over. He said, “Mom, let’s do the transplant here. Other people have made it through, and so can we. If there’s a chance for a cure, we should go for it.” I said, “All right. We’ll do it here.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In December 2023, I was admitted to GoBroad Shanghai Zhaxin Hospital and began the pre-transplant preparations. In January 2024, I entered the transplant unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002F8e56e75844acb35dcfb851dbcf254110_20260911221622.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"8e56e75844acb35dcfb851dbcf254110_20260911221622.png\" alt=\"68c61719-38e9-4125-ae26-90e694d50676.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: What was it like in the transplant unit? Were you nervous or afraid?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Before I went in, I was definitely worried and scared. I had read stories online saying that some transplant units felt cold, clinical, and depressing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But on the day I entered the unit, the nurse manager, my husband, and my son walked me in together. The moment I got there, I realized it was nothing like I had imagined. The room had soft, warm off-white tones, and even the flooring and blinds made the space feel comfortable. It was not a large room, but I actually slept very well that first day. Most of my worries disappeared almost immediately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Things also moved quickly. Before long, the doctors and nurses were starting my high-dose conditioning chemotherapy. Everyone was very kind. They checked on me often and would stop to chat, which helped me gradually relax.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What touched me most was that Dr. Huixia Liu came to see me early every morning. I was in Room 1, and every time she came in she would greet me warmly and ask how I was doing. I could not make sense of my blood test results, so she would point to the numbers on her phone and say, “Your blood counts have started to come up today!” The numbers were still only just beginning to rise, but she was so happy and told me it meant “the seeds have started to sprout.” She encouraged me every single day, and that gave me something to look forward to.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During my time in the transplant unit, I did not have many major problems apart from a fever, and I did not have diarrhea. Near the time I was ready to leave the unit, however, I developed some mouth ulcers. I have to admit I was partly to blame. The unit provided a medicated mouth rinse, and the nurses had explained exactly how to use it, including holding it in the mouth long enough for it to reach the back of the throat. I disliked the taste and did not follow the instructions as carefully as I should have, and then the ulcers appeared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The mouth ulcers had already started a little while I was still in the unit, but the week after I came out was the hardest. I could barely drink or eat because it hurt so much. Fortunately, Dr. Chuxian Zhao’s team responded quickly and provided daily oral care. After about a week, as my blood counts continued to recover, the inflammation settled and the ulcers healed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I left the transplant unit in the second half of January. I then stayed in the hospital for nearly two more months for recovery and observation, and finally went home in mid-March. Overall, the process went quite smoothly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: You once thought about giving up. What changed your mind and helped you keep going?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: At the local hospital, I had three rounds of chemotherapy without achieving remission, and my condition had become very serious. I remember lying in bed drenched in sweat, staring out the window and thinking, “It’s all right. If this is what fate has decided, then I’ll accept it.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I got sick, my son and I would occasionally argue. I have a quick temper, and so does he, so sometimes we would talk back to each other. But after I became ill, he changed completely. When I wanted to give up on transplant, he would not allow it. He held my hand and said, “Mom, I’ll donate my stem cells. I’ll find a way to handle the money - even if I have to sell the house.” He simply refused to give up on me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My family was the biggest reason I kept going. My husband and son were incredibly attentive. If I showed even a little anxiety or started saying, “How did I end up with such a serious illness?”, they would stop me from dwelling on it. When I felt physically miserable, my son would send me videos of my little grandson. Seeing his sweet face always cheered me up. I told myself I had to stay alive and fight for more time with my family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Thank you to my son for giving me a second chance at life. Thank you to my family for never giving up on me. And thank you to the doctors and nurses at the hospital for caring for me so attentively. I would not be where I am today without all of you.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: Are there any lessons from your post-transplant recovery that you would like to share with other patients?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: One experience really stayed with me. It was May 2024, about half a year after my transplant, and I had been eating a very light diet. I am from Changzhou, and one day I casually mentioned that I was craving the local pickled radish. My daughter-in-law kindly went out and bought some for me. It was homemade-style pickled radish from a market stall. I ate just one piece, and by that evening I had diarrhea.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I immediately messaged Dr. Chuxian Zhao, and she told me to come to the hospital right away. Fortunately, we treated it promptly and the diarrhea was quickly brought under control. Since then, I have stayed away from pickled foods.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We also paid a lot of attention to hygiene at home. My son bought an air purifier specifically for my bedroom. Whenever I was resting in bed, he would turn it on to keep the air fresh. I wore a mask whenever I went out, and if anyone in the family had a cold or cough, I took extra precautions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There was also one small care tip I learned in the transplant unit: using a cotton swab to apply a small amount of chlortetracycline eye ointment just inside the nostrils to help prevent bleeding from fragile nasal capillaries. I sometimes did this in dry weather to reduce nosebleeds. (*Please note: This is based on one patient’s personal care experience and may not be appropriate for everyone. Always follow the treatment and medication guidance of your own medical team.)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: After everything you have been through, what are you hoping for in the years ahead?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: It has been two years since my transplant, and I feel that I have recovered very well. At home, I like trying out recipes, and when I have time I knit little sweaters for my grandson. Sometimes my husband and I take a walk together in the evening as the sun sets. Life is quiet and peaceful now, and that is enough for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I do not have any grand plans for the future. My biggest wish is simply to watch my grandson grow up healthy and happy. Being at home, safe and well, with my family close by - that is the kind of happiness that means the most to me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002F61c31b0bd8fb7e6f29d1a396f0009605_20260911221915.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"61c31b0bd8fb7e6f29d1a396f0009605_20260911221915.png\" alt=\"d973ad1b-9637-4250-b6b5-988b1bfa5a5c.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Everyday moments from Ms. Chao’s life after recovery\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian ZHAO (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nFor patients with acute myeloid leukemia (AML) transformed from myelofibrosis (MF), allogeneic hematopoietic stem cell transplantation is currently the only treatment with the potential to achieve long-term survival and, in some cases, cure.\n\nMs. Chao underwent a related haploidentical transplant. Her underlying disease is now in complete remission, and both her blood counts and physical condition have recovered well.\n\nIt has been deeply moving to see Ms. Chao’s optimism and the love and support shared within her family. We hope these peaceful, happy days continue for many years to come.","2026-09-11",{"slug":330,"title":331,"summary":332,"cover":333,"disease":334,"treatment":335,"patientType":82,"publishedAt":336,"contentHtml":337,"expertView":338,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"t-lymphoblastic-lymphoma-targeted-therapy","At 9, She Faced High-Risk T-Lymphoblastic Lymphoma\u002FLeukemia. Precision Care in Beijing Brought Complete Remission - and a New Beginning","From traveling to Beijing just days after diagnosis to completing high-risk chemotherapy and moving into maintenance treatment, this resilient young girl is gradually getting back to the childhood she loves.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F95f8d7d641055105d3e97975d434ae29.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp"," T-Lymphoblastic Lymphoma\u002FLeukemia","Chemotherapy, Targeted Therapy, Pediatric","2026-03-06","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Nine-year-old Mango developed a lump below her collarbone and was diagnosed with T-lymphoblastic lymphoma\u002Fleukemia (T-LBL\u002FT-ALL). Five days after the diagnosis, her parents brought her to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital for further care. Taking into account high-risk features including a bulky mediastinal mass, central nervous system involvement, and an NUP214-ABL1 fusion, Professor Yonghong Zhang's team carried out a comprehensive assessment and developed an individualized plan combining a pediatric high-risk chemotherapy protocol with targeted therapy. Treatment was adjusted dynamically according to her response, with close management throughout. After intensive therapy, her tumor achieved complete remission and bone marrow measurable residual disease (MRD) became negative. She remains in deep remission and has now entered maintenance treatment. Her family's journey reflects the importance of timely diagnosis, risk-adapted treatment, and careful long-term management for children with high-risk T-lymphoblastic lymphoma\u002Fleukemia, as well as the strength that family support and a positive outlook can bring during a long course of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the Lunar New Year of the Year of the Horse, while families across China were heading home to reunite, Mango (pseudonym) and her family from Henan spent this meaningful holiday in Beijing. In April 2025, 9-year-old Mango was diagnosed with T-lymphoblastic lymphoma\u002Fleukemia at another hospital. After careful consideration, her family decided to travel to Beijing GoBroad Boren Hospital to seek care from Professor Yonghong Zhang's team. After admission, the team completed a comprehensive assessment based on Mango's disease characteristics and developed a personalized treatment plan combining a pediatric high-risk chemotherapy protocol with targeted therapy. Her treatment was adjusted throughout according to her condition and response. Following systematic treatment, Mango achieved sustained deep remission and has now entered the maintenance phase. Recovering at home after discharge, she is gradually regaining her strength and rediscovering the colorful childhood that belongs to her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F40ede07260ff1a1fcb6183ab565f7112_20260912213228.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"40ede07260ff1a1fcb6183ab565f7112_20260912213228.png\" alt=\"e52eefa7-ad06-4d86-bcb9-efdcc4e70ec9.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">A Photo at Discharge\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Happy Family Suddenly Faced the Unexpected: Their 9-Year-Old Daughter Was Diagnosed with Lymphoma\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Like any parent, I never imagined the word "lymphoma" would have anything to do with my daughter, Mango. She had always been healthy and was tall for her age, and we had rarely had to worry about her health while she was growing up. Then, in early April 2025, a small lump suddenly appeared below her left collarbone. It improved slightly after she took anti-inflammatory medication, but something still did not feel right, so we took her to a local hospital for a thorough evaluation. That visit changed everything. Her blood test showed an abnormally high white blood cell count, and the doctor recommended immediate admission for further tests. Bone marrow aspiration, lumbar puncture, pathology - one test followed another, and it all felt overwhelming.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When the diagnosis of "T-lymphoblastic lymphoma\u002Fleukemia" was finally confirmed, it felt as if my whole world stopped. The shock was almost impossible to process, and fear, denial, and helplessness came all at once. Mango was in third grade at the time. When she saw the sign for the hematology-oncology department, she quietly asked me, "Mom, do I have a tumor?" I fought back tears and tried to reassure her while hiding my own fear. We were also afraid to tell the elderly grandparents at home because we worried the news would be too much for them, so we only said Mango needed to stay in the hospital for a few days of observation. Her father and I carried all the fear, anxiety, and pressure between us.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Heading to Beijing Without Delay: Making the Most of a Critical Treatment Window\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because there was no time to lose, Mango began chemotherapy at the local hospital. At the same time, we faced one of the hardest decisions we had ever made as parents: where should we take our daughter for the best possible care?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Just when we felt completely lost, a phone call from a friend gave us hope. Her child had been diagnosed with lymphoma back in 2017 and had been treated successfully at Beijing GoBroad Boren Hospital. She strongly recommended Professor Yonghong Zhang, telling us that Professor Zhang was a leading expert in pediatric lymphoma with extensive clinical experience. We later learned that our local hospital was also a member of the China Net Childhood Lymphoma (CNCL), a national collaborative network led by Professor Zhang. While we were still hesitating, our friend said something that finally made the decision clear: "Your child is different from everything else in life. She has her whole future ahead of her. Put everything else aside - saving her life comes first."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On April 16, 2025, just five days after Mango's diagnosis, we completed her discharge from the local hospital that morning and traveled to Beijing GoBroad Boren Hospital that afternoon. With no other choice, we left our younger child - barely one year old and only just learning to say "Mom" and "Dad" - in the care of the grandparents. We felt terribly guilty as parents, but there was no alternative. For Mango, we had to do everything we could.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, it was without question one of the most decisive and important choices we made for our daughter. Mango was newly diagnosed, received a timely diagnosis, and was able to reach an experienced specialist team quickly, without losing valuable time along the way. For lymphoma, timely and standardized treatment can be critical to outcomes. Mango was unlucky to become ill, but we also feel fortunate that, when we were most uncertain, we found clear guidance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>An Individualized Treatment Plan - and a Brave Girl Facing Every Challenge with Optimism\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once we arrived at Beijing GoBroad Boren Hospital, the medical team moved quickly and methodically. Professor Yonghong Zhang's team completed a comprehensive reassessment and disease evaluation, and genetic testing results soon became available. Mango was found to have several adverse molecular features, including an NUP214-ABL1 fusion, as well as a NOTCH1-related mutation, which has been associated with more favorable outcomes in some studies. Taking into account her disease subtype, bulky tumor, and central nervous system involvement, the team promptly developed a personalized treatment plan combining chemotherapy with targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The treatment that followed felt like a series of difficult hurdles, each bringing a new challenge. Chemotherapy-related bone marrow suppression, recurrent infections, persistent high fevers, and oral and perianal ulcers all took a toll on Mango and weighed heavily on our entire family. As her mother, I went from being a parent who only had a vague fear of the disease to someone trying to learn everything I could about daily care - how to look after her mouth, recognize signs of infection, and prepare nutritious meals. I kept telling myself that I had to be the person she could rely on most, her safest and warmest source of support.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fortunately, the hard work began to bring good news. After the first intensive chemotherapy course using the VDLP regimen, follow-up showed that Mango's mediastinal tumor had shrunk by 75%, while abnormal cells in the bone marrow had also decreased substantially. At the interim assessment, imaging showed complete remission, and bone marrow measurable residual disease (MRD) had become negative. It was an important milestone - a sign that Mango had won a meaningful early victory in her treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even now, when I think back on everything she endured - especially the way she tried to hold back her tears during bone marrow aspirations and lumbar punctures - my heart still aches. As her mother, I do not want her memories of this period to be only white hospital rooms and painful procedures. I tell her that illness is one unusual chapter in life. It can teach us how precious health is and how much it matters to have family beside us. I also hope she will understand that life brings both easy and difficult seasons; what matters is how we choose to face them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What comforts me most is that Mango turned out to be even stronger than I imagined. She quickly created her own little world in the hospital - playing games, editing short videos, folding paper stars, drawing, and finding ways to make each day interesting. She especially loved taking part in activities at the hospital's "Ward School." Even Professor Yonghong Zhang praised the remarkable sense of ease and composure Mango had for a child her age. That optimism and calm helped carry her through the hardest part of the journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Expert Care for the Disease, Compassionate Support for the Child\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During our time at Beijing GoBroad Boren Hospital, what we experienced was not only highly professional medical care, but also warmth and compassion woven into the everyday details of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">No matter how busy she was, Professor Yonghong Zhang never missed her weekly rounds. She carefully reviewed Mango's records, followed every detail of her condition, and patiently answered every question we had. Her expertise and calm confidence gave us enormous reassurance when things felt difficult. Dr. Ying Liu made rounds almost twice a day, and we often saw her working on the ward even on weekends. Dr. Yang Liu, Dr. Yali Peng, and other members of the team were always willing to answer questions. They closely followed Mango's treatment while also paying attention to how she was feeling emotionally. Nurse Manager Rong Zhang and her nursing team were skilled and gentle, doing everything they could to minimize discomfort during procedures while offering encouragement and companionship. That human warmth, alongside professional care, became a steady source of strength that helped us keep moving forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Remission Continues: Grateful for Every Step, Hopeful for What Comes Next\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Mango has completed all intensive chemotherapy and remains in sustained remission. She has now entered an 18-month maintenance phase. On the day she was discharged, we took a group photo with the medical team and wrote a thank-you letter. The words were simple, but every line came from the heart. To express our gratitude to Professor Yonghong Zhang and the entire team, we also had a small trophy made to thank them for giving Mango renewed hope through both expertise and compassion. Mango herself made Lunar New Year gifts by hand for the doctors and nurses who had cared for and stayed beside her over the past year.\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px; text-align: center;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F737d3c98c5ed0632f9246352f5e1095f_20260912213302.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"737d3c98c5ed0632f9246352f5e1095f_20260912213302.png\" alt=\"1918fd0c-f387-4ef2-8dcd-a246fd78a86d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back on nearly a year of cancer treatment brings so many emotions. Like many parents, I used to worry about my child's school performance. Now, our one wish is simply that she stays safe and healthy. This experience has stayed with me deeply, and I would like to share a few thoughts with other parents going through something similar:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Trust expertise and seek the right team early. When a child faces a serious illness, finding an experienced, specialized medical team is an important first step toward effective treatment. When we first learned that Beijing GoBroad Boren Hospital is a privately run hospital, we had some reservations - a bias that many families may share. Our experience changed that view. The hospital brings together nationally recognized pediatric lymphoma specialists, including Professor Yonghong Zhang and her team, with internationally aligned treatment approaches, standardized clinical processes, efficient care, and a strong emphasis on the patient and family experience.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Take care of your own emotions. A parent's emotional state can affect a child directly. No matter how frightened or overwhelmed you may feel, try to offer your child steadiness, encouragement, and a calm presence as you face treatment together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Be attentive to daily care and work closely with the medical team. Treatment is not only the responsibility of doctors. Family caregiving matters too. Nutrition, hygiene, infection prevention, and many other small details can all play a role in a child's recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Face practical challenges realistically and ask for support. The financial pressure of a serious illness is real. Families can proactively learn about national medical insurance policies for major illnesses and available charitable assistance programs, and apply for any support for which they are eligible. Family members also need to support one another through difficult times. While we were in Beijing, Mango's father registered as a food-delivery rider and took on deliveries when he could to help ease some of the financial burden.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Mango is gradually regaining her strength, and the lively, energetic girl we remember is coming back. This journey through cancer has been extraordinarily difficult, but it has also taught our family more deeply what life means and made us more grateful for every act of kindness and every person who has helped protect her along the way. We believe that, after everything she has weathered, Mango will keep moving forward into a bright future of her own.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Ying Liu, on behalf of Professor Yonghong Zhang's team): \n\nAmong pediatric non-Hodgkin lymphomas, lymphoblastic lymphoma is the second most common subtype, and approximately 70%-80% of cases are T-lymphoblastic lymphoma (T-LBL). Children with T-LBL commonly present with a bulky mediastinal mass, sometimes with airway compression, and many also have bone marrow involvement. At present, international collaborative groups report 5-year disease-free survival rates above 80% for pediatric T-LBL. The average long-term disease-free survival rate in China is approximately 60%-70%, while the 5-year disease-free survival rate for newly diagnosed pediatric T-LBL at the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital is 83%.\n\nA key reason for this improvement is the use of precise risk-stratified treatment based on adverse prognostic factors. Assessing these factors in T-LBL requires dynamic and comprehensive evaluation across multiple dimensions, including immunophenotype, high-risk genetic features, clinical stage and risk group, and early treatment response. Specific factors include the presence of a bulky mediastinal mass; myeloid antigen expression or an early T-cell precursor phenotype on immunophenotyping; high-risk molecular abnormalities such as MLL rearrangement, C-MYC rearrangement, SIL\u002FTAL1 fusion, PTEN mutation, loss of heterozygosity on the long arm of chromosome 6, and NOTCH fusion; delayed remission at interim assessment; substantially prolonged chemotherapy courses; and inadequate dosing of key chemotherapy agents.\n\nLooking back at children with relapsed or refractory T-LBL treated at our center, some had previously received incomplete assessment of adverse prognostic factors. In some cases, immunophenotyping had not identified an early T-cell precursor phenotype in time; in others, limitations in genetic testing meant high-risk alterations such as PTEN mutations were missed. In still others, interim assessments relied only on bone marrow testing while overlooking tumor evaluation, or focused only on imaging while omitting bone marrow MRD testing, leading to an inaccurate assessment of remission status. These gaps may prevent some patients from being escalated to a high-risk treatment protocol when needed, or even cause them to miss the optimal window for transplant when transplantation is indicated. Complications such as infection can also delay chemotherapy, while pancreatitis and other adverse events may affect the use of key drugs such as asparaginase. For newly diagnosed T-LBL, systematic, standardized management throughout the entire treatment course is therefore essential.\n\nIn Mango's case, she was diagnosed at our hospital with stage IV T-lymphoblastic lymphoma, CNS3, with a bulky mediastinal mass at presentation and an NUP214-ABL1 fusion detected in the tumor cells. These features placed her in the high-risk group, and she received a high-risk treatment protocol. Interim assessment showed complete remission. At key points during consolidation and delayed intensification, both imaging and bone marrow MRD monitoring confirmed ongoing remission. She has now successfully entered maintenance therapy combined with a tyrosine kinase inhibitor. We wish Mango a smooth treatment journey and a happy, healthy childhood.\n\nThis case highlights how risk-stratified treatment based on multidimensional prognostic assessment, together with careful management at every stage of therapy, can be critical to improving cure rates in children with T-LBL. We hope this story helps more families understand the disease, seek timely diagnosis and treatment, and follow standardized care so that more children can have the opportunity for cure.",{"slug":340,"title":341,"summary":342,"cover":343,"disease":164,"treatment":272,"patientType":68,"publishedAt":344,"contentHtml":345,"expertView":346,"disclaimer":72,"hasAlternate":73,"updatedAt":319},"primary-mediastinal-b-cell-lymphoma-transplant-recovery","Diagnosed with Primary Mediastinal Large B-Cell Lymphoma, She Studied for Graduate School from Her Hospital Bed — Today, She Has Graduated and Started Her Career","After being diagnosed with primary mediastinal large B-cell lymphoma during her senior year of college, Xiao Min underwent an autologous hematopoietic stem cell transplant; she was admitted to graduate school while recovering and has since returned to a normal work and personal life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F69c6aa4201de62945fb981e916797358.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-02-28","\u003Cp style=\"margin: 7px 0;\">\u003Cspan style=\"font-size: 15px;\">Summary: Shortly after starting her senior year of college, Xiaomin sought medical care for a persistent cough, chest pressure, and fever. She was diagnosed with primary mediastinal large B-cell lymphoma. After coming to GoBroad Shanghai Zhaxin Hospital, she received chemotherapy and underwent an autologous hematopoietic stem cell transplant in March 2020. Treatment brought loss of appetite and other physical challenges, but Xiaomin did not let life stop at the hospital bed. Whenever she felt well enough, she began preparing for graduate school entrance exams. After discharge, she continued studying while recovering at home and was admitted to graduate school the following year. She has since completed her master’s degree and started her career. Today, Xiaomin is back to a stable work and daily routine and has completed her long-term follow-up. Her story follows a young patient from diagnosis and treatment back to campus and into the workplace — a reminder that life can keep moving forward beyond illness.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F5191b52818fc8231cf00c659c2f8af15_20260910153138.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5191b52818fc8231cf00c659c2f8af15_20260910153138.png\" alt=\"b6039c99-4338-4a22-8d8e-3df8feb2563c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In September 2019, shortly after the start of her senior year of college, Xiaomin (a pseudonym) had been coughing on and off for more than a month. She thought it was just a common cold and did not pay much attention to it. A hospital visit, however, brought an unexpected diagnosis: primary mediastinal large B-cell lymphoma. Suddenly, the future she had carefully planned seemed to come to a halt.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With her family by her side, Xiaomin came to GoBroad Shanghai Zhaxin Hospital for treatment. Her medical team developed a treatment plan tailored to her condition. In March 2020, she successfully underwent an autologous hematopoietic stem cell transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Days in the hospital could feel long and difficult, and Xiaomin did not want to spend them focused only on the pain of treatment. During the periods when she felt a little better, she gave herself a new goal: preparing for graduate school. From then on, it became common to see her quietly reading and working through practice questions in her hospital room. After she was discharged home, she kept going — recovering physically while continuing to study. The following year, she was admitted to graduate school.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Xiaomin has completed her master’s degree and has been working for more than two years. Like many other young adults, she keeps a regular nine-to-six schedule, works hard, and enjoys everyday life. She carries an upbeat energy with her, and when she smiles, her eyes still have the same bright spark.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Not long ago, Xiaomin took time out from work to return to the hospital for follow-up. After successfully completing this important long-term checkup, she smiled and said, “I’ve graduated from the hospital too!”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, Xiaomin hopes her experience can encourage other young patients facing a similar journey: “No matter what happens, don’t give up. There is still so much life ahead of us. Hold on to hope, and keep moving forward one step at a time.”\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F2f11b31465caf8b4428212e9bfcdafea_20260910153158.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"2f11b31465caf8b4428212e9bfcdafea_20260910153158.png\" alt=\"2f994a65-572f-4c55-8bc0-ad6d2ea91ce2.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">January 2026: Xiaomin with Dr. Chuxian Zhao and Nurse Manager Bo Wang\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: Looking back to 2019, what symptoms did you first notice, and how were you eventually diagnosed with lymphoma?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: My lymphoma was in the mediastinum. At first, I only had a cough. When I lay down, it felt as though something was pressing on my chest, which was very uncomfortable. Since coughing was my only symptom at the beginning, I did not think much of it. I assumed it was a cold and tried cough and cold medicines, but nothing really helped.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Later, I went to a hospital near my university. The doctor suspected pneumonia, so I was admitted right away. I continued to have a fever that would not come down. After two or three days of tests, I was diagnosed with lymphoma. As soon as we received the diagnosis, my family and I transferred to Shanghai that same day. My family had heard that Professor Wang Chun was highly experienced in treating blood disorders, so the next day we went directly to GoBroad Shanghai Zhaxin Hospital for consultation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: Do you remember the moment the doctors told you that you had primary mediastinal diffuse large B-cell lymphoma?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I actually did not have much of an emotional reaction that day. Maybe the shock was so great that my mind could not process it right away. Looking back now, it does scare me a little, but I am also glad I went to the hospital as soon as I felt something was wrong and did not delay getting checked.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I later searched online for information about the disease, and of course I was frightened. But I was fortunate to have come to GoBroad Shanghai Zhaxin Hospital right from the start of treatment, and the medical team stepped in quickly. Knowing I was surrounded by experienced doctors gradually helped me feel more settled.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The doctors explained the plan to me: four to five cycles of chemotherapy, followed by an autologous hematopoietic stem cell transplant. I had already read a little about transplantation, and the doctors also discussed the possible risks in detail with my family. I agreed almost immediately. Partly, it was because I was young and the doctors felt the risks were relatively manageable. More importantly, the team had given me confidence from the very first cycle of chemotherapy, and I had responded very well to the initial treatment. I trusted them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The transplant went smoothly, and I was able to leave the transplant unit after about 20 days. I am very grateful that I found the right hospital from the beginning. Treatment was not easy, but I felt reassured at every step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: Is there a moment from your treatment that still stands out vividly in your memory?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: There were definitely periods that were very difficult. The chemotherapy used for an autologous transplant is high-dose, and it made me feel extremely unwell. I had almost no appetite during that time, and every day felt hard to get through.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There are so many moments I still remember. During an earlier round of chemotherapy, my veins were difficult to access and an IV could not be placed in the usual way, so one of the nurses had to place the line in my thigh. I had never experienced anything like that before and was quite scared. But she was incredibly gentle and paid close attention to how I was feeling throughout the procedure. The doctors also came to see me every day, explained how treatment was going, and reassured me not to be afraid. From the very beginning, the whole team helped me build confidence in facing the illness.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was also deeply touched by the caregiver who looked after me in the transplant unit. During the first few days, I felt so unwell that I barely wanted to speak. She would help me wash every day and quietly tell me, “You’ll feel better soon.” Those simple words meant a lot. At this hospital, I felt that everyone — doctors, nurses, and other staff — cared about how patients were feeling emotionally, not just physically. They kept giving us encouragement when we needed it most.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was never afraid of injections. What I dreaded most was taking medicine, especially steroids, because they tasted so bitter. Every dose required a lot of mental preparation. The doctors and nurses would gently coax me along, saying, “It’s okay, take it — you’ll be through this soon.” They comforted me almost like they were reassuring a child. Even now, remembering those moments still feels very warm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: You were preparing for graduate school while going through treatment. Was that difficult, and what helped you keep going?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I had my transplant in March 2020, when I was still in my senior year of college. By the time treatment ended and I returned home, graduation was coming up. I knew that after a serious illness, I probably would not be ready to jump straight into a job. I thought this might be a good opportunity to continue my education and give myself a clearer direction for the future. That was when I decided to apply to graduate school.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">While I was in treatment, I only studied now and then. Chemotherapy made me feel awful, and I needed something to take my mind off it. At first I watched videos or played games, but after a while I felt I was simply passing time. So I started studying for ten or fifteen minutes a day whenever I could. It was not intense studying — it was more a way to give my days some structure and shift my focus. I only began studying seriously after I returned home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I graduated from college in 2020. While recovering at home, I studied for the entrance exam, and in 2021 I was admitted to the Japanese Translation program at my own university.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, my mindset definitely changed depending on how I felt physically. On good days, I could focus and study. On difficult days, all I could do was lie down and get through them. But I kept doing a little whenever I could, and slowly I made my way forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I went on to complete three years of graduate school and found a job I really wanted after graduation. I have now been working for more than two years, usually nine to six, and my daily life is really no different from anyone else’s.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: Did your experience with illness change how you think about your education, your goals, or life in general?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: It changed me in many ways. The biggest change is that I learned to take better care of myself. Before, I barely paid attention to minor illnesses. Now, whenever I feel even slightly unwell, I take it seriously. Getting enough rest and protecting my health have become some of my highest priorities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It also changed my relationship with my parents. I think a lot of people become less expressive with their parents as they grow up. This illness made me truly understand how important they are to me, and it taught me to be more open about how I feel. In the end, I learned both to care for myself more and to show more love to the people around me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If a young patient asked me today whether treatment will derail their life or future plans, I would say: you do not have to feel lost, and you do not have to be afraid. This may be one difficult — even painful — chapter in your life, but it does not have to define everything that comes after. Trust your doctors, trust medical science, and work closely with your care team. After recovery, keep looking after your health. You can still return to everyday life and keep pursuing the future you want.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: What does reaching this five-year “graduation” milestone mean to you, and what do you hope for the future?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: I graduated from college, then graduate school — and now I’ve graduated from the hospital too!\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Actually, I have been doing well for almost six years. I was so busy with work that I did not have time to come back for my five-year follow-up earlier. For me, this visit feels more like a chance to close one chapter. I have finally passed an important “exam” and handed in an answer I can be proud of. I can tell myself: I finished this chapter. I did it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As for the future, there will always be unknowns. I do not have any grand plan. I just want to stay grounded and take care of the life in front of me. The future can unfold in its own time.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian ZHAO (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nPrimary mediastinal large B-cell lymphoma is an aggressive B-cell lymphoma that most commonly affects young women. A typical presentation is a rapidly enlarging mass in the anterior mediastinum. For patients who respond well to first-line high-dose chemotherapy, consolidation with autologous hematopoietic stem cell transplantation may offer the possibility of cure.\n\nI remember Xiaomin as the quiet, hardworking student everyone has known in a classroom — the kind of person you suddenly think of years after graduation. She kept a notebook with a cute cartoon cover beside her, filled her textbooks with color-coded highlights, and would sometimes quietly watch anime at the little bedside table while enjoying one of her favorite snacks.\n\nSeeing Xiaomin again, she is still every bit as gentle and warm, but now with an added sense of calm. She is more talkative than before, too. To me, she is a quietly strong young woman, carrying warmth within her and a bright road ahead.",{"slug":348,"title":349,"summary":350,"cover":351,"disease":255,"treatment":90,"patientType":68,"publishedAt":352,"contentHtml":353,"expertView":354,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"aplastic-anemia-transplant-recovery","After 16 Years with Aplastic Anemia, a Sudden Deterioration: At 62, He Found a New Beginning Through Transplant","After living with aplastic anemia and PNH for 16 years, Mr. Zhang faced a sudden deterioration and a serious infection. At 62, he underwent hematopoietic stem cell transplantation and successfully left protective isolation, beginning a new stage of recovery.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F52d2c4b47874e92012183a3b5c1f830f.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-02-13","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Mr. Zhang (pseudonym) was diagnosed with aplastic anemia accompanied by paroxysmal nocturnal hemoglobinuria (PNH) in 2009. For more than a decade, regular treatment and follow-up kept his condition stable. In 2025, however, his disease suddenly worsened and could no longer be controlled with conventional treatment, making hematopoietic stem cell transplantation an important option for long-term remission. After arriving at Beijing GoBroad Boren Hospital at age 62, he was evaluated by Dr. Tong WU's team. Given his age, underlying health conditions, and severe pulmonary infection, the team developed an individualized plan and first focused on controlling the infection to make transplantation possible. In December 2025, he underwent a related-donor haploidentical hematopoietic stem cell transplant and successfully left protective isolation in January 2026. He is now recovering well, with gradual hematopoietic recovery and improvement in PNH-related findings. His 16-year journey reflects both the progress of medicine and the perseverance that can carry patients through difficult turning points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2009, Beijing resident Mr. Zhang (pseudonym) was unexpectedly diagnosed with aplastic anemia accompanied by PNH (paroxysmal nocturnal hemoglobinuria). For years afterward, he attended regular follow-up visits at a hospital in Beijing, took his medications as prescribed, and remained relatively stable. Then, in August 2025, his condition deteriorated rapidly. His doctors told him that hematopoietic stem cell transplantation had become his only potentially curative option. At 62, Mr. Zhang came to Beijing GoBroad Boren Hospital in search of that possibility. After overcoming several major challenges around transplantation, he successfully left protective isolation in early January 2026 - closing one chapter of a 16-year illness journey and beginning another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F97c1c7e8cece4b7baafbf7598591b083_20260912225624.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"97c1c7e8cece4b7baafbf7598591b083_20260912225624.png\" alt=\"13ba5670-41ad-4e09-8d04-a05de9ce38cf.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Successfully Leaving Protective Isolation After Transplant\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Sixteen Stable Years, Then a Sudden Turn for the Worse\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2009, Mr. Zhang began experiencing intermittent fatigue, poor appetite, and weight loss. After strenuous activity, his urine would sometimes turn a dark tea color. A bone marrow examination at a major tertiary hospital in Beijing led to the diagnosis of aplastic anemia with PNH, bringing sudden uncertainty into what had been an otherwise ordinary family life. Fortunately, with appropriate treatment and oral medications, his condition was brought under stable control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"For more than ten years, we followed the doctor's advice, took the medications, and went back for regular checkups. He couldn't do heavy physical work like other people, but overall life was stable. We thought we could keep going like that," recalled his wife, Ms. Zhu (pseudonym).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But in August 2025, things changed without warning. Mr. Zhang became increasingly fatigued and dizzy, and his usual medications were no longer able to keep the disease under control. "They tried all the medications available at the hospital, but his numbers just kept falling. Our whole family panicked," Ms. Zhu recalled, still remembering how anxious that period felt.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As the family struggled to see a way forward, Mr. Zhang's treating physician offered a crucial recommendation: "At this point, hematopoietic stem cell transplantation is the only potentially curative option. Dr. Tong WU at Beijing GoBroad Boren Hospital has extensive experience in this field. You could go and speak with her." For the family, that recommendation offered a clear direction at a time when they desperately needed one.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>At 62, a Serious Infection Becomes the First Hurdle Before Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2025, Mr. Zhang and his family arrived at Beijing GoBroad Boren Hospital and met Dr. Tong WU. What they had not expected was that the first major challenge would not be the transplant itself, but a difficult pulmonary infection. "When he was first admitted, he was coughing badly, with chest tightness and shortness of breath. The lung infection just wasn't coming under control, and we were very worried he might miss the right window for transplant," Ms. Zhu said. Watching him struggle during those days was extremely difficult for the family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The medical team responded quickly. Taking into account Mr. Zhang's age, overall condition, and the severity of his pulmonary infection, Dr. WU and her team developed an individualized plan with one immediate priority: bring the infection under control and create a safer foundation for transplantation. His vital signs were closely monitored around the clock, the lung infection was assessed every day, anti-infective therapy was adjusted as his condition changed, and the nursing team provided careful supportive care throughout. After more than 20 days of intensive treatment, the infection was effectively controlled and his clinical indicators gradually stabilized, allowing him to proceed to transplantation. "Once the infection was under control, we finally felt we could breathe again. It also made us even more confident that coming to Boren was the right decision," Ms. Zhu said.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Through Transplant: Care, Determination, and a New Beginning\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In mid-December 2025, Mr. Zhang entered the transplant unit and began hematopoietic stem cell transplantation. To stay close and support him, Ms. Zhu rented a room near the hospital and settled into a daily routine of traveling between the apartment and the hospital, preparing all three meals herself. "The doctors specifically reminded us that infection can sometimes be linked to unsafe food during this period. We didn't want to take any chances. I bought fresh ingredients every morning, paid close attention to hygiene when cooking, and disinfected the tableware after every use." Preparing and delivering meals every day was exhausting, but for Ms. Zhu, knowing that he could eat safely made it worthwhile.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The nearly month-long stay in the transplant unit tested both Mr. Zhang's body and his resolve. Side effects from the conditioning regimen were difficult to endure. Whenever he felt discouraged, however, the medical team was there. The doctors checked on how he was feeling each day and adjusted treatment as his condition changed. The nurses not only managed infusions and daily care, but also talked with him, reassured him, and kept encouraging him. That combination of clinical expertise and compassionate support helped him find the strength to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Leaving Protective Isolation and Starting a New Chapter\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On January 12, 2026, after nearly a month of waiting and treatment, Mr. Zhang successfully left protective isolation. He had lost about 10 kilograms since admission, but he was in good spirits and smiling again. "The moment he came out, we saw how relieved the doctors and nurses looked. Our whole family was overwhelmed with emotion. It felt as though a huge weight had finally been lifted," Ms. Zhu said.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Zhang continued to recover well after leaving the transplant unit. His blood cell counts steadily increased, his appetite improved, and he felt stronger day by day. Looking back on their experience at Beijing GoBroad Boren Hospital, Mr. Zhang and Ms. Zhu said they were especially grateful for both the medical care and the way the team communicated with them. "From the admission assessment and infection treatment to the transplant and post-transplant care, we felt supported at every step. Whenever we had questions, the doctors and nurses took the time to explain things carefully and patiently."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the hospital stay, the family also met patients who had traveled from many parts of China - Shanxi, Gansu, Guangzhou, Hainan - as well as patients from overseas. Many told them they had come after recommendations from other patients or physicians. For Ms. Zhu, meeting so many families on similar journeys was reassuring. "We also want to share our experience with other people living with aplastic anemia, so that those going through a difficult time can see that there may still be options. Even for an older patient, transplant can sometimes offer a new chance at life."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Mr. Zhang continues to regain his strength and is moving closer to returning to everyday life. Looking back over 16 years, the journey has included the challenge of living with a chronic illness, the fear of a sudden deterioration, and the relief of reaching a new beginning after transplant. His experience is a story shaped by both medical care and the resilience to keep moving forward.\u003C\u002Fspan>\u003C\u002Fp>","Clinical Commentary (Dr. Fang Fang, from the teams of Dr. Tong WU and Dr. Yongqiang ZHAO): \n\nThe patient is a 62-year-old man with a 16-year history of aplastic anemia accompanied by PNH. He had moderate anemia and thrombocytopenia and had been treated with androgen therapy, including stanozolol, as well as prednisolone. His transfusion requirements were relatively low and his condition remained generally stable. In October 2025, he developed fever, cough with sputum, and blood-streaked sputum, together with a severe pulmonary infection, severe anemia, and profound thrombocytopenia. Pathogen screening after admission, including targeted testing of respiratory specimens, identified Aspergillus fumigatus, Ralstonia mannitolilytica, and human herpesvirus 7 (HHV-7). The pulmonary infection improved after active anti-infective treatment. A suitable related donor was available and passed the donor evaluation, and the patient proceeded to a related-donor haploidentical hematopoietic stem cell transplant. Given his age, impaired cardiac and renal function, and limited treatment tolerance, a reduced-intensity conditioning regimen was selected. Conditioning and stem cell infusion were completed without major difficulty. Leukocyte engraftment and platelet engraftment were both achieved on day +11. At the one-month post-transplant assessment, PNH-FLAER testing showed normal CD55 and CD59 expression on red blood cells and normal CD55, CD59, and FLAER findings in granulocytes. Bone marrow morphology, cytogenetics, and chimerism studies showed no abnormalities. The patient was in generally stable condition and was expected to be discharged soon.",{"slug":356,"title":357,"summary":358,"cover":359,"disease":80,"treatment":272,"patientType":68,"publishedAt":352,"contentHtml":360,"expertView":361,"disclaimer":72,"hasAlternate":73,"updatedAt":319},"ph-positive-all-transplant-recover","Five Years After Leukemia Relapse and Stem Cell Transplant, He Gives Flowers to the Wife Who Cared for Him for Seven Years","After being diagnosed with Ph-positive acute lymphoblastic leukemia, Mr. Xu endured a relapse and underwent an allogeneic hematopoietic stem cell transplant; supported by his wife throughout the past seven years, he has now reached the five-year mark of recovery—a moment of \"graduation.\"","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F24e646c1b05ae3f3f2f6689c6f580978.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: In 2019, Mr. Xu was diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) after persistent headaches and a low-grade fever. His treatment journey included a severe fungal lung infection, relapse, and several difficult treatment decisions. In February 2021, he ultimately underwent an allogeneic hematopoietic stem cell transplant from an unrelated donor. After transplant, he faced severe oral mucositis, diarrhea, infections, and ischemic strokes. With treatment from his medical team and seven years of steadfast care from his wife, Mrs. Dai, he made it through one challenge after another and, five years after transplant, reached his recovery "graduation" milestone. Their story follows not only one leukemia patient's path from relapse and transplant to long-term stability, but also the devotion, responsibility, and love of a partner who never left his side.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002Fe36eccf37659b66c8a818a9b46684920_20260910151833.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e36eccf37659b66c8a818a9b46684920_20260910151833.png\" alt=\"f770fb68-ae69-47ec-af5f-6869ec1ea5f6.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Blood disorders can involve long and intensive treatment journeys, and patients often need tremendous support from their families. In countless homes, the person who takes on much of that responsibility is the patient's spouse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At GoBroad Shanghai Zhaxin Hospital \u002F Shanghai Liquan Hospital, there are many couples like this. Some are newly married, while others have shared decades together. When serious illness enters their lives, they become each other's strongest source of support.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Love is not always spoken aloud. More often, it is seen in the day-to-day care, the sleepless nights, and simply being there. Mr. Xu and Mrs. Dai are one such couple.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, 63-year-old Mr. Xu marked five years of recovery with a special "graduation" ceremony at GoBroad Shanghai Zhaxin Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At this meaningful moment, he turned and handed the flowers he was holding to Mrs. Dai, who had cared for him for seven years. The bouquet said what words could not: thank you for never leaving my side.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Xu and Mrs. Dai also sat down with us to look back on the difficult road they had traveled together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002Fd9dabea1b4a6523cac7da0e451e6bfa9_20260910151848.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d9dabea1b4a6523cac7da0e451e6bfa9_20260910151848.png\" alt=\"f7ae437e-bf57-4d7a-a394-27bf15f8b350.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">February 2026: Mr. Xu with members of his care team\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- Patient Q&A -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: From an unexpected diagnosis to the first turning point, can you take us back to how the illness was discovered, how the diagnosis was confirmed, and how treatment began?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Xu: In mid-to-late March 2019, I went to the hospital after several days of headaches and an unexplained low-grade fever. In early April, the results came back: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph-positive B-ALL). A hard fight had begun without warning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After my third round of chemotherapy, I developed a severe fungal infection in my lungs with a large pleural effusion. The doctors performed a drainage procedure and removed more than 2 liters of fluid, so chemotherapy had to be paused. By late September, after going from hospital to hospital, I arrived at the Department of Hematology at Shanghai General Hospital. Professor Chun Wang carefully reviewed my case. Because a repeat genetic test was negative, he recommended moving quickly to an autologous hematopoietic stem cell transplant, which generally allows faster immune recovery, but only if three consecutive fusion-gene tests were negative.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In early 2020, I followed Professor Wang to the newly opened GoBroad Shanghai Zhaxin Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As soon as I was admitted, we repeated the genetic test for the third time. Unfortunately, because pneumonia had delayed my chemotherapy earlier, the leukemia cells had started to return. At that point, if we wanted to clear the disease and still aim for a cure, we needed a more intensive approach. Allogeneic hematopoietic stem cell transplantation became the only option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The thought of an allogeneic transplant was frightening. We knew there could be severe infections and unpredictable graft-versus-host complications, so the whole family hesitated. Just when we felt we were running out of options, a new treatment plan gave us a way forward. We first got the fusion-gene test back to negative, then went through six alternating cycles of chemotherapy at different intensities, followed by a third-generation targeted therapy to keep the disease under control. By June of the following year, I had finished all the chemotherapy and went home to recover, full of hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: When the disease came back and you were facing another major decision, what ultimately made you choose allogeneic hematopoietic stem cell transplantation?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Dai: One day in August 2020, he suddenly felt a pain near his right cheek and ear, almost like an insect bite. Dermatology treatment did not help, and soon the entire right side of his face was swollen and he had a fever. At one point, we even wondered if it was mumps. Dr. Jun Zhu treated him and the symptoms improved with medication, but they came back quickly after the medication was stopped. We told Dr. Zhu what had happened, and he immediately became concerned and told us to come into the hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The leukemia had fully relapsed, and this time the symptoms were more aggressive than ever. The doctors were preparing him for cell therapy, which meant his regular medication had to be stopped beforehand. As soon as the medication was discontinued, an ulcerated lesion appeared in the middle of his chin and became so deep that the bone could be seen. Overnight, his scalp was covered in tiny raised spots, almost like heat rash. On top of that, he had severe bone pain all over his body, especially around the joints. It hurt so much that he could not even step over the small threshold into our bathroom at home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At that point, we had nowhere else to turn. An allogeneic stem cell transplant was our only hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It was during the COVID-19 pandemic, and our daughter was away at school and could not come home. We therefore started a donor search through the China Marrow Donor Program while he received a new bispecific antibody therapy. Before long, we received good news: a matched donor had been found, and the volunteer was willing to donate. Our whole family is still deeply grateful to this stranger we have never met.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In February 2021, he underwent an allogeneic hematopoietic stem cell transplant and successfully left the transplant unit. But we soon realized that getting through the transplant itself was only the first step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the first three years, one problem seemed to follow another. It felt like fighting monsters: as soon as we beat one, another appeared. So we faced them one at a time, and got through them one at a time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: Looking back on the entire treatment journey, what was the hardest period for you?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Dai: The most difficult time was right after the transplant. His mouth was covered in severe ulcers, so painful that he could not eat anything. The diarrhea was just as bad - five or six times a day, sometimes six or seven. He was so weak that he could barely make the few steps from the bed to the bathroom, and often did not get there in time. I would finish cleaning up, turn around, and it would happen again. It went on all day, and the room could become chaotic.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I especially want to thank Dr. Chuxian Zhao. She was incredibly responsible and attentive. She asked me to let her know every time he had a bowel movement so she could assess it herself. At first I called her each time, but there were so many that I felt bad asking her to come over again and again. So I started taking photos and sending them to her instead - six or seven times a day. I felt embarrassed, but Dr. Zhao never showed any impatience. She carefully reviewed every single photo.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The doctors explained that his gut function was essentially having to rebuild and readapt. At that stage, almost everything he ate passed straight through, so food had to be added back slowly and carefully.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We started with the clearest rice porridge water, one spoonful at a time, almost like feeding a newborn. When he improved a little, I minced Chinese yam very finely and added tiny amounts to the porridge. Every meal felt like an experiment, and every day felt like walking a tightrope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: Mrs. Dai, you have been the person standing behind Mr. Xu throughout this journey. What have you learned from caring for him over the years that you would like to share with other families?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Dai: Leaving the transplant unit was really only the first step in a very long recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By then, his body had been through so much that he seemed even more fragile than a newborn, and his risk of infection was far higher than that of a healthy person. From that day on, I did not dare let my guard down. I handled everything myself. We had a medical-grade sterilizing device at home, and every day I cleaned the floors and tables with Dettol disinfectant. I removed as much clutter as I could so there were fewer places for germs to collect. Even with all that, he still developed pneumonia repeatedly. Sometimes all it took was one cough or a slightly different sound in his breathing for my heart to drop. We would go to the hospital, and sure enough, it would be pneumonia. Over the years, I developed my own internal "alarm" - just hearing his cough was enough to tell me something was wrong.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For a patient recovering from a stem cell transplant, food safety became one of the biggest things I watched. From the day he left the transplant unit, every meal mattered. I cooked food fresh for every meal, never served leftovers, and avoided raw, cold, or externally prepared foods. One thing a doctor told me stayed with me: "If hygiene is done properly, the patient has a better chance of going the distance. Once an infection happens, no one can predict the consequences." I was not willing to take that risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I was also extremely careful with fruit. For apples and pears, I washed them under running water first, then wiped the outside with a disinfecting wipe or rinsed them with boiling water. The knife was disinfected, my hands were washed, and once I started peeling, I peeled straight through without touching the flesh with my fingers. The fruit went directly into a disinfected bowl, and he picked it up himself with chopsticks. Bananas and oranges were easier because they could be peeled. Blueberries and strawberries were hard to clean thoroughly, so I simply did not buy them. Over the past two years, his blood counts have stabilized and his immunity has improved, so I no longer disinfect the outer skin, but I still keep the rule of not touching the peeled fruit with my hands.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What scared me was the thought that one unsafe bite could undo years of hard work. I cannot speak for everything, but when it came to what he ate, I watched it as carefully as I could, and thankfully we never had a major problem from food.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It was not until last year that I finally felt comfortable taking him on a trip. We drove to a hotel with friends. Before we left, I packed a disinfection lamp, along with our own sheets, duvet cover, and pillowcases. When we reached the hotel, I went straight to our room, made the bed with everything we had brought, set up the disinfection lamp, and only let him come in after the room had been disinfected. Our friends said I was too nervous. But after everything we had been through, taking a chance was one thing I just could not bring myself to do.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: Mr. Xu, it has now been five years since your transplant, and today you received a commemorative pin marking this milestone. How are you feeling?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Xu: Before I got sick, I was constantly busy with work and traveled often, so I did not spend much time with my family. Around the time I was diagnosed, I once thought about taking a trip to the grasslands and seeing China's vast landscapes one more time, then coming home and simply letting nature take its course, even if that meant stopping treatment. But then I thought about my daughter and my wife. How could I bear to leave them? No matter how hard things became, I kept going. I did not ask for much - I just wanted one more day with them, then another. As long as I am still here, there is hope. As long as I can keep going, our family is still whole.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So to have reached today, the people I most want to thank are the medical team at GoBroad Shanghai Zhaxin Hospital for being with me every step of the way.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Your expertise pulled me back from the edge and carried me through one stage after another. After all these years together, the doctors and nurses here feel like family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, I am "graduating" here. This pin is not only a reminder of my recovery. It belongs to everyone at Zhaxin and to our family - a medal for the battle we fought and won together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002Fe0c0cebb5109388fa312f7284d13e7a6_20260910152045.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e0c0cebb5109388fa312f7284d13e7a6_20260910152045.png\" alt=\"1131c9b2-a962-41a9-a238-07fed560872c.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: With Valentine's Day just around the corner, is there anything the two of you would like to say to each other?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mrs. Dai: I was busy with work before I retired too, leaving early and coming home late every day. I had imagined that after retirement I would finally have time to slow down, travel, and enjoy life. Instead, he fell ill in April, one month before I retired in May. From then on, the two of us became inseparable - and that has lasted for more than seven years.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From the day he became ill, I never really relaxed. My whole life revolved around taking care of him. Only in the past two years, once his condition became stable, did I start occasionally meeting up with old friends again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After 30 years of marriage, romantic love grows into something deeper - family, responsibility, and commitment. And after living that responsibility day after day, it simply becomes instinct.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If he coughs once, my heart skips. If he walks across the room, my eyes follow him. After seven years, caring for him has become part of everyday life. As long as he is here, our family is still here. And my responsibility is still right here too.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mr. Xu: My wife and I have really made it through one difficult hurdle after another. The transplant brought my blood disease under control, but then life gave us another challenge. In 2023, I had three ischemic strokes. Every time, she noticed the warning signs quickly and got me to the hospital right away. Again and again, her decisiveness helped pull me through a dangerous moment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am incredibly lucky to have her in my life. She jokes that she must have owed me something in a past life, which is why she has had to work so hard for me in this one. But what I have never said out loud is this: I must have saved the world in a past life to be lucky enough to marry you in this one.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian Zhao (Associate Chief Physician, MD; Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nOn a February afternoon, news of Mr. Xu's five-year \"graduation\" quickly spread through every floor of the inpatient wards. Everyone who had cared for him was delighted.\n\nMrs. Dai has been an exemplary family caregiver. Her attentive care helped Mr. Xu through one challenge after another, and the home-care experience she has built over the years can also offer useful perspective to other families.\n\nTime and experience have given this commemorative pin its special weight. It carries the love and devotion that Mr. Xu and Mrs. Dai have shared throughout the years.\n\nAs the New Year begins, I wish Mr. Xu and Mrs. Dai continued health, many smiles, lasting happiness, and peaceful days ahead.",{"slug":363,"title":364,"summary":365,"cover":366,"disease":255,"treatment":90,"patientType":82,"publishedAt":367,"contentHtml":368,"expertView":369,"disclaimer":72,"hasAlternate":73,"updatedAt":319},"severe-aplastic-anemia-transplant-recovery","Five Years After Transplant for Severe Aplastic Anemia: Back to School and Now at University","Diagnosed with severe aplastic anemia at the age of 16, the individual returned to school after undergoing allogeneic hematopoietic stem cell transplantation and has now embarked on university life.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F660a00304a3aca46213fdef11fe951bf.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-02-06","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: At 16, Xiaojie was diagnosed with severe aplastic anemia (SAA) after developing bleeding gums and severe abdominal pain. With his condition critical, he underwent an allogeneic hematopoietic stem cell transplant from his father in February 2021. During treatment, he faced persistent pain and skin graft-versus-host disease (GVHD), but gradually recovered with the support of his medical team and family. Two years later, he returned to school, completed high school, and earned a place at his dream university. Now, five years after transplant, he is back to everyday life. His story is one of perseverance, return, and growing forward - and a source of hope for others living with aplastic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F49bb6bb1fefed39c7ae727015ee27994_20260910151026.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"49bb6bb1fefed39c7ae727015ee27994_20260910151026.png\" alt=\"3605b141-f4a6-466e-b142-b8c340c89c04.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2021, during winter break in his first year of high school, 16-year-old Xiaojie noticed that his gums had been bleeding for several days. At first, he did not think much of it. Then one night, he woke from sleep with severe abdominal pain. An emergency hospital visit led to a diagnosis of severe aplastic anemia (SAA). The illness came on suddenly, confronting a teenager with a life-threatening challenge he had never imagined. The following month, Xiaojie underwent an allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital, with his father as the donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After more than 20 difficult days in the transplant unit, Xiaojie was finally able to leave protective isolation. That day felt brighter than usual. But an unexpected challenge followed: intense pain shot through his body from head to toe, almost like an electric current. Around the clock, the medical team cared for him with both expertise and compassion, helping him through one painful day at a time. Gradually, the pain eased and his strength returned, and he was eventually discharged. Even then, a lingering ache stayed with him on and off for nearly a year.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the next two years, Xiaojie returned to the hospital regularly for follow-up visits, always accompanied by his family. As his health steadily improved, he was finally able to put on his backpack again, return to school, and pick up the studies that illness had interrupted. More than two years of life may have been put on hold, but his determination had not faded.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He went on to finish high school, perform well in China's national college entrance examination, and earn a place at the university he had hoped to attend.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Xiaojie is a second-year university student. At the five-year milestone after transplant, his doctor presented him with a commemorative pin recognizing that he had reached the milestone of clinical cure. It honors everything he has come through and carries a wish for many healthy years ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiaojie also chose to share his story - a journey shaped by pain and hope, support and growth - with other patients still finding their way forward. He believes every difficult journey deserves to be seen, and one person's story may become a light for someone else in a dark moment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F9b7af499c393df0bf11c06059e4d48b9_20260910151048.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9b7af499c393df0bf11c06059e4d48b9_20260910151048.png\" alt=\"e1963d0c-7274-49bf-b68e-ad0e4c104a4a.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">February 2026: Xiaojie with Dr. Ying Jiang and Nurse Manager Xia Yan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- Patient Q&A -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: Can you take us back to when you were diagnosed? What symptoms were you having?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: It was winter break during my first year of high school. My gums had been bleeding for several days, but I did not think much of it. Then one night, I suddenly developed severe abdominal pain. I went to the hospital and was diagnosed with aplastic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back, I was in shock. I mainly remember how anxious my family was and how urgently they were trying to find the right hospital. My platelet count was already extremely low, so the situation was actually very dangerous.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With my family beside me, we first went to Professor Wang Chun's clinic, and I was admitted that same day. Dr. Ying Jiang was my attending physician. She was very clear that I should undergo an allogeneic hematopoietic stem cell transplant as soon as possible. Treatment moved quickly. HLA matching was done with my father, and before long I entered the transplant unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At that point, we really did not have many options. Transplant was essentially the only treatment that offered a way forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: How did you get through your time in the transplant unit? Did it feel lonely without your parents by your side?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Before I went in, I thought it would simply be a different place to rest and that nothing would be too unusual. Once treatment started, the physical reactions made me realize it was much harder than I had expected. My family could not stay with me, and when I felt unwell, I sometimes felt lonely too.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I did not want my parents to worry, and I often felt too unwell to reply to my mother's messages right away. But during the brief visiting time each day, she would always come and see me through the glass. We did not need to say anything. I could see the concern and encouragement in her eyes, and that quiet support gave me strength to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I am not very good at expressing my feelings, but I always knew how much my parents loved and supported me. When things were hard, I would tell myself: I have to get through this.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In some ways, the days in the transplant unit passed quickly. The doctors, nurses, and caregivers were always there, looking after me and helping me make it through the hardest period one day at a time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: What was the hardest part of treatment for you?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: During recovery after transplant, my skin became darker and was repeatedly itchy, and I also had severe pain throughout my body. For a while, I needed pain-relief injections almost every day just to get some relief. The doctors explained that the donor cells from my father and my body were learning to coexist, and that the graft-versus-host reaction was part of this 'conversation' inside my body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The pain often made it hard to eat or sleep, but I kept telling myself: hold on, get through this, and things will get better. After leaving the transplant unit, I remained in the hospital for more than three months. As the pain gradually eased, I was finally able to go home and return for regular follow-up visits.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The pain did not disappear completely right away. It was more like a slowly receding tide that would still come back from time to time. It took almost a year after transplant before it finally went away for good.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: When were you able to return to school?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: About two years after transplant, I had mostly recovered. At follow-up, my doctors felt I was ready to go back to class, and I felt I could keep up too. So I returned to the first year of high school and continued the studies I had had to put on hold.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Walking back onto campus after more than two years brought up so many emotions. There was a deep sense of relief, and the joy of seeing sunlight again after a long storm. Eventually, all of those feelings settled into a sense of calm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before I got sick, I put a lot of pressure on myself academically and always wanted to do my best. After returning to school, I became much more balanced. I realized that health comes first, and grades were no longer my number-one priority. That did not mean I stopped working hard.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I have always believed that illness is only one chapter in a life. If it could not break me, then it would make me stronger. I graduated two years later than my classmates, but I still earned a place at the university I wanted to attend.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Now I am a second-year university student. I go to class, take part in activities, and eat out with friends just like everyone else. I am fairly disciplined in daily life. I do not have strict food restrictions, but I usually choose clean, healthy food. Every now and then I might have a skewer or two of barbecue, but I keep it moderate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: What does reaching the five-year 'graduation' milestone mean to you, and what do you hope for next?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: Looking back on these years, I feel deeply grateful. My mother was always there, taking care of every detail. My father donated the stem cells that helped give me my life back. My grandparents did everything they could to prepare food I was able to eat at the time. I remember what each of them did for me.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During my time in the transplant unit, one of the caregivers also gave me a lot of warmth and support. She patiently passed messages back and forth between my mother and me and carefully handled the food my family brought. I am also deeply grateful to Dr. Ying Jiang and her team. Their expertise and attentive medical care helped me regain my health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It has not been an easy road. I could only make it to where I am today because so many people stood by me and supported me along the way. And now, I have finally passed this five-year 'final exam'!\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It closes one chapter and opens the next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the rest of my life, I will remember that I have already been through a life-or-death experience. Whatever comes next, I will face it with more courage and more calm.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Ying Jiang (Associate Chief Physician, MD; Medical Team Leader, GoBroad Shanghai Zhaxin Hospital):\n\nXiaojie came to GoBroad Shanghai Zhaxin Hospital in late January 2021 and was diagnosed with severe aplastic anemia, together with an intra-abdominal infection and gingival bleeding. It was only two weeks before the Spring Festival, a period when blood donation often falls and blood supplies can become tight. In that setting, restoring his blood counts as quickly as possible became a key treatment priority.\n\nWe promptly initiated an allogeneic hematopoietic stem cell transplantation plan. By February 23, his platelet count had returned to normal and neutrophil engraftment had been achieved. After transplant, he developed immune-mediated pain and cutaneous graft-versus-host disease. His symptoms gradually improved after adjustments to immunosuppressive therapy and other supportive treatment.\n\nToday, Xiaojie has returned to everyday life, gone back to school, and continued his education. His recovery reflects not only his own perseverance, but also the steady support and companionship of his family throughout treatment.\n\nWishing you health, happiness, and many good days ahead.",{"slug":371,"title":372,"summary":373,"cover":374,"disease":375,"treatment":272,"patientType":82,"publishedAt":376,"contentHtml":377,"expertView":378,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"mpal-hsct-recovery","A 7-Year-Old Boy with Rare Mixed Phenotype Leukemia Finds a New Beginning","After multiple rounds of chemotherapy failed to bring his disease into remission, an accurate diagnosis and individualized treatment helped him successfully undergo hematopoietic stem cell transplantation and get back to being a child again.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F24f4dcb244034ac66321607e19d3840f.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Mixed Phenotype Acute Leukemia\u002FLymphoma","2026-01-30","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Seven-year-old Xiaole developed persistent fever, thrombocytopenia, and other symptoms and was initially diagnosed with T-lymphoblastic lymphoma\u002Fleukemia with myeloid expression. Despite multiple rounds of standard chemotherapy, his disease continued to progress. After he was transferred to Beijing GoBroad Boren Hospital, Prof. Yonghong Zhang’s team brought together multidisciplinary expertise, genetic testing, and precision diagnostics to identify the underlying disease as mixed phenotype acute leukemia\u002Flymphoma (T\u002FB\u002Fmyeloid) driven by an NRAS somatic mosaic mutation. The team then developed an individualized treatment strategy combining targeted therapy with allogeneic hematopoietic stem cell transplantation. In March 2025, Xiaole successfully underwent a related haploidentical transplant. He remains in complete remission and is steadily recovering. His story shows how an accurate diagnosis and tailored treatment can open a path forward for a child with a rare and complex blood cancer, while also highlighting the value of multidisciplinary care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In May 2024, seven-year-old Xiaole (pseudonym) was diagnosed at another hospital with stage IV T-lymphoblastic lymphoma\u002Fleukemia with myeloid expression (CNS1). Yet after multiple rounds of standard chemotherapy, his disease still did not go into remission, and treatment seemed to have reached an impasse. In November 2024, after his local doctor invited Prof. Yonghong Zhang for a consultation, Xiaole was transferred to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital to understand why the disease was proving so difficult to treat. The team first carried out a comprehensive review of his case, then quickly convened a multidisciplinary consultation and incorporated genetic testing and other precision diagnostic tools. This ultimately revealed the key driver of his disease: mixed phenotype acute leukemia (MPAL) driven by an NRAS somatic mosaic mutation. The team designed an individualized plan using pathway-directed targeted therapy together with chemotherapy to bring the disease under control and create the right conditions for transplantation. In March 2025, Xiaole successfully underwent a related haploidentical hematopoietic stem cell transplant. With close supportive care from the medical team, he made it through critical post-transplant challenges including infection and graft-versus-host disease (GVHD).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, more than 10 months after transplantation, Xiaole remains in complete remission (CR). His strength is returning, his familiar smile is back, and childhood is once again filling his days with color.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F3be2728e5d56d4dff003653f399958c7_20260912211602.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3be2728e5d56d4dff003653f399958c7_20260912211602.png\" alt=\"c890892b-a3af-45b2-be8f-81618cc453ae.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Xiaole after treatment and discharge\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>From Common Symptoms to a Rare Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The story began in early 2024, when Xiaole developed a cough and fever. At first, his family thought it was simply a common cold and took him to a local hospital for symptomatic treatment. A month or two later, however, small red spots appeared on his skin, raising new concerns. His family took him from their home in Anhui to a hematology department at a hospital in Zhejiang. The initial test results were worrying: his platelet count was low, and his liver, spleen, and lymph nodes were enlarged. After a series of detailed examinations, the family received a diagnosis they had never expected: T-lymphoblastic lymphoma with myeloid expression (stage IV, CNS1), with NRAS and DDX3X mutations also identified.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“I was completely stunned. It felt like a dream. I had never even heard of lymphoma before...” Xiaole’s mother still remembers the shock and helplessness she felt when she first heard the diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Determined to save their son, Xiaole’s family went through several courses of chemotherapy at the local hospital. But instead of improving as hoped, the disease repeatedly pushed back, leaving the family feeling that they were running out of options. At a time when they were anxious, confused, and close to despair, a message in a patient support group gave them a new lead: Prof. Yonghong Zhang’s team at Beijing GoBroad Boren Hospital was known for extensive experience in pediatric lymphoma, particularly relapsed and refractory disease. After Xiaole’s local doctor invited Prof. Zhang for a consultation, the family made the trip to Beijing in November 2024, determined to pursue every possible option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Precision Diagnosis: Finding the Driver and a Path Forward\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Faced with this unusually complex case, Prof. Yonghong Zhang’s team immediately began a comprehensive review. The new evaluation revealed a more complicated picture: in addition to hepatosplenomegaly, Xiaole’s bone marrow contained three populations of tumor cells with abnormal T-cell, B-cell, and myeloid phenotypes, consistent with a mixed-lineage leukemia. NGS screening for susceptibility genes related to hematologic and immune disorders also showed an NRAS variant allele frequency of 93.36%, yet the variant was not inherited from either parent. Through a joint molecular and clinical review, the team determined that the NRAS change was a somatic mosaic mutation arising early in embryonic development. Because it was neither an inherited germline variant nor a tumor-specific mutation, it helped explain the highly unusual clinical presentation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That precise diagnosis became the turning point. Early in treatment, the team tried several combinations of chemotherapy and targeted agents, but the disease continued to progress. In February 2025, as the tumor burden remained difficult to control, Prof. Zhang’s team rapidly convened another multidisciplinary consultation. After repeated review and discussion, they reached the integrated diagnosis of mixed phenotype acute leukemia\u002Flymphoma. The NRAS somatic mosaic mutation was driving a malignant hematopoietic stem-cell clone capable of differentiating along multiple lineages, helping explain why several lines of chemotherapy had failed to achieve a meaningful response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The experts agreed that allogeneic hematopoietic stem cell transplantation offered the only realistic path toward rebuilding Xiaole’s blood-forming and immune systems and pursuing a potential cure. Before transplantation, however, the disease first had to be controlled. Prof. Zhang’s team therefore developed a bridging regimen combining two targeted agents. Encouragingly, after only four days of targeted therapy, Xiaole’s enlarged spleen had already shrunk noticeably. That early response gave both the family and the medical team renewed confidence that transplantation might now be within reach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Through the Darkest Days: A Vigil in the Transplant Unit\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On February 19, 2025, Xiaole entered the transplant unit and began conditioning. His hematopoietic stem cells were infused over two days, March 5 and 6. For his family, these “seeds of life” carried their deepest hopes, as well as the medical team’s careful preparation for what came next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The conditioning regimen took a heavy toll on Xiaole. The wait for blood-cell recovery was filled with uncertainty, and the fear of infection weighed constantly on the family. His mother later described that period as “the darkest time of our lives,” when every day seemed to bring a new worry.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But Xiaole was not facing it alone. The medical team stayed close throughout the transplant journey. With careful monitoring and supportive care, his neutrophils engrafted on day 16 and his platelets on day 25. He then faced one challenge after another, including infection and intestinal GVHD. Each time, the team responded promptly and precisely, helping him safely through the complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The signs of a new beginning became clearer with each follow-up. At one month after transplantation, imaging showed no obvious tumor lesions, bone marrow testing showed complete donor chimerism, and the NRAS mutation was no longer detected in either bone marrow or peripheral blood. At the two-month assessment, Xiaole had achieved complete remission, confirming that the disease was under effective control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Ff76791f054f8c67719415d39021f3e47_20260912211632.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"f76791f054f8c67719415d39021f3e47_20260912211632.png\" alt=\"09ac912d-40ad-4150-9110-8cce7106c647.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Xiaole returned to the general ward after leaving the transplant unit\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A New Beginning: Gratitude for the Return of Everyday Happiness\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, more than 10 months after his transplant, Xiaole remains in complete remission and continues to regain his strength. The child who once spent his days consumed by illness is now laughing and playing with friends again, just like other children his age. “The best decision I made was bringing him to Boren,” his mother said. Her voice still trembled as she looked back on the journey - with memories of how difficult it had been, but also with gratitude for where her son is today.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In a thank-you letter to the hospital, Xiaole’s mother wrote: “Looking back on this journey, I know clearly that the expertise of the Boren medical team paved the way for his recovery... What you protected was not only his health, but the ordinary days and future that every family treasures most.” She also shared how much Xiaole enjoyed the hospital’s regular arts-and-crafts classes and holiday activities. These seemingly simple moments helped preserve the fun, interaction, and sense of childhood he deserved, bringing warmth and color to an otherwise difficult treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“To families facing something similar, I want to say this: no matter how complicated or rare the disease is, keep looking for answers and don’t give up on finding a way forward for your child. Trust an experienced medical team.” These are the words Xiaole’s mother most hopes other families in difficult situations can hear.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002Fdfabaac6e5713c84c5d2722f400cb666_20260912211730.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"dfabaac6e5713c84c5d2722f400cb666_20260912211730.png\" alt=\"45d8fe55-4262-48f0-98bf-c0394d7ba023.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Thank-you letter from Xiaole’s mother\u003C\u002Fspan>\u003C\u002Fp>","Case Commentary from Prof. Yonghong Zhang’s Team: \nXiaole, a seven-year-old boy, first presented in late February 2024 with thrombocytopenia and enlargement of the liver, spleen, and lymph nodes. In May 2024, he underwent bone marrow aspiration and excisional biopsy of a left axillary lymph node at another hospital. Based on lymph-node histopathology and immunohistochemistry, flow-cytometric immunophenotyping, hematologic malignancy-related gene mutation testing, and whole-transcriptome sequencing, he was diagnosed with stage IV T-lymphoblastic lymphoma\u002Fleukemia with myeloid expression (CNS1). Beginning June 20, 2024, he received treatment according to the CNCL-NHL-2017-LBL high-risk protocol, including VDLP, CAM1, CAM2, and HR-1. During treatment, however, lesions in the lymph nodes, bone marrow, and spleen all progressed. He was therefore transferred to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital under Prof. Yonghong Zhang for further evaluation and treatment.\n\nWe integrated the patient’s MICM findings - morphology, immunology, cytogenetics, and molecular biology - from the lymph nodes, bone marrow, and peripheral blood and diagnosed progressive mixed phenotype acute leukemia\u002Flymphoma involving T-cell, B-cell, and myeloid lineages. He subsequently received four second-line chemotherapy courses designed to cover both lymphoid and myeloid components, together with several targeted agents. Although the lymph-node disease improved, the proportions of the three abnormal T-, B-, and myeloid cell populations in the bone marrow fluctuated and showed no clear overall decline, while the spleen repeatedly enlarged. This heterogeneous response suggested that chemotherapy directed at both lymphoid and myeloid disease was addressing the manifestations without fully treating the underlying driver.\n\nTo identify what was driving the disease, we re-examined the patient’s molecular and immunophenotypic features. The NRAS mutation was detected in bone marrow, lymph-node tissue, and peripheral blood. It was neither germline nor tumor-specific, but rather a somatic mosaic mutation. Such RAS somatic mosaicism can produce different immunophenotypes across tissues within the lymphohematopoietic system. In addition to mixed phenotype leukemia\u002Flymphoma, the patient also had RAS-associated autoimmune leukoproliferative disorder (RALD), creating an overlap of malignancy, clonal hematopoiesis, and immune dysregulation. This helped explain the inconsistent responses to chemotherapy.\n\nBecause the NRAS somatic mosaic mutation was identified as the key disease driver, we discontinued chemotherapy and switched to a multi-agent targeted approach to control tumor progression. The hepatosplenomegaly improved after targeted treatment, while preparations were made for allogeneic hematopoietic stem cell transplantation to rebuild hematopoietic and immune function.\n\nA related haploidentical hematopoietic stem cell transplant was initiated on February 19, 2025. At the one-month assessment on April 14, 2025, ultrasound showed no obvious tumor lesions and the spleen was no longer palpable below the costal margin. Bone marrow chimerism was 100% donor-derived, and both bone marrow flow cytometry and testing for the NRAS mutation were negative. Quantitative NGS for the NRAS mutation in peripheral blood was negative, while quantitative NGS of peripheral-blood cell-free nucleic acid showed an NRAS level of 0.42%. At the two-month assessment on May 6, 2025, imaging again showed no tumor lesions and no palpable splenomegaly. Bone marrow flow cytometry and NRAS mutation testing remained negative; quantitative peripheral-blood NGS remained negative, and the NRAS mutation in peripheral-blood cell-free nucleic acid also became undetectable, indicating deep molecular remission. The patient has now maintained remission for eight months.\n\nTo our knowledge, this is the first reported case worldwide of a mosaic RASopathy presenting as mixed phenotype leukemia\u002Flymphoma together with RAS-associated autoimmune leukoproliferative disorder. Targeted therapy with a MEK inhibitor and an mTOR inhibitor, followed by allogeneic hematopoietic stem cell transplantation, achieved sustained remission.",{"slug":380,"title":381,"summary":382,"cover":383,"disease":384,"treatment":90,"patientType":68,"publishedAt":376,"contentHtml":385,"expertView":386,"disclaimer":72,"hasAlternate":73,"updatedAt":319},"angioimmunoblastic-t-cell-lymphoma-recovery","A 76-Year-Old \"Graduate\" Marks a Five-Year Milestone","Diagnosed with angioimmunoblastic T-cell lymphoma at age 71, the patient underwent hematopoietic stem cell transplantation after facing the challenges of chemotherapy, and five years later, returned to a life shared with family.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fabdeedbac8984562f87563ca0a0f2e38.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Angioimmunoblastic T-Cell Lymphoma","\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Summary: At 71, Mr. Chen was diagnosed with angioimmunoblastic T-cell lymphoma (AITL). After several rounds of chemotherapy, he had still not achieved a complete remission. Despite the challenges of his age and hard-to-control disease, Mr. Chen and his family kept looking for another option. In December 2020, after evaluation by Professor Chun Wang's team at GoBroad Shanghai Zhaxin Hospital, he underwent a related-donor haploidentical allogeneic hematopoietic stem cell transplant (allo-HSCT). Five years later, he remains in long-term remission and is back to enjoying everyday life with his family. His story is about an older patient who kept moving forward through a difficult diagnosis - and about the hope his journey may offer others facing cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F35252919cd75794ce6b8cb5556ffbab0_20260910141545.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"35252919cd75794ce6b8cb5556ffbab0_20260910141545.png\" alt=\"23c41c91-c188-449e-8a7a-7e47e1063aae.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">In July 2020, 71-year-old Mr. Chen went to the hospital with a widespread rash and fever. The diagnosis - angioimmunoblastic T-cell lymphoma - came out of nowhere and suddenly disrupted the quiet life he had known. He and his family chose to face it together. But after several rounds of chemotherapy, he achieved only a partial response, and the future began to feel much less certain.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Being 71 and still not in complete remission made the road ahead especially difficult. At the time, only a small number of centers in China would consider allogeneic hematopoietic stem cell transplantation for a patient of his age. Even as their options narrowed, Mr. Chen and his family kept calling, asking and searching for a possible path forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A turning point came when they reached Professor Chun Wang's team at GoBroad Shanghai Zhaxin Hospital. In December 2020, at age 71 and with the full support of his family, Mr. Chen underwent a related-donor haploidentical allogeneic hematopoietic stem cell transplant. It was a demanding decision, both medically and personally - one made by a patient and a family who understood the risks but chose to pursue a chance for long-term survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Five years on, that decision has led to the outcome they had hoped for. Mr. Chen achieved complete remission and is considered clinically cured. Just as importantly, he has returned to the ordinary moments he once feared he might lose: meals at home, time with his children and grandchildren, and the quiet rhythm of everyday family life. What once felt far away is now part of his daily life again.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">At this five-year milestone, Mr. Chen hopes his experience can encourage other older patients still making their way through treatment. He says: "No matter how small an instruction from your doctor may seem, follow it. Even when it is hard, keep going. During treatment, we need to trust our medical team, but we also need to hold on to our own determination. Do not give up hope. A better tomorrow is worth holding on for."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F9f6386b62bef3fbf3f284d35bef89742_20260910141607.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9f6386b62bef3fbf3f284d35bef89742_20260910141607.png\" alt=\"e88a461f-781f-459d-901a-bca0f492e2c1.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">December 2020\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260910\u002F22b6fc93e764f86a5c06829984758d4c_20260910141624.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"22b6fc93e764f86a5c06829984758d4c_20260910141624.png\" alt=\"0e5f81dc-7370-4914-847e-af4908997537.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">January 2026\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>- In Conversation with Mr. Chen -\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: When you were diagnosed, how did you and your family react? What did the doctors tell you at the time?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: In July 2020, I was diagnosed with lymphoma at a hospital in Guangzhou. It was the first time I had ever heard of the disease. My Mandarin is not very good, so I had trouble following everything the doctors were saying. My son was worried the news would be too much for me. He only told me that the doctors said it was treatable, but treatment would take time and come with some risks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">After the diagnosis, I had four months of chemotherapy at the local hospital, but the lymphoma never went into complete remission. I knew the situation was probably serious, so I insisted that my son tell me the truth. He finally told me that the doctors felt a complete cure would be very difficult and that even with active treatment, my outlook might not be good. I was devastated. It took me a long time to come to terms with it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: Why did you ultimately decide to seek treatment at GoBroad Shanghai Zhaxin Hospital?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: As a family, we still were not ready to give up. My son kept looking for information and learned that allogeneic hematopoietic stem cell transplantation might offer a chance of cure for angioimmunoblastic T-cell lymphoma. But I was already 71. He contacted several hospitals, and none were willing to take me on for transplant because of my age.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Eventually, we were referred to Professor Chun Wang, a specialist in hematopoietic stem cell transplantation. We had three in-depth discussions with his team. At first, Professor Wang had reservations: I was older, and I still had not reached complete remission after several rounds of chemotherapy, so transplant would be very challenging. But my family and I strongly wanted to pursue treatment, and I was otherwise in relatively stable condition. After careful evaluation, he agreed to take my case.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">In December 2020, I underwent an allogeneic hematopoietic stem cell transplant at GoBroad Shanghai Zhaxin Hospital, using stem cells donated by my son.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: As an older transplant patient, what worried you and your family most about the risks? What ultimately led you to go ahead?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: Before the transplant, all of us understood there were real risks. But without transplant, chemotherapy alone was unlikely to give me either a good quality of life or much time. I thought: if there is still a chance of a cure, why not take it?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">My family gave me tremendous support. My sons told me: "Do not worry about the cost or caregiving. As long as you have the confidence and determination to do this, we will be behind you all the way." With them behind me, I wanted even more to gain more time and be there with my family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">The care team at Zhaxin also gave me a lot of confidence. My attending physician, Dr. Chuxian Zhao, checked on me every day and paid attention to every detail. The doctors and nurses were always there, almost like family. That made me feel safe and strengthened my resolve to continue treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: What was the hardest or most memorable period during transplant, and what helped you get through it?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: Once I entered the transplant isolation unit, I had to stay there for about a month. It was very difficult. After the transplant, I had a high fever for 12 days. I felt terrible physically. The food in Shanghai was sweeter than I was used to, so I barely had any appetite, and I also had diarrhea every day. I felt exhausted and anxious.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">During that period, the caregiver who looked after me was a huge support. She kept telling me, "Do not be afraid. Just keep going." She also reassured me that my condition was actually not too bad and that the diarrhea was not severe. Maybe she was simply trying to comfort me, but it helped more than she probably knew.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">What reassured me most was Dr. Zhao. She came to see me every day, checked how I was doing, and encouraged me not to get too anxious because things would improve step by step. She told me: "Keep hope and confidence. Once your blood counts start to recover, your body will get stronger day by day. When the cells grow back, it is like new energy returning to your body."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">And she was right. Once I got through the hardest stretch, my blood counts gradually recovered and I felt stronger each day. Eventually, I was well enough to leave the transplant isolation unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: What would you like to share with other patients about recovery after transplant?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: For me, the hardest part was the time in the transplant unit. Once I was out, recovery went fairly smoothly and I did not have much discomfort. As soon as I felt a little stronger, I started walking up and down the ward corridor every day for about an hour. Sometimes a nurse on duty would see me and ask, "You are already up and walking this early?" I would say, "Yes - I want to keep moving and build my strength back up."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">After I went home, I was very careful about daily life. Apart from my morning walk, I mostly stayed home and avoided crowded places. One habit helped me a lot: unless it was raining, I walked for an hour every day, about five kilometers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">I also paid close attention to nutrition. I am allergic to milk and eggs, and for a while after transplant I was eating a very limited diet. When I got home, a local doctor told me I was a little malnourished. So my advice is: food safety matters, but so does variety. Try to eat a balanced diet and keep regular meal times.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: What does reaching the five-year "graduation" milestone mean to you and your family? What are you hoping for next?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">A: "Graduating" at five years means that life has given my family and me more time - and more warmth. Being able to return to ordinary life and spend each peaceful day with my family is already the greatest gift.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">We are a big family. After the children finish work, they come home and we eat together and chat. My oldest grandson is in college now. During school holidays, we often travel as a family, and I have been to quite a few places with them. Having this time with the people I love makes me very happy and grateful.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">Looking ahead, I hope life can stay this simple and warm: to watch my grandchildren grow up, and to share many more seasons and trips with my family. Every day feels like a gift.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Chuxian Zhao (Director, Hematopoietic Stem Cell Transplantation Center, GoBroad Shanghai Zhaxin Hospital):\n\nUnder Professor Chun Wang's leadership, our team has continued to explore better treatment approaches for difficult-to-treat T-cell lymphomas. At our center, patients with relapsed\u002Frefractory T-cell non-Hodgkin lymphoma (R\u002FR T-NHL) have achieved a long-term disease-free survival rate of 58%.\n\nWith advances in transplant medicine, age alone is no longer an absolute barrier to allogeneic hematopoietic stem cell transplantation. Patients over 70 who are otherwise physically fit may still be candidates for allogeneic transplantation with curative intent.\n\nThat said, older patients still face multiple challenges during treatment, including organ function and physical recovery. Every patient who recovers and returns to life after treatment is a tremendous source of encouragement for our team.\n\nMr. Chen's bright smile is the best gift our care team could receive.",{"slug":388,"title":389,"summary":390,"cover":391,"disease":392,"treatment":90,"patientType":82,"publishedAt":393,"contentHtml":394,"expertView":395,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"severe-beta-thalassemia-hsct-recovery","From Lifelong Transfusions to a New Beginning: An 18-Year-Old with Thalassemia Steps into a New Chapter","After years of waiting and finally undergoing a transplant, he now has the chance to pursue his dreams like any other young person.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F081394ca31fe27a69fb513f0728804af.webp?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Severe Beta-Thalassemia","2026-01-23","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Eighteen-year-old Aguang (pseudonym) was diagnosed with severe beta-thalassemia shortly after birth. For years, regular blood transfusions and iron chelation therapy were essential to keeping him well. Over 15 years of living with the disease, he waited for a fully matched donor and once lost a transplant opportunity when a donor withdrew. After finishing the college entrance examination, Aguang came with his family to GoBroad Chunfu Institute of Hematology & Oncology for evaluation. As haploidentical hematopoietic stem cell transplantation (HSCT) became increasingly established, he ultimately chose a PTCy-based haploidentical transplant. In July 2025, the transplant was successfully completed. He is now recovering well, with stable blood counts, and is gradually leaving long-term transfusions and iron chelation behind. His story reflects the journey from being constrained by thalassemia to reclaiming everyday young adulthood — made possible by advances in medicine, the support of his family, and his own determination.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the college entrance examination, while his classmates were planning graduation trips, 18-year-old Aguang (pseudonym) and his mother, Ms. Chun (pseudonym), were preparing for a far more important journey: hematopoietic stem cell transplantation, a treatment that could free him from the lifelong burden of severe thalassemia. In the summer of 2025, Aguang and his mother came to GoBroad Chunfu Institute of Hematology & Oncology, where he was treated by Dr. Jianyun Liao and underwent a PTCy-based haploidentical transplant. Five months after transplantation, his follow-up results remain stable. He plans to begin university next September, ready to start this new chapter with a healthier body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>01 Diagnosed with Severe Thalassemia: The Weight of “Lifelong” Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2008, before Aguang was seven months old, his parents took him to a local hospital because he looked pale and had little appetite. The diagnosis — severe beta-thalassemia — came as a devastating blow to the family.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“Severe beta-thalassemia means lifelong blood transfusions and iron chelation therapy...” Ms. Chun understood every word on the report, but together they felt unbearably heavy. The idea of “lifelong” suddenly carried a weight she could hardly describe.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On the advice of a local doctor, Ms. Chun took her baby to see Prof. Chunfu Li, who was then practicing at Nanfang Hospital. Prof. Li told her, “Thalassemia can achieve deep remission. If the hematopoietic stem cell transplant is successful, your child can live like other children.” As parents, giving up was never really an option. But that reassuring answer gave Ms. Chun the courage to keep going.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>02 Searching for a Fully Matched Donor: Hope, Lost and Found\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the time, transplantation from a fully HLA-matched donor was the more established option. After no one in the family proved to be a match, Ms. Chun turned to the China Marrow Donor Program (CMDP), hoping to find what felt like a genetic needle in a haystack. Two years — more than 700 days — passed between hope and disappointment. Then, when Aguang was three, the call finally came: “We found one. There is a fully matched donor.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The day the match was confirmed, Ms. Chun held both of her children and cried, believing the hardest part was finally over. But the transplant plan was abruptly halted. Shortly before stem cell collection, the donor decided not to proceed and cut off contact. To see hope burn so brightly and then disappear was, for the family, even harder than never having found it at all. Ms. Chun asked Prof. Li, “If a fully matched transplant is no longer possible, is there another way to treat this disease?” Prof. Li explained that a haploidentical transplant could also be considered, but the approach was not yet mature at the time. If the family was willing, they could wait, because medicine would continue to advance. Ms. Chun kept searching, but another fully matched donor never came.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Waiting became something the whole family learned to live with — waiting for transplant technology to mature, and waiting for another chance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>03 Longing to Break Free from Thalassemia: 15 Years Tied to Transfusions\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 173 cm tall, lean but not frail, Aguang looked much like any other teenager thanks to the careful support of his mother and older sister. But he always knew his life was different.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As Aguang grew older and gained weight, his transfusion needs steadily increased — from one unit of red blood cells every 40 days to 4.5 units every 20 days, just to keep his hemoglobin at around 60 g\u002FL. What does 60 g\u002FL feel like? Aguang compared it to a phone that is always stuck at 15% battery, with just enough power for the most basic functions. “Even sitting up in bed, I had to wait about 30 seconds or my vision would go dark. I couldn’t run or jump. In PE class, I was always the one watching from the sidelines.” Long-term transfusions brought another concern: his ferritin levels remained around 2,000–3,000 ng\u002FmL. Excess iron could build up in organs such as the liver and heart, creating another threat to his health. To manage it, he needed long-term oral iron chelation therapy as well as deferoxamine injections.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To make sure Aguang could continue receiving transfusions and iron chelation, the family cut back on every nonessential expense. Ms. Chun saved wherever she could. She ate the simplest meals at her workplace cafeteria, avoided extra spending, and volunteered for holiday shifts whenever others preferred to take time off, simply to earn a little more overtime pay.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But there was one thing hard work alone could not solve: blood shortages. For many people, a notice about low blood supplies might be just another headline. For Aguang’s family, it could directly affect whether he could maintain his everyday health. That uncertainty was frightening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>04 Expert Support: Turning Fear of the Unknown into Risks That Could Be Managed\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The possibility of transplantation came up again after Aguang finished the college entrance examination and received his university admission letter. Still unsure whether they should keep waiting for a fully matched donor, Ms. Chun returned to GoBroad Chunfu Institute of Hematology & Oncology to speak with Prof. Li and Dr. Liao. Dr. Jianyun Liao gave the family a clear answer: “There is no need to keep waiting for a full match. Haploidentical transplantation is now a well-established approach, with strong success rates.” Hope returned, but so did a new set of very real concerns. The family held countless discussions, and this time the final decision rested with Aguang, who had just turned 18. “I was afraid. I worried that if the transplant failed, I might lose even the life I had then. Would donating stem cells harm my sister? Could the transplant affect my fertility? Would I still be able to have a family one day?” Dr. Liao’s team addressed each concern carefully and patiently. They shared detailed transplant data and examples of successful adult cases to help the family understand that haploidentical transplantation had become a mature and safe option. Aguang’s sister also underwent a thorough donor evaluation, helping ease the family’s concerns. Before transplantation, the team coordinated with a reproductive medicine center to preserve Aguang’s fertility, keeping more possibilities open for his future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Every conversation with Dr. Liao gave Aguang greater confidence, turning unknown fears into risks he could understand and prepare for. In the end, he made the decision himself to move forward with transplantation. In July 2025, with his mother by his side, Aguang was admitted to the transplant isolation unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>05 Leaving the Transplant Unit: Taking the Future Back into His Own Hands\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When the isolation-room door closed, it separated Aguang from the outside world — but it also marked the beginning of a new chapter. Dr. Liao, the physicians, and the nursing team became the closest partners Aguang and his mother had through the transplant. Ms. Chun still remembers those days vividly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“Before we went in, I was so scared that I couldn’t sleep at night. But once we were there, I realized Dr. Liao and the nurses were even more attentive than I had imagined.” When Aguang developed a fever during chemotherapy, the nurses stayed by his bedside through the night to monitor him and guide his care. When he lost his appetite and refused to eat, Dr. Liao patiently encouraged him: “Think of food as part of your medicine. You need the strength to get through this.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These small acts of care became a source of warmth during a difficult time. Aguang’s cooperation, his family’s trust, and the medical team’s expertise and compassion helped the transplant move forward smoothly. After leaving protective isolation, signs of recovery showed up in everyday details: his hemoglobin stabilized at around 120 g\u002FL, he gained about 10 kg, color returned to his face, and the transfusion bags and chelation pump that had been part of his life for years were finally gone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before transplantation, Aguang had already received his university admission letter. He chose to take a year off so he could focus on follow-up care and recovery. His hope is simple: to begin university in good health — to run, jump, join clubs he enjoys, and take part in internships with his classmates. For most people, these are ordinary parts of student life. For Aguang, they represent something far more meaningful: the freedom to move forward.\u003C\u002Fspan>\u003C\u002Fp>","Dr. Jianyun Liao (Chief Physician, GoBroad Chunfu Institute of Hematology & Oncology):\n\nHematopoietic stem cell transplantation is an important curative treatment for severe thalassemia. In the past, transplantation was often limited by the difficulty of finding a fully matched donor.\n\nToday, as transplant techniques have become more mature, haploidentical transplant strategies have also continued to improve. Parents and siblings can serve as donors, greatly expanding donor availability. Transplant safety has improved substantially, and age-related limitations have become less restrictive, giving more older adolescent and adult patients like Aguang an opportunity for long-term recovery.\n\nComprehensive pre-transplant evaluation — including fertility preservation when appropriate — together with high-quality post-transplant management can help protect patients’ long-term quality of life. Patients and families are encouraged to stay hopeful and seek evaluation and treatment at experienced medical centers.",{"slug":397,"title":398,"summary":399,"cover":400,"disease":181,"treatment":401,"patientType":68,"publishedAt":402,"contentHtml":403,"expertView":404,"disclaimer":72,"hasAlternate":73,"updatedAt":117},"aml-cik-treatment","After Her Fusion Gene Stayed Positive Through Multiple Rounds of Chemotherapy, CIK-Based Treatment Brought Deep Remission","Diagnosed with acute myeloid leukemia at 49, she went through multiple rounds of chemotherapy, yet her fusion gene remained detectable. After coming to Beijing GoBroad Boren Hospital for individualized treatment including CIK cell immunotherapy, she achieved deep remission. She has now stopped all anti-cancer medications and has remained in remission for more than three years.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fee64fdb4a2341584de4c88b6c478d565.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","CIK Cell Immunotherapy, Targeted Therapy","2026-01-16","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: At 49, Ms. Yu was diagnosed with AML-M2 with a positive CBFβ-MYH11 fusion. She underwent multiple rounds of chemotherapy. Although her bone marrow morphology showed remission, the fusion gene remained detectable, leaving treatment at an impasse. On the recommendation of another patient, she came to Beijing GoBroad Boren Hospital, where Dr. Chunrong Tong, Dr. Defeng Zhao, and their team developed an individualized treatment plan. In addition to chemotherapy and targeted therapy, CIK cell immunotherapy was incorporated into her treatment, and the CBFβ-MYH11 fusion eventually became undetectable, marking deep remission. Her journey later included another setback when leukemia involved the central nervous system. The team promptly adjusted the treatment strategy with intrathecal therapy, radiotherapy, and long-term maintenance treatment, helping her regain and sustain remission. In November 2025, she successfully stopped all anti-cancer medications, including targeted therapy. She now only needs follow-up every six months and has remained in remission for more than three years. Her experience highlights the value of individualized precision treatment, cellular immunotherapy, and consistent long-term management for AML, and offers hope to patients whose treatment has reached a difficult crossroads.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In September 2021, 49-year-old Ms. Yu (pseudonym), a full-time mother, was focused on supporting her son through his final year of high school and preparation for the gaokao, China's national college entrance examination. Then an AML-M2 diagnosis, with a positive CBFβ-MYH11 fusion, suddenly disrupted the family's life. She underwent multiple rounds of chemotherapy at a local hospital, but the key fusion gene remained detectable and treatment reached an impasse. In March 2022, encouraged by another patient, Ms. Yu traveled to Beijing GoBroad Boren Hospital. Dr. Chunrong Tong, Dr. Defeng Zhao, and their team quickly carried out a comprehensive assessment and designed an individualized treatment plan combining chemotherapy, targeted therapy, and CIK cell immunotherapy. With treatment tailored closely to her disease, the fusion gene finally became undetectable and she achieved deep remission. In November 2025, she stopped all anti-cancer medications, including targeted therapy, and now only needs follow-up every six months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Today, Ms. Yu has remained in remission for more than three years and continues to regain her strength. Her son has also gone on to attend a top university. From having their lives suddenly thrown off course by leukemia to finding stability and hope again, the family has finally entered a new chapter.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260912\u002F07135c7bd6558a0544e6f35ea402e83d_20260912225228.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"07135c7bd6558a0544e6f35ea402e83d_20260912225228.png\" alt=\"412e86b2-af2a-4ff5-a3da-798cb1cb09db.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>The Diagnosis: Leukemia Arrived During Her Son's Final Year of High School\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In August 2021, I began having unexplained pain in my right leg. I went to the hospital several times, but no clear cause was found. Then in September, a bone marrow aspiration finally gave us the diagnosis: AML-M2 with a positive CBFβ-MYH11 fusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first thing I asked after the diagnosis was, "Do I still have a year? Will I be able to stay with my son until he finishes his final year of high school?"\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">My husband stayed with me in the hospital, while our son was trying to cope with both schoolwork and the changes at home. I know he must have cried many times when I could not see him, but whenever he was with me, he stayed positive and upbeat. That gave me enormous comfort.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Treatment Roadblock: Multiple Courses of Chemotherapy, but the Fusion Gene Remained Detectable\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After five months of treatment, my bone marrow showed morphologic remission, but the CBFβ-MYH11 fusion fell only from 26.76% to 0.03% and never became undetectable. We felt completely stuck. A family member of another patient in the same ward suggested that we seek further care at a specialized hematology hospital. My husband consulted several hematology specialists online, and the professionalism, sincerity, and clear treatment approach of Dr. Chunrong Tong at Beijing GoBroad Boren Hospital gave us hope. We decided to come to Boren.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Seeking Care in Beijing: CIK Cell Immunotherapy Brings a Breakthrough\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Four years later, I still remember the first time I met Dr. Chunrong Tong. After carefully explaining the treatment plan, she gently patted my shoulder and said with confidence, "I've successfully treated patients like you before. Give me two months - let me help you beat this." I burst into tears. In that moment, her calm confidence gave me a sense that there was finally a way through.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">I knew Dr. Tong was not making a casual promise. Her confidence came from decades of clinical experience and from having treated many patients with difficult blood cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After a detailed review of my disease, Dr. Tong and the team developed a step-by-step individualized plan. In the first phase, I received a combination of several anti-cancer medications while the team closely monitored my results. After treatment, the fusion-gene level decreased slightly, but not enough. In April 2022, the team adjusted the plan and moved into a second phase, optimizing the medications and combining a CD38 monoclonal antibody, epigenetic therapy, and multiple targeted agents. Unfortunately, the fusion gene was still detectable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The real turning point came after CIK cell immunotherapy. My CIK cells were collected on May 21, 2022, and I received two infusions on May 31 and June 1. By then, I was trying not to expect too much. Because earlier treatments had not worked as well as we hoped, the transplant team had already discussed transplantation with me. After the second infusion, I even returned home before the test results came back, carrying a mix of emotions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On June 14, 2022, my attending doctor called me, clearly excited: "Your fusion gene is negative!" I opened the hospital app on my phone and saw the result I had waited so long for: "Fusion gene: 0.00%." Nearly a year of struggle, uncertainty, pain, and disappointment suddenly gave way to hope. Dr. Defeng Zhao called soon afterward to congratulate me. I will never forget the joy in his voice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Second Setback: CNS Leukemia Relapse, Followed by Another Carefully Tailored Treatment Plan\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Just when I thought the hardest part was behind me and was looking forward to fewer follow-up visits, another challenge arrived. In October 2022, a routine lumbar puncture showed a cerebrospinal fluid CBFβ-MYH11 fusion level of 6.78%, and I was diagnosed with central nervous system leukemia. In addition to intrathecal therapy, I needed radiotherapy at another hospital. During the cold Beijing winter, my son, who was on school break, accompanied me every day as we carried the heavy radiotherapy positioning mold back and forth between two hospitals. Before I went into the treatment room, we would look at each other without saying much - but that look seemed to say everything.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Radiotherapy made the hair that had finally grown back fall out again. I dealt with nausea, fatigue, dizziness, and vomiting, but with careful medical management and my family's support, I completed the full course of treatment. By March 2023, follow-up testing showed that the fusion gene in my cerebrospinal fluid remained undetectable. I had made it through another major hurdle.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Chunrong Tong and Dr. Defeng Zhao then developed a long-term treatment plan for me, with regular return visits to maintain remission, reduce the risk of relapse, and consolidate the response. As my condition became more stable, the interval between follow-up visits gradually became longer. In November 2025, I returned to Beijing GoBroad Boren Hospital for another review. The results were reassuring: my disease remained in remission. After that visit, I was finally able to stop all anti-cancer medications, including targeted therapy. From now on, I only need a follow-up every six months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Care Beyond Treatment: The Small Moments That Helped Me Through\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking back on this long and winding leukemia journey, I realize that the moments of kindness along the way were far more numerous than I ever noticed at the time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At Boren, I received not only expert medical care, but also thoughtful support in the smallest details. While I was anxiously waiting for bone marrow results, my attending doctor would call the laboratory in advance just so I could hear the result half an hour sooner. When chemotherapy affected my appetite, one of the doctors caring for me took a detour in the rain on the way to work to buy me freshly baked bread. Dr. Defeng Zhao made time to chat with me every day, helping ease my anxiety during treatment. When I was too weak to walk, the nurses pushed me in a wheelchair to different departments for tests. A member of the cleaning staff would sometimes bring me homemade snacks. The mother of another patient in my room carefully helped arrange my meals as if I were her own daughter. I was cared for by so many people along the way. Sometimes medicine can cure; often it can help; and always, compassion can comfort.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A New Chapter: Seeing Life Differently and Passing the Kindness On\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This illness changed the way I see life. I often hear other patients ask, "Why me? Why did this happen to me?" One line from a film has stayed with me: "Some of life's sweetest joys grow out of sorrow, and some of its most beautiful things are born from hardship. We go through difficult times ourselves, and only then learn how to comfort others."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The summer breeze, autumn leaves, and winter snow once felt ordinary. Now they are some of the most beautiful things in the world to me. Walking through the hospital corridors, I would see the names of doctors and nurses who had volunteered to donate blood. Their faces and smiles comforted me more than once. I do not know them personally, but I will always remember their kindness. I came to feel that faith does not need a shrine; compassion can be found in ordinary people all around us.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Thank you, Boren. If there were a book of angels on earth, your names would be written in gold on the very first page.\u003C\u002Fspan>\u003C\u002Fp>","Case Commentary from Dr. Defeng Zhao: \nThe patient was diagnosed with AML-M2 with a CBFβ-MYH11 fusion. Despite multiple rounds of chemotherapy at another hospital, the fusion gene remained detectable and she had not achieved deep remission. We used targeted therapy, including CIK cell therapy, and her bone marrow fusion-gene level subsequently fell to zero, indicating deep remission of the leukemia. At Beijing GoBroad Boren Hospital, our strategy is to continue targeted therapy together with immunomodulatory treatment for three years, with the goal of maintaining deep remission, preventing relapse, and working toward clinical cure. For patients with relapsed or refractory AML, selecting an appropriate targeted agent, combining it with immunomodulatory therapy, and using cellular therapy when appropriate can be an effective way to achieve another remission. These approaches can also be relatively well tolerated and may have a limited impact on quality of life.",[],[407],{"slug":408,"kind":409,"title":410,"summary":411,"contentHtml":412,"toc":413,"relatedQuestions":414,"ymyl":415,"hasAlternate":73,"updatedAt":115},"transplant-care-manual","manual","Hematopoietic Stem Cell Transplant Care Handbook","From pre-transplant preparation and laminar-flow ward precautions to post-discharge follow-up, a systematic overview of care essentials for patients and families throughout the transplant journey.","\u003Cp>This handbook covers pre-transplant evaluation and conditioning, infection prevention and diet management during transplant, and follow-up visits and medication during the post-discharge immune reconstitution period. Please follow the guidance of your medical team.\u003C\u002Fp>",[],[],{"author":416,"reviewedBy":417,"lastReviewed":418,"datePublished":419,"citations":420,"disclaimer":423},"GoBroad Care Patient Services","Dr. Zhou (Transplant, Associate Chief Physician)","2026-05-30","2026-03-05",[421],{"title":422},"Expert Consensus on Nursing Care for Stem Cell Transplant Patients","This content is for general information only and is not a substitute for professional medical advice, diagnosis, or treatment. If you feel unwell, please seek medical care promptly.",[425,433,440,446,452,458,464,470,476,482,488,494,501,509,516,523,529,535,542,548,555,562,569,576,583,590,596,603,609,615,622,628,634,640,646,652,659,665,672,678,684,690,696,702,708,715,721,727,733,739,745,751,758,764],{"slug":426,"title":427,"summary":428,"cover":429,"category":430,"publishedAt":69,"contentHtml":431,"hasAlternate":73,"updatedAt":432},"hematopoietic-stem-cell-transplantation-full-cycle-management","From Age 1 to 76, from CAR-T Bridging to Second Transplant: The Full-Course Transplant Care Behind Nearly 1,500 HSCTs at Beijing GoBroad Boren Hospital","Drawing on experience from nearly 1,500 transplants, Beijing GoBroad Boren Hospital has developed a full-course transplant management approach for complex settings such as CAR-T bridging, second transplantation, and transplantation in older adults.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fb6fd64af72d2898cad307604a028a8f5.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Medical Advances","\u003Cp>\u003Cspan style=\"font-size: 15px;\">Summary: Since establishing its transplant program in 2017, the hematopoietic stem cell transplantation team at Beijing GoBroad Boren Hospital has completed nearly 1,500 transplants in patients ranging from 1 to 76 years old. Across complex treatment settings including CAR-T bridging to transplant, second transplantation, salvage transplantation, and transplantation in older adults, the team has developed a full-course management approach covering pre-transplant assessment, donor selection, individualized conditioning, prevention and management of post-transplant complications, and maintenance therapy. This allows transplant pathways to be tailored for patients with leukemia, lymphoma, aplastic anemia, hemophagocytic lymphohistiocytosis, and other hematologic diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"text-align: center;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"text-align: center;\">Stable Six Months After Transplant at Age 76\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"text-align: center;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In May 2026, Ms. Xiao (pseudonym), a 76-year-old patient from Shaanxi Province, returned for her six-month follow-up after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Her clinical indicators remained stable and her overall condition continued to improve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Ms. Xiao had chronic myelomonocytic leukemia (CMML) that transformed into acute myeloid leukemia (AML). She also had several underlying conditions, including diabetes, hypertension, and hypertrophic cardiomyopathy. After a comprehensive assessment, she proceeded with allogeneic hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Her case is not an isolated example of transplantation in an older adult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">At Beijing GoBroad Boren Hospital, patients undergoing hematopoietic stem cell transplantation have ranged in age from 1 to 76 years. The program treats both malignant and non-malignant hematologic diseases, including leukemia, lymphoma, aplastic anemia, and hemophagocytic lymphohistiocytosis (HLH). Clinical settings include first transplantation, second transplantation, CAR-T bridging to transplant, salvage transplantation, and transplantation in older adults.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Since the transplant program was established in 2017, the team at Beijing GoBroad Boren Hospital has completed nearly 1,500 transplants and developed a full-course management system spanning pre-transplant assessment, donor selection, conditioning-plan design, prevention and management of complications, and post-transplant maintenance therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">What Sets the Transplant Team at Beijing GoBroad Boren Hospital Apart?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The Department of Hematology II (Hematopoietic Stem Cell Transplantation) at Beijing GoBroad Boren Hospital is led by Dr. Tong WU and brings together specialists with extensive adult and pediatric transplant experience across clinical care, teaching, and research.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Dr. Tong WU has 40 years of experience in hematologic disease care and hematopoietic stem cell transplantation and has completed several thousand allogeneic transplants. Her team has built extensive clinical experience in several key areas:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">· Assessing transplant indications and choosing the right timing\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">· Donor selection\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">· Designing individualized conditioning regimens\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">· Preventing and managing post-transplant complications\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">· Post-transplant maintenance therapy\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Since 2017, the team has completed nearly 1,500 transplants in patients ranging from 1 to 76 years old.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The team reports comparable outcomes across matched sibling, unrelated-donor, and haploidentical related-donor transplantation. It has also accumulated substantial experience in second allogeneic transplantation, transplantation in older adults, and transplantation for relapsed or refractory hematologic malignancies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Which Complex Transplant Settings Does the Team Focus On?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For some patients with relapsed or refractory acute lymphoblastic leukemia (ALL), whether to proceed to allogeneic HSCT after CAR-T therapy depends on factors such as the depth of remission and the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The Beijing GoBroad Boren Hospital team has completed CAR-T followed by allogeneic HSCT in more than 300 patients with B-cell acute lymphoblastic leukemia (B-ALL). The reported 3-year overall survival (OS) rate is 74.5%, and the 3-year disease-free survival (DFS) rate is 64.0%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">T-ALL patients have undergone CAR-T followed by allogeneic HSCT in more than 100 cases, with a reported 2-year OS of 60.4% and a 2-year DFS of 60.0%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">These data provide additional clinical evidence supporting the potential for long-term disease-free survival in selected patients with ALL that is resistant to conventional chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Second Allogeneic Hematopoietic Stem Cell Transplantation\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">A second allogeneic hematopoietic stem cell transplant generally carries higher risks of transplant-related mortality and disease relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Using strategies such as reduced-intensity conditioning (RIC), family-based analysis of inherited susceptibility variants to help optimize donor selection, and post-transplant maintenance therapy, the team reports a 1-year OS of 80.6%, a 1-year DFS of 72.5%, and transplant-related mortality of 2.3% after second allogeneic HSCT.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Salvage Transplantation\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For relapsed or refractory acute myeloid leukemia (AML), the team uses individualized conditioning and post-transplant maintenance strategies. The reported 2-year OS and DFS after salvage transplantation are 56.4% and 48.6%, respectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For relapsed or refractory NK\u002FT-cell lymphoma treated with an appropriate allogeneic HSCT strategy, the reported 2-year OS and DFS are 57.6% and 52.1%, respectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Hematopoietic Stem Cell Transplantation in Older Adults\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The team has been performing transplantation in older adults for many years, using individualized reduced-intensity conditioning and post-transplant maintenance to balance treatment effectiveness with safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">More than 100 older adult patients have undergone transplantation. The reported overall DFS is 65.0%; among patients who were in remission before transplant, DFS is 74.1%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Which Diseases May Be Considered for Hematopoietic Stem Cell Transplantation?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The transplant program at Beijing GoBroad Boren Hospital mainly covers two broad groups of diseases:\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Hematologic Malignancies\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Including:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Acute myeloid leukemia (AML)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Acute lymphoblastic leukemia (ALL)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Myelodysplastic syndromes (MDS)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Chronic myeloid leukemia (CML)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Chronic myelomonocytic leukemia (CMML)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Juvenile myelomonocytic leukemia (JMML)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Primary myelofibrosis\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">B-cell, T-cell, and NK\u002FT-cell lymphomas\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Multiple myeloma\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Bone Marrow Failure and Immune-Related Disorders\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Including:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Acquired and inherited aplastic anemia\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Paroxysmal nocturnal hemoglobinuria (PNH)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Hemophagocytic lymphohistiocytosis (HLH)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Chronic active Epstein-Barr virus infection (CAEBV)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Primary immunodeficiency disorders\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Whether transplantation is appropriate, when it should be performed, and which transplant approach should be used all require individualized assessment based on the disease type, remission status, age, underlying health conditions, donor availability, and other factors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Does “Full-Course” Transplant Management Mean?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Hematopoietic stem cell transplantation is much more than the stem cell infusion itself. To improve transplant outcomes, the Beijing GoBroad Boren Hospital team focuses on four key stages:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Achieving the Best Possible Disease Control Before Transplant\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For patients whose disease has responded inadequately to conventional treatment, immunotherapy, targeted therapy, or other approaches may be used according to disease characteristics to achieve a better remission before transplantation and reduce the risk of post-transplant relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Selecting the Most Appropriate Donor for the Individual Patient\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The team evaluates both related and unrelated donors using tools that may include family-based analysis of inherited susceptibility variants, with the goal of identifying a donor who is better suited to the individual patient, supporting stable hematopoietic and immune reconstitution and potentially reducing certain complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Designing an Individualized Conditioning Regimen\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Conditioning is tailored according to factors such as age, disease type, previous treatment, and organ function, with the aim of balancing disease control against treatment-related toxicity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Continuing Relapse and Complication Management After Transplant\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For some patients, individualized maintenance therapy may be needed after transplantation according to relapse risk, with the aim of further reducing the chance of disease recurrence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">At the same time, post-transplant complications such as infection, graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (TMA) require ongoing monitoring and management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Is Precision Monitoring Used Throughout the Transplant Process?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Before transplantation, the team routinely performs pharmacogenomic testing and combines it with therapeutic drug monitoring to support safer and more effective medication planning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For disease monitoring, methods such as flow cytometry, RT-PCR, next-generation sequencing (NGS), and digital PCR may be used to assess measurable residual disease (MRD), helping the team identify changes early and intervene when needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For infection management, NGS-based testing may be used to help identify infectious pathogens and guide subsequent treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For GVHD and other abnormal immune responses, relevant laboratory parameters are assessed to help determine the type and severity of the problem and guide targeted treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">In managing post-transplant complications such as GVHD, infection, and TMA, the team emphasizes prevention, early recognition, and timely intervention.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Academic Research: Findings Presented Repeatedly at Major International Hematology Meetings\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Research from the Beijing GoBroad Boren Hospital transplant team has been presented more than 40 times as oral presentations or posters at major international hematology and transplantation meetings, including:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">European Hematology Association (EHA) Congress\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">American Society of Hematology (ASH) Annual Meeting\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Asia-Pacific Blood and Marrow Transplantation Group (APBMT) Annual Congress\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The team has published more than 10 studies on topics including B-ALL CAR-T bridging to transplant, long-term follow-up after T-ALL CAR-T bridging to transplant, second allogeneic HSCT, and allogeneic HSCT for relapsed or refractory NK\u002FT-cell lymphoma. Publications have appeared in journals including British Journal of Haematology, Frontiers in Immunology, Frontiers in Oncology, Transplantation and Cellular Therapy, Chinese Journal of Hematology, and Blood Advances.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Support May Patients Need Beyond the Transplant Itself?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Hematopoietic stem cell transplantation often involves a long period of treatment, recovery, and follow-up. In addition to medical needs, patients and families may also face practical challenges such as donor searches, day-to-day caregiving, children's education, and treatment costs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Beijing GoBroad Boren Hospital has a Patient Services Department that assists with unrelated-donor searches, HLA-matching coordination, and other transplant-related services.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Dr. Tong WU also holds two free video consultation sessions each month, while the medical and nursing teams provide ongoing information support through online patient education and health-information programs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For day-to-day support, the hospital's community kitchen and patient-family support services benefit more than 5,000 people each year. The ward school provides nearly 1,000 regular classes annually and has served more than 25,000 pediatric patients in total.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">The hospital also works with Beijing Puhui Health Insurance, local inclusive supplementary health-insurance programs in other regions, and multiple commercial insurers to provide additional support for patients and families\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"text-align: center;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"text-align: center;\">From a Single Transplant to Full-Course Management\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"text-align: center;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">From age 1 to 76, from first transplant to second transplant, and from CAR-T bridging to transplantation in older adults, the experience gained from nearly 1,500 transplants at Beijing GoBroad Boren Hospital goes beyond technical expertise in the transplant procedure itself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For patients with complex hematologic diseases, what matters is the entire treatment pathway: when to proceed to transplant, how to control disease beforehand, which donor to choose, what conditioning regimen to use, how to reduce post-transplant relapse and complications, and how to plan long-term follow-up. Together, these steps form full-course hematopoietic stem cell transplant management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px;\">Frequently Asked Questions\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: Does being older mean I cannot have a hematopoietic stem cell transplant?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Age alone does not determine transplant eligibility. The decision requires an overall assessment of disease status, heart and lung function, other underlying conditions, physical fitness and treatment tolerance, and the expected benefits and risks of transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">At Beijing GoBroad Boren Hospital, transplant patients have ranged in age from 1 to 76 years, and the team has completed more than 100 transplants in older adults.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Q: Do all patients need a hematopoietic stem cell transplant after CAR-T therapy?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">No. Not every patient needs to proceed to transplantation after CAR-T.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For some patients with relapsed or refractory acute lymphoblastic leukemia, the decision to bridge from CAR-T to allogeneic HSCT is based on factors such as the depth of remission after CAR-T, the risk of relapse, and previous treatment history.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Q: If the disease relapses after a first transplant, can a second transplant still be considered?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">For some patients, a second allogeneic hematopoietic stem cell transplant may be considered after a comprehensive evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Suitability for a second transplant depends on factors including disease status after the first transplant, the timing of relapse, the patient's overall condition, donor options, and complications from the previous transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Q: What is the single most important part of a hematopoietic stem cell transplant?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">There is no single step that determines the outcome on its own.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Disease control before transplant, donor selection, conditioning, and post-transplant management of infection, GVHD, relapse monitoring, and maintenance therapy are all interconnected and require continuous, full-course management.\u003C\u002Fspan>\u003C\u002Fp>\u003Ch3>\u003Cspan style=\"font-size: 15px;\">Q: Is long-term follow-up still needed after hematopoietic stem cell transplantation?\u003C\u002Fspan>\u003C\u002Fh3>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Yes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 15px;\">Even after transplantation is complete, patients still need ongoing monitoring of the underlying disease, measurable residual disease, donor chimerism, immune recovery, and transplant-related complications such as infection and GVHD. The timing and content of follow-up should be individualized by the treating physician according to the patient's recovery.\u003C\u002Fspan>\u003C\u002Fp>","2026-09-14",{"slug":434,"title":435,"summary":436,"cover":437,"category":438,"publishedAt":107,"contentHtml":439,"hasAlternate":73,"updatedAt":74},"car-t-therapy-suitable-candidates-guide","Expert Guide: CAR-T, the “Special Forces” of Cancer Treatment — Who May Benefit, and Is It Worth Considering?","The opening article in Beijing GoBroad Boren Hospital’s CAR-T Q&A series answers four questions patients commonly ask: how CAR-T works, when it should be considered, what outcomes may be possible, and how treatment-related risks are managed.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fb17a37371df690f48352cb302d6b2b66.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Expert Insights","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This introductory article in Beijing GoBroad Boren Hospital’s CAR-T Q&A series focuses on several practical questions that matter most to patients and families. It explains how CAR-T differs fundamentally from chemotherapy and targeted therapy by using genetically engineered immune cells as a “living drug”; why CAR-T should not always be reserved until every other option has failed; how treatment outcomes can be influenced by factors such as a patient’s overall condition and tumor burden; and how adverse events such as cytokine release syndrome (CRS) can be monitored and managed at experienced treatment centers. The article also discusses how CAR-T has changed the treatment landscape for relapsed or refractory hematologic malignancies and why timely specialist evaluation may be important when disease responds poorly to chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What happens when chemotherapy stops working? Is CAR-T only a last resort, or can it offer another meaningful treatment opportunity? How serious are the side effects, and how should patients think about the risks and potential benefits?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many patients with blood cancers and their families face exactly these questions. Some people describe CAR-T as a “miracle treatment,” while others see it as a final attempt after everything else has failed. The cost of treatment and concerns about “cytokine storms” can also make the decision feel overwhelming. In this first article of Beijing GoBroad Boren Hospital’s CAR-T Q&A series, we address some of the questions patients and families ask most often.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. CAR-T Is Often Called the “Special Forces” of Cancer Treatment. How Is It Different from Chemotherapy and Targeted Therapy?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A simple analogy can help explain the difference:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy and radiotherapy can be compared to broad-area attacks. They are effective against rapidly dividing cancer cells, but they can also affect healthy tissues such as hair follicles, the gastrointestinal tract, and blood-forming cells. This is why treatment can cause side effects such as hair loss, nausea, vomiting, and low blood counts.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Targeted therapies are more like precision tools. They are designed to recognize specific molecular targets on or within cancer cells. However, cancer cells can change over time, and loss or alteration of a target can contribute to drug resistance and relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T takes a different approach. Rather than introducing an external drug alone, it uses a patient’s own T cells, which are collected, genetically engineered and expanded in the laboratory, and then infused back into the body as a “living” cellular therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">The process can be summarized in four steps:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Collection: T cells are collected from the patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Engineering: In the laboratory, the T cells are modified to express a chimeric antigen receptor (CAR) that can recognize a specific target on cancer cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Expansion: The engineered CAR-T cells are multiplied to produce enough cells for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Infusion: The CAR-T cells are infused back into the patient, where they can recognize and attack cancer cells carrying the target antigen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In simple terms, chemotherapy and targeted therapy are medicines given from outside the body, while CAR-T works by reprogramming part of the patient’s own immune system to recognize cancer more effectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another important difference is that conventional medicines are gradually metabolized and cleared from the body. CAR-T cells are living cells: after infusion, they can expand and may persist for a period of time, continuing to provide immune surveillance. This ability is one reason CAR-T can produce deep and sometimes durable remissions in selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. If Chemotherapy Is Not Working Well, Is CAR-T Only the “Last Step”?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Not necessarily. For many patients, the timing of CAR-T evaluation can be just as important as the decision to use CAR-T itself. It should not automatically be viewed as something to consider only when every other option has been exhausted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At present, CAR-T is used most extensively in hematologic malignancies, particularly certain B-cell leukemias, lymphomas, and multiple myeloma. For patients who have not achieved a complete response after two or more treatment approaches, or whose disease relapses soon after remission, early assessment by a CAR-T team may be appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Why consider evaluation earlier? CAR-T outcomes can be influenced by the patient’s overall health, organ function, immune-cell fitness, and tumor burden. Clinical experience suggests that treatment may be easier to deliver and potentially more effective when the disease burden is better controlled and the patient is in stronger overall condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients with better overall fitness and a lower tumor burden may have more favorable conditions for CAR-T expansion and treatment response, and may also face a lower risk of severe toxicity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If CAR-T is postponed until after many additional treatments, when organ function and immune reserve have already declined, manufacturing and treatment can become more difficult, and the risk of serious complications such as severe CRS may increase.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Key message: CAR-T does not always need to wait until there are “no options left.” If leukemia, lymphoma, or myeloma is responding poorly to treatment, discussing CAR-T eligibility and timing with an experienced cellular-therapy team can help clarify the next steps.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. CAR-T Can Be Expensive. What Is a Realistic Chance of Long-Term Remission or Cure?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is one of the most important and practical questions for patients and families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T has significantly changed the treatment landscape for relapsed or refractory hematologic malignancies. The source article notes that Beijing GoBroad Boren Hospital has accumulated experience from nearly 5,000 CAR-T clinical research and treatment cases across B-ALL, lymphoma, multiple myeloma, T-ALL, and other diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment outcome is closely related to the individual clinical situation and timing:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For selected patients whose tumor burden is well controlled and who receive CAR-T at an appropriate time, treatment can achieve a deep response, including measurable residual disease (MRD) negativity. For some patients, this can support longer-term survival and, in certain disease settings, the possibility of clinical cure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For some high-risk patients, CAR-T may also serve as a bridge to hematopoietic stem cell transplantation: the goal is to achieve a deep remission first and then use transplantation to consolidate that response and reduce relapse risk when clinically appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T is not a universal cure, and no treatment can guarantee a 100% cure rate. Outcomes vary substantially by disease type, disease biology, prior treatment, target expression, tumor burden, and the patient’s overall condition. What CAR-T has done is create meaningful new possibilities for some patients whose disease previously had very limited treatment options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. How Safe Is CAR-T? What Side Effects Should Patients Know About?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Safety is a major concern for almost every patient considering CAR-T. At experienced centers, many treatment-related adverse events can be anticipated, closely monitored, and managed with timely intervention.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One of the most common adverse events is cytokine release syndrome (CRS), an inflammatory reaction that can cause fever, chills, low blood pressure, shortness of breath, and other symptoms. Many cases are mild to moderate and can be managed with supportive care and, when needed, treatments such as anti-IL-6 therapy. Severe CRS requires prompt, intensive management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some patients may also develop neurologic toxicity, sometimes referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), with symptoms such as difficulty speaking, tremor, confusion, or seizures. Low blood counts and low immunoglobulin levels can also occur after treatment, and some patients may need supportive treatments such as immunoglobulin replacement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So, is the risk worth taking?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The answer depends on the individual risk-benefit balance. For some patients with chemotherapy-refractory disease, remaining standard options may be limited and the expected course of the disease may be poor. CAR-T carries a period of treatment-related risk, but it may also offer the possibility of a deeper and more durable response. The decision should be based on the patient’s disease status, available alternatives, overall health, and personal treatment goals.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another important factor is the experience of the treatment team. The source article notes that the hospital has managed thousands of CAR-T treatment episodes and has developed structured protocols for fever management, corticosteroid use, and escalation to intensive care when necessary. The goal is not to assume that side effects will be harmless, but to recognize them early and have a clear plan for managing them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ultimately, the decision is about weighing a known, closely monitored period of treatment risk against the potential for disease control that may be difficult to achieve with conventional therapy alone. An experienced CAR-T team can help patients and families understand that balance more clearly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. If I Have CAR-T, Will I Still Need a Stem Cell Transplant? How Are the Two Used Together?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T and hematopoietic stem cell transplantation are not always an either-or choice. Depending on the disease, they may be alternatives in some settings or used sequentially in others.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For lymphoma, including certain cases of diffuse large B-cell lymphoma (DLBCL), CAR-T may be used as an alternative treatment strategy when disease is resistant to chemotherapy and transplantation is not the preferred or feasible option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For some high-risk leukemias, including acute lymphoblastic leukemia (ALL), CAR-T may be used to achieve a deep remission, such as MRD negativity, before proceeding to transplantation to consolidate the response and lower the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Whether CAR-T, transplantation, or a combination of the two is most appropriate depends on the disease type, risk classification, response to previous treatment, overall health, donor availability, and other individual factors. Patients should discuss these considerations in detail with their treating team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Final Takeaway\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T is neither a “miracle cure” nor simply a last-resort treatment. It has specific indications, a structured treatment process, and real risks that require careful management. For some patients with high-risk hematologic malignancies, it may be considered earlier in the treatment pathway and may also be used to create a bridge to transplantation. If you are wondering whether CAR-T could be relevant to your situation, bring your complete medical records to an experienced cellular-therapy team for a comprehensive assessment and discuss which treatment approach best fits your individual disease.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":441,"title":442,"summary":443,"cover":444,"category":438,"publishedAt":124,"contentHtml":445,"hasAlternate":73,"updatedAt":74},"bone-marrow-report-interpretation-guide","Dr. Jiao ZONG × Dr. Yuehui LIN: A 5% Blast Count Does Not Automatically Mean Relapse — How to Read a Bone Marrow Report","Two specialists explain the key findings in a blood and bone marrow cell morphology report from both laboratory and clinical perspectives, reminding patients that an increased blast count does not necessarily mean relapse and must be interpreted in context.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F42e364f76e835eb09b2fd9e33ca82577.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Jiao ZONG and Dr. Yuehui LIN of Beijing GoBroad Boren Hospital explain how to read a cell morphology report from both laboratory and clinical perspectives. The article reviews the clinical meaning of differential cell counts and morphologic descriptions, and emphasizes that blasts above 5% are a warning sign rather than proof of relapse. Physiologic factors, medication history, infection, flow cytometry, molecular testing, and other findings must be considered together. The goal is to help patients and families understand common report terminology more accurately and avoid unnecessary panic or misinterpretation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When patients and families receive a cell morphology report from a bone marrow or peripheral blood smear, the page can feel overwhelming: numbers, symbols, and unfamiliar terms everywhere. Blasts, immature lymphocytes, atypical lymphocytes — what do these terms actually mean, and which findings deserve the most attention?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this article, Jiao ZONG and Dr. Yuehui LIN of Beijing GoBroad Boren Hospital explain the report from both laboratory and clinical perspectives, helping readers make sense of this important “map” of what may be happening in the blood and bone marrow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. What Is Cell Morphology, and Why Is It Tested?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A complete blood count (CBC) tells us how many blood cells are present. Think of looking at a supermarket from far away: you can count how many apples and bananas there are, but you cannot tell whether the fruit is fresh, unripe, or spoiled.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cell morphology takes a much closer look. Special stains are used to make different cell types and stages of development easier to distinguish. Under a microscope, laboratory specialists assess each cell’s size, shape, internal structure, degree of maturity, and overall appearance, then classify normal, immature, and abnormal cells one by one.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A CBC alone has important limitations. Sometimes cell counts appear to be within the normal range even though the cells themselves are abnormal. Subtle problems such as immaturity or abnormal cell shape may not be visible from blood counts alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cell morphology is often one of the first steps in diagnosis. It can quickly detect abnormalities and help point the clinical team toward a likely benign or malignant process. You can think of it as a signpost: it helps show which direction further testing should take and where the most suspicious findings may be.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During treatment, repeat morphology testing can also provide a direct view of treatment response, bone marrow recovery, and sometimes early warning signs of change.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, a patient may initially have blasts and immature lymphoid cells in the bone marrow. After treatment, those cells may gradually disappear. Later, a new group of large, uniform-looking cells may appear. With special cytochemical staining, the laboratory may find that these cells look different from the original disease, raising the possibility of a lineage change. Recognizing this difference early can alert the clinical team and help avoid misinterpretation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F244e21669daf804512898358900b0c79_20260913073752.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"244e21669daf804512898358900b0c79_20260913073752.png\" alt=\"d1f46b44-368c-4cc2-ae32-58b11fbdcd4f.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That is the value of morphology: it is not only about whether certain cells are present or how many there are, but also whether they look normal and, most importantly, what kind of cells they are.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F7d165b57b544719378b9af9fbff5c861_20260913073813.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7d165b57b544719378b9af9fbff5c861_20260913073813.png\" alt=\"cf5555f3-e140-4a3e-997d-d7c9fff14926.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. How Do You Read a Cell Morphology Report, and What Should You Focus On?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A CBC is relatively straightforward, with arrows often showing whether a value is high or low. A morphology report is different. It does not only ask whether a cell count is outside the reference range; the appearance of the cells also matters.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A morphology report generally contains four parts:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Patient information\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Differential cell count\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Morphologic description\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Interpretive conclusion\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For a peripheral blood smear, the laboratory specialist classifies 100–200 cells or more and records the proportions of neutrophils, lymphocytes, monocytes, and other cell types.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In normal adult peripheral blood, neutrophils account for about 50%–70%, lymphocytes 20%–40%, and monocytes 3%–8%; eosinophils and basophils are uncommon. In young children, especially those under 6, lymphocytes may physiologically reach 40%–60% without indicating disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F138ef4b2442952dbdd90dc70b980a4be_20260913073835.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"138ef4b2442952dbdd90dc70b980a4be_20260913073835.png\" alt=\"0ce099bb-4b81-478f-baa7-12f52de36786.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If a report says “atypical lymphocytes are seen” or “increased lymphocyte proportion,” do not panic. These findings are warning signals, not a diagnosis by themselves. Whether they are clinically significant depends on the overall picture and may require correlation with symptoms, flow cytometry, and molecular testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cem>Q1: If Blasts Are Seen, Does That Mean the Disease Has Relapsed?\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Cell development is a little like human growth from infancy to adulthood. Blasts are like newborns: only a small number should normally be present in the bone marrow. Immature cells are more like children, while mature cells are like adults.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>A small number of blasts can be present in normal bone marrow. If they have a normal appearance and are not increased, they may simply represent normal developing cells.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cem>Q2: What Kind of Blasts Should Raise Concern?\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Normal blasts are generally medium-sized, with a regular nucleus and fine chromatin, giving them a relatively uniform, orderly appearance.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Malignant blasts may look different: they can be larger, have irregular nuclei, prominent nucleoli, finely dispersed chromatin, or other abnormal features. Their morphology can therefore provide important clues that the cells may not be normal.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Two things matter most: how many cells there are and what they look like.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From a numerical standpoint, 5% is an important threshold. If blasts in the bone marrow exceed 5%, morphology raises a “yellow flag.” But a blast count at or above 5% on morphology alone does not automatically prove relapse — it means the finding needs further investigation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Why? Several situations can cause a temporary increase in blast-like or immature cells:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Normal physiologic states: In growing children, the bone marrow can be highly active, and blasts may occasionally reach 5% or even higher without representing disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ After growth factor treatment or during recovery from chemotherapy: When the marrow responds strongly to granulocyte colony-stimulating factor or recovers after chemotherapy, the blast proportion may temporarily increase as a reactive change.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Infection and certain other conditions: Reactive bone marrow proliferation can sometimes resemble a leukemoid response. Some viral infections may also cause lymphocytes to take on a more immature appearance, even though they are not malignant leukemia cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ After immunotherapies such as CAR-T: Some reactive lymphocytes may look blast-like under the microscope but are actually part of a normal treatment-related immune response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is why morphology is only the first step. The word “abnormal” on a morphology report does not automatically mean the disease has relapsed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Do Atypical Lymphocytes Always Mean Something Is Wrong?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Not necessarily. “Atypical lymphocytes” are commonly reported, and the term can understandably worry patients and parents.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Normal lymphocytes usually have a fairly regular appearance. Atypical lymphocytes may be larger, have more abundant cytoplasm, and appear irregular. One of the most common reasons is viral infection. After infections such as Epstein-Barr virus (EBV) or cytomegalovirus (CMV), lymphocytes can become activated and change in appearance as part of a normal immune response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After CAR-T therapy, reports may also describe “a small number of lymphocytes with irregular morphology, abundant cytoplasm, and purplish-red granules.” These cells are often reactive rather than malignant and may return to normal over time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">True leukemic immature lymphoid cells look different. They may be large, have prominent nucleoli, vacuoles, and irregular morphology. These are the cells that require closer attention. Flow cytometry and molecular testing can then be used together to help determine their significance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Three Tools Together Give the Clearest Answer\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A morphology report is best interpreted together with three complementary tools:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Morphology — shows what the cells look like, including both number and appearance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Flow cytometry — identifies the cell-surface “ID card” by using antibodies to detect specific antigens and helps determine whether a cell population is normal or malignant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Molecular testing — looks for abnormalities inside the cells, such as mutations or chromosomal rearrangements, providing additional evidence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F6cb22fe64f67572fa049b697f6b7a03b_20260913073910.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6cb22fe64f67572fa049b697f6b7a03b_20260913073910.png\" alt=\"b5b7d711-d2e4-4fd2-914f-c0805962c570.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The article emphasizes that flow cytometry and molecular testing provide important confirmation of cell identity. Morphology may identify a suspicious population, but the final interpretation of relapse should integrate these findings rather than rely on morphology alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>So How Should You Interpret the 5% Warning Threshold?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The 5% threshold needs context. The article gives a real example of a healthy child being evaluated as a stem cell donor. On bone marrow examination, immature lymphoid cells accounted for 20%–30% — a surprisingly high proportion — but they were confirmed to be normal B-cell precursors related to the child’s stage of development.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This illustrates that bone marrow activity varies from person to person. In children especially, active growth can be accompanied by a naturally higher proportion of immature cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In other words, the identity of the cells matters just as much as the number. If the cells are from the expected lineage and look normal, a somewhat higher proportion may still be benign. If their origin is unclear or their morphology is abnormal, even a small population may deserve further evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The key message for patients and parents is not to panic simply because a morphology report mentions abnormal cells or blasts. Morphology acts like an early scout: it helps detect and flag possible problems, but the final interpretation should be made together with flow cytometry, molecular testing, and the patient’s clinical context.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":447,"title":448,"summary":449,"cover":450,"category":430,"publishedAt":141,"contentHtml":451,"hasAlternate":73,"updatedAt":432},"myeloma-car-t-first-relapse-guideline-innovation-drug","Cancer Treatment Updates: CAR-T Moves Earlier in Relapsed Myeloma, a New Bispecific Antibody Enters Priority Review, and Innovative Drugs Join China's Essential Medicines List","Three recent cancer-care updates: a new myeloma guideline moves CAR-T earlier in the treatment pathway, the world's first PD-L1\u002F4-1BB bispecific antibody to reach the marketing stage has entered China's priority-review pathway, and the updated National Essential Medicines List adds a number of innovative therapies.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fdd3c7fee327f6d404d252fa1d8b60855.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This article highlights several recent developments in hematologic and solid-tumor care. The Guidelines for the Diagnosis and Management of First Relapsed Multiple Myeloma in China (2026) introduce the concepts of early relapse and functional high-risk disease and recommend considering CAR-T therapy earlier, including at first relapse for selected patients. The marketing application for opamtistomig (LBL-024), a PD-L1\u002F4-1BB bispecific antibody, has entered the priority-review pathway at China's Center for Drug Evaluation (CDE). The National Essential Medicines List (2026 Edition) adds 117 medicines, including several innovative therapies for hematologic malignancies, solid tumors, and autoimmune diseases, and takes effect on September 1, 2026.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">July brought several new developments across hematologic malignancies, solid tumors, and autoimmune diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These include updated treatment guidelines, innovative medicines moving through regulatory review, and continued progress in the clinical use and payment support of CAR-T therapy. Here is a patient-friendly roundup of several updates that may be particularly relevant to patients and families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Updated Myeloma Guideline: Some Patients May Consider CAR-T Earlier\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In March 2026, the Guidelines for the Diagnosis and Management of First Relapsed Multiple Myeloma in China (2026) were formally published. One of the most important changes for patients with myeloma is that CAR-T therapy has moved earlier in the treatment pathway.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The guideline notes that multiple myeloma is still considered incurable, but the first relapse can be an important opportunity to achieve another deep response. At this stage, many patients may still have relatively preserved immune function and overall fitness, which can make them better able to benefit from newer treatment options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the first time, the guideline introduces the concepts of "early relapse" and "functional high-risk" disease. For patients in these higher-risk groups, CAR-T cell therapy and bispecific antibodies are recommended as important treatment options rather than being reserved only for very late-line treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The guideline also emphasizes reassessment after relapse, including cytogenetic testing and PET\u002FCT when appropriate, so that treatment can be tailored to the type of relapse. Not every relapse requires treatment to begin immediately.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Source: CAR-T Home\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>PD-L1\u002F4-1BB Bispecific Antibody Opamtistomig Enters Priority Review\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July, Nanjing Leads Biolabs Co., Ltd. announced that the marketing application for its investigational PD-L1\u002F4-1BB bispecific antibody opamtistomig (LBL-024) had been proposed for priority review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). If approved, it would become the first PD-L1\u002F4-1BB bispecific antibody to reach the market globally. The proposed indication is advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The marketing application is based on a pivotal registrational study led by Prof. Lin Shen. The study is evaluating the efficacy and safety of opamtistomig in patients with advanced EP-NEC whose disease progressed after at least two prior lines of systemic therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F14a3537793ad897fa1660d0342838741_20260914000932.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"14a3537793ad897fa1660d0342838741_20260914000932.png\" alt=\"0302d8cb-bdcc-4e3a-be1c-16da6cc38dd0.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Screenshot source: CDE website\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">EP-NEC is an aggressive cancer. Once the disease progresses after first-line platinum-based chemotherapy, later-line treatment options have historically been limited, which is why new therapeutic approaches are closely watched.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Beyond EP-NEC, opamtistomig is also being studied in a range of solid tumors, including lung, gastric, liver, biliary tract, esophageal, triple-negative breast, and ovarian cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The drug remains under regulatory review. Whether it is ultimately approved, and the exact indication included in any approval, will depend on the regulator's final decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Sources: Nanjing Leads Biolabs Co., Ltd.; Center for Drug Evaluation (CDE), NMPA\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>More CAR-T Products, More Individualized Treatment Options\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As one of the earlier clinical centers in China to provide CAR-T therapy, Beijing GoBroad Boren Hospital has completed institutional filing for seven approved CAR-T products. These products cover two established targets, CD19 and BCMA, with indications including B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and other diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In addition to approved products, the hospital is also conducting multiple CAR-T clinical studies in diseases such as acute lymphoblastic leukemia and multiple myeloma, providing additional treatment opportunities for eligible patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F2dbd4471b94e01016deff149e53f073e_20260914001012.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"2dbd4471b94e01016deff149e53f073e_20260914001012.png\" alt=\"8ae6ea90-93af-47f3-8dae-ebd2e8b518ae.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Source: Beijing GoBroad Boren Hospital\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>China Updates Its National Essential Medicines List, Adding More Innovative Therapies\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">China's National Health Commission recently released the National Essential Medicines List (2026 Edition), which takes effect on September 1, 2026.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The National Essential Medicines List is not the same as China's national medical-insurance reimbursement list. Instead, it is a key national framework intended to support the availability and standardized use of essential medicines in healthcare institutions. Inclusion can help improve clinical access to these medicines.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The updated list adds 117 medicines, including a number of innovative treatments relevant to hematologic malignancies, solid tumors, and autoimmune diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fbdec1f4b8f02a6dcd4737b85cdedb11a_20260914001028.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"bdec1f4b8f02a6dcd4737b85cdedb11a_20260914001028.png\" alt=\"7fbea53f-6331-4d2c-b48e-a1b294000188.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients, this means that more innovative medicines with established clinical value are gradually being incorporated into China's essential-medicines system, which may support broader and more standardized access over time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Source: National Health Commission, National Essential Medicines List (2026 Edition)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From updated treatment guidelines and new medicines moving through regulatory review to expanding clinical research and access support, these changes may not immediately alter every patient's treatment plan, but they continue to broaden the range of options that may be available in the future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We will continue to follow new developments in hematologic malignancies, solid tumors, autoimmune diseases, neuroscience, and related fields, and translate complex medical information into updates that are easier for patients and families to understand.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":453,"title":454,"summary":455,"cover":456,"category":438,"publishedAt":141,"contentHtml":457,"hasAlternate":73,"updatedAt":74},"gastric-cancer-adverse-reactions-home-management-guide","Professor Jun Zhou: Managing Side Effects of Chemotherapy, Targeted Therapy, and Immunotherapy for Gastric Cancer — What You Can Handle at Home and When to Seek Care","Professor Jun Zhou explains the common and less obvious side effects of chemotherapy, targeted therapy, and immunotherapy for gastric cancer, and highlights six situations that require prompt medical attention.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F83a52d1569003049e9c416b95cf15123.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Side effects during cancer treatment are often preventable, manageable, and reversible, and appropriate management can make a meaningful difference to quality of life. Professor Jun Zhou of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, reviews three major categories of treatment-related side effects in gastric cancer: gastrointestinal symptoms, myelosuppression, and liver toxicity from chemotherapy; hypertension, bleeding, thrombosis, and proteinuria from targeted therapy; and thyroid dysfunction, immune-related myocarditis, and other immune-related adverse events from immunotherapy. The article also highlights less obvious complications such as interstitial lung disease\u002Fpneumonitis and identifies six situations in which patients should seek medical care promptly, including fever above 38.5°C, breathing problems, cardiac symptoms, inability to maintain food or fluid intake, neurologic symptoms, and gastric-cancer emergencies such as bleeding, obstruction, or perforation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cancer treatment is often a long journey. In addition to the disease itself, treatment-related side effects can be difficult for patients and families to manage. Nausea, vomiting, fatigue, hand-foot syndrome, diarrhea, and constipation do not simply have to be endured. With appropriate management, many of these symptoms can be reduced and quality of life can be improved.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For this article, we invited Professor Jun Zhou, Deputy Medical Director and Director of Gastrointestinal Oncology at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, to explain how patients can recognize and manage common side effects during gastric cancer treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Q1: What are the most common side effects of gastric cancer treatment, and how can patients manage them at home?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Professor Jun Zhou: The first thing I want patients to know is that having side effects does not mean the treatment has failed, and it does not mean your body cannot tolerate treatment. Most treatment-related side effects can be prevented, managed, or reversed. The key is to recognize them early and intervene early.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment options for gastric cancer have expanded considerably — from the chemotherapy era decades ago, to targeted therapy, immunotherapy, and now emerging approaches such as CAR-T cell therapy. Different treatments have different side-effect profiles. Let me go through some of the issues patients encounter most often.[1-5]\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Chemotherapy-Related Side Effects\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many of the side effects traditionally associated with gastric cancer treatment come from chemotherapy. Common examples include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Gastrointestinal side effects: Nausea and vomiting are among the most common. They often occur soon after chemotherapy and can make it difficult to eat. Some patients may also develop constipation or diarrhea.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Bone marrow toxicity: This can cause low white blood cell counts, low platelet counts, and anemia. Decreases in white blood cells and platelets are particularly common. Anemia is already common in patients with gastric cancer and may become more pronounced after chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Liver toxicity: Many anticancer drugs are metabolized by the liver and may cause liver injury, which can show up as elevated liver enzymes and, in some cases, increased bilirubin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hair loss: This usually has little direct effect on physical health and is reversible in most cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Targeted Therapy-Related Side Effects\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With the use of targeted therapies, the range of side effects seen in gastric cancer has become more diverse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, ramucirumab and fruquintinib are commonly used in later-line treatment settings. Potential side effects include hypertension, bleeding, thrombosis, and proteinuria.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Immunotherapy-Related Side Effects\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Immunotherapy is now widely used in gastric cancer in China, and immune-related adverse events can affect many different organs. Common issues include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Endocrine changes: Thyroid dysfunction is among the most common. Some patients may initially develop hyperthyroidism, which can cause irritability or restlessness, and later develop hypothyroidism, which may cause fatigue and excessive sleepiness. These problems can usually be managed with appropriate medication.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Immune-related myocarditis: This is rare — occurring in fewer than 0.5% of patients according to the source article — but it can be serious. Careful assessment before immunotherapy is therefore important, especially in patients with active autoimmune disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Immune-related adverse events can also affect the liver, spleen, lungs, kidneys, joints, and other organs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Whatever the type of side effect, regular monitoring, early recognition, and timely management are essential. The goal is to minimize the impact of adverse events while allowing treatment to continue as safely as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Q2: Are there less common side effects that patients with gastric cancer should pay particular attention to?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Professor Jun Zhou: Some treatment-related side effects can be relatively difficult to notice at first. One important example is interstitial lung disease (ILD)\u002Fpneumonitis, which may be associated with antibody-drug conjugates (ADCs), immunotherapy, radiotherapy, or other treatments. It is often detected through chest CT imaging.[6]\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If regular CT follow-up is difficult, pay close attention to new symptoms such as chest tightness, a persistent dry cough, or a noticeable decline in exercise tolerance. If these occur, contact your medical team and arrange appropriate evaluation promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Whether you are in the hospital or at home, paying attention to changes in your body is an important part of self-management. Recognizing treatment-related adverse events early can help keep treatment safer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Q3: Which symptoms require a hospital visit, and which mild side effects can usually be managed at home?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Professor Jun Zhou: This question is more important than any single medication or home-management tip. There are several situations in which patients should seek medical care promptly:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Fever. If your temperature is above 38.5°C, go to the hospital for a complete blood count and biochemical tests. In particular, the medical team will need to check whether white blood cell and neutrophil counts have fallen significantly. When these counts are very low, the risk of serious bacterial infection can rise sharply. Do not wait at home for a high fever to pass.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Breathing problems. Chest tightness, shortness of breath, a dry cough, or coughing up blood may indicate a serious lung complication such as interstitial lung disease\u002Fpneumonitis. This is particularly important for patients receiving ADC therapy. Seek medical evaluation promptly if these symptoms occur.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Cardiac symptoms. New palpitations, an irregular heartbeat, or the feeling that your heart is racing or pounding unusually hard should be evaluated as soon as possible. Serious cardiac complications can progress quickly.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. You cannot maintain basic food or fluid intake. Severe vomiting or diarrhea can make it impossible to eat or drink and may lead to dehydration or electrolyte imbalance. Hospital assessment may be needed so fluids and electrolytes can be replaced appropriately.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. Neurologic symptoms. New confusion or drowsiness, weakness or difficulty moving the arms or legs, memory changes, or slurred speech require medical evaluation. These symptoms may have several possible causes, including stroke or brain metastases, and should not be managed at home.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>6. Gastric Cancer Emergencies\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">a) Bleeding. Tumor-related bleeding can cause major upper gastrointestinal hemorrhage, with symptoms such as vomiting blood, black stools, or even low blood pressure and shock. Significant tumor-related bleeding cannot be managed safely at home. Contact your treating team immediately; if they cannot be reached, go to the emergency department of a hospital equipped to provide urgent care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">b) Obstruction. Gastric outlet obstruction is a common form of obstruction in gastric cancer. Food can accumulate in the stomach and may also place pressure on nearby organs. If obstruction is suspected, the source article advises stopping food and fluid intake and going to the hospital for assessment and treatment. Management may include drainage, stent placement, or palliative surgery, depending on the situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">c) Perforation. Gastric cancer can cause gastric perforation, and tumors that have spread within the abdomen may also lead to intestinal perforation. Patients often develop sudden, severe pain. The pain may temporarily ease, but this does not mean the condition is improving; digestive contents may still be leaking into the abdominal cavity and causing ongoing injury. This is an emergency and requires immediate hospital evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Milder side effects — such as mild nausea, diarrhea, constipation, fatigue, or hand-foot syndrome — may often be managed at home according to the care plan provided by your medical team. Keep a record of what happened, when it started, how severe it was, and what you did to manage it, and share that information at your next appointment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>One final message: if you are unsure whether a symptom is important, tell your doctor. Experienced clinicians are rarely concerned that patients ask too many questions; what worries them is hearing “everything was fine” only after a problem has become severe. Good symptom management can help treatment continue more safely and steadily.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">This article is based on the references below and is intended for general education only. Please follow the recommendations of your treating physician for your individual treatment and side-effect management plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px;\">\u003Cstrong>\u003Cspan style=\"font-size: 16px; color: rgb(127, 127, 127);\">References:\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[1] Chinese Society of Clinical Oncology (CSCO) Guidelines for the Prevention and Treatment of Anticancer Therapy-Related Nausea and Vomiting (2025).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[2] https:\u002F\u002Fwww.cancer.org\u002Fcancer\u002Fmanaging-cancer\u002Fside-effects\u002Ffatigue-weakness-sleep\u002Ffatigue.html\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[3] https:\u002F\u002Fwww.cancer.org\u002Fcancer\u002Fmanaging-cancer\u002Fside-effects\u002Fhair-skin-nails\u002Fhand-foot-syndrome.html\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[4] https:\u002F\u002Fwww.cancer.org\u002Fcancer\u002Fmanaging-cancer\u002Fside-effects\u002Fstool-or-urine-changes\u002Fconstipation.html\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[5] https:\u002F\u002Fwww.cancer.org\u002Fcancer\u002Fmanaging-cancer\u002Fside-effects\u002Fstool-or-urine-changes\u002Fdiarrhea.html\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">[6] Zhou C, Deng H, Yang Y, et al. Cancer therapy-related interstitial lung disease. Chinese Medical Journal. 2025;138(3):264-277.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":459,"title":460,"summary":461,"cover":462,"category":430,"publishedAt":149,"contentHtml":463,"hasAlternate":73,"updatedAt":432},"cd19-car-t-castleman-disease-remission","International Journal Publication | Dr. Yajing Zhang & Prof. Minghui Duan: First Global Report of Durable Treatment-Free Remission in Castleman Disease After CD19 CAR-T Therapy","Dr. Yajing Zhang of Beijing GoBroad Boren Hospital and Prof. Minghui Duan of Peking Union Medical College Hospital co-authored the first reported case of refractory Castleman disease achieving durable complete remission after CD19 CAR-T cell therapy.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1e08ba3d982c9ddc6564640fed623b2b.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: A collaborative study led by Dr. Yajing Zhang of Beijing GoBroad Boren Hospital and Prof. Minghui Duan of Peking Union Medical College Hospital was published in Hematological Oncology. It is the first systematic report worldwide of a patient with refractory HHV-8-negative idiopathic multicentric Castleman disease (iMCD) achieving complete, treatment-free remission for more than 12 months after CD19 CAR-T cell therapy. The patient had lived with the disease for over 12 years and had not achieved durable disease control despite multiple prior treatments, including COP and CHOP. After CAR-T therapy, she experienced only grade 1 cytokine release syndrome (CRS), presenting as a low-grade fever, and no immune effector cell-associated neurotoxicity syndrome (ICANS). She was able to return to normal daily life and began planning for pregnancy. Mechanistically, the case provides important clinical evidence supporting a B-cell-centric model of disease in refractory iMCD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Idiopathic multicentric Castleman disease (iMCD) is a rare, potentially life-threatening lymphoproliferative disorder characterized by marked clinical heterogeneity and complex immune dysregulation. Safe and effective therapies capable of producing durable remission remain limited, making iMCD a particularly challenging immune-mediated rare disease. In recent years, the use of CAR-T cell therapy has expanded beyond B-cell malignancies into immune-mediated diseases, but clinical exploration in rare lymphoproliferative disorders such as iMCD is still at an early stage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, a collaborative study was published in the international journal Hematological Oncology, with Dr. Yajing Zhang of Beijing GoBroad Boren Hospital as first author, Prof. Minghui Duan of Peking Union Medical College Hospital as corresponding author, and Prof. Lu Zhang of Peking Union Medical College Hospital and Dr. Hongsheng Zhang of Fudan University\u002FYake Biotechnology as co-corresponding authors. The study is the first systematic report worldwide of a patient with refractory HHV-8-negative iMCD achieving complete, treatment-free remission lasting more than 12 months after CD19 CAR-T cell therapy. It also provides important clinical evidence supporting a “B-cell-centric model” of disease and offers new insights into potential treatment strategies for Castleman disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case Overview\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Twelve Years Without Durable Disease Control: A New Treatment Approach for Long-Standing Refractory iMCD\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study reports a 31-year-old woman diagnosed with HHV-8-negative iMCD with the idiopathic plasmacytic lymphadenopathy (IPL) subtype. Her disease course had lasted more than 12 years. She had previously received multiple lines of therapy, including COP, CHOP, thalidomide, bortezomib, and sirolimus, but none achieved sustained disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fc8f4b008f85e6f3373f28941770684f8_20260914001725.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c8f4b008f85e6f3373f28941770684f8_20260914001725.png\" alt=\"75e73828-0a09-4365-b30a-605d1f7cbdc3.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1. Lymph Node Histopathology and Immunohistochemistry\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">H&E staining showed largely preserved lymph node architecture with the characteristic “onion-skin” appearance caused by concentric expansion of the mantle zones. CD138 immunohistochemistry showed extensive diffuse plasma cell proliferation in the interfollicular areas, consistent with the iMCD-IPL phenotype.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient had persistent systemic inflammation, with markedly elevated CRP, ESR, and IL-6; hypergammaglobulinemia, with IgG peaking at 68.0 g\u002FL; generalized lymphadenopathy and splenomegaly; and recurrent systemic inflammatory symptoms. With standard treatments and anti-IL-6 pathway therapy either providing limited benefit or being unavailable, her disease remained chronically active, suggesting that a more upstream abnormality in immune regulation might be driving the condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. A Shared Decision: Why CD19 CAR-T?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Years of repeated treatment had failed to bring the disease under lasting control and had taken a major toll on the young woman's work, daily life, and future plans. After carefully reviewing her treatment history and weighing potential benefits and risks, the medical team discussed several possible treatment paths with her.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Options included IL-6-targeted therapy with siltuximab, the current standard treatment for iMCD but one that typically requires ongoing administration; B-cell-depleting therapy with rituximab, which targets B cells but may have limitations in the depth and durability of response; and additional chemotherapy or immunomodulatory regimens, several of which she had already received with limited disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient hoped for an approach that might offer long-term treatment-free remission after a single course of therapy. Given her longstanding inflammatory burden and evidence of abnormal B-cell activation, she and the medical team ultimately made a shared decision to proceed with CD19 CAR-T cell therapy. She provided informed consent under clinical study ChiCTR1900025419.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Treatment Course: Robust CAR-T Expansion With a Favorable Safety Profile\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After standard lymphodepleting chemotherapy with fludarabine and cyclophosphamide (FC), the patient received an infusion of autologous CD19 CAR-T cells at a dose of 1 × 10^6 CAR+ T cells\u002Fkg. She developed grade 1 cytokine release syndrome (CRS), consisting only of a low-grade fever, which resolved with supportive care. No ICANS occurred. CAR-T cell expansion peaked on day 11 after infusion, while B-cell depletion persisted from day 7 through day 198. Overall, treatment was well tolerated, with no grade 3 or higher adverse events observed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fe7bbe51a3883a2928a66cb32e0d45217_20260914001746.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e7bbe51a3883a2928a66cb32e0d45217_20260914001746.png\" alt=\"69ba83c0-b322-4354-8e8d-0f8d998a6be9.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure 2. Comprehensive Assessment of Response to CD19 CAR-T Therapy in iMCD\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(A) Body temperature monitoring showed a brief low-grade fever, with a maximum temperature of 38.2°C.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(B-C) Expansion and persistence of CD19 CAR-T cells in peripheral blood, detectable from day 11 through day 58 after infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(D) Changes in peripheral blood CD19+ lymphocyte counts before and after treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(E) Serial changes in inflammatory markers, including CRP, ESR, and IL-6, from baseline through post-treatment follow-up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(F) Changes in hemoglobin levels over time, showing gradual recovery after treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(G) Changes in serum immunoglobulin levels (IgG, IgA, and IgM) at different time points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Durable Remission and a Return to Life: Disease Control Alongside Improved Quality of Life\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After treatment, the patient showed rapid and sustained systemic improvement. Inflammatory markers, including CRP, ESR, and IL-6, fell quickly and remained within the normal range over time. Her anemia improved substantially, her blood counts gradually recovered, and immunoglobulin levels decreased as expected following CD19-directed B-cell depletion. Her systemic symptoms resolved completely.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At more than 12 months of follow-up, the patient remained in complete remission without further treatment. Just as importantly, sustained disease control translated into a meaningful improvement in her quality of life. She returned to normal work and everyday activities, began making plans for the future again, and is now preparing for pregnancy. After years of chronic inflammation, repeated treatment, and restrictions on daily life, she has regained confidence in what lies ahead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. Mechanistic Insights: From B-Cell Depletion to Restoration of Immune Homeostasis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Serial immune monitoring showed that CD19 CAR-T therapy induced sustained depletion of peripheral B cells, closely paralleling the patient's clinical remission. At the same time, systemic inflammatory markers, including CRP, ESR, and IL-6, fell in a coordinated pattern and approached normal levels, suggesting a broader resetting of the inflammatory cascade toward immune homeostasis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These findings suggest that, in the iMCD-IPL subtype, B cells may be more than downstream participants in inflammation and may play an important role in regulating inflammatory pathways such as IL-6. The observation further supports a B-cell-centric model of disease and suggests that CD19 CAR-T therapy may help restore immune homeostasis by systematically eliminating abnormal B-cell populations, potentially contributing to durable disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Expert Commentary: One Case, One New Possibility\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As CAR-T cell therapy expands from hematologic malignancies into immune dysregulation and rare diseases, mechanism-driven treatment is beginning to reshape how complex immune-mediated disorders are approached. This study represents an important step in exploring CAR-T therapy for rare inflammatory disorders such as Castleman disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Yajing Zhang noted that, from a patient's perspective, the key message from this case is that even when Castleman disease has remained difficult to control for years and repeated treatments have provided limited benefit, it may still be worthwhile to revisit the diagnosis, disease subtype, and underlying mechanisms. For clinicians, the case suggests that future treatment may need to move beyond simply “controlling inflammation” toward identifying the mechanisms driving disease and restoring immune balance. This is one of the most important roles of rare-disease research: learning deeply from an individual patient to uncover new possibilities and advance our understanding of the disease itself. The value of treatment is also not measured only by normalized laboratory results, but by whether a patient can return to work and everyday life, reconnect with family and society, and regain the confidence to plan for the future. For younger patients in particular, being able to return to life, make plans for a family, and look ahead again may be among the most meaningful outcomes treatment can offer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Minghui Duan noted that, for some patients with refractory Castleman disease, the key may be to identify deeper abnormalities within the immune system rather than focusing only on suppressing visible inflammatory manifestations. This suggests that future treatment may need to go beyond blocking inflammatory pathways and explore ways to restore immune balance. CAR-T therapy has shown potential in this setting, but its clinical use still requires rigorous patient assessment, standardized management, and long-term follow-up by experienced teams. For patients with recurrent disease or limited response to conventional therapies, CAR-T may offer an important direction for further exploration. Future clinical practice will need to account for disease subtype and individual patient differences while continuing to refine treatment strategies based on a deeper understanding of disease mechanisms. The change seen in this young patient—from years of repeated treatment to returning to work and daily life—not only reflects durable disease control, but also highlights the potential of precision immunotherapy to improve quality of life.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":465,"title":466,"summary":467,"cover":468,"category":438,"publishedAt":149,"contentHtml":469,"hasAlternate":73,"updatedAt":74},"blood-disease-transplant-decision-guide","Do I Really Need a Stem Cell Transplant? A Guide to Transplant Decisions Across Different Blood Disorders","Understand the key differences between autologous and allogeneic stem cell transplantation, how transplant indications and donor selection vary by disease, and where transplantation fits in the CAR-T era.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F564e49916e976e98f1a5ffab751fc057.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This article provides patients with blood disorders and their families with a structured guide to transplant decision-making. It first explains the key differences between autologous transplantation, which uses the patient's own stem cells and does not cause graft-versus-host disease, and allogeneic transplantation, which uses donor cells and can provide a graft-versus-leukemia effect. It then reviews which diseases may be considered for autologous or allogeneic transplantation and outlines a donor-selection hierarchy for allogeneic transplantation, including matched sibling, haploidentical, unrelated, and cord blood donors, based on the source article's summary of CSCO guidance. The article also addresses a common question in the CAR-T era: can CAR-T replace transplantation? Rather than viewing the two approaches as competitors, it explains that CAR-T may allow some patients to avoid transplant while helping others reach a deeper remission before proceeding to transplant. The central message is that transplant decisions should always be individualized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For many patients with blood disorders and their families, one of the most confusing questions after diagnosis is not simply, "How serious is this disease?" but rather, "Do I actually need a stem cell transplant?"\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some people are told that transplant offers the best chance of cure. Others hear that chemotherapy alone may be enough. Some have heard that CAR-T is a newer, potentially safer option that could make transplant unnecessary, while others are so worried about graft-versus-host disease that they hesitate to consider transplant at all. With so many different messages, how do you make sense of the choices?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Start with the Basics: Autologous and Allogeneic Transplants Are Very Different\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before asking whether you need a transplant, it is important to understand that there are two fundamentally different types of hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Autologous hematopoietic stem cell transplantation (auto-HSCT): the stem cells come from the patient. The patient's own stem cells are collected and frozen in advance, followed by high-dose chemotherapy to eliminate as much residual cancer as possible. The stored stem cells are then infused back into the body. Advantages include no need to find a donor and no risk of graft-versus-host disease. Treatment-related complications are generally fewer than with allogeneic transplantation. However, because there is no donor-derived graft-versus-tumor effect, relapse risk may be higher in some diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Allogeneic hematopoietic stem cell transplantation (allo-HSCT): the stem cells come from a healthy donor, such as a family member or an unrelated volunteer. Donor immune cells can help eliminate residual malignant cells through the graft-versus-leukemia effect, which can lower relapse risk. However, allogeneic transplantation can also cause graft-versus-host disease (GVHD) and may require ongoing immunosuppressive therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The indications for these two transplant approaches are very different, so they should not be treated as interchangeable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. Who May Be Considered for Autologous Transplant, and Who May Need Allogeneic Transplant?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In general, autologous transplantation is more often used for diseases that are sensitive to chemotherapy and can achieve a deep remission. Allogeneic transplantation is more commonly considered for high-risk, relapsed\u002Frefractory disease or situations in which autologous transplantation is unlikely to provide sufficient disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For a quick overview, the source article summarizes common transplant recommendations for different blood disorders in the table below:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F38e8ede4e59a5ec1fb75e0f3cd17796a_20260913222031.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"38e8ede4e59a5ec1fb75e0f3cd17796a_20260913222031.png\" alt=\"3b46014b-9943-4ddc-997f-ae4c5bf7d4fa.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Note: The table is a simplified overview. An individual transplant decision should be made by the treating physician based on the patient's specific clinical situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. How Is a Donor Chosen for Allogeneic Transplantation?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the source article's summary of the 2025 Chinese Society of Clinical Oncology (CSCO) guidelines, the main donor options for allogeneic transplantation fall into four categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F586d822e62f260eb4cb671e526ee4211_20260913222105.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"586d822e62f260eb4cb671e526ee4211_20260913222105.png\" alt=\"25ee316b-75ba-4851-b782-887cd3cdcb5d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The source article summarizes donor priority as follows:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1) A fully HLA-matched sibling donor is generally preferred. 2) If no suitable matched sibling donor is available, a haploidentical donor may be prioritized, particularly for patients with high-risk relapse or those who need an urgent transplant. 3) Unrelated donors and cord blood donors may serve as alternative options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Donor selection is always individualized. In practice, the patient's clinical condition, urgency of transplantation, donor characteristics, and other factors all need to be considered together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The source article notes that haploidentical transplantation is widely used in China and that the 2025 CSCO guidelines prioritize haploidentical transplantation for selected diseases such as high-risk leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. An Important Reminder: Transplant Decisions Are Not Black and White\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A transplant decision is highly individualized and cannot be made by applying a guideline mechanically. The source article cites 2025 guidance from the European Society for Blood and Marrow Transplantation (EBMT), emphasizing that several factors should be considered together:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Disease risk: the expected benefit of transplantation can differ substantially across risk groups.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Transplant-related risk: this includes assessment of non-relapse mortality (NRM).\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Non-transplant treatment options: these may include evolving targeted therapies, immunotherapies such as CAR-T, and other cellular therapies.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Comorbidities and overall fitness: age alone is no longer an absolute cutoff, but organ function, performance status, and other health factors still matter.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Quality of life, patient-reported outcomes, and long-term effects: the goal of treatment is not only to help patients live longer, but also to help them live well.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Timing also matters. The source article notes that transplantation is often considered earlier after a patient reaches complete remission, when disease burden is lower and organ function may be better preserved, potentially reducing transplant-related risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. In the CAR-T Era, Is Transplantation Still Necessary?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This has become one of the most common questions patients ask.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T can be thought of as a "living medicine." T cells are collected from the patient, engineered to recognize a specific target on cancer cells, and then infused back into the body so they can seek out and attack those cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So can CAR-T replace transplantation? The answer is not simply yes or no. For some patients, CAR-T may reduce the need for transplant. For others, it can create a stronger remission and make transplantation more feasible or more effective.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For diffuse large B-cell lymphoma (DLBCL): according to the source article, autologous transplantation remains a standard consolidation option for patients whose disease is sensitive to chemotherapy. For patients with chemotherapy-resistant disease or those who are not suitable candidates for transplant, CAR-T may be considered as an alternative approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For multiple myeloma: CAR-T and autologous transplantation are not necessarily competing strategies. The source article notes that increasing research is exploring how the two may be used in combination - for example, using autologous transplantation to achieve a deep remission and CAR-T to further target residual disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For acute lymphoblastic leukemia (ALL): CAR-T can be highly effective at reducing disease burden and inducing remission, but durable long-term control with CAR-T alone remains an area of ongoing study. For selected high-risk patients, the source article states that bridging to allogeneic transplantation after CAR-T may offer a better chance of long-term disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Put simply, CAR-T and transplantation address different parts of the treatment challenge. CAR-T can help achieve disease control or remission, while transplantation may provide additional long-term protection against relapse in selected patients. Which approach is appropriate depends on the disease type, risk category, treatment response, overall health, and many other factors, and should be decided through shared discussion with the treating team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Final Thoughts\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">"Do I really need a transplant?" There is no single answer that applies to everyone. The right answer depends on the individual patient and disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hematopoietic stem cell transplantation is not the only treatment path, and not every patient needs one. For some lower-risk leukemias, chemotherapy may be sufficient. For high-risk or relapsed\u002Frefractory disease, allogeneic transplantation may offer an important chance for cure. For some lymphomas, CAR-T may be an alternative to transplant. For selected high-risk ALL patients, CAR-T followed by allogeneic transplantation may offer the best chance of long-term disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients and families facing a transplant decision should have a detailed discussion with their treating physician about disease risk, treatment response, overall health, and the potential benefits and risks of transplantation. A multidisciplinary team (MDT) assessment can help support a more evidence-based and individualized decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Please note: This installment of our "100 Questions About Transplantation" series reviews common transplant indications across different blood disorders and the role CAR-T may play. Future articles will continue to address practical questions patients and families often have before, during, and after transplantation.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":471,"title":472,"summary":473,"cover":474,"category":438,"publishedAt":149,"contentHtml":475,"hasAlternate":73,"updatedAt":74},"lung-cancer-leptomeningeal-metastasis-recognition","Don't Miss Hidden Spread in Lung Cancer: Recognizing Leptomeningeal Metastasis","Dr. Shuang LI uses a clinical case to explain the subtle symptoms of leptomeningeal metastasis from lung cancer, the diagnostic value of black-blood MRI sequences, and the role of multidisciplinary care.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fb3d44991ccae941d49cd98598e0044b6.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, shares key points on recognizing and managing leptomeningeal metastasis (LM) from lung cancer. Because symptoms can be subtle and conventional imaging may miss the disease, specialized MRI sequences such as black-blood imaging, together with cerebrospinal fluid (CSF) cytology, can be important for diagnosis. The hospital has established a multidisciplinary LM team and an integrated pathway covering black-blood MRI, CSF sample management, standardized neurologic assessment, and intrathecal therapy, providing coordinated care for patients with advanced lung cancer involving the central nervous system.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, the wider use of targeted therapies and other newer treatments has helped many patients with advanced lung cancer live longer. Most people are familiar with “brain metastases,” which usually refers to tumors that have spread into the brain tissue itself. As survival has improved, leptomeningeal metastasis is also being detected more often.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What exactly is leptomeningeal metastasis? In simple terms, it means that cancer cells have spread to the thin membranes surrounding the brain and spinal cord - the leptomeninges - and into the subarachnoid space. Some patients may have no visible metastases within the brain tissue itself, yet large numbers of tumor cells can still be found in the cerebrospinal fluid. These cells may attach to and cluster along the surface of the spinal cord, leading to a range of neurologic symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Subtle Symptoms, Potentially Serious Consequences\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Leptomeningeal metastasis can develop quietly and may be easy to miss. Possible symptoms include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Signs of increased intracranial pressure: persistent nausea, headache, or vomiting.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Neurologic symptoms: these vary depending on which nerves or areas of the nervous system are affected.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cranial nerve involvement may cause difficulty swallowing or blurred vision.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Involvement of the cauda equina may lead to problems such as loss of bladder or bowel control.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why Can Routine Tests Miss It?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is one of the main diagnostic challenges. Conventional CT and routine MRI may not always show leptomeningeal disease clearly. Some patients need specialized MRI sequences to reveal signs of meningeal involvement. The images below illustrate the difference in one case:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F332f4eaebcabf4931779eb227dc698c3_20260913215227.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"332f4eaebcabf4931779eb227dc698c3_20260913215227.png\" alt=\"41362df8-a701-4813-9afc-206aead83800.png\"\u002F> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Conventional contrast-enhanced MRI mainly shows enhancement of blood vessels within the brain tissue and may not clearly distinguish whether leptomeningeal metastasis is present.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fb1fc2a066ff0e3970cd180ca26cc76a3_20260913215256.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"b1fc2a066ff0e3970cd180ca26cc76a3_20260913215256.png\" alt=\"d727cef1-1ba3-4086-86eb-322de8388cda.png\"\u002F> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">On a specialized black-blood MRI sequence, the meninges show clear thickening and enhancement, raising suspicion for leptomeningeal metastasis. This illustrates why specialized MRI sequences can be important when LM is suspected.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case Example: Lung Adenocarcinoma With Leptomeningeal Metastasis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In November 2025, the patient was admitted after a sudden episode of impaired consciousness. A conventional CT scan showed no acute intracranial hemorrhage, cerebral infarction, or obvious space-occupying lesion. During a diagnostic lumbar puncture, the cerebrospinal fluid pressure measured 300 mmH2O, above the usual reference range of approximately 80-180 mmH2O. CSF cytology detected malignant cells, and together with the clinical findings, this supported a diagnosis of leptomeningeal metastasis. During the course of the illness, the patient had experienced headache, nausea, and vomiting, followed by impaired consciousness as the condition progressed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At follow-up in January 2026, the patient's symptoms had improved significantly. Repeat CSF testing showed that pressure and protein levels had returned to the reference range, and no malignant cells were detected on cytology. Black-blood MRI also showed resolution of the previously abnormal enhancement along the cerebral sulci and gyri, indicating radiographic improvement of the meningeal involvement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To address common challenges in the diagnosis and treatment of leptomeningeal metastasis from lung cancer, our hospital has established a dedicated LM multidisciplinary team (LM-MDT), bringing together specialists from radiology, laboratory medicine, oncology, ultrasound, and other disciplines. The team has developed an integrated care pathway covering black-blood MRI, standardized CSF sample management, neurologic assessment, and intrathecal drug administration, while also conducting exploratory clinical studies aimed at improving diagnostic and treatment standards. Through this multidisciplinary model, the team seeks to provide coordinated, full-course care for patients with advanced lung cancer and central nervous system metastases.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":477,"title":478,"summary":479,"cover":480,"category":438,"publishedAt":156,"contentHtml":481,"hasAlternate":73,"updatedAt":432},"nkt-lymphoma-full-examination-guide-diagnosis-transplant","A Patient's Guide to NK\u002FT-Cell Lymphoma Testing: What Each Test Is For, From Diagnosis to Transplant","A practical guide to the key tests used at four major stages of NK\u002FT-cell lymphoma care: initial diagnosis, treatment monitoring, complication screening, and pre-transplant evaluation.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fbf3fe0b7c78b81784f166d32d37f759f.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: The diagnosis and treatment of NK\u002FT-cell lymphoma can involve a long list of tests, which can be confusing for patients and families. This guide explains the main tests used across four stages - initial diagnosis, treatment monitoring, complication screening, and pre-transplant evaluation - including tissue biopsy, immunohistochemistry, EBER in situ hybridization, FISH, next-generation sequencing (NGS), PD-L1 testing, comprehensive bone marrow evaluation, circulating tumor DNA (ctDNA) liquid biopsy, a seven-parameter functional flow cytometry panel for hemophagocytic lymphohistiocytosis (HLH), high-resolution HLA typing, and KIR genotyping. It explains what each test is designed to assess, how similar-looking tests differ, and why the results may matter for treatment decisions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If you are being evaluated for, or have been diagnosed with, NK\u002FT-cell lymphoma, a long list of test orders can feel overwhelming. Many patients and families have the same questions:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Do I really need this test?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>These two tests look similar - are they testing the same thing?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Which results are especially important when doctors are watching for serious complications?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>...\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This guide walks through the major tests used during initial diagnosis, treatment monitoring, complication screening, and preparation for transplantation, with a focus on what each test does and why it may be clinically useful.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Accurate Diagnosis | Understanding the Disease Before Treatment Begins\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Diagnosis is the foundation of treatment. The main goals are to confirm the lymphoma subtype, assess how aggressive it may be, and determine whether the disease has spread beyond the original site.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Tissue Biopsy | The Most Important Source of Diagnostic Evidence\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A sample of the lesion is collected and examined under a microscope. NK\u002FT-cell lymphoma often contains large areas of tissue necrosis, so an inadequate sample can lead to a missed diagnosis. Doctors may therefore recommend image-guided sampling from more than one area or an excisional biopsy to improve the chance of obtaining viable tumor tissue.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Expert Pathology Review | A Second Look at a Difficult Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">NK\u002FT-cell lymphoma is rare and can be difficult to diagnose. Necrotic tissue may be confused with inflammation or with other types of lymphoma. For challenging cases, our hospital works with Prof. Zifen Gao, an expert in lymphoma pathology, for additional pathology review. A precise diagnosis is an important first step toward choosing the right treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Immunohistochemistry (IHC) | Identifying the Tumor's Protein Profile\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">IHC uses antibodies to detect proteins expressed by tumor cells and is an important part of confirming the diagnosis:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Typical positive markers: CD2, cytoplasmic CD3epsilon, CD56, TIA-1, granzyme B, and perforin\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Typical negative markers: CD20 and surface CD3\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ki-67, MYC, and CD30 may also be tested to provide additional information that can help guide treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. EBER In Situ Hybridization (EBER-ISH) | Detecting Epstein-Barr Virus in Tumor Cells\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Approximately 90%-100% of NK\u002FT-cell lymphomas are associated with Epstein-Barr virus (EBV). A positive EBER result strongly supports the diagnosis and is widely regarded as one of the key diagnostic standards.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. FISH | Looking for Chromosomal Abnormalities\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fluorescence in situ hybridization (FISH) can identify certain chromosomal deletions or amplifications. Examples may include 6q21 deletion, PD-L1 amplification, STAT3 amplification, and TP53 deletion. Not every patient will have these abnormalities. When present, they may contribute to risk assessment, but their absence does not rule out the diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>6. T-Cell Receptor (TCR) Gene Rearrangement Testing | Assessing Clonality\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This test can help distinguish a reactive or inflammatory process from a malignant clonal process. It may be added in diagnostically difficult cases and should always be interpreted together with the pathology findings.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>7. Next-Generation Sequencing (NGS) | Mapping the Tumor's Genetic Changes\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">NGS can screen multiple clinically relevant gene alterations at the same time. These may include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Tumor suppressor gene inactivation: TP53 and DDX3X (frequently mutated and associated with higher-risk disease)\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Activation of oncogenic pathways: STAT3 and STAT5B\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Epigenetic alterations: KMT2D, BCOR, and ARID1A\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If an ECSIT V140A variant is detected, clinicians should be particularly alert to the possibility of secondary hemophagocytic lymphohistiocytosis (HLH).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>8. PD-L1 (SP263) Testing | Assessing Potential Suitability for Immunotherapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Around 30%-70% of patients may show high PD-L1 expression. Doctors interpret this result together with other factors, such as disease stage and EBV DNA level, before deciding whether immunotherapy may be appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>9. Comprehensive Bone Marrow Evaluation | Checking for Systemic Involvement\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Bone marrow testing may be recommended for patients with anemia, thrombocytopenia, multiple suspicious lesions, or other high-risk features. The evaluation may include bone marrow aspiration, bone marrow biopsy, and flow cytometric immunophenotyping.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Treatment Monitoring | A Dynamic View of Disease Through the Blood\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>ctDNA Liquid Biopsy | Tracking Changes During Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A blood test can measure circulating tumor DNA (ctDNA), fragments of tumor-derived DNA released into the bloodstream. Falling levels may suggest that treatment is working, while rising levels may raise concern for disease recurrence. However, ctDNA does not replace a tissue biopsy. If your doctor recommends another biopsy, it remains important to follow that advice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Complication Screening | Watching Closely for Hemophagocytic Lymphohistiocytosis (HLH)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">HLH secondary to NK\u002FT-cell lymphoma is a medical emergency. If persistent high fever, pancytopenia, or enlargement of the liver or spleen occurs, a complete HLH evaluation should be arranged promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Seven-Parameter Functional Flow Cytometry Panel for HLH | Assessing Immune Cell Function\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This panel evaluates NK-cell activity together with CD107a, perforin, granzyme B, MUNC13-4, SAP, and XIAP. It helps assess whether immune-cell killing function is impaired and can support the distinction between primary (genetic) HLH and secondary, tumor-associated HLH.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>10-Cytokine Panel | Measuring the Intensity of Systemic Inflammation\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This panel helps quantify inflammatory activity and can support both HLH diagnosis and treatment monitoring. Important markers may include CXCL9, IFN-gamma, and sCD163. CXCL9 is considered a sensitive marker in NK\u002FT-cell lymphoma-associated HLH.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>EBV-Infected Cell Subset Analysis | Identifying Which Immune Cells Carry the Virus\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This test determines which immune-cell population is predominantly infected by EBV - T cells, B cells, or NK cells. If T\u002FNK cells are mainly involved, the HLH may be more closely related to NK\u002FT-cell lymphoma; if B cells are predominantly involved, doctors may need to consider other possibilities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>NGS Genetic Testing | Distinguishing Primary from Secondary HLH\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Testing for genes associated with primary HLH, such as PRF1 and UNC13D, can help determine whether HLH is inherited or secondary to the lymphoma. This distinction can be important when planning treatment and selecting a stem cell donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Pre-Transplant Evaluation | Preparing as Safely as Possible for Stem Cell Transplantation\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For some patients with high-risk, relapsed, or refractory disease, allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be an important potentially curative treatment. Pre-transplant testing focuses on identifying the most suitable donor, reducing the risk of graft rejection, and avoiding the use of a donor who may carry the same inherited disease-causing variant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. High-Resolution HLA Typing | Assessing Donor-Recipient Immune Compatibility\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">HLA molecules help the immune system distinguish self from non-self. In general, closer HLA matching is associated with a lower risk of immune incompatibility. Testing commonly includes six key loci: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. KIR Genotyping | Evaluating Donor NK-Cell Characteristics\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">KIR genotyping examines regulatory genes on donor NK cells and may provide additional information about the donor's potential antitumor immune activity, helping clinicians optimize donor selection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Donor-Specific Antibody (DSA) Testing | Identifying Risk of Graft Rejection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This test checks whether the patient has antibodies directed against the donor's HLA. A positive result can substantially increase the risk of graft rejection or engraftment failure, and may require treatment before transplant or selection of a different donor. Because DSA levels can change over time, the test should be repeated within four weeks before transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Whole-Exome Sequencing for Inherited Predisposition | Screening Patient and Donor for Germline Risk\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Testing both the patient and potential donor has two main goals:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Screen for disease-causing inherited variants associated with conditions such as HLH, helping avoid selection of a donor who carries the same pathogenic variant and could potentially recreate the same inherited immune defect after transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Assess potential long-term prognostic risks.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Precision Treatment Starts with an Accurate Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"break-after: avoid;\">\u003Cspan style=\"font-size: 15px; text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\"break-after: avoid;\">\u003Cspan style=\"font-size: 15px; text-align: justify;\">Understand why each test has been ordered\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"break-after: avoid;\">\u003Cspan style=\"font-size: 15px; text-align: justify;\">Know what each result may contribute to your care\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\"break-after: avoid;\">\u003Cspan style=\"font-size: 15px; text-align: justify;\">Stay in close communication with your treating team and complete recommended testing\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With clear information, appropriate testing, and regular follow-up, patients and families can move through each stage of treatment with greater confidence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">This article is for general educational purposes only. The tests and treatment plan that are appropriate for you should be determined by your treating physician.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":483,"title":484,"summary":485,"cover":486,"category":430,"publishedAt":165,"contentHtml":487,"hasAlternate":73,"updatedAt":432},"from-drug-availability-to-accessibility-blood-cancer","From Approval to Access: Recent Developments Patients with Blood Cancers and Solid Tumors Should Know About","Since June 2026, several developments have moved new treatments closer to patients — including approval of the world's first CAR-T therapy for a solid tumor, the launch of China's annual reimbursement-list review, real-world access to a BCMA-targeted ADC, and new progress in an original CD5 CAR-T program.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F40719faae769dbec8068e252d941e170.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This article highlights several major developments in hematology and oncology in China since June 2026. The world's first CAR-T product for a solid tumor was approved for CLDN18.2-positive advanced gastric cancer; China's National Healthcare Security Administration launched its annual reimbursement-list adjustment, opening the application pathway for a number of innovative anticancer drugs; the first in-hospital prescription in China of belantamab mafodotin provided another treatment option for relapsed\u002Frefractory multiple myeloma; Dr. Jing Pan's team presented new data on a nanobody-based dual-epitope CD5 CAR-T approach at the EHA Congress; and several GoBroad hospitals expanded access to approved CAR-T products. Together, these changes reflect a broader shift from having innovative therapies available in principle to making them more accessible in clinical practice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For many people living with blood cancers or solid tumors, every newly approved drug, research breakthrough, or additional treatment option can represent another reason for hope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Since June 2026, a number of developments in hematology and oncology in China have drawn particular attention: innovative drugs have received regulatory approval, advanced therapies have moved into real-world clinical use, original research has been presented internationally, and more specialized medical resources have become available to patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Below, we highlight several updates that may matter to patients and families — and explain what these changes could mean in practical terms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>The World's First CAR-T Therapy for a Solid Tumor Is Approved\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2026, China's National Medical Products Administration (NMPA) approved a CLDN18.2-targeted CAR-T product for patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This became the world's first approved CAR-T therapy for a solid tumor. Until now, CAR-T has been used mainly in hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. The approval marks an important step in extending cell therapy beyond blood cancers into solid tumors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For some patients with gastric cancer whose disease has progressed after multiple lines of treatment, this may provide an additional treatment option. Beijing GoBroad Hospital can now evaluate and treat eligible patients in accordance with the nationally approved indication. (Sources: National Medical Products Administration [NMPA]; Beijing GoBroad Hospital)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Annual Reimbursement-List Review Begins, Bringing Innovative Drugs One Step Closer to Patients\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June, China's National Healthcare Security Administration (NHSA) formally launched the 2026 adjustment of the National Reimbursement Drug List, with a number of innovative anticancer medicines entering the application process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For many patients, an innovative drug may represent a new treatment possibility — but high out-of-pocket costs can also make long-term treatment difficult to continue.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One of the most important goals of the reimbursement-list adjustment is to give clinically valuable new medicines a pathway to national reimbursement negotiations, which may help reduce the financial burden of sustained treatment for patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The final negotiation results have not yet been announced. Even so, the start of the review means that a number of innovative medicines have moved one step closer to becoming more affordable and more sustainable for long-term use. (Source: National Healthcare Security Administration [NHSA])\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>BCMA-Targeted ADC Enters Real-World Use, Adding Another Option for Multiple Myeloma\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with relapsed\u002Frefractory multiple myeloma, treatment is often a long journey involving one therapy after another. As the number of prior treatment lines increases, the disease may continue to relapse or progress while available options become more limited.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On June 26, 2026, Dr. Yajing Zhang and her team at Beijing GoBroad Boren Hospital issued China's first in-hospital prescription of belantamab mafodotin for a patient with relapsed\u002Frefractory multiple myeloma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC). It recognizes BCMA on the surface of myeloma cells and delivers its cytotoxic payload into the tumor cell. Unlike CAR-T therapy, it does not require collection, ex vivo manufacturing, and reinfusion of a patient's or donor's T cells, offering a different treatment pathway for selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Zhang also emphasized that a newly available drug is not automatically suitable for every patient. Eye examinations are needed before treatment, and the cornea, vision, platelet count, infection risk, and other safety parameters require close monitoring during therapy. Careful, standardized management is essential to balance efficacy and safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients whose myeloma has relapsed after multiple lines of treatment — including some who have already received CAR-T — the arrival of this therapy means not simply “one more drug,” but another option within an increasingly complex treatment pathway. (Source: Beijing GoBroad Boren Hospital)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>China-Developed CAR-T Research Opens a New Investigational Direction for Relapsed\u002FRefractory T-ALL\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the 2026 European Hematology Association (EHA) Congress, the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, together with Dr. Jing Pan's team at Beijing GoBroad Hospital, presented new findings from an original nanobody-based, dual-epitope NbCD5 CAR-T program building on earlier research published in Nature Medicine.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Clinical data showed that the new dual-epitope CD5 CAR-T cells reached peak expansion earlier in vivo and were associated with a shorter duration of cytokine release syndrome (CRS). In long-term follow-up, no additional deaths due to severe infection were reported.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The importance of this work lies in its attempt to address a long-standing safety challenge in CAR-T therapy for T-cell malignancies: how to preserve antitumor activity while reducing the risk of serious infections and other complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study reflects how China-based research teams are developing new solutions around real clinical challenges and may offer another investigational direction for patients with relapsed\u002Frefractory T-ALL in the future. (Source: Hematology News)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>From “CAR-T Is Available” to “CAR-T Is Delivered as Standardized Care”\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T cell therapy has become an important treatment option for relapsed\u002Frefractory hematologic malignancies. As more products receive regulatory approval, clinical pathways become more standardized, and supportive policies continue to develop, CAR-T is gradually moving from a frontier technology into broader routine clinical practice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, GoBroad Chunfu Institute of Hematology & Oncology completed the required institutional filing for six NMPA-approved CAR-T products, covering established targets including CD19 and BCMA and supporting treatment across several relapsed\u002Frefractory hematologic malignancies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F54d0e0a9ead53ce89a5a56bb6ca8d2fd_20260914001409.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"54d0e0a9ead53ce89a5a56bb6ca8d2fd_20260914001409.png\" alt=\"03da12ad-face-49c2-b876-942eaa9bc1e4.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital have also introduced multiple approved CAR-T products into clinical practice, providing standardized treatment services for patients who meet the approved indications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fc1e1aef07d5db2a9559ea7cfdb868991_20260914001421.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c1e1aef07d5db2a9559ea7cfdb868991_20260914001421.png\" alt=\"c9407201-9ccf-4a7b-b186-bcc877ae0e5d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T treatment is much more than a single cell infusion. It is a full-course process that includes indication assessment, bridging therapy when needed, cell collection and infusion, monitoring and management of complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and long-term follow-up and infection management. Each step can affect the final treatment outcome.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, GoBroad hospitals have continued to strengthen their full-course CAR-T management systems. Through multidisciplinary collaboration, they aim to provide patients with more standardized and safer support throughout treatment. (Sources: GoBroad Chunfu Institute of Hematology & Oncology; GoBroad Shanghai Zhaxin Hospital)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>More Oncology Specialists Join Shanghai GoBroad Cancer Hospital\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Alongside new drugs and technologies, access to experienced specialists can also make a meaningful difference for patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, colorectal cancer specialist Professor Xinxiang Li and his team joined Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University. Their work will focus on colorectal cancer specialty development, clinical care, and clinical research, helping provide patients with more standardized and continuous specialist services.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Thoracic surgery specialist Professor Qun Wang has also joined Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, further strengthening the hospital's thoracic oncology program and expanding access to specialized, individualized care for patients with thoracic tumors. (Source: Shanghai GoBroad Cancer Hospital)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Every newly approved medicine, original research program, specialist appointment, and improvement in the care system helps move treatment forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These developments may not immediately change every patient's current treatment plan. But over time, they can broaden the range of available options, improve the quality and continuity of care, and create more possibilities for what comes next.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It is important to remember that every new drug and new technology has specific approved indications and eligibility criteria. Whether a treatment is appropriate should be assessed by a specialist based on the disease type and stage, previous treatments, overall health, and relevant test results.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We will continue to follow new drugs, technologies, and research developments in hematology and oncology and share the updates that may matter most to patients and families.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":489,"title":490,"summary":491,"cover":492,"category":438,"publishedAt":173,"contentHtml":493,"hasAlternate":73,"updatedAt":432},"car-t-therapy-balance-art-experience","Why Does CAR-T Treatment Require Experience? The Art of Finding the Right Balance","Dr. Su LI of GoBroad Shanghai Liquan Hospital explains why CAR-T treatment requires a careful balance between cell expansion and treatment-related risks, and why clinical experience matters throughout the entire treatment journey.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fdad97005d8188b291c2743a9c177a634.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Drawing on extensive clinical experience, Dr. Su LI, Director of the Department of Hematology at GoBroad Shanghai Liquan Hospital, explains how CAR-T therapy works, how cytokine release syndrome (CRS) is assessed and managed, and how combination strategies may be used for high-risk patients. CAR-T treatment requires a delicate balance: insufficient expansion may limit efficacy, while excessive activation can increase the risk of serious adverse events. Through real-world cases, the article shows how experienced teams can adjust treatment in complex situations involving high-risk disease, older patients, and extramedullary lesions, with the goal of achieving deep responses while maintaining safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, CAR-T cell therapy has created new treatment possibilities for many patients with relapsed or refractory hematologic malignancies. But with this advanced treatment, sometimes described as a "living drug," success depends on much more than the day of cell infusion. It also relies on the medical team's ability to assess risk, monitor changes, manage complications, and make timely adjustments throughout the treatment process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At a recent patient education session, Dr. Su LI, Director of the Department of Hematology and the Myeloma Center at GoBroad Shanghai Liquan Hospital, used real clinical cases to explain some of the complex science behind CAR-T therapy in a clear and practical way, helping patients and families understand why experience matters.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. What Is CAR-T Therapy?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T is a form of cellular immunotherapy that uses genetic engineering to modify a patient's own T cells so they can recognize and attack specific tumor targets. In simple terms, the process has three main steps. First, T cells are collected from the patient. These immune cells are part of the body's natural defense system. Next, the cells are modified in the laboratory to express a chimeric antigen receptor, or CAR, which helps them recognize a specific target on tumor cells. Finally, the engineered CAR-T cells are infused back into the patient, where they can expand, identify target-bearing tumor cells, and help eliminate them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Why Is CAR-T Treatment an Art of Balance?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Li explains that CAR-T treatment involves a delicate balance between efficacy and risk. Ideally, the infused cells expand enough in the body to control the tumor, but not so aggressively that they trigger severe treatment-related toxicity. Managing that balance is one of the areas where an experienced clinical team can make a major difference.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If CAR-T cells do not expand sufficiently, the antitumor effect may be limited. In this situation, the team may consider timely treatment adjustments to support a better response. On the other hand, excessive immune activation can lead to serious adverse events such as cytokine release syndrome (CRS) or neurotoxicity. Early recognition of warning signs, accurate grading, and timely intervention are therefore essential to patient safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. How Is Cytokine Release Syndrome (CRS) Managed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CRS is one of the most common adverse reactions associated with CAR-T therapy. Symptoms can include fever, fatigue, muscle aches, and other systemic effects. Some cases are mild, but severe CRS can become life-threatening if it is not recognized and treated promptly. To manage this risk, the team at GoBroad Shanghai Liquan Hospital uses a structured, stepwise approach across the treatment course:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Clinical understanding: Using accumulated clinical experience to recognize how CRS may develop and progress;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Early detection: Closely monitoring for subtle changes in symptoms and vital signs so warning signals can be identified as early as possible;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Accurate grading: Assessing severity using internationally recognized criteria together with clinical judgment to guide the next treatment decision;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Timely intervention: Providing individualized treatment and adjusting the approach dynamically to help patients move through the high-risk period as safely as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. High-Risk Patients Require Even More Clinical Experience\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients with a high tumor burden or central nervous system involvement may face additional challenges during CAR-T therapy. In these more complex situations, experience matters at every stage: anticipating potential risks before treatment, preparing contingency plans, and responding quickly when unexpected problems arise. This overall clinical capability can help improve treatment benefit while protecting patient safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Breaking Through a Treatment Challenge: Extramedullary Relapse and Combination Therapy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some patients with multiple myeloma develop extramedullary disease, meaning tumor deposits appear outside the bone marrow. In these cases, CAR-T therapy alone may not always provide sufficient control, and combination strategies may be considered. At GoBroad Shanghai Liquan Hospital, individualized approaches for extramedullary disease may include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T combined with radiotherapy to target localized extramedullary lesions;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T combined with autologous hematopoietic stem cell transplantation, using complementary treatment approaches to deepen the overall response.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A Strong Start: Paying Close Attention to Cell Collection Quality\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The starting material for CAR-T therapy is the patient's own T cells. Their number and functional quality can affect the manufacturing process and treatment outcome. For patients with relapsed or refractory disease, previous therapies may have reduced lymphocyte counts, making cell collection more challenging.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With extensive experience in cell collection, the Liquan team focuses on choosing the right collection window, making adjustments in advance when needed, and following standardized quality-control procedures to build a strong foundation for treatment from the very beginning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Clinical Practice: Managing Complex Cases and Using Combination Strategies\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Through several representative cases, Dr. Li illustrated how the team manages difficult situations involving high-risk disease, extramedullary involvement, and older patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When CAR-T cell expansion is insufficient or immune activation becomes excessive, close monitoring and flexible treatment adjustments may help patients move past these treatment challenges. For patients with large, high-risk extramedullary masses, carefully selected combination therapy can help control local disease. The team has also treated a 73-year-old patient with multiple underlying health conditions who achieved a deep response with acceptable treatment tolerance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These cases highlight that CAR-T outcomes depend not only on the cell product itself, but also on how the entire treatment course is managed: anticipating risks, intervening at the right time, and understanding the differences between individual patients. This combination of clinical judgment and multidisciplinary care can help extend CAR-T treatment to some patients who may previously have been considered especially difficult to treat because of age, disease burden, or other risk factors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>CAR-T treatment is not a single event. It brings together advanced technology and day-to-day clinical decision-making. As Dr. Li emphasizes, an experienced team is important for finding the right balance between efficacy and safety, with the goal of helping each patient achieve the best possible and most durable treatment outcome.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>",{"slug":495,"title":496,"summary":497,"cover":498,"category":438,"publishedAt":499,"contentHtml":500,"hasAlternate":73,"updatedAt":74},"drug-eluting-microsphere-embolization-therapy","A Precision, Minimally Invasive Approach to Cancer: Drug-Eluting Microsphere Embolization","Drug-eluting microsphere embolization combines blockage of the tumor blood supply with sustained local drug release, offering a minimally invasive treatment option for selected patients with advanced, metastatic solid tumors who may have limited tolerance for intensive systemic therapy.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F510d4c1067eeca5ae2aae2597180c6ed.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-06-26","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This article introduces drug-eluting microsphere embolization, a minimally invasive treatment approach used in selected advanced solid tumors. Through a fine catheter, drug-loaded microspheres are delivered into arteries supplying the tumor. The treatment combines two mechanisms: embolization to reduce the tumor blood supply and sustained local release of chemotherapy, which can continue within the treated area for more than one month. Using a clinical case as an example, the article compares this approach with conventional systemic chemotherapy in terms of systemic side effects, duration of local tumor control, and procedural burden, and discusses its potential role for patients whose disease has progressed after multiple lines of treatment and whose overall condition makes more intensive therapy difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many patients with advanced solid tumors face increasingly difficult treatment decisions, especially when the cancer has spread to multiple sites, has continued to progress after several rounds of chemotherapy or interventional treatment, and the body is becoming less able to tolerate further intensive therapy. Systemic chemotherapy may cause substantial side effects, conventional interventional approaches may provide limited control, and surgery may no longer be feasible. For highly proliferative tumors that are prone to progression, one important clinical goal is to find treatments that can target the disease more precisely while minimizing additional physical burden. This article uses a real clinical case to explain a minimally invasive option for selected advanced solid tumors: drug-eluting microsphere embolization.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Drug-Eluting Microsphere Embolization Works\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Drug-eluting microsphere embolization is a catheter-based, minimally invasive treatment that does not require open surgery. Through a puncture site, a fine catheter is guided into the arteries supplying the tumor, where large numbers of drug-loaded polymer microspheres are delivered. These microspheres work through two complementary mechanisms. First, embolization reduces the tumor blood supply by blocking small vessels that feed the lesion, limiting the delivery of oxygen and nutrients and helping suppress tumor growth. Second, the microspheres remain within the treated area and gradually release chemotherapy over time, creating a high local drug concentration while reducing systemic exposure compared with conventional intravenous chemotherapy. This approach is particularly relevant to selected hypervascular solid tumors and may also be considered in some patients whose disease has progressed after standard treatment or who have limited tolerance for further intensive systemic therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Clinical Case: Treatment Challenges and the Potential Role of Drug-Eluting Microsphere Embolization\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient in this case had a pancreatic neuroendocrine tumor with multiple liver metastases. The Ki-67 index - an immunohistochemical marker used to estimate how actively tumor cells are proliferating - was 35%, indicating a highly proliferative tumor with a substantial risk of progression. The patient had a long treatment history and limited benefit from conventional approaches, including biopsy of a liver lesion, conventional transarterial intervention, first-line CAPTEM chemotherapy, and 12 cycles of second-line FOLFOX chemotherapy. Disease control remained unstable, fluctuating between stable disease and partial response. In 2026, the disease continued to worsen, with new peritoneal metastases, abdominopelvic fluid accumulation, suspected bone metastases, and tumor thrombus involving the portal and splenic veins. Despite two further vascular interventional procedures and intraperitoneal cisplatin, the patient continued to experience poor appetite, weight loss, and declining overall condition. Against this background, drug-eluting microsphere embolization was considered as a way to address some of the limitations of previous treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>01 Reducing Systemic Treatment Burden in a Patient with Limited Physical Reserve\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient had already received multiple cycles of first- and second-line systemic chemotherapy. Prolonged systemic treatment had been accompanied by poor appetite, weight loss, and deterioration in overall condition. Because conventional chemotherapy circulates throughout the body rather than remaining confined to the tumor, it can affect normal tissues as well as cancer cells and may cause adverse effects such as nausea, fatigue, and further physical depletion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With drug-eluting microsphere embolization, chemotherapy is delivered primarily to the local tumor area, such as liver metastases, while systemic exposure may be lower than with conventional intravenous chemotherapy. For selected patients, this may help reduce the overall treatment burden and preserve physical function and quality of life. The degree of benefit and toxicity still depends on the individual patient, the drug used, the treated area, and the overall treatment plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>02 Sustained Local Drug Release for More Durable Tumor Control\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this case, previous chemotherapy and conventional interventional treatment had not provided stable, lasting disease control. The source article attributes part of this challenge to the relatively limited duration of effect from earlier treatments: systemically administered chemotherapy is metabolized over time, while conventional embolization may provide only temporary interruption of the tumor blood supply. In a highly proliferative tumor, residual cancer cells may then continue to grow, contributing to repeated progression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Drug-eluting microspheres can continue releasing chemotherapy within the treated lesion for more than one month, providing sustained local drug exposure. The goal is to maintain pressure on highly active tumor cells for a longer period and improve the stability of local disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>03 Minimally Invasive and Potentially Repeatable\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient had already undergone multiple interventional procedures, chemotherapy, and intraperitoneal treatment and had limited tolerance for major surgery or highly intensive systemic therapy. Drug-eluting microsphere embolization is performed through a small puncture site, typically under local anesthesia. Recovery may be relatively quick, and some patients are able to get out of bed the following day, with a comparatively short hospital stay.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The procedure may also be repeated when clinically appropriate. For a patient with multiple liver metastases and tumor thrombus, staged or repeated minimally invasive treatment may provide another way to manage local disease over time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>04 A Potential Option for Selected Complex Metastatic Disease\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The main disease burden in this case was multiple liver metastases, which were described as hypervascular lesions. This type of tumor can be suitable for arterial embolization-based treatment in selected patients. Age, overall fitness, prior treatment exposure, disease distribution, liver function, vascular anatomy, and other clinical factors still need to be assessed carefully before treatment. For this patient, the treating team considered drug-eluting microsphere embolization a potential option because of the extensive metastatic disease, reduced physical reserve, and limited benefit from previous treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>For this patient with a highly proliferative pancreatic neuroendocrine tumor, multiple metastases, progression after several lines of therapy, and declining physical condition, drug-eluting microsphere embolization was considered one of the treatment options that best matched the clinical situation. The approach combines arterial embolization with sustained local chemotherapy, with the aim of reducing tumor blood supply while maintaining a longer local drug effect. In an appropriately selected patient, this may help limit systemic treatment burden while supporting control of liver metastases and other target lesions. As with any interventional cancer treatment, expected benefits, risks, and treatment goals should be assessed individually by a multidisciplinary team.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Advanced and metastatic cancer can be difficult to treat, but the range of minimally invasive interventional options continues to expand. For some patients whose disease has progressed after multiple lines of therapy or who have limited tolerance for further intensive treatment, carefully selected local therapies may offer another way to control disease and maintain quality of life. The most appropriate treatment should always be based on the tumor type, disease extent, previous treatment, organ function, and the patient's overall condition.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Patient Education Note:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">This article is intended for general medical and health education only. It does not constitute medical advice, a guarantee of treatment effectiveness, or a recommendation to seek care at any specific institution. Cancer treatment is highly individualized. Tumor type, stage, overall health, organ function, and previous treatment history can all affect treatment decisions. Any treatment plan should be developed by qualified specialists after a comprehensive evaluation. Patients should not use this article to self-diagnose or choose a treatment without professional medical advice.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":502,"title":503,"summary":504,"cover":505,"category":506,"publishedAt":507,"contentHtml":508,"hasAlternate":73,"updatedAt":74},"unrelated-hematopoietic-stem-cell-transplant-milestone","Seeds of Life, 100 New Beginnings: GoBroad Shanghai Zhaxin & Liquan Hospitals Reach 100 Unrelated HSCTs","GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital have completed their 100th unrelated hematopoietic stem cell transplant, marking a milestone made possible by volunteer donors from the China Marrow Donor Program (CMDP) and the dedication of multidisciplinary transplant teams.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ff3bfba60a1761d230fb90db11b14391e.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","Charitable Activities","2026-06-18","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In June 2026, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital completed their 100th unrelated hematopoietic stem cell transplant. Both are designated transplant hospitals within the China Marrow Donor Program (CMDP). Led by Dr. Chun WANG, the hospitals have completed more than 900 hematopoietic stem cell transplants over the past six years. This article explains the carefully coordinated process of an unrelated-donor search, from HLA matching and donor confirmation to stem cell collection, transport, infusion, and follow-up. It also highlights why unrelated donors can be especially important when a suitable family donor is unavailable. To date, 80 healthcare professionals from the hospitals have also registered with the CMDP as potential donors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F6201ab4936b30cf972e381078214792b_20260913225147.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6201ab4936b30cf972e381078214792b_20260913225147.png\" alt=\"2f75d018-4d41-44bc-aa61-2dbc9956b4f9.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What can a one-in-100,000 chance mean? Somewhere among millions of people, two strangers can become connected by a single bag of hematopoietic stem cells - a true "seed of life."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In June 2026, in the transplant ward at GoBroad Shanghai Zhaxin Hospital, hematopoietic stem cells carrying the hope of a new beginning were infused into a patient with severe aplastic anemia. The cells came from an unrelated donor she had never met. After a full matching process coordinated through the China Marrow Donor Program (CMDP), the donation traveled across the country and finally reached her bedside, bringing a new possibility for recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This was the hospitals' 100th unrelated hematopoietic stem cell transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From the first case to the 100th, and from 355 donor searches to 100 successful infusions, every number represents far more than a clinical milestone. Behind it are volunteer donors, coordinators, clinicians, nurses, laboratory professionals, and many others working together to give patients another chance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital are comprehensive hospitals with a strong focus on hematologic diseases, and both are designated hematopoietic stem cell collection and transplant hospitals within the China Marrow Donor Program. Over the past six years, the transplant program has been led by Dr. Chun WANG, former Director of the Department of Hematology at Shanghai General Hospital. Together with a core multidisciplinary team with extensive tertiary-hospital experience, the hospitals have made hematopoietic stem cell transplantation a key part of care for complex and high-risk blood disorders. To date, they have completed more than 900 hematopoietic stem cell transplants, including unrelated-donor procedures, across a wide range of complex hematologic conditions. The hospitals have also developed an integrated care system spanning transplantation, cellular therapy, post-transplant management, multidisciplinary care, and specialized nursing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Within those more than 900 transplants, the 100th unrelated-donor transplant marks a particularly meaningful milestone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>01 What Is an Unrelated Donor Search? A Carefully Coordinated Path from Match to Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">An unrelated donor search is a tightly coordinated process involving authorized transplant hospitals and the China Marrow Donor Program. Hospitals that participate in the CMDP network must meet defined qualification requirements and have dedicated coordinators who stay in close contact with the registry. The process can include searching for a potential unrelated donor, confirming HLA compatibility, coordinating stem cell collection, arranging safe transport to the transplant center, completing the transplant, and supporting long-term follow-up. Each step depends on careful communication, timing, and quality control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Finding a fully HLA-matched unrelated donor can still be challenging because human leukocyte antigen (HLA) types are highly diverse. The source article cites the chance of finding a fully matched unrelated donor as approximately one in 100,000. For a patient and donor who have never met, that rare match can create a life-changing connection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fbdd00fbd2e0ed0d195b592543d500245_20260913225228.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"bdd00fbd2e0ed0d195b592543d500245_20260913225228.png\" alt=\"8f53124a-47c9-4846-8c55-4b8cee435c0e.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 16px;\"> \u003Cstrong style=\"text-align: center;\">02 When a Family Donor Is Not Available, an Unrelated Donor May Open Another Path\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Finding a suitable donor has long been one of the biggest challenges in hematopoietic stem cell transplantation. Today, advances in haploidentical transplantation mean that donor options are no longer limited to fully matched relatives. However, some patients still cannot use a family donor - for example, an only child without siblings, or a family in which inherited genetic abnormalities make a related donor unsuitable. In these situations, an unrelated donor may become an especially important, and sometimes the only feasible, transplant option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The China Marrow Donor Program continues to expand. The source article reports a registry of more than 3.78 million potential donors. Each person who registers creates another possibility for a patient in need. Combined with advances in modern transplantation, unrelated-donor transplantation can offer an important treatment pathway for patients who otherwise have limited donor options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>03 Beyond Clinical Care: A Commitment to Donation and Social Responsibility\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Since their establishment, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital have incorporated social responsibility into their medical mission. The hospitals regularly organize voluntary blood-donation activities and hematopoietic stem cell donor-registration drives.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To date, 80 healthcare professionals from the hospitals have provided blood samples and formally registered with the China Marrow Donor Program as potential donors. In May 2023, a hematologist from GoBroad Shanghai Zhaxin Hospital went one step further and donated hematopoietic stem cells to a patient they had never met. This act of generosity reflects GoBroad's patient-centered philosophy: "The Needs of the Patient Come First."\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5bb39f4026fb04f8c7eab7007d95f1d3_20260913225301.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5bb39f4026fb04f8c7eab7007d95f1d3_20260913225301.png\" alt=\"307b9bf7-1821-4ee0-b839-e4e55d74172e.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cem>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>The 100th Transplant Is a Milestone - and a New Starting Point\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\u003Cp style=\";\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F13960260031af286bbe13afbce8fcf5f_20260913225338.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"13960260031af286bbe13afbce8fcf5f_20260913225338.png\" alt=\"341e064a-a2d9-4ed5-bfe8-1e8de0b5cbff.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Reaching 100 unrelated-donor transplants would not have been possible without close coordination at every stage. We extend our sincere appreciation to the professionals of the China Marrow Donor Program, every volunteer unrelated donor, and all those involved in transport, coordination, laboratory testing, nursing, and other behind-the-scenes work. Every contribution has helped make transplantation possible for patients and families facing serious blood disorders.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As they move forward from this 100-case milestone, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital will continue to work closely with the China Marrow Donor Program and partners across the community. Guided by the principle that "The Needs of the Patient Come First," the hospitals will continue strengthening transplant care while bringing compassionate support to more patients with hematologic diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From the first unrelated-donor transplant to the 100th, and from zero to more than 900 hematopoietic stem cell transplants overall, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital continue to build experience in caring for patients with complex blood disorders - combining clinical expertise with long-term, patient-centered care.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":510,"title":511,"summary":512,"cover":513,"category":438,"publishedAt":514,"contentHtml":515,"hasAlternate":73,"updatedAt":74},"autologous-stem-cell-collection-faq-guide","What Should You Know Before Autologous Stem Cell Collection? 21 Questions Patients Ask Most Often","This Q&A walks patients through the full autologous stem cell collection process and answers 21 common questions about mobilization injections, the collection procedure, recovery afterward, and special situations in which collection may need to be delayed or adjusted.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F099e0153a4bd3e3946a5a1dd6109343d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-06-16","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Designed for patients and families preparing for autologous stem cell transplantation, this article answers 21 frequently asked questions in a practical Q&A format. Topics include managing side effects from stem cell mobilization with G-CSF, diet and daily routine during mobilization, what to expect during the 3-5-hour peripheral blood stem cell collection procedure, how tingling in the hands or feet is managed, how collected stem cells are cryopreserved and how long they can be stored, and how collection plans may be adjusted for older adults, patients with low body weight, impaired kidney function, and other special circumstances. The goal is to help patients understand each step and feel more prepared for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients and families preparing for autologous stem cell transplantation often have many questions about stem cell collection: Why is it needed? What happens during the procedure? Will it affect the body?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Autologous stem cell collection is a well-established and generally safe procedure. To help patients feel more prepared, we have put together answers to 21 questions that come up most often, covering mobilization injections, the collection process, recovery afterward, and special considerations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Common Questions About Autologous Stem Cell Collection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: What is autologous stem cell collection, and why are my own stem cells collected?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Autologous collection means collecting healthy hematopoietic stem cells from your own blood in advance and storing them at very low temperatures. After high-dose chemotherapy or conditioning treatment, the stem cells are infused back into your body to help the bone marrow restore blood cell production more quickly and reduce the risk of severe bone marrow suppression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It is commonly used for patients with lymphoma, multiple myeloma, neuroblastoma, and some high-risk or refractory solid tumors when autologous transplantation is part of the treatment plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: Stem cells normally stay in the bone marrow. How are they collected?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before collection, your doctor will first mobilize the stem cells. Granulocyte colony-stimulating factor (G-CSF) is usually given by subcutaneous injection for 3-5 days to encourage stem cells to move from the bone marrow into the peripheral blood. Your blood counts and peripheral blood CD34+ cell level will be monitored regularly. Collection can begin once the target level is reached.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: Are stem cells collected only through the bloodstream? Do I need a bone marrow harvest?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Peripheral blood collection using an apheresis machine is now generally preferred. Blood circulates through the machine outside the body, the stem cells are separated out, and the remaining blood components are returned to you. A bone marrow harvest under general anesthesia is not routinely needed. If your peripheral veins are not suitable, a central venous catheter may be placed for collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5a2dd78b0791e5b75faea6a29391ccf9_20260913074426.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5a2dd78b0791e5b75faea6a29391ccf9_20260913074426.png\" alt=\"df0bd53d-b695-453d-b009-2ad642b77da1.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: What symptoms can mobilization injections cause? Are the side effects serious?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Common reactions include aching or bone pain in the lower back, pelvis, arms, or legs, fatigue, and a mild fever - often similar to flu-like symptoms. These effects are usually temporary and often resolve within 2-3 days after the medication is stopped. Pain relief can be used if needed. According to the article, mobilization does not cause permanent organ damage or affect fertility. A small number of patients may also experience mild fatigue or reduced appetite.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q5: What should I pay attention to with diet and daily routine during mobilization?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Stay well hydrated, avoid staying up late, avoid strenuous exercise, and eat enough protein. The article recommends drinking more than 2,000 mL of fluids a day and choosing protein-rich foods such as eggs, lean meat, and milk, while keeping meals relatively light and avoiding very greasy or spicy foods. Try to get adequate sleep and avoid vigorous activity or injuries that could lead to bleeding. You do not need to fast.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q6: What if not enough stem cells are released after mobilization?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the peripheral blood CD34+ cell count remains low, your doctor may add plerixafor to support mobilization and repeat the assessment 1-2 days later before collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q7: How long does one autologous stem cell collection session take?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A single collection usually takes about 3-5 hours. You will remain lying down while blood is drawn through an arm vein or femoral vein and processed automatically by the apheresis machine. Most patients reach the target stem cell dose after one or two collection sessions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q8: Can stem cell collection cause major bleeding?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After the apheresis machine separates the stem cells, the remaining red blood cells and plasma are returned to your body. The procedure itself does not remove large amounts of blood and is not expected to cause anemia or major bleeding. The basic principle is similar to other forms of extracorporeal blood processing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q9: Why do my hands, feet, or lips sometimes tingle during collection? What can be done?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The anticoagulant citrate used during collection can temporarily lower the calcium level in the blood, causing tingling or numbness around the lips, hands, or feet. Oral calcium taken in small amounts or intravenous calcium can usually relieve the symptoms quickly, and they generally resolve after collection ends.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q10: What if my veins are difficult to access?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the veins in both arms are not suitable, a central venous catheter may be placed in the internal jugular or subclavian vein before collection. In some cases, radial artery access may be established. These access routes allow blood to flow to and from the collection circuit and can reduce the need for repeated needle sticks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q11: Is stem cell collection painful?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The experience can feel different at three stages:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Needle insertion: There is usually only a brief sting when the IV needle is inserted, similar to a routine blood draw or infusion. Local anesthetic is used when a central venous catheter is placed. For patients who cannot cooperate with the procedure, intravenous analgesia or anesthesia may be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. During the 3-5-hour machine collection: You mainly need to remain lying down, and there is usually no significant pain. Tingling in the hands, feet, or lips may occur because citrate can temporarily lower calcium levels; this usually improves quickly with calcium replacement and is not considered pain.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Bone pain from mobilization is not the same as pain from collection. G-CSF injections may cause aching in the lower back or bones during the mobilization phase, but for many patients this has already eased by the day of collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F2127a2d0a23be7df3d28302853848cfd_20260913074454.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"2127a2d0a23be7df3d28302853848cfd_20260913074454.png\" alt=\"4d726d1e-568e-46d1-b357-b75ddcfeb591.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q12: Do I need to fast on the day of collection? When can I eat or drink?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">No fasting is required. You can eat your usual meals and drink fluids in moderation, while avoiding very heavy or greasy food. Small amounts of water and light snacks may be taken during collection. It is also helpful to empty your bladder before the procedure begins.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q13: How long does it take to recover after stem cell collection?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Bone pain related to mobilization usually improves within 1-3 days, while fatigue often gets better gradually over 3-7 days. Blood counts generally return to baseline in about a week. The collection does not permanently damage the bone marrow's ability to make blood cells, and hematopoietic stem cells can regenerate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q14: How are the collected stem cells stored, and how long can they be kept?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A cryoprotective agent is added to the collected stem cells, which are then stored in liquid nitrogen at -196°C. They can be kept for years - sometimes more than a decade - and are thawed and infused when it is time for transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q15: If one collection is not enough, will collecting again the next day harm my body?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the first collection does not yield enough cells, your doctor may arrange another collection based on your individual situation. A second collection is used to reach the stem cell dose needed for transplantation and generally does not cause significant additional harm to the body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q16: How should I care for bruising or oozing at the needle site after collection?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Keep firm pressure on the puncture site and the pressure dressing in place for about 3-4 hours, and keep the area dry for 24 hours. A small bruise can be managed with a cold compress. If bleeding or oozing continues, contact the medical team promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>When Stem Cell Collection May Need to Be Delayed: Contraindications and Special Situations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q17: In what situations should stem cell collection be postponed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Collection should generally be delayed in patients with severe heart, lung, or kidney failure; an uncontrolled serious infection; an uncorrected coagulation disorder; or an acute active thrombosis. After the underlying problem has been medically optimized, the patient can be reassessed for collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q18: Can older adults or patients with low body weight undergo stem cell collection?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Yes. The medical team can individualize the plan after assessing heart and lung function, liver and kidney function, and coagulation status. The amount of blood processed and the duration of collection can be adjusted, and machine settings can be tailored for children or patients with low body weight. Dongguan Taixin Hospital \u002F GoBroad Chunfu Institute of Hematology & Oncology is a member collection center of the China Marrow Donor Program. From the opening of the department in July 2018 through June 2026, the center completed 1,265 hematopoietic stem cell collections. The smallest patient weighed 8.9 kg, and the youngest was 11 months old.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Special Considerations for Autologous Stem Cell Collection in Patients With Neuroblastoma (NB)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q19: How successful is stem cell collection in patients with neuroblastoma?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With standardized treatment, the overall collection success rate for high-risk neuroblastoma is reported in the article as above 90%. Mobilization with G-CSF after two or three cycles of standard induction chemotherapy has a reported success rate of 92%-95%. During bone marrow recovery after chemotherapy, large numbers of stem cells enter the bloodstream, and most patients can collect the target dose in one or two sessions. A CD34+ cell dose of at least 2 × 10^6\u002Fkg is generally sufficient for a single transplant, while the target for tandem transplantation is at least 5 × 10^6\u002Fkg.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Main reasons collection may fail or fall short of the target include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Too many prior cycles of chemotherapy or chemoimmunotherapy, resulting in significant bone marrow injury\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Tumor involvement of the bone marrow or a high level of residual tumor in the marrow\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Bone marrow damage from radiotherapy\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Repeated severe infections\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with these risk factors, the medical team may consider rescue mobilization with plerixafor after evaluation. The article reports a collection success rate of about 50%-60% after combination mobilization in this setting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q20: What if one round of mobilization does not produce enough cells? What should I know about trying again?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">① If the peripheral blood CD34+ count is low: plerixafor may be added, with an additional collection later the same day or the next day.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">② If the total yield from the current round remains insufficient: another collection may be planned after the next cycle of chemotherapy or chemoimmunotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Collection should be postponed when there is extensive tumor involvement of the bone marrow, within 3 months after radiotherapy, during a severe infection with fever, or when there is significant liver or kidney dysfunction.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q21: What laboratory results are checked before collection? (Blood tests and flow-cytometry thresholds)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Blood count requirements after G-CSF mobilization and before starting apheresis\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">WBC ≥5.0 × 10^9\u002FL; neutrophils >2.0 × 10^9\u002FL; platelets (PLT) ≥80 × 10^9\u002FL. If the platelet count is too low, the risk of bleeding during collection may be higher and platelet support may be prepared as clinically appropriate. Hemoglobin (Hb) should be >90 g\u002FL, without moderate or severe anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Key factor:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Peripheral blood CD34+ cells measured by flow cytometry. Blood counts are monitored regularly after G-CSF, and a peripheral blood CD34+ level of ≥20 cells\u002FμL is used in the article as a threshold for starting a single-day collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Target total dose: a final cryopreserved CD34+ cell dose of ≥2.0 × 10^6\u002Fkg is considered adequate; ≥5 × 10^6\u002Fkg provides a larger collection and can support tandem transplantation, which is commonly used in neuroblastoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Organ function and infection-related requirements\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Liver and kidney function: ALT\u002FAST <2 times the upper limit of normal; creatinine and urea within the normal range; no severe hypoalbuminemia. There should be no active bacterial or viral infection, body temperature should be normal, CRP and procalcitonin should be within the expected range, coagulation function should be generally acceptable, and there should be no active bleeding or thrombosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Bone marrow status: A repeat bone marrow aspiration is needed before collection to assess measurable residual disease (MRD).\u003C\u002Fspan>\u003C\u002Fp>",{"slug":517,"title":518,"summary":519,"cover":520,"category":430,"publishedAt":521,"contentHtml":522,"hasAlternate":73,"updatedAt":432},"car-t-therapy-tp53-mutation-large-b-cell-lymphoma-prognosis","Frontiers in Immunology | Prof. Kai Hu’s Team: CAR-T Cell Therapy May Mitigate the Adverse Impact of TP53 Mutations in Large B-Cell Lymphoma (LBCL)","A retrospective study by Prof. Kai Hu’s team, published in Frontiers in Immunology, found that CAR-T cell therapy was associated with a substantially higher objective response rate and longer overall survival in patients with relapsed\u002Frefractory large B-cell lymphoma (LBCL) harboring TP53 mutations.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ff087e5c9f9d0d0e43dbf1184980431b6.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-06-15","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Prof. Kai Hu’s team at Beijing GoBroad Hospital published a retrospective study in Frontiers in Immunology analyzing 195 patients with relapsed\u002Frefractory large B-cell lymphoma. The study found that, among patients with TP53 mutations, CAR-T cell therapy was associated with significantly better outcomes than chemotherapy-based treatment, including a higher objective response rate and longer overall survival. The researchers also explored how the location of TP53 mutations may affect prognosis, offering new insights into more precise treatment strategies in the CAR-T era.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">TP53 mutations have long been considered one of the most important adverse molecular prognostic markers in large B-cell lymphoma (LBCL) and have been strongly associated with poorer survival outcomes in the chemoimmunotherapy era. Whether this unfavorable prognostic effect persists in the era of CAR-T cell therapy, however, remains controversial, particularly because direct comparisons with non-CAR-T treatment cohorts have been limited.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, Rui Liu from Prof. Kai Hu’s team in the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital published a paper in Frontiers in Immunology titled “Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.” The study provides new insights into the use of CAR-T cell therapy for relapsed\u002Frefractory LBCL with TP53 mutations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F7f743af59f9fd64ca467bfde7c8b979f_20260914012601.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7f743af59f9fd64ca467bfde7c8b979f_20260914012601.png\" alt=\"6b1e8616-5dde-4371-bcd6-302a7ef002cd.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Research Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Kai Hu explained: “To better understand how TP53 mutations affect outcomes with CAR-T therapy in relapsed\u002Frefractory large B-cell lymphoma (LBCL), our center retrospectively analyzed 195 patients with R\u002FR LBCL who underwent next-generation sequencing (NGS). Among them, 151 received CD19-directed CAR-T cell therapy and 44 received chemotherapy-based non-CAR-T treatment. Patients were divided into four groups according to TP53 status and treatment modality. We also performed subgroup analyses based on TP53 mutation type—missense versus disruptive mutations—and the protein domain in which the mutation occurred.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Results\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Clinical Outcomes With Different Treatment Approaches\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study compared CAR-T therapy with conventional chemotherapy-based treatment across different TP53 mutation groups:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with TP53 mutations:\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Objective response rate (ORR): Significantly higher with CAR-T therapy (56.6% vs. 18.2%).\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Overall survival (OS): Median OS was 12.13 months in the CAR-T group, compared with only 2.20 months in the chemotherapy group (P<0.0001).\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with TP53 wild-type disease, CAR-T therapy also outperformed chemotherapy, with median OS of 25.15 months versus 8.28 months, respectively (P=0.0030) (Fig. 2A).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. CAR-T Outcomes According to TP53 Status\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among the 151 patients who received CAR-T therapy:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Similar response rates: The TP53-mutated and TP53 wild-type groups had comparable ORRs (56.6% vs. 45.9%) and complete response rates (CRR; 39.6% vs. 35.7%).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Differences in survival: Despite similar response rates, median OS (12.13 months) and median progression-free survival (PFS; 6.87 months) were shorter in the TP53-mutated group than in the wild-type group (OS, 25.15 months; PFS, 8.98 months).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Ff9c2623e3bada47c84b133559ccc0138_20260914012633.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"f9c2623e3bada47c84b133559ccc0138_20260914012633.png\" alt=\"a9383413-7b61-4761-9340-7042d68b3920.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Genomic Landscape and the Impact of Mutation Location\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mutation profile: TP53 was the most frequently mutated gene in the cohort (38.7%), followed by KMT2D (30.9%) and PIM1 (22.7%).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Why the mutation domain matters:\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">DNA-binding domain (DBD) mutations: 89% of TP53 mutations occurred in the DBD, and patients with these mutations had poorer outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Non-DBD mutations: Patients with TP53 mutations outside the DNA-binding domain had significantly better OS than those with DBD mutations (median OS: not reached vs. 9.86 months; P=0.046).\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mutation type: No significant survival difference was observed between missense and disruptive mutations, such as truncating mutations.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Histologic interaction: Among patients with TP53 mutations, those with high-grade B-cell lymphoma (HGBL) and double-\u002Ftriple-hit features showed a trend toward poorer survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Ffa2ea651c858a01550b6b9df2284d2bf_20260914012658.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"fa2ea651c858a01550b6b9df2284d2bf_20260914012658.png\" alt=\"ec3b1dfa-5fd5-4e30-a752-3a487e674725.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Kai Hu noted that the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital has accumulated extensive experience with CAR-T therapy in recent years. As the number of real-world CAR-T cases continues to grow, the clinical challenges are becoming increasingly complex. In clinical practice, patients with TP53 mutations are often highly resistant to chemotherapy, while CAR-T therapy can provide meaningful benefit for some of these patients. Going forward, important priorities in hematologic oncology include choosing the right timing for CAR-T therapy and developing more individualized, precise, and longitudinal management strategies. By integrating clinical, pathologic, molecular, and imaging data, clinicians may be able to identify earlier which patients with relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) who do not respond to conventional treatment could benefit from precision CAR-T approaches. Monitoring tools such as circulating tumor DNA (ctDNA) may also help detect signs of relapse earlier, allowing earlier intervention and potentially extending survival.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":524,"title":525,"summary":526,"cover":527,"category":438,"publishedAt":198,"contentHtml":528,"hasAlternate":73,"updatedAt":432},"anemia-microcytic-anemia-explained-experts","Dr. Liping JING & Dr. Wenrui YANG: Anemia and Microcytic Anemia - What You Need to Know","Two hematology specialists explain the common types of microcytic anemia, key points in differential diagnosis, and practical home-care considerations, with particular emphasis on distinguishing iron-deficiency anemia from anemia of chronic disease.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F0a4b419e76aca067992269bb17eb073b.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Liping JING and Dr. Wenrui YANG from the Anemia Diagnosis & Treatment Center at Beijing GoBroad Boren Hospital explain the common types of microcytic anemia, how they are differentiated, and how treatment approaches vary. The article reviews the three main causes and typical symptoms of iron-deficiency anemia, explains why ferritin is an important clue when distinguishing anemia of chronic disease from iron deficiency, and introduces the diagnosis and day-to-day management of hereditary spherocytosis and thalassemia. The goal is to help children with hematologic or oncologic conditions and their families better understand and manage anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To help children with hematologic or oncologic conditions and their families better understand the common causes of microcytic anemia, how it is recognized, how it may relate to an underlying disease, and what monitoring and home-care measures may be appropriate, we invited Dr. Liping JING and Dr. Wenrui YANG from the Anemia Diagnosis & Treatment Center at Beijing GoBroad Boren Hospital to answer some common questions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. What Is Anemia? What Is Microcytic Anemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Anemia is more than simply "looking pale." Medically, anemia means that the red blood cell count, hemoglobin level, or hematocrit is below the normal range for a person's age, sex, and altitude.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So what does "microcytic anemia" mean? When you look at a complete blood count (CBC), in addition to hemoglobin and platelets, two red blood cell indices are especially useful:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. MCV (mean corpuscular volume): This reflects the average size of red blood cells. In adults, the usual reference range is about 80-100 fL; an MCV below 80 fL is generally considered microcytic. In children, the cutoff varies with age and can be lower; around 70 fL may fall into the microcytic range in younger children.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. MCHC (mean corpuscular hemoglobin concentration): This reflects the concentration of hemoglobin inside red blood cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When red blood cells are both smaller than usual and contain less hemoglobin, the pattern is called microcytic hypochromic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. What Are the Common Types of Microcytic Anemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Common causes include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Iron-deficiency anemia - the most common type\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Anemia of chronic disease, also called anemia of inflammation\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Thalassemia and hereditary spherocytosis\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Rare forms such as sideroblastic anemia\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Anemia caused by lead poisoning\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. Iron-Deficiency Anemia\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Put simply, iron-deficiency anemia occurs when the body does not have enough iron. Iron is a key building block for hemoglobin, the protein in red blood cells that carries oxygen. When iron is lacking, the body produces fewer red blood cells, and those cells tend to be smaller, paler, and less effective at carrying oxygen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Why does iron deficiency happen? There are three main reasons:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">1. Excessive blood loss - the most common cause\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Examples include heavy menstrual bleeding in women of reproductive age, gastrointestinal bleeding such as from peptic ulcers or hemorrhoids, and acute blood loss after trauma or surgery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">2. Low iron intake or poor absorption\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Examples include a long-term diet with insufficient iron-rich foods, or impaired absorption after major gastric or duodenal surgery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">3. Increased iron requirements\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Iron requirements increase during pregnancy and breastfeeding, and in growing children as blood volume expands and the body develops.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Symptoms Can Iron-Deficiency Anemia Cause?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ General symptoms: weakness, easy fatigue, dizziness, ringing in the ears, palpitations, and shortness of breath with activity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Physical changes: pale or sallow skin, reduced complexion, thin nails, and pale inner eyelids.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ In children: difficulty concentrating and reduced memory or attention.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Other characteristic symptoms: pica (craving non-food substances such as soil or plaster), spoon-shaped nails (koilonychia), restless legs syndrome, cracks or inflammation at the corners of the mouth, and difficulty swallowing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. Anemia of Chronic Disease (Anemia of Inflammation)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Anemia of chronic disease, also known as anemia of inflammation, is caused by an underlying condition. Chronic infection, inflammatory disease, cancer, and rheumatologic or autoimmune disorders can all contribute.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What is happening in the body?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The mechanism is different from true iron deficiency. In iron-deficiency anemia, the body genuinely does not have enough iron. In anemia of chronic disease, iron may be present in adequate or even increased amounts, but inflammation causes much of it to be sequestered and less available to the bone marrow for red blood cell production. This is sometimes described as impaired iron utilization.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Inflammation can also suppress erythropoietin (EPO) production and shorten red blood cell survival. The result may also present with a microcytic, hypochromic pattern.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How Can Anemia of Chronic Disease Be Distinguished from Iron-Deficiency Anemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ferritin is an important clue:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Iron-deficiency anemia: ferritin is typically low.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Anemia of chronic disease: ferritin is often normal or elevated.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This distinction matters because the treatment approaches are different. Ferritin should still be interpreted together with the overall clinical picture and other iron studies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How Is Anemia of Chronic Disease Treated?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Treat the underlying disease - this is the cornerstone of management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ In selected patients, treatment may include erythropoiesis-stimulating therapy such as EPO or roxadustat.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Iron supplementation is generally considered when true iron deficiency is also present.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. Hereditary Spherocytosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hereditary spherocytosis is a genetic red blood cell disorder. The name is long, but the key idea is simple: the red blood cells become spherical rather than having their usual biconcave-disc shape.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Genetic changes affect proteins in the red blood cell membrane skeleton. As a result, the cells become rounder, less flexible, and more fragile. They have difficulty passing through the spleen and are more likely to be trapped and destroyed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Hereditary spherocytosis can be inherited in different ways:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ About 75% of cases follow a dominant inheritance pattern, meaning one parent may also be affected, sometimes so mildly that the condition has never been recognized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ The remaining cases may involve recessive inheritance or a new spontaneous genetic change.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Symptoms Can Hereditary Spherocytosis Cause?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Severity varies widely. Some people have such mild disease that it is never diagnosed, while others develop significant anemia from childhood. Common features include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Anemia and jaundice due to increased bilirubin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ An enlarged spleen, which is common in affected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Gallstones caused by excess bilirubin released during red blood cell breakdown.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How Is Hereditary Spherocytosis Diagnosed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ CBC findings may include a low MCV and MCH with a normal or elevated MCHC, producing a relatively hyperchromic pattern.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ A peripheral blood smear may show spherocytes, sometimes accounting for more than 15% of red blood cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Further testing may include an eosin-5-maleimide (EMA) binding test by flow cytometry or genetic testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How Is Hereditary Spherocytosis Treated?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Splenectomy can reduce red blood cell destruction and is an effective treatment for selected patients, but not everyone needs surgery. Splenectomy is generally avoided in young children, especially those under 6 years of age, because the spleen plays an important role in immune defense and removing it too early can increase the risk of serious infection. Mild cases may only require observation. Infection prevention is also important because infections can trigger hemolytic or aplastic crises.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>6. Thalassemia\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Why Is It Called Thalassemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The name comes from the fact that the condition was first recognized around the Mediterranean. The genetic variants that cause thalassemia became more common in regions where malaria was historically widespread because carrying certain thalassemia traits could provide some protection against severe malaria. Today, however, those same variants can cause clinically significant anemia in affected individuals.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Where Is Thalassemia More Common in China?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Thalassemia is most common south of the Yangtze River, particularly in Guangdong, Guangxi, and Hainan, and is also seen frequently in Yunnan, Guizhou, Sichuan, and Jiangxi. According to the figures cited in the source article, alpha-thalassemia carrier rates exceed 40% in Hainan and approach 25% in Guangxi. With population movement, sporadic cases are now also seen in northern China.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. What Causes Thalassemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Normal adult hemoglobin is made from two alpha-globin chains and two beta-globin chains. In thalassemia, genetic changes reduce or prevent production of either the alpha or beta chains. The resulting imbalance produces abnormal hemoglobin and unstable red blood cells that are more easily destroyed, leading to hemolytic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. What Is Alpha-Thalassemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Alpha-thalassemia is most often caused by gene deletions. Each person normally has four alpha-globin genes - two inherited from each parent. The clinical picture depends largely on how many genes are affected:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Silent carrier: Three genes function normally and one is affected. There is usually little or no anemia, and the CBC may be close to normal, so the condition can easily be missed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Alpha-thalassemia trait: Two genes function normally and two are affected. There may be no anemia or only mild anemia, usually with a microcytic, hypochromic pattern.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Hemoglobin H (HbH) disease: Only one alpha-globin gene functions normally and three are affected. Babies may appear well at birth, but anemia and splenomegaly can develop after infancy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Hb Bart's hydrops fetalis: All four alpha-globin genes are absent or nonfunctional. This is the most severe form and can lead to fetal death or death soon after birth.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Important: Silent-carrier and mild thalassemia can easily be mistaken for iron-deficiency anemia. If iron supplementation does not improve the blood counts as expected, further evaluation may be needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. What Is Beta-Thalassemia?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Beta-thalassemia is often classified by clinical severity:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Mild \u002F carrier form (heterozygous): Symptoms are usually mild, and many people are unaware they have it. Mild jaundice or enlargement of the liver and spleen may occur.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Intermediate form: Severity falls between mild and severe disease, and anemia may worsen with age.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Severe form: Significant anemia usually develops in the first 1-2 years of life, can affect growth and bone development, and often requires long-term transfusion support.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How Is Thalassemia Treated?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Mild disease \u002F silent carrier state: Treatment is usually not required. General health and infection prevention remain important because illness or other physiologic stress can worsen hemolysis in some patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ For patients who require regular transfusions: transfusion programs may aim to maintain hemoglobin above about 90 g\u002FL to support normal growth and reduce skeletal complications in children. Long-term transfusion can cause iron overload, so iron chelation therapy may also be needed, using agents such as deferiprone, deferoxamine, or deferasirox.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Luspatercept: This medicine promotes late-stage red blood cell maturation and can reduce transfusion burden in some patients. The source article notes an approximately 33% reduction in transfusion burden and states that the drug has been included in China's medical insurance coverage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Hematopoietic stem cell transplantation: This can be a potentially curative option for patients with severe beta-thalassemia. The source article reports transplant success rates above 90% in appropriate patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Splenectomy: This may be considered in selected patients with massive splenomegaly, hypersplenism, or very high transfusion requirements, but it does not cure thalassemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Gene therapy: Clinical studies are ongoing, and some patients have achieved transfusion independence. However, access remains limited and treatment costs are high.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":530,"title":531,"summary":532,"cover":533,"category":438,"publishedAt":198,"contentHtml":534,"hasAlternate":73,"updatedAt":74},"allogeneic-stem-cell-transplant-donor-selection-guide","Dr. Tong Wu: How Donors Are Selected for Allogeneic Hematopoietic Stem Cell Transplantation","Dr. Tong Wu explains five key factors in donor selection for allogeneic hematopoietic stem cell transplantation: HLA matching, non-HLA factors, hematopoietic and immune function, inherited predisposition, and personal and family medical history.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ffe5541f33049aa968a7254f5688db666.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Donor selection can directly affect outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dr. Tong Wu of Beijing GoBroad Boren Hospital explains five major areas that should be considered: matching at 10 HLA alleles across HLA-A, -B, -C, -DR, and -DQ; non-HLA factors such as donor age, CMV\u002FEBV serostatus, sex, blood type, stem cell source and cell dose, and donor-specific HLA antibodies (DSA); the donor's hematopoietic and immune function; screening for inherited predisposition variants that may affect engraftment or increase the risk of donor-derived leukemia; and review of the donor's personal and family medical history. The article also outlines the usual order of donor preference and considerations for different disease settings.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>For patients preparing for allogeneic hematopoietic stem cell transplantation, choosing the right donor is an important part of the treatment plan and can influence transplant outcomes. Patients and families often have many questions about how donors are evaluated and prioritized. In this article, Dr. Tong Wu of Beijing GoBroad Boren Hospital explains the core principles and major factors involved in donor selection.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Allogeneic hematopoietic stem cell transplantation is used mainly for two broad groups of conditions. The first includes hematologic malignancies such as leukemia, myelodysplastic syndromes, lymphoma, and myeloma. The second includes nonmalignant disorders such as aplastic anemia and congenital immunodeficiency disorders.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Five major factors are considered when selecting a donor for allogeneic hematopoietic stem cell transplantation:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ HLA matching\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Non-HLA factors\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Hematopoietic and immune function\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Inherited genetic predisposition\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Personal and family medical history\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. HLA Matching\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before transplantation, HLA typing usually includes HLA-A, -B, -C, -DR, and -DQ. Because each locus has two alleles, this is commonly referred to as a 10\u002F10 HLA match.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A donor who matches at all 10 alleles is considered fully matched. A fully matched donor is often a sibling, although a 10\u002F10 matched unrelated donor may also be identified through a donor registry. In some cases, a 9\u002F10 matched unrelated donor may also be considered for transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to data from the Center for International Blood and Marrow Transplant Research (CIBMTR), each additional HLA mismatch in unrelated donor transplantation is associated with an approximately 10% reduction in post-transplant survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In experienced transplant centers, outcomes with a matched sibling donor and a haploidentical related donor can be comparable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. Non-HLA Factors\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If several donors meet the HLA requirements, how should the team choose among them?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Age: Donor age is one of the most important considerations after HLA matching. In unrelated donor transplantation, a donor who is 10 years younger has been associated with an approximately 3% improvement in survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) serostatus: Ideally, donor and recipient CMV IgG and EBV IgG status should be aligned. For example, a CMV IgG-positive patient would preferably receive cells from a CMV IgG-positive donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Sex: A female donor for a male recipient may increase the risk of graft-versus-host disease (GVHD), and a female donor with multiple prior pregnancies may increase GVHD risk in both male and female recipients. In pediatric haploidentical transplantation, a mother may be preferred over a father in some settings, which has been linked to long-term bidirectional microchimerism established during pregnancy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">ABO blood type: Donor-recipient ABO incompatibility usually has a limited effect on overall transplant outcomes and can often be managed by appropriate graft processing, such as red blood cell or plasma depletion. However, ABO mismatch may be associated with delayed hemolysis, delayed red-cell engraftment, or pure red cell aplasia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Stem cell source and cell dose: Stem cells may come from bone marrow (BM), peripheral blood stem cells (PBSCs), or umbilical cord blood. BM and PBSC transplantation can achieve similar survival outcomes. PBSCs generally engraft more quickly but are associated with a higher risk of chronic GVHD. An adequate stem cell dose is important for transplant outcomes. The article recommends more than 3 × 10^6 CD34+ cells\u002Fkg for PBSC grafts and more than 0.2 × 10^6 CD34+ cells\u002Fkg for cord blood grafts.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">HLA antibodies: Some patients have donor-specific HLA antibodies (DSA) in their serum. Testing is especially important when the donor and recipient are not fully HLA matched. A positive DSA result increases the risk of graft failure and may reduce post-transplant survival. If the only available donor is DSA-positive, antibody-reduction treatment may be needed before transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A commonly used international order of donor preference is: first, a matched sibling donor; second, a fully matched unrelated donor; and then a 9\u002F10 matched unrelated donor, a haploidentical related donor, or cord blood, depending on the clinical situation.\u003C\u002Fspan>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F9639e3f91609a7a953d35b92f387a186_20260913222540.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9639e3f91609a7a953d35b92f387a186_20260913222540.png\" alt=\"e708db67-0f31-4270-8621-a77e1f3bc5c6.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. Hematopoietic and Immune Function\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Transplantation rebuilds the recipient's hematopoietic and immune systems using cells from the donor. For this reason, the health and function of the donor's blood-forming and immune systems are important to transplant outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How can these functions be assessed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hematopoietic function can be evaluated through a complete blood count, bone marrow cellularity, and the proportion of CD34+ cells in the bone marrow. Immune function may be assessed through lymphocyte subsets, immunoglobulin levels, and markers such as granzyme and perforin in NK cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. Inherited Genetic Predisposition\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mutations acquired by tumor cells are called somatic mutations, while inherited or constitutional variants are referred to as germline variants.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some inherited predisposition variants can increase a person's risk of developing hematologic malignancies or solid tumors. In general, variants with a greater functional impact may be associated with disease developing at a younger age.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If a donor carries a clinically significant inherited predisposition variant, using that donor's stem cells may be associated with poor stem cell mobilization, graft failure, poor graft function, or, in rare cases, donor-derived leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. Personal and Family Medical History\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many people carry genetic variants of one kind or another. The key question is whether those variants have meaningful functional effects. This is one reason a careful personal and family medical history is important when evaluating a potential donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some people may consider themselves healthy because they have no major illness, while also having conditions such as asthma, hyperthyroidism, or psoriasis. These conditions may involve immune dysregulation and can be relevant when assessing whether someone is an appropriate donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Family history is reviewed for clustering of cancers or immune-related diseases, a history of infectious diseases, unexplained childhood deaths, and consanguinity, among other factors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ A matched sibling donor is generally the first choice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ For hematologic malignancies, matched unrelated and matched sibling donor transplantation can achieve similar disease-free survival. Among non-HLA factors in unrelated donor transplantation, donor age is particularly important, with younger donors generally associated with better outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ When choosing among a haploidentical related donor, a mismatched unrelated donor, and cord blood, the decision depends on the transplant center's experience, how urgently transplantation is needed, donor age, and DSA status.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ For nonmalignant hematologic diseases, bone marrow is generally preferred as the stem cell source because it is associated with less chronic GVHD and may support better long-term quality of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ In adults with hematologic malignancies, bone marrow and PBSC transplantation can achieve similar survival outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Selecting a donor with healthy hematopoietic and immune function and a favorable inherited genetic background can support post-transplant hematopoietic and immune recovery and may reduce complications such as GVHD, infection, and relapse, helping improve long-term disease-free survival.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":536,"title":537,"summary":538,"cover":539,"category":438,"publishedAt":540,"contentHtml":541,"hasAlternate":73,"updatedAt":432},"digestive-early-cancer-screening-high-risk-groups-guide","Bloating or Poor Appetite? Don’t Brush It Off — Early Gastrointestinal Cancers Can Be Easy to Miss","A practical guide to why early gastrointestinal cancers are easy to miss, four common screening approaches, and how high-risk groups are identified for colorectal, gastric, and esophageal cancers.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F114347c0ceba82a992605ffaee184bbf.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-06-06","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Early gastrointestinal cancers often cause few or no typical symptoms, and by the time clear discomfort appears, the disease may already be more advanced. This article explains why early gastrointestinal cancers can be difficult to detect and why early-stage disease may still be highly treatable. It compares four commonly used screening approaches — upper and lower GI endoscopy, fecal occult blood testing and stool DNA testing, tumor markers, and imaging — and outlines when each may be useful. Based on the 2025 edition of China’s Guidelines for Cancer Screening in Health Examination Institutions, it also summarizes criteria used to identify people at higher risk of colorectal, gastric, and esophageal cancers, helping readers better understand the value of screening and choose appropriate tests in time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Occasional bloating, abdominal discomfort, or loss of appetite is easy to dismiss as a minor stomach problem. Many people simply take some medication and wait for it to pass. At an annual checkup, some may even skip a digital rectal examination or avoid gastroscopy and colonoscopy because they worry about discomfort, inconvenience, or embarrassment. It is tempting to think that if there is no severe pain or obvious symptom, cancer must be far away. The reality is that many gastrointestinal cancers may not cause clear, typical symptoms until they have already progressed, potentially missing the best window for treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to 2022 cancer data released by China’s National Cancer Center, colorectal cancer, gastric cancer, and esophageal cancer rank among the ten most common cancers in China, placing second, fifth, and seventh respectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because early gastrointestinal cancers can be highly silent and may cause few typical symptoms, proactive screening, early detection, and timely evaluation are especially important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why Are Early Gastrointestinal Cancers So Easy to Miss?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The digestive tract is a continuous tube running from the mouth to the anus. The esophagus, stomach, and intestines are among the sites where gastrointestinal cancers commonly arise. Outside the mouth and throat, the wall of the digestive tract is generally described in four layers: the mucosa, submucosa, muscular layer, and outer layer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Early gastrointestinal cancer generally refers to cancer that remains confined to the superficial mucosal layer. A simple way to picture it is like damage that has affected only the surface of a wall without penetrating deeply or spreading elsewhere. At this stage, two features are especially important:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Symptoms can be very subtle. Many patients have no specific symptoms at all, or only mild bloating or reduced appetite. These signs can easily be mistaken for gastritis, enteritis, or another common digestive problem — or simply ignored.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Early disease may be highly curable. When the lesion remains localized and the risk of spread is very low, timely, appropriate treatment can lead to excellent outcomes. The article notes that five-year survival can exceed 90% in early-stage disease.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the early window is missed, cancer cells may invade deeper layers, spread, or metastasize, leading to advanced disease. Using gastric cancer as an example, the article notes a cure rate above 90% for early gastric cancer, compared with a five-year survival rate below 10% for advanced gastric cancer — underscoring why early detection and treatment matter.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Tests Are Used to Screen for Early Gastrointestinal Cancer?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some people have annual health checks yet still miss early gastrointestinal cancers because the right screening test was not included. Below are four commonly used screening approaches and the roles they may play:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Endoscopy (Gastroscopy and Colonoscopy): The Gold Standard for Early Detection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Endoscopy remains one of the most important tools for detecting early gastrointestinal cancer. Gastroscopy and colonoscopy allow doctors to directly examine the lining of the esophagus, stomach, and bowel. If a suspicious lesion is found, a tissue sample can be taken immediately for pathology to determine whether it is benign or malignant. In selected early lesions, minimally invasive endoscopic removal may also be performed during the same procedure, combining diagnosis and treatment with relatively limited trauma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people concerned about discomfort, sedation-assisted or anesthesia-supported endoscopy is now widely used. Patients should discuss the available options, suitability, and risks with their medical team rather than avoiding screening solely because of fear of pain.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Fecal Occult Blood Testing and Stool DNA Testing: Convenient Non-Invasive Screening Options\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Both are non-invasive screening approaches used for colorectal cancer. Fecal occult blood testing is inexpensive and easy to perform, making it a common first-line screening option. False-positive results can occur, so repeat testing or additional examinations may be needed. Stool DNA testing is another non-invasive option that may offer higher detection accuracy and is increasingly used in colorectal cancer screening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Tumor Markers: Helpful as Additional Information, but Not Diagnostic on Their Own\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Commonly used tumor markers in gastrointestinal cancers include carcinoembryonic antigen (CEA), CA19-9, CA72-4, CA125, and alpha-fetoprotein (AFP). These blood tests can provide supporting information, but they cannot confirm or rule out cancer on their own. An abnormal result does not automatically mean cancer is present, and a normal result cannot fully exclude early-stage disease. Tumor markers must therefore be interpreted together with other tests and cannot replace gastroscopy or colonoscopy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Imaging: An Important Complement for Deeper Abdominal Organs\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For cancers involving deeper abdominal organs, such as the liver or pancreas, ultrasound, CT, and other imaging tests may be used as part of risk assessment or early detection. These examinations complement endoscopy by evaluating areas that cannot be directly visualized through the gastrointestinal tract.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Who Is Considered at Higher Risk for Early Gastrointestinal Cancer?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Colorectal Cancer\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the 2025 edition of China’s Guidelines for Cancer Screening in Health Examination Institutions, higher-risk groups for colorectal cancer include people at increased risk of sporadic colorectal cancer and those with hereditary colorectal cancer syndromes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Higher Risk of Sporadic Colorectal Cancer\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Risk is scored using age, sex, first-degree family history, smoking history, and body mass index (BMI):\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Age 49 or younger: 0 points; age 50-59: 1 point; age 60 or older: 2 points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Female: 0 points; male: 1 point.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">History of smoking: 1 point; no smoking history: 0 points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">BMI 23 kg\u002Fm² or above: 1 point; BMI below 23 kg\u002Fm²: 0 points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A first-degree relative with colorectal cancer: 1 point. If one first-degree relative was diagnosed before age 60, or if two first-degree relatives have colorectal cancer: 4 points. No first-degree family history: 0 points.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Age 50 or older and never having undergone colonoscopy: 3 points. A total score of 4 or more is considered high risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) Higher Risk of Hereditary Colorectal Cancer\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This includes people with Lynch syndrome, familial adenomatous polyposis (FAP), and other hereditary colorectal cancer syndromes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Gastric Cancer\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the same 2025 guideline, people aged 45 or older are considered at higher risk if they meet any one of the following criteria:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Living in an area with a high incidence of gastric cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A first-degree relative — such as a parent, child, or sibling — with a history of gastric cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A positive urea breath test (UBT), serum Helicobacter pylori (H. pylori) antibody test, or stool H. pylori antigen test.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A smoking history totaling six months or more.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Heavy alcohol use, a high-salt diet, frequent consumption of pickled foods, or other unhealthy dietary and lifestyle patterns.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A history of chronic atrophic gastritis, gastric ulcer, gastric polyps, a gastric remnant after surgery, hypertrophic gastritis, pernicious anemia, or related conditions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Esophageal Cancer\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the same 2025 guideline, people aged 45 or older are considered at higher risk if they meet any one of the following criteria:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Long-term residence in an area with a high incidence of esophageal cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A first-degree relative — such as a parent, child, or sibling — with a history of esophageal cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Long-term habits such as consuming very hot foods or drinks, a high-salt diet, frequent pickled foods, a smoking history totaling six months or more, or heavy alcohol use.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A history of chronic esophagitis, Barrett’s esophagus, esophageal diverticulum, achalasia, reflux esophagitis, or benign esophageal stricture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A history of diagnosis or treatment for precancerous esophageal lesions, including esophageal squamous dysplasia or Barrett’s esophagus-associated dysplasia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Gastrointestinal cancer is not something to panic about — but delaying evaluation or avoiding screening can allow an early, more treatable disease to go unnoticed. Pay attention to persistent digestive symptoms, understand your personal risk, and complete appropriate screening when recommended. Early detection, accurate diagnosis, and timely treatment can make a meaningful difference.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":543,"title":544,"summary":545,"cover":546,"category":506,"publishedAt":220,"contentHtml":547,"hasAlternate":73,"updatedAt":432},"guarding-little-wishes-children-blood-disease-ward-school","Helping Little Wishes Shine for Children in the Hospital Ward","At the Sunshine Charity Ward School, children with leukemia put their wishes on paper in a special drawing class, sharing the everyday joys they miss during long-term treatment and the dreams they continue to hold onto.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F61196b26c5d0ac25ea044fed41db8ab6.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Tencent News's “A Day in the Life” feature visited the ward school jointly established by New Sunshine Charity Foundation and Beijing GoBroad Boren Hospital to document a special drawing class built around the children's own ideas and wishes. Children being treated for leukemia and lymphoma drew the foods they wanted to eat, the people they hoped to see, and the things they wished they could do - simple parts of everyday childhood that treatment had temporarily put on hold. The story calls for greater attention to the emotional world of children living with blood disorders. Their small but deeply felt wishes bring light to the long road of recovery and warmth to everyone caring for them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Not long ago, Tencent News's “A Day in the Life” feature visited the ward school jointly run by New Sunshine Charity Foundation and Beijing GoBroad Boren Hospital. The team documented a special class centered on one simple theme: “I have an idea.” The children put their thoughts on paper, inviting us into a world that belongs entirely to them.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Most of the children at the ward school are being treated for leukemia or lymphoma. Their treatment may last six months, two years, or even longer, and much of that time is spent in the hospital. Long periods of isolation and strict dietary restrictions mean they miss many of the simple joys of childhood. But this is not a story about suffering. It is a story about everyone around them working together to create hope.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>An “I Have an Idea” Class at the Ward School\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Unlike an ordinary classroom, every lesson at the ward school comes with uncertainty. Before class begins, no one knows exactly which children will be well enough to attend. Their conditions can change from day to day, and whether they can walk into the classroom in the afternoon may depend entirely on that morning's test results.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Classes and activities are held at the ward school from Monday to Friday. For many of the children, this is one of the few times during the day when they can see and spend time with other children. Some need to be carried into the classroom by a parent because moving around is difficult. But once they arrive, there is a visible sense of ease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The theme of this drawing class was “I have an idea.” Compared with the bigger word “dream,” an “idea” can feel closer and more immediate to a child in hospital. It reminds them that life continues beyond treatment, and that there is still a wider world outside the ward waiting to be explored.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fd05d4424e529fa4ea5c9aeba4c7d96ab_20260914010125.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d05d4424e529fa4ea5c9aeba4c7d96ab_20260914010125.png\" alt=\"9af5e3bf-148e-4758-a82a-e7f8a03b6276.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">The children raise their hands to share their ideas in class\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some children drew the foods they wished they could eat: potato chips, ice cream, crayfish - things that are often off-limits during treatment. Others drew the people they wanted to see: an older brother, classmates, close friends - even if all they wanted was to have a meal together and talk about everyday life. Some drew the things they hoped to do: walk through a park when the roses are in bloom, or fly a kite in warmer weather because, as one child put it, “I've never tried it before.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F8353255e947e9bd6f9ac235bfacf388a_20260914010139.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"8353255e947e9bd6f9ac235bfacf388a_20260914010139.png\" alt=\"dc2d7469-0ad6-47f1-acf8-5dbb63825647.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">The children draw their own “ideas”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Each sheet of paper holds a piece of everyday life that illness has temporarily put on pause - and a hope the children have never let go of.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>The Long Road of Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F44a558285d4f907b355ec3af64ecad28_20260914010157.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"44a558285d4f907b355ec3af64ecad28_20260914010157.png\" alt=\"52d23c10-bea6-46fd-a85c-a1d2bcdd5d1c.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Xinxin (left) and Xiao Ze (right)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Ms. Qiao Li from the hospital's Patient Services Department took the production team to see an unoccupied high-dependency room. A thick protective curtain surrounded the bed, separating it from the outside world. In that moment, “isolation” was no longer simply a medical term; it was part of a child's everyday life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In Xinxin and Xiao Ze's room, Xinxin's mother explained that treatment often lasts at least six months, and the children spend most of that time in hospital. There are countless precautions in daily life: anything they touch may need to be disinfected, and even minor bumps and injuries must be avoided. Food is just as tightly controlled. Snacks that other children can reach for without thinking are often completely off-limits. Xinxin said that after chemotherapy, even when she manages to eat, she often vomits afterward: “It's really hard to put the weight back on.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These children are growing up at an age when curiosity about the outside world comes naturally and personalities are still taking shape. Yet their physical world can gradually shrink to a hospital room, treatment schedules, and laboratory results. Within those limits, parents, hospital staff, and charitable organizations all work to make sure life does not become only about treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Children's Day was approaching, and Xinxin and Xiao Ze were rehearsing a short skit. When we first met them, neither looked especially energetic. But the moment someone called “action,” they quickly slipped into character. A line of dialogue, a gesture, an unexpected twist in the scene - each one brought laughter to the room.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Drawing Rebellion, Dreams, and the Person You Want to Be\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Ff100486a0c85d09b3d8283cb44ec28a7_20260914010219.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"f100486a0c85d09b3d8283cb44ec28a7_20260914010219.png\" alt=\"9d967ef0-e4ce-4f9d-91c5-5a80b82000b5.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">How Nuonuo imagines herself\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Nuonuo is now 20. She first came to the ward school when she was 13. Over the past seven years, she has undergone hematopoietic stem cell transplantation and lived through countless difficult days of illness and recovery. Now she hopes to become a more authentic version of herself. Her drawing reflects that wish: in everyday life, she can be a little melancholy, sometimes with a rebellious streak, and often she simply wants to spend time quietly on her own. Dyeing her hair or getting her ears pierced may be the outward signs of rebellion, but her real act of defiance is refusing to give in to what life has handed her - and continuing to fight because she does not want her parents to be sad. Nuonuo says she would like to hold a concert at the ward school and sing with her friends, because they are all “teammates fighting the same illness.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F135952057217d4c4c2c322f727689464_20260914010233.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"135952057217d4c4c2c322f727689464_20260914010233.png\" alt=\"92569eb6-1937-4334-b581-89694c627bd2.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Yanyan's Favorite Starry Sky and Garden\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fifteen-year-old Yanyan is quiet and shy, but she has a wide range of interests. She loves astronomy and has read many books about it. Her favorite is the Andromeda Galaxy, simply because she finds it beautiful. She also loves plants and has grown succulents and wild grasses. “If you take good care of them, even little grasses can be beautiful,” she says. Looking ahead, Yanyan hopes to become an artist. “I want to save some of the money I make from selling my paintings, and use some of it to help children around the world who are going through what we are.” She also has her own thoughts about treatment. Staying strong, she says, depends not only on doctors, but also on the emotional support of parents and the children themselves: “If the adults are unhappy in front of the children all the time, it becomes harder for the children to keep going too.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F23752d790cbf6fb27bde92e4f3eb703f_20260914010247.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"23752d790cbf6fb27bde92e4f3eb703f_20260914010247.png\" alt=\"7f03154b-75d9-42e1-a37d-13b4a73e5108.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Teacher Xinxin with children from the ward school\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For every child at the Sunshine Charity Ward School at Beijing GoBroad Boren Hospital, even a small wish can be hard-won. It may take months of treatment and countless difficult days before something simple becomes possible again. That is what makes these little wishes so precious. Each one shines in its own way, lighting the children's path through recovery and warming the people who walk beside them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Teacher Xinxin from the Sunshine Charity Ward School said, “I hope more people can see how rich and vivid these children's inner worlds are, and I hope more people will pay attention to children living with blood disorders.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That commitment is also at the heart of GoBroad Healthcare Group's approach to care. We hope every child facing serious illness can keep growing toward the light, carrying their hopes forward until brighter days finally arrive.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":549,"title":550,"summary":551,"cover":552,"category":438,"publishedAt":553,"contentHtml":554,"hasAlternate":73,"updatedAt":74},"targeted-therapy-dic-emergency-warning","Targeted Therapy Is Not a One-and-Done Solution: Watch for These Serious Cancer-Related Emergencies","Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, uses a case of EGFR-mutant lung cancer to explain how to recognize dangerous complications such as disseminated intravascular coagulation (DIC) and how they are managed.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fd669d227da31b8e9ebc88f89ef774141.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-05-29","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, discusses a real clinical case involving a patient with lung cancer harboring an EGFR exon 21 L858R mutation who developed disseminated intravascular coagulation (DIC) after resistance to targeted therapy and rapid disease progression. The article explains how cancer-associated DIC develops, why clotting and bleeding can occur at the same time, and which warning signs patients and families should watch for. It also emphasizes an important point: targeted therapy itself is not necessarily the cause of DIC. Rather, rapidly progressive cancer can trigger severe coagulation abnormalities. Close monitoring, early recognition of emergencies, and individualized treatment that combines control of the underlying cancer, correction of coagulation abnormalities, and supportive care are all essential parts of whole-course cancer management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As precision oncology continues to advance, targeted therapies have helped many patients with driver mutation-positive lung cancer live longer and maintain a better quality of life. But even after a period of stable disease, some patients may experience sudden progression or develop serious, potentially life-threatening complications.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Using a real case from clinical rounds, this article highlights one dangerous but easily overlooked cancer-related emergency. The goal is to help patients and families recognize warning signs earlier and seek medical care promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>01 A Real Clinical Case: A Life-Threatening Complication After Disease Progression\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During a recent ward round at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, Dr. Shuang LI reviewed the case of a 54-year-old woman with lung cancer and an EGFR exon 21 L858R sensitizing mutation. This type of mutation is generally sensitive to EGFR-targeted therapy. The patient had previously received standard third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, which controlled her disease for a period of time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During treatment, however, resistance to targeted therapy developed and the cancer progressed rapidly. She subsequently developed a critical complication: disseminated intravascular coagulation (DIC). It is important to understand that patients with rapidly progressive cancer can develop DIC because of the cancer itself, regardless of whether targeted therapy is being used. Rapid tumor growth, tumor necrosis, and vascular invasion can release large amounts of procoagulant substances into the bloodstream and activate the body's coagulation system. In this case, the rapid progression after targeted therapy resistance accelerated an already dangerous process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>02 What Is Cancer-Associated DIC?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Disseminated intravascular coagulation (DIC) is a severe disorder of blood clotting that can occur in advanced cancer. It is a medical emergency that can cause a patient's condition to deteriorate quickly and may become life-threatening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>In simple terms, the process may involve three overlapping problems:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Tiny blood clots form throughout small and larger blood vessels, blocking circulation and reducing blood and oxygen supply to organs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) Large amounts of platelets and clotting factors are consumed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(3) As these clotting components are depleted, serious bleeding can develop, including bruising or bleeding of the skin and mucous membranes, internal bleeding, or intracranial hemorrhage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Typical Clinical Features\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Clotting and bleeding may occur at the same time, without a clear boundary between the two phases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) The condition can progress very quickly and requires urgent medical intervention.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(3) Platelet counts may fall markedly, and coagulation tests may become significantly abnormal.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>When this patient was admitted, she had already developed:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Shortness of breath and inability to lie flat, requiring supplemental oxygen;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) Widespread small thrombi in the bronchial arteries, as well as thrombosis in the superior and inferior vena cava;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(3) Pleural and pericardial effusions;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(4) Enlarged lymph nodes in multiple areas, including the axillae, supraclavicular regions, and lower neck.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Should Patients and Families Take Away from This?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Resistance to targeted therapy can eventually develop, and the cancer may then progress rapidly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) Rapid cancer progression can trigger medical emergencies such as coagulation disorders and organ failure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(3) Unexplained chest tightness, shortness of breath, inability to lie flat, extensive bruising, or unusual bleeding should be assessed urgently by a medical team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>03 Individualized, Multidisciplinary Treatment Can Create a Window for Recovery\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For critically ill patients with cancer-associated DIC, treatment needs to be rapid, individualized, and multidimensional.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(1) Treat the underlying cancer: adjust anticancer therapy according to the mechanism of resistance and work to regain disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(2) Manage the emergency: correct coagulation abnormalities according to the patient's current DIC pattern and clinical status.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 0 0 0 28px;text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">(3) Provide supportive care: replace blood components or clotting factors when appropriate, use anticoagulation selectively when indicated, and protect organ function.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After intensive, individualized treatment and close monitoring, the patient's cancer was brought under better control. Her pleural and pericardial effusions decreased substantially, enlarged lymph nodes regressed, her breathing improved, and she was again able to lie flat. Her overall clinical condition improved significantly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This case shows that a cancer-related emergency does not always mean there are no options left. Early recognition, rapid intervention, and appropriate treatment may still create an opportunity to stabilize the patient and improve the situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>DIC can develop as cancer progresses. If you notice large unexplained bruises, persistent gum or nose bleeding, continued oozing from an injection or puncture site, or these symptoms together with chest tightness, severe shortness of breath, inability to lie flat, dizziness, profound weakness, or low blood pressure, seek emergency medical care immediately. Do not wait for the symptoms to resolve on their own. Early recognition and treatment are critical for safety.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Targeted therapy has transformed lung cancer care and made longer-term disease control possible for many patients. But effective treatment also requires whole-course management, close follow-up, and prompt recognition of emergencies.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Cancer treatment is an ongoing process. Changes in symptoms, laboratory results, or sudden new discomfort can all be important signals from the body. Understanding these warning signs, attending regular follow-up, communicating promptly with the care team, and acting quickly when needed can help protect both treatment safety and effectiveness.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>",{"slug":556,"title":557,"summary":558,"cover":559,"category":438,"publishedAt":560,"contentHtml":561,"hasAlternate":73,"updatedAt":74},"lymphoma-genetic-testing-zhang-yajing","Dr. Yajing Zhang: Lymphoma Has Many Subtypes—Why Is Genetic Testing So Important?","Dr. Yajing Zhang explains how genetic testing can support more precise lymphoma diagnosis, help assess prognosis, guide targeted treatment choices, and enable dynamic disease monitoring—making truly individualized care possible.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1c810ce674d64e11d0e23495f80d4cb2.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-05-15","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Yajing Zhang explains why genetic testing has become an important part of modern lymphoma care. Because lymphoma includes many distinct subtypes, genetic testing can help refine the diagnosis, identify high-risk alterations such as “double-hit” rearrangements, guide the selection of targeted therapies such as BTK inhibitors, and provide additional information when considering advanced treatments including CAR-T therapy. Liquid biopsy and circulating tumor DNA (ctDNA) can also be used in some settings for dynamic monitoring during and after treatment. Together, these tools help move lymphoma care away from a one-size-fits-all approach toward treatment strategies tailored to each patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Hello, I'm Dr. Yajing Zhang.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>In clinic, I often see the same situation: patients and families have only just begun to process a lymphoma diagnosis when their doctor recommends another test that may sound complicated—genetic testing.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Many people understandably ask, “Doctor, hasn't the pathology report already confirmed the diagnosis? Why do I still need genetic testing? It's another significant expense—is it really necessary?”\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>These are very reasonable concerns. Today, I'd like to explain why genetic testing can be such an important step in lymphoma care. One way to think about it is as a personalized “road map” that helps us tailor treatment more closely to the biology of your disease.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Lymphoma Is Not One Disease—It Is a Large Family of Diseases\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">First, it's important to understand that “lymphoma” is not a single disease. It is an umbrella term covering more than 100 subtypes. Think of the word “fruit”: apples, bananas, and grapes are all fruit, but they are very different from one another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The same is true for lymphoma. Indolent lymphomas, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and many other subtypes can behave very differently. Traditional pathology helps identify what type of lymphoma is present, but in some cases it may not tell us the whole biological story.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even within the same lymphoma subtype, tumors can differ at the molecular level. Genetic testing looks more deeply at the tumor's “genetic code” to identify abnormalities that may influence how quickly it grows, how aggressive it is, and—most importantly—what treatments it may be more likely to respond to.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is why lymphoma treatment should not follow a one-size-fits-all model. The goal is to build an individualized treatment plan around the specific features of each patient's disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. Genetic Testing: A Personalized Road Map for Diagnosis and Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This “road map” can help answer three key questions:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>(1) Can We Make the Diagnosis More Precise?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lymphoma can sometimes be difficult to classify correctly at the initial diagnosis, especially when it arises in less common sites such as the eye, nose, or central nervous system. By analyzing the genetic features of tumor cells, genetic testing can provide additional information that helps doctors define the lymphoma subtype more precisely. The more accurate the starting point, the more confidently the treatment plan can be mapped out.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>(2) What Can Genetic Findings Tell Us About Prognosis?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even among patients with the same diagnosis—for example, diffuse large B-cell lymphoma—some respond well to standard treatment and remain disease-free for years, while others are more likely to relapse. Part of that difference can be explained by the tumor's genetic features.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, the presence of MYC and BCL2 rearrangements—often referred to as a “double-hit” pattern—may indicate more aggressive disease and a less favorable prognosis. Knowing this early can help the care team assess risk more clearly and consider whether a more individualized treatment strategy is appropriate, rather than waiting until the disease relapses.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>(3) Can Genetic Testing Help Guide Treatment Choices?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is one of the most practical reasons for doing genetic testing: it may reveal molecular targets that can help guide treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Targeted therapy: For example, finding an MYD88 mutation may, in certain lymphoma settings, suggest potential sensitivity to a BTK inhibitor such as zanubrutinib. In other words, identifying a molecular “weak point” in the tumor may help doctors choose treatment more purposefully and reduce unnecessary trial-and-error.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Advanced therapies such as CAR-T: For patients with relapsed or refractory lymphoma, CAR-T cell therapy may offer another treatment option. Genetic testing can provide additional information about tumor biology that may help doctors assess the overall treatment strategy, anticipate response patterns and potential risks, and consider whether combination approaches may be appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. Dynamic Monitoring: A Real-Time View of the Treatment Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment decisions do not stop once therapy begins. During treatment and follow-up, a “liquid biopsy” using peripheral blood may be used to monitor changes in circulating tumor DNA (ctDNA).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">You can think of this as the “live traffic” function on a navigation app. In some settings, ctDNA can reveal molecular signs of recurrence before they become visible on conventional imaging such as CT, giving the medical team an opportunity to investigate further and adjust the treatment plan when appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Facing complex tests and an unfamiliar diagnosis can be overwhelming. But advances in modern medicine mean that many lymphoma subtypes can now be cured or controlled for long periods, and treatment options continue to expand.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Genetic testing is one of the tools that can help bring greater clarity to that process. Its purpose is not simply to add another test, but to give patients and doctors more information for choosing a more individualized path forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">It helps move care from a broad, one-size-fits-all approach toward a treatment strategy designed around the individual patient. That is the goal of truly personalized medicine.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":563,"title":564,"summary":565,"cover":566,"category":506,"publishedAt":567,"contentHtml":568,"hasAlternate":73,"updatedAt":432},"beijing-gaobo-hospital-international-patient-care-event","Beijing GoBroad Hospital’s Thoracic Oncology & Tumor Immunotherapy Departments Host International Patient Care Event","The Department of Thoracic Oncology and Department of Tumor Immunotherapy at Beijing GoBroad Hospital hosted a special event for international patients, bringing patients, families, and care teams together through poetry, a cancer survivor’s story, and handmade cards.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F3b2e5752f8bd688ab0ac3e4cdf23dbbe.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-05-12","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: The Department of Thoracic Oncology and Department of Tumor Immunotherapy at Beijing GoBroad Hospital organized an in-person event centered on compassionate care for international patients. The program included a poetry reading offering encouragement, a cancer survivor advocate sharing a personal treatment journey, and handmade cards presented by a 13-year-old international patient. Beyond medical treatment, the event created a warm space for patients and families to feel supported and connected. Guided by the principle that “The Needs of the Patient Come First,” the departments continue to place humanistic care alongside professional treatment and precision oncology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Care can be a bridge between patients and their medical teams. The Department of Thoracic Oncology and Department of Tumor Immunotherapy at Beijing GoBroad Hospital recently organized a warm, in-person gathering for international patients receiving care at the hospital. Doctors, nurses, patients, and family members came together outside the usual clinical setting to share encouragement, companionship, and moments of connection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The atmosphere was relaxed and welcoming, with conversation and laughter replacing the usual sounds of tests and treatment. The medical team thoughtfully planned a series of activities that combined health education with emotional support, giving everyone present a chance to experience care beyond the clinical setting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F547e887db2cfb2a46438263b6dde6fd8_20260914011154.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"547e887db2cfb2a46438263b6dde6fd8_20260914011154.png\" alt=\"577c02bf-14b9-48b1-bdf0-3930cd0e3c11.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Poetry and encouragement. The event opened with a heartfelt poetry reading, expressing respect for life, best wishes for patients, and determination in the face of cancer. The gentle but steady words offered encouragement and hope, while also helping patients and medical staff feel closer to one another.\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fd484b2436a30fed9dca8bf30271d08a0_20260914011206.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d484b2436a30fed9dca8bf30271d08a0_20260914011206.png\" alt=\"28e435de-d244-41df-b513-671ce7720246.png\"\u002F>\u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A survivor’s story. A cancer survivor advocate from China joined the event to share a personal treatment journey — from the uncertainty and fear that followed diagnosis, through the challenges of treatment, to a more positive and active life today. The story resonated with patients and families in the room and encouraged them to stay engaged with professional treatment while holding on to hope through difficult periods.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F3ba7123febf133400b6f33ef7950958c_20260914011218.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3ba7123febf133400b6f33ef7950958c_20260914011218.png\" alt=\"68d10eb4-15cb-4884-a43c-03b735c7275f.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A heartfelt gift from a young patient. One of the most touching moments came from a 13-year-old international patient, who had made a series of cards by hand. Each card included a photo taken with members of the medical team, capturing warm moments shared during treatment. The handwritten messages, filled with gratitude and childlike sincerity, deeply moved the doctors and nurses and became one of the most memorable parts of the event.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fa2390dbd4270b9b563571328b7866cf9_20260914011245.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"a2390dbd4270b9b563571328b7866cf9_20260914011245.png\" alt=\"2c61b63d-d9bd-49c6-8b87-d5ece8bfcd95.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than a patient-care activity, the gathering became a shared moment of understanding between patients, families, and the medical team. From the poetry reading to the survivor’s story and the handmade cards, each part of the event reflected the team’s attention to the emotional as well as medical needs of patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F9b213c6ba1da9e569293923344bcacd5_20260914011257.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9b213c6ba1da9e569293923344bcacd5_20260914011257.png\" alt=\"48a20d73-dea4-4fc0-8e15-279e25e2af85.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The departments have long followed the principle that “The Needs of the Patient Come First.” Alongside advancing clinical expertise and precision treatment, the team places strong emphasis on compassionate communication and support throughout the patient journey. This international patient care event offered another opportunity to bring that philosophy into everyday care, helping patients feel less alone and more supported during treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking ahead, Beijing GoBroad Hospital will continue to organize patient-centered activities alongside high-quality medical care. By combining professional expertise with empathy and ongoing support, the hospital hopes to accompany patients and families through every stage of treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":570,"title":571,"summary":572,"cover":573,"category":438,"publishedAt":574,"contentHtml":575,"hasAlternate":73,"updatedAt":432},"cell-therapy-choice-considerations-patients","When Cell Therapy Becomes an Option, What Should Patients Really Consider?","When considering cell therapy, the treatment itself is only part of the picture. The medical team's experience and ability to manage the entire treatment journey can be just as important to outcomes.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F74e65fe9e2820809e192966951acbc52.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-05-11","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: As cell therapies such as CAR-T become more widely available, patients may need to look beyond the technology itself when making treatment decisions. Cell therapy is not a single procedure. It is a complete care pathway that includes pre-treatment evaluation, treatment timing and coordination, management of adverse reactions, and long-term follow-up. A medical team's systematic clinical capabilities, accumulated experience, and track record of verifiable outcomes are therefore important factors for patients and families to consider.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Following widely reported CAR-T success stories such as Emily's, cell therapy has attracted growing attention worldwide because of its unique therapeutic potential. Today, patients with relapsed or refractory hematologic malignancies, solid tumors, and even certain autoimmune diseases may encounter cell therapy as a possible treatment option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The arrival of new treatment technologies in clinical practice gives patients more options. At the same time, the field of cell therapy has entered a new stage of development: the question is no longer simply whether a center can offer the technology, but whether it can deliver the treatment in a standardized, consistent, and safe way. Greater standardization can help protect patient safety and support better long-term outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As the technology becomes more widely available, many patients naturally ask: what should I focus on when deciding whether and where to receive cell therapy?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At first, many patients focus on how advanced a technology is or where it is available. Once treatment actually begins, however, it often becomes clear that outcomes depend on much more than the technology itself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Cell Therapy Is Not a Single Procedure - It Is an Entire Treatment Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many people think of CAR-T and other cell therapies as a single cell infusion. For patients, however, the infusion is only one step in a much longer treatment process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before treatment begins, doctors first assess the patient's current condition, disease status and progression, and previous treatment history to determine whether this treatment pathway is appropriate. The team then needs to plan the next steps, decide on the right timing, coordinate cell therapy with other treatments when necessary, adjust the plan as the disease changes, and complete key steps such as cell collection, manufacturing, and infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During treatment, patients may experience fever, inflammatory reactions such as cytokine release syndrome (CRS), neurologic toxicities such as immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and challenges related to immune recovery. These issues require ongoing assessment and timely management by the clinical team. After treatment, continued follow-up is also needed to monitor response and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Each step is connected to the next, and each can influence the overall treatment course. That is why consistent, professional management across the full pathway matters at least as much as the cell infusion itself.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>If the Technology Is Similar, Why Can Patient Outcomes Still Differ?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As more patients receive CAR-T and other cell therapies, one thing has become increasingly clear: treatment experiences and outcomes can vary from one patient to another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These differences often come down not just to the technology itself, but to how the treatment is delivered. Was the pre-treatment assessment thorough? Was the timing appropriate? Were adverse events recognized and managed quickly? Was follow-up consistent after treatment? Taken together, these details can make a meaningful difference.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In practical terms, patients are not choosing a single technology in isolation. They are choosing an entire system of clinical care capable of supporting that treatment safely and reliably.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>When Patients Make a Choice, What Are They Really Choosing?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients often start with questions such as: "Which technology is newer?" "Which treatment is more advanced?" or "Where can I receive it?" These are understandable questions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But once the full treatment pathway is laid out, a more important question becomes clear: not simply whether a technology is available, but who can deliver it well. In other words, patients are choosing the medical team that will support and manage the entire course of treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Key capabilities of an experienced cell therapy team include:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">Systematic risk assessment and patient stratification;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">Appropriate treatment timing and individualized treatment planning;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">Rapid recognition and effective management of unexpected adverse reactions;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">Dynamic treatment adjustment through multidisciplinary collaboration;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">Structured long-term follow-up to monitor recovery after treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These capabilities may not always be immediately visible, but for patients they can matter more than how "new" a technology sounds. For complex diseases such as hematologic malignancies, the real decision is often not which single technology to choose, but which clinical team can manage risk across the entire treatment journey and deliver the plan consistently.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Are These Clinical Capabilities Built Over Time?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There are no shortcuts to clinical expertise. Accurate judgment and mature treatment pathways are built through repeated real-world experience. Patients differ in disease type, risk level, physical condition, and prior treatment, so clinicians must continually refine their decision-making and care processes in practice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This experience is not built at one isolated step; it develops across the entire care pathway. According to the source article, GoBroad Healthcare Group has completed more than 5,000 CAR-T treatments. Across different diseases and risk groups, its clinical teams have developed structured treatment pathways and continued to refine how pre-treatment evaluation, treatment management, and post-treatment follow-up connect with one another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As experience accumulates, assessment and decision-making can also begin earlier for some patients. For an experienced team, the goal is not simply to "treat earlier," but to identify sooner which patients may be suitable for cell therapy and to make the right decision at the right time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This does not mean that earlier is always better. The decision should be based on comprehensive evaluation, standardized management, and multidisciplinary judgment, so that patients who are truly suitable can receive treatment at the most appropriate stage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Look for Clinical Results That Can Be Evaluated and Verified\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients and families, trust should not be based on introductions alone. It is also important to look at real, verifiable clinical outcomes. Strong clinical experience means not only being able to deliver a technology in practice, but also having that work evaluated and recognized by the wider medical community.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At GoBroad Healthcare Group, this experience is supported by both a large clinical case base and an active research program. According to the source article, more than 60 studies related to cellular immunotherapy have been published in international medical journals including Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, and Blood. Since 2018, more than 300 original studies have been selected for presentation at major international meetings such as ASH, ASCO, EHA, and EBMT, including more than 160 CAR-T-related studies. These ongoing clinical and scientific efforts provide additional, visible evidence of a team's ability to deliver treatment in a systematic and sustainable way.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">GoBroad's work in cell therapy spans different diseases and stages of treatment, gradually building a body of evidence from clinical practice through to mechanistic research. In relapsed or refractory B-cell malignancies, teams have systematically explored sequential CD19\u002FCD22 and CD19\u002FCD20\u002FCD22 CAR-T strategies, including globally first clinical applications of related approaches in pediatric B-ALL and Burkitt lymphoma. In T-cell malignancies, a widely recognized therapeutic challenge, the team conducted a first-in-human Phase I study of CD7 CAR-T and was the first to report the clinical use of allogeneic CD5 CAR-T in relapsed or refractory T-ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the mechanistic level, the teams also reported the cellular and molecular features of immune dysregulation after CD5- or CD7-targeted CAR-T therapy, and identified an association between TP53 mutations and CD19-negative relapse after CD19 CAR-T treatment. Together, these studies have helped inform areas such as relapse-risk assessment, response evaluation, and planning of subsequent treatment strategies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As this work continues to be discussed and cited internationally, the related clinical pathways and treatment strategies are also being considered more broadly. This cycle - starting from clinical practice, generating evidence, and returning that evidence to patient care - helps validate and further refine accumulated experience. For patients, sustained clinical and research activity can therefore be another useful indicator of whether a team has stable, long-term treatment capabilities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>As the Field Evolves, the Fundamentals of Choosing Care Stay the Same\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cell therapy is no longer limited to hematologic malignancies. Research and clinical use are expanding into areas such as autoimmune diseases and solid tumors, which means more patients may encounter these therapies as potential treatment options in the future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As the technology itself becomes more mature, differences in care will continue to depend heavily on clinical experience, treatment-process management, risk handling, and long-term follow-up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Greater standardization across the field is good news for patients. It means stronger safety controls, more consistent treatment quality, and more complete management across the full care pathway. When making a decision, patients do not need to focus only on the technology itself. A more useful question is whether the team and hospital can safely, consistently, and responsibly manage the entire treatment journey.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Conclusion: What Should Patients Look for When Making a Decision?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients considering cell therapy, the key question is increasingly not simply "Can this be done?" but "Can this be done well?" Outcomes depend on multiple connected steps across the entire care pathway; the technology itself is only the starting point.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As cell therapy matures, experience, systems, and team capability are becoming increasingly important. Patients should look beyond whether a treatment is "new" and consider whether the assessment is thorough, the care pathway is well managed, and the clinical team can take responsibility for the full course of treatment. These are the factors that matter most as cell therapy moves into a more mature stage of clinical practice.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":577,"title":578,"summary":579,"cover":580,"category":438,"publishedAt":581,"contentHtml":582,"hasAlternate":73,"updatedAt":74},"gastrointestinal-cancer-early-screening-treatment","Dr. Jun ZHOU: Taking Charge of Your Health - A Practical Guide to Gastrointestinal Cancer","Dr. Jun ZHOU of Shanghai GoBroad Cancer Hospital emphasizes the importance of gastroscopy and colonoscopy for early detection of gastrointestinal cancers and discusses recent advances in targeted therapy and immunotherapy for gastric cancer.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F4c6988e8c9f2a9f14d5828adbfea1cc1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-29","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Jun ZHOU, Deputy Medical Director and Director of Gastrointestinal Oncology at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, explains why early screening, diagnosis, and treatment matter in gastrointestinal cancers. Gastroscopy and colonoscopy can help detect early gastric and colorectal cancers before obvious symptoms appear, and patients with stage I disease generally have more treatment options and better long-term outcomes after appropriate care. For locally advanced or metastatic gastric cancer, treatment has expanded beyond chemotherapy to include targeted therapies against HER2, CLDN18.2, FGFR2b, c-MET, and other targets, while immunotherapy-based combinations continue to broaden treatment possibilities for different groups of patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cancer rarely appears completely out of the blue. In many cases, there is a window of opportunity in which screening and early detection can make a meaningful difference. For gastrointestinal cancers in particular, gastroscopy and colonoscopy can help identify early lesions before clear symptoms develop. When symptoms do appear, the disease may already be locally advanced or metastatic, but that does not mean treatment options have run out. Advances in chemotherapy, targeted therapy, immunotherapy, and other approaches are giving patients more ways to manage disease at different stages. Dr. Jun ZHOU, Deputy Medical Director and Director of Gastrointestinal Oncology at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, shares practical guidance on screening, diagnosis, and treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: Why are gastroscopy and colonoscopy so important for early detection of gastrointestinal cancers?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Jun ZHOU: As Cancer Prevention and Control Awareness Week approaches, it is worth emphasizing three key principles in cancer care: early screening, early diagnosis, and early treatment. Screening is especially important for gastrointestinal cancers. Gastroscopy and colonoscopy are commonly used examinations that can help detect early gastric and colorectal cancers even when a person has no obvious symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In China, gastric cancer ranks fifth in incidence among malignant tumors and third in cancer-related mortality. Early gastric lesions detected through gastroscopy are often stage I or II and may be treated with endoscopic procedures or surgery, depending on the individual case. Patients with stage I disease generally have a relatively high 5-year survival rate after appropriate treatment. This is why timely screening, diagnosis, and treatment can make such an important difference.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: By the time gastric cancer causes obvious symptoms, what stage is it usually at? What treatment options may still be available?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Jun ZHOU: When patients first seek care because of clear symptoms, the disease is often already at a locally advanced or metastatic stage. Common symptoms can include upper abdominal discomfort, nausea or vomiting, a sensation of food sticking when swallowing, or signs of obstruction. Some patients may also develop symptoms related to distant metastases, such as abnormal liver function with liver involvement or bone pain with bone metastases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In these situations, systemic treatment can still play an important role. Perioperative or conversion treatment may help shrink or downstage the tumor in some patients, making surgery possible even when it was not an option at the initial assessment. For selected patients, this can help improve overall outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: What are some of the latest treatment advances for locally advanced or metastatic gastric cancer?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Jun ZHOU: If treatment cannot convert the disease to a stage where surgery is feasible, long-term, guideline-based systemic therapy can still help patients control the disease and improve survival. Chemotherapy remains an important foundation of treatment, but today's options extend well beyond chemotherapy alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Gastric cancer treatment has increasingly moved into the era of targeted therapy and immunotherapy. Research that began with HER2 more than two decades ago has expanded to other targets, including CLDN18.2, FGFR2b, and c-MET. A growing number of drugs directed at these and other targets have been studied in gastric cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Therapies targeting HER2 and CLDN18.2 are now increasingly used or studied, including monoclonal antibodies and antibody-drug conjugates (ADCs). Immunotherapy has also become an important part of gastric cancer treatment, and CAR-T cell therapy is being actively explored in this field. Clinical experience and ongoing research suggest that combinations such as immunotherapy plus chemotherapy or targeted therapy may offer additional possibilities for improving outcomes in selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Cancer prevention and treatment are not a single step, but a continuum of early detection, timely intervention, and evidence-based care. Screening can help identify disease at an earlier, more treatable stage. Even when cancer is diagnosed at a later stage, standardized systemic therapy, evolving targeted and immune-based treatments, and carefully selected combination strategies can still offer meaningful opportunities to control disease and improve outcomes. The most important message for patients and families is to take screening seriously, seek medical evaluation when needed, and make treatment decisions together with an experienced clinical team.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>",{"slug":584,"title":585,"summary":586,"cover":587,"category":430,"publishedAt":588,"contentHtml":589,"hasAlternate":73,"updatedAt":432},"hematology-autoimmune-breakthrough-new-drugs-affordable-care","New Advances in Hematology and Autoimmune Care: New Therapies, New Drug Access and More Affordable, Patient-Friendly Care","A roundup of recent developments patients may want to know about, including CAR-T therapy for lupus, consolidation options for central nervous system lymphoma, low-dose CD7 CAR-T, a newly available pediatric leukemia CAR-T therapy, and the National Pediatric Cancer Surveillance Annual Report (2024).","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F2f4cfdbac1388fe4ae409159e9d02162.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-28","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Recent developments in hematology and oncology include encouraging results with autologous CD19 CAR-T therapy for systemic lupus erythematosus, with the potential for sustained drug-free remission; evidence supporting autologous stem cell transplantation (ASCT) as a preferred consolidation option for chemosensitive relapsed\u002Frefractory central nervous system lymphoma; a reported 92.5% overall response rate with low-dose CD7 CAR-T therapy in T-cell lymphoma; the first use in Beijing of the pediatric CAR-T product puzolcabtagene autoleucel, now included in Beijing Puhui Health Insurance special-drug coverage; and new national data showing a 76.42% overall 5-year survival rate for childhood cancer in China. Together, these updates offer patients and families a practical overview of recent progress in treatment and care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people living with blood disorders or cancer, advances in treatment and the arrival of new therapies can directly affect treatment options, quality of life, and access to care. Recent research findings, authoritative data releases and healthcare policy updates offer useful information for patients, families and healthcare professionals. Here is a concise roundup of several key developments, with a focus on what they may mean for patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Autologous CD19 CAR-T for Systemic Lupus Erythematosus: A Step Toward Drug-Free Remission\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A team led by Dr. Jing PAN, who holds appointments at both the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, and Beijing GoBroad Hospital, together with Prof. Xiaoming Feng's team at the School of Basic Medical Sciences, Hangzhou Normal University, recently published an important study in Molecular Therapy on autologous CD19 CAR-T cell therapy for systemic lupus erythematosus (SLE).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many people with SLE require long-term immunosuppressive therapy, which can bring cumulative side effects and still may not fully prevent disease flares. The study enrolled 18 patients who had not responded adequately to multiple immunosuppressive treatments, including 15 children, and treated them with autologous CD19 CAR-T cells. The safety profile was generally favorable, with mostly mild adverse effects. At 6 months, 14 patients had achieved remission, and most were able to stop immunosuppressive medication, suggesting a potential path toward sustained drug-free remission. (Source: BioArtMED)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F6d61e7488fa388ba6945a0b84fa56dc0_20260914020610.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6d61e7488fa388ba6945a0b84fa56dc0_20260914020610.png\" alt=\"28241cd8-7c69-4c4e-98e6-5768aa6be4d2.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Relapsed\u002FRefractory CNS Lymphoma: ASCT Remains a Preferred Consolidation Option for Chemosensitive Patients\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed or refractory central nervous system lymphoma (R\u002FR CNSL) can be difficult to treat, and choosing the right consolidation strategy after a patient responds to salvage therapy is especially important. A recent study from Dr. Kai HU's team at Beijing GoBroad Hospital, published in Cancer Immunology, Immunotherapy, compared consolidation approaches in this setting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study included 60 patients who had regained complete remission and compared outcomes after autologous stem cell transplantation (ASCT) versus CAR-T therapy as consolidation. Three-year progression-free survival was 80% in the ASCT group versus 64.8% in the CAR-T group, and the cumulative incidence of relapse or progression was lower with ASCT (20% vs. 30.2%). The benefit was particularly notable in patients with primary CNS lymphoma. In practical terms, ASCT remains a preferred consolidation option for eligible, chemosensitive patients, while CAR-T may be considered for patients who are not candidates for ASCT. (Source: Xueye Shixun)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Febc8b2d335a699b27241c868ce77acfe_20260914020629.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ebc8b2d335a699b27241c868ce77acfe_20260914020629.png\" alt=\"4139ffa0-c848-4cc4-ae5c-2bb8a2e195ad.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Low-Dose CD7 CAR-T for Relapsed\u002FRefractory T-Cell Lymphoma: High Response Rate with Manageable Toxicity\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed or refractory T-cell lymphoma remains challenging, particularly for patients with chemotherapy resistance, high tumor burden or rapidly progressive disease. Dr. Fan YANG from the team led by Dr. Kai HU at Beijing GoBroad Hospital recently published a study in Blood Cancer Journal exploring a low-dose CD7 CAR-T strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study enrolled 40 patients with difficult-to-treat disease and used a low dose of 1 x 10^5 (+\u002F-30%) CAR-T cells\u002Fkg. The overall response rate reached 92.5%, while the risk of severe infection was substantially reduced. A key goal of this strategy is to rapidly lower tumor burden and create a treatment window for patients to proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Follow-up data showed improved 2-year survival among patients who bridged to transplant, offering another potential pathway for patients with otherwise very limited treatment options. (Source: Xueye Shixun)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F6e1164618cb5258dbcc57ec2744853da_20260914020645.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6e1164618cb5258dbcc57ec2744853da_20260914020645.png\" alt=\"b6c79bd5-62df-4ae4-be5a-5596ece5db8f.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Pediatric Leukemia: First Beijing Use of puzolcabtagene autoleucel\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Families of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) recently received an important new treatment update: puzolcabtagene autoleucel injection (brand name: Pulidekai®), China's first domestically developed Class 1 biologic CAR-T therapy approved for children and adolescents with this indication, has now been administered to a patient at Beijing GoBroad Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The treatment was delivered by the team led by Dr. Jing PAN, Director of the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital. The therapy has also been included in the special-drug coverage of Beijing Puhui Health Insurance, a city-customized supplementary commercial health insurance program. This may help reduce the financial burden of treatment and improve access for more eligible children and families. (Source: Beijing GoBroad Hospital)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F7ba343934d5612aebfd3d57d0c225f5d_20260914020712.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7ba343934d5612aebfd3d57d0c225f5d_20260914020712.png\" alt=\"628244fc-f2c6-4571-8dc7-6ca73d44aa0d.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>National Pediatric Cancer Surveillance Annual Report (2024) Released\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On April 25, 2026, the National Center for Pediatric Cancer Surveillance officially released the National Pediatric Cancer Surveillance Annual Report (2024) at the China National Convention Center in Beijing. As one of China's most comprehensive and authoritative annual reports on childhood cancer surveillance, it provides important information relevant to diagnosis and treatment, rehabilitation, long-term survival and family support.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fede5f29690952d1b587c3e56f0d40491_20260914020728.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ede5f29690952d1b587c3e56f0d40491_20260914020728.png\" alt=\"4c46781d-b897-47f4-8dae-88e936fd1c15.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the report, the overall 5-year survival rate for childhood cancer in China has reached 76.42%. The surveillance network now covers 1,750 medical institutions across 29 provincial-level regions and includes data from more than 410,000 pediatric cancer patients. The report describes survival differences by cancer type, age and sex, and identifies the first year after diagnosis as a key window for improving long-term outcomes. It also places greater emphasis on long-term follow-up for childhood cancer survivors, including physical and mental health, late complications, psychological support and the financial burden on families. These data provide an important evidence base for childhood cancer care, rehabilitation services, charitable assistance and family support across China. (Sources: National Center for Pediatric Cancer Surveillance, Xinhua News Agency and CCTV News)\u003C\u002Fspan>\u003C\u002Fp>",{"slug":591,"title":592,"summary":593,"cover":594,"category":438,"publishedAt":588,"contentHtml":595,"hasAlternate":73,"updatedAt":432},"why-so-many-tests-for-blood-diseases","Why Are So Many Tests Needed for Blood Disorders? An Expert Explains 6 Core Tests and What Each One Tells Us","Why do people with blood disorders need so many different tests? Here is a patient-friendly guide to six core laboratory tests, what they look for, and how they differ.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F7f1464fdc29c243b8e6f477c04da3d6e.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Many patients and families wonder why the diagnostic process for a blood disorder may involve blood tests, bone marrow aspiration, flow cytometry, chromosome analysis, FISH, genetic testing, and more. Are these tests repeating the same thing? What does each one actually tell the doctor? Drawing on her clinical experience, Dr. Chunrong Tong of Beijing GoBroad Boren Hospital explains the MICM integrated diagnostic approach and introduces six core laboratory methods - morphology, pathology, flow cytometry, chromosome karyotyping, FISH, and genetic testing. Understanding how these methods complement one another can make it easier to see why each test may matter for diagnosis, treatment planning, and response assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cbr\u002F>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>During the diagnostic process for a blood disorder, many families ask the same question: why are so many tests necessary? There may be blood draws, bone marrow procedures, and repeated samples sent to different laboratories - but what is each test looking for, and can any of them be skipped? In reality, blood disorders are usually diagnosed by combining information from multiple tests. A single method is often not enough to give a reliable answer. Here, Dr. Chunrong Tong of Beijing GoBroad Boren Hospital explains what the main laboratory tests are designed to show, along with their strengths and limitations.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When doctors order several tests for a suspected blood disorder, they are not simply repeating the same test in different forms. Each method looks at the disease from a different angle, and the results work together to build a more accurate diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In clinical practice, evaluation is often organized across five core laboratory areas - morphology, pathology, flow cytometry, cytogenetics, and molecular diagnostics, although laboratory names may vary by hospital. Together, these areas may include cell morphology and cytochemical staining, pathology and immunohistochemistry, flow cytometry, chromosome karyotyping, FISH, genetic testing, and related methods.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 1: Cell Morphology and Cytochemical Staining\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is one of the most basic and fastest first steps in diagnosing hematologic malignancies. Put simply, a sample of bone marrow or blood is spread onto a glass slide, stained, and examined under a microscope so the doctor can directly assess what the cells look like.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Direct and visual. Some abnormal cells have distinctive features that an experienced specialist can recognize immediately, helping narrow the diagnostic possibilities very quickly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Often gives a reliable estimate of cell proportions. Morphology commonly uses the first pull of a bone marrow aspirate, which is placed directly onto a slide with minimal processing and usually less dilution by peripheral blood. Later samples used for flow cytometry, genetic testing, or chromosome analysis may come from subsequent aspirates and can sometimes show a lower proportion of abnormal cells than is actually present.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Provides important diagnostic clues. Morphology does more than separate normal-looking from abnormal-looking cells. It can point the team toward additional testing. For example, frequent mitotic figures may suggest rapid cell proliferation and prompt consideration of tests such as Ki-67. In some cases, blood or bone marrow smears may also show clues suggesting an infectious process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Fast and relatively inexpensive. In some settings, results can be available within 20 to 30 minutes. The test uses routine stains rather than complex reagents, so it is generally one of the least costly laboratory methods.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The biggest limitation is that morphology depends heavily on the observer's eyes and experience. Diagnostic quality can vary depending on how many different types of cases the specialist has seen.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, two groups of cells may look very similar under the microscope and initially resemble lymphoma, yet the final diagnosis may turn out to be epidemic hemorrhagic fever, a viral infection. Without enough experience, the appearance alone could be misleading.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 2: Pathology and Immunohistochemistry\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Morphology looks at individual cells on a smear. Pathology and immunohistochemistry, by contrast, examine tissue - for example, a lymph node or tumor biopsy that is processed into thin sections and viewed under a microscope.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Tissue is fixed promptly, helping preserve information. A biopsy specimen is usually placed in formalin soon after it is obtained, so much of the cellular and structural information is retained. Some other testing methods require more cell processing, during which certain information may be lost.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Can provide a more representative view of how much of the tissue is malignant. Because the pathologist examines an intact tissue section, it may more accurately show the proportion and distribution of tumor cells within that tissue.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Useful for cells that are difficult to obtain by aspiration, uncommon, or large. Examples include myelofibrosis, multiple myeloma, lymphoma - especially Hodgkin lymphoma (HL) - metastatic carcinoma, histiocytes, macrophages, and dendritic cells. These cells may be scarce or absent in bone marrow aspirate fluid but visible in a tissue section.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Shows tissue architecture and where abnormal cells are located. This is especially important in lymphoma because the pattern and organization of cells can be part of the diagnosis. Mantle cell lymphoma and follicular lymphoma, for example, have characteristic tissue patterns that can be seen on pathology sections but cannot be fully assessed by flow cytometry or genetic testing alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Slower, and still influenced by the pathologist's experience and knowledge. Tissue must be fixed, embedded, sectioned, and stained, so the process takes longer than preparing a blood or bone marrow smear.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Some abnormalities are difficult to identify when tissue architecture is largely preserved, the cells show only subtle morphologic changes, or malignant cells make up only a small proportion of the sample.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Sampling error is possible. Some malignant cells mainly circulate in body fluids, making it difficult to obtain representative tissue. And if a biopsy misses the area containing tumor cells, the result may be negative even though disease is present elsewhere.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 3: Flow Cytometry (FCM)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Flow cytometry is one of the core technologies used in diagnosing hematologic malignancies. It differs from routine immunohistochemistry: conventional immunohistochemistry usually evaluates markers on tissue sections, while flow cytometry suspends cells in fluid and passes them through an instrument one by one, allowing multiple markers to be measured on each cell at the same time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Fast, practical, and information-rich. In some laboratories, a report can be available within about two hours. Tens of thousands to hundreds of thousands of cells can be assessed in one run, with many markers and multiple parameters analyzed simultaneously, giving flow cytometry high sensitivity and broad coverage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Helps distinguish normal from malignant cells and identify cell lineage and maturation. For example, two patients may both have a morphology report showing '8% blasts' after treatment. Morphology alone may not tell whether those blasts are normal regenerating cells or residual leukemia cells. Flow cytometry can often make that distinction more clearly. This is one reason it is among the most widely used methods for measurable residual disease (MRD) monitoring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Can help identify immunotherapy targets and monitor treatment response. Targets such as CD19, CD20, and BCMA are commonly assessed by flow cytometry to determine whether they are expressed on the abnormal cells. If the target is present, a corresponding CAR-T therapy or antibody-based treatment may be considered. Flow cytometry can also track changes during treatment, assess response, and show whether a target has been lost.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. It does not show tissue architecture. Because tissue is broken down into individual cells for flow cytometry, the test cannot show how those cells were originally arranged, whether they formed nodules, or whether they invaded a capsule. For diseases such as Hodgkin lymphoma (HL), where tissue structure matters, flow cytometry cannot replace pathology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Some cells are easily lost during processing. Cells from diffuse large B-cell lymphoma (DLBCL), erythroblasts, and certain other cell types may break apart or be lost during staining and washing. As a result, the tumor-cell percentage reported by flow cytometry can sometimes be lower than the true proportion. For some diseases, including M6 erythroleukemia and myelodysplastic syndromes (MDS), morphology may provide advantages that flow cytometry does not.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Samples need to be processed quickly. Aspirates, biopsy material, and body-fluid specimens generally need prompt handling; prolonged delays can reduce cell viability and affect accuracy. This places high demands on coordination between the clinical team and laboratory.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. The technique requires substantial expertise. Antibody selection, panel design, instrument setup, and data interpretation all require experience and specialized knowledge. The same specimen can be interpreted differently depending on technical quality and expertise.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">5. Its prognostic value is generally less direct than that of chromosome and molecular genetic findings.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 4: Chromosome Karyotyping\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chromosomes carry much of the genetic information inside our cells. Karyotyping uses a microscope to examine chromosome number and structure - for example, whether a chromosome is missing or duplicated, or whether two chromosomes have exchanged segments in a translocation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Provides independent diagnostic and prognostic information. Certain chromosome abnormalities are hallmarks of specific blood cancers. For example, chronic myeloid leukemia (CML) is characterized by the Philadelphia chromosome, involving a translocation between chromosomes 9 and 22, while acute promyelocytic leukemia (APL\u002FM3) is characterized by a translocation between chromosomes 15 and 17. Chromosome abnormalities can also provide important information about prognosis and relapse risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Can reveal broader, previously unsuspected abnormalities. Karyotyping gives a 'big-picture' view of the chromosomes. Even if the specific gene involved is not yet known, a structural chromosome change may still be visible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Results take time. Cells usually need to be cultured and allowed to divide before the chromosomes can be examined, so testing commonly takes about 7 to 14 days.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Interpretation is highly dependent on technical expertise. Chromosomes must be recognized and analyzed visually, so experienced laboratory staff are essential.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. If malignant cells do not divide, the result may be falsely negative. Karyotyping requires cells to reach metaphase. If tumor cells do not divide well in culture, or too few of them divide, an abnormality may not be detected even when it is present.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Sensitivity is relatively low. Only a limited number of cells are analyzed. When malignant cells make up less than about 5% to 10% of the sample, abnormalities may be missed. For this reason, karyotyping is not well suited to MRD monitoring.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 5: FISH (Fluorescence In Situ Hybridization)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">FISH can be thought of as a more targeted way to look for specific chromosome or gene-region abnormalities. Fluorescent probes are designed to bind to selected chromosome or gene locations, producing visible signals when the target is present or rearranged.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Provides independent diagnostic and prognostic information. When a particular chromosome abnormality is already known to be clinically relevant, FISH can help confirm it.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Can detect abnormalities that are too small to distinguish clearly under a standard microscope. A targeted fluorescent probe may identify changes that conventional karyotyping cannot resolve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Does not require dividing cells. Unlike karyotyping, FISH can be performed without waiting for cells to grow and enter mitosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. More cells can be analyzed, improving sensitivity. Hundreds of cells can be reviewed in a single test, allowing a more representative estimate of how many cells carry the abnormality. For residual leukemia, FISH is generally more sensitive than conventional karyotyping.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">5. Faster turnaround and somewhat less dependence on visual pattern recognition. Results are often available within 1 to 2 days, and the fluorescent signals can be directly counted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">6. Can sometimes be performed retrospectively. Previously prepared bone marrow slides or paraffin-embedded tissue sections may be suitable for FISH, which can help clarify or revisit a diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Probes are costly, and each probe usually tests only one or a small number of specific abnormalities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. FISH can only look for abnormalities the laboratory has chosen to target. The probe has to be designed for a known abnormality, so unexpected changes may be missed. In simple terms, karyotyping provides a broader overview, while FISH performs a focused search.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Method 6: Genetic Testing\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Genetic testing looks at disease at the DNA and RNA level - for example, whether a gene carries a mutation or fusion, or whether a particular gene is being expressed at an abnormal level.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Advantages\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Provides independent diagnostic and prognostic information. Many gene abnormalities can serve as disease-defining markers, including NPM1 mutations and biallelic CEBPA mutations. Molecular findings can also help refine risk classification.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Can detect abnormalities that chromosome analysis and FISH may miss. Some gene changes are too small to alter chromosome structure and are not covered by available FISH probes. Sequencing and other molecular methods can identify these changes. Combining chromosome analysis, FISH, and genetic testing can provide a more complete picture of prognosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Turnaround is generally shorter than conventional chromosome analysis for many molecular tests, with results often available within 1 to 2 weeks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Results are somewhat less dependent on an individual observer's visual experience, provided the laboratory uses standardized procedures and strict quality control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">5. Can provide highly sensitive MRD monitoring for patients with trackable molecular markers. PCR or sequencing can follow specific mutations or fusion genes over time, with sensitivity reaching approximately 1 in 10,000 or even 1 in 100,000 cells in appropriate settings.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Limitations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Laboratory design, processing, and data analysis must be of very high quality. Molecular testing involves many steps and large amounts of data, so problems at any stage can affect accuracy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. It cannot diagnose every blood cancer on its own. Not all hematologic malignancies have a known or detectable driver abnormality, so morphology, flow cytometry, chromosome analysis, pathology, and other methods may still be essential.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At this point, you may be wondering: if all six tests have been completed, is that enough? Not always. Beyond these core laboratory tests within an integrated MICM evaluation, two other types of assessment may also be important during the course of care. One is pathogen testing, which helps determine whether viral or bacterial infections - such as Epstein-Barr virus (EBV) - are affecting the patient's condition. The other is therapeutic drug monitoring and pharmacogenetic testing, which can help doctors individualize medication use, improve effectiveness, and reduce toxicity risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The key point is that no single test can answer every question. Doctors need to integrate information from several dimensions to diagnose the disease more accurately, choose treatment, and assess response. Understanding what each test can and cannot tell you can also make the diagnostic and treatment process easier for patients and families to follow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Disclaimer: Expert opinions are provided for general reference only. Please consult your treating physician for advice specific to your condition.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":597,"title":598,"summary":599,"cover":600,"category":430,"publishedAt":601,"contentHtml":602,"hasAlternate":73,"updatedAt":432},"cd19-car-t-sle-clinical-trial-results","International Journal Publication | Dr. Jing PAN and Prof. Xiaoming Feng's Teams Report Phase 1\u002F2 Trial of Autologous CD19 CAR-T Therapy in Pediatric and Adult SLE","The teams led by Dr. Jing PAN and Prof. Xiaoming Feng published phase 1\u002F2 trial results in Molecular Therapy, showing that autologous CD19 CAR-T therapy enabled most patients with SLE to achieve deep remission without ongoing immunosuppressive treatment.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F4b33fd7abbb0314fa1ccf58a7ea6e1b0.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-27","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: The team led by Dr. Jing PAN at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, together with Prof. Xiaoming Feng's team at Hangzhou Normal University, published the results of a phase 1\u002F2 clinical trial of autologous CD19 CAR-T therapy in pediatric and adult systemic lupus erythematosus (SLE) in Molecular Therapy. The study enrolled 18 patients, including 15 children. At month 6, 14 patients achieved DORIS-defined remission; among the 15 pediatric patients, 11 achieved DORIS remission. Anti-dsDNA antibodies became negative in 88.9% of patients who were positive at baseline. The safety profile was generally favorable, with only mild cytokine release syndrome (CRS) and neurotoxicity reported and no grade 3 or higher infections. The findings provide important clinical evidence supporting the potential of CD19 CAR-T therapy to help some patients with SLE achieve sustained remission without long-term immunosuppressive medication.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people living with systemic lupus erythematosus (SLE), long-term dependence on immunosuppressive therapy can bring cumulative toxicity, while disease flares may still recur. Achieving durable remission without continuous medication therefore remains an important unmet need in SLE care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, the team led by Dr. Jing PAN, who holds appointments at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, and Beijing GoBroad Hospital, collaborated with Prof. Xiaoming Feng's team at the School of Basic Medical Sciences, Hangzhou Normal University, to publish a study in Molecular Therapy titled "Autologous CD19 CAR-T cell therapy for pediatric and adult systemic lupus erythematosus: a phase 1\u002F2 trial." The study reports detailed safety and efficacy data from a phase 1\u002F2 clinical trial of autologous CD19 CAR-T therapy in pediatric and adult patients with SLE. The results suggest that CD19 CAR-T therapy can induce deep clinical remission in many patients after immunosuppressive drugs are discontinued, supporting further exploration of sustained medication-free remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F413a546f870a180cebe9eb1ec120ba82_20260914005010.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"413a546f870a180cebe9eb1ec120ba82_20260914005010.png\" alt=\"50328c28-144e-46cd-b2ce-fd56334bb4a2.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">SLE is a chronic autoimmune disease that can affect multiple organ systems. Its pathogenesis is driven in part by abnormally active autoreactive B cells, which continuously produce autoantibodies against nuclear antigens such as double-stranded DNA. This immune dysregulation can trigger systemic inflammation and progressive tissue damage involving organs such as the kidneys, liver, lungs, and skin. Pediatric SLE is often more severe than adult-onset disease. To maintain disease control, many patients require long-term or even lifelong glucocorticoids and other immunosuppressive therapies, which can increase the risk of infection and other complications; in children, prolonged treatment may also affect growth and development. Although B-cell-targeted monoclonal antibodies are available, durable medication-free remission remains difficult to achieve. In recent years, CAR-T therapy has shown strong clinical activity in hematologic malignancies and is increasingly being explored in autoimmune diseases. However, previous studies in SLE have generally involved small numbers of patients, creating a need for larger and more rigorous clinical trials to better define who may benefit and how durable the effect may be.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study had two stages: dose escalation (phase 1) and dose expansion (phase 2). The main endpoints in phase 1 were the type and incidence of dose-limiting toxicities (DLTs) within 28 days after infusion, as well as the severity and incidence of adverse events (AEs) within 30 days. In phase 2, the primary endpoints were objective response rates at months 3 and 6, defined by the proportion of participants achieving an SRI-4 response. To identify an appropriate treatment dose while balancing safety and efficacy, the investigators used the TITE-BOIN12 trial design.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A total of 18 patients with SLE were enrolled. All had previously failed at least two immunosuppressive therapies, such as glucocorticoids, mycophenolate mofetil, or belimumab. The cohort included 15 children and 3 adults and represented a broad range of disease manifestations: 8 patients had lupus nephritis (LN), 2 had autoimmune hemolytic anemia (AIHA), and 1 had immune thrombocytopenia (ITP). To explore the value of earlier intervention, the study also included 3 patients with relatively low baseline disease activity (SLEDAI-2K score <4) but a high level of medication dependence. The starting dose in phase 1 was 1 x 10^6 CAR-T cells\u002Fkg. No dose-limiting toxicity was observed at this dose, and it received the highest overall benefit-risk score under the TITE-BOIN12 algorithm. It was therefore selected as the recommended phase 2 dose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this SLE study, treatment-related immune toxicity was generally mild. Thirteen patients developed grade 1 cytokine release syndrome (CRS), mainly presenting as fever. Three patients experienced mild grade 1 neurotoxicity (ICANS), including headache. No grade 3 or higher infections were reported. Fifteen patients developed grade 3 or higher cytopenias, but all subsequently recovered to grade 2 or lower.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among the 15 evaluable patients with baseline SLEDAI-2K scores >=4, 12 achieved an SRI-4 response at month 6. Across all 18 patients, 14 achieved DORIS-defined remission at month 6, 2 reached lupus low disease activity state (LLDAS), and 2 did not respond. The cohort was predominantly pediatric: among the 15 children, 11 achieved DORIS remission, 2 reached LLDAS, and 2 did not respond at month 6. Among the 8 patients with lupus nephritis, 5 achieved DORIS remission, 1 reached LLDAS, and 2 did not respond. Some patients with class IV-V lupus nephritis who had not responded at month 3 showed improvement by month 6. Among 7 patients with proteinuria at baseline, 4 had proteinuria levels fall below 0.5 g\u002F24 h by month 6. In all 4 patients with low complement levels at baseline, C3 and\u002For C4 returned to the normal range within 30 days. Of 9 patients who were positive for anti-dsDNA antibodies at baseline, 8 became negative, and 7 remained negative during follow-up. With a median follow-up of 10.2 months, 13 of the 14 patients who initially achieved DORIS remission, together with both patients who reached LLDAS, maintained remission or low disease activity without ongoing immunosuppressive therapy; one patient experienced disease relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Overall, this phase 1\u002F2 trial - which included patients with manifestations such as ITP, AIHA, and lupus nephritis - provides preliminary evidence that autologous CD19 CAR-T therapy can be both feasible and effective in SLE. The findings also suggest that cellular therapy before irreversible organ damage develops may help slow disease progression and reduce patients' long-term exposure to immunosuppressive treatment and its associated toxicity.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":604,"title":605,"summary":606,"cover":607,"category":430,"publishedAt":601,"contentHtml":608,"hasAlternate":73,"updatedAt":432},"asct-vs-car-t-consolidation-cns-lymphoma","International Journal Publication | Dr. Kai HU's Team: ASCT Associated with Better PFS Than CAR-T as Consolidation in R\u002FR CNSL Patients Who Regain Complete Remission","A study from Dr. Kai HU's team found that among chemosensitive patients with relapsed\u002Frefractory central nervous system lymphoma who regained complete remission, ASCT consolidation was associated with better 3-year progression-free survival than CAR-T therapy and a lower relapse rate.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F201d3d670a2924ce5fb14a8c866fe0f0.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Kai HU's team at Beijing GoBroad Hospital published a study in Cancer Immunology, Immunotherapy comparing autologous hematopoietic stem cell transplantation (ASCT) with CAR-T cell therapy as consolidation in patients with relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) who had regained complete remission. The study included 60 patients. Three-year progression-free survival was significantly higher in the ASCT group than in the CAR-T group (80% vs. 64.8%), and the cumulative incidence of relapse\u002Fprogression was lower (20% vs. 30.2%). The findings provide useful evidence to support consolidation-treatment decisions in this setting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) is difficult to treat, and outcomes can vary considerably depending on a range of clinical factors. For some patients who respond to salvage therapy and regain remission, guideline-based care commonly includes autologous hematopoietic stem cell transplantation (ASCT) as consolidation. In recent years, CAR-T cell therapy has also shown encouraging activity with manageable toxicity in R\u002FR CNSL. This has raised an important clinical question: for patients whose disease remains chemosensitive and who regain remission after relapse, can CAR-T consolidation achieve outcomes comparable to ASCT? Evidence directly comparing the two approaches has been limited.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, Dr. Kai HU's team from the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital published a paper in Cancer Immunology, Immunotherapy titled "Outcomes in patients with refractory\u002Frelapsed CNS lymphoma treated in complete remission: autologous transplantation vs. CAR-T therapy." Dr. Fan YANG was the first author. The study addresses this clinical question and provides new evidence to help guide consolidation choices for R\u002FR CNSL patients who have regained complete remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai HU explained: Relapsed\u002Frefractory central nervous system lymphoma is particularly challenging to treat. For patients whose disease remains chemosensitive and who can still achieve complete remission, the choice of consolidation therapy is critical. A practical question in clinical care is whether CAR-T consolidation can achieve a depth and durability of remission comparable to autologous hematopoietic stem cell transplantation (ASCT), thereby reducing the risk of later relapse and supporting long-term survival. To explore this question, Dr. Fan YANG and the team retrospectively analyzed 60 patients with R\u002FR CNSL who regained complete remission after chemotherapy. Among them, 42 patients (70%) had primary CNS lymphoma (PCNSL), while 18 (30%) had diffuse large B-cell lymphoma (DLBCL) with secondary CNS involvement. The study compared survival outcomes and relapse rates after subsequent ASCT or CAR-T consolidation. Patients who had previously undergone ASCT were excluded.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Key Findings\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Compared with CAR-T, ASCT Consolidation Was Associated with Better 3-Year PFS and a Lower Cumulative Incidence of Relapse\u002FProgression\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The median follow-up was 12.1 months (range, 1.28-59.9 months). Compared with the CAR-T group, patients who received ASCT while in complete remission had superior progression-free survival (PFS): 3-year PFS was 80% (95% CI, 48.4%-93.4%) with ASCT versus 64.8% (95% CI, 38.9%-81.9%) with CAR-T (P=0.026). The cumulative incidence of relapse\u002Fprogression was also lower: 20% (95% CI, 4.12%-44.39%) versus 30.2% (95% CI, 11.0%-52.2%) at 3 years (P=0.038). Among patients with primary CNS lymphoma (PCNSL), 2-year PFS was significantly higher in the ASCT group [92.9% (95% CI, 59.1%-99.9%) vs. 65.7% (95% CI, 31.0%-86.0%); P=0.026]. Among patients with secondary CNS lymphoma (SCNSL), 2-year PFS and overall survival (OS) numerically favored ASCT, although the differences were not statistically significant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F999d5546e64c2d0362d8984f70e058d0_20260914003942.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"999d5546e64c2d0362d8984f70e058d0_20260914003942.png\" alt=\"31a33058-2498-4e7a-a4f3-f927c9d5ac35.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. CAR-T Cell Expansion Was Detected in Cerebrospinal Fluid, with a Manageable Safety Profile\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The median CAR-T cell dose infused was 1.75 x 10^6 cells\u002Fkg (range, 0.16 x 10^6 to 10 x 10^6 cells\u002Fkg). Marked expansion of CAR-T cells in peripheral blood was observed in 36 of 37 patients after infusion (Figure 2A). The median peak level of CD19+ CAR-T cells was 7,465 lentiviral copies\u002Fμg DNA (range, 1,246-36,107), with a median time to peak of 10 days (range, 6-28 days). Cerebrospinal fluid was evaluated in 10 patients after infusion (Figure 2B), and CAR-T cells were detected in four. The peak level of CD19+ CAR-T cells in cerebrospinal fluid was 2,415 lentiviral copies\u002Fμg DNA (range, 81-2,914 copies\u002Fμg DNA).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F3491f83f0b053741fc962f20fa35d062_20260914003958.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3491f83f0b053741fc962f20fa35d062_20260914003958.png\" alt=\"14d35ed5-25f5-426c-9f23-9c3711f4504f.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 2\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The most common adverse event was neutropenia, reported in 57 patients (95%), followed by infection in 34 patients (56.7%) and hypogammaglobulinemia in 28 patients (46.7%). In the CAR-T group, six patients (22.3%) developed grade 1 cytokine release syndrome (CRS), and three (11.1%) experienced grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS). Overall, the safety profile was considered manageable.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Both ASCT and CAR-T Consolidation Showed Signals of Disease Control in Patients with TP53 or MYD88\u002FCD79B Alterations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among patients with these molecular alterations who received ASCT (n=7) or CAR-T therapy (n=11) after achieving complete remission, all patients in the ASCT group with detectable TP53 or MYD88\u002FCD79B alterations were alive at the time of analysis. Among patients with TP53 alterations, one experienced disease progression and two remained in complete remission. Among those with MYD88\u002FCD79B alterations, one progressed and the remaining nine were in complete remission. In the CAR-T group, all five patients with TP53 alterations were alive; one experienced progression and four remained in complete remission. Among 16 patients with MYD88\u002FCD79B alterations, one died after disease progression, two were alive with active disease, and 13 remained in complete remission. Larger studies are needed to better understand how consolidation therapy may affect outcomes in molecularly defined subgroups.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The team's preliminary findings suggest that ASCT remains a preferred consolidation strategy for R\u002FR CNSL patients who are sensitive to second-line chemotherapy and achieve complete remission. For patients who are in complete remission but are not eligible for ASCT, CAR-T therapy may be a potentially feasible consolidation option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai HU noted that the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital has accumulated substantial experience with CAR-T therapy for central nervous system lymphoma. As CAR-T use expands in real-world practice, clinicians are encountering increasingly complex treatment decisions. Identifying the right timing for CAR-T and developing individualized, precise, and longitudinal management strategies remain important priorities in hematologic oncology. In the future, integrated clinical, pathologic, molecular, and imaging assessments may help identify R\u002FR CNSL patients who are unlikely to benefit from conventional treatment but may benefit from precision CAR-T strategies. Tools such as circulating tumor DNA (ctDNA) monitoring may also help detect signs of relapse earlier and support more timely intervention, with the goal of extending survival.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":610,"title":611,"summary":612,"cover":613,"category":438,"publishedAt":280,"contentHtml":614,"hasAlternate":73,"updatedAt":74},"lung-cancer-precision-prevention-treatment-guide","Dr. Shuang LI Explains Precision Prevention and Treatment of Lung Cancer","Dr. Shuang LI answers key questions about who should be screened for lung cancer, the role of annual low-dose CT, precision treatment options, participation in clinical trials, and multidisciplinary team (MDT) care.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ffe972f01906240619fae3f376fac5566.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Early screening and treatment are central to lung cancer prevention and control. Dr. Shuang LI of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, addresses four questions patients commonly ask. People at higher risk - including those aged 50 or older with a long smoking history, a family history of lung cancer, or long-term exposure to cooking fumes - should pay particular attention to regular low-dose CT screening. Lung cancer treatment has entered an era of increasingly individualized, precision care: pathologic subtype should be established first, followed by molecular testing when appropriate. Treatment options now include targeted tyrosine kinase inhibitors (TKIs), PD-1\u002FPD-L1 immunotherapy, bispecific antibodies, antibody-drug conjugates (ADCs), and other approaches. Clinical trials vary by development stage, and patients can discuss potentially suitable studies with their treating physicians. MDT care brings together specialists from different disciplines to develop an individualized treatment plan and support whole-course management.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q1: Why is early lung cancer screening so important? Who should pay particular attention to screening, what screening method is recommended, and what should you do if a pulmonary nodule is found?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">       \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Shuang LI: Early screening is one of the most important tools for lung cancer prevention and control. People at higher risk who should be especially alert and consider regular screening include those aged 50 or older, people with a long-term smoking history or significant secondhand-smoke exposure, those with long-term occupational or environmental exposure to carcinogens such as dust or asbestos, and people with a family history of lung cancer in a parent or child. For Chinese women in particular, long-term exposure to cooking fumes may also be an important risk factor to consider. The screening method currently recommended is annual low-dose computed tomography (LDCT). LDCT can identify many pulmonary nodules, but not every nodule is lung cancer. Doctors assess the size and appearance of a nodule and, importantly, how it changes over time to help determine whether it is more likely benign or suspicious for cancer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If a pulmonary nodule is detected on low-dose CT, it is important to seek medical evaluation promptly so that a specialist can determine whether further testing, surveillance, or treatment is needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q2: What major advances have been made in lung cancer treatment in recent years? What treatment options are now available?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">              \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Shuang LI: Lung cancer has seen a particularly rapid pace of progress over the past two decades, with many new medicines, technologies, and treatment strategies emerging. The first point to understand is that lung cancer is not a single disease. Treatment has moved firmly toward individualized, precision care, which means an accurate diagnosis must come first. Clinically, the first step is to determine the pathologic type - for example, whether the cancer is non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). For NSCLC, molecular testing is also important to identify actionable driver alterations that may guide treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lung cancer treatment now goes far beyond conventional chemotherapy. Options can include small-molecule tyrosine kinase inhibitors (TKIs) for patients with suitable molecular targets, PD-1\u002FPD-L1 immune checkpoint inhibitors, and bispecific antibodies such as PD-1\u002FCTLA-4- or PD-1\u002FVEGF-directed agents. Antibody-drug conjugates (ADCs) have also become an important area of development, including HER2-directed ADCs. Overall, treatment may involve chemotherapy, targeted therapy, immunotherapy, ADCs, anti-angiogenic approaches such as VEGF-directed treatment, bispecific antibodies, and other emerging multi-specific strategies, depending on the individual patient's disease characteristics.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q3: How should patients understand and evaluate clinical trials? What can participating in a trial mean for them?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Shuang LI: Clinical trials attract a great deal of interest, but it is important to understand that Phase I, Phase II, and Phase III studies have different purposes. Some trials evaluate new uses of medicines that are already approved and have accumulated substantial safety and efficacy data. These studies may focus on expanding indications, optimizing treatment strategies, or exploring whether a drug can provide benefit in a new clinical setting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Other trials study medicines before they are approved for routine use and are designed to evaluate their safety and effectiveness in people at different stages of development. For patients considering a clinical trial, an important first step is to understand the question the study is designed to answer. Trials of investigational therapies may explore new targets, new treatment combinations, or innovative medicines, and can provide another potential treatment option for eligible patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For most patients and families without a medical background, the best approach is to discuss clinical-trial options directly with the treating physician and identify studies that are genuinely appropriate for the patient's condition. For people with limited standard treatment options, some early-phase studies may provide access to new therapeutic approaches and may also reduce some treatment-related financial burden. Phase III trials may also offer earlier access to newer treatment strategies that have not yet been incorporated into routine clinical guidelines. Whether a trial is suitable should always be assessed on an individual basis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Q4: This year's Cancer Prevention and Control Awareness Week emphasizes that "integration is key." How does this relate to the multidisciplinary team, or MDT, model?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Shuang LI: The core idea is that cancer care often requires specialists from multiple disciplines to work together - what we commonly call an MDT approach. Imaging specialists assess radiologic findings, while pathologists establish the pathologic diagnosis, including key molecular pathology results. Surgeons evaluate whether an operation is appropriate and, if so, the best timing. Medical oncologists develop systemic treatment plans, including whether a patient needs neoadjuvant therapy, first-line treatment for advanced disease, targeted therapy, or chemotherapy combined with immunotherapy. If radiotherapy is needed, the team must also decide where it fits into the overall plan and whether the goal is curative or palliative. Other specialists may also be involved when patients have conditions such as chronic obstructive pulmonary disease (COPD), heart disease, or diabetes. By considering the cancer stage together with the patient's overall health and coexisting conditions, the MDT can develop a more complete, standardized, and individualized treatment plan and support whole-course cancer care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Cancer prevention and treatment cover many different tumor types. Beyond lung cancer, gastrointestinal health also deserves attention, including appropriate screening for gastric disease and cancer and long-term management across the full course of care.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>",{"slug":616,"title":617,"summary":618,"cover":619,"category":438,"publishedAt":620,"contentHtml":621,"hasAlternate":73,"updatedAt":74},"avoid-misdiagnosis-lymphoma-family-cooperation","Expert Guide: How Can Lymphoma Misdiagnosis Be Avoided? What Patients and Families Can Do to Support a More Accurate Diagnosis","Prof. Zifen GAO and Dr. Yuehui LIN explain how integrated lymphoma diagnosis works, why misdiagnosis can occur, and how patients and families can help improve diagnostic accuracy.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F086051d8f4f9547d92445bb991ef0767.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-04-14","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Prof. Zifen GAO of the GoBroad Diagnostic Center and Dr. Yuehui LIN of Beijing GoBroad Boren Hospital explain why lymphoma pathology can be complex and why an integrated diagnostic approach is important. The article describes how morphology, immunophenotyping, and molecular testing are interpreted together; reviews common causes of diagnostic error, including inadequate specimens, atypical disease features, and incomplete testing; and uses a real case to illustrate the full diagnostic process in a difficult lymphoma case. It also offers practical guidance on how patients and families can prepare specimens and medical records for consultation and cooperate with additional testing when needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In lymphoma care, the pathology diagnosis is one of the most important factors guiding treatment. Yet many patients and families are left with the same questions:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Why can a biopsy still fail to provide a clear diagnosis? Why might pathology slides need to be reviewed at more than one hospital?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To address these concerns, Prof. Zifen GAO of the GoBroad Diagnostic Center and Dr. Yuehui LIN of Beijing GoBroad Boren Hospital explain why lymphoma can be difficult to diagnose and how integrated diagnostics can improve accuracy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Key Features of Lymphoma\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There are three important characteristics of lymphoma that patients and families may find helpful to understand:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. It can occur in many parts of the body. Lymphoma can involve almost any site other than structures such as hair and nails, including lymph nodes, the head and neck, chest, abdomen, skin, and bone.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Many types are highly treatable. Lymphoma is among the malignancies that can respond particularly well to treatment, and some subtypes can achieve high cure rates with approaches such as chemotherapy and targeted therapy.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Diagnosis can be difficult. Lymphoma cells may look very similar to normal lymphocytes under the microscope. Unlike many solid-tumor cells, which may show obvious abnormal morphology, lymphoma cells can resemble lymphocytes at different stages of differentiation. For this reason, morphology alone is often not enough to determine whether a lymphoid proliferation is benign or malignant.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. Why Integrated Diagnosis Matters\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lymphoma diagnosis should not rely on microscopic appearance alone. Several types of information usually need to be interpreted together:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Morphology is the foundation. Hematoxylin and eosin (H&E) staining allows pathologists to assess cell size, shape, arrangement, and tissue architecture and to begin distinguishing inflammation, reactive hyperplasia, and neoplasia. However, morphology alone has limitations and may not reliably establish the lineage or maturation stage of abnormal cells.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Immunophenotyping is critical. Antibody-based testing can identify abnormal cells at the cellular level through flow cytometry and at the tissue level through immunohistochemistry (IHC). Markers such as Ki-67, anaplastic lymphoma kinase (ALK), MYC, and lineage-associated proteins can help determine whether a process is malignant and define the immunophenotype and differentiation stage of the tumor cells. Distinguishing T-cell lymphoma from B-cell lymphoma is especially important because treatment approaches can differ substantially.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Molecular testing provides additional evidence. Some abnormalities are not apparent at the protein level and may require tests such as fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), or next-generation sequencing (NGS). These tests can identify tumor-associated genetic alterations and provide molecular evidence that supports the diagnosis.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Importantly, molecular results should not be interpreted in isolation from morphology and immunophenotyping. They are most useful as part of the overall diagnostic picture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Bringing these elements together - morphology, protein expression, and molecular findings - is what is meant by an integrated diagnosis. Clinical presentation and laboratory findings are also important parts of the final interpretation.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In many countries with established hematopathology systems, integrated hematologic cancer diagnoses are issued by pathologists, with the relevant diagnostic laboratories coordinated within pathology services. In China, different testing platforms have historically been distributed across separate departments, which can make integration more challenging. Even so, the integrated diagnostic model is increasingly being adopted because it can improve the precision of lymphoma diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. How Diagnostic Wording Affects Clinical Decisions\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The wording in a pathology report can indicate how certain the diagnosis is and whether it is ready to guide treatment:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Definitive diagnosis: Wording such as a specific lymphoma subtype indicates that the available evidence is sufficient for a clear conclusion. This type of diagnosis can be used by the clinical team to plan treatment.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Qualified or uncertain diagnosis: Wording such as "consistent with," "consider," "favor," or "possibly" indicates that some uncertainty remains. A report at this level may require additional investigation before it is used to guide definitive treatment. Starting treatment on an uncertain diagnosis can be risky if the underlying disease has been classified incorrectly.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Pathologists are deliberately cautious because an incorrect diagnosis can lead to ineffective treatment and, in some cases, irreversible harm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. Common Reasons Lymphoma Can Be Misdiagnosed\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Diagnostic discrepancies are not uncommon in lymphoma. The source article cites a series of more than 2,000 patients with refractory or relapsed lymphoma in which the initial diagnosis was incorrect in nearly 40% of cases. It also cites a French study involving more than 30,000 cases, in which close to 20% of diagnostic revisions had the potential to alter treatment. These findings highlight why expert review can be important in difficult cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Common causes include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Specimen-related problems: A needle biopsy may miss the actual lesion, or delayed fixation may allow tissue autolysis and reduce specimen quality.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The main ways to obtain tissue include excisional biopsy, core needle biopsy, and fine-needle aspiration. For a suspicious malignant lymph node, excisional biopsy is often preferred because it provides intact tissue architecture; the source article reports a diagnostic and staging accuracy of 96.8%. Core needle biopsy is widely used and can be highly informative, but in some cases the sample may be too limited or may not fully represent the lesion. Fine-needle aspiration is generally not recommended as the sole method for diagnosing lymphoma because it mainly provides individual cells without the tissue architecture that is often essential for lymphoma classification.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Atypical disease features: Some cases have unusual morphology and are difficult to classify.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Incomplete testing: Essential immunophenotypic markers or molecular studies may not have been performed.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Technical limitations: Some institutions may have limited testing platforms or variable quality-control systems.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. Experience-related factors: Pathologists without dedicated hematopathology experience may have less familiarity with unusual lymphoma patterns.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For difficult cases, specialist pathology consultation can therefore be an important step toward a more accurate diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. Integrated Diagnosis in Practice: A Case Example\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The following case illustrates how the different parts of an integrated diagnosis come together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Case Example\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient was a 22-year-old man who developed facial swelling, thickened lips, and enlargement of the liver and spleen beginning in December 2019. He later developed slurred speech and behavioral or mental-status changes. Over the next two years, he was evaluated at several hospitals in Shanghai and underwent a lip biopsy, tonsillectomy, and stereotactic brain biopsy, but no definitive diagnosis was reached.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In September 2021, he was referred to the hospital where Prof. Gao was practicing. The team reviewed his previous pathology slides. The lip biopsy showed a dense cellular proliferation, but the morphology was atypical. The brain biopsy contained abnormal cells, but there were insufficient immunophenotypic markers to determine their nature.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A skin biopsy showed no abnormality. The team recommended another biopsy. With the family's cooperation, an ultrasound-guided biopsy was obtained from an area of thickened muscle around the shoulder and upper arm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>The new evaluation showed:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Morphology: Normal muscle fibers were extensively destroyed and replaced by a relatively uniform population of abnormal, medium-to-large cells with clear cytoplasm. The morphology strongly suggested a T-cell neoplasm.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Immunophenotype: The abnormal cells were CD8-positive cytotoxic T cells, with a high Ki-67 proliferation index and loss of additional T-cell markers.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Molecular and flow-cytometric findings: Flow cytometry and gene-rearrangement testing both demonstrated a monoclonal T-cell population, supporting a malignant diagnosis.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The final diagnosis was mature T-cell lymphoma. The subtype was too rare to be classified more specifically, but the evidence clearly established a malignant tumor of T-cell origin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once the diagnosis was clarified, the clinical team developed a targeted treatment plan. At reassessment two months later, lesions throughout the body had largely resolved, the brain lesions had improved substantially, and the patient's symptoms were markedly better.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This case shows why an accurate diagnosis is the foundation of precision treatment, and why integrated diagnostics can be especially valuable in complex cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>6. How Patients and Families Can Help Support an Accurate Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients and families can help in several practical ways:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Help obtain the best possible specimen. When a lymph node biopsy is needed, clinicians generally select the most abnormal node - considering features such as firmness and imaging findings, not simply size. When several lymph-node regions are involved, the source article describes a preference for supraclavicular, cervical, axillary, and then inguinal nodes when clinically appropriate. An intact lymph node with a short-axis diameter of about 1.5-2 cm may provide a useful specimen. Needle biopsies can carry a risk of sampling error, and tissue should be fixed promptly after collection to reduce autolysis.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. When seeking a pathology review, try to obtain the original stained slides when possible. Some institutions provide only unstained slides rather than lending the original H&E and immunohistochemistry slides. Unstained slides are cut from different levels of the tissue block and are not exact copies of the original section, so they may not fully represent the same area of disease. Original stained slides can therefore be especially valuable for expert review.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Bring complete medical records to the consultation. This should include previous pathology reports, imaging studies, and a clear treatment history. Information showing that a previous treatment did not work can be particularly important because it may prompt reconsideration of the diagnosis.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Complete additional testing when recommended. If the pathologist or treating team recommends further immunohistochemistry or molecular testing, these studies may be necessary to clarify the diagnosis and guide the next treatment decision.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>7. What Integrated Hematologic Cancer Diagnosis Aims to Achieve\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">An integrated diagnostic approach has three main goals:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Provide a clear diagnosis so the clinical team can select an appropriate treatment plan.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Provide prognostic information, such as the proliferation index or genetic alterations associated with higher-risk disease.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Help guide treatment selection by identifying potential therapeutic targets and relevant drug options.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Precision treatment depends on precision diagnosis, and an individualized treatment plan can only be built on a sufficiently accurate understanding of the disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Pathologists have traditionally worked largely behind the scenes. Today, specialist consultations and more direct communication with patients and families are helping both sides better understand the diagnostic process. Pathology teams across centers continue to advance integrated diagnosis with the goal of providing more accurate and timely answers for patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Disclaimer: Expert opinions are provided for general reference only. Please consult your treating physician for individualized diagnosis and treatment decisions.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":623,"title":624,"summary":625,"cover":626,"category":430,"publishedAt":289,"contentHtml":627,"hasAlternate":73,"updatedAt":432},"low-dose-cd7-car-t-t-cell-lymphoma-clinical-study","International Journal Publication | Team Led by Dr. Kai Hu and Dr. Fan Yang Reports Phase I and Long-Term Follow-Up Data on Low-Dose CD7 CAR-T for Relapsed\u002FRefractory T-Cell Lymphoma","Dr. Kai Hu and Dr. Fan Yang's team published a study in Blood Cancer Journal showing that low-dose CD7 CAR-T maintained high response rates while reducing myelosuppressive toxicity.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F5f5846b9fe622b6bf1150e899c82c654.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Fan Yang from Dr. Kai Hu's team at Beijing GoBroad Hospital published a study in Blood Cancer Journal reporting Phase I clinical trial data and two-year follow-up results for low-dose CD7 CAR-T cell therapy in 40 patients with relapsed\u002Frefractory T-cell lymphoma. The low-dose strategy maintained a high response rate (ORR 92.5%; CR 77.5%) while reducing myelosuppressive toxicity. The study also showed that patients who achieved a response and then proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT) had longer survival. The two-year PFS and OS rates were reported as 40.1% and 53.7%, respectively.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, CAR-T cell therapy has become increasingly established in B-cell lymphoma, and clinical research on CD7-targeted CAR-T therapy for relapsed\u002Frefractory T-cell lymphoma has also expanded. Early studies have shown high short-term response rates with CD7 CAR-T. At the same time, prolonged post-treatment myelosuppression has been a concern because it can increase the risk of complications such as infection and may prevent some patients from proceeding to allo-HSCT. So how can clinicians preserve the high response rate of CD7 CAR-T while reducing later hematologic toxicity?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, Dr. Fan Yang from the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital, working with Dr. Kai Hu's team, published a paper in Blood Cancer Journal titled "Low-dose CD7 chimeric antigen receptor T cells for relapsed\u002Frefractory T-cell lymphomas: a single-arm, open-label, phase Ia\u002FIb study." The paper reports the team's Phase I study and long-term follow-up of low-dose CD7 CAR-T therapy in relapsed\u002Frefractory T-cell lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai Hu explained that relapsed\u002Frefractory T-cell lymphoma remains difficult to treat. For many patients, achieving another remission and then proceeding to allo-HSCT is an important route toward longer survival and potential cure. However, these patients are often highly resistant to chemotherapy, may be critically ill, have a high tumor burden, and face complications such as infection. Without an effective way to induce remission, many are not in a condition to undergo allo-HSCT. Preclinical and early clinical studies have demonstrated high initial response rates with CD7 CAR-T, but have also reported prolonged suppression of bone marrow hematopoiesis after treatment. To address this, our team conducted a Phase Ia dose-escalation study followed by a Phase Ib dose-expansion study, lowering the infused dose of CD7 CAR-T cells to explore whether a lower dose could preserve clinical activity while reducing adverse effects. We also report two-year follow-up data from the study.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study enrolled 40 patients with highly complex, refractory disease (median age 32 years; range 18-72). Thirty-five had T-lymphoblastic leukemia\u002Flymphoma and five had mature T-cell lymphoma. Patients had received a median of three prior lines of therapy (range 2-4), and 22 (55%) had previously undergone hematopoietic stem cell transplantation: 17 allo-HSCT and 5 autologous HSCT. Overall, 27.5% had bone marrow blasts above 25%, and 25% had central nervous system involvement. Phase Ia used a 3+3 dose-escalation design with three dose levels: 1 × 10⁴, 5 × 10⁴, and 1 × 10⁵ (±30%) CAR-T cells\u002Fkg. No dose-limiting toxicities (DLTs) were observed in the nine Phase Ia patients. In Phase Ib, 31 patients received 1 × 10⁵ (±30%) CAR-T cells\u002Fkg as the expansion dose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Key Findings\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Low-dose CD7 CAR-T showed robust in vivo expansion with manageable adverse events, although cytopenias remained an important concern\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CD7 CAR-T cells expanded well in vivo. By flow cytometry (Figure 1A), the median time to peak expansion was day 14 after infusion (range 7-30 days), with a median peripheral-blood count of 82.1 × 10⁶\u002FL (range 0.643-734). CAR transgene copies remained detectable by PCR for up to 396 days (Figure 1B). Among 10 patients with central nervous system involvement, CAR gene copies were detected in the cerebrospinal fluid of 7 patients (Figure 1C). Expansion did not differ significantly according to treatment response or whether the CAR-T cells were autologous or donor-derived.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F26762ecd8a6ed27573fc577a00c8565d_20260914005538.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"26762ecd8a6ed27573fc577a00c8565d_20260914005538.png\" alt=\"ede7d061-8b45-4f82-af29-acd06a47f239.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure 1\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cytokine release syndrome (CRS) occurred in 92.5% of patients, with only two cases of grade 3 CRS. Two patients developed immune effector cell-associated neurotoxicity syndrome (ICANS), one grade 1 and one grade 4. The most common adverse events were hematologic toxicities: grade ≥3 neutropenia occurred in 97.5% (39\u002F40) and grade ≥3 thrombocytopenia in 85% (34\u002F40). In some patients with delayed blood count recovery after donor-derived CD7 CAR-T, infusion of purified donor CD34+ cells successfully supported hematopoietic recovery. Within 30 days, 30% of patients (12\u002F40) developed infections, including 7 grade 3 infections. Among patients who had previously undergone HSCT, acute graft-versus-host disease (aGVHD) occurred in 23.5% (4\u002F17), all grade 1. Chronic GVHD (cGVHD) occurred in 30.8% (4\u002F13), including one case of grade 3 extensive cGVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Low-dose CD7 CAR-T produced high response rates, including in patients with extranodal disease and central nervous system involvement\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Across all dose levels, the overall response rate (ORR) was 92.5% (37\u002F40), with a complete response (CR) rate of 77.5% (31\u002F40). In the Phase Ib cohort (n=31), the ORR was 93.5% (29\u002F31) and the CR rate was 80.6% (25\u002F31). All five patients with mature T-cell lymphoma responded: two achieved partial response (PR) and three achieved CR. Among 17 patients who relapsed after HSCT and received donor-derived CAR-T cells, the ORR was 100% (14 CR, 3 PR). Response rates also remained high in patients with extranodal disease (90.6%, 29\u002F32) and those with central nervous system involvement (100%, 6\u002F6).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Bridging to allo-HSCT after remission induced by low-dose CD7 CAR-T was associated with longer survival\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With a median follow-up of 30 months (range 14-58 months), median progression-free survival (PFS) and overall survival (OS) among responders were 7.05 months (95% CI: 3.42-NE) and 16.34 months (95% CI: 4.47-NE), respectively. The two-year PFS and OS rates were 40.1% (95% CI: 22.2%-57.5%) and 36.9% (95% CI: 20.0%-53.9%). Among patients who proceeded to allo-HSCT after achieving remission with CD7 CAR-T, the two-year OS rate was 54.1% (95% CI: 26.7%-75.2%), compared with 23.1% (95% CI: 5.6%-47.5%) in those who did not receive allo-HSCT (n=13; P=0.038). Two-year PFS was also 54.1% (95% CI: 26.7%-75.2%) in the allo-HSCT group versus 23.1% (95% CI: 5.6%-47.5%) in the comparison group (P=0.063). Compared with the non-HSCT group, the allo-HSCT group also showed a trend toward a lower two-year cumulative relapse rate (25.5% vs. 64.3%, P=0.149). Among 11 patients who relapsed and underwent repeat assessment of tumor surface antigens, 4 remained CD7-positive, 2 showed low CD7 expression, and 5 had CD7-negative relapse. Antigen escape may therefore be an important mechanism of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F4fcd60c9773eadd16f8b4b50d5e7f6ba_20260914005556.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"4fcd60c9773eadd16f8b4b50d5e7f6ba_20260914005556.png\" alt=\"c839e31d-c5ad-439b-a4b6-4f290825567a.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure 2\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study suggests that low-dose CD7 CAR-T can produce high response rates in relapsed\u002Frefractory T-cell lymphoma with manageable toxicity. For patients who respond, subsequent allo-HSCT may provide an opportunity for improved long-term survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai Hu: In relapsed\u002Frefractory T-cell lymphoma, a CD7 CAR-T infusion dose of 1 × 10⁵ (±30%) CAR-T cells\u002Fkg can produce substantial clinical activity. At the same time, we observed that although short-term response rates are high, consolidation with allo-HSCT after CD7 CAR-T may help reduce relapse and prolong survival. Many questions remain. For example, three patients showed in vivo CD7 CAR-T expansion but did not respond, so the mechanisms of primary CAR-T resistance require further study. The long-term immunologic effects of CD7-targeted depletion on B-cell, T-cell, and NK-cell subsets also remain unclear. In addition, patients with T-cell lymphoma who relapse after allo-HSCT and then receive donor-derived CD7 CAR-T appear to experience more pronounced hematologic toxicity. The optimal supportive-care approach and timing of a possible second transplant in this population require further investigation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The Department of Lymphoma and Myeloma at Beijing GoBroad Hospital has accumulated extensive experience in CAR-T therapy for lymphoma. As real-world use of CAR-T continues to expand, the clinical questions are becoming increasingly complex. Choosing the right timing for CAR-T and developing individualized, precise, full-course management strategies remain major priorities in hematologic oncology. Looking ahead, integrated clinical, pathologic, molecular, and imaging diagnostics may help identify earlier which patients are unlikely to benefit from conventional treatment but may benefit from precision CAR-T strategies. Monitoring approaches such as circulating tumor DNA (ctDNA) may also help detect signs of relapse earlier and create opportunities for earlier intervention, with the goal of extending survival.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":629,"title":630,"summary":631,"cover":632,"category":438,"publishedAt":289,"contentHtml":633,"hasAlternate":73,"updatedAt":74},"acute-leukemia-care-guide","A Practical Care Guide for Acute Leukemia: Essential Information for Patients and Families","From everyday care and the management of anemia, bleeding, and infection to chemotherapy, radiotherapy, and catheter care, this guide covers key nursing and self-care considerations throughout acute leukemia treatment.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ff512d21e1fd54cb40801b5f1d4060a4d.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This guide is designed for patients with acute leukemia and their families, covering practical care needs from daily routines through active treatment. It includes infection-prevention measures such as laminar-flow bed isolation, nutrition with adequate protein and calories, appropriate rest and activity, and oral and perianal hygiene. It also explains how care may differ for anemia, bleeding - including nosebleeds, gum bleeding, and suspected intracranial bleeding - and infection. Additional sections address PICC care during chemotherapy, ways to manage nausea, vomiting, constipation, and diarrhea, cold compresses after pre-transplant radiotherapy, side-effect monitoring with targeted therapies, and post-transplant GVHD care. Psychological support is also highlighted to help patients and families feel more informed and supported throughout treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Acute leukemia can bring challenges such as anemia, bleeding, and infection, but thoughtful day-to-day care can make the treatment journey safer and more manageable. This guide brings together practical advice on everyday care, symptom management, and treatment support to help patients and families feel more prepared at each stage.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Everyday Care: Creating a Safer, More Supportive Recovery Environment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine care forms the foundation of treatment support. Families can focus on four key areas:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Keep the Environment Clean and Reduce Infection Risk\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Open windows each day to keep indoor air circulating, and avoid keeping flowers, plants, or pets indoors, as they may carry microorganisms.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients and family members should wear masks as advised. The source recommends N95 masks as the preferred option, including valved N95 masks for children aged 1-4, while children under 1 year should go out as little as possible. Avoid contact with people who have colds, influenza, or other contagious illnesses.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If a hospitalized patient's white blood cell count is low, the medical team may recommend a laminar-flow bed or another protective environment to further reduce infection risk.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Balance Rest and Activity to Avoid Injury\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Activity should match how the patient feels. Mild fatigue may still allow short walks, while moderate or severe fatigue may require reduced activity and more bed rest. For patients with an enlarged spleen, the source recommends lying on the left side and avoiding bending or impact to the abdomen to reduce the risk of splenic injury.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Children should be supervised during activity. Avoid running, jumping, or strenuous exercise that could lead to falls, bumps, or bleeding.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Support Recovery with Nutrition\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Choose foods that are high in protein, calories, and vitamins, such as eggs, milk, lean meat, and fresh fruits and vegetables. Avoid spicy foods and foods that are hard, rough, or sharp, as these can injure the oral lining.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If mouth ulcers develop, cook food until soft or choose easier-to-swallow options such as porridge or soft noodles. Avoid leftovers, pickled foods, smoked foods, and supplements such as cordyceps or ginseng, which may interfere with treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Watch Closely and Communicate Early\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Check the skin each day for bruising and look for swollen gums. Adults and children should have their temperature checked regularly. If fever develops, the source recommends recording the temperature every 30 minutes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Symptom-Based Care: What to Do in Different Situations\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Anemia, bleeding, and infection are among the most common problems in acute leukemia and require different approaches.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Anemia: Adjust Care According to Hemoglobin Level\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Care may differ depending on whether anemia is mild, moderate, or severe:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mild anemia (hemoglobin from the lower limit of normal down to 90 g\u002FL): light activity may be appropriate, but avoid overexertion.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Moderate to severe anemia (hemoglobin below 90 g\u002FL): reduce unnecessary activity and rest in bed when needed. If palpitations or shortness of breath occur, low-flow oxygen may be given as directed by the medical team.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Severe anemia: blood transfusion may be needed. After transfusion, watch for possible reactions such as rash or fever and report them promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Bleeding: Stay Calm and Act Quickly\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Nosebleed: pinch the soft part of the nose with your fingers and place a cold towel over the bridge of the nose. After 5 minutes, release pressure gently.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Bleeding gums: keep the mouth clean. If bleeding occurs, apply gentle pressure with sterile cotton. Rinse gently for at least 1 minute each time.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Possible intracranial bleeding: if projectile vomiting or loss of consciousness occurs, lay the patient flat with the head turned to one side and contact the medical team immediately while awaiting emergency treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When the platelet count is below 20 × 10⁹\u002FL, there is a risk of spontaneous bleeding even without injury. The source advises bed rest and avoidance of strenuous activity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Infection: Prevention First, Prompt Management When Needed\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Preventive measures:\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1) Environmental cleaning: the source recommends wiping floors, tables, and door handles daily with a chlorine-containing disinfectant. It also recommends ultraviolet disinfection once a day for 30 minutes, starting the timing 5 minutes after the lamp is switched on. Patients should leave the room during UV disinfection; if a patient cannot leave the bed, the source recommends shielding the eyes and skin with UV-protective covering.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2) Protective isolation: when the granulocyte count is below 0.5 × 10⁹\u002FL, protective isolation may be required, such as wearing isolation clothing and using a laminar-flow bed. Limit the number of caregivers and visitors and reduce contact with people from outside the household or care team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3) Personal hygiene: follow the principle of "three short, six clean" - keep hair, fingernails, and facial hair short, and keep the hair, skin, mouth, hands and feet, perineum, and perianal area clean.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Preventing Oral Mucositis During Chemotherapy, Radiotherapy, or Transplantation\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1) Prevention:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Check the mouth every day for ulcers, pain, or changes in taste.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Choose mouthwash according to the situation: the source recommends a broad-spectrum antibacterial mouthwash for routine use and nystatin rinse when fungal infection is present.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Rinse correctly: hold the mouthwash in the mouth and move the cheeks and tongue so the liquid reaches all areas of the oral mucosa. Rinse for at least 1 minute.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2) Toothbrushing: use a soft-bristled toothbrush when the platelet count is below 50 × 10⁹\u002FL. When the platelet count is below 20 × 10⁹\u002FL, the source advises avoiding toothbrushing and using a gentle mouthwash instead.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Treatment Support: Chemotherapy, Radiotherapy, Medications, and Catheter Care\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Care during treatment should closely follow the medical plan, with particular attention to managing side effects and maintaining treatment safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Chemotherapy Care\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A PICC line can be an important access route during chemotherapy. Protect it carefully when dressing or undressing and avoid pulling or tugging on the catheter.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For nausea or vomiting, take prescribed antiemetic medication in advance and rinse the mouth with warm water after vomiting. The source suggests a cup of honey water for constipation and rice water to replace fluids during diarrhea.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hair loss is temporary. A wig or hat can be prepared in advance, and the scalp can be washed gently with baby shampoo after hair loss begins.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Avoid foods or substances that may harm the liver or kidneys, such as moldy food or excessive medication use. Numbness or tingling in the fingertips may indicate neurotoxicity; keep warm and avoid contact with cold water.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Radiotherapy Care\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Drink more water the day before radiotherapy. Gently clean the treatment area with warm water and avoid irritating soaps. If the skin peels, do not pull at it - allow it to shed naturally.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After pre-transplant radiotherapy, the source recommends applying cold packs to both cheeks to help prevent parotitis. Rest quietly for 30 minutes after treatment and choose nutritious foods such as fish and spinach.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Medication and Catheter Care\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Targeted therapies may cause rash. Tell the doctor promptly so the treatment plan can be adjusted if needed. Medications that require refrigeration should be stored in the refrigerator compartment as instructed and protected from direct sunlight.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the PICC dressing becomes loose, contact a nurse for replacement immediately. When dressing, put the sleeve on the catheter side first; when undressing, remove that sleeve last to reduce the risk of catheter dislodgement.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Diet and Activity: Hydration and Appropriate Exercise\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Daily Fluid Intake\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For adults without edema or a fluid restriction, the source recommends more than 2,000 mL of fluid per day, or about 8 cups. For children, daily fluid needs are estimated by body weight:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Up to 10 kg: 100 mL\u002Fkg per day. For example, a 5 kg child would receive about 500 mL per day.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">10-20 kg: 100 mL\u002Fkg for the first 10 kg, plus 50 mL\u002Fkg for each kilogram above 10 kg. For example, a 15 kg child: 10 × 100 + 5 × 50 = 1,250 mL per day.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Above 20 kg: 1,500 mL per day for the first 20 kg, plus 20 mL\u002Fkg for each kilogram above 20 kg. For example, a 25 kg child: 1,500 + 5 × 20 = 1,600 mL per day.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For children with diarrhea or vomiting, additional fluid may be needed to replace daily losses. The source gives an example of adding 50-100 mL for each episode of diarrhea.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Exercise\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When the platelet count is above 50 × 10⁹\u002FL, the source suggests outdoor walking of no more than 5,000 steps per day, while keeping warm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Two months after hematopoietic stem cell transplantation, if the white blood cell count is above 3 × 10⁹\u002FL, outdoor activity such as walking or tai chi may be increased gradually, while strenuous exercise should still be avoided.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Important: Know the Early Signs of Infection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Tell the medical team immediately if any of the following occurs, so a possible infection can be assessed promptly:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Axillary temperature above 37.5°C, or an abnormal temperature in a child;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Chills or shaking;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. Cough, runny nose, or sore throat;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">4. Burning with urination, urinary frequency, urgency, or pain, which may indicate a urinary tract infection;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">5. More than two episodes of loose stool in one day, which may indicate an intestinal infection;\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">6. Redness, swelling, or pain around the perineum, genitals, or anus; 7. Redness, warmth, swelling, or pain of the skin or at an injection site, which may indicate a local infection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The road through leukemia treatment may be long, but every normal temperature reading, every meal you are able to eat, and every restful night's sleep can be a small milestone. We hope every patient can move steadily toward recovery and return to everyday life.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":635,"title":636,"summary":637,"cover":638,"category":506,"publishedAt":307,"contentHtml":639,"hasAlternate":73,"updatedAt":432},"children-photography-exhibition-hospital","I Left Two Cameras with Children in the Hospital. A Month Later, Their Photos Left Me Speechless...","Children receiving long-term treatment for blood disorders captured moments of warmth and beauty through their own cameras, and a photography exhibition brought a glimpse of spring into the hospital.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fc3c5f57244ea04a6a36e3a4f47cbc1d1.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Beijing GoBroad Boren Hospital, the Sunshine Charity Ward School, and photographer and content creator Yang from the social media account “Yibu Che Shenghu” jointly organized a photography exhibition for children undergoing long-term treatment for blood disorders. After attending a photography class in February, the children were given two cameras to document light and shadow, family members, and small moments from everyday life. The article shares the stories of several young photographers, including 15-year-old Nini, Nuo Nuo, who is nearly 10 years post-transplant, and 12-year-old Han Han. Their photographs capture sunlight on an orange leaf, an art stall during Chinese New Year, the national flag beneath Zhengyang Gate, and a mother making a heart gesture for the camera. A camera was also donated to the Ward School so that the children could keep recording their lives, while the event called greater attention to the educational and companionship needs of children facing long hospital stays.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A little after 8:00 a.m. on March 25, a surprise was quietly taking shape in the first-floor lobby of the outpatient building at Beijing GoBroad Boren Hospital (the “Hospital”). Yang, who runs the social media account “Yibu Che Shenghu,” had joined the Sunshine Charity Ward School and the Hospital to prepare a photography exhibition for the children.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The photographers behind the images were children undergoing long-term treatment for blood disorders. In February, Yang had visited the Ward School to teach them a photography class. He left two cameras behind and encouraged the children to take whatever caught their eye, promising that they would look through the photos together after Chinese New Year.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A month later, the children’s photographs amazed everyone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fefdec3dee5b06f84b7c6b9c41c8885b8_20260914011459.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"efdec3dee5b06f84b7c6b9c41c8885b8_20260914011459.png\" alt=\"03c75d38-1080-43eb-8af0-d1836c603c69.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F1623614dbd36f92ddfb22855be08db7b_20260914011508.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1623614dbd36f92ddfb22855be08db7b_20260914011508.png\" alt=\"2a8876be-5743-47e6-bc58-e659bdb30da9.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Yang unveils the photography exhibition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hospital rooms may be white, but through the children’s lenses, the world is full of color -\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Leaves and sunlight, paint and brushes at a street stall, buildings and lanterns seen on outings, the family members they love most, and the warm everyday moments they share at the nearby “patient family home.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At 10:00 a.m., the young photographers began arriving in the outpatient lobby with their families. All of them had completed stem cell transplantation and were living near the Hospital while returning regularly for follow-up visits or treatment for graft-versus-host disease (GVHD).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the children, simply being able to come out and join the exhibition was a joyful occasion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Nini, a 15-year-old girl from Sichuan, still speaks with a warm Sichuan accent. Four months after her transplant, she was looking well and already thinking about home. “Once it’s been six months since my transplant, I can go home,” she said with anticipation. Her photographs “Verdant Glow” and “Spring” drew praise from Yang and everyone at the exhibition. Explaining one image, she said, “It’s an orange leaf that was lying on the table. Light happened to be refracted through a water bottle onto it, and I thought it looked beautiful.” An ordinary leaf and an unexpected beam of light became a landscape through her eyes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F9617fc554a2e660437509bea5ac734ab_20260914011524.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9617fc554a2e660437509bea5ac734ab_20260914011524.png\" alt=\"0a54b079-a749-4b50-a25d-96212e501185.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Nini’s photograph, “Verdant Glow”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F81c8c50f15fe2719e82d336564d78254_20260914011536.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"81c8c50f15fe2719e82d336564d78254_20260914011536.png\" alt=\"26661ce0-a4ac-4791-af84-72eec60ddcd2.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Nini’s photograph, “Spring”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Nuo Nuo, 20, is nearly 10 years post-transplant and continues to receive treatment for GVHD and other treatment-related effects. Her body may still be tied to the hospital for now, but she has never lost her eye for beauty. During Chinese New Year, she went for a walk through the hutongs and noticed someone painting at a small street stall. She photographed the casually scattered brushes, along with glowing lanterns, a bright lion dance, and sparrows perched on tree branches - small moments of life outside the hospital, carefully collected through her lens.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F701a557bc930e5e5d2b828dddd105796_20260914011546.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"701a557bc930e5e5d2b828dddd105796_20260914011546.png\" alt=\"8ac33b38-c94e-41d1-a64a-b16be550166e.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Nuo Nuo’s photograph, “A Carnival of Paint”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fd65b620acbbf46a211582cb61e989ceb_20260914011559.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d65b620acbbf46a211582cb61e989ceb_20260914011559.png\" alt=\"76b99a78-76ee-44c6-8cc2-0a5d27c9dd5e.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Nuo Nuo’s photograph, “A Curtain of Lantern Light”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Han Han, 12, is something of a class favorite at the Ward School. Dressed in a red jacket and red cap, he was full of energy, nearly two years after his transplant. He was unable to go home for Chinese New Year, so his family took him to Qianmen Street, where he photographed Zhengyang Gate and the red national flag in the sunlight. “I still can’t eat the food there...” he said, sounding a little disappointed. “Keep getting stronger, and you’ll be able to one day,” someone told him. He nodded and smiled.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F17f64b9e2842391fd212ec86266198d3_20260914011612.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"17f64b9e2842391fd212ec86266198d3_20260914011612.png\" alt=\"ea6f4198-7c37-4b7b-88bc-ef57c1c39819.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Han Han’s photograph, “Beneath Zhengyang Gate”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fbd51772b64689374b0f7d07ddbdc0269_20260914011623.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"bd51772b64689374b0f7d07ddbdc0269_20260914011623.png\" alt=\"a423753b-8c51-4b8e-9515-1b6d9dae6d25.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Han Han poses with his photograph.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Through 18-year-old Shan Shan’s camera, family love and the warmth of their temporary home take center stage. While staying at the “patient family home” over Chinese New Year, he photographed his family making dumplings and celebrating with the traditional Chinese character for “fortune.” On a recent outing, his mother sat on a bench among rose bushes, holding a bouquet and making a heart gesture toward the camera. Shan Shan called the photo “Rose Princess.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F64e0eda5ef7f974cb0cdd23aa17897ee_20260914011636.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"64e0eda5ef7f974cb0cdd23aa17897ee_20260914011636.png\" alt=\"a1dda177-9ed4-43d0-8f1f-208076ad6586.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Shan Shan’s photograph, “Rose Princess”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F57c1fa53870548a162033a67188149ad_20260914011647.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"57c1fa53870548a162033a67188149ad_20260914011647.png\" alt=\"12175a2d-0521-4edc-8f50-aec9eb97bdbf.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Shan Shan with his family\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Yan Yan sat in a wheelchair wearing a beautiful Chinese-style jacket, her hair carefully braided - a small detail that made her mother’s love easy to see. She and her mother live nearby. Her mother said their family had received a great deal of help from kind-hearted people during Yan Yan’s treatment, and she now volunteers part-time as a way of giving something back. Several years ago, treatment side effects led to muscle wasting in Yan Yan’s legs, and she has needed a wheelchair since then. Even so, she remains in good spirits. “As long as she’s happy,” her mother said. Recently, her mother took her to Zhuozhou to see a lantern festival, where Yan Yan photographed this Jade Rabbit display.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Faaa3339d21eec7807d6ac7ae228b8acd_20260914011658.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"aaa3339d21eec7807d6ac7ae228b8acd_20260914011658.png\" alt=\"1b32be95-5965-45f9-b5d2-3d8be2f8fae4.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Yan Yan’s photograph, “Jade Rabbit”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fd42d3c52c26ab2c1d6d0cff8518eabf6_20260914011709.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d42d3c52c26ab2c1d6d0cff8518eabf6_20260914011709.png\" alt=\"7f84e64d-cc29-49ae-aba4-a9a5403f12d4.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Yan Yan beams as she receives her certificate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chen Chen, 11, arrived dressed all in black and looking effortlessly cool. Nearly two years after his transplant, he appeared to be recovering well, laughing and joking with the other children - the kind of carefree moments every child deserves. For his photograph “Fortune at the Table,” he casually arranged sunflower seeds and fruit during Chinese New Year, turning an ordinary scene into a picture filled with festive warmth.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fa611c2624a58b7b656fc4e177d454b84_20260914011722.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"a611c2624a58b7b656fc4e177d454b84_20260914011722.png\" alt=\"48ff0449-7805-4ec0-bc79-ca9ea64789fb.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Chen Chen’s photograph, “Fortune at the Table”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As the exhibition came to a close, Yang presented each young photographer with a certificate and a picture book. He also donated a camera to the Ward School so the children could continue taking pictures whenever inspiration struck and keep documenting the good moments in their lives. Yang said he hopes to return for more activities in the future. On behalf of the Ward School, teacher Xin Xin gave Yang a gift from the children and their parents: two large bags of oranges.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F819e252f676b27b984c0fbd55d24338d_20260914011733.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"819e252f676b27b984c0fbd55d24338d_20260914011733.png\" alt=\"78a28c83-d596-4b5b-b175-811784f66d6c.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Group photo at the end of the event\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hospital rooms may be white, but the world in a child’s eyes has never been colorless.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The Sunshine Charity Ward School exists for exactly this reason. The program provides companion-based education for children aged 3-14 who are hospitalized long-term with serious illnesses, helping bring learning, connection, and color back into their lives. We believe illness may limit where a child can go, but it cannot take away curiosity about the world, the ability to see beauty, or the desire to enjoy life. Give them a little light, and their world can shine.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Our thanks to Yang, creator of “Yibu Che Shenghu,” for opening a window for the children through photography and adding another touch of color to the Ward School with his kindness.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">And thank you to every young photographer. The beautiful moments you captured remind us that even in a hospital, spring can still be found.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":641,"title":642,"summary":643,"cover":644,"category":438,"publishedAt":307,"contentHtml":645,"hasAlternate":73,"updatedAt":432},"cd7-car-t-relapsed-refractory-acute-leukemia","xpert Insights: CD7 CAR-T for Relapsed\u002FRefractory Acute Leukemia Offers New Treatment Possibilities","Specialists at Beijing GoBroad Boren Hospital share two real-world cases illustrating the clinical use of CD7 CAR-T in relapsed\u002Frefractory acute leukemia.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fb71ed3b552f5d9dcc76b2e376405b9cb.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: A specialist team at Beijing GoBroad Boren Hospital shares two clinical cases of CD7 CAR-T cell therapy for relapsed\u002Frefractory acute leukemia. A 12-year-old boy with T-cell acute lymphoblastic leukemia (T-ALL) and severe infection achieved MRD-negative complete remission after three CAR-T infusions and was able to proceed to hematopoietic stem cell transplantation. An 18-year-old with primary refractory mixed phenotype acute leukemia (MPAL) achieved his first remission after two CAR-T infusions. Together, the two cases illustrate how CD7 CAR-T may provide another treatment option for selected patients whose disease has not responded to conventional therapy, while adding practical experience for the management of these complex cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed\u002Frefractory acute leukemia (R\u002FR AL) remains one of the most difficult challenges in hematology. Conventional treatment may provide limited benefit, and outcomes can be poor. CAR-T cell therapy has opened a new treatment window for some patients. CD7 is highly expressed on many T-lineage leukemia cells, making it a potential therapeutic target. In this article, Dr. Lihong An and Dr. Huanhuan Guan from the team led by Dr. Shuangyou Liu at Beijing GoBroad Boren Hospital share two clinical cases of CD7 CAR-T therapy in relapsed\u002Frefractory acute leukemia, offering a closer look at how this approach has been used in practice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case 1\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>T-ALL with Severe Infection: MRD-Negative Complete Remission After Three CAR-T Infusions\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Patient Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient was a 12-year-old boy who first presented on January 13, 2025, with scattered bleeding spots across his body. His white blood cell count was 321.93 × 10⁹\u002FL. Bone marrow aspiration and integrated MICM testing confirmed T-cell acute lymphoblastic leukemia (T-ALL) with a SIL-TAL1 fusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He first received one cycle of VDLD induction chemotherapy and achieved complete remission, followed by regular treatment according to the CCLG-ALL-2018 protocol. In early September of the same year, he developed a perianal infection and septic shock during a period of neutropenia and required intensive anti-infective treatment as well as repeated perianal debridement. In October, vision in his right eye deteriorated and was eventually lost. Repeated lumbar punctures showed a markedly elevated white blood cell count in the cerebrospinal fluid, reaching as high as 2,115 × 10⁶\u002FL, and flow cytometry showed that 98.82% of the cells were T-ALL cells. While receiving repeated lumbar punctures with intrathecal therapy at another hospital, his nutritional status became extremely poor. He required an ileostomy for bowel diversion and continued to have severe postoperative perianal suppuration and pulmonary infection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To pursue CAR-T therapy, he was transferred to Beijing GoBroad Boren Hospital on November 4, 2025.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Evaluation and Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fb204be4a5ddd58b6f399e87b0443673d_20260914000110.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"b204be4a5ddd58b6f399e87b0443673d_20260914000110.png\" alt=\"4ca19992-f488-473f-ba44-d97e8499168c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Acute lymphoblastic leukemia (ALL) is a type of acute leukemia and the most common malignancy in children. It arises from abnormal B- or T-lineage lymphoid precursor cells. As leukemia cells proliferate and accumulate in the bone marrow, they suppress normal blood-cell production, which can lead to anemia, thrombocytopenia, and neutropenia. Leukemia cells may also spread outside the bone marrow to sites such as the meninges, gonads, thymus, liver, spleen, lymph nodes, or bone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this child, relapse initially involved the central nervous system and later progressed to more widespread disease. His CAR-T treatment course lasted about six weeks. The first two CAR-T infusions, together with decitabine used in an attempt to promote CAR-T expansion, did not produce the expected response, and hematologic relapse occurred. The medical team considered proceeding directly to transplantation once the infection was controlled and his nutritional status improved, to avoid losing disease control. After careful discussion and continued treatment, a third infusion was given. This time, the CAR-T cells expanded successfully, CD7-positive cells became undetectable, and the patient ultimately achieved complete remission in both bone marrow and cerebrospinal fluid. He was then able to bridge successfully to hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case 2\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Primary Refractory Mixed Phenotype Acute Leukemia: Complete Remission After Two CAR-T Infusions\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Patient Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient was an 18-year-old male who initially presented with a mass on the right side of his neck. On September 29, 2025, his white blood cell count was 345.84 × 10⁹\u002FL. On October 1, he was evaluated at a tertiary hospital in Beijing. Bone marrow MICM testing led to a diagnosis of T\u002FB mixed phenotype acute leukemia (MPAL). He subsequently received CODP chemotherapy, venetoclax plus daratumumab, and double-induction chemotherapy with Hyper-CVAD-B, but none produced an adequate response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">He was transferred to Beijing GoBroad Boren Hospital with febrile neutropenia. After intensive anti-infective treatment, peripheral-blood flow cytometry showed 85.11% abnormal immature lymphoid cells expressing both T- and B-lineage markers, together with aberrant expression of the myeloid antigen CD13. He was transferred to the team for further treatment on November 17.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Evaluation and Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F9a832bf288377fa14a8a24a8855d09c7_20260914000132.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9a832bf288377fa14a8a24a8855d09c7_20260914000132.png\" alt=\"7b13eb51-9f0a-4773-8690-2069f33c8f2c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Mixed phenotype acute leukemia (MPAL) is a rare form of acute leukemia in which leukemia cells express markers from more than one hematopoietic lineage, either simultaneously or sequentially. Its clinical features can resemble those of other acute leukemias, but patients may have very high circulating leukemia-cell counts and more frequent enlargement of the liver and spleen, reflecting a high disease burden and aggressive biology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient had not responded to prior double-induction chemotherapy combined with antibody and targeted therapies and was considered to have primary refractory MPAL. At admission to Beijing GoBroad Boren Hospital, he had febrile neutropenia and a high tumor burden. While treating the infection aggressively, the team worked to control the leukemia burden and closely monitored the proportion of circulating tumor cells. This allowed them to capture a very narrow window for cell collection and begin manufacturing humanized CD7 (hCD7) CAR-T cells at an appropriate time. The first manufactured product yielded a relatively low cell dose, and no meaningful CAR-T expansion was detected after infusion. Ten days after the second infusion, the patient developed fever followed by liver injury, coagulation abnormalities, and other cytokine-mediated reactions. CAR-T expansion remained slow at first, and the proportion of CD7-positive cells stayed high. About two weeks after the second infusion, flow cytometry began to show progressive CAR-T expansion and a gradual decline in CD7-positive cells. One month after infusion, bone marrow assessment showed morphologic remission, with only a small amount of residual leukemia detected by flow cytometry and a clear CAR-T cell population still present. This was the first remission achieved since diagnosis and created a more favorable window for subsequent allogeneic hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Expert Perspective\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For these two patients with relapsed\u002Frefractory acute leukemia that had not responded to conventional treatment, CD7 CAR-T provided another potential treatment pathway and produced meaningful clinical responses. Treatment-related adverse events that occurred during therapy were managed with supportive and symptom-directed care. These cases add practical experience to the emerging use of CD7 CAR-T in R\u002FR acute leukemia and suggest that it may be an option worth considering for carefully selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Looking ahead, we will continue to refine CD7 CAR-T–related technologies and explore how this approach may be combined with other treatment strategies. The goal is to improve both efficacy and safety and to create more treatment possibilities for patients with relapsed or refractory hematologic malignancies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: justify; break-after: avoid;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Disclaimer: The cases described in this article are based on real clinical treatment experiences and are shared for informational purposes only. They should not be used as treatment guidance for other patients.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":647,"title":648,"summary":649,"cover":650,"category":438,"publishedAt":307,"contentHtml":651,"hasAlternate":73,"updatedAt":74},"shen-lin-immunology-cell-immunotherapy-explained","Prof. Lin Shen Explains Immunotherapy | Understanding Cellular Immunotherapy","hrough a doctor-patient conversation, Prof. Lin Shen explains how cellular immunotherapy works, how CAR-T cells recognize and attack cancer, and how treatment-specific side effects such as cytokine release syndrome can be identified and managed.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F2791af927d7d38fee690e05c1d2e8c6d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In a conversational Q&A, Prof. Lin Shen walks patients and families through the principles and key features of cellular immunotherapy. The discussion explains how immune cells attack cancer, how CAR-T therapy uses engineered T cells to more precisely recognize tumor cells, and how treatment-specific side effects such as cytokine release syndrome (CRS) are recognized and managed. The goal is to help patients better understand how cellular immunotherapy differs from conventional chemotherapy and make more informed treatment decisions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Oncologists hear many questions from patients and families every day: “What is cancer immunotherapy?” “How is immunotherapy different from chemotherapy?” “How does immunotherapy kill cancer cells?” These questions show that many people still have uncertainties about immunotherapy - and that patients and families often share the same concerns.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">We grouped together the questions patients ask most often, drew on the frontline experience of oncology doctors and nurses, and also listened to feedback from patients and families. The aim is to explain the issues people care about most in clear, easy-to-understand language.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Doctor, you mentioned cellular immunotherapy to me yesterday. I still don't really understand it, so I brought my child with me today. Could you explain it to us in a little more detail?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Of course. Please, have a seat. Mr. Liu, as you know, we've already tried most of the treatment options currently available for your condition, but the tumor is still growing. So the next option we're considering is cellular immunotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: I understand. But what exactly is cellular immunotherapy?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Our bodies naturally contain immune cells. You can think of them as the body's security guards. Under normal circumstances, they recognize and attack invading bacteria and viruses - and they can also attack cancer cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Then why does my tumor keep growing?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Cancer cells are very good at escaping the immune system. They can disguise themselves, send misleading signals, or suppress immune-cell function. This allows them to evade immune attack, continue multiplying, and drive tumor growth.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: If cancer cells are that good at escaping, can cellular immunotherapy still work?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Cellular immunotherapy involves collecting immune cells from the patient and processing and expanding them outside the body. The goal is both to restore or strengthen their ability to attack cancer and to increase their numbers. The cells are then infused back into the patient so they can target tumor cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: I think I understand the idea. It sounds reasonable - but how well does it actually work?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: What I've described so far is the principle behind the treatment. Many forms of cellular immunotherapy are still being studied in clinical trials. In June 2021, China's first approved cellular immunotherapy product entered the market.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Doctor, I have one more question. I hope you don't mind me asking. A few years ago, there was a young man in the news who also received something called cellular immunotherapy. He spent a lot of money, but it didn't seem to help at all. How is that different?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: There are many different immune-cell approaches, including dendritic cells (DCs), cytokine-induced killer (CIK) cells, DC\u002FCIK therapy, chimeric antigen receptor T-cell (CAR-T) therapy, and T-cell receptor-engineered T-cell (TCR-T) therapy. These technologies have continued to evolve, and some have become considerably more mature in recent years.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: In my case, which type of cellular immunotherapy would you recommend?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: We would recommend CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: What makes this treatment different?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: First, CAR-T therapy modifies your own T cells - not dendritic cells (DCs) or cytokine-induced killer (CIK) cells. T cells are powerful immune cells and can mount a strong attack against cancer cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Second, in the laboratory, genetic engineering is used to give the T cells a chimeric antigen receptor, or CAR. You can think of the CAR as a highly specific navigation system that helps guide the T cells toward a particular target on cancer cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Third, these engineered T cells are stimulated and expanded in large numbers outside the body, and then infused back into the patient to attack the tumor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Once the T cells have been modified, can they cause side effects? Will it feel like chemotherapy?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: The side-effect profile is different from chemotherapy. CAR-T therapy does not typically cause the same pattern of nausea, vomiting, fatigue, and bone marrow suppression associated with chemotherapy. However, when the T cells become highly activated and attack tumor cells, they can release large amounts of cytokines. This can lead to treatment-specific reactions such as fever, low blood pressure, and low oxygen levels.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: I see. Thank you for explaining it. We'll think it over before making a decision.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cem>\u003Cspan style=\"font-size: 15px;\">Getting Ready to Begin Cellular Immunotherapy\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Mr. Liu, we've completed all the preparation for your cellular immunotherapy. Your cells will be infused tomorrow. How are you feeling - ready to go?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Doctor, what is there to prepare for? I've already been through some very tough chemotherapy. Surely this can't be harder than that?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Mr. Liu, cellular immunotherapy works very differently from chemotherapy, so the reactions we watch for are also different.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: I know they're different treatments, but aren't they both trying to kill the tumor? I assumed the side effects would be similar.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Not exactly. Chemotherapy mainly relies on the cytotoxic effects of drugs to damage cancer cells. Cellular immunotherapy uses immune cells that originally came from your own body. It generally does not produce the same pattern of nausea, vomiting, or bone marrow suppression seen with chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: So does that mean it's much safer and easier to tolerate? What reactions should I expect most?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Fever is one of the most common reactions. It's one of the ways the immune system signals that it is highly activated. If the immune response becomes too intense, the fever can be persistent and high, and in more severe cases blood pressure and oxygen levels can fall. This is called cytokine release syndrome, or CRS.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: How often do these reactions happen?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Fever is very common. Low blood pressure and low oxygen levels are less common, and when they do occur, they can usually be managed with medication and supportive care. Other reactions can also occur, but most are relatively mild.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: That's reassuring. What other side effects can happen?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: The rise in cytokines can also increase the permeability of normal blood vessels, allowing fluid to leak into surrounding soft tissues and cause swelling. A small number of patients may also develop effects involving the central nervous system.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: Central nervous system effects? What can those look like?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: They can present in different ways, including difficulty speaking clearly, drowsiness, changes in consciousness, impaired thinking or cognition, reduced movement or weakness, and, in severe cases, brain swelling or seizures.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: If a severe reaction does happen, can it be treated?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Lin Shen: Yes. With prompt and appropriate management, most of these reactions can be controlled effectively. In most cases, they are reversible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: That's good to know. Thank you, doctor. I feel much more reassured after hearing your explanation, and I'll work closely with the medical team throughout treatment.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":653,"title":654,"summary":655,"cover":656,"category":430,"publishedAt":657,"contentHtml":658,"hasAlternate":73,"updatedAt":432},"patient-medical-news-roundup-2026","Recent Updates for Patients: Lower Drug Prices Through Centralized Procurement, New Reimbursed Medicines, and Progress in China-Developed Cancer Drugs","A quick roundup of recent updates on centralized procurement, reimbursement, new medicines, and clinical research to help patients stay informed about treatment developments.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F3a5b50b6cd9367aff79ef86395f18be4.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-03-18","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Several recent policy and treatment updates may be especially relevant to patients with blood disorders and cancer. These include lower prices for some platelet-boosting medicines following national centralized procurement, implementation of the updated National Reimbursement Drug List, the addition of several innovative lung cancer medicines to reimbursement coverage, and new clinical data for a China-developed HER2-targeting ADC. These developments may help ease medication costs while expanding treatment options. This article summarizes recent policy, drug, and clinical research updates to help patients and families stay informed and support informed discussions with their healthcare teams.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As “BoYi Tongxing,” a dedicated community for patients with blood disorders and cancer, we closely follow the issues that matter most to patients. We have recently gathered several practical updates—from lower drug prices under centralized procurement and new clinical data for important cancer therapies to personal income tax relief related to major medical expenses. We hope these updates provide timely and useful information for patients and families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Centralized Procurement Takes Effect, Lowering Prices of Platelet-Boosting Medicines\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Platelet-boosting medicines are essential for many patients with leukemia, but their cost has placed significant pressure on some families. In February 2026, the 11th round of China’s national centralized drug procurement took effect. Across 55 medicines, prices fell by an average of 57%, while six products—including avatrombopag tablets—saw price reductions of more than 98%. Prices for several platelet-boosting medicines have already been adjusted in provinces including Gansu and Hebei, and some patients have received prescriptions at the new procurement prices. Patients can check with their hospital or doctor, or consult official local channels, to confirm whether the policy has been implemented in their area.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F6b3615e7d03478bfad4a8b4259a08d24_20260914020218.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6b3615e7d03478bfad4a8b4259a08d24_20260914020218.png\" alt=\"1b396bc6-6f4e-4b14-9661-41a89920c473.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>More Lung Cancer Medicines Added to Reimbursement Coverage and Available at Shanghai GoBroad Cancer Hospital\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">China’s updated National Reimbursement Drug List (NRDL) took effect on January 1, 2026, adding 114 medicines, including 37 anticancer drugs. Several medicines for lung cancer are now included in reimbursement coverage and can be prescribed at Shanghai GoBroad Cancer Hospital. Key information is summarized below:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Trastuzumab Rezetecan for Injection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a HER2 (ERBB2) activating mutation who have received at least one prior systemic therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Antibody-drug conjugate (ADC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Garsorasib Tablets\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Pralsetinib Capsules\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Selpercatinib Capsules\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Taletrectinib Adipate Capsules\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Fulzerasib Tablets\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Eligible patients: Adults with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">◆ Drug type: Targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>New Clinical Data for a China-Developed Cancer Drug Bring New Treatment Potential for Gastrointestinal Cancers\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Phase I clinical data have been published for trastuzumab rezetecan, a China-developed HER2-targeting antibody-drug conjugate (ADC), in patients with advanced gastric\u002Fgastroesophageal junction adenocarcinoma (GC\u002FGEJ) and colorectal cancer (CRC). The findings were published in the Journal of Clinical Oncology (JCO; impact factor: 43.4). Professor Jin Li, President of Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, served as the corresponding author. The early-phase results showed promising antitumor activity and safety findings in patients with HER2-expressing GC\u002FGEJ and CRC.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A Phase III study of trastuzumab rezetecan as second-line treatment for GC\u002FGEJ (NCT06123494) is currently underway. In addition, the application for a new indication in colorectal cancer has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration and granted priority review.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F224fcd928cd42b9a667a70c99967f33b_20260914020256.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"224fcd928cd42b9a667a70c99967f33b_20260914020256.png\" alt=\"332139e6-1100-4ad7-8d6a-e9b5e0bfdc72.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Study Published in JCO\u003C\u002Fspan>\u003C\u002Fp>",{"slug":660,"title":661,"summary":662,"cover":663,"category":438,"publishedAt":657,"contentHtml":664,"hasAlternate":73,"updatedAt":74},"nkt-cell-lymphoma-pathology-diagnosis-code-guide","Expert Guide: Decoding the Pathology of NK\u002FT-Cell Lymphoma","A closer look at the diagnostic challenges, pathological features, association with Epstein-Barr virus (EBV), and the role of the tumor microenvironment in treatment response in NK\u002FT-cell lymphoma.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F935ff2b34fac3d4918db4363e0712c35.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: NK\u002FT-cell lymphoma is an aggressive and complex type of non-Hodgkin lymphoma that can be difficult to diagnose because its symptoms may be subtle and lymphoma itself includes more than 100 distinct subtypes. From a pathology perspective, this article explains why lymphoma diagnosis can be challenging and introduces modern diagnostic tools such as immunohistochemistry, flow cytometry, and molecular testing. It also highlights the close association between NK\u002FT-cell lymphoma and Epstein-Barr virus (EBV), its tendency to involve the nasal cavity and upper aerodigestive tract, and characteristic features such as vascular invasion and tissue necrosis. The article further explores how diagnostic accuracy and the tumor microenvironment can influence treatment response, helping patients understand why an accurate diagnosis is the foundation of effective treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">NK\u002FT-cell lymphoma is an aggressive and complex form of non-Hodgkin lymphoma. Because many patients are unfamiliar with the disease, the path to the right diagnosis and treatment can sometimes involve unnecessary detours. Through this educational series, we hope to help patients understand the disease step by step - starting with diagnosis - so they can approach treatment with clearer information and greater confidence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why Is Lymphoma So Difficult to Diagnose?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lymphoma is often described as one of the most challenging cancers to diagnose.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Why? One reason is that its symptoms can be surprisingly nonspecific. Some patients may simply have a fever that feels like a common cold. Others may develop a small skin rash or seek medical care because of an ulcer. These symptoms do not immediately suggest cancer, so lymphoma can easily be overlooked or mistaken for another condition.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another challenge is the sheer number of lymphoma subtypes - more than 100. Each subtype is a distinct disease and may require a different treatment approach. For pathologists and clinicians, accurately identifying the right subtype among so many possibilities is a demanding task.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">From a pathology perspective, lymphoma cells can also look very different from one another. They may be large, small, or intermediate in size, with different nuclear and cytoplasmic features. Under the microscope, lymphocytes, neutrophils, eosinophils, histiocytes, and other cells may all be mixed together. Identifying the tumor cells and determining whether they are of B-cell or T-cell origin cannot be done reliably by morphology alone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Fortunately, modern medicine provides a powerful set of diagnostic tools. Immunohistochemistry acts like an “identity label” for cells by showing which proteins they express. Flow cytometry can rapidly analyze cell characteristics, while molecular testing can provide confirmation at the genetic level. These methods complement and validate one another, greatly improving diagnostic accuracy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why Does an Accurate Diagnosis Matter So Much for Treatment?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Precision treatment starts with the right diagnosis. Without a clear diagnosis, it is impossible to select the most appropriate and effective treatment strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Although lymphoma diagnosis can be complex, treatment options have expanded considerably. Depending on the disease, patients may receive conventional chemotherapy and radiotherapy, targeted therapies, or advanced cellular therapies. NK\u002FT-cell lymphoma, for example, can involve the nasal cavity, skin, gastrointestinal tract, lymph nodes, and other sites, and each presentation requires careful diagnostic evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As treatment becomes more diverse and more precise, the need for diagnostic accuracy becomes even greater. If the correct diagnosis is established early, patients can move more quickly toward the treatment approach that best fits their disease. If the diagnosis is inaccurate, treatment may be delayed or directed down the wrong path, potentially affecting outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Are the Key Features of NK\u002FT-Cell Lymphoma?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">NK\u002FT-cell lymphoma has several characteristic clinical and pathological features. Understanding them can help support earlier recognition and more accurate diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">First, it is closely associated with Epstein-Barr virus (EBV) infection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This association may partly help explain why the disease tends to occur in certain populations and anatomical sites.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Second, it has several characteristic sites of involvement.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because EBV is commonly transmitted through respiratory and oral secretions, the nasal cavity and nearby upper aerodigestive tract - including the nasopharynx, oropharynx, and palate - are classic sites where NK\u002FT-cell lymphoma may occur. Early symptoms can include nasal obstruction, nosebleeds, and facial swelling, which may initially be mistaken for rhinitis or sinusitis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Its local effects, however, can be much more destructive.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The biology of this lymphoma gives it a strong tendency toward local invasion. Tumor cells may infiltrate blood vessel walls, leading to vascular occlusion and thrombosis. Reduced blood supply can then cause ischemia and tissue necrosis. The tumor cells can also release substances that further damage surrounding tissue. As a result, patients may develop progressive ulceration and necrosis, and in severe cases there can be destruction of midline facial structures.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">NK\u002FT-cell lymphoma can also occur outside the nasal cavity, including in the skin - particularly the legs - as well as soft tissues, the gastrointestinal tract, liver, spleen, and other sites.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Because these extranodal presentations may occur without typical nasal symptoms, they can be easier to miss or misdiagnose. Both clinicians and patients therefore need to remain alert to unusual presentations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The cellular origin of NK\u002FT-cell lymphoma is distinctive. The tumor is not simply a conventional T-cell or NK-cell lymphoma; its cells are cytotoxic lymphocytes that may express features associated with both T cells and NK cells, which is why the term “NK\u002FT” is used. Accurate identification cannot rely on cell appearance alone. Pathologists combine tissue architecture, patterns of tissue damage, and specific immunophenotypic markers to establish the diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why Can Treatment Outcomes Differ So Much Between Patients With the Same Lymphoma?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A question that often arises in clinical practice is: if two patients have the same type of lymphoma, why can one respond very well to treatment while another does not?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Pathologists are looking for answers from two main directions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Question 1: Is the Diagnosis Correct?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When a patient is not responding well to treatment - especially in relapsed or refractory disease - one of the first questions pathologists ask is whether the original diagnosis should be reviewed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is not uncertainty for its own sake; it is part of a careful scientific approach. With more than 100 lymphoma subtypes and highly variable microscopic appearances, even a subtle diagnostic difference can lead to a different treatment strategy. For patients with an unsatisfactory response, reassessing the pathology is therefore an important first step.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Question 2: Who Are the Tumor's “Neighbors”?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the diagnosis is correct, the next place to look is at a more microscopic level: the tumor microenvironment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A tumor does not exist in isolation. Many different types of cells surround the tumor cells, almost like “neighbors.” Which cells are present? How many are there? How close are they to the tumor cells? These spatial relationships can influence how the disease behaves and how it responds to treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some of these neighboring cells may support antitumor immunity, and having more of them close to the tumor could be associated with a better prognosis. Others may promote tumor growth or suppress immune responses, potentially making treatment more difficult.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A New Technology: Giving Different Cells Different “Colors”\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">So how can pathologists see these cellular “neighbors” more clearly? One emerging approach is multiplex immunohistochemistry (mIHC), which can help reveal the complexity of the tumor microenvironment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In simple terms, the technique is like giving different cell types different colors. Fluorescent labels are used to mark specific proteins on different immune cells, allowing multiple cell populations to be visualized within the same tissue sample.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This creates a kind of “cell map” under the microscope: How many tumor cells are present? Which immune cells surround them? Are those immune cells clustered close to the tumor, or are they farther away? These spatial relationships can provide important information for prognosis and treatment selection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By showing both what kinds of cells are present and where they are located, mIHC can provide more visual and quantifiable information about the tumor immune microenvironment. This may help clinicians better understand treatment response and identify potentially suitable treatment strategies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This technology is gradually moving into clinical use, particularly in relapsed or refractory cases. Analyzing the tumor microenvironment may provide additional information when clinicians are considering treatment options.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Integrated Diagnosis: Putting the Whole Puzzle Together\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">No single test can fully explain why treatment outcomes differ between patients. A comprehensive lymphoma diagnosis requires multiple types of information to be considered together:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Morphology: evaluating the microscopic architecture of tissues and the appearance of individual cells;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Immunohistochemistry: using antigen-antibody reactions to assess protein expression, classify the lymphoma, identify cell lineage, and help guide treatment;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Molecular testing: identifying gene mutations, fusions, and other molecular pathological changes that can support precision diagnosis and treatment;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Flow cytometry: rapidly analyzing the immunophenotype, cell cycle, and functional characteristics of individual cells using multiple parameters;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Cytogenetics: evaluating abnormalities in chromosome number and structure.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Integrated diagnosis means bringing all of these findings together so that pathologists can build a more complete picture of each patient's disease. That picture may help explain differences in treatment response and guide more precise treatment decisions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As integrated diagnostics and new technologies continue to advance, clinicians may be able to obtain more prognostic information before treatment begins and select treatment strategies that are better matched to each patient's disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Patients Should Know\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients diagnosed with NK\u002FT-cell lymphoma, the moment of diagnosis can bring fear and uncertainty. Although this is an aggressive disease, there is extensive clinical experience in its diagnosis and treatment in China, and treatment approaches continue to evolve.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first priority is to obtain an accurate diagnosis from an experienced pathology team and then choose a standardized treatment strategy based on the extent and characteristics of the disease. Precision treatment depends on precision diagnosis. Getting the diagnosis right at the beginning gives every subsequent treatment decision a stronger foundation.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":666,"title":667,"summary":668,"cover":669,"category":438,"publishedAt":670,"contentHtml":671,"hasAlternate":73,"updatedAt":74},"aplastic-anemia-vaccination-guide","Can People with Aplastic Anemia Get Vaccinated? A Practical Guide","This guide explains the potential benefits and risks of vaccination for people with aplastic anemia, when vaccination may be considered, which vaccine types are generally preferred or avoided, and six practical steps for safer vaccination.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fd91e9c7e7ad35e63f1f532d67596a51e.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-03-13","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: This article addresses common questions about vaccination in people with aplastic anemia (AA). Because AA involves immune dysfunction and many patients receive immunosuppressive therapy, vaccination decisions require careful consideration. The article recommends avoiding non-essential vaccination during unstable disease or significant immunosuppression and suggests considering vaccination when the disease is stable, blood counts are relatively stable, immunosuppressive therapy has been stopped for at least six months or reduced to low-dose maintenance, and there is no active infection. Inactivated and recombinant protein vaccines are generally preferred, while live attenuated vaccines are usually avoided in patients with moderate to severe immunosuppression. It also outlines six practical steps: consult a hematology specialist, complete an individualized assessment, keep vaccination records, monitor for reactions, repeat blood counts as advised, and continue everyday infection-prevention measures.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">"Doctor, can I get a flu shot if I have aplastic anemia?"\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">"I've heard vaccines can cause problems in people with weakened immunity. Is vaccination safe for me?"\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">…\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people with aplastic anemia (AA), deciding whether to get vaccinated can be confusing. On one hand, there is concern about infection; on the other, patients may worry that a vaccine could have unwanted effects on their condition. So can people with AA be vaccinated, and how can vaccination be approached more safely?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Aplastic Anemia and the Immune System: Why Is Vaccination More Complicated?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Aplastic anemia is closely associated with abnormal T-cell immune activity that can damage hematopoietic stem and progenitor cells in the bone marrow, leading to bone marrow failure and pancytopenia. This immune dysregulation is considered an important mechanism in AA and makes vaccination decisions more complex.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On one hand, low white blood cell counts - particularly neutropenia - can increase the risk of infection, so vaccination may offer important protection in selected situations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On the other hand, abnormal immune function may reduce the immune response to a vaccine and, in some circumstances, may also raise concerns about triggering further immune dysregulation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Do Vaccines Work, and What Is Different for People with AA?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Vaccines essentially give the immune system an advance introduction to a pathogen. They stimulate B cells to produce antibodies and prepare T cells to respond, so the immune system can react more quickly if the real pathogen is encountered later. This protective effect depends on the immune system being able to mount an appropriate response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In people with AA, however, this response may be altered. During the early phase of treatment, intensive immunosuppressive therapy can suppress normal immune function. Vaccination at this stage may produce little or no immune response, or only low antibody levels, resulting in limited protection. The article also notes a theoretical concern that immune stimulation could worsen immune dysregulation in some patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Vaccination in Aplastic Anemia: How Should the Benefits and Risks Be Balanced?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Key principle: avoid non-essential vaccination unless there is a clear clinical need.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people with AA, routine vaccination may be deferred when it is not medically necessary, particularly during active disease or significant immunosuppression. In certain urgent situations, such as tetanus- or rabies-related exposure, the article notes that passive immunization products may be considered as clinically appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>When Might Vaccination Be Considered?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If vaccination is needed, the article suggests considering it when:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The disease is stable and blood counts are relatively stable;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Immunosuppressive therapy has been stopped for at least six months, or the patient is on low-dose maintenance immunosuppression;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There is no active infection.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Which Vaccine Types May Be Considered? (Only After Specialist Assessment)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Vaccines that may be considered:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. Inactivated vaccines: These generally have a more favorable safety profile in immunocompromised patients. Examples include the injectable inactivated influenza vaccine and pneumococcal vaccines.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Recombinant protein vaccines: Examples include recombinant hepatitis B vaccines, which are generally considered non-live vaccines.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Vaccines generally not recommended during moderate to severe immunosuppression:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Live attenuated vaccines: These are usually avoided in patients with moderate to severe immunosuppression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Examples listed in the source article include MMR (measles, mumps, and rubella) and varicella\u002Fzoster vaccines, because live attenuated vaccines may pose an infection risk in immunocompromised patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Six Practical Steps for Safer Vaccination\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Talk to Your Specialist First\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before receiving any vaccine, speak with your treating hematologist.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Have a Full Clinical Assessment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Your doctor will assess your disease status, current treatment, blood counts, and immune status before making a recommendation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Keep a Vaccination Record\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Record the vaccine name, batch or lot number, and date of vaccination so the information is available for future follow-up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Monitor Closely After Vaccination\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Watch for any unusual reactions. Some people may experience temporary fever, fatigue, or redness and swelling at the injection site. These reactions often resolve on their own, but seek medical advice promptly if symptoms are severe, persistent, or otherwise concerning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. Repeat Blood Counts as Advised\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A small number of patients may experience temporary fluctuations in blood counts after vaccination. Follow-up complete blood counts (CBCs) may therefore be recommended.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>6. Continue Infection-Prevention Measures\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Vaccination does not replace everyday precautions. Continue measures such as good hand hygiene, masking when appropriate, and avoiding crowded settings during periods of high respiratory infection activity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Frequently Asked Questions\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: Do vaccines work less well in people with aplastic anemia?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: They can. Immunosuppression may reduce the immune response to vaccination. Even so, partial protection may still be clinically meaningful in selected patients, which is why the decision should be individualized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q: Do patients with AA-PNH who are starting complement inhibitors such as eculizumab or iptacopan need vaccines beforehand?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A: The source article recommends pneumococcal and meningococcal vaccination before complement-inhibitor therapy in patients with AA-PNH overlap syndrome, with the aim of reducing the risk of serious infection. The exact vaccines and timing should be planned in advance with the treating team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>In summary, having aplastic anemia does not automatically mean that vaccination is off-limits. The key is to choose the right vaccine, at the right time, for the right patient. Vaccination can be one part of infection prevention in AA, but decisions should be individualized and made under specialist guidance.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Before any vaccination, stay in close communication with your treating physician and develop a vaccination plan that fits your disease status, treatment, and immune recovery.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Please note: This article is for general educational purposes only and is not a substitute for individualized medical advice. Vaccination plans should always be discussed with your treating physician, because disease status and treatment vary from person to person.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":673,"title":674,"summary":675,"cover":676,"category":430,"publishedAt":325,"contentHtml":677,"hasAlternate":73,"updatedAt":432},"ruikang-trastuzumab-her2-gastric-colorectal-phase1","Professor Jin Li's Team Reports Phase I Results of Trastuzumab Rezetecan in HER2-Expressing Gastric\u002FGEJ Adenocarcinoma and Colorectal Cancer","Phase I data for trastuzumab rezetecan, a China-developed HER2-targeted antibody-drug conjugate (ADC), in gastric and colorectal cancer have been published in the Journal of Clinical Oncology (JCO), showing encouraging antitumor activity with a manageable safety profile.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F4160ebd172c0f129c7d94639fbf7bc87.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Professor Jin Li's team at Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, published Phase I clinical data in the Journal of Clinical Oncology on trastuzumab rezetecan, a China-developed HER2-targeted antibody-drug conjugate, in patients with advanced gastric\u002Fgastroesophageal junction (GC\u002FGEJ) adenocarcinoma and colorectal cancer (CRC). The study enrolled 100 patients. Among patients with HER2-positive GC\u002FGEJ, the objective response rate (ORR) was 45.0% and median progression-free survival (PFS) was 9.0 months. Among patients with HER2-positive CRC, the ORR was 40.5% and median PFS was 9.5 months. The Phase I results showed promising preliminary efficacy and a manageable safety profile.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On March 4, Phase I clinical data were published for trastuzumab rezetecan, a novel HER2-targeted antibody-drug conjugate (ADC) developed in China, in patients with advanced gastric\u002Fgastroesophageal junction adenocarcinoma (GC\u002FGEJ) and colorectal cancer (CRC). The results appeared in the Journal of Clinical Oncology (JCO; impact factor 43.4), a leading journal in oncology. Professor Jin Li of Shanghai GoBroad Cancer Hospital, Affiliated to China Pharmaceutical University, served as the corresponding author. The preliminary findings showed encouraging antitumor activity and a manageable safety profile in patients with HER2-expressing GC\u002FGEJ and CRC.[1]\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F0f78385cf31a0445e6f70c7e85ea1ae6_20260914012131.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0f78385cf31a0445e6f70c7e85ea1ae6_20260914012131.png\" alt=\"c02acb57-a9c6-4d05-b5e0-10e473618544.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Study Published in JCO\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to GLOBOCAN 2022, GC\u002FGEJ ranks fifth globally for both incidence and mortality, while CRC ranks third for incidence and second for mortality, making both major global health burdens.[2] HER2 alterations are associated with the development and progression of multiple cancers and have become an important therapeutic target in several tumor types, including gastrointestinal cancers.[3,4] HER2 is expressed in approximately 40% of patients with GC\u002FGEJ[5] and is overexpressed in about 3%-11% of patients with CRC.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Trastuzumab rezetecan (development code SHR-A1811) is a next-generation HER2-targeted ADC. It consists of trastuzumab linked through a cleavable linker to SHR169265, a potent DNA topoisomerase I inhibitor. Its design combines a highly active payload with a relatively low drug-to-antibody ratio (DAR), with the aim of balancing antitumor activity and safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F3fc828160954d8f8d5459a12d647f35f_20260914012149.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3fc828160954d8f8d5459a12d647f35f_20260914012149.png\" alt=\"7dbae056-405f-4326-bc00-5dbb202c8a32.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1. Structure of Trastuzumab Rezetecan\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Design and Methods\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This Phase I trial included three parts: dose escalation, pharmacokinetic expansion, and clinical expansion. Eligible patients had HER2-expressing GC\u002FGEJ or CRC (IHC 1+, 2+, or 3+, or ISH-positive) and had either failed standard treatment, were unable to tolerate standard treatment, or had no available standard treatment option. Dose escalation used the i3+3 design, with trastuzumab rezetecan administered at 3.2 mg\u002Fkg, 4.8 mg\u002Fkg, 6.4 mg\u002Fkg, and 8.0 mg\u002Fkg. Two to three dose levels were selected for pharmacokinetic expansion, followed by further collection of safety and efficacy data in the clinical expansion phase.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Ffcb8e88d0a003759339a59691ec7dcfe_20260914012203.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"fcb8e88d0a003759339a59691ec7dcfe_20260914012203.png\" alt=\"c0fd20c6-3d92-4cb1-978f-b39ed4b4e3d8.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 2. Study Design\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Results\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Baseline Patient Characteristics\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A total of 100 patients were enrolled: 15 in dose escalation, 18 in pharmacokinetic expansion, and 67 in clinical expansion. Fifty-seven patients had GC\u002FGEJ (52 gastric cancer and 5 gastroesophageal junction cancer); 96.5% had an ECOG performance status of 1, and 50.9% had previously received anti-HER2 therapy. Forty-three patients had CRC (11 left-sided colon, 12 right-sided colon, and 20 rectal cancers); 90.7% had an ECOG performance status of 1, and 27.9% had previously received anti-HER2 therapy. As of February 29, 2024, 11 patients remained on treatment and 89 had discontinued, mainly because of disease progression.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F5479b787e5cad688fd6204942d70ec1c_20260914012228.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5479b787e5cad688fd6204942d70ec1c_20260914012228.png\" alt=\"1418162c-4f6c-4516-951a-326293accd07.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Table 1. Baseline Patient Characteristics\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Clinical Efficacy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">All 100 patients received at least one dose of trastuzumab rezetecan, including 57 patients with HER2-expressing GC\u002FGEJ and 43 with HER2-expressing CRC. As of February 29, 2024, the median follow-up was 11.4 months for the GC\u002FGEJ group and 13.8 months for the CRC group.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among 40 patients with HER2-positive GC\u002FGEJ, the ORR was 45.0%, the disease control rate (DCR) was 87.5%, median duration of response (DoR) was 5.5 months, median PFS was 9.0 months, and median overall survival (OS) was 16.3 months. Among 28 patients who had previously received HER2-targeted therapy, 14 achieved a response, for an ORR of 50.0%. In 12 patients with HER2 IHC 2+\u002FISH-negative GC\u002FGEJ, the ORR was 25.0%, DCR was 91.7%, median PFS was 12.2 months, and median OS was not yet mature.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among 32 patients with GC\u002FGEJ who received trastuzumab rezetecan at 6.4 mg\u002Fkg, the ORR was 50.0%, DCR was 84.4%, median DoR was 5.7 months, median PFS was 8.4 months, and median OS was 16.3 months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among 37 patients with HER2-positive CRC, the ORR was 40.5%, DCR was 91.9%, median DoR was 6.1 months, median PFS was 9.5 months, and median OS was 22.7 months. Among 11 patients who had previously received HER2-targeted therapy, 4 achieved a response, for an ORR of 36.4%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Among 32 patients with HER2-positive CRC who received trastuzumab rezetecan at 6.4 mg\u002Fkg, the ORR was 40.6% and DCR was 93.8%; median PFS was 9.5 months and median OS was 22.7 months.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F7a20a82a4ad9b1c38b9fb62f83bb7321_20260914012243.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7a20a82a4ad9b1c38b9fb62f83bb7321_20260914012243.png\" alt=\"e68cbe77-d6b3-403f-8fe2-c646655758cc.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Table 2. Tumor Response\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fec9531ea721752a13f14216bdd51acad_20260914012253.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ec9531ea721752a13f14216bdd51acad_20260914012253.png\" alt=\"b19bb0b5-a06e-46ff-bb28-e0657562e346.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 3. Waterfall Plot: Best Percentage Change from Baseline in Target Lesions in Patients with HER2-Positive or HER2 IHC 2+\u002FISH-Negative GC\u002FGEJ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F7f1ceaadc48ec5d8f4f793c84858644b_20260914012306.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"7f1ceaadc48ec5d8f4f793c84858644b_20260914012306.png\" alt=\"02bfe7b2-aee0-4516-a6bc-c2a68cbf76b4.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 4. Swimmer Plot: Tumor Response in Patients with HER2-Positive GC\u002FGEJ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F4b4f64618d891837663b7db8270a55fa_20260914012317.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"4b4f64618d891837663b7db8270a55fa_20260914012317.png\" alt=\"40b7ec00-4f34-4584-80bd-5ee4f9a8ef5a.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 5. Swimmer Plot: Tumor Response in Patients with HER2 IHC 2+\u002FISH-Negative GC\u002FGEJ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F42c5bc656c8a18055149cfe1c71e2e9c_20260914012330.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"42c5bc656c8a18055149cfe1c71e2e9c_20260914012330.png\" alt=\"2e0d4eb1-8a6f-4244-a69e-d9b9adafa386.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 6. Waterfall Plot: Best Percentage Change from Baseline in Target Lesions in Patients with HER2-Positive CRC\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F0f4addf2238e34dd43082c6cd30bc954_20260914012342.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0f4addf2238e34dd43082c6cd30bc954_20260914012342.png\" alt=\"cbce1b32-3d8a-423d-bc18-ece1742a64b4.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 7. Swimmer Plot: Tumor Response in Patients with HER2-Positive CRC\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Safety\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Of the 100 patients, 96 (96%) experienced treatment-related adverse events (TRAEs) of any grade, and 66 (66%) reported grade 3 or 4 TRAEs. The most common included decreased neutrophil count (49 patients, 49%), decreased white blood cell count (39 patients, 39%), and anemia (29 patients, 29%).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Serious TRAEs occurred in 33 patients (33.0%), including decreased platelet count in 10 patients (10.0%), anemia in 8 (8.0%), and decreased neutrophil count in 7 (7.0%).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Overall, trastuzumab rezetecan showed encouraging antitumor activity with a manageable safety profile in patients with advanced GC\u002FGEJ and CRC. A Phase III study of trastuzumab rezetecan as second-line treatment for GC\u002FGEJ (NCT06123494) is ongoing. In addition, the marketing application for a new colorectal cancer indication has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and granted priority review. These developments may bring additional treatment options to patients in the future.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">References:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">[1] Liu T, Luo S, Yuan X, et al. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. J Clin Oncol. Published online March 4, 2026.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">[2] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">[3] Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">[4] Ingold Heppner B, Behrens HM, Balschun K, et al: HER2\u002Fneu testing in primary colorectal carcinoma. Br J Cancer 111:1977-84, 2014\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 12px; color: rgb(136, 136, 136);\">[5]  Van Cutsem E, Bang YJ, Feng-Yi F, et al: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476-84, 2015\u003C\u002Fspan>\u003C\u002Fp>",{"slug":679,"title":680,"summary":681,"cover":682,"category":430,"publishedAt":336,"contentHtml":683,"hasAlternate":73,"updatedAt":432},"bcma-car-t-plasma-cell-leukemia-survival-benefit","International Journal Publication | Dr. Xiaoyan KE and Dr. Kai HU's Team: BCMA CAR-T Brings Short-Term Remission and Survival Benefit in R\u002FR PCL","A study from the teams of Dr. Xiaoyan KE and Dr. Kai HU, published in Frontiers in Immunology, reported a 75% overall response rate with BCMA CAR-T therapy in patients with triple-class refractory relapsed\u002Frefractory plasma cell leukemia.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F64c4f6d28557b2afd3bbfef48322a38b.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Relapsed\u002Frefractory primary plasma cell leukemia (R\u002FR PCL) is rare, highly aggressive, and associated with poor outcomes after conventional treatment. A retrospective cohort study from the teams of Dr. Xiaoyan KE and Dr. Kai HU at Beijing GoBroad Hospital analyzed outcomes in 12 patients with triple-class refractory R\u002FR PCL treated with BCMA CAR-T therapy. The overall response rate was 75%, with a median progression-free survival of 8.9 months and a median overall survival of 15.5 months. Among patients who subsequently underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation, some achieved deep remission and long-term disease-free survival. The findings provide early evidence for a potential treatment strategy in this very high-risk patient population.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed\u002Frefractory primary plasma cell leukemia (R\u002FR PCL) is a rare but highly aggressive hematologic malignancy. Response rates with conventional treatment are low, and long-term outcomes remain poor, making it one of the most challenging conditions managed by lymphoma and myeloma specialists. In recent years, CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in R\u002FR PCL, but data on long-term outcomes and the best treatment strategy after CAR-T remain limited.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, the lymphoma and myeloma team at Beijing GoBroad Hospital, led by Dr. Xiaoyan KE and Dr. Kai HU, published a study in Frontiers in Immunology titled "Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study." The first author was Dr. Yuelu GUO. The study summarizes the team's recent clinical experience with BCMA CAR-T in R\u002FR PCL and explores possible strategies after CAR-T treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Background\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Kai HU noted that primary plasma cell leukemia (PCL), although rare, is highly aggressive. Even with newer therapies, newly diagnosed PCL has been reported to have a median progression-free survival (PFS) of only 5.5 months. Outcomes become especially poor after relapse, particularly in patients with triple-class refractory disease - meaning resistance to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. To further evaluate the efficacy and safety of BCMA CAR-T in R\u002FR PCL, the team retrospectively analyzed 12 patients with triple-class refractory R\u002FR PCL who received BCMA CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Key Findings\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. BCMA CAR-T Achieved a 75% Response Rate in Triple-Class Refractory PCL, with Mostly Low-Grade CRS\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The overall response rate (ORR) after BCMA CAR-T therapy was 75% (9\u002F12). One patient achieved complete response (CR), four achieved partial response (PR), and four achieved very good partial response (VGPR). Grade 1-2 cytokine release syndrome (CRS) occurred in 83.3% of patients (10\u002F12). At the same time, grade 3-4 cytopenias were common, highlighting the need for careful infection prevention, monitoring, and supportive care after BCMA CAR-T therapy in patients with R\u002FR PCL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. BCMA CAR-T Provided Survival Benefit in R\u002FR PCL, with Encouraging Outcomes in Patients Who Bridged to Allogeneic Transplant\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Further analysis showed a median PFS of 8.9 months (95% CI, 4.6 months to not reached). The 1-year and 2-year PFS rates were 33.3% (95% CI, 7.8%-62.3%) and 22.2% (95% CI, 3.4%-51.3%), respectively. Median overall survival (OS) was 15.5 months (95% CI, 5.7 months to not reached). The 1-year OS rate was 55.6% (95% CI, 20.4%-80.5%), and the 2-year OS rate was 22.2% (95% CI, 3.4%-51.3%). Notably, among the four patients who underwent allogeneic transplantation as consolidation, two remained in stringent complete response (sCR) and achieved disease-free survival.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These preliminary findings may help inform treatment planning. For patients with R\u002FR PCL who respond to BCMA CAR-T therapy, consolidation with allogeneic hematopoietic stem cell transplantation may deepen the response and could support longer disease-free survival in selected patients. Larger prospective studies are still needed to clarify which patients are most likely to benefit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Xiaoyan KE noted that the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital has accumulated extensive clinical experience with CAR-T therapy. As more patients receive CAR-T in real-world practice, the clinical questions are becoming increasingly complex. Current experience suggests that BCMA CAR-T can produce short-term remission in highly aggressive R\u002FR PCL, but additional consolidation may be needed to improve the depth and durability of response. Allogeneic hematopoietic stem cell transplantation may be one strategy for selected patients who respond to CAR-T. At the same time, identifying the right timing for CAR-T and developing more individualized, precise, and longitudinal management strategies remain important clinical priorities. Going forward, integrated clinical, pathologic, molecular, and imaging assessment may help identify R\u002FR PCL patients who are unlikely to benefit from conventional therapy but may benefit from precision CAR-T approaches. Monitoring tools such as circulating tumor DNA (ctDNA) may also help detect signs of relapse earlier and support more timely intervention.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":685,"title":686,"summary":687,"cover":688,"category":438,"publishedAt":336,"contentHtml":689,"hasAlternate":73,"updatedAt":74},"micm-integrated-diagnosis-hematologic-malignancy","Expert Guide: Why Is MICM Integrated Diagnosis So Important in Hematologic Malignancies?","Dr. Chunrong TONG of Beijing GoBroad Boren Hospital explains how MICM integrated diagnosis combines four dimensions of testing to classify hematologic malignancies more precisely and support individualized treatment planning.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Ff9dd0a3e0d1162a7cc8b13b2c23a6fa3.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Chunrong TONG of Beijing GoBroad Boren Hospital explains the central role of MICM integrated diagnosis in the care of malignant hematologic diseases. MICM brings together morphology, immunology, cytogenetics, and molecular biology, while an expanded MICM-PP framework also incorporates pathogen testing and pharmacology\u002Fpharmacogenomics. Together, these data can help clinicians define the disease more precisely, assess risk, and tailor treatment. Dr. Tong emphasizes that an accurate clinical diagnosis should never rely on a single laboratory report; medical history, family history, treatment and exposure history, and laboratory findings all need to be interpreted together.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">MICM integrated diagnosis combines Morphology (M), Immunology (I), Cytogenetics (C), and Molecular Biology (M), and is a core diagnostic framework for malignant hematologic diseases. In the expanded approach described here, pathogen-related testing (P) and pharmacology\u002Fpharmacogenomics (P) are also incorporated.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Many patients and families still have questions about MICM integrated diagnosis. We therefore invited Dr. Chunrong TONG of Beijing GoBroad Boren Hospital to explain why integrated testing matters for precise disease classification and individualized treatment in hematologic malignancies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Is the Difference Between a Laboratory Result and a Clinical Diagnosis?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients often bring in a test report and ask, "Dr. Tong, the report says I have this disease. Does that mean this is definitely my diagnosis?" Not necessarily. A laboratory report gives one set of test results. What the medical team ultimately needs to establish is a complete clinical diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">That diagnosis cannot be determined from a single report. It requires several types of information to be considered together, including laboratory findings as well as the patient's medical history, family history, medication history, and exposure history.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, if a patient has had an elevated white blood cell count for 10 years, the clinical pattern may point more toward a chronic leukemia; if the change developed over only a few days, an acute leukemia may be more likely. This is why a detailed history matters.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another example is a patient who previously had a different cancer and received chemotherapy or radiotherapy, then later develops leukemia. In that setting, the leukemia may be secondary to prior treatment and classified as therapy-related leukemia. For such patients, the team may often consider allogeneic hematopoietic stem cell transplantation (allo-HSCT). A single piece of clinical history can therefore influence the overall treatment direction.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Family history is also important. This is one reason clinicians may recommend testing for inherited susceptibility variants. Some diseases develop through an interaction between an underlying genetic predisposition and external triggers. Just as hypertension, diabetes, or certain cancers may cluster within families, a person's genetic background can also matter in hematologic disease.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Medication and toxic-exposure history should also be reviewed. Long-term exposure to harmful substances may contribute to chromosomal instability and genetic mutations. According to the clinical framework described in this article, such patients may be less likely to achieve durable control with medication alone and may need transplantation to be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Allergy history and exposure to infectious diseases can also matter. One example is adult T-cell leukemia\u002Flymphoma (ATLL), a virus-associated hematologic malignancy that is more common in certain endemic regions, including parts of coastal Japan and coastal Fujian in China. Without asking about relevant exposure and epidemiologic history, clinicians may be less likely to consider this diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Clinical information alone is still not enough. Laboratory and imaging data are also needed, including complete blood counts, bone marrow studies, and imaging. For hematologic malignancies, the article describes MICM-PP - adding Pathogen and Pharmacology (PP) components to MICM - as a comprehensive integrated diagnostic approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Is MICM?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">MICM is an integrated diagnostic and classification framework used in hematology. It combines four layers of testing to characterize disease from cell appearance and immune phenotype through chromosomes and genes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In practical terms, the four components are:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- M (Morphology): Evaluation of cell appearance under the microscope, together with cytochemical staining and histopathology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- I (Immunology): Flow cytometry is used to analyze cell-surface markers, or antigens, while immunohistochemistry can assess marker expression in tissue. These methods help determine cell lineage and characteristics. Protein quantification or electrophoresis may also be used when needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- C (Cytogenetics): Testing looks for chromosomal abnormalities such as gains, losses, or translocations. Common methods include conventional karyotyping and fluorescence in situ hybridization (FISH).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- M (Molecular Biology): Molecular testing examines abnormalities at the gene level. This may include fusion-gene screening and quantification, mutation testing involving tumor-related genes, inherited susceptibility genes, and pharmacogenetic variants, copy-number analysis, IgH\u002FTCR clonality testing to help determine whether a proliferation is neoplastic, pathogen-gene testing, and donor-recipient chimerism monitoring after transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When these four layers of information are interpreted together, clinicians can classify the disease more precisely, estimate relapse risk, and identify potentially relevant targeted therapies, supporting a more individualized treatment strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Is MICM-PP?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">MICM-PP expands the traditional MICM framework by adding two additional components beginning with the letter P, with the goal of supporting more precise individualized care:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first P - Pathogen testing: This looks for viral, bacterial, or other infectious agents, such as Epstein-Barr virus (EBV) or Helicobacter pylori. Methods may include pathogen-gene testing and pathogen assessment in tissue.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The second P - Pharmacology and pharmacogenomics: Drug concentrations can be monitored together with genetic information related to drug metabolism, helping clinicians adjust dosing more precisely and safely.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">An accurate diagnosis is not determined by a single report. Morphology, immunology, cytogenetics, molecular biology, pathogen testing, pharmacology, and other information need to be integrated before a clear clinical conclusion can be reached and an appropriate treatment plan can be developed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Diagnosis is also not necessarily a one-time event. During treatment, the medical team may refine or update the diagnosis as the patient responds and new follow-up results become available.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Is the Purpose of MICM Integrated Diagnosis?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment for malignant hematologic diseases can be broadly divided into transplant and non-transplant approaches. Transplantation includes autologous and allogeneic hematopoietic stem cell transplantation. Non-transplant treatment may include surgery in selected situations, chemotherapy, targeted therapy, immunotherapy, hypomethylating therapy, and other approaches. With so many possibilities, MICM integrated diagnosis helps clinicians decide which pathway may be most appropriate for an individual patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Whether a patient should undergo transplantation depends in part on disease-risk stratification. That risk assessment is built from multiple findings, including morphology, flow cytometry, cytogenetics, and molecular testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The choice of transplant approach can also depend on the diagnostic findings. Autologous transplantation uses the patient's own stem cells, but the source article notes that inherited susceptibility variants or substantial prior treatment-related stem-cell injury may limit the suitability of this approach. In such situations, allogeneic transplantation may need to be considered. This is one reason inherited susceptibility testing can be relevant to later treatment planning.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">What Options Are Available If Transplantation Is Not Needed or Not Suitable?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- Surgery: Hematologic malignancies are usually systemic diseases and generally are not treated primarily with surgery. However, surgery may sometimes be considered when a large localized mass is compressing an important organ and symptom relief is needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- Chemotherapy: Not every hematologic malignancy is equally sensitive to chemotherapy. The source article gives chromosome 7 loss as one example associated with poorer chemotherapy response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- Targeted therapy: Many targeted medicines are selected according to specific genetic alterations. Molecular testing can therefore help identify which therapies may be relevant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">- Immunotherapy: Treatments such as antibody-based therapies and CAR-T depend on the antigens expressed by tumor cells. For example, CD19-directed CAR-T therapy or blinatumomab requires an appropriate CD19-positive disease context.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The purpose of performing multiple MICM tests is to answer practical treatment questions as clearly as possible: Does this patient need a transplant? If so, when? Which medicines should be used, in what combination and at what dose? What should the treatment goal be? Integrated diagnostic data help inform each of these decisions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case Example\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>A 47-year-old patient had skin bleeding spots, fever, and fatigue for 17 days. At presentation, the white blood cell count was reported as 61. A peripheral blood smear from the local hospital occasionally showed immature monocytes, and blasts plus immature monocytes accounted for 65% of cells in the bone marrow.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Based on morphology, the case could be diagnosed as acute monocytic leukemia. Flow cytometry was also consistent with acute myeloid leukemia (AML). However, the most important additional information came from molecular testing, which identified several mutations, including DNMT3A, NPM1, IDH1, and JAK2.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These molecular findings led to several important clinical interpretations:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>First: Reassessing Risk Stratification\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If cytogenetics alone were considered, the patient's karyotype was normal and would traditionally have placed the patient in an intermediate-risk group. The molecular findings changed that interpretation: multiple mutations were considered adverse prognostic features. More importantly, after chemotherapy-induced remission, the DNMT3A mutation remained detectable at a variant frequency of 29%. The treating team interpreted this persistence as evidence of an underlying abnormal hematopoietic clone, with implications for relapse risk and the possibility of additional hematologic malignancy after repeated chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Despite the normal karyotype, the patient was therefore ultimately classified as high risk. This illustrates the independent prognostic value of molecular information: it can reveal risk that conventional cytogenetics may not capture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Second: Helping Guide Drug Selection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The source article notes that several mutations may provide potential treatment targets. It states that DNMT3A mutation may suggest sensitivity to hypomethylating agents such as decitabine or azacitidine; NPM1-mutated disease may be treated in combination with all-trans retinoic acid (ATRA); JAK2 mutation may prompt consideration of a JAK inhibitor such as ruxolitinib; and IDH2-mutated disease has available IDH2 inhibitors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Based on this framework, an initial regimen containing a hypomethylating agent - for example, decitabine combined with venetoclax - may be considered, with additional targeted agents added according to the clinical situation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Third: Determining Whether Transplantation Is Needed\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The article states that cure rates with chemotherapy alone are below 40% for intermediate-risk AML. In this case, the patient also had several high-risk features, including a high white blood cell count at diagnosis, DNMT3A, GATA2, and JAK2 mutations described as adverse prognostic findings, and persistence of the DNMT3A clone after remission. The treating team therefore concluded that chemotherapy alone would be insufficient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The recommendation was to first achieve complete remission and then proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT) as soon as appropriate. After transplantation, the source article notes that agents such as ATRA or JAK inhibitors may also be considered as targeted strategies to help reduce relapse risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Fourth: Planning Long-Term Monitoring\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient had an NPM1 mutation, which can be used as a molecular marker for follow-up. Quantitative PCR can be performed at regular intervals, and flow cytometry can be used to monitor measurable residual disease (MRD). When needed, deep sequencing of additional genes can provide further quantitative information. Using several complementary methods can give the clinical team a more complete picture of treatment response.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What Does This Case Show?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Morphology indicated acute monocytic leukemia.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Flow cytometry showed a myeloid malignancy with monocytic differentiation.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Cytogenetics showed a normal karyotype, which would traditionally suggest intermediate risk.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Molecular testing, however, indicated a higher-risk patient, identified potential treatment targets, provided measurable markers for follow-up, and supported the need to consider transplantation.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This is the value of integrated diagnosis: each layer of information contributes to a treatment decision - which medicines to use, how deep a response to aim for, whether transplantation is needed, and how response should be monitored.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Treatment decisions should be built on these clinical and laboratory data rather than on a single test in isolation. The goal of integrated diagnosis is not to make testing more complicated, but to make treatment more precise. When the direction is clearer from the start, each subsequent step can be planned with greater confidence.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":691,"title":692,"summary":693,"cover":694,"category":506,"publishedAt":344,"contentHtml":695,"hasAlternate":73,"updatedAt":432},"gaobo-guangdong-rare-disease-center","GoBroad (Guangdong) Rare Disease Center Launches Innovative “Full-Cycle Support” Model, Advancing Systematic Solutions for Rare Diseases","The GoBroad (Guangdong) Rare Disease Center has officially opened and launched the Guardian AnAn 2.0 charitable support program, introducing a full-cycle assistance model that helps provide financial support throughout the hematopoietic stem cell transplantation journey.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Faa610522a4f42c2a7a6b5ded0e960884.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Ahead of Rare Disease Day 2026, the GoBroad (Guangdong) Rare Disease Center was officially inaugurated at Dongguan Taixin Hospital. The center brings together multidisciplinary care and precision genetic diagnostics, with hematopoietic stem cell transplantation (HSCT) as a core capability and broader treatment pathways including CAR-T and other immunotherapies. At the same event, the Guardian AnAn 2.0 charitable support program was launched, expanding assistance from basic financial support to coverage for serious complications during transplantation, second-transplant support, and humanitarian assistance. The program is designed for families affected by thalassemia, aplastic anemia, and primary immunodeficiency disorders. Prof. Chunfu LI said the model is intended to address a common challenge in rare disease care: advanced medical technology may be available, but patients still need a coordinated system that supports them throughout treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some children with severe thalassemia once depended on regular blood transfusions simply to get through each day. A child with pure red cell aplasia went through repeated consultations, unsuccessful steroid treatment, and transfusion dependence before finally receiving a hematopoietic stem cell transplant. A child with neuroblastoma traveled all the way from Russia in search of a more advanced, systematic treatment strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These stories once unfolded separately across different cities and departments. On February 27, 2026, on the eve of the 19th Rare Disease Day, they found a shared point of connection: the GoBroad (Guangdong) Rare Disease Center was officially inaugurated at Dongguan Taixin Hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Jointly established by the GoBroad Chunfu Institute of Hematology & Oncology and Dongguan Taixin Hospital, the center is a regional platform for rare disease diagnosis and treatment. With HSCT as a core clinical capability, it integrates multidisciplinary care and precision genetic diagnostics, expands comprehensive treatment pathways including CAR-T and other immunotherapies, and connects medical care with charitable support and long-term follow-up. The goal is to move rare disease care toward a more coordinated and systematic model. Under the theme “Advancing Systematic Solutions for Rare Diseases,” the launch event also introduced the Guardian AnAn 2.0 charitable support program and featured patient stories and expert media discussions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fdb2042ac04d8784be7e9aa9448e0f906_20260914010441.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"db2042ac04d8784be7e9aa9448e0f906_20260914010441.png\" alt=\"4962383d-62af-44ea-b859-bef64f503926.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">The GoBroad (Guangdong) Rare Disease Center Is Officially Inaugurated\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>From Specialized Expertise to System Building: Rare Disease Care Enters a More Integrated Stage\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Rare diseases may be individually uncommon, but the real challenge is making sure patients can access coordinated care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More than 7,000 rare diseases have been identified worldwide, and over 80% are associated with genetic factors. In China, the number of people living with rare diseases is estimated to exceed 20 million. Because each individual condition affects relatively few people, recognition at the primary-care level may be limited and care pathways can be fragmented. As a result, many families spend years seeking a definitive diagnosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hematopoietic stem cell transplantation is currently one of the most established curative treatment options for several rare hematologic disorders, including thalassemia, aplastic anemia, and primary immunodeficiency disorders, and transplant-based strategies are also used in selected malignant rare diseases such as neuroblastoma. With advances in haploidentical transplantation, the lack of a fully matched donor is no longer the barrier it once was for many families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">But advances in technology do not automatically translate into better outcomes for every patient. Even when a donor is available, families may still face financial pressure. Serious infections or other complications can arise during transplantation. Some patients may need another transplant, while others may struggle with the long-term costs of medication and follow-up after discharge. These are real barriers that can interrupt care and prevent patients from fully benefiting from available treatments.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the inauguration ceremony, Prof. Chunfu LI, President of the GoBroad Chunfu Institute of Hematology & Oncology, said that the central purpose of establishing the rare disease center is to bring resources together through a platform-based model and address a key gap in the field: medical technology may be in place, but the surrounding care system may still be incomplete.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F90903cc0c9e74760e098aed39813c5ad_20260914010502.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"90903cc0c9e74760e098aed39813c5ad_20260914010502.png\" alt=\"ea556fbc-c487-4c00-8dcc-4ec2a29dacc4.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Prof. Chunfu LI, President of the GoBroad Chunfu Institute of Hematology & Oncology, Speaks at the Inauguration Ceremony\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">“Building a rare disease center is, at its core, about building a complete care system: multidisciplinary collaboration, standardized clinical pathways, regional referral networks, and long-term follow-up data. These are not just formalities; they can directly affect survival and quality of life,” Prof. LI said. The GoBroad (Guangdong) Rare Disease Center will bring together expertise in hematology, pediatrics, rheumatology and immunology, oncology, imaging, critical care, and genetic diagnostics. Through a multidisciplinary team (MDT) model, standardized transplant pathways, regional referral collaboration, and long-term follow-up, the center aims to connect diagnosis, treatment, and survivorship management into one coordinated continuum of care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Innovating Charitable Support: Staying With Families Throughout the Transplant Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Another major announcement at the event was the launch of the Guardian AnAn 2.0 charitable support program.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F0d1d9b929b32639475ee6cd3eca0b2a5_20260914010524.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0d1d9b929b32639475ee6cd3eca0b2a5_20260914010524.png\" alt=\"e016ee77-f1e4-4327-986e-f15d64100cc9.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Ms. Yong MENG, Chair of the Beijing Zhongci Public Welfare Foundation, Introduces the Guardian AnAn 2.0 Charitable Support Program\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Supported by the Beijing Zhongci Public Welfare Foundation, the program upgrades the previous one-time assistance model into a full-cycle support system covering the entire HSCT journey. It is available to eligible families of patients with thalassemia, aplastic anemia (including pure red cell aplasia), and primary immunodeficiency disorders (PID) who undergo HSCT at the GoBroad Chunfu Institute of Hematology & Oncology.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The upgraded program provides four levels of assistance: basic support when patients enter the transplant pathway (RMB 10,000-30,000); additional support if serious infections, GVHD, or other complications occur during the peri-transplant period (RMB 10,000-30,000); dedicated assistance for complex cases requiring a second transplant (up to RMB 100,000); and humanitarian assistance for exceptional medical circumstances, activated after individual assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The new provision of up to RMB 100,000 for a second transplant drew particular attention. “At the GoBroad Chunfu Institute of Hematology & Oncology, we want to take responsibility for every patient who chooses us,” Prof. LI said. “That responsibility is not only about pursuing better medical technology. It is also about whether we can stand with families when the treatment journey becomes more difficult, help share some of the risk, and reduce the chance that financial pressure forces a family to stop treatment. We do not want practical hardship to become the reason someone has to give up.” He added that the team has confidence in its medical and technical capabilities and expects that only a small number of families will ultimately need this higher level of follow-up assistance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the event, Ms. Yong MENG, Chair of the Beijing Zhongci Public Welfare Foundation, emphasized the close connection between charitable support and medical care. Stable financial assistance can help patients stay on treatment and reduce interruptions caused by overwhelming financial pressure, supporting greater continuity and quality of care. Medical advances create treatment opportunities, while charitable programs can lower the barriers to accessing and completing care. Together, they can form a more sustainable support system for rare disease patients and families.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Patient Stories: From Facing Rare Disease Alone to Receiving Systematic Support\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the inauguration ceremony, four patients and family members shared their experiences, turning medical progress into stories of everyday life, treatment, and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Xiao Zhong, 18, and Xiao Qin, 23, had spent much of their childhood and adolescence living around blood transfusions and iron chelation for severe thalassemia. As they entered adulthood, both chose hematopoietic stem cell transplantation in the hope of ending lifelong transfusion dependence. As transplantation techniques have matured and donor options have expanded, more older adolescents and adults with thalassemia may now have the opportunity to pursue curative treatment and move toward the future with greater independence.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The importance of social support beyond medical technology was also reflected in the story shared by the mother of a child with pure red cell aplasia (PRCA). Because PRCA is rare and can be difficult to diagnose, the family went through a long diagnostic journey before the child was fortunate to find a donor through the China Marrow Donor Program and successfully undergo transplantation. After recovery, the mother created a patient mutual-support group. Having once received help herself, she began helping other families by sharing experience, offering emotional support, and connecting them with useful information.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The final story came from the family of a child with neuroblastoma who traveled from Russia to China for treatment. Their cross-border journey involved close multidisciplinary collaboration between the GoBroad Chunfu Institute of Hematology & Oncology and Sun Yat-sen University Cancer Center. The expert team developed a systematic and individualized treatment plan that included immunotherapy. This collaboration across institutions and specialties illustrates how coordinated care can support patients with especially complex rare diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fd014b634faebed00b8f65a47e2d79447_20260914010542.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d014b634faebed00b8f65a47e2d79447_20260914010542.png\" alt=\"6aa568a7-bebf-4d39-8c83-7504dc7e2096.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">A Russian Patient Celebrates Chinese New Year in China and Shares Good Wishes\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Together, these four stories span nonmalignant and malignant disease, domestic and international patients, and children, adolescents, and young adults. They reflect a broader shift in rare disease care: from passive waiting to earlier and more active intervention; from one-time treatment to long-term survivorship and quality-of-life management; and from families feeling isolated to patients being supported by a coordinated system.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Clinical Innovation: Expanding Both Safety and Treatment Options\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fe388f9a704c578eeb495681ec99fde6d_20260914010558.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e388f9a704c578eeb495681ec99fde6d_20260914010558.png\" alt=\"ff604ba3-7bbe-4a18-abbc-6f235bba0f42.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Experts Discuss Advances in Rare Disease Diagnosis and Treatment\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the expert discussion that followed, clinicians from several specialties shared recent developments in rare disease care.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Limited donor availability was once one of the biggest barriers preventing families from moving forward with transplantation. As haploidentical transplantation has matured, a parent can often serve as a donor, substantially reducing the time patients may otherwise spend waiting for a registry match.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More systematic peri-transplant management has also played a major role in improving transplant safety. High-resolution HLA typing, optimized GVHD-prevention strategies, standardized infection prevention and control, quantitative monitoring, and preemptive treatment have all contributed to reducing transplant-related mortality.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">On the treatment side, CAR-T and other targeted immunotherapies are increasingly being integrated with transplant strategies, creating additional options for patients with relapsed or refractory disease. In high-risk neuroblastoma, multimodal approaches combining chemotherapy, targeted therapy, and transplantation are being used more widely, while CAR-T therapy for glioma remains an area of active exploration. By bringing cases and multidisciplinary expertise together, the GoBroad (Guangdong) Rare Disease Center aims to build local clinical experience and develop care pathways suited to patients in China.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Chunfu LI noted that as medical technology advances, the focus in rare disease care is shifting from whether a disease can be treated to how to treat it better and help patients live longer. This requires earlier recognition, coordinated referrals, standardized follow-up, and family-centered support - the areas the GoBroad (Guangdong) Rare Disease Center aims to address through a systematic model.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":697,"title":698,"summary":699,"cover":700,"category":438,"publishedAt":344,"contentHtml":701,"hasAlternate":73,"updatedAt":74},"pediatric-relapsed-refractory-b-all-cart-tdh-transplant","Dr. Huaying Liu on New Treatment Options for Relapsed\u002FRefractory Pediatric B-ALL","Dr. Huaying Liu of the GoBroad Chunfu Institute of Hematology & Oncology explains the emerging use of CAR-T therapy combined with TCRαβ+ cell-depleted hematopoietic stem cell transplantation (TDH) for children with relapsed\u002Frefractory acute lymphoblastic leukemia.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F86e55ac3c1ed1e0254bd82e0e902d24d.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Huaying Liu of the GoBroad Chunfu Institute of Hematology & Oncology provides a practical overview of treatment for relapsed\u002Frefractory pediatric B-cell acute lymphoblastic leukemia (B-ALL). She discusses disease classification and risk stratification, immunotherapy strategies such as CAR-T cell therapy and bispecific antibodies, indications for hematopoietic stem cell transplantation, and the principles and potential clinical advantages of TCRαβ+ cell-depleted hematopoietic stem cell transplantation (TDH). The article is designed to help families better understand current treatment options and the role of newer approaches in pediatric ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a key treatment for serious hematologic diseases. TCRαβ+ cell-depleted hematopoietic stem cell transplantation (TDH) selectively removes αβ T cells from the graft outside the body because these cells can contribute to graft-versus-host disease (GVHD), while preserving CD34+ stem cells and large numbers of immune cells such as NK cells and γδ T cells. The aim is to support earlier hematopoietic recovery, reduce the risk of GVHD, and improve long-term quality of life. This approach has shown encouraging outcomes in both international and Chinese practice, but it remains unfamiliar to many families. Here, Dr. Huaying Liu of the GoBroad Chunfu Institute of Hematology & Oncology explains how CAR-T therapy and TDH transplantation may be used together in children with ALL.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Leukemia is one of the most common cancers in children, accounting for around 30% of pediatric cancer diagnoses. Nearly three-quarters of childhood leukemia cases are acute lymphoblastic leukemia (ALL). B-ALL accounts for about 85% of ALL, with the remainder made up of T-ALL and other rare subtypes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Diagnosis of ALL is first established through an integrated MICM assessment - morphology, immunology, cytogenetics, and molecular genetics. Patients are then assigned to risk groups according to relevant clinical and biological factors. The exact criteria vary slightly among cooperative groups, but the overall principles are similar.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Risk assessment generally considers the child's age at diagnosis, peripheral white blood cell count, presence of extramedullary leukemia, immunophenotype, cytogenetic findings, and response to treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">International systems used by groups such as the Children's Oncology Group (COG) and St. Jude generally classify children into low-, standard-, high-, and very-high-risk groups. In China, risk stratification more commonly uses three groups: low, intermediate, and high risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Factors associated with a more favorable prognosis include B-ALL, age 1-9.9 years, an initial white blood cell count below 50 × 10^9\u002FL, hyperdiploidy, and ETV6-RUNX1 (TEL-AML1), among others.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Factors associated with a less favorable prognosis include age ≥10 years, an initial white blood cell count ≥50 × 10^9\u002FL, T-ALL, certain genetic abnormalities such as BCR::ABL1, KMT2A rearrangements, IKZF1 deletion, low hypodiploidy, and TCF3-HLF fusion, as well as central nervous system leukemia (CNS-3) or testicular leukemia at diagnosis.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">An increasing number of genetic markers are being incorporated into risk assessment. Their clinical significance should be interpreted in context, taking into account coexisting genetic changes and the patient's response to treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With standardized diagnosis and treatment, the 5-year overall survival (OS) rate for childhood ALL in China is now close to 90%. However, some children still develop refractory or relapsed disease and face a less favorable prognosis.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Defining Relapsed\u002FRefractory ALL and Choosing a Treatment Strategy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Relapsed ALL: leukemia that returns after complete remission (CR), with >5% blasts again detected in the bone marrow or peripheral blood, or leukemia reappearing at any extramedullary site.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Refractory ALL: failure to achieve complete remission (CR) after standard induction therapy, two or more relapses, persistent extramedullary leukemia, or persistently positive measurable residual disease (MRD).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For relapsed\u002Frefractory B-ALL - particularly early relapse, relapse after transplantation, or multiple relapses - conventional chemotherapy often has limited efficacy, and immunologically targeted therapies are now commonly prioritized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>According to the 2025 CSCO Guidelines for Malignant Hematologic Diseases, commonly used immunotherapies include:\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. CAR-T cell therapy: The main targets are CD19 and CD22. Treatment may use a single target, dual targets, or sequential or combined infusion of different CAR-T products.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Bispecific antibody: Blinatumomab, which targets CD3 and CD19.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Antibody-drug conjugate (ADC): Inotuzumab ozogamicin, which targets CD22.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before CAR-T therapy, patients require a comprehensive assessment of disease status, genetic background, and any extramedullary involvement. During treatment, complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infection require close, full-course management. After treatment, continued monitoring is needed for CAR-T cell expansion, B-cell recovery, MRD, and changes in tumor-associated genetic markers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A growing body of research and expert consensus in China and internationally suggests that bridging to hematopoietic stem cell transplantation after CAR-T therapy can reduce relapse risk and improve long-term leukemia-free survival in some children with relapsed\u002Frefractory ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>When Is Hematopoietic Stem Cell Transplantation Considered, and Which Transplant Platform May Be Used?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for children with relapsed\u002Frefractory ALL. Both international and Chinese guidelines and consensus recommendations are available. Current Chinese transplant recommendations (referencing the 2022 edition) outline specific indications for low- and intermediate-risk patients in Tables 1 and 2, while allo-HSCT is recommended for all children classified as high risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F43f87aaef3f7d07827afba20c1f05a6b_20260913235057.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"43f87aaef3f7d07827afba20c1f05a6b_20260913235057.png\" alt=\"f338abed-9eaa-46e8-8ae2-fd3673b4620a.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Table 1\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F6f625d8e6ffe89d3c16cdfd0d9ccd7ea_20260913235110.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6f625d8e6ffe89d3c16cdfd0d9ccd7ea_20260913235110.png\" alt=\"4f07f9dd-1305-4264-b576-057e3363c82c.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Table 2\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>I. Philadelphia Chromosome-Negative ALL (Ph- ALL)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. First Complete Remission (CR1)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">① Failure to achieve CR after induction therapy; or achievement of CR after induction with measurable residual disease (MRD, assessed by flow cytometry [FCM]) remaining ≥10^-2. For patients with post-induction MRD between 10^-2 and 10^-3, close monitoring of bone marrow MRD is recommended.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">② Persistent MRD by FCM ≥10^-4 after ≥3 months of standardized chemotherapy. For children who are FCM-negative after ≥3 months of standardized chemotherapy but remain positive for a fusion gene, close quantitative monitoring of the fusion gene is recommended; allo-HSCT is recommended if the fusion-gene level shows a progressive increase.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">③ MRD becomes positive on two occasions at any point during treatment, based on FCM or RQ-PCR for a specific fusion gene (FCM MRD ≥0.01%). Based on MRD monitoring, allo-HSCT at an experienced transplant center is recommended.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">④ For patients with MLL rearrangements, allo-HSCT at an experienced center is recommended for those with MLL-AF6 positivity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">⑤ Presence of a TCF3-HLF fusion gene.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">⑥ Hypodiploidy (<44 chromosomes).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Second Complete Remission (CR2)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">① For children with very early relapse (within 18 months of starting treatment) or early relapse (more than 18 months from diagnosis but within 6 months after completion of first-line therapy, or within 36 months of starting treatment), allo-HSCT is recommended in CR2. For late bone marrow relapse (>36 months), allo-HSCT is recommended after CR2 if MRD remains positive (>10^-4).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">② Extramedullary relapse occurring within 18 months of treatment; extramedullary relapse occurring ≥18 months after treatment when remission has not been achieved after 4-8 weeks of therapy; or bone marrow relapse accompanied by extramedullary relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">3. All Patients in CR3 or Beyond\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>II. Philadelphia Chromosome-Positive ALL (Ph+ ALL)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">① Children with Philadelphia chromosome-positive ALL or BCR\u002FABL fusion-positive ALL who do not achieve remission after standard induction chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">② After 3 months of regular chemotherapy combined with an oral tyrosine kinase inhibitor (TKI), such as imatinib or dasatinib, the quantitative BCR\u002FABL fusion level has fallen by less than 3 log levels from baseline.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">③ Presence of the ABL T315I mutation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">1. First Complete Remission (CR1)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">① Failure to achieve bone marrow CR after a standard induction regimen; or achievement of CR with MRD by FCM remaining ≥10^-2.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">② At the end of intensification therapy (approximately 2.5-3 months after treatment begins), MRD remains >10^-3, or extramedullary leukemia persists, including disease in the mediastinum, lymph nodes, central nervous system, or other sites.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">③ MRD by FCM becomes positive on two or more occasions at any point during treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">④ Isolated extramedullary relapse within 18 months of starting treatment; for extramedullary relapse occurring ≥18 months after treatment begins, treatment response and bone marrow MRD should be closely monitored. Allo-HSCT is required for patients with a poor treatment response or concomitant bone marrow MRD relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">2. Second Complete Remission (CR2)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Any bone marrow and\u002For extramedullary relapse. Donor selection should take into account the patient's disease status, donor availability and characteristics, and the transplant center's experience.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, as transplant techniques have continued to improve, related haploidentical transplantation has increasingly become a preferred option in leukemia treatment. It expands donor availability - virtually every patient can identify a potential haploidentical family donor - while modern transplant strategies focus not only on successful engraftment, but also on preserving the graft-versus-leukemia (GVL) effect to help prevent relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Three major haploidentical transplant platforms are widely used internationally. A key difference among them is when and how T cells are depleted to prevent GVHD:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first is αβ T-cell-depleted transplantation, an ex vivo T-cell depletion approach. TDH is one example. Before stem cell infusion, magnetic bead selection is used outside the body to selectively remove αβ T cells from the graft because these cells can contribute to GVHD, while preserving stem cells, NK cells, and other immune cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The second is an antithymocyte globulin (ATG)-based transplant platform, often referred to as the “Beijing protocol,” which uses in vivo T-cell depletion. ATG is given intravenously during conditioning before transplantation to deplete T cells in the patient's body and reduce the risk of GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The third is post-transplant cyclophosphamide (PTCy), another in vivo T-cell depletion strategy. Cyclophosphamide is given on days +3 and +4 after stem cell infusion to selectively eliminate activated T cells that might attack the recipient's tissues. The ATG- and PTCy-based approaches generally require immunosuppressive medication after transplantation to prevent GVHD. With TDH, immunosuppression may be avoided or used only briefly and at low doses, allowing other immune cells, including NK cells, to better contribute to antileukemia activity after transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Our center uses the TDH transplant platform. Because many parents are unfamiliar with this approach, the basic principle is explained below.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>How TDH Works\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>A donor stem cell collection contains not only CD34+ hematopoietic stem cells, but also substantial numbers of immune cells, including T cells, B cells, and NK cells. T cells include both αβ T cells and γδ T cells. Magnetic bead selection can selectively remove αβ T cells while preserving abundant CD34+ stem cells, γδ T cells, NK cells, monocytes, and other components of the graft. After infusion, these cells can support rapid hematopoietic recovery and contribute to anti-infective and antitumor immunity.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">With conventional haploidentical transplantation, GVHD can remain an important complication. Severe GVHD may lead to life-threatening problems and affect overall outcomes, while persistent chronic GVHD can substantially reduce a patient's quality of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Our center is one of the institutions in China with a large number of TDH transplants and extensive accumulated clinical data. TDH has been used at our center for a range of conditions, including nonmalignant hematologic diseases such as severe thalassemia and aplastic anemia; malignant hematologic diseases such as ALL, AML, and JMML; and immunodeficiency disorders. In particular, encouraging outcomes have been observed in children with relapsed\u002Frefractory ALL undergoing TDH transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Since 2022, our center has presented related research findings at major meetings in China and internationally, including the American Society of Hematology (ASH) Annual Meeting. Two studies of TDH transplantation in leukemia were selected for presentation as abstracts at the 2025 ASH Annual Meeting.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>As of July 2025, 55 children with relapsed\u002Frefractory ALL had received CAR-T therapy followed by TDH transplantation at our center, including 51 with B-ALL and 4 with T-ALL. The median age at transplantation was 8 years, and the median follow-up was 29 months. The 2-year overall survival (OS) rate was 90.6%, leukemia-free survival (LFS) was 86.8%, the relapse rate was 4.2%, and non-relapse mortality was 9.4%.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Analysis of all children with relapsed\u002Frefractory ALL who underwent TDH transplantation showed different outcomes depending on the remission status at the time of transplant (CR1, CR2, or ≥CR3). The 2-year OS rates were 95.2% for CR1, 93.9% for CR2, and 67.5% for ≥CR3. The corresponding 2-year LFS rates were 95.2%, 83.2%, and 58.3%. The cumulative incidences of grade II-IV acute GVHD and chronic GVHD were 9.1% and 12.7%, respectively.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For children with high-risk or relapsed\u002Frefractory ALL who have an indication for transplantation, early allo-HSCT should therefore be considered. TDH transplantation may support durable remission with a relatively low rate of GVHD. Early tumor-genetic testing is also recommended to identify adverse prognostic alterations and determine whether targeted therapies may be available. Even after transplantation, MRD should be monitored regularly, and additional consolidation approaches - such as oral targeted therapy or scheduled donor lymphocyte infusions (DLI) - may be considered to further reduce the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Case Example\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Xiao Yu, a girl born in 2011, was diagnosed with B-ALL at age 3 in 2014. She completed standard chemotherapy but did not undergo regular follow-up. In 2020, she experienced her first relapse in the bone marrow and received an autologous murine-derived CD19 CAR-T product at another hospital. During treatment, she developed sepsis, grade 3 CRS, and grade 2 ICANS. She achieved remission and was observed afterward, but regular follow-up was not maintained.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>In 2021, 14 months after CAR-T therapy, she experienced a second bone marrow relapse. After coming to our center, bone marrow flow cytometry showed MRD of 79.5%, with CD19 and CD22 positivity. Lymphoid malignancy genetic testing detected KRAS at 35.94%, with predicted sensitivity to trametinib and cobimetinib. She first received cytoreductive chemotherapy, followed by sequential infusion of humanized CD19 CAR-T and CD22 CAR-T cells. Grade 1 CRS occurred during treatment. Flow cytometry MRD and KRAS testing both became negative. She subsequently proceeded to TDH transplantation using her mother as the donor.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>She is now more than three years post-transplant and returned to regular schooling two years ago.\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Although childhood ALL cannot currently be prevented, it has become a highly treatable disease. When facing the diagnosis, families should focus on three pillars: standardized treatment, close partnership with the medical team, and strong social support. Continuing to pursue appropriate treatment can give each child the best possible chance of cure.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":703,"title":704,"summary":705,"cover":706,"category":430,"publishedAt":352,"contentHtml":707,"hasAlternate":73,"updatedAt":432},"car-t-transplant-purtscher-like-retinopathy-first-report","International Journal Publication | Collaborative Team of Dr. Tong Wu, Dr. Zhihui Li, and Prof. Yong Tao Reports First Case of Purtscher-Like Retinopathy After CAR-T Bridging to Allo-HSCT","A collaborative team from Beijing GoBroad Boren Hospital and Beijing Chaoyang Hospital, Capital Medical University, has published the first report of Purtscher-like retinopathy after CAR-T therapy bridging to allogeneic HSCT, highlighting a potential association with transplant-associated thrombotic microangiopathy (TA-TMA).","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fee8ac27d6f72cd3d9eb3f1c05256b5a4.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: A collaborative team led by Dr. Tong Wu and Dr. Zhihui Li of Beijing GoBroad Boren Hospital and Prof. Yong Tao of Beijing Chaoyang Hospital, Capital Medical University, published a case report in Frontiers in Immunology describing, for the first time, a rare case of Purtscher-like retinopathy (PLR) in a child with relapsed B-ALL after CAR-T therapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study details the retinal imaging features of PLR, the response to anti-VEGF treatment, and its potential mechanistic relationship with transplant-associated thrombotic microangiopathy (TA-TMA). The findings highlight the importance of recognizing atypical complications that may reflect broader systemic changes in patients receiving complex immunotherapy and transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As CAR-T cell therapy becomes more widely used for relapsed or refractory hematologic malignancies, more patients are achieving deep remissions and moving on to hematopoietic stem cell transplantation. At the same time, the use of multiple sequential immunotherapies can make post-transplant complications more complex. In this setting, recognizing atypical complications early and avoiding delays in intervention has become an increasingly important issue in clinical practice.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, a collaborative team with Dr. Tong Wu of Beijing GoBroad Boren Hospital and Prof. Yong Tao of Beijing Chaoyang Hospital, Capital Medical University, as co-corresponding authors, and Dr. Zhihui Li of Beijing GoBroad Boren Hospital as first author, published a case report in Frontiers in Immunology. The team provided the first systematic report of a rare case of Purtscher-like retinopathy (PLR) occurring after CAR-T therapy bridging to allogeneic hematopoietic stem cell transplantation and explored its potential mechanistic association with transplant-associated thrombotic microangiopathy (TA-TMA).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Zhihui Li noted that, in clinical practice, some complications do not initially present with typical hematologic abnormalities. Instead, they may first appear as localized, nonspecific symptoms, making early recognition more difficult. Against this background, the team systematically reviewed and analyzed the rare ocular findings that developed after CAR-T therapy and transplantation in this case, with the aim of drawing attention to the possible systemic significance behind atypical manifestations in patients receiving complex immunotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F94596ae7b7b7ff4daae06d18c233b9d1_20260914004633.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"94596ae7b7b7ff4daae06d18c233b9d1_20260914004633.png\" alt=\"5508bf1f-9772-4275-bfe0-99ea045e3624.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case Overview\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>From Multiple Lines of Immunotherapy to Transplantation: Reviewing a Complex Treatment Journey\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study describes a child with relapsed B-cell acute lymphoblastic leukemia (B-ALL). After the initial diagnosis, the patient received standard treatment and achieved remission, but experienced the first hematologic relapse approximately 2.5 years later. To regain disease control, the patient received CD19 CAR-T cell therapy and achieved remission, followed sequentially by CD22 CAR-T cell therapy to further consolidate disease control and reduce the risk of antigen escape.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In 2024, the disease progressed again and relapsed with extramedullary involvement. At this stage, the treatment strategy shifted toward antibody-based immunotherapy in an effort to achieve another remission. The patient received an anti-CD22 antibody-drug conjugate, inotuzumab ozogamicin, together with immunomodulatory therapy such as belimumab. Once an appropriate transplant window was achieved, the patient proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Recognizing and Managing Sudden Vision Changes: Imaging Features of PLR and Response to Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Approximately 160 days after transplantation, the patient developed sudden, painless loss of vision accompanied by visual distortion, with no history of trauma. A comprehensive ophthalmologic evaluation, including fundus photography (Figure 1A & B), optical coherence tomography (OCT; Figure 2A & B), and fluorescein fundus angiography, led to a diagnosis of Purtscher-like retinopathy (PLR).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient first received a 0.5 mg intravitreal injection of ranibizumab in the left eye, administered once monthly. Six days after the first injection, vision in the left eye improved markedly, with substantial reductions in optic disc edema and retinal hemorrhage (Figures 1D and 2D).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To further investigate the underlying mechanism, the research team performed a cytometric bead array (CBA) analysis of aqueous humor. Levels of basic fibroblast growth factor (bFGF) and vascular cell adhesion molecule-1 (VCAM-1) were significantly elevated, suggesting disruption of the blood-retinal barrier.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During this period, vision in the right eye deteriorated rapidly, accompanied by increased retinal hemorrhage and cotton-wool spots, as well as worsening optic disc edema (Figures 1C and 2F). The team subsequently initiated a 0.5 mg intravitreal ranibizumab injection in the right eye.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Eight days after the first injection in the right eye, vision in the left eye continued to improve. Although vision in the right eye did not improve further, fundus examinations of both eyes showed marked reductions in retinal hemorrhage, cotton-wool spots, and optic disc edema (Figures 1E, F; Figures 2E, F), suggesting that anti-VEGF therapy had a positive effect on controlling retinal microvascular lesions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F3ff84a50cd576455cb72fb3705fcbb56_20260914004653.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3ff84a50cd576455cb72fb3705fcbb56_20260914004653.png\" alt=\"bda04518-8bc3-4a8e-a08a-c16b122bc23f.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1. Fundus photographs of both eyes\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(A, B) Multiple retinal hemorrhages, cotton-wool spots, and yellow-white Purtscher flecken are visible in the posterior poles of both eyes, with more extensive involvement in the left eye.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(C) Compared with the earlier examination, retinal hemorrhage, cotton-wool spots, and Purtscher flecken are markedly increased in the right eye.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(D) Six days after intravitreal ranibizumab injection in the left eye, retinal hemorrhage is partially absorbed, while the cotton-wool spots and Purtscher flecken show little change.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(E) Eight days after intravitreal ranibizumab injection in the right eye, retinal hemorrhage, cotton-wool spots, and Purtscher flecken are markedly reduced compared with the previous examination.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(F) Fifteen days after intravitreal ranibizumab injection in the left eye, retinal hemorrhage shows further absorption, with additional reductions in cotton-wool spots and Purtscher flecken.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\"> \u003C\u002Fspan>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F52242665c0afc019502f6708790fb5ba_20260914004709.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"52242665c0afc019502f6708790fb5ba_20260914004709.png\" alt=\"ae1618a0-060e-4d3e-8c5f-b2a0e9dd408e.png\" style=\"font-size: 15px;\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 2. OCT images of both eyes\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(A) Right eye (February 19): Edema and thickening of the inner retina with cystoid macular edema measuring approximately 249 μm.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(B) Left eye (February 19): Marked edema and thickening of the inner retina, with cystoid macular edema measuring approximately 885 μm and multiple focal hyperreflective lesions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(C) Right eye (March 3): Further worsening of inner retinal edema and thickening, with cystoid macular edema measuring approximately 822 μm, markedly increased from the previous examination.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(D) Left eye (March 3): Reduced inner retinal edema and thickening, with cystoid macular edema measuring approximately 358 μm, markedly decreased from the previous examination.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(E) Right eye (March 12): Marked improvement in inner retinal edema and thickening, with cystoid macular edema measuring approximately 253 μm, substantially reduced from prior examinations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">(F) Left eye (March 12): Cystoid macular edema measures approximately 260 μm, with little change compared with the previous image.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>From Retinal Findings to Systemic Assessment: Recognition and Management of TA-TMA\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">While evaluating and treating the ocular lesions, the research team also carried out a systemic assessment. On post-transplant day 179, lymphocyte subset analysis showed a CD4\u002FCD8 ratio of 0.22, B cells at 5.05%, and NK cells at 21.68%, indicating limited immune reconstitution.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">By post-transplant day 194, the patient had developed severe thrombocytopenia, with a nadir platelet count of 40 × 10^9\u002FL, marked proteinuria (24-hour urinary protein, 2,400 mg), renal impairment (serum creatinine, 133.9 μmol\u002FL), and complement activation (C5b-9, 298 ng\u002FmL), together with serous effusions in multiple body cavities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Following a systematic evaluation, graft-versus-host disease (GVHD), calcineurin inhibitor toxicity, and other potential causes were excluded. Together with an increased proportion of schistocytes in peripheral blood (0.8%), the findings led to a diagnosis of transplant-associated thrombotic microangiopathy (TA-TMA).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For TA-TMA, the patient received defibrotide and eculizumab, together with supportive treatment including diuretics, antihypertensive therapy, and management of capillary leak. The patient's overall condition subsequently stabilized.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Zhihui Li noted that this study provides the first systematic report of Purtscher-like retinopathy occurring in a child with relapsed B-ALL after CAR-T therapy bridging to allogeneic hematopoietic stem cell transplantation. Importantly, in this case, the retinal manifestations appeared before some of the systemic abnormalities, offering a new perspective on how post-transplant microvascular complications may evolve. As immunotherapy and transplantation are increasingly integrated, clinicians need to pay closer attention to atypical symptoms such as sudden vision changes. Combining imaging evaluation with systemic assessment may help identify underlying microvascular injury or complement-related abnormalities at an earlier stage and allow timely management. Multidisciplinary collaboration and careful, individualized assessment may further improve the recognition and management of post-transplant complications, enhancing overall treatment safety and outcomes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Yong Tao commented: “As patients with hematologic diseases increasingly survive intensive treatment, protecting quality of life becomes equally important. Vision accounts for more than 90% of the information people take in from the world, and irreversible vision loss can place a heavy burden on the patient's daily life, work, and family. This report describes Purtscher-like retinopathy in a child with relapsed B-ALL after CAR-T therapy bridging to allogeneic hematopoietic stem cell transplantation. Although active treatment reduced retinal edema and gradually improved ischemic changes, the patient was still left with severe, irreversible visual impairment. We hope this case encourages clinicians to move screening earlier in the care pathway by considering routine fundus examinations for high-risk patients, using AI-assisted screening where appropriate, identifying retinal abnormalities as early as possible, and intervening promptly.”\u003C\u002Fspan>\u003C\u002Fp>",{"slug":709,"title":710,"summary":711,"cover":712,"category":438,"publishedAt":713,"contentHtml":714,"hasAlternate":73,"updatedAt":74},"tcr-ab-t-depleted-haploidentical-transplant","Expert Q&A: How Is TCRαβ-Depleted Transplantation Different from Conventional HSCT, and How Do You Choose?","Dr. Huaying LIU of GoBroad Chunfu Institute of Hematology & Oncology explains, in a patient-friendly Q&A, how TCRαβ-depleted transplantation works, who may be considered for it, and how it differs from conventional transplant approaches.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fa0468e38a1958a556c0093d212a62ff4.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-02-12","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: In this Q&A, Dr. Huaying LIU of GoBroad Chunfu Institute of Hematology & Oncology answers common questions about TCRαβ+ T-cell-depleted hematopoietic stem cell transplantation (TDH). She explains how TDH differs from the Beijing protocol, which uses ATG for in vivo T-cell depletion, and the post-transplant cyclophosphamide (PTCy) approach. TDH instead uses ex vivo immunomagnetic separation to selectively deplete αβ T cells while preserving beneficial immune cells such as γδ T cells and natural killer (NK) cells. The article also discusses potential advantages such as a lower risk of graft-versus-host disease (GVHD), reduced need for routine post-transplant immunosuppression, and earlier hematopoietic recovery, as well as strategies used to reduce relapse risk, including pre-transplant CAR-T therapy, donor lymphocyte infusion (DLI), and targeted maintenance treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">TCRαβ+ T-cell-depleted hematopoietic stem cell transplantation (TDH) is one of the major approaches to haploidentical transplantation and is designed to reduce the risk of graft-versus-host disease (GVHD). To address questions commonly raised by patients and families, Dr. Huaying LIU of GoBroad Chunfu Institute of Hematology & Oncology explains the key issues in a Q&A format.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q1: A 3-year-old girl was diagnosed with high-risk B-cell acute lymphoblastic leukemia (B-ALL) in late August 2025 and is now in consolidation therapy under the SCCG-ALL-2023 high-risk protocol. Her high-risk features include NF1 and MYC mutations, p16 deletion, severe hypodiploidy (only about 26 chromosomes), and CNS3 involvement at diagnosis. Her treatment response has been very good: flow cytometry was negative by day 33 and the CNS leukemia cleared. With this combination of very high-risk genetics but a strong early treatment response, is transplantation still necessary? If MRD remains negative, could chemotherapy alone be sufficient? How do these risk factors affect long-term survival, and what are the most important decision points going forward?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Regardless of the pediatric ALL cooperative-group protocol being used, the basic treatment principle is similar: therapy is guided by risk stratification. Risk groups are defined using clinical, cytogenetic, and molecular features that are widely recognized as being closely related to prognosis, together with treatment-response indicators such as measurable residual disease (MRD).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Although this child has responded well so far, transplantation would still be the preferred option because of the prognostic significance of her high-risk features. The exact transplant strategy may differ between centers. If transplantation cannot be performed immediately for practical or clinical reasons, bone marrow MRD should be monitored closely during subsequent chemotherapy, particularly molecular and cytogenetic markers. If a marker converts from negative to positive, treatment should be adjusted promptly. Immunotherapy may be considered when appropriate, with the goal of restoring bone marrow MRD or molecular negativity before proceeding to transplantation as early as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q2: How does T-cell-depleted transplantation differ from conventional transplantation? When might TDH be considered, and what are its potential advantages?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: TDH has been used extensively in Europe and the United States, and GoBroad Chunfu Institute of Hematology & Oncology has accumulated substantial experience with this approach in China. During hematopoietic stem cell transplantation, three of the major concerns for both doctors and patients are infection, graft-versus-host disease (GVHD), and relapse, especially in malignant hematologic diseases. Historically, fully matched donors were often preferred. Subsequent clinical experience has shown that haploidentical transplantation may provide a stronger graft-versus-leukemia effect in some hematologic malignancies. At the same time, haploidentical transplantation can carry higher risks, and both acute and chronic GVHD can affect quality of life, increase the risk of infection and other complications, and in severe cases become life-threatening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">There are currently three major approaches to haploidentical transplantation. The first is the Beijing protocol, which uses antithymocyte globulin (ATG) during conditioning for in vivo T-cell depletion. The second is the post-transplant cyclophosphamide (PTCy) approach, in which cyclophosphamide is given three to four days after stem cell infusion to eliminate alloreactive T cells in vivo. The third is TDH. Before the graft is infused, immunomagnetic separation is used ex vivo to remove the αβ T cells most responsible for GVHD while preserving a graft rich in CD34+ hematopoietic stem cells, γδ T cells, NK cells, monocytes, and other components.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After infusion, these retained cells can support faster hematopoietic recovery and contribute to anti-infective and antitumor immunity. Patients receiving TDH do not routinely require immunosuppressive medication for GVHD prophylaxis. Whether TDH is appropriate for an individual patient still depends on a comprehensive assessment of disease type, overall health, genetic background, tumor burden, and other clinical factors.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q3: Compared with conventional transplantation, would a child usually spend more or less time in the hospital and in protective isolation? Does the overall treatment experience feel very different?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Conventional transplantation includes both fully matched and haploidentical approaches. For malignant hematologic diseases, our transplant strategy also takes post-transplant relapse risk into account when selecting the donor and platform. Compared with other haploidentical approaches, TDH is associated in our experience with relatively early neutrophil and megakaryocyte engraftment, a shorter period of severe neutropenia, and a lower infection risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Earlier platelet engraftment may also reduce bleeding risk and the need for blood product transfusions, which can shorten the time a child needs to remain in the transplant unit. One of the biggest differences between TDH and many other transplant approaches is that routine post-transplant immunosuppressive therapy is generally not required. After leaving protective isolation, children therefore take fewer oral medications and do not need regular outpatient blood tests to monitor immunosuppressant drug levels and adjust dosing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q4: What T-cell-depletion method does your center use? Are the stem cells processed outside the body, or are medications given to the child to remove T cells?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Our TDH approach uses ex vivo T-cell depletion. We selectively remove αβ T cells from the mobilized hematopoietic stem cell graft before infusion using immunomagnetic separation. This process is performed on the collected stem cell product, so there is no need to give the patient a special medication solely for the purpose of removing these αβ T cells in vivo.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q5: Some families worry that removing T cells might increase the risk of leukemia relapse. What measures do you use to reduce that risk? For example, are newer drugs or targeted therapies used after transplant, or are planned donor lymphocyte infusions given?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Earlier forms of ex vivo T-cell-depleted transplantation used in China often referred to CD34-positive selection, which is different from the TCRαβ+ T-cell-depletion strategy used at our center. Recent international multicenter transplant data suggest that TCRαβ+ depletion (TDH) does not increase the risk of leukemia relapse compared with other transplant approaches.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Our center's five-year treatment data also show a relatively low relapse risk after TDH. This reflects not only the transplant platform itself, but also the comprehensive treatment strategy we use for leukemia. For each patient, we develop a full-course treatment plan that includes achieving deep MRD remission before transplant, individualizing the transplant strategy, and providing post-transplant consolidation or maintenance treatment when appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For example, immunotherapies such as blinatumomab or CAR-T may be used before transplant in selected patients. After transplant, targeted drugs may be chosen according to the patient's molecular findings, and scheduled donor lymphocyte infusions (DLI) may also be used as part of maintenance or relapse-prevention strategies. The exact plan depends on factors such as genetic test results and whether a suitable therapeutic target is available. Because routine oral immunosuppressive therapy is not required after TDH, DLI can often be started relatively early. The GVHD risk associated with this approach is generally lower and can be managed closely. At our center, dose-escalated DLI is typically started at a median of around 40 days after transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q6: Does T-cell-depleted transplantation mean a child will have almost no immune protection for a long time after transplant? How does your center monitor and prevent infections, including viruses such as CMV and EBV?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Hematopoietic stem cell transplantation is fundamentally a process of rebuilding both blood formation and the immune system, so immune recovery takes time after any transplant. The graft used in TDH contains not only large numbers of CD34+ hematopoietic stem cells, but also γδ T cells, NK cells, and other immune components.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After infusion, these cells can support relatively rapid hematopoietic recovery and contribute to infection control. As mentioned earlier, because the GVHD risk is lower after TDH, DLI can be introduced relatively early, and donor lymphocytes themselves can provide adoptive immune support. In addition to DLI, our center can also use memory T-cell infusions. Donor lymphocytes undergo CD45RA depletion so that memory T cells can be collected and cryopreserved, then infused later in gradually increasing doses when needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This strategy can be used to help prevent and treat common viral infections after transplant, including CMV and EBV. We also start antiviral prophylaxis early when indicated and monitor viral levels closely - for example, weekly in the early post-transplant period, then every two weeks, and later monthly as appropriate. Antiviral treatment is adjusted promptly based on the results. Cellular infusions can also be used to strengthen antiviral immunity in selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q7: If everything goes smoothly, can TDH substantially reduce the risk of severe GVHD? Could that have meaningful long-term benefits for a child's growth and development, including height, learning, and pubertal development?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Yes. Compared with other transplant approaches, TDH is associated with a markedly lower incidence of both acute and chronic GVHD. Reducing GVHD is particularly important for children's long-term growth and development. A lower GVHD rate can substantially reduce the need for immunosuppressive therapy, and prolonged or intensive use of these medications can itself contribute to complications affecting growth, development, endocrine function, and other areas. Chronic GVHD is also an important long-term concern. Dr. Liu also cited a recent retrospective analysis from an Italian transplant team using TDH in children with relapsed\u002Frefractory leukemia (R\u002FR ALL\u002FAML): the 10-year GVHD-free, relapse-free survival (GRFS) was 65.1%, and among patients who were MRD-negative before transplant, 10-year disease-free survival (DFS) was 73.6%. Patients transplanted in CR1 or CR2 had better outcomes than those transplanted in CR3.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At last year's American Society of Hematology (ASH) Annual Meeting, a U.S. research team also presented a comparison of TDH and PTCy, reporting better GVHD-free, relapse-free survival (GRFS) with TDH. Our center also presented a poster at ASH last year on TDH for pediatric relapsed\u002Frefractory ALL. The two-year overall survival (OS) was 90.1%, and two-year leukemia-free survival (LFS) was 83.2%. Among patients who received TDH after CAR-T therapy, two-year OS was 90.8%, two-year LFS was 87.3%, and the relapse rate was 3.6%. The main causes of treatment failure remained relapse and infection. Our team continues to refine the strategy in an effort to further reduce both risks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cstrong>\u003Cspan style=\"font-size: 15px;\">Q8: After TDH, approximately how long does immune recovery take before a child can return to school and resume more normal contact with the outside world?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Huaying Liu: Immune recovery after transplantation is complex and dynamic and involves the reconstitution of multiple immune-cell subsets. Post-transplant complications such as GVHD and infections, including CMV, as well as the use of immunosuppressive medications, can delay immune recovery. Immune function should be monitored regularly - often monthly early on, with the interval gradually extended to every three months, every six months, and eventually once a year depending on the patient's recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients receiving TDH often achieve hematopoietic recovery relatively early. Because GVHD rates are lower and routine oral immunosuppressive therapy is generally not needed, memory T-cell infusions or dose-escalated DLI can be used earlier when appropriate to provide adoptive immune support. Patients whose B-cell function has not yet recovered may also receive immunoglobulin replacement when indicated. In many patients, immune function gradually recovers over approximately the first year after transplant. Once immune reconstitution is adequate, the child may be able to return to school and resume broader contact with the outside environment, based on the medical team's assessment.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":716,"title":717,"summary":718,"cover":719,"category":438,"publishedAt":713,"contentHtml":720,"hasAlternate":73,"updatedAt":74},"lumbar-puncture-csf-cns-leukemia-diagnosis-guide","Expert Guide: Lumbar Puncture and CSF Testing - A Key Step in Detecting CNS Leukemia","A practical guide to five types of cerebrospinal fluid (CSF) testing performed after lumbar puncture, with real cases showing why the tests complement one another in diagnosing central nervous system leukemia.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fb2be9ee9fe9436dd6f421dac60f7dc28.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Central nervous system leukemia (CNS leukemia) is one of the most common extramedullary manifestations of acute lymphoblastic leukemia. Examining cerebrospinal fluid (CSF) obtained by lumbar puncture is a key part of diagnosis. This article explains five major types of CSF testing - routine analysis, biochemical testing, cytomorphology, flow cytometry, and molecular testing - and uses four real cases to show how the results complement one another. Routine cell counts and biochemistry are mainly screening tools; flow cytometry offers high sensitivity for detecting very small populations of abnormal cells; and molecular testing can be particularly useful in patients with known fusion genes or other genetic abnormalities. Integrating multiple test results is important for accurately identifying CNS leukemia and reducing the risk of missed disease and relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Central nervous system leukemia (CNS leukemia) is one of the most common extramedullary manifestations of acute lymphoblastic leukemia (ALL).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Doctors commonly perform a lumbar puncture (spinal tap) to collect cerebrospinal fluid (CSF) and check for leukemia cells, helping determine whether the central nervous system is involved. It is important to remember, however, that CNS leukemia can also present as an intracranial mass, spinal cord involvement, or involvement of the eyes or cranial nerves.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Diagnosing CNS leukemia requires sensitive molecular and immunologic methods rather than relying on cell counts alone. Timely and accurate testing can help reduce the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This article explains how CSF obtained through lumbar puncture is evaluated for CNS leukemia, and uses real cases to show why the different tests are important and how they complement one another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>CSF Tests and What They Tell Us\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The main goal of CSF testing is to determine whether leukemia cells are present in the cerebrospinal fluid. In some patients, CSF testing can also help evaluate other central nervous system problems, such as infection or autoimmune encephalitis. Common tests include:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Routine CSF Analysis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine analysis includes assessing the appearance of the CSF - for example, whether it is clear and what color it is - as well as measuring white blood cells, red blood cells, mononuclear cells, and polymorphonuclear cells. Example reports:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F0f2629f7515ec52c1ae355be481bbb09_20260913233747.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0f2629f7515ec52c1ae355be481bbb09_20260913233747.png\" alt=\"9a1baa42-e800-42d5-8f29-e70d5fcc3e7a.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Routine CSF analysis: normal\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F1c62e25aecaba36c4e0ce4834733ef28_20260913233759.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1c62e25aecaba36c4e0ce4834733ef28_20260913233759.png\" alt=\"d7d58587-c54c-48aa-8eae-35a24cd4155f.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Routine CSF analysis: traumatic tap\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Normally, CSF is clear and colorless, and the white blood cell count falls within the reference range. When leukemia cells are present, especially in large numbers, the fluid may appear pale yellow and the white blood cell count is often elevated. If blood enters the CSF sample and red blood cells are detected, the fluid may look red or pink; in this situation, the first step is to determine whether the blood was introduced by a traumatic lumbar puncture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Infections can also raise the CSF white blood cell count and change the appearance of the fluid. When that happens, other tests are needed to help determine the cause.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. CSF Biochemistry\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This usually includes chloride, glucose, and total CSF protein. Example report:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F95b3007ba6b8253f30a7c2b9cce01edf_20260913233813.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"95b3007ba6b8253f30a7c2b9cce01edf_20260913233813.png\" alt=\"4f3636a3-3ec1-4668-be0e-b6f023e76ca9.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">CSF biochemistry: normal\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Under normal circumstances, CSF biochemical values fall within their reference ranges. In patients with CNS leukemia, findings may include elevated protein and\u002For low chloride and\u002For low glucose. Similar changes can also occur with infection, so the results need to be interpreted together with other tests.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine CSF analysis and biochemistry are both basic tests performed with lumbar puncture. Because they can be affected by infection, chemotherapy-related changes, or a traumatic tap, they cannot confirm CNS leukemia on their own and are best used as initial screening tools.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. CSF Cytomorphology\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This test uses manual microscopic examination to classify the cells present in CSF. Example report:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fafd368ada3213faa4ed09ac53f732ea1_20260913233826.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"afd368ada3213faa4ed09ac53f732ea1_20260913233826.png\" alt=\"3284ecea-c8eb-4cd5-a5b1-ff154e458342.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Manual review allows the laboratory team to directly examine the cellular components in the CSF.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Its main advantage is that the findings can be visually clear and specific. However, because the test relies on manual examination, its sensitivity is relatively limited, so the result often needs to be interpreted together with other tests.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. CSF Flow Cytometry\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Principle: Flow cytometry identifies malignant cells by detecting characteristic combinations of antigens on the surface of leukemia cells. The principle is similar to immunophenotyping of bone marrow samples. Key feature:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Flow cytometry is highly sensitive and can detect very small populations of residual abnormal cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Example report:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F765593740cb72c22fd1c0ef4a187e55d_20260913233840.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"765593740cb72c22fd1c0ef4a187e55d_20260913233840.png\" alt=\"1f46d25c-f0c8-4f7a-8d2c-b54d5cd0d9ad.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">CSF flow cytometry in a patient with acute promyelocytic leukemia (APL)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>5. Molecular Testing of CSF\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Principle: Molecular testing looks for leukemia-specific genetic markers - such as the BCR::ABL1 fusion gene or NPM1 variants - using PCR or next-generation sequencing (NGS). It is mainly applicable to patients with a known genetic abnormality, such as Ph-positive ALL or APL. It is used less broadly than immunophenotyping, but for a defined molecular marker it may offer even greater analytical sensitivity than flow cytometry.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Example report:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fcc25aebb8e009344412213cf8f9c55d0_20260913233850.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"cc25aebb8e009344412213cf8f9c55d0_20260913233850.png\" alt=\"db643768-139b-49a8-9133-88d24d7b3677.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">CSF fusion-gene testing in a patient with APL and a previous history of CNS leukemia\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CSF cytology, flow cytometry, and genetic testing can also be used more broadly when evaluating hematologic diseases involving the central nervous system. In primary or secondary CNS hematologic disease, particularly when abnormalities are confined to the CNS, CSF may be one of the most important specimens available. A comprehensive workup can include broad flow-cytometric screening, molecular testing, and in selected cases even cytogenetic studies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Patient Case Examples\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Case 1\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine CSF analysis and biochemistry were normal, but cytomorphology and flow cytometry detected CNS leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: 23-year-old woman with mixed-phenotype acute leukemia. She had no clinical symptoms.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5aed65f7baeb7b13ea97edb3478114e1_20260913233913.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5aed65f7baeb7b13ea97edb3478114e1_20260913233913.png\" alt=\"b6f41a22-0417-4fbf-8363-230d219656ca.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Routine CSF white blood cell count: 0\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F78805a221a988e79ef3f42d7c5bfd418_20260913233929.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"78805a221a988e79ef3f42d7c5bfd418_20260913233929.png\" alt=\"image.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F00c69905848eb7155a7be19b52141d8a_20260913233941.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"00c69905848eb7155a7be19b52141d8a_20260913233941.png\" alt=\"d9d176e6-3059-4553-a69b-6fa5492de442.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fe8d2aa4ed5b347993ae0965c12321d72_20260913234002.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e8d2aa4ed5b347993ae0965c12321d72_20260913234002.png\" alt=\"41a24ba1-4cfe-4cec-85d2-4dd62cd659e5.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Case 2\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine CSF findings were normal. CSF glucose and chloride were above the reference range, while cytomorphology and flow cytometry showed no abnormalities. CNS leukemia was detected only because quantitative testing for a fusion gene in CSF was positive.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: 14-year-old boy with acute lymphoblastic leukemia.\u003C\u002Fspan>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Faa229856eae77a7e540fb0cdb2f765b3_20260913234021.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"aa229856eae77a7e540fb0cdb2f765b3_20260913234021.png\" alt=\"bfd983fd-2c16-4ba9-b01a-6618e3ac18e2.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fca2d7655303f92607e39ad29b62feadb_20260913234033.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"ca2d7655303f92607e39ad29b62feadb_20260913234033.png\" alt=\"b161877a-7370-4ba4-9673-96b412205608.png\"\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F287f4ce26c056c3814336b33efcf1b14_20260913234058.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"287f4ce26c056c3814336b33efcf1b14_20260913234058.png\" alt=\"7e4fdeb7-64cf-46ab-a912-bf73fc4e3677.png\"\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Case 3\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine CSF testing showed an elevated white blood cell count, while biochemistry was normal and cytomorphology, flow cytometry, and molecular testing were all negative. The elevated cells were considered reactive, and CNS leukemia was excluded. Patient:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">24-year-old man with acute lymphoblastic leukemia and a ZBTB5-JAK2 fusion gene.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Ffaa46762b0a55e413f4d3fff26d674e9_20260913234126.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"faa46762b0a55e413f4d3fff26d674e9_20260913234126.png\" alt=\"1f7260d5-4b94-4f64-957f-b3593a7fc899.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Routine CSF white blood cell count: 18, elevated\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fe309cd4206e006aa760eaac61a16341f_20260913234134.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"e309cd4206e006aa760eaac61a16341f_20260913234134.png\" alt=\"c189495e-fbe4-4288-a429-e8f4c71548cb.png\"\u002F>\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fadbb9bd93f66560046599c2006f04f78_20260913234153.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"adbb9bd93f66560046599c2006f04f78_20260913234153.png\" alt=\"2421e4d6-46a4-4204-975b-ecc5004a58d8.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F0b2597a80fbbceba1a2c39a461b8e620_20260913234202.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0b2597a80fbbceba1a2c39a461b8e620_20260913234202.png\" alt=\"3db1998d-07ab-45d7-9d56-a380d888ac55.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F9be31431b3740595a3ea3a428ccb0977_20260913234211.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"9be31431b3740595a3ea3a428ccb0977_20260913234211.png\" alt=\"9ad0e2d1-87d6-4165-a5b2-10977c2cbb8a.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Case 4\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Routine CSF testing showed an elevated white blood cell count, and all biochemical parameters were abnormal. Cytomorphology, flow cytometry, and molecular testing showed no evidence of leukemia. A CAR-T cell assay detected CAR-T cells in the CSF, supporting that the elevated cells represented CAR-T cells entering the central nervous system rather than CNS leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patient: 38-year-old man with T-cell acute lymphoblastic leukemia, positive for a SET-CAN fusion gene, after CD7 CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F07aae51c2bdede839467593e556f730f_20260913234225.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"07aae51c2bdede839467593e556f730f_20260913234225.png\" alt=\"8721105a-98db-4f3a-b098-4a26cb6e6152.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Routine CSF white blood cell count: 52, elevated\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fc21a479c6a611bcf736df849158ed0af_20260913234235.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c21a479c6a611bcf736df849158ed0af_20260913234235.png\" alt=\"efa37f7d-c67f-4c62-a786-e3d5a2a1621f.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F370c6b5254bf28c3e2b753935e2d3b5a_20260913234245.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"370c6b5254bf28c3e2b753935e2d3b5a_20260913234245.png\" alt=\"dbe1b781-f23d-4298-91ae-50c1416a7717.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fd63ed45bf76ee640ea084681027d14d5_20260913234301.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"d63ed45bf76ee640ea084681027d14d5_20260913234301.png\" alt=\"85d51f98-52c8-4c5d-b9f0-3b49ace2517d.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F1ba23cf725a4490fcecdce4b0bb0203d_20260913234312.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"1ba23cf725a4490fcecdce4b0bb0203d_20260913234312.png\" alt=\"858f3ad2-f821-46c8-badb-d9ed8c1508ea.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 15px;\"> \u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fc6cb6b9fbcb71fd5faa5deb29509ce0b_20260913234325.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c6cb6b9fbcb71fd5faa5deb29509ce0b_20260913234325.png\" alt=\"ffb8636d-f75a-4794-9075-b81ee1f4095d.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Testing Strategy\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with hematologic malignancies undergoing lumbar puncture and CSF testing, several points are worth keeping in mind:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Tests Commonly Recommended for CSF\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Basic tests: routine cell count, biochemistry (protein\u002Fglucose), cytomorphology (microscopic review of cell morphology), and flow-cytometric immunophenotyping.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Advanced tests: if a fusion gene or gene mutation has already been identified, related molecular testing may be added, such as testing for MLL rearrangements or TP53 mutations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with hematologic malignancies, the article recommends sending the above tests whenever CSF is collected by lumbar puncture.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Common Misunderstandings About the CSF White Blood Cell Count\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A high white blood cell count does not necessarily mean CNS leukemia: infection, chemotherapy-related changes, or procedural trauma can also cause an increase.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A normal white blood cell count does not rule out CNS leukemia: some patients with relapse may have only a very small amount of disease detectable by flow cytometry or molecular testing, while routine CSF findings remain normal.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Why Are Lumbar Puncture and Intrathecal Therapy Needed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Lumbar puncture and intrathecal therapy are important parts of the diagnostic and treatment process for patients with hematologic malignancies for several reasons:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even when there is no CNS leukemia at the initial diagnosis, regular CSF monitoring remains important, particularly cytomorphology and flow-cytometric immunophenotyping. Intrathecal therapy can also be used to prevent or treat CNS leukemia. In clinical practice, relapse can occasionally occur only in the central nervous system, and patients may have no symptoms when it happens. Routine CSF testing may also appear unremarkable, while cytomorphology, flow cytometry, or molecular testing identifies disease. Conversely, normal CSF testing does not necessarily exclude every form of CNS involvement. If central nervous system disease is still suspected, additional evaluation such as brain MRI may be needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If you have questions about CSF testing or central nervous system leukemia, or would like advice based on your own condition, you can contact a specialist online through the Internet Hospital for an individualized consultation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">*This article is for general health education only and is not a substitute for professional medical advice. Please follow the recommendations of your treating physician.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":722,"title":723,"summary":724,"cover":725,"category":430,"publishedAt":367,"contentHtml":726,"hasAlternate":73,"updatedAt":432},"car-t-tp53-mutant-cns-lymphoma-efficacy-study","International Journal Publication | Prof. Xiaoyan Ke & Prof. Kai Hu's Team: CAR-T Cell Therapy Shows Promising Efficacy in TP53-Mutated R\u002FR CNSL","A study by Prof. Xiaoyan Ke and Prof. Kai Hu's team, published in Frontiers in Medicine, found that CAR-T cell therapy remained effective in patients with relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) harboring TP53 mutations.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1b767a6937f370bbcff5677109999b4f.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Patients with relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) harboring TP53 mutations are often highly resistant to chemotherapy and have poor outcomes. A study by Prof. Xiaoyan Ke and Prof. Kai Hu's team at Beijing GoBroad Hospital, published in Frontiers in Medicine, analyzed data from 61 patients with R\u002FR CNSL. Among patients with TP53 mutations who received CAR-T cell therapy, both the overall response rate and complete response rate reached 64.5%, comparable with outcomes in patients with wild-type TP53. Subgroup analysis also showed significantly longer survival in TP53-mutated patients with the non-GCB subtype. These findings provide new clinical evidence and a useful reference for CAR-T treatment in patients with high-risk genetic alterations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients with relapsed\u002Frefractory central nervous system lymphoma (R\u002FR CNSL) generally face poor outcomes, with prognosis varying considerably according to multiple factors. TP53 mutations are considered one of the key genetic factors associated with treatment outcome and have long posed a challenge in lymphoma care. In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has shown encouraging efficacy and safety in R\u002FR CNSL. However, relatively little has been known about whether TP53 mutations affect response to CAR-T therapy, making this an important area for further study.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, Dr. Danyang Li from the team led by Prof. Xiaoyan Ke and Prof. Kai Hu of the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital published a study in Frontiers in Medicine entitled “CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier.” The study offers new insights into the use of CAR-T cell therapy for patients with TP53-mutated R\u002FR CNSL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Kai Hu explained: “Relapsed\u002Frefractory central nervous system lymphoma can be particularly difficult to treat. When the disease remains sensitive to chemotherapy, patients may achieve remission and can often benefit from autologous hematopoietic stem cell transplantation. In real-world practice, however, many patients develop chemotherapy resistance after relapse, and TP53 mutations are common among these difficult-to-treat cases. To better understand this population, our team analyzed 61 patients with R\u002FR CNSL, including 43 who received CAR-T cell therapy. We compared overall survival (OS) and progression-free survival (PFS) between patients with TP53 mutations (TP53+) and those with wild-type TP53 (TP53−), and also evaluated other factors associated with prognosis.”\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Research Highlights\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. CAR-T Therapy Achieved Comparable Responses in TP53+ and TP53− R\u002FR CNSL\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study showed that both the overall response rate (ORR) and complete response rate (CRR) were 64.5% in the TP53+ group. In the TP53− group, ORR and CRR were 73.3% and 69.2%, respectively, indicating broadly comparable response rates between the two groups. Median progression-free survival (PFS) was 12.77 months in the TP53+ group (95% CI: 6.33–∞), compared with 22.4 months in the TP53− group (95% CI: 6.13–∞); however, the difference was not statistically significant. These findings suggest that CAR-T cell therapy can also be effective for patients with TP53-mutated R\u002FR CNSL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F6a3b0cfecd69d42126a67c440436601b_20260914005242.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"6a3b0cfecd69d42126a67c440436601b_20260914005242.png\" alt=\"d3f728ba-1ef1-4ac7-a0fb-4ac619600de0.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. TP53+ Non-GCB R\u002FR CNSL May Derive Greater Benefit, With Significantly Longer Survival\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Subgroup analysis further showed that cell-of-origin (COO) classification was an important factor affecting long-term survival in patients with R\u002FR CNSL. Within the TP53+ group, patients with the non-germinal center B-cell-like (non-GCB) subtype had significantly longer overall survival than those with the GCB subtype (P=0.003).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The center's preliminary findings suggest that CAR-T cell therapy is an effective option for patients with TP53-mutated R\u002FR CNSL and may be particularly beneficial for those with a non-GCB phenotype. These data may help clinicians when considering treatment strategies for this high-risk patient population.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary and Outlook\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Prof. Xiaoyan Ke noted that the Department of Lymphoma and Myeloma at Beijing GoBroad Hospital has accumulated substantial experience with CAR-T therapy in recent years. As the number of real-world CAR-T cases continues to grow, the clinical questions encountered are becoming increasingly complex. Experience suggests that patients with TP53 mutations are often highly resistant to chemotherapy, while CAR-T therapy can still offer meaningful benefit. Identifying the right timing for CAR-T treatment and developing individualized, precise, end-to-end management strategies remain important priorities in hematologic oncology. Looking ahead, integrated assessment using clinical, pathological, molecular, and imaging data may help identify R\u002FR CNSL patients who do not respond to conventional therapy but are more likely to benefit from precision CAR-T treatment. Monitoring approaches such as circulating tumor DNA (ctDNA) may also help detect signs of relapse earlier, allowing treatment to be initiated sooner and potentially extending survival.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":728,"title":729,"summary":730,"cover":731,"category":438,"publishedAt":376,"contentHtml":732,"hasAlternate":73,"updatedAt":432},"car-t-therapy-care-guide","Expert Guide: How Should You Care for Yourself After CAR-T Therapy? A Step-by-Step Guide from Hospital to Home","A practical, step-by-step guide to key care needs throughout CAR-T treatment - from lymphodepleting chemotherapy and the hospital stay to managing common side effects and preventing infection at home.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F608429bac1d86d41b588dd7f530cbb2c.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Written by Dr. Yuelin HE of GoBroad Chunfu Institute of Hematology & Oncology, this article walks patients and families through the key care considerations across the CAR-T treatment journey. It covers management of low blood counts during lymphodepleting chemotherapy, oral and perianal care, PICC maintenance, diet and room hygiene, as well as what to expect during CAR-T cell infusion. It also explains common signs of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), how these reactions are managed, and practical infection-prevention measures after discharge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T cell therapy has opened up new treatment possibilities for people with relapsed or refractory blood cancers. But care during treatment and after discharge is also an important part of the journey. Good day-to-day care can help patients tolerate treatment more safely and reduce avoidable discomfort and complications. This guide covers the key points from hospitalization through recovery at home.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Care During Your Hospital Stay\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Before CAR-T: The Lymphodepletion Phase\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before CAR-T infusion, doctors usually give lymphodepleting chemotherapy - commonly drugs such as fludarabine and cyclophosphamide - to reduce some of the body's existing lymphocytes and create a better environment for the CAR-T cells to expand. Because blood counts may fall during this phase, several precautions are especially important:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What if your platelet count is low?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If your platelet count is below 50 × 10⁹\u002FL, use a soft-bristled toothbrush and brush gently to avoid injuring your gums. If it falls below 20 × 10⁹\u002FL, spend more time resting in bed, avoid rubbing your eyes or picking your nose, and watch for small bleeding spots or bruising on the skin.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What if your white blood cell or neutrophil count is low?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the neutrophil count falls below 0.5 × 10⁹\u002FL, you may need additional protective isolation, such as a laminar-flow bed. Food hygiene becomes especially important: avoid raw or cold foods, brush your teeth carefully every day, and keep the perianal area clean to reduce the risk of infection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What if your hemoglobin is low?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">You may feel tired, weak, or dizzy. Avoid standing up suddenly, as this can increase the risk of falling. Having a family member or caregiver nearby can also be helpful.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Everyday Care Basics\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These steps may seem simple, but they can make a real difference in comfort and infection prevention during treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Oral care:\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After each meal, alternate warm water with chlorhexidine mouthwash (or sodium bicarbonate mouthwash) for about 3-5 minutes. Start with about 20 mL of mouthwash and gently puff out your cheeks around 10 times so the liquid reaches between the teeth and along the inner cheeks. Use your tongue gently, almost like a soft brush, to reach the teeth, palate, and floor of the mouth. Finally, tilt your head back and gargle so the rinse reaches toward the throat. Aim for about 3 minutes of thorough rinsing to help reduce oral infection risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Perianal care:\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Each evening or after a bowel movement, use a warm sitz bath with diluted povidone-iodine solution or potassium permanganate for about 15 minutes. The water should be warm, not hot. Make sure the buttocks are fully immersed; leaning slightly forward may be more comfortable. Try to maintain regular bowel habits. If you are constipated, do not strain - ask your doctor whether options such as lactulose or a glycerin enema are appropriate. If you have diarrhea, check the skin around the anus for redness or breakdown and clean the area promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>PICC care:\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Check the catheter insertion site every day for redness, swelling, or drainage. The dressing is generally changed once a week, and if it becomes wet or loose, ask a nurse to replace it as soon as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Diet:\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Choose foods that are high in protein and vitamins and easy to digest, such as eggs, lean meat, and fresh vegetables. Avoid raw, cold, or spicy foods, and reheat food thoroughly before eating. Aim for at least 2,000 mL of fluids a day to support hydration and metabolism.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>How should the room be managed?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Keep the room clean and ventilate it three times a day for about 30 minutes each time. Visitors should be limited or avoided during this period, and fresh flowers should not be kept in the room because they may increase infection risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>What should you know about the CAR-T cell infusion?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">During the infusion itself, the main thing is to follow the instructions of your doctors and nurses and let them know promptly if you feel unwell.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">About 30 minutes before infusion, an IV line will be prepared, premedications such as anti-allergy medicines may be given, and your heart rate, blood pressure, and other vital signs will be checked. If the CAR-T cells have been frozen and thawed, the preservative used during storage may cause a temporary cooked-corn-like smell or taste. This is expected. Raising the head of the bed and breathing in through your nose and out through your mouth may make you more comfortable. After the infusion, nurses will monitor you closely for about an hour. Tell the medical team right away if you notice symptoms such as palpitations or chills.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. What Reactions Can Happen After Infusion, and How Are They Managed?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Cytokine Release Syndrome (CRS)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CRS is a relatively common reaction after CAR-T therapy. In this article, it is described as occurring most often within 1-14 days after infusion. Symptoms may include fever, low blood pressure, or shortness of breath.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What should you do if you develop a fever?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If your temperature rises above 37.5°C, tell the medical team promptly. Fever-reducing medication or cooling measures such as an ice cap or ice packs may be used as directed. Drink warm fluids, and do not take fever medicine on your own without speaking to the care team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What should you do if your blood pressure is low?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Change positions slowly. One practical approach is the 'three 30-second rule': pause for 30 seconds before sitting up; after sitting up, remain at the bedside for 30 seconds; then stand while holding onto something stable and wait another 30 seconds before walking. If you have been sweating heavily with fever, fluids and electrolytes may need to be replenished to help prevent dehydration-related low blood pressure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What if you feel short of breath or have low oxygen levels?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If breathing becomes difficult, the medical team may give supplemental oxygen and help keep the airway clear. If needed, oxygen may be delivered through a mask or more advanced breathing support may be used. Follow the team's instructions and report any worsening symptoms promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this article, ICANS is described as most often occurring 6-34 days after infusion. Possible symptoms include headache, confusion, changes in awareness, or seizures.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What should you and your family watch for?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The medical team may ask simple orientation questions each day, such as 'What is today's date?' or 'Where are you?' and may ask you to do a simple calculation. These checks help assess neurologic status. Tell the team promptly if headache or dizziness becomes worse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>What if a seizure occurs?\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Seizure-safety supplies may be kept at the bedside, and the medical team will respond immediately if a seizure occurs. Family members should not try to force the patient's mouth open or physically restrain the body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. Care at Home After Discharge\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Infection prevention is the priority.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Home environment: Ventilate the home 2-3 times a day. Avoid keeping pets or indoor plants, and avoid direct contact with soil.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Personal hygiene: Bathe and change clothes regularly. Avoid scratching the skin. Use the mouthwash recommended by your medical team, keep the perianal area clean, and avoid rubbing your eyes or picking your nose.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Food hygiene: Prepare fresh food at home. Avoid takeout, overnight leftovers, and spicy or irritating foods.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Do not ignore new symptoms: If you develop abdominal pain, dizziness, vomiting, blisters or a blister-like rash, or sharp pins-and-needles pain, seek medical attention promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>From the Doctor\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Care during CAR-T treatment and after discharge is an important part of the overall treatment process. Good daily care and self-management can help patients work more safely and effectively with their medical team throughout CAR-T therapy.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":734,"title":735,"summary":736,"cover":737,"category":430,"publishedAt":376,"contentHtml":738,"hasAlternate":73,"updatedAt":432},"car-t-sequential-therapy-allo-hsct-lymphoma-boren-team"," International Journal Publication | Beijing GoBroad Boren Team Reports Long-Term Remission with Sequential Multi-Target CAR-T After Post-Transplant DLBCL Relapse","A case report from the Beijing GoBroad Boren Hospital team, published in Frontiers in Immunology, describes long-term remission in a patient with relapsed\u002Frefractory DLBCL after allogeneic hematopoietic stem cell transplantation (allo-HSCT) following sequential CAR-T infusions targeting CD20, CD22 and CD19.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F47b94d22ceee42a24dca0c547ea06982.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: A team led by Dr. Chunrong TONG at Beijing GoBroad Boren Hospital published a case report in Frontiers in Immunology describing a patient with relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) after allo-HSCT who achieved long-term remission after sequential pseudoallogeneic CAR-T therapy targeting CD20, CD22 and CD19. The case suggests that a sequential, multi-target CAR-T strategy may help reduce relapse related to antigen escape and may offer a potential treatment approach for selected patients with complex post-transplant relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>Patients with refractory or relapsed diffuse large B-cell lymphoma (R\u002FR DLBCL) generally have a poor prognosis. Reported median overall survival (OS) is about 6 months, with an overall response rate (ORR) of 26% and a complete remission (CR) rate of 7%. For patients with chemosensitive R\u002FR DLBCL, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is commonly used as consolidation after salvage therapy. However, only around half of patients achieve durable remission after ASCT, and outcomes are poorer in aggressive subtypes such as activated B-cell-like (ABC) DLBCL, double-expressor lymphoma, and double- or triple-hit lymphoma (DHL\u002FTHL).\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem> \u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>CD19-targeted chimeric antigen receptor (CAR) T-cell therapy is another treatment option. Although CAR-T therapy can produce high complete remission rates, only about 30%-40% of patients achieve durable remission. Because relapse remains a concern after CAR-T, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often considered as consolidation in acute B-cell lymphoblastic leukemia to help prolong remission.\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, the team led by Dr. Chunrong TONG at Beijing GoBroad Boren Hospital, together with Drs. Shaomei FENG, Qinlong ZHENG, Biping DENG, Zhihui LI and Defeng ZHAO, reported the case in Frontiers in Immunology under the title “Sequential pseudoallogeneic CAR20\u002F22\u002F19 T-cell therapy in patient with diffuse large B-cell lymphoma relapse after allo-HSCT: a case report.” The patient had relapsed despite multiple prior treatments, including immunochemotherapy, ASCT, radiotherapy, autologous CD19 CAR-T and allo-HSCT, and later received sequential pseudoallogeneic CAR-T cells targeting CD20, CD22 and CD19. The report suggests that this approach may be both feasible and effective in selected patients with DLBCL relapsing after allo-HSCT, and may help reduce relapse driven by antigen escape.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002Fc13204ab6adeb9ca55789e2b42ae29c1_20260914005812.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c13204ab6adeb9ca55789e2b42ae29c1_20260914005812.png\" alt=\"30a6bee3-a6d4-40df-b75b-648b03f3bf84.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure: The study was published in Frontiers in Immunology\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Case Overview: Treatment History and Relapse\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The patient was a 38-year-old woman diagnosed with DLBCL of the left breast in March 2018. After immunochemotherapy, ASCT and radiotherapy, she relapsed in May 2019 and was referred to our hospital. A peripheral blood smear showed an increased proportion of abnormal cells, with 36% classified as uncharacterized cells. These cells were slightly enlarged, with round, oval or irregular nuclei, abundant basophilic cytoplasm and visible nucleoli. Bone marrow examination showed active hematopoiesis with 71% abnormal lymphocytes, consistent with leukemic bone marrow involvement by lymphoma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F8c9d65a8b53e378aa4bef6543ce8c083_20260914005829.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"8c9d65a8b53e378aa4bef6543ce8c083_20260914005829.png\" alt=\"30223cb6-6483-436e-a37c-9713440c2e8a.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure: Clinical course of the patient\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Autologous CD19 CAR-T and allo-HSCT: After combination treatment with L-asparaginase, dexamethasone, vindesine and the BCL-2 inhibitor venetoclax, the tumor burden in peripheral blood decreased, with abnormal lymphocytes falling to 9%. Cerebrospinal fluid morphology and flow cytometry were both negative. In May 2019, the patient received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (FC). Three days later, autologous CD19 CAR-T cells were infused at a total dose of 5 x 10^5\u002Fkg; CD3+ T cells accounted for 79.4% and CD3+ CAR T cells for 25.0%.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">After CAR-T infusion, the number of CAR-positive T cells continued to increase, peaking on day 14 and becoming undetectable by day 33 (see Table 1). Treatment was generally well tolerated. The patient developed only grade 1 cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS). At day 30 after CAR-T therapy, PET\u002FCT showed complete remission (CR), and bone marrow and cerebrospinal fluid assessments remained negative. Peripheral blood genetic susceptibility testing identified variants in TLR5, CDKN2A and STK11.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In July 2019, the patient underwent allo-HSCT using a reduced-intensity conditioning regimen of busulfan, fludarabine and antithymocyte globulin (BU\u002FFlu\u002FATG). Peripheral blood stem cells from her older brother were infused. Neutrophil and platelet engraftment were achieved on days 16 and 14, respectively. Short-course methotrexate, cyclosporine and mycophenolate mofetil were used for graft-versus-host disease (GVHD) prophylaxis. The patient developed cutaneous GVHD during treatment, which improved after adjustment of immunosuppressive therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In January 2020, follow-up PET\u002FCT showed new hypermetabolic nodules in both breasts, raising concern for lymphoma relapse. Biopsy of the left breast confirmed recurrent DLBCL. Bone marrow and cerebrospinal fluid remained negative. Cytogenetic analysis showed a donor karyotype, and bone marrow testing confirmed complete donor chimerism.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Sequential Pseudoallogeneic CAR-T Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In March 2020, the patient received FC lymphodepletion. Three days later, she received the first pseudoallogeneic CD20 CAR-T infusion. The cells were collected from the allo-HSCT recipient and manufactured in-house, at a total dose of 1.6 x 10^5\u002Fkg; CD3+ T cells accounted for 82.7% and CD3+ CAR T cells for 9.75%. CAR-positive T cells expanded after infusion, peaked on day 13 and remained detectable through day 149 (see Table 1). Only grade 1 CRS occurred, with no ICANS. PET\u002FCT at day 30 showed CR, while bone marrow and cerebrospinal fluid remained negative.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F0cc64c81433092d445ced85782dd3bc8_20260914005905.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0cc64c81433092d445ced85782dd3bc8_20260914005905.png\" alt=\"655f4317-40ab-4906-b3ba-b3635b166f94.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Table 1: Characteristics of the infused CAR-T cells\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To address heterogeneity in antigen expression and reduce the risk of relapse caused by antigen downregulation or loss, the patient subsequently received sequential pseudoallogeneic CD22 CAR-T cells in 2021 and CD19 CAR-T cells in 2022. The CD22 CAR-T dose was 1.16 x 10^4\u002Fkg, with CD3+ T cells accounting for 76.6% and CD3+ CAR T cells for 3.46%. The CD19 CAR-T dose was 3.23 x 10^4\u002Fkg, with CD3+ T cells accounting for 72.8% and CD3+ CAR T cells for 8.15% (Table 1). Both treatments were well tolerated, with no CRS or ICANS. The patient was discharged one week after each CAR-T infusion, so in-vivo CAR-T expansion was not monitored. At the time of this report, she had remained in complete remission for 5 years, with bone marrow morphology in CR, negative minimal residual disease, complete donor chimerism and no GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The authors concluded that pseudoallogeneic CAR-T therapy may be safe and effective for selected patients with DLBCL who relapse after allo-HSCT. Sequential administration of CAR-T cells targeting CD20, CD22 and CD19 may help reduce relapse related to antigen escape. Larger clinical studies are still needed to confirm the safety and efficacy of this approach and to determine whether it can reliably reduce antigen-escape relapse in DLBCL after allo-HSCT.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This report describes the first case of long-term, sustained complete remission in a patient with R\u002FR DLBCL after allo-HSCT treated with sequential pseudoallogeneic CAR-T cells targeting CD20, CD22 and CD19. The patient had relapsed despite multiple lines of therapy, including immunochemotherapy, ASCT, radiotherapy, autologous CD19 CAR-T and allo-HSCT. After sequential CD20-, CD22- and CD19-targeted pseudoallogeneic CAR-T infusions, she achieved durable complete remission, maintained for 5 years as reported in this article. Overall tolerability was favorable, with only low-grade CRS and no severe ICANS or GVHD.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For the particularly challenging group of patients with R\u002FR DLBCL relapsing after allo-HSCT, this case suggests that sequential, multi-target pseudoallogeneic CAR-T therapy may be a feasible salvage option. One possible advantage is broader antigen coverage, which may reduce the risk of relapse caused by antigen escape. Because this is a single case report, however, larger studies are needed before the approach can be generalized to other patients.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":740,"title":741,"summary":742,"cover":743,"category":438,"publishedAt":393,"contentHtml":744,"hasAlternate":73,"updatedAt":432},"car-t-treatment-process-six-steps-guide","Expert Guide: What Are the Steps in CAR T-Cell Therapy?","Dr. Yuelin He explains the six key steps of CAR T-cell therapy, from eligibility assessment to post-infusion monitoring, and what patients should know at each stage.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1ccb9f9b0a76c579753d9262a228ac9d.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: CAR T-cell therapy is an advanced, highly personalized cancer treatment that involves several carefully coordinated steps: eligibility assessment, T-cell collection, CAR T-cell manufacturing and expansion, lymphodepleting chemotherapy, CAR T-cell infusion, and post-infusion monitoring. In this guide, Dr. Yuelin He of the GoBroad Chunfu Institute of Hematology & Oncology explains what patients can expect and how to prepare at each stage, including the 3–4 hours typically needed for cell collection, the 2–4-week manufacturing period, the purpose of lymphodepleting chemotherapy, premedication before infusion, monitoring for cytokine release syndrome and other side effects, and the importance of regular follow-up after treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once you and your doctor have completed the necessary evaluation and decided that CAR T-cell therapy may be right for you, what does the treatment journey actually involve?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In general, CAR T-cell therapy involves six main steps: eligibility assessment → T-cell collection → CAR T-cell manufacturing and expansion → lymphodepleting chemotherapy → CAR T-cell infusion → monitoring and follow-up.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">What do patients need to do during each step, and what should they keep in mind along the way?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Eligibility Assessment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The first step is to talk with your doctor about whether CAR T-cell therapy is an appropriate option for you.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Your doctor will review your overall health, test results, previous treatment history, and treatment goals, and will discuss the potential benefits and risks of CAR T-cell therapy with you. Together, you can decide whether to move forward.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. T-Cell Collection\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If you decide to proceed with CAR T-cell therapy, the next step is to collect your T cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This process, called leukapheresis, is similar in some ways to a blood donation. Blood is passed through an apheresis machine, which separates out the T lymphocytes needed for treatment, while the remaining blood components are returned to your body. The procedure usually takes about 3–4 hours. If your white blood cell count is low, your care team may recommend medication beforehand to help increase the number of cells available for collection.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. CAR T-Cell Manufacturing and Expansion\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The collected T cells are sent to a laboratory, where genetic engineering is used to add a chimeric antigen receptor (CAR)—essentially a “navigation system” that helps the cells recognize cancer cells. The modified cells are then expanded to produce a large number of CAR T cells. This manufacturing process usually takes about 2–4 weeks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. Lymphodepleting Chemotherapy (Preconditioning)\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before CAR T-cell infusion, patients receive lymphodepleting chemotherapy. This treatment reduces the body's existing lymphocytes and creates a more favorable environment for the infused CAR T cells to expand and work effectively. Lymphodepleting chemotherapy usually lasts about three days, followed by a rest period of around two to three days before CAR T-cell infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the tumor burden is high or the disease is progressing quickly, bridging therapy may also be needed before CAR T-cell infusion to help control the disease while the CAR T cells are being prepared.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. CAR T-Cell Infusion\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before the infusion, the medical team will check and record your vital signs and may use cardiac monitoring as needed. About 30–60 minutes before the CAR T cells are given, you will also receive premedication to reduce the risk of allergic or infusion-related reactions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The CAR T-cell infusion itself is usually straightforward. The cells are generally given through a vein using an infusion or transfusion set, and the process typically takes about 15–30 minutes. Afterward, the team will watch closely for symptoms such as fever, difficulty breathing, or rash, and will manage any discomfort promptly if it occurs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>6. Monitoring and Follow-Up\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Once the infusion is complete, the CAR T cells can begin recognizing and attacking tumor cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients usually remain in the hospital for a period of close observation. The medical team will monitor for CAR T-related side effects, particularly cytokine release syndrome (CRS) and neurotoxicity, so that any problems can be identified and treated promptly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">At the same time, your doctors will use blood tests, imaging, and other assessments to evaluate whether the CAR T-cell therapy is working. An initial response assessment is commonly performed within the first month after infusion.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If the treatment is effective, regular follow-up remains essential. Follow-up helps monitor for disease recurrence and allows the care team to identify and manage any longer-term side effects related to CAR T-cell therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>From the Doctor\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Compared with conventional drug treatment, CAR T-cell therapy involves a more complex treatment process. Staying in close communication with your care team throughout the journey is therefore very important and helps ensure that each stage of treatment is managed appropriately.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":746,"title":747,"summary":748,"cover":749,"category":430,"publishedAt":402,"contentHtml":750,"hasAlternate":73,"updatedAt":432},"protein-biomarkers-childhood-ball-diagnosis-risk-model","International Journal Publication | Dr. Qinlong Zheng and Collaborators Identify 9 Key Protein Biomarkers and Develop a New Model for Pediatric B-ALL Diagnosis and Risk Assessment","A collaborative team led in part by Dr. Qinlong Zheng published a study in Cancer Letters using Olink proteomics to identify nine key protein biomarkers and develop a high-performing model for pediatric B-ALL diagnosis and risk assessment.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F1c0d53541e5bf9f4b837b68c344814ba.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Qinlong Zheng of Beijing GoBroad Boren Hospital, together with collaborating investigators, published a study in Cancer Letters using Olink proteomics to identify nine key protein biomarkers that were differentially expressed between children with B-cell acute lymphoblastic leukemia (B-ALL) and B-ALL patients in complete molecular remission (CMR). The resulting diagnostic model achieved an area under the curve (AUC) of 0.98 in the validation cohort, providing new proteomics-based evidence and potential tools for more precise assessment and clinical decision-making in pediatric B-ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Genomic analysis has fundamentally reshaped risk assessment and clinical decision-making in pediatric B-cell acute lymphoblastic leukemia (B-ALL). However, genomic testing can be complex, time-consuming, and costly, which may limit rapid use in some clinical settings. Proteomics offers a complementary perspective by capturing dynamic changes in disease biology and the immune microenvironment at the functional protein level, creating new possibilities for more precise assessment and clinical translation in pediatric B-ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Recently, Dr. Qinlong Zheng of Beijing GoBroad Boren Hospital, one of the corresponding authors, collaborated with Professor Yizhi Jiang, Professor Dongping Huang, and their team at The First Affiliated Hospital of Wannan Medical College on a study published in Cancer Letters (IF 10.1). Using Olink proteomics, the researchers systematically profiled protein expression in pediatric B-ALL and identified and validated nine key biomarkers that differed between patients with active B-ALL and CMR controls: CXCL13, NCR1, ADA, IL6, HO-1, CCL3, CCL4, CD27, and ADGRG1. The findings provide a new proteomics-based perspective for more precise assessment and clinical decision-making in pediatric B-ALL.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F0fb1d7d85d4a7cbe5620fbd4b9f79b03_20260914004402.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"0fb1d7d85d4a7cbe5620fbd4b9f79b03_20260914004402.png\" alt=\"8d701d64-ae57-4f31-929d-4e4cb9cea66f.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Design\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study included 50 children with B-ALL and 43 control samples from B-ALL patients who had achieved complete molecular remission (CMR). Participants were divided into discovery and validation cohorts. The discovery cohort included 30 patients with B-ALL and 26 CMR controls, while the validation cohort included 20 patients with B-ALL and 17 CMR controls.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The researchers used Olink proteomic analysis with the Olink Target 96 Oncology Response protein panel. After screening for differentially expressed proteins (DEPs), statistical modeling was used to identify the protein combination with the strongest discriminatory performance. Key findings were then independently validated using enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Study Results\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Key Finding: Pediatric B-ALL Has a Distinctive Protein Expression Profile\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The study first identified clear differences in protein expression between pediatric B-ALL and CMR controls. A total of 37 differentially expressed proteins were found, involving regulators of cellular function, chemokines and inflammatory mediators, and tumor-related proteins. Together, these proteins were able to clearly distinguish active disease from molecular remission.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">These findings suggest that pediatric B-ALL involves not only abnormal proliferation of leukemia cells, but also substantial remodeling of the bone marrow immune microenvironment. Proteomics can capture these functional changes at the protein level.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F3b4ce0a1f37f156ccf0bb6b7e6ae0b82_20260914004430.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3b4ce0a1f37f156ccf0bb6b7e6ae0b82_20260914004430.png\" alt=\"3dea7867-b4f1-4a57-ab42-aef639d24623.png\"\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1. Thirty-Seven Differentially Expressed Proteins Identified Between Pediatric B-ALL and CMR Control Samples\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Key Finding: A 9-Protein Panel Showed Near Clinical-Grade Discriminatory Performance\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Based on the differentially expressed proteins, the researchers used a LASSO regression model to identify nine key proteins — CXCL13, NCR1, ADA, IL6, HO-1, CCL3, CCL4, CD27, and ADGRG1 — and used them to build a diagnostic model.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The model achieved an area under the curve (AUC) of 1.00 in the discovery cohort and 0.98 in the validation cohort, demonstrating very strong ability to distinguish pediatric B-ALL from CMR controls.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260914\u002F77449f53e70dee9693ee39dbc126c468_20260914004442.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"77449f53e70dee9693ee39dbc126c468_20260914004442.png\" alt=\"ca74e971-ff20-481a-976a-d51aa7caf821.png\"\u002F>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Figure 2. Diagnostic Performance of LASSO-Selected Differentially Expressed Proteins in Pediatric B-ALL. AUC curves show the discriminatory performance of the most significant DEPs in the discovery cohort (a) and validation cohort (b).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Key Finding: Key Proteins Were Consistently Validated by ELISA and IHC\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">To strengthen reproducibility and translational potential, the researchers validated key protein signals using independent methods. ELISA was used to confirm trends in plasma protein levels, while IHC was used to evaluate protein expression in patient-derived xenograft (PDX) tissues.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Proteins including CCL3, CCL4, and CD27 showed consistent patterns across different testing platforms, supporting their stability and potential clinical relevance.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>4. Key Finding: Higher Levels of Differential Proteins Were Associated with Genetic Alterations Linked to Poorer Prognosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The researchers also found that several differentially expressed proteins were present at higher levels in children carrying genetic alterations associated with poorer prognosis. These proteins included CD27, TNF, CCL3, CCL4, IL12RB1, PDCD1, and GZMB.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This suggests that pediatric B-ALL with poor-risk genetic alterations may also be accompanied by more pronounced immune- and inflammation-related protein changes.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Overall, the study uses proteomics to provide a new perspective beyond existing molecular classification frameworks for pediatric B-ALL. The findings may help make disease assessment and risk evaluation more refined and support clinical decisions that better reflect each child's underlying disease biology. Over time, this could help clinicians pursue effective treatment while reducing unnecessary treatment burden and improving long-term outcomes and quality of life for children with leukemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The publication also reflects the growing capabilities of the Molecular Diagnostics Laboratory at GoBroad Diagnostic Center. As an important platform supporting precision care in hematologic malignancies, the laboratory has developed an integrated workflow covering molecular classification and detection of key genetic alterations, support for measurable residual disease (MRD) testing, standardized quality control across the full sample-processing pathway, and biomarker discovery, validation, and translation. These capabilities provide clinicians with stable, traceable, and potentially translatable evidence for diagnosis and monitoring, while also supporting consistent data generation in multicenter collaborative research. Building on this platform, GoBroad will continue integrating advanced testing with clinical pathways and accelerating the translation of research findings into practical decision-making tools, with the goal of making precision medicine more meaningful for patients.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":752,"title":753,"summary":754,"cover":755,"category":438,"publishedAt":756,"contentHtml":757,"hasAlternate":73,"updatedAt":74},"dsa-clearance-before-stem-cell-transplantation","Dr. Jianyun Liao: Why Is DSA Desensitization Needed Before Stem Cell Transplantation? Is Strong DSA Positivity a Contraindication?","Dr. Jianyun LIAO of GoBroad Chunfu Institute of Hematology & Oncology explains how donor-specific antibodies (DSAs) can affect transplantation, why DSA positivity is not an absolute contraindication, and how appropriate desensitization may help improve transplant success.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F2d62ae80bd6ce25a76779000f11dcf14.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-01-09","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Jianyun LIAO of GoBroad Chunfu Institute of Hematology & Oncology discusses donor-specific antibodies (DSAs) before hematopoietic stem cell transplantation in patients with transfusion-dependent severe thalassemia. She explains how DSAs develop, how their strength is assessed using mean fluorescence intensity (MFI), and how they may contribute to graft failure or poor hematopoietic recovery. The article also reviews desensitization strategies including rituximab, bortezomib, plasma exchange, and combination approaches, emphasizing early screening and individualized intervention to reduce transplant-related risk and help patients reach transplantation at the right time.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F59922df01d8c7ed1e6b7f7e98a2399e4_20260913225739.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"59922df01d8c7ed1e6b7f7e98a2399e4_20260913225739.png\" alt=\"47444833-0fac-4174-ad90-b0dec264e78b.png\"\u002F> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For people with transfusion-dependent thalassemia, hematopoietic stem cell transplantation can be thought of as rebuilding the body's blood-forming and immune systems. The goal is for healthy donor stem cells to engraft and establish new, functioning hematopoiesis and immunity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As people with thalassemia grow older, the burden of ongoing transfusions and iron chelation often increases. In patients who have received many transfusions over time, another challenge may emerge: donor-specific antibodies (DSAs). These antibodies can recognize and attack donor cells, potentially interfering with engraftment and increasing the risk of transplant failure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Jianyun LIAO of GoBroad Chunfu Institute of Hematology & Oncology explains where DSAs come from, how they are assessed, and how DSA levels may be reduced before transplant to help lower transplant-related risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What Are Donor-Specific Antibodies, and Where Do They Come From?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">When a transplant recipient has previously been exposed to another person's human leukocyte antigens (HLA) through blood transfusions, a prior transplant, pregnancy, or other circumstances, the immune system may develop immunologic memory and produce antibodies. If those antibodies specifically recognize HLA antigens carried by the intended donor, they are called donor-specific antibodies, or DSAs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with thalassemia, repeated red blood cell transfusions can expose the immune system to residual leukocytes and soluble HLA antigens. Over time, this may stimulate antibody formation, and the risk generally increases with a greater number of transfusions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Is DSA Strength Assessed, and Why Does It Matter?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">DSA strength is commonly assessed using mean fluorescence intensity (MFI). In general, higher MFI values are associated with a greater risk of transplant failure:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">• MFI 1,000-5,000: low to intermediate risk\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">• MFI 5,000-10,000 or C1q positive: high risk\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">• MFI >10,000: very high risk\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">• MFI >20,000: often associated with a very high risk of transplant failure\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>1. Graft Failure or Delayed Engraftment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Patients with moderate or higher DSA levels (MFI >5,000) are more likely to experience primary graft failure. DSAs can attack donor hematopoietic stem cells through complement-mediated mechanisms or antibody-dependent cellular cytotoxicity, preventing the donor cells from successfully engrafting in the recipient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>2. Poor Hematopoietic Recovery\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Even when DSA levels are not high enough to cause immediate and complete graft failure, they may still interfere with donor stem cell expansion after transplantation. This can lead to delayed neutrophil and platelet recovery, persistent cytopenias, and prolonged transfusion dependence. This condition is often referred to as poor graft function.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Data presented at meetings of the European Society for Blood and Marrow Transplantation (EBMT) have reported poor graft function rates of 28%-42% among DSA-positive patients. Poor graft function can significantly affect quality of life and may increase the risk of serious complications such as infection and bleeding.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>3. Higher Risk of Other Complications\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">More intensive immunosuppressive treatment may be needed to overcome the effects of DSAs, which can in turn increase risks such as infection and drug-related toxicity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How Can the Impact of DSAs Be Reduced?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">DSA positivity is not an absolute contraindication to transplantation. With appropriate screening, desensitization, and an individualized transplant strategy, DSA levels can often be reduced, helping lower transplant-related risk and improve the likelihood of successful engraftment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Before transplant, treatments such as rituximab and bortezomib may be used to reduce antibody production. High-dose intravenous immunoglobulin (IVIG) may also be given as part of a desensitization strategy to help reduce the impact of circulating antibodies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Plasma exchange or immunoadsorption: these approaches remove antibody-containing plasma from the patient's blood and return the blood cells together with replacement plasma or fluid, allowing DSA levels to be reduced more rapidly.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Donor platelet or buffy coat infusion before transplant may also be used to help neutralize antibodies. For very high-risk patients with DSA MFI >10,000 or C1q positivity, a combination desensitization approach is often used to lower antibody levels as much as possible before transplantation and improve the chance of successful engraftment.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">Important Considerations\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">• DSA desensitization should be individualized. Before treatment, the medical team needs to assess antibody strength, including MFI level, complement-binding status such as C1q positivity, and the patient's overall condition.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">• During desensitization, DSA levels, hematopoietic function, and infection risk should be monitored closely. In some patients, antibody levels may rebound.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\"> \u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cem>\u003Cspan style=\"font-size: 15px; color: rgb(127, 127, 127);\">• When feasible, choosing a donor against whom the patient does not have DSAs can help avoid this additional source of transplant risk.\u003C\u002Fspan>\u003C\u002Fem>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Hematopoietic stem cell transplantation is an important treatment option for people with thalassemia. As patients grow older, the cumulative burden of transfusion and iron chelation may increase, and the likelihood of developing DSAs may also rise. For DSA-positive patients, identifying and addressing these antibodies before transplantation can help improve the chance of engraftment, reduce transplant-related complications, and support better quality of life. If a patient meets transplant indications, has a suitable donor, and is medically fit for transplantation, the timing of transplant should be discussed carefully with the treating team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 12px;\">Please note: This article is for general educational purposes only. Because every patient's situation is different, please discuss your individual circumstances with your treating physician, who can provide recommendations based on a full clinical assessment.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":759,"title":760,"summary":761,"cover":762,"category":438,"publishedAt":756,"contentHtml":763,"hasAlternate":73,"updatedAt":432},"car-t-therapy-vs-chemotherapy-explained","What Is CAR-T Therapy? How Is It Different from Chemotherapy?","An expert explains how CAR-T cell therapy works and how it differs from conventional chemotherapy in its treatment mechanism, who it may be suitable for, and its side-effect profile.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fa64eb73dc464d230eb5c5620265d63df.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Full summary: CAR-T cell therapy is a form of cellular immunotherapy in which a patient's own T cells are genetically engineered to recognize and attack tumor cells. Dr. Yuelin HE of GoBroad Chunfu Institute of Hematology & Oncology explains that CAR-T and chemotherapy are not substitutes for one another; they may be used at different stages or in combination depending on the disease and treatment goals. Some patients can achieve complete remission after CAR-T therapy, but it is not appropriate for everyone. Treatment decisions should be individualized based on factors such as pathological subtype, stage, molecular features, treatment history, and response to previous therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">If you are living with a hematologic malignancy, another type of cancer, or an autoimmune disease, you may reach a point where familiar options such as chemotherapy, radiation therapy, or targeted therapy have already been tried but have not provided the results you hoped for. At that point, it is understandable to wonder what other options may be available.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In recent years, CAR-T cell therapy has reshaped parts of the treatment landscape for blood cancers, other cancers, and some autoimmune diseases, offering a new option for selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">GoBroad Chunfu Institute of Hematology & Oncology has created a CAR-T Knowledge Hub to help patients and families understand this treatment step by step. Today's topic: What is CAR-T, and how is it different from chemotherapy?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. What Is CAR-T?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T therapy is a form of cellular immunotherapy and a newer approach to cancer treatment, alongside established treatments such as surgery, radiation therapy, and chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In simple terms, T lymphocytes are collected from the patient and genetically engineered to express a CAR, or chimeric antigen receptor. This receptor enables the modified T cells - now called CAR-T cells - to recognize a specific target on tumor cells. After the CAR-T cells are infused back into the patient, they can expand in the body, identify cells carrying that target, and attack and eliminate them.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002F3d0a6bf45d57d6a5fd3eb73154e970cc_20260911163528.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"3d0a6bf45d57d6a5fd3eb73154e970cc_20260911163528.png\" alt=\"303bf47f-0d4f-4751-a74c-a698d106db62.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px; text-align: center;\">Image source: Lekha Mikkilineni and James N. Kochenderfer. Blood. 2017;130(24):2594-2602.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. How Is CAR-T Different from Chemotherapy?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T and chemotherapy are different treatment approaches, and each has its own potential benefits and limitations.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";\">\u003Cspan style=\"font-size: 15px;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260911\u002F09b672225b149c17bee24cd1b91e45c9_20260911163601.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"09b672225b149c17bee24cd1b91e45c9_20260911163601.png\" alt=\"103ccd91-9fdb-4aa5-997d-59452b02f2d0.png\"\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Chemotherapy is a well-established treatment with decades of clinical experience behind it. Its common side effects are relatively well characterized, and treatment is often delivered over multiple cycles, so the overall treatment course may be longer.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">CAR-T is a newer form of cell therapy, and some patients can achieve complete remission after treatment. However, CAR-T is not necessary or suitable for every patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Some patients with blood cancers or other malignancies may also need additional treatment in sequence, such as hematopoietic stem cell transplantation or targeted therapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For this reason, CAR-T and chemotherapy should not be viewed as treatments that simply replace one another. They may be used at different points in the treatment journey, depending on the individual situation. The most appropriate approach should be determined by the medical team after considering factors such as pathological subtype, disease stage, molecular features, treatment history, and response to previous chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;break-after: avoid;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Expert Perspective\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As treatment for hematologic malignancies continues to evolve, conventional chemotherapy and immunotherapies such as CAR-T are likely to be used more widely in combination or sequence, with the aim of helping more patients achieve longer survival and a better quality of life.\u003C\u002Fspan>\u003C\u002Fp>",{"slug":765,"title":766,"summary":767,"cover":768,"category":438,"publishedAt":769,"contentHtml":770,"hasAlternate":73,"updatedAt":74},"tumor-genetic-report-survival-guide","Finding Treatment Clues in a Tumor Genetic Report: Prof. Qinlong Zheng & Dr. Yuehui Lin Explain What Matters","Dr. Yuehui Lin of Beijing GoBroad Boren Hospital and Prof. Qinlong Zheng of the GoBroad Diagnostic Center explain how genetic testing can support precise diagnosis, risk stratification, and individualized targeted treatment decisions in acute myeloid leukemia (AML).","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002F67978bbcdbc43bca943f9024bf259f70.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp","2026-01-08","\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Summary: Dr. Yuehui Lin of Beijing GoBroad Boren Hospital and Prof. Qinlong Zheng of the GoBroad Diagnostic Center explain how to read a genetic report for hematologic malignancies from three key perspectives: diagnosis, prognosis, and treatment. The diagnostic section reviews the MICM-based integrated workup for AML under current WHO\u002FICC classifications and the importance of screening for inherited predisposition genes such as TP53 and DDX41. The prognosis section explains the three-tier molecular-genetic risk stratification used in Chinese AML guidelines and why the exact type and location of a TP53 alteration matter. The treatment section links actionable targets such as FLT3, IDH1\u002F2, BCL-2, and JAK2 with corresponding treatment options, illustrating how AML care is moving from a one-size-fits-all model toward truly individualized treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In the era of precision medicine, genetic testing has become an important map and compass in modern cancer care. It can reveal the molecular drivers of disease and provide useful guidance at key decision points - helping clinicians refine the diagnosis, assess prognosis and risk, identify potential targeted therapies, monitor for relapse, investigate drug resistance, and sometimes uncover inherited cancer-predisposition risks. Yet in everyday practice, patients and families often face very practical questions: Do I need genetic testing? Which test should I have? When should it be done? And once I receive a report filled with unfamiliar terms and numbers, which findings actually matter for my treatment?\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">In this article, Dr. Yuehui Lin, Director of Ward 9, Department of Hematology I (Hematology\u002FOncology) at Beijing GoBroad Boren Hospital, and Prof. Qinlong Zheng, Director of the Molecular Diagnostics Laboratory at the GoBroad Diagnostic Center, take a closer look at these questions. Step by step, they explain how to identify the most meaningful clues in a complex tumor genetic report and turn laboratory data into information that can guide real-world treatment decisions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>1. Diagnosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The diagnosis and treatment of hematologic malignancies have entered an era of integrated precision medicine. At diagnosis, clinicians need to bring together morphology, immunophenotyping, cytogenetics, and molecular genetics to achieve accurate WHO classification and ELN risk stratification. These findings help determine disease risk, the intensity of chemotherapy, whether a targeted therapy may be appropriate, and whether allogeneic hematopoietic stem cell transplantation (allo-HSCT) should be considered early. Before transplantation, inherited predisposition testing may also be considered for the patient and potential donors to identify clinically significant variants involving genes such as TP53, BRCA, and DNA-repair pathways. This information can help inform donor selection, conditioning strategies, and, where relevant, targeted treatment options. The ultimate goal is a full-course management strategy spanning diagnosis, classification, treatment, transplantation, measurable residual disease (MRD), and long-term follow-up - maximizing benefit while minimizing toxicity.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Yuehui Lin reviewed the diagnosis and classification of acute myeloid leukemia (AML) under the fifth edition of the WHO classification and the ICC. At initial diagnosis, AML requires a comprehensive MICM workup: morphology, flow-cytometric immunophenotyping, conventional cytogenetics with relevant FISH testing, and broad molecular genetic testing. This helps identify fusion genes such as PML::RARA, RUNX1::RUNX1T1, and CBFB::MYH11, as well as somatic and germline alterations involving genes including NPM1, CEBPA, FLT3-ITD, DDX41, ETV6, ANKRD26, and GATA2. When an inherited hematologic malignancy syndrome is suspected, paired testing using peripheral blood or buccal mucosa may be used to confirm germline pathogenic or likely pathogenic variants such as DDX41, TP53, RUNX1, CEBPA, GATA2, and ETV6. Reporting both tumor-associated and inherited predisposition variants can provide important evidence for risk stratification, targeted therapy selection, donor screening, and family assessment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F86c07318592cf876f56ba317d46ebb08_20260913215944.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"86c07318592cf876f56ba317d46ebb08_20260913215944.png\" alt=\"ab22e182-94dd-4cb5-b93a-7d5b4aed78ea.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 1. Diagnosis and Classification of Acute Myeloid Leukemia in the WHO 5th Edition and ICC\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F78805a221a988e79ef3f42d7c5bfd418_20260913215952.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"78805a221a988e79ef3f42d7c5bfd418_20260913215952.png\" alt=\"image.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 2. WHO 5th Edition and ICC Classification of Myeloid Neoplasms With Germline Predisposition\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>2. Prognosis\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">According to the Chinese guidelines for the diagnosis and treatment of acute myeloid leukemia (AML), molecular and genetic prognostic assessment should be performed promptly after diagnosis to classify patients into favorable-, intermediate-, or adverse-risk groups. The article notes that adverse-risk features may include TP53 alterations with a variant allele frequency (VAF) of at least 10%, complex karyotype, high-burden FLT3-ITD, and alterations in genes such as ASXL1, RUNX1, and BCOR. For TP53 in particular, the report must be interpreted carefully to distinguish clearly pathogenic alterations from variants of uncertain significance. The clinical meaning depends not only on whether TP53 appears on the report, but also on the exact variant, its location, functional significance, and allele burden.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002F5aaa47e9c9592fc5bcce02d77e6be6d8_20260913220013.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"5aaa47e9c9592fc5bcce02d77e6be6d8_20260913220013.png\" alt=\"1419acf8-838e-43f7-b6bd-b175f6f0cc3b.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 3. AML Prognostic Risk Stratification in Chinese Clinical Guidelines\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">The article also notes that the 2025 CSCO and CACA guidelines stratify AML into favorable-, intermediate-, and adverse-risk groups according to genetic features, helping clinicians decide whether standard chemotherapy may be sufficient or whether intensified treatment and transplantation should be considered. Examples listed in the article include t(8;21)\u002FRUNX1-RUNX1T1, inv(16)\u002FCBFB-MYH11, and NPM1-mutated\u002FFLT3-ITD-low disease in the favorable-risk category, while TP53-mutated disease, high-burden FLT3-ITD, and complex karyotype are described as adverse-risk features that may prompt earlier use of targeted therapy and consideration of allo-HSCT.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>3. Treatment\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">As AML treatment becomes increasingly precise and more focused on long-term disease control, care has evolved beyond conventional chemotherapy alone toward a multidimensional strategy that can combine chemotherapy, targeted therapy, immunotherapy, and transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cul class=\" list-paddingleft-2\" style=\"list-style-type: disc;\">\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with FLT3 mutations, FLT3 inhibitors such as gilteritinib or midostaurin may be incorporated into treatment, including in combination with chemotherapy when appropriate;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For IDH1-mutated disease, ivosidenib may be considered; for IDH2-mutated disease, enasidenib is a targeted option;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients in whom BCL-2-directed treatment is appropriate, venetoclax combined with a hypomethylating agent has become an important regimen;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For patients with JAK2 V617F, JAK inhibition such as ruxolitinib may be considered in relevant disease settings;\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003Cli>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">For rare but potentially targetable fusions such as ETV6-ABL1, ABL1 inhibitors - including dasatinib, olverembatinib, or ponatinib - may be considered depending on the clinical context.\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">This shift in risk stratification and treatment selection reflects the broader move in AML care from standardized treatment for everyone toward strategies tailored to each patient's molecular profile, creating more opportunities for individualized treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Dr. Yuehui Lin noted that targeted approaches can reduce reliance on conventional intensive chemotherapy and, in selected patients with molecularly defined AML such as FLT3- or IDH-mutated disease, may make lower-toxicity or even chemotherapy-free treatment strategies possible. Comprehensive mutation profiling at diagnosis can help the care team match each patient with a more individualized treatment pathway, with the aim of extending survival while preserving quality of life.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>4. Treatment Response Monitoring\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">A central part of response monitoring is the dynamic assessment of measurable residual disease (MRD). Multiparameter flow cytometry (MFC), with sensitivity down to around 10^-4, is commonly used. For patients with trackable fusion genes, real-time quantitative PCR (RQ-PCR) can provide additional monitoring. For patients with somatic mutations, the article describes using the individualized mutation profile identified on the patient's diagnostic next-generation sequencing (NGS) panel for deep sequencing, with sensitivity approaching 10^-6 in some settings. Serial monitoring may be performed in bone marrow and, when appropriate, peripheral blood.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">One important point: the timing of testing, the type of sample, and the clinical purpose of each test need to be considered together. These decisions should be made with guidance from an experienced clinician.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cimg src=\"https:\u002F\u002Fgaobo-byh-h5.oss-accelerate.aliyuncs.com\u002Fimages\u002F20260913\u002Fc5833950977d3e38728a232ccc8da5c8_20260913220105.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp\" title=\"c5833950977d3e38728a232ccc8da5c8_20260913220105.png\" alt=\"9929a554-fa8d-43c8-87fa-14c9b6a861b5.png\"\u002F>\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"color: rgb(127, 127, 127); font-size: 15px;\">Figure 4. Molecular Testing Across the Full Course of Disease Management\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: center;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>5. Case Examples\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Case 1 involved a boy born in 2008 who was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) and an initial white blood cell count of 1202 × 10^9\u002FL. A local 43-fusion-gene panel and a small mutation panel were negative, and he did not achieve remission after two courses of treatment under the CCLG-ALL-2018 protocol. After transfer to our hospital, he received CD19 CAR-T cell therapy and achieved complete remission, followed immediately by haploidentical hematopoietic stem cell transplantation. The disease later relapsed again and responded poorly to several additional treatments. A review of bone marrow RNA sequencing performed at his first admission identified an ABL1 fusion, prompting adjustment of targeted and immune-based therapy. He subsequently achieved remission and continues to maintain molecular remission. The case illustrates how deeper molecular testing can reveal actionable information that may guide targeted and immunotherapeutic strategies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\"> \u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\";text-align: justify;\">\u003Cspan style=\"font-size: 15px;\">Case 2 involved a 73-year-old patient with acute myeloid leukemia (AML). The initial white blood cell count was not markedly elevated, and NGS detected FLT3-ITD, NPM1, and IDH2 mutations. The patient received a lower-intensity combination strategy using a hypomethylating agent plus the FLT3 inhibitor gilteritinib and\u002For the IDH2 inhibitor enasidenib, without standard intensive chemotherapy. After three treatment cycles, morphologic complete remission was achieved, although the NPM1 mutation remained detectable at 0.12%. The patient continued maintenance with azacitidine (AZA) plus gilteritinib and has remained in molecular remission for 39 months without hematopoietic stem cell transplantation. The patient required 17 hospital admissions and 9 units of red blood cell transfusion before becoming transfusion independent. The case highlights how real-time NGS-based MRD assessment and multiparameter flow cytometry can help guide treatment adjustment in older patients or those who may not tolerate intensive chemotherapy.\u003C\u002Fspan>\u003C\u002Fp>",1789384045556]